{
    "605700d294d57fd879000021_1": [
        {
            "start_logit": 9.3046875,
            "end_logit": 9.421875,
            "text": "MRJP1",
            "probability": 1.0
        },
        {
            "start_logit": -1.05078125,
            "end_logit": 9.421875,
            "text": "P1",
            "probability": 3.218650817871094e-05
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -1.1513671875,
            "text": "MR",
            "probability": 2.586841583251953e-05
        },
        {
            "start_logit": -5.7421875,
            "end_logit": 9.421875,
            "text": "JP1",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -5.84765625,
            "text": "MRJP1, MRJP2, MRJP4, and MRJP5",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -6.32421875,
            "text": "MRJP1, MRJP2, MRJP4, and MRJP",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.203125,
            "end_logit": 9.421875,
            "text": "exposure of nurse bees to pesticides reduced the expression of four of the major royal jelly proteins (MRJP1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 9.421875,
            "text": "nurse bees to pesticides reduced the expression of four of the major royal jelly proteins (MRJP1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 9.421875,
            "text": "(MRJP1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 9.421875,
            "text": "expression of four of the major royal jelly proteins (MRJP1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.30078125,
            "text": "MRJP1, MRJP2, MRJP4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.30859375,
            "text": "MRJP1, MRJP2, MRJP4, and MRJP5)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 9.421875,
            "text": "The exposure of nurse bees to pesticides reduced the expression of four of the major royal jelly proteins (MRJP1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.36328125,
            "text": "MRJP1, MRJP2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.38671875,
            "text": "MRJP1, MRJP2, MRJP4, and MRJ",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 9.421875,
            "text": "proteins (MRJP1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 9.421875,
            "text": "royal jelly proteins (MRJP1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.05078125,
            "end_logit": -5.84765625,
            "text": "P1, MRJP2, MRJP4, and MRJP5",
            "probability": 0.0
        },
        {
            "start_logit": -1.05078125,
            "end_logit": -6.32421875,
            "text": "P1, MRJP2, MRJP4, and MRJP",
            "probability": 0.0
        },
        {
            "start_logit": -1.05078125,
            "end_logit": -7.30078125,
            "text": "P1, MRJP2, MRJP4",
            "probability": 0.0
        }
    ],
    "5883bce3e56acf5176000003_1": [
        {
            "start_logit": 9.125,
            "end_logit": 9.359375,
            "text": "PeakXus",
            "probability": 1.0
        },
        {
            "start_logit": -1.267578125,
            "end_logit": 9.359375,
            "text": "us",
            "probability": 3.069639205932617e-05
        },
        {
            "start_logit": 9.125,
            "end_logit": -1.5869140625,
            "text": "Peak",
            "probability": 1.7642974853515625e-05
        },
        {
            "start_logit": -6.140625,
            "end_logit": 9.359375,
            "text": "Xus",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.26953125,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nexus and ChIP-Exo experiments.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.2890625,
            "text": "PeakXus: comprehensive transcription factor binding site discovery",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.42578125,
            "text": "PeakXus: comprehensive transcription factor binding site",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.4375,
            "text": "PeakXus: comprehensive transcription factor binding",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.46875,
            "text": "PeakXus: comprehensive transcription factor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.48046875,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nexus and ChIP-Exo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.5078125,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nexus and ChIP-Exo experiments",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.53515625,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nexus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.546875,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nexus and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.56640625,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.56640625,
            "text": "PeakXus:",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.578125,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Ne",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.58984375,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nex",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.267578125,
            "end_logit": -7.26953125,
            "text": "us: comprehensive transcription factor binding site discovery from ChIP-Nexus and ChIP-Exo experiments.",
            "probability": 0.0
        },
        {
            "start_logit": -1.267578125,
            "end_logit": -7.2890625,
            "text": "us: comprehensive transcription factor binding site discovery",
            "probability": 0.0
        },
        {
            "start_logit": -1.267578125,
            "end_logit": -7.42578125,
            "text": "us: comprehensive transcription factor binding site",
            "probability": 0.0
        }
    ],
    "5883bce3e56acf5176000003_2": [
        {
            "start_logit": 9.0859375,
            "end_logit": 9.3671875,
            "text": "PeakXus",
            "probability": 1.0
        },
        {
            "start_logit": -1.2265625,
            "end_logit": 9.3671875,
            "text": "us",
            "probability": 3.319978713989258e-05
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -1.6455078125,
            "text": "Peak",
            "probability": 1.6450881958007812e-05
        },
        {
            "start_logit": -3.302734375,
            "end_logit": 9.3671875,
            "text": "peak caller PeakXus",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": -6.08203125,
            "end_logit": 9.3671875,
            "text": "Xus",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.40234375,
            "end_logit": 9.3671875,
            "text": "describe a peak caller PeakXus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.32421875,
            "text": "PeakXus that is specifically designed",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.3671875,
            "text": "PeakXus that",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.41015625,
            "text": "PeakXus that is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.302734375,
            "end_logit": -1.6455078125,
            "text": "peak caller Peak",
            "probability": 0.0
        },
        {
            "start_logit": -1.2265625,
            "end_logit": -7.32421875,
            "text": "us that is specifically designed",
            "probability": 0.0
        },
        {
            "start_logit": -1.2265625,
            "end_logit": -7.3671875,
            "text": "us that",
            "probability": 0.0
        },
        {
            "start_logit": -1.2265625,
            "end_logit": -7.41015625,
            "text": "us that is",
            "probability": 0.0
        },
        {
            "start_logit": -7.40234375,
            "end_logit": -1.6455078125,
            "text": "describe a peak caller Peak",
            "probability": 0.0
        },
        {
            "start_logit": -3.302734375,
            "end_logit": -5.8984375,
            "text": "peak caller",
            "probability": 0.0
        },
        {
            "start_logit": -3.302734375,
            "end_logit": -6.88671875,
            "text": "peak call",
            "probability": 0.0
        },
        {
            "start_logit": -3.302734375,
            "end_logit": -7.32421875,
            "text": "peak caller PeakXus that is specifically designed",
            "probability": 0.0
        },
        {
            "start_logit": -3.302734375,
            "end_logit": -7.3671875,
            "text": "peak caller PeakXus that",
            "probability": 0.0
        },
        {
            "start_logit": -3.302734375,
            "end_logit": -7.41015625,
            "text": "peak caller PeakXus that is",
            "probability": 0.0
        },
        {
            "start_logit": -7.40234375,
            "end_logit": -5.8984375,
            "text": "describe a peak caller",
            "probability": 0.0
        }
    ],
    "5883bce3e56acf5176000003_3": [
        {
            "start_logit": 9.1171875,
            "end_logit": 8.921875,
            "text": "Q-nexus",
            "probability": 1.0
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -1.564453125,
            "text": "Q",
            "probability": 2.8192996978759766e-05
        },
        {
            "start_logit": -2.244140625,
            "end_logit": 8.921875,
            "text": "us",
            "probability": 1.1742115020751953e-05
        },
        {
            "start_logit": -6.140625,
            "end_logit": 8.921875,
            "text": "-nexus",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.77734375,
            "text": "Q-nexus: a comprehensive and efficient analysis pipeline",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.85546875,
            "text": "Q-nexus: a comprehensive and efficient analysis pipeline designed for ChIP-nexus.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.6875,
            "end_logit": 8.921875,
            "text": "nexus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.97265625,
            "text": "Q-nexus:",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.93359375,
            "end_logit": 8.921875,
            "text": "xus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.1796875,
            "text": "Q-nexus: a comprehensive and efficient analysis pipeline designed",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.18359375,
            "text": "Q-nexus: a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.42578125,
            "text": "Q-nex",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.46484375,
            "text": "Q-nexus: a comprehensive and efficient analysis pipeline designed for",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.52734375,
            "text": "Q-nexus: a comprehensive and efficient analysis pipeline designed for ChIP-ne",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.244140625,
            "end_logit": -6.77734375,
            "text": "us: a comprehensive and efficient analysis pipeline",
            "probability": 0.0
        },
        {
            "start_logit": -2.244140625,
            "end_logit": -6.85546875,
            "text": "us: a comprehensive and efficient analysis pipeline designed for ChIP-nexus.",
            "probability": 0.0
        },
        {
            "start_logit": -2.244140625,
            "end_logit": -6.97265625,
            "text": "us:",
            "probability": 0.0
        },
        {
            "start_logit": -2.244140625,
            "end_logit": -7.1796875,
            "text": "us: a comprehensive and efficient analysis pipeline designed",
            "probability": 0.0
        },
        {
            "start_logit": -2.244140625,
            "end_logit": -7.18359375,
            "text": "us: a",
            "probability": 0.0
        },
        {
            "start_logit": -2.244140625,
            "end_logit": -7.46484375,
            "text": "us: a comprehensive and efficient analysis pipeline designed for",
            "probability": 0.0
        }
    ],
    "5883bce3e56acf5176000003_4": [
        {
            "start_logit": 9.1171875,
            "end_logit": 8.921875,
            "text": "Q-nexus",
            "probability": 1.0
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -1.564453125,
            "text": "Q",
            "probability": 2.8192996978759766e-05
        },
        {
            "start_logit": -2.244140625,
            "end_logit": 8.921875,
            "text": "us",
            "probability": 1.1742115020751953e-05
        },
        {
            "start_logit": -6.140625,
            "end_logit": 8.921875,
            "text": "-nexus",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.77734375,
            "text": "Q-nexus: a comprehensive and efficient analysis pipeline",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.85546875,
            "text": "Q-nexus: a comprehensive and efficient analysis pipeline designed for ChIP-nexus.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.6875,
            "end_logit": 8.921875,
            "text": "nexus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.97265625,
            "text": "Q-nexus:",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.93359375,
            "end_logit": 8.921875,
            "text": "xus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.1796875,
            "text": "Q-nexus: a comprehensive and efficient analysis pipeline designed",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.18359375,
            "text": "Q-nexus: a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.42578125,
            "text": "Q-nex",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.46484375,
            "text": "Q-nexus: a comprehensive and efficient analysis pipeline designed for",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.52734375,
            "text": "Q-nexus: a comprehensive and efficient analysis pipeline designed for ChIP-ne",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.244140625,
            "end_logit": -6.77734375,
            "text": "us: a comprehensive and efficient analysis pipeline",
            "probability": 0.0
        },
        {
            "start_logit": -2.244140625,
            "end_logit": -6.85546875,
            "text": "us: a comprehensive and efficient analysis pipeline designed for ChIP-nexus.",
            "probability": 0.0
        },
        {
            "start_logit": -2.244140625,
            "end_logit": -6.97265625,
            "text": "us:",
            "probability": 0.0
        },
        {
            "start_logit": -2.244140625,
            "end_logit": -7.1796875,
            "text": "us: a comprehensive and efficient analysis pipeline designed",
            "probability": 0.0
        },
        {
            "start_logit": -2.244140625,
            "end_logit": -7.18359375,
            "text": "us: a",
            "probability": 0.0
        },
        {
            "start_logit": -2.244140625,
            "end_logit": -7.46484375,
            "text": "us: a comprehensive and efficient analysis pipeline designed for",
            "probability": 0.0
        }
    ],
    "5883bce3e56acf5176000003_5": [
        {
            "start_logit": 9.125,
            "end_logit": 9.359375,
            "text": "PeakXus",
            "probability": 1.0
        },
        {
            "start_logit": -1.267578125,
            "end_logit": 9.359375,
            "text": "us",
            "probability": 3.069639205932617e-05
        },
        {
            "start_logit": 9.125,
            "end_logit": -1.5869140625,
            "text": "Peak",
            "probability": 1.7642974853515625e-05
        },
        {
            "start_logit": -6.140625,
            "end_logit": 9.359375,
            "text": "Xus",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.26953125,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nexus and ChIP-Exo experiments.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.2890625,
            "text": "PeakXus: comprehensive transcription factor binding site discovery",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.42578125,
            "text": "PeakXus: comprehensive transcription factor binding site",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.4375,
            "text": "PeakXus: comprehensive transcription factor binding",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.46875,
            "text": "PeakXus: comprehensive transcription factor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.48046875,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nexus and ChIP-Exo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.5078125,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nexus and ChIP-Exo experiments",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.53515625,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nexus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.546875,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nexus and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.56640625,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.56640625,
            "text": "PeakXus:",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.578125,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Ne",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.58984375,
            "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nex",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.267578125,
            "end_logit": -7.26953125,
            "text": "us: comprehensive transcription factor binding site discovery from ChIP-Nexus and ChIP-Exo experiments.",
            "probability": 0.0
        },
        {
            "start_logit": -1.267578125,
            "end_logit": -7.2890625,
            "text": "us: comprehensive transcription factor binding site discovery",
            "probability": 0.0
        },
        {
            "start_logit": -1.267578125,
            "end_logit": -7.42578125,
            "text": "us: comprehensive transcription factor binding site",
            "probability": 0.0
        }
    ],
    "58da14178acda34529000011_1": [
        {
            "start_logit": 7.6171875,
            "end_logit": 8.0078125,
            "text": "13",
            "probability": 1.0
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -6.79296875,
            "text": "13;22",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -6.88671875,
            "text": "13;22) Robertsonian translocation carrier by FISH: a comparison of locus-specific probe and whole chromosome painting",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.4375,
            "end_logit": 8.0078125,
            "text": "(13",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -7.05859375,
            "text": "13;22) Robertsonian translocation carrier by FISH: a comparison of locus-specific probe and whole chromosome pain",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -7.1328125,
            "text": "13;",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -7.15625,
            "text": "13;22) Robertsonian translocation carrier by FISH: a comparison of locus-specific probe and whole chromosome painting.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 8.0078125,
            "text": "a (13",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -7.2578125,
            "text": "13;22) Robertsonian translocation carrier by FISH",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 8.0078125,
            "text": "Sperm segregation analysis of a (13",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -7.28125,
            "text": "13;22) Robertsonian translocation carrier by FISH: a comparison of locus-specific probe and whole chromosome",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -7.3671875,
            "text": "13;22) Robertsonian translocation carrier by FISH: a",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -7.43359375,
            "text": "13;22) Robertsonian translocation carrier by FISH: a comparison of locus-specific probe and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -7.47265625,
            "text": "13;22) Robertsonian translocation carrier by FISH: a comparison of locus-specific probe",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -7.5078125,
            "text": "13;22) Robertsonian translocation",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -7.51171875,
            "text": "13;22) Robertsonian translocation carrier by FISH: a comparison of locus-specific",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -7.5234375,
            "text": "13;22) Robertsonian translocation carrier",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.1015625,
            "end_logit": -6.88671875,
            "text": "comparison of locus-specific probe and whole chromosome painting",
            "probability": 0.0
        },
        {
            "start_logit": -6.9765625,
            "end_logit": -7.15625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.1015625,
            "end_logit": -7.05859375,
            "text": "comparison of locus-specific probe and whole chromosome pain",
            "probability": 0.0
        }
    ],
    "58da14178acda34529000011_2": [
        {
            "start_logit": 7.8828125,
            "end_logit": 7.70703125,
            "text": "13",
            "probability": 1.0
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.1640625,
            "text": "13;",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.17578125,
            "text": "13;22) Robertsonian translocation constitutes a rare form of rearrangement between acrocentric human chromosomes.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.2109375,
            "text": "13;22",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.1171875,
            "end_logit": 7.70703125,
            "text": "t(13",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.3515625,
            "text": "13;22) Robertsonian translocation constitutes",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.44140625,
            "text": "13;22) Robertsonian translocation constitutes a rare form of rearrangement between acrocentric human chromosomes. Most of the meiotic segregation studies",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 7.70703125,
            "text": "The t(13",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.94140625,
            "end_logit": -5.0625,
            "text": ". Most of the meiotic segregation studies of human Robertsonian translocations have been performed on common t(13;14",
            "probability": 0.0
        },
        {
            "start_logit": -6.94140625,
            "end_logit": -5.12109375,
            "text": ". Most of the meiotic segregation studies of human Robertsonian translocations have been performed on common t(13",
            "probability": 0.0
        },
        {
            "start_logit": -7.4140625,
            "end_logit": -5.0625,
            "text": "common t(13;14",
            "probability": 0.0
        },
        {
            "start_logit": -7.421875,
            "end_logit": -5.0625,
            "text": "14",
            "probability": 0.0
        },
        {
            "start_logit": -7.4140625,
            "end_logit": -5.12109375,
            "text": "common t(13",
            "probability": 0.0
        },
        {
            "start_logit": -7.5,
            "end_logit": -5.0625,
            "text": "t(13;14",
            "probability": 0.0
        },
        {
            "start_logit": -7.5078125,
            "end_logit": -5.0625,
            "text": "on common t(13;14",
            "probability": 0.0
        },
        {
            "start_logit": -7.5,
            "end_logit": -5.12109375,
            "text": "t(13",
            "probability": 0.0
        },
        {
            "start_logit": -7.5078125,
            "end_logit": -5.12109375,
            "text": "on common t(13",
            "probability": 0.0
        },
        {
            "start_logit": -7.58984375,
            "end_logit": -5.0625,
            "text": "meiotic segregation studies of human Robertsonian translocations have been performed on common t(13;14",
            "probability": 0.0
        },
        {
            "start_logit": -7.6015625,
            "end_logit": -5.0625,
            "text": "human Robertsonian translocations have been performed on common t(13;14",
            "probability": 0.0
        },
        {
            "start_logit": -7.6015625,
            "end_logit": -5.0625,
            "text": "human chromosomes. Most of the meiotic segregation studies of human Robertsonian translocations have been performed on common t(13;14",
            "probability": 0.0
        }
    ],
    "58da14178acda34529000011_3": [
        {
            "start_logit": 2.396484375,
            "end_logit": 4.33203125,
            "text": "chromosomes 13-15",
            "probability": 0.9892578125
        },
        {
            "start_logit": -2.517578125,
            "end_logit": 4.33203125,
            "text": "13-15",
            "probability": 0.007266998291015625
        },
        {
            "start_logit": 2.396484375,
            "end_logit": -1.8369140625,
            "text": "chromosomes 13-15, 21",
            "probability": 0.0020732879638671875
        },
        {
            "start_logit": -4.609375,
            "end_logit": 4.33203125,
            "text": "15",
            "probability": 0.0008988380432128906
        },
        {
            "start_logit": 2.396484375,
            "end_logit": -4.2109375,
            "text": "chromosomes 13-15, 21, and 22",
            "probability": 0.00019359588623046875
        },
        {
            "start_logit": -6.4140625,
            "end_logit": 4.33203125,
            "text": ". ROBs are whole-arm rearrangements between the acrocentric chromosomes 13-15",
            "probability": 0.00014734268188476562
        },
        {
            "start_logit": -6.875,
            "end_logit": 4.33203125,
            "text": "rearrangements between the acrocentric chromosomes 13-15",
            "probability": 9.357929229736328e-05
        },
        {
            "start_logit": 2.396484375,
            "end_logit": -5.03515625,
            "text": "chromosomes 13-15, 21, and 22. ROBs can be classified into two groups depending on their frequency of occurrence, common (rob(13",
            "probability": 8.45789909362793e-05
        },
        {
            "start_logit": -7.02734375,
            "end_logit": 4.33203125,
            "text": "whole-arm rearrangements between the acrocentric chromosomes 13-15",
            "probability": 8.0108642578125e-05
        },
        {
            "start_logit": 2.396484375,
            "end_logit": -5.6328125,
            "text": "chromosomes 13",
            "probability": 4.673004150390625e-05
        },
        {
            "start_logit": 2.396484375,
            "end_logit": -6.24609375,
            "text": "chromosomes 13-15, 21, and 22.",
            "probability": 2.5153160095214844e-05
        },
        {
            "start_logit": -2.18359375,
            "end_logit": -1.8369140625,
            "text": "21",
            "probability": 2.1219253540039062e-05
        },
        {
            "start_logit": 2.396484375,
            "end_logit": -6.6640625,
            "text": "chromosomes 13-15, 21, and 22. ROBs can be classified into two groups depending on their frequency of occurrence, common (rob",
            "probability": 1.6629695892333984e-05
        },
        {
            "start_logit": -2.517578125,
            "end_logit": -1.8369140625,
            "text": "13-15, 21",
            "probability": 1.52587890625e-05
        },
        {
            "start_logit": -2.18359375,
            "end_logit": -4.2109375,
            "text": "21, and 22",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -4.609375,
            "end_logit": -1.8369140625,
            "text": "15, 21",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -2.517578125,
            "end_logit": -4.2109375,
            "text": "13-15, 21, and 22",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -2.18359375,
            "end_logit": -5.03515625,
            "text": "21, and 22. ROBs can be classified into two groups depending on their frequency of occurrence, common (rob(13",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -2.517578125,
            "end_logit": -5.03515625,
            "text": "13-15, 21, and 22. ROBs can be classified into two groups depending on their frequency of occurrence, common (rob(13",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -5.84375,
            "end_logit": -1.8369140625,
            "text": ", 21",
            "probability": 5.364418029785156e-07
        }
    ],
    "58da14178acda34529000011_4": [
        {
            "start_logit": 7.1640625,
            "end_logit": 8.4140625,
            "text": "chromosomes 13",
            "probability": 0.7373046875
        },
        {
            "start_logit": 6.13671875,
            "end_logit": 8.4140625,
            "text": "13",
            "probability": 0.2626953125
        },
        {
            "start_logit": 7.1640625,
            "end_logit": -4.1875,
            "text": "chromosomes",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": 7.1640625,
            "end_logit": -4.27734375,
            "text": "chromosomes 13, 14, and 21",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": 7.1640625,
            "end_logit": -4.64453125,
            "text": "chromosomes 13, 14",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 6.13671875,
            "end_logit": -4.27734375,
            "text": "13, 14, and 21",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.60546875,
            "end_logit": 8.4140625,
            "text": ". Previous studies have shown that the breakpoints are consistently located within specific regions of the proximal short arms of chromosomes 13",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 6.13671875,
            "end_logit": -4.64453125,
            "text": "13, 14",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.359375,
            "end_logit": 8.4140625,
            "text": "breakpoints are consistently located within specific regions of the proximal short arms of chromosomes 13",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.37890625,
            "end_logit": 8.4140625,
            "text": "of chromosomes 13",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.4375,
            "end_logit": 8.4140625,
            "text": "that the breakpoints are consistently located within specific regions of the proximal short arms of chromosomes 13",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.1640625,
            "end_logit": -6.8125,
            "text": "chromosomes 13, 14, and 21.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.13671875,
            "end_logit": -6.8125,
            "text": "13, 14, and 21.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.453125,
            "end_logit": -5.71875,
            "text": "Rob(14q21q",
            "probability": 0.0
        },
        {
            "start_logit": -4.453125,
            "end_logit": -5.83984375,
            "text": "Rob(14",
            "probability": 0.0
        },
        {
            "start_logit": -4.453125,
            "end_logit": -5.921875,
            "text": "Rob(14q21q) and rob(13",
            "probability": 0.0
        },
        {
            "start_logit": -6.109375,
            "end_logit": -4.27734375,
            "text": "21",
            "probability": 0.0
        },
        {
            "start_logit": -6.60546875,
            "end_logit": -4.1875,
            "text": ". Previous studies have shown that the breakpoints are consistently located within specific regions of the proximal short arms of chromosomes",
            "probability": 0.0
        },
        {
            "start_logit": -6.6015625,
            "end_logit": -4.27734375,
            "text": "14, and 21",
            "probability": 0.0
        },
        {
            "start_logit": -6.60546875,
            "end_logit": -4.27734375,
            "text": ". Previous studies have shown that the breakpoints are consistently located within specific regions of the proximal short arms of chromosomes 13, 14, and 21",
            "probability": 0.0
        }
    ],
    "58da14178acda34529000011_5": [
        {
            "start_logit": 7.3984375,
            "end_logit": 8.0234375,
            "text": "22",
            "probability": 1.0
        },
        {
            "start_logit": -3.859375,
            "end_logit": 8.0234375,
            "text": "Chromosome 22",
            "probability": 1.2934207916259766e-05
        },
        {
            "start_logit": 7.3984375,
            "end_logit": -7.0859375,
            "text": "22, most probably, is the only chromosome where chAB4 is found in the direct neighbourhood of the centromere.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.3984375,
            "end_logit": -7.53515625,
            "text": "22, most probably, is the only chromosome where chAB4 is",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.3984375,
            "end_logit": -7.58203125,
            "text": "22, most probably, is the only chromosome where chAB4",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.3984375,
            "end_logit": -7.6015625,
            "text": "22, most probably, is the only chromosome where chAB4 is found in the direct neighbourhood of the centromere. Fluorescence in situ hybridization analyses",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -3.859375,
            "end_logit": -7.0859375,
            "text": "Chromosome 22, most probably, is the only chromosome where chAB4 is found in the direct neighbourhood of the centromere.",
            "probability": 0.0
        },
        {
            "start_logit": -3.859375,
            "end_logit": -7.53515625,
            "text": "Chromosome 22, most probably, is the only chromosome where chAB4 is",
            "probability": 0.0
        },
        {
            "start_logit": -3.859375,
            "end_logit": -7.58203125,
            "text": "Chromosome 22, most probably, is the only chromosome where chAB4",
            "probability": 0.0
        },
        {
            "start_logit": -3.859375,
            "end_logit": -7.6015625,
            "text": "Chromosome 22, most probably, is the only chromosome where chAB4 is found in the direct neighbourhood of the centromere. Fluorescence in situ hybridization analyses",
            "probability": 0.0
        },
        {
            "start_logit": -6.6953125,
            "end_logit": -7.01171875,
            "text": ". Fluorescence in situ hybridization analyses of metaphase chromosomes of carriers of rob(21q22",
            "probability": 0.0
        },
        {
            "start_logit": -6.69140625,
            "end_logit": -7.08203125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.6953125,
            "end_logit": -7.0859375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.6953125,
            "end_logit": -7.3046875,
            "text": ". Fluorescence in situ hybridization analyses of metaphase chromosomes of carriers of rob",
            "probability": 0.0
        },
        {
            "start_logit": -6.6953125,
            "end_logit": -7.33984375,
            "text": ". Fluorescence in situ hybridization analyses of metaphase chromosomes of carriers of rob(21q22q",
            "probability": 0.0
        },
        {
            "start_logit": -6.6953125,
            "end_logit": -7.3828125,
            "text": ". Fluorescence in situ hybridization analyses of metaphase chromosomes of carriers of rob(21",
            "probability": 0.0
        },
        {
            "start_logit": -6.6953125,
            "end_logit": -7.48828125,
            "text": ". Fluorescence in situ hybridization analyses of metaphase chromosomes of carriers of rob(21q22q) revealed breakpoint diversity for this",
            "probability": 0.0
        },
        {
            "start_logit": -6.6953125,
            "end_logit": -7.515625,
            "text": ". Fluorescence in situ hybridization analyses of metaphase chromosomes of carriers of rob(21q22q) revealed",
            "probability": 0.0
        },
        {
            "start_logit": -6.6953125,
            "end_logit": -7.54296875,
            "text": ". Fluorescence in situ hybridization analyses of metaphase chromosomes of carriers of rob(21q22q) revealed breakpoint diversity for",
            "probability": 0.0
        },
        {
            "start_logit": -6.6953125,
            "end_logit": -7.54296875,
            "text": ". Fluorescence in situ hybridization analyses of metaphase chromosomes of carriers of rob(21q",
            "probability": 0.0
        }
    ],
    "58da14178acda34529000011_6": [
        {
            "start_logit": 7.5859375,
            "end_logit": 7.76953125,
            "text": "13",
            "probability": 0.91748046875
        },
        {
            "start_logit": 7.5859375,
            "end_logit": 5.2890625,
            "text": "13, 14",
            "probability": 0.07647705078125
        },
        {
            "start_logit": 4.91015625,
            "end_logit": 5.2890625,
            "text": "14",
            "probability": 0.00528717041015625
        },
        {
            "start_logit": -0.634765625,
            "end_logit": 7.76953125,
            "text": "chromosomes 13",
            "probability": 0.0002455711364746094
        },
        {
            "start_logit": -0.634765625,
            "end_logit": 5.2890625,
            "text": "chromosomes 13, 14",
            "probability": 2.0623207092285156e-05
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -6.1328125,
            "text": "13, 14 and 21",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 7.76953125,
            "text": "on chromosomes 13",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -7.1015625,
            "text": "13, 14 and 21. The presence of this alpha subfamily may",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.32421875,
            "end_logit": 7.76953125,
            "text": "process is suggested for the evolution of an alpha satellite subfamily recently found on chromosomes 13",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -7.15625,
            "text": "13, 14 and 21.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -4.9453125,
            "end_logit": 5.2890625,
            "text": ", 14",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -7.29296875,
            "text": "13, 14 and 21. The presence of this alpha subfamily may allow pairing between these chromosomes leading to the observed non-random",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -7.3046875,
            "text": "13, 14 and 21. The presence of this alpha subfamily may allow",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -7.31640625,
            "text": "13, 14 and 21. The presence of this alpha subfamily may allow pairing between these chromosomes leading to the observed non-random participation of these chromosomes",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 7.76953125,
            "text": "alpha satellite subfamily recently found on chromosomes 13",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -7.33984375,
            "text": "13, 14 and 21. The presence of this alpha subfamily may allow pairing between these chromosomes leading",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 7.76953125,
            "text": "for the evolution of an alpha satellite subfamily recently found on chromosomes 13",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -7.41796875,
            "text": "13, 14 and 21. The presence of this alpha subfamily may allow pairing between these chromosomes leading to",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 4.91015625,
            "end_logit": -6.1328125,
            "text": "14 and 21",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 5.2890625,
            "text": "on chromosomes 13, 14",
            "probability": 5.960464477539063e-08
        }
    ],
    "58da14178acda34529000011_7": [
        {
            "start_logit": 6.82421875,
            "end_logit": 7.6875,
            "text": "13",
            "probability": 1.0
        },
        {
            "start_logit": 6.82421875,
            "end_logit": -4.2109375,
            "text": "13/14",
            "probability": 6.735324859619141e-06
        },
        {
            "start_logit": -5.37109375,
            "end_logit": 7.6875,
            "text": "and a 13",
            "probability": 5.0067901611328125e-06
        },
        {
            "start_logit": -5.7421875,
            "end_logit": 7.6875,
            "text": "15/21 and a 13",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": -6.76171875,
            "end_logit": 7.6875,
            "text": "a 13",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -6.91015625,
            "end_logit": 7.6875,
            "text": "and five carriers of a 15/21 and a 13",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -7.0625,
            "end_logit": 7.6875,
            "text": "a 15/21 and a 13",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -7.109375,
            "end_logit": 7.6875,
            "text": "in ten and five carriers of a 15/21 and a 13",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -7.125,
            "end_logit": 7.6875,
            "text": "carriers of a 15/21 and a 13",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -7.140625,
            "end_logit": 7.6875,
            "text": "association of acrocentric chromosomes was examined in ten and five carriers of a 15/21 and a 13",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 7.6875,
            "text": "pattern of association of acrocentric chromosomes was examined in ten and five carriers of a 15/21 and a 13",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 6.82421875,
            "end_logit": -6.66796875,
            "text": "13/14 Robertsonian translocation, respectively, and was compared with that of the same numbers of relatives with normal karyotypes.",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 6.82421875,
            "end_logit": -6.8203125,
            "text": "13/",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 6.82421875,
            "end_logit": -7.0390625,
            "text": "13/14 Robertsonian translocation, respectively, and was compared with that of the same numbers of relatives with normal karyotypes",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 6.82421875,
            "end_logit": -7.22265625,
            "text": "13/14 Robertsonian translocation, respectively, and was compared",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 6.82421875,
            "end_logit": -7.328125,
            "text": "13/14 Robertsonian translocation",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 6.82421875,
            "end_logit": -7.47265625,
            "text": "13/14 Robertsonia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.7421875,
            "end_logit": -2.294921875,
            "text": "15",
            "probability": 0.0
        },
        {
            "start_logit": -6.91015625,
            "end_logit": -2.294921875,
            "text": "and five carriers of a 15",
            "probability": 0.0
        },
        {
            "start_logit": -7.0625,
            "end_logit": -2.294921875,
            "text": "a 15",
            "probability": 0.0
        }
    ],
    "58da14178acda34529000011_8": [
        {
            "start_logit": 7.67578125,
            "end_logit": 7.7734375,
            "text": "13",
            "probability": 1.0
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -4.13671875,
            "text": "13, 14",
            "probability": 6.67572021484375e-06
        },
        {
            "start_logit": -5.1640625,
            "end_logit": 7.7734375,
            "text": "chromosomes 13",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": -6.48828125,
            "end_logit": 7.7734375,
            "text": "alpha satellite sequences on human acrocentric chromosomes with selectivity for chromosomes 13",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -6.8671875,
            "text": "13, 14 and 21",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.10546875,
            "text": "13, 14 and 21: implications for recombination between nonhomologues and Robertsonian translocations.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.421875,
            "end_logit": 7.7734375,
            "text": "Homologous alpha satellite sequences on human acrocentric chromosomes with selectivity for chromosomes 13",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 7.7734375,
            "text": "for chromosomes 13",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 7.7734375,
            "text": "with selectivity for chromosomes 13",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.56640625,
            "text": "13, 14 and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.5703125,
            "text": "13, 14 and 21: implications for recombination between nonhomologues and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.5703125,
            "text": "13, 14 and 21: implications for recombination between nonhomologues and Robertsonian translocations",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.59375,
            "text": "13, 14 and 21: implications for recombination between nonhomologues and Robertsonia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.60546875,
            "text": "13, 14 and 21: implications for recombination between",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.64453125,
            "text": "13, 14 and 21: implications for recombination between nonhomologue",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.67578125,
            "text": "13, 14 and 21: implications for recombination between nonhomologues and Roberts",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.1640625,
            "end_logit": -4.13671875,
            "text": "chromosomes 13, 14",
            "probability": 0.0
        },
        {
            "start_logit": -5.58203125,
            "end_logit": -4.13671875,
            "text": "14",
            "probability": 0.0
        },
        {
            "start_logit": -6.48828125,
            "end_logit": -4.13671875,
            "text": "alpha satellite sequences on human acrocentric chromosomes with selectivity for chromosomes 13, 14",
            "probability": 0.0
        },
        {
            "start_logit": -6.49609375,
            "end_logit": -4.13671875,
            "text": ", 14",
            "probability": 0.0
        }
    ],
    "58da14178acda34529000011_9": [
        {
            "start_logit": 4.63671875,
            "end_logit": 8.515625,
            "text": "13",
            "probability": 1.0
        },
        {
            "start_logit": -3.96875,
            "end_logit": 8.515625,
            "text": "trisomy 13",
            "probability": 0.0001823902130126953
        },
        {
            "start_logit": -7.421875,
            "end_logit": 8.515625,
            "text": "duplications, two reciprocal translocations, two inversions, two additions, one Robertsonian translocation associating trisomy 13",
            "probability": 5.781650543212891e-06
        },
        {
            "start_logit": -7.43359375,
            "end_logit": 8.515625,
            "text": "additions, one Robertsonian translocation associating trisomy 13",
            "probability": 5.662441253662109e-06
        },
        {
            "start_logit": -7.484375,
            "end_logit": 8.515625,
            "text": ", one Robertsonian translocation associating trisomy 13",
            "probability": 5.424022674560547e-06
        },
        {
            "start_logit": 4.63671875,
            "end_logit": -7.4375,
            "text": "13, one 9q heteromorphism and one complex chromosome rearrangement",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 4.63671875,
            "end_logit": -7.46484375,
            "text": "13, one 9q heteromorphism and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 4.63671875,
            "end_logit": -7.4765625,
            "text": "13, one 9q heteromorphism and one complex chromosome rearrangement were",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.96875,
            "end_logit": -7.4375,
            "text": "trisomy 13, one 9q heteromorphism and one complex chromosome rearrangement",
            "probability": 0.0
        },
        {
            "start_logit": -3.96875,
            "end_logit": -7.46484375,
            "text": "trisomy 13, one 9q heteromorphism and",
            "probability": 0.0
        },
        {
            "start_logit": -3.96875,
            "end_logit": -7.4765625,
            "text": "trisomy 13, one 9q heteromorphism and one complex chromosome rearrangement were",
            "probability": 0.0
        },
        {
            "start_logit": -7.22265625,
            "end_logit": -7.46875,
            "text": "deletions and microdeletions, four situations with abnormal long \"p\" arm of acrocentric chromosomes",
            "probability": 0.0
        },
        {
            "start_logit": -7.22265625,
            "end_logit": -7.5,
            "text": "deletions and microdeletions, four situations with abnormal long \"p\" arm of acrocentric",
            "probability": 0.0
        },
        {
            "start_logit": -7.22265625,
            "end_logit": -7.5,
            "text": "deletions and microdeletions, four situations with abnormal long \"p\" arm of acrocentric chromosomes, two duplications, two reciprocal translocations,",
            "probability": 0.0
        },
        {
            "start_logit": -7.22265625,
            "end_logit": -7.515625,
            "text": "deletions and",
            "probability": 0.0
        },
        {
            "start_logit": -7.22265625,
            "end_logit": -7.515625,
            "text": "deletions and microdeletions, four situations with abnormal long \"p\" arm of acrocentric chromosomes, two",
            "probability": 0.0
        },
        {
            "start_logit": -7.22265625,
            "end_logit": -7.5234375,
            "text": "deletions and microdeletions, four situations with abnormal long \"p\" arm of acrocentric chromosomes, two duplications, two reciprocal translocations",
            "probability": 0.0
        },
        {
            "start_logit": -7.22265625,
            "end_logit": -7.52734375,
            "text": "deletions and microdeletions, four situations with abnormal long \"p\" arm of acrocentric chromosomes, two duplications, two reciprocal translocations, two",
            "probability": 0.0
        },
        {
            "start_logit": -7.296875,
            "end_logit": -7.46875,
            "text": "structural chromosomal anomalies and polymorphic variants, six deletions and microdeletions, four situations with abnormal long \"p\" arm of acrocentric chromosomes",
            "probability": 0.0
        },
        {
            "start_logit": -7.296875,
            "end_logit": -7.5,
            "text": "structural chromosomal anomalies and polymorphic variants, six deletions and microdeletions, four situations with abnormal long \"p\" arm of acrocentric",
            "probability": 0.0
        }
    ],
    "58da14178acda34529000011_10": [
        {
            "start_logit": 7.1484375,
            "end_logit": 5.75,
            "text": "14q",
            "probability": 0.99609375
        },
        {
            "start_logit": 7.1484375,
            "end_logit": 0.0927734375,
            "text": "14",
            "probability": 0.003482818603515625
        },
        {
            "start_logit": -2.919921875,
            "end_logit": 5.75,
            "text": "chromosomes 14q",
            "probability": 4.214048385620117e-05
        },
        {
            "start_logit": -4.6328125,
            "end_logit": 5.75,
            "text": "q",
            "probability": 7.62939453125e-06
        },
        {
            "start_logit": 7.1484375,
            "end_logit": -6.43359375,
            "text": "14q and 21q in human oogenesis with the use of dual color fluorescent in situ hybridization with whole chromosome paints.",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": 7.1484375,
            "end_logit": -6.57421875,
            "text": "14q and 21q in human oogenesis with the use of dual color fluorescent in situ hybridization with whole chromosome paints.The oocytes",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": 7.1484375,
            "end_logit": -6.578125,
            "text": "14q and 21q in human oogenesis with the use of dual color fluorescent in situ hybridization with whole chromosome paints",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": 7.1484375,
            "end_logit": -6.84375,
            "text": "14q and 21q in human oogenesis",
            "probability": 3.3974647521972656e-06
        },
        {
            "start_logit": 7.1484375,
            "end_logit": -7.01953125,
            "text": "14q and 21q in human oogenesis with the use of dual color fluorescent in situ hybridization with whole chromosome paints.The oocytes from",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": 7.1484375,
            "end_logit": -7.03515625,
            "text": "14q and",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": 7.1484375,
            "end_logit": -7.12109375,
            "text": "14q and 21",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": 7.1484375,
            "end_logit": -7.16015625,
            "text": "14q and 21q in human oogenesis with the use of dual color fluorescent in situ hybridization with whole chromosome pain",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": -6.87890625,
            "end_logit": 5.75,
            "text": "study was to search for cytologic evidence of robertsonian translocation formation that involves chromosomes 14q",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -6.9296875,
            "end_logit": 5.75,
            "text": "involves chromosomes 14q",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -7.0859375,
            "end_logit": 5.75,
            "text": "to search for cytologic evidence of robertsonian translocation formation that involves chromosomes 14q",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -2.919921875,
            "end_logit": 0.0927734375,
            "text": "chromosomes 14",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.87890625,
            "end_logit": 0.0927734375,
            "text": "study was to search for cytologic evidence of robertsonian translocation formation that involves chromosomes 14",
            "probability": 0.0
        },
        {
            "start_logit": -6.9296875,
            "end_logit": 0.0927734375,
            "text": "involves chromosomes 14",
            "probability": 0.0
        },
        {
            "start_logit": -7.0859375,
            "end_logit": 0.0927734375,
            "text": "to search for cytologic evidence of robertsonian translocation formation that involves chromosomes 14",
            "probability": 0.0
        },
        {
            "start_logit": -4.45703125,
            "end_logit": -3.26171875,
            "text": "14",
            "probability": 0.0
        }
    ],
    "58da14178acda34529000011_11": [
        {
            "start_logit": 7.71875,
            "end_logit": 7.91796875,
            "text": "13",
            "probability": 1.0
        },
        {
            "start_logit": -6.4296875,
            "end_logit": 7.91796875,
            "text": "t(13",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 7.71875,
            "end_logit": -6.55078125,
            "text": "13;22",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.71875,
            "end_logit": -6.953125,
            "text": "13;",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.71875,
            "end_logit": -7.390625,
            "text": "13;22) Robertsonian translocation constitutes",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.640625,
            "end_logit": 7.91796875,
            "text": "(13",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 7.91796875,
            "text": "The t(13",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.71875,
            "end_logit": -7.4609375,
            "text": "13;22)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.71875,
            "end_logit": -7.55078125,
            "text": "13;22) Robertsonian translocation",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.71875,
            "end_logit": -7.59765625,
            "text": "13;22) Robertsonian translocation constitutes a",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.71875,
            "end_logit": -7.60546875,
            "text": "13;22) Robertsonian translocation constitutes a rare",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.71875,
            "end_logit": -7.60546875,
            "text": "13;22) Robertsonian translocation constitutes a rare form of rearrangement between",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.71875,
            "end_logit": -7.609375,
            "text": "13;22) Robertsonia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.4296875,
            "end_logit": -6.55078125,
            "text": "t(13;22",
            "probability": 0.0
        },
        {
            "start_logit": -6.4296875,
            "end_logit": -6.953125,
            "text": "t(13;",
            "probability": 0.0
        },
        {
            "start_logit": -6.4296875,
            "end_logit": -7.390625,
            "text": "t(13;22) Robertsonian translocation constitutes",
            "probability": 0.0
        },
        {
            "start_logit": -6.4296875,
            "end_logit": -7.4609375,
            "text": "t(13;22)",
            "probability": 0.0
        },
        {
            "start_logit": -6.4296875,
            "end_logit": -7.55078125,
            "text": "t(13;22) Robertsonian translocation",
            "probability": 0.0
        },
        {
            "start_logit": -6.4296875,
            "end_logit": -7.5859375,
            "text": "t(",
            "probability": 0.0
        },
        {
            "start_logit": -6.4296875,
            "end_logit": -7.59765625,
            "text": "t(13;22) Robertsonian translocation constitutes a",
            "probability": 0.0
        }
    ],
    "58da14178acda34529000011_12": [
        {
            "start_logit": 7.67578125,
            "end_logit": 7.7734375,
            "text": "13",
            "probability": 1.0
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -4.13671875,
            "text": "13, 14",
            "probability": 6.67572021484375e-06
        },
        {
            "start_logit": -5.1640625,
            "end_logit": 7.7734375,
            "text": "chromosomes 13",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": -6.48828125,
            "end_logit": 7.7734375,
            "text": "alpha satellite sequences on human acrocentric chromosomes with selectivity for chromosomes 13",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -6.8671875,
            "text": "13, 14 and 21",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.10546875,
            "text": "13, 14 and 21: implications for recombination between nonhomologues and Robertsonian translocations.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.421875,
            "end_logit": 7.7734375,
            "text": "Homologous alpha satellite sequences on human acrocentric chromosomes with selectivity for chromosomes 13",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 7.7734375,
            "text": "for chromosomes 13",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 7.7734375,
            "text": "with selectivity for chromosomes 13",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.56640625,
            "text": "13, 14 and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.5703125,
            "text": "13, 14 and 21: implications for recombination between nonhomologues and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.5703125,
            "text": "13, 14 and 21: implications for recombination between nonhomologues and Robertsonian translocations",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.59375,
            "text": "13, 14 and 21: implications for recombination between nonhomologues and Robertsonia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.60546875,
            "text": "13, 14 and 21: implications for recombination between",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.64453125,
            "text": "13, 14 and 21: implications for recombination between nonhomologue",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.67578125,
            "text": "13, 14 and 21: implications for recombination between nonhomologues and Roberts",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.1640625,
            "end_logit": -4.13671875,
            "text": "chromosomes 13, 14",
            "probability": 0.0
        },
        {
            "start_logit": -5.58203125,
            "end_logit": -4.13671875,
            "text": "14",
            "probability": 0.0
        },
        {
            "start_logit": -6.48828125,
            "end_logit": -4.13671875,
            "text": "alpha satellite sequences on human acrocentric chromosomes with selectivity for chromosomes 13, 14",
            "probability": 0.0
        },
        {
            "start_logit": -6.49609375,
            "end_logit": -4.13671875,
            "text": ", 14",
            "probability": 0.0
        }
    ],
    "58da14178acda34529000011_13": [
        {
            "start_logit": 7.69921875,
            "end_logit": 7.9296875,
            "text": "13",
            "probability": 1.0
        },
        {
            "start_logit": -6.07421875,
            "end_logit": 7.9296875,
            "text": "t(13",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -6.2890625,
            "text": "13;22",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -6.90625,
            "text": "13;",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -7.30859375,
            "text": "13;22) Robertsonian translocation constitutes a rare form of rearrangement between acrocentric human chromosomes.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -7.34375,
            "text": "13;22) Robertsonian translocation constitutes",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.578125,
            "end_logit": 7.9296875,
            "text": "(13",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 7.9296875,
            "text": "The t(13",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -7.4140625,
            "text": "13;22)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -7.5,
            "text": "13;22) Robertsonian translocation",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -7.546875,
            "text": "13;22) Robertsonian translocation constitutes a rare",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -7.58203125,
            "text": "13;22) Robertsonian translocation constitutes a",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -7.5859375,
            "text": "13;22) Robertsonia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -7.59375,
            "text": "13;22) Robertsonian translocation constitutes a rare form of rearrangement between",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.07421875,
            "end_logit": -6.2890625,
            "text": "t(13;22",
            "probability": 0.0
        },
        {
            "start_logit": -6.07421875,
            "end_logit": -6.90625,
            "text": "t(13;",
            "probability": 0.0
        },
        {
            "start_logit": -6.07421875,
            "end_logit": -7.30859375,
            "text": "t(13;22) Robertsonian translocation constitutes a rare form of rearrangement between acrocentric human chromosomes.",
            "probability": 0.0
        },
        {
            "start_logit": -6.07421875,
            "end_logit": -7.34375,
            "text": "t(13;22) Robertsonian translocation constitutes",
            "probability": 0.0
        },
        {
            "start_logit": -6.07421875,
            "end_logit": -7.4140625,
            "text": "t(13;22)",
            "probability": 0.0
        },
        {
            "start_logit": -6.07421875,
            "end_logit": -7.5,
            "text": "t(13;22) Robertsonian translocation",
            "probability": 0.0
        }
    ],
    "5c6ffdd47c78d69471000058_1": [
        {
            "start_logit": 9.2265625,
            "end_logit": 9.421875,
            "text": "miR-214",
            "probability": 1.0
        },
        {
            "start_logit": -0.9580078125,
            "end_logit": 9.421875,
            "text": "214",
            "probability": 3.737211227416992e-05
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -1.2431640625,
            "text": "miR",
            "probability": 2.3186206817626953e-05
        },
        {
            "start_logit": -5.703125,
            "end_logit": 9.421875,
            "text": "-214",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.39453125,
            "end_logit": 9.421875,
            "text": "review, we discuss the role of miR-214",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.51171875,
            "end_logit": 9.421875,
            "text": "role of miR-214",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.171875,
            "end_logit": 9.421875,
            "text": "discuss the role of miR-214",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37890625,
            "end_logit": 9.421875,
            "text": ", we discuss the role of miR-214",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 9.421875,
            "text": "this review, we discuss the role of miR-214",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.32421875,
            "text": "miR-214 in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.390625,
            "text": "miR-214 in various cardiac disease conditions, including ischaemic heart diseases, cardiac hypertrophy, pulmonary arterial hypertension (PAH), angiogenesis following vascular injury",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.41796875,
            "text": "miR-214 in various cardiac disease conditions, including ischaemic heart diseases",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.421875,
            "text": "miR-214 in various cardiac disease conditions, including ischaemic heart diseases, cardiac hypertrophy, pulmonary arterial hypertension (PAH)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.44921875,
            "text": "miR-214 in various cardiac disease conditions, including ischaemic heart diseases, cardiac hypertrophy, pulmonary arterial hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.53515625,
            "text": "miR-214 in various cardiac disease conditions,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.55078125,
            "text": "miR-214 in various cardiac disease conditions, including ischaemic heart diseases, cardiac hypertrophy, pulmonary arterial hypertension (PAH), angiogenesis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.5625,
            "text": "miR-214 in various cardiac disease conditions, including ischaemic heart diseases, cardiac hypertrophy, pulmonary arterial hypertension (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.578125,
            "text": "miR-214 in various cardiac disease conditions, including ischaemic heart diseases, cardiac hypertrophy, pulmonary arterial hypertension (PAH), angiogenesis following vascular injury and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.59375,
            "text": "miR-214 in various cardiac disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.39453125,
            "end_logit": -1.2431640625,
            "text": "review, we discuss the role of miR",
            "probability": 0.0
        }
    ],
    "5c6ffdd47c78d69471000058_2": [
        {
            "start_logit": 9.3515625,
            "end_logit": 9.3984375,
            "text": "miR-423-5p",
            "probability": 1.0
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -0.9052734375,
            "text": "miR",
            "probability": 3.349781036376953e-05
        },
        {
            "start_logit": -1.046875,
            "end_logit": 9.3984375,
            "text": "5p",
            "probability": 3.045797348022461e-05
        },
        {
            "start_logit": -5.7421875,
            "end_logit": 9.3984375,
            "text": "-423-5p",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.13671875,
            "end_logit": 9.3984375,
            "text": "423-5p",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.234375,
            "end_logit": 9.3984375,
            "text": "3-5p",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.49609375,
            "end_logit": 9.3984375,
            "text": "-5p",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.80859375,
            "end_logit": 9.3984375,
            "text": "levels of c-miRNAs such as miR-423-5p",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.8125,
            "end_logit": 9.3984375,
            "text": "as miR-423-5p",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.984375,
            "end_logit": 9.3984375,
            "text": "serum levels of c-miRNAs such as miR-423-5p",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.00390625,
            "end_logit": 9.3984375,
            "text": "miRNAs such as miR-423-5p",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -7.2421875,
            "text": "miR-423-5p have",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 9.3984375,
            "text": "Likewise, serum levels of c-miRNAs such as miR-423-5p",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -7.3359375,
            "text": "miR-423-5p have been evaluated",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 9.3984375,
            "text": "such as miR-423-5p",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.38671875,
            "end_logit": 9.3984375,
            "text": ", serum levels of c-miRNAs such as miR-423-5p",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -7.48828125,
            "text": "miR-423-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -7.48828125,
            "text": "miR-42",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -7.49609375,
            "text": "miR-423-5p have been",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -7.5078125,
            "text": "miR-423-5p have been evaluated as potential biomarkers",
            "probability": 5.960464477539063e-08
        }
    ],
    "5c6ffdd47c78d69471000058_3": [
        {
            "start_logit": 9.3359375,
            "end_logit": 9.4609375,
            "text": "miR-423-5p",
            "probability": 1.0
        },
        {
            "start_logit": -0.85888671875,
            "end_logit": 9.4609375,
            "text": "5p",
            "probability": 3.737211227416992e-05
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -0.97509765625,
            "text": "miR",
            "probability": 2.9325485229492188e-05
        },
        {
            "start_logit": -5.6484375,
            "end_logit": 9.4609375,
            "text": "-423-5p",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.16015625,
            "end_logit": 9.4609375,
            "text": "423-5p",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.22265625,
            "end_logit": 9.4609375,
            "text": "3-5p",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.4140625,
            "end_logit": 9.4609375,
            "text": "-5p",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.52734375,
            "end_logit": 9.4609375,
            "text": "miRNAs such as miR-423-5p",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.5703125,
            "end_logit": 9.4609375,
            "text": "as miR-423-5p",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.02734375,
            "end_logit": 9.4609375,
            "text": "circulating miRNAs such as miR-423-5p",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.03125,
            "text": "miR-423-5p are",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1796875,
            "end_logit": 9.4609375,
            "text": "Serum levels of circulating miRNAs such as miR-423-5p",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.203125,
            "end_logit": 9.4609375,
            "text": "levels of circulating miRNAs such as miR-423-5p",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.109375,
            "text": "miR-42",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.12890625,
            "text": "miR-423-5p are being evaluated as potential biomarkers in the diagnosis and prognosis of heart failure.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.3203125,
            "text": "miR-423-5p are being evaluated",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.37109375,
            "text": "miR-423-5p are being",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.44140625,
            "text": "miR-423-5p are being evaluated as potential biomarkers",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.4921875,
            "text": "miR-423-5p are being evaluated as potential biomarkers in the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.4921875,
            "text": "miR-423-",
            "probability": 5.960464477539063e-08
        }
    ],
    "5c6ffdd47c78d69471000058_4": [
        {
            "start_logit": 9.390625,
            "end_logit": 9.453125,
            "text": "miR-423-5p",
            "probability": 1.0
        },
        {
            "start_logit": 9.390625,
            "end_logit": -0.8046875,
            "text": "miR",
            "probability": 3.510713577270508e-05
        },
        {
            "start_logit": -0.91064453125,
            "end_logit": 9.453125,
            "text": "5p",
            "probability": 3.349781036376953e-05
        },
        {
            "start_logit": -5.4609375,
            "end_logit": 9.453125,
            "text": "-423-5p",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.9609375,
            "end_logit": 9.453125,
            "text": "423-5p",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.1015625,
            "end_logit": 9.453125,
            "text": "3-5p",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.39453125,
            "end_logit": 9.453125,
            "text": "-5p",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.68359375,
            "end_logit": 9.453125,
            "text": "levels of c-miRNAs such as miR-423-5p",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.72265625,
            "end_logit": 9.453125,
            "text": "as miR-423-5p",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9453125,
            "end_logit": 9.453125,
            "text": "serum levels of c-miRNAs such as miR-423-5p",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.94921875,
            "end_logit": 9.453125,
            "text": "miRNAs such as miR-423-5p",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.1640625,
            "text": "miR-423-5p have been evaluated as potential biomarkers in the diagnosis and prognosis of heart failure.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.25390625,
            "end_logit": 9.453125,
            "text": "Likewise, serum levels of c-miRNAs such as miR-423-5p",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.21484375,
            "text": "miR-423-5p have",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.296875,
            "text": "miR-423-5p have been evaluated",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.40234375,
            "text": "miR-423-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.4375,
            "text": "miR-42",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.46484375,
            "text": "miR-423-5p have been",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.50390625,
            "text": "miR-423",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.50390625,
            "text": "miR-423-5p have been evaluated as potential biomarkers",
            "probability": 5.960464477539063e-08
        }
    ],
    "53137541e3eabad021000010_1": [
        {
            "start_logit": 8.015625,
            "end_logit": 7.59375,
            "text": "OCT4",
            "probability": 1.0
        },
        {
            "start_logit": 8.015625,
            "end_logit": -5.6640625,
            "text": "OCT4, SOX2, MYC, and KLF4",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": 8.015625,
            "end_logit": -6.453125,
            "text": "OCT4, SOX2",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -6.80859375,
            "text": "OCT4, SOX2, MYC, and KL",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -6.890625,
            "text": "OCT4, SOX2, MYC",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -7.40234375,
            "text": "OCT4, SOX2, MYC, and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -7.62890625,
            "text": "OCT4, SOX2, MYC,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.45703125,
            "end_logit": -5.6640625,
            "text": "KLF4",
            "probability": 0.0
        },
        {
            "start_logit": -7.48828125,
            "end_logit": -5.6640625,
            "text": ", MYC, and KLF4",
            "probability": 0.0
        },
        {
            "start_logit": -7.578125,
            "end_logit": -5.6640625,
            "text": ", SOX2, MYC, and KLF4",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": -5.6640625,
            "text": "SOX2, MYC, and KLF4",
            "probability": 0.0
        },
        {
            "start_logit": -7.65625,
            "end_logit": -5.6640625,
            "text": ", and KLF4",
            "probability": 0.0
        },
        {
            "start_logit": -7.578125,
            "end_logit": -6.453125,
            "text": ", SOX2",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": -6.453125,
            "text": "SOX2",
            "probability": 0.0
        },
        {
            "start_logit": -7.45703125,
            "end_logit": -6.80859375,
            "text": "KL",
            "probability": 0.0
        },
        {
            "start_logit": -7.48828125,
            "end_logit": -6.80859375,
            "text": ", MYC, and KL",
            "probability": 0.0
        },
        {
            "start_logit": -7.48828125,
            "end_logit": -6.890625,
            "text": ", MYC",
            "probability": 0.0
        },
        {
            "start_logit": -7.578125,
            "end_logit": -6.80859375,
            "text": ", SOX2, MYC, and KL",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": -6.80859375,
            "text": "SOX2, MYC, and KL",
            "probability": 0.0
        },
        {
            "start_logit": -7.578125,
            "end_logit": -6.890625,
            "text": ", SOX2, MYC",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_2": [
        {
            "start_logit": 8.0703125,
            "end_logit": 7.54296875,
            "text": "Oct4",
            "probability": 1.0
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -5.7890625,
            "text": "Oct4, Sox2",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -6.0625,
            "text": "Oct4, Sox2, Klf4 and c-Myc",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -6.640625,
            "text": "Oct4, Sox2, Klf4",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -7.03125,
            "text": "Oct4, Sox2, Klf4 and c-Myc)",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -7.375,
            "text": "Oct4, Sox2, Kl",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -7.453125,
            "text": "Oct4, Sox2, Klf4 and c",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -7.53515625,
            "text": "Oct4, Sox2, Klf4 and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -7.63671875,
            "text": "Oct4, Sox2, Klf4 and c-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.22265625,
            "end_logit": 7.54296875,
            "text": "(Oct4",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 7.54296875,
            "text": "Yamanaka factors' (Oct4",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 7.54296875,
            "text": "' (Oct4",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 7.54296875,
            "text": "factors' (Oct4",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.22265625,
            "end_logit": -5.7890625,
            "text": "(Oct4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -7.23046875,
            "end_logit": -5.7890625,
            "text": "Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -7.2890625,
            "end_logit": -5.7890625,
            "text": ", Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -7.08984375,
            "end_logit": -6.0625,
            "text": "Klf4 and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -7.22265625,
            "end_logit": -6.0625,
            "text": "(Oct4, Sox2, Klf4 and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -7.23046875,
            "end_logit": -6.0625,
            "text": "Sox2, Klf4 and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -7.2890625,
            "end_logit": -6.0625,
            "text": ", Sox2, Klf4 and c-Myc",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_3": [
        {
            "start_logit": 8.046875,
            "end_logit": 7.5703125,
            "text": "Oct4",
            "probability": 1.0
        },
        {
            "start_logit": 8.046875,
            "end_logit": -6.33984375,
            "text": "Oct4, Sox2",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -6.34375,
            "text": "Oct4, Sox2, Klf4, and c-Myc",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -6.81640625,
            "text": "Oct4, Sox2, Klf4",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.1875,
            "text": "Oct4, Sox2, Klf4, and c-Myc)",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.39453125,
            "text": "Oct4, Sox2, Kl",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.46484375,
            "text": "Oct4, Sox2, Klf4, and c",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.63671875,
            "text": "Oct4, Sox2, Klf4, and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.640625,
            "text": "Oct4, Sox2, Klf4, and c-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.671875,
            "text": "Oct4, Sox2, Klf4,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 7.5703125,
            "text": "(Oct4",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 7.5703125,
            "text": "Yamanaka factors (Oct4",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 7.5703125,
            "text": "factors (Oct4",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.265625,
            "end_logit": -6.34375,
            "text": "Klf4, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -7.3984375,
            "end_logit": -6.33984375,
            "text": "(Oct4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -7.3984375,
            "end_logit": -6.34375,
            "text": "(Oct4, Sox2, Klf4, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -7.40234375,
            "end_logit": -6.33984375,
            "text": "Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -7.40234375,
            "end_logit": -6.34375,
            "text": "Sox2, Klf4, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -7.4296875,
            "end_logit": -6.34375,
            "text": ", Klf4, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -7.48828125,
            "end_logit": -6.33984375,
            "text": ", Sox2",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_4": [
        {
            "start_logit": 5.30078125,
            "end_logit": 3.8515625,
            "text": "c-myc",
            "probability": 0.9892578125
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -0.685546875,
            "text": "c-myc, KLF4",
            "probability": 0.01056671142578125
        },
        {
            "start_logit": 1.34375,
            "end_logit": -0.685546875,
            "text": "KLF4",
            "probability": 0.00020134449005126953
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -5.04296875,
            "text": "c-myc, KLF4, Oct3/4 and SOX2",
            "probability": 0.00013518333435058594
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -5.70703125,
            "text": "c",
            "probability": 6.955862045288086e-05
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -6.7421875,
            "text": "c-myc, KLF4, Oct3/4 and SOX2)",
            "probability": 2.485513687133789e-05
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -7.31640625,
            "text": "c-myc, KLF4, Oct3/4",
            "probability": 1.3887882232666016e-05
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -7.31640625,
            "text": "c-myc, KLF4, Oct3/4 and",
            "probability": 1.3887882232666016e-05
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -7.46484375,
            "text": "c-myc, KLF4, Oct3/",
            "probability": 1.1980533599853516e-05
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -7.4921875,
            "text": "c-myc, KLF4, Oct3",
            "probability": 1.1742115020751953e-05
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -7.51953125,
            "text": "c-myc, KL",
            "probability": 1.138448715209961e-05
        },
        {
            "start_logit": -6.1171875,
            "end_logit": 3.8515625,
            "text": "myc",
            "probability": 1.0848045349121094e-05
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -7.58203125,
            "text": "c-myc, KLF4, Oct",
            "probability": 1.0669231414794922e-05
        },
        {
            "start_logit": -6.6015625,
            "end_logit": 3.8515625,
            "text": "-myc",
            "probability": 6.67572021484375e-06
        },
        {
            "start_logit": -6.9921875,
            "end_logit": 3.8515625,
            "text": "(c-myc",
            "probability": 4.5299530029296875e-06
        },
        {
            "start_logit": 1.34375,
            "end_logit": -5.04296875,
            "text": "KLF4, Oct3/4 and SOX2",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 3.8515625,
            "text": "factors (c-myc",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": -7.703125,
            "end_logit": 3.8515625,
            "text": "Yamanaka factors (c-myc",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": 1.34375,
            "end_logit": -6.7421875,
            "text": "KLF4, Oct3/4 and SOX2)",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 1.34375,
            "end_logit": -7.31640625,
            "text": "KLF4, Oct3/4",
            "probability": 2.980232238769531e-07
        }
    ],
    "53137541e3eabad021000010_5": [
        {
            "start_logit": 8.09375,
            "end_logit": 7.53125,
            "text": "Oct4",
            "probability": 1.0
        },
        {
            "start_logit": 8.09375,
            "end_logit": -5.91796875,
            "text": "Oct4, Sox2",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 8.09375,
            "end_logit": -6.7890625,
            "text": "Oct4, Sox2, Klf4, and c-Myc",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -7.2734375,
            "text": "Oct4, Sox2, Klf4, and c-Myc)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -7.35546875,
            "text": "Oct4, Sox2, Klf4",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -7.5546875,
            "text": "Oct4, Sox2, Klf4, and c",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -7.58203125,
            "text": "Oct4, Sox2, Kl",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -7.65625,
            "text": "Oct4, Sox2, Klf4, and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.09765625,
            "end_logit": 7.53125,
            "text": ", Oct4",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -7.6875,
            "text": "Oct4, Sox2, Klf4, and c-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 7.53125,
            "text": "., Oct4",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 7.53125,
            "text": "Yamanaka factors (i.e., Oct4",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 7.53125,
            "text": "i.e., Oct4",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.640625,
            "end_logit": 7.53125,
            "text": "factors (i.e., Oct4",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.09765625,
            "end_logit": -5.91796875,
            "text": ", Oct4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -7.26171875,
            "end_logit": -5.91796875,
            "text": "., Oct4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -7.421875,
            "end_logit": -5.91796875,
            "text": ", Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -7.42578125,
            "end_logit": -5.91796875,
            "text": "Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -7.61328125,
            "end_logit": -5.91796875,
            "text": "Yamanaka factors (i.e., Oct4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -7.62109375,
            "end_logit": -5.91796875,
            "text": "i.e., Oct4, Sox2",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_6": [
        {
            "start_logit": 8.0859375,
            "end_logit": 7.078125,
            "text": "Sox2",
            "probability": 1.0
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -6.140625,
            "text": "Sox2, Klf4, and c-Myc",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -6.40234375,
            "text": "Sox2, Klf4",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -5.84765625,
            "end_logit": 7.078125,
            "text": ", Sox2",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -7.1640625,
            "text": "Sox2, Kl",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -7.3046875,
            "text": "Sox2, Klf4, and c-Myc)",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -7.50390625,
            "text": "Sox2, Klf4, and c",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -7.6640625,
            "text": "Sox2, Klf4, and",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.765625,
            "end_logit": 7.078125,
            "text": "Oct3/4, Sox2",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.08984375,
            "end_logit": 7.078125,
            "text": "4, Sox2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 7.078125,
            "text": "(Oct3/4, Sox2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 7.078125,
            "text": "factors (Oct3/4, Sox2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 7.078125,
            "text": "Yamanaka factors (Oct3/4, Sox2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.84765625,
            "end_logit": -6.140625,
            "text": ", Sox2, Klf4, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -5.84765625,
            "end_logit": -6.40234375,
            "text": ", Sox2, Klf4",
            "probability": 0.0
        },
        {
            "start_logit": -6.765625,
            "end_logit": -6.140625,
            "text": "Oct3/4, Sox2, Klf4, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -5.84765625,
            "end_logit": -7.1640625,
            "text": ", Sox2, Kl",
            "probability": 0.0
        },
        {
            "start_logit": -6.87890625,
            "end_logit": -6.140625,
            "text": "Klf4, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -5.84765625,
            "end_logit": -7.3046875,
            "text": ", Sox2, Klf4, and c-Myc)",
            "probability": 0.0
        },
        {
            "start_logit": -6.765625,
            "end_logit": -6.40234375,
            "text": "Oct3/4, Sox2, Klf4",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_7": [
        {
            "start_logit": 8.015625,
            "end_logit": 7.59375,
            "text": "OCT4",
            "probability": 1.0
        },
        {
            "start_logit": 8.015625,
            "end_logit": -6.625,
            "text": "OCT4, SOX2, KLF4, cMYC - OSKM",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -6.67578125,
            "text": "OCT4, SOX2",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -6.69140625,
            "text": "OCT4, SOX2, KLF4",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -7.0859375,
            "text": "OCT4, SOX2, KL",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -7.12109375,
            "text": "OCT4, SOX2, KLF4, cMYC - OSK",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -7.30859375,
            "text": "OCT4, SOX2, KLF4, cMYC - OS",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -7.375,
            "text": "OCT4, SOX2, KLF4, cMYC",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -7.42578125,
            "text": "OCT4,",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -7.49609375,
            "text": "OCT4, SOX2, KLF4, cMYC -",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.671875,
            "end_logit": 7.59375,
            "text": "Yamanaka factors (OCT4",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.67578125,
            "end_logit": 7.59375,
            "text": "factors (OCT4",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.515625,
            "end_logit": -6.625,
            "text": "cMYC - OSKM",
            "probability": 0.0
        },
        {
            "start_logit": -7.61328125,
            "end_logit": -6.625,
            "text": ", KLF4, cMYC - OSKM",
            "probability": 0.0
        },
        {
            "start_logit": -7.6328125,
            "end_logit": -6.625,
            "text": ", cMYC - OSKM",
            "probability": 0.0
        },
        {
            "start_logit": -7.65234375,
            "end_logit": -6.625,
            "text": "KLF4, cMYC - OSKM",
            "probability": 0.0
        },
        {
            "start_logit": -7.671875,
            "end_logit": -6.625,
            "text": "Yamanaka factors (OCT4, SOX2, KLF4, cMYC - OSKM",
            "probability": 0.0
        },
        {
            "start_logit": -7.67578125,
            "end_logit": -6.625,
            "text": "factors (OCT4, SOX2, KLF4, cMYC - OSKM",
            "probability": 0.0
        },
        {
            "start_logit": -7.61328125,
            "end_logit": -6.69140625,
            "text": ", KLF4",
            "probability": 0.0
        },
        {
            "start_logit": -7.65234375,
            "end_logit": -6.69140625,
            "text": "KLF4",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_8": [
        {
            "start_logit": 8.046875,
            "end_logit": 7.5703125,
            "text": "Oct4",
            "probability": 1.0
        },
        {
            "start_logit": 8.046875,
            "end_logit": -6.23046875,
            "text": "Oct4, Sox2, Klf4 and cMyc",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 8.046875,
            "end_logit": -6.6640625,
            "text": "Oct4, Sox2",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.09375,
            "text": "Oct4, Sox2, Klf4",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.1015625,
            "text": "Oct4, Sox2, Klf4 and cMyc (4TF",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.17578125,
            "text": "Oct4, Sox2, Klf4 and cMyc (4TF, Yamanaka factors)",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.19921875,
            "text": "Oct4, Sox2, Kl",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.33984375,
            "text": "Oct4, Sox2, Klf4 and cM",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.47265625,
            "text": "Oct4, Sox2, Klf4 and cMyc (",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.4921875,
            "text": "Oct4, Sox2, Klf4 and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.5,
            "text": "Oct4, Sox2, Klf4 and cMyc (4T",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.5703125,
            "text": "Oct4, Sox2, Klf4 and cMyc (4TF, Yamanaka factors",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.60546875,
            "text": "Oct4, Sox2, Klf4 and cMyc (4TF, Yama",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.60546875,
            "text": "Oct4, Sox2, Klf4 and cMyc (4TF, Yamanaka",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.609375,
            "text": "Oct4, Sox2, Klf4 and cMyc (4TF, Yamana",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.609375,
            "text": "Oct4, Sox2, Klf4 and cMyc (4TF,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.62109375,
            "text": "Oct4,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.640625,
            "text": "Oct4, Sox2, Klf4 and cMyc (4",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.48828125,
            "end_logit": -6.23046875,
            "text": "cMyc",
            "probability": 0.0
        },
        {
            "start_logit": -6.48828125,
            "end_logit": -7.1015625,
            "text": "cMyc (4TF",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_9": [
        {
            "start_logit": 4.3125,
            "end_logit": 3.876953125,
            "text": "Myc",
            "probability": 0.998046875
        },
        {
            "start_logit": -2.30859375,
            "end_logit": 3.876953125,
            "text": "Pou5f1, Myc",
            "probability": 0.0013341903686523438
        },
        {
            "start_logit": 4.3125,
            "end_logit": -4.9375,
            "text": "Myc, Klf4, and Sox2",
            "probability": 0.00014865398406982422
        },
        {
            "start_logit": 4.3125,
            "end_logit": -6.11328125,
            "text": "Myc, Klf4",
            "probability": 4.601478576660156e-05
        },
        {
            "start_logit": -6.11328125,
            "end_logit": 3.876953125,
            "text": ", Myc",
            "probability": 2.9742717742919922e-05
        },
        {
            "start_logit": 4.3125,
            "end_logit": -7.01171875,
            "text": "Myc, Klf4, and Sox2)",
            "probability": 1.8596649169921875e-05
        },
        {
            "start_logit": -6.99609375,
            "end_logit": 3.876953125,
            "text": "(Pou5f1, Myc",
            "probability": 1.233816146850586e-05
        },
        {
            "start_logit": -7.0,
            "end_logit": 3.876953125,
            "text": "u5f1, Myc",
            "probability": 1.2218952178955078e-05
        },
        {
            "start_logit": 4.3125,
            "end_logit": -7.4375,
            "text": "Myc, Kl",
            "probability": 1.2218952178955078e-05
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 3.876953125,
            "text": "5f1, Myc",
            "probability": 6.9141387939453125e-06
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 3.876953125,
            "text": "factors (Pou5f1, Myc",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 3.876953125,
            "text": "Yamanaka factors (Pou5f1, Myc",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": -2.30859375,
            "end_logit": -3.98046875,
            "text": "Pou5f1",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -2.30859375,
            "end_logit": -4.9375,
            "text": "Pou5f1, Myc, Klf4, and Sox2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -2.30859375,
            "end_logit": -6.11328125,
            "text": "Pou5f1, Myc, Klf4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.30859375,
            "end_logit": -6.2421875,
            "text": "Pou5",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.30859375,
            "end_logit": -7.01171875,
            "text": "Pou5f1, Myc, Klf4, and Sox2)",
            "probability": 0.0
        },
        {
            "start_logit": -2.30859375,
            "end_logit": -7.40625,
            "text": "Pou",
            "probability": 0.0
        },
        {
            "start_logit": -2.30859375,
            "end_logit": -7.4375,
            "text": "Pou5f1, Myc, Kl",
            "probability": 0.0
        },
        {
            "start_logit": -5.85546875,
            "end_logit": -4.9375,
            "text": "Klf4, and Sox2",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_10": [
        {
            "start_logit": 5.54296875,
            "end_logit": 3.927734375,
            "text": "c-Myc",
            "probability": 0.9990234375
        },
        {
            "start_logit": 5.54296875,
            "end_logit": -3.587890625,
            "text": "c-Myc, Klf4, Oct3/4, and Sox2",
            "probability": 0.0005440711975097656
        },
        {
            "start_logit": 5.54296875,
            "end_logit": -4.33984375,
            "text": "c-Myc, Klf4",
            "probability": 0.0002570152282714844
        },
        {
            "start_logit": 5.54296875,
            "end_logit": -5.69921875,
            "text": "c",
            "probability": 6.598234176635742e-05
        },
        {
            "start_logit": 5.54296875,
            "end_logit": -7.33984375,
            "text": "c-Myc, Klf4,",
            "probability": 1.2814998626708984e-05
        },
        {
            "start_logit": 5.54296875,
            "end_logit": -7.453125,
            "text": "c-Myc, Klf4, Oct3",
            "probability": 1.150369644165039e-05
        },
        {
            "start_logit": 5.54296875,
            "end_logit": -7.4765625,
            "text": "c-Myc, Klf4, Oct3/4, and Sox2 (the so-called \"Yamanaka factors\")",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": 5.54296875,
            "end_logit": -7.484375,
            "text": "c-Myc, Klf4, Oct3/4",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": 5.54296875,
            "end_logit": -7.5,
            "text": "c-Myc, Klf4, Oct3/4, and Sox2 (",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": 5.54296875,
            "end_logit": -7.5390625,
            "text": "c-Myc, Klf4, Oct3/4, and Sox2 (the so-called",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": 5.54296875,
            "end_logit": -7.5390625,
            "text": "c-Myc, Klf4, Oct3/",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": 5.54296875,
            "end_logit": -7.55078125,
            "text": "c-Myc, Klf4, Oct",
            "probability": 1.0371208190917969e-05
        },
        {
            "start_logit": 5.54296875,
            "end_logit": -7.578125,
            "text": "c-Myc, Kl",
            "probability": 1.0132789611816406e-05
        },
        {
            "start_logit": 5.54296875,
            "end_logit": -7.58203125,
            "text": "c-Myc, Klf4, Oct3/4, and Sox2 (the so-called \"Yama",
            "probability": 1.0073184967041016e-05
        },
        {
            "start_logit": -6.4921875,
            "end_logit": 3.927734375,
            "text": "Myc",
            "probability": 5.9604644775390625e-06
        },
        {
            "start_logit": -6.77734375,
            "end_logit": 3.927734375,
            "text": "-Myc",
            "probability": 4.470348358154297e-06
        },
        {
            "start_logit": -3.650390625,
            "end_logit": -3.587890625,
            "text": "Klf4, Oct3/4, and Sox2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.650390625,
            "end_logit": -4.33984375,
            "text": "Klf4",
            "probability": 0.0
        },
        {
            "start_logit": -4.7109375,
            "end_logit": -3.587890625,
            "text": "Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -6.4921875,
            "end_logit": -3.587890625,
            "text": "Myc, Klf4, Oct3/4, and Sox2",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_11": [
        {
            "start_logit": 7.6484375,
            "end_logit": 6.0546875,
            "text": "Sox2",
            "probability": 1.0
        },
        {
            "start_logit": 7.6484375,
            "end_logit": -5.4921875,
            "text": "Sox2, Klf4, and c-Myc",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": 7.6484375,
            "end_logit": -6.09765625,
            "text": "Sox2, Klf4",
            "probability": 5.245208740234375e-06
        },
        {
            "start_logit": -5.0859375,
            "end_logit": 6.0546875,
            "text": ", Sox2",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": 7.6484375,
            "end_logit": -6.953125,
            "text": "Sox2, Kl",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": 7.6484375,
            "end_logit": -7.4375,
            "text": "Sox2, Klf4, and c",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 7.6484375,
            "end_logit": -7.50390625,
            "text": "Sox2, Klf4, and",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 7.6484375,
            "end_logit": -7.50390625,
            "text": "Sox2, Klf4,",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 7.6484375,
            "end_logit": -7.63671875,
            "text": "Sox2, Klf4, and c-",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -6.7421875,
            "end_logit": 6.0546875,
            "text": "Oct3/4, Sox2",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.078125,
            "end_logit": 6.0546875,
            "text": "4, Sox2",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.1328125,
            "end_logit": 6.0546875,
            "text": ", Oct3/4, Sox2",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 6.0546875,
            "text": "factors, Oct3/4, Sox2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 6.0546875,
            "text": "Yamanaka factors, Oct3/4, Sox2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.66796875,
            "end_logit": 6.0546875,
            "text": "naka factors, Oct3/4, Sox2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.0859375,
            "end_logit": -5.4921875,
            "text": ", Sox2, Klf4, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -5.0859375,
            "end_logit": -6.09765625,
            "text": ", Sox2, Klf4",
            "probability": 0.0
        },
        {
            "start_logit": -5.0859375,
            "end_logit": -6.953125,
            "text": ", Sox2, Kl",
            "probability": 0.0
        },
        {
            "start_logit": -6.7421875,
            "end_logit": -5.4921875,
            "text": "Oct3/4, Sox2, Klf4, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -6.74609375,
            "end_logit": -5.4921875,
            "text": "Klf4, and c-Myc",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_12": [
        {
            "start_logit": 7.43359375,
            "end_logit": 8.1875,
            "text": "Sox2",
            "probability": 1.0
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 8.1875,
            "text": "namely Sox2",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 8.1875,
            "text": "Yamanaka factors, namely Sox2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 8.1875,
            "text": "factors, namely Sox2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.43359375,
            "end_logit": -6.9921875,
            "text": "Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.43359375,
            "end_logit": -7.265625,
            "text": "Sox2, Oct3/4 (Pou5f1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.43359375,
            "end_logit": -7.2890625,
            "text": "Sox2, Oct3/4 (Pou5f1), Klf4",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.43359375,
            "end_logit": -7.3046875,
            "text": "Sox2, Oct3/4 (Pou5f1)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.43359375,
            "end_logit": -7.390625,
            "text": "Sox2, Oct3/4",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.43359375,
            "end_logit": -7.4140625,
            "text": "Sox2, Oct3/4 (Pou5",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.43359375,
            "end_logit": -7.50390625,
            "text": "Sox2, Oct3/4 (Pou5f1), Klf4, and c",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.43359375,
            "end_logit": -7.5078125,
            "text": "Sox2, Oct3/4 (Pou5f1), Kl",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.43359375,
            "end_logit": -7.5234375,
            "text": "Sox2, Oct3/4 (Pou5f1), Klf4, and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.43359375,
            "end_logit": -7.5390625,
            "text": "Sox2, Oct3/4 (Pou5f1), Klf4,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.43359375,
            "end_logit": -7.58203125,
            "text": "Sox2, Oct3/4 (Pou",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.43359375,
            "end_logit": -7.6015625,
            "text": "Sox2, Oct3/",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.43359375,
            "end_logit": -7.6015625,
            "text": "Sox2, Oct3",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.43359375,
            "end_logit": -7.63671875,
            "text": "Sox2, Oct3/4 (Pou5f1), Klf4, and c-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.43359375,
            "end_logit": -7.67578125,
            "text": "Sox2, Oct",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.43359375,
            "end_logit": -7.6796875,
            "text": "Sox2, Oct3/4 (Po",
            "probability": 1.1920928955078125e-07
        }
    ],
    "53137541e3eabad021000010_13": [
        {
            "start_logit": 7.98046875,
            "end_logit": 7.65625,
            "text": "Oct4",
            "probability": 1.0
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -6.34765625,
            "text": "Oct4, Sox2",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -6.3515625,
            "text": "Oct4, Sox2, Klf4 and c-Myc",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -7.10546875,
            "text": "Oct4, Sox2, Klf4",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -7.2578125,
            "text": "Oct4, Sox2, Klf4 and c-Myc, also known",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -7.41015625,
            "text": "Oct4, Sox2, Kl",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -7.45703125,
            "text": "Oct4, Sox2, Klf4 and c-Myc, also known as the Yamanaka factors.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -7.47265625,
            "text": "Oct4, Sox2, Klf4 and c",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -7.484375,
            "text": "Oct4, Sox2, Klf4 and c-Myc, also known as",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -7.58203125,
            "text": "Oct4, Sox2, Klf4 and c-Myc,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -7.6015625,
            "text": "Oct4, Sox2, Klf4 and c-Myc, also known as the Yamanaka factors",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -7.60546875,
            "text": "Oct4, Sox2, Klf4 and c-Myc, also known as the",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -7.60546875,
            "text": "Oct4, Sox2, Klf4 and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -7.625,
            "text": "Oct4, Sox2, Klf4 and c-Myc, also",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -7.6328125,
            "text": "Oct4, Sox2, Klf4 and c-Myc, also known as the Yamanaka",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -7.64453125,
            "text": "Oct4, Sox2, Klf4 and c-Myc, also known as the Yama",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.98046875,
            "end_logit": -7.6484375,
            "text": "Oct4, Sox2, Klf4 and c-Myc, also known as the Yamana",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.5,
            "end_logit": -6.34765625,
            "text": ", Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -7.5,
            "end_logit": -6.3515625,
            "text": ", Sox2, Klf4 and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -6.3515625,
            "text": "c-Myc",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_14": [
        {
            "start_logit": 8.0078125,
            "end_logit": 7.62109375,
            "text": "SOX2",
            "probability": 1.0
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -6.35546875,
            "text": "SOX2, OCT3/4, and KLF4",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -6.75,
            "text": "SOX2, OCT3/4, and KLF4, with or without c-MYC",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -6.94921875,
            "text": "SOX2, OCT3/4, and KL",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.32421875,
            "text": "SOX2, OCT3/4, and KLF4, with or without c-MYC)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.34375,
            "text": "SOX2, OCT3/4",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.48828125,
            "text": "SOX2, OCT3/4, and KLF4, with or",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.61328125,
            "text": "SOX2, OCT3/4, and KLF4, with or without c",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.62890625,
            "text": "SOX2, OCT3/4, and KLF4, with or without c-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.63671875,
            "text": "SOX2, OCT3",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.2890625,
            "end_logit": 7.62109375,
            "text": "(SOX2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.6796875,
            "text": "SOX2, OCT3/",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 7.62109375,
            "text": "factors (SOX2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 7.62109375,
            "text": "Yamanaka factors (SOX2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.12109375,
            "end_logit": -6.35546875,
            "text": "KLF4",
            "probability": 0.0
        },
        {
            "start_logit": -7.2890625,
            "end_logit": -6.35546875,
            "text": "(SOX2, OCT3/4, and KLF4",
            "probability": 0.0
        },
        {
            "start_logit": -7.34765625,
            "end_logit": -6.35546875,
            "text": "OCT3/4, and KLF4",
            "probability": 0.0
        },
        {
            "start_logit": -7.38671875,
            "end_logit": -6.35546875,
            "text": ", OCT3/4, and KLF4",
            "probability": 0.0
        },
        {
            "start_logit": -7.3984375,
            "end_logit": -6.35546875,
            "text": "and KLF4",
            "probability": 0.0
        },
        {
            "start_logit": -7.484375,
            "end_logit": -6.35546875,
            "text": ", and KLF4",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_15": [
        {
            "start_logit": 7.73828125,
            "end_logit": 7.8984375,
            "text": "Oct4",
            "probability": 1.0
        },
        {
            "start_logit": 7.73828125,
            "end_logit": -5.70703125,
            "text": "Oct4, Sox2, Klf4, and c-Myc",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 7.73828125,
            "end_logit": -6.48828125,
            "text": "Oct4, Sox2",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.73828125,
            "end_logit": -6.84765625,
            "text": "Oct4, Sox2, Klf4",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.73828125,
            "end_logit": -7.3828125,
            "text": "Oct4, Sox2, Klf4, and c",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 7.8984375,
            "text": "factors Oct4",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.59375,
            "end_logit": 7.8984375,
            "text": "Yamanaka factors Oct4",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.73828125,
            "end_logit": -7.46484375,
            "text": "Oct4, Sox2, Kl",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.73828125,
            "end_logit": -7.50390625,
            "text": "Oct4, Sox2, Klf4, and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.73828125,
            "end_logit": -7.51171875,
            "text": "Oct4, Sox2, Klf4,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.73828125,
            "end_logit": -7.578125,
            "text": "Oct4,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.73828125,
            "end_logit": -7.5859375,
            "text": "Oct4, Sox2, Klf4, and c-",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.38671875,
            "end_logit": -5.70703125,
            "text": "Klf4, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -7.49609375,
            "end_logit": -5.70703125,
            "text": ", Klf4, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": -5.70703125,
            "text": "factors Oct4, Sox2, Klf4, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -7.59375,
            "end_logit": -5.70703125,
            "text": "Yamanaka factors Oct4, Sox2, Klf4, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -7.625,
            "end_logit": -5.70703125,
            "text": "and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -7.6328125,
            "end_logit": -5.70703125,
            "text": ", Sox2, Klf4, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": -6.48828125,
            "text": "factors Oct4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -7.59375,
            "end_logit": -6.48828125,
            "text": "Yamanaka factors Oct4, Sox2",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_16": [
        {
            "start_logit": 7.69921875,
            "end_logit": 5.9921875,
            "text": "Sox2",
            "probability": 1.0
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -5.3125,
            "text": "Sox2, Klf4",
            "probability": 1.239776611328125e-05
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -5.47265625,
            "text": "Sox2, Klf4, c-Myc",
            "probability": 1.055002212524414e-05
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -7.1015625,
            "text": "Sox2, Klf4, c-Myc)",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -5.42578125,
            "end_logit": 5.9921875,
            "text": ", Sox2",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -7.26953125,
            "text": "Sox2, Kl",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": -5.703125,
            "end_logit": 5.9921875,
            "text": "Oct3/4, Sox2",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -7.48828125,
            "text": "Sox2, Klf4, c",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -7.2578125,
            "end_logit": 5.9921875,
            "text": "amanaka factors (Oct3/4, Sox2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.328125,
            "end_logit": 5.9921875,
            "text": "4, Sox2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.43359375,
            "end_logit": 5.9921875,
            "text": "factors (Oct3/4, Sox2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 5.9921875,
            "text": "(Oct3/4, Sox2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 5.9921875,
            "text": "anaka factors (Oct3/4, Sox2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.42578125,
            "end_logit": -5.3125,
            "text": ", Sox2, Klf4",
            "probability": 0.0
        },
        {
            "start_logit": -5.42578125,
            "end_logit": -5.47265625,
            "text": ", Sox2, Klf4, c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -5.703125,
            "end_logit": -5.3125,
            "text": "Oct3/4, Sox2, Klf4",
            "probability": 0.0
        },
        {
            "start_logit": -5.70703125,
            "end_logit": -5.3125,
            "text": "Klf4",
            "probability": 0.0
        },
        {
            "start_logit": -5.703125,
            "end_logit": -5.47265625,
            "text": "Oct3/4, Sox2, Klf4, c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -5.70703125,
            "end_logit": -5.47265625,
            "text": "Klf4, c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -5.42578125,
            "end_logit": -7.1015625,
            "text": ", Sox2, Klf4, c-Myc)",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_17": [
        {
            "start_logit": 8.140625,
            "end_logit": 7.46484375,
            "text": "Sox2",
            "probability": 1.0
        },
        {
            "start_logit": 8.140625,
            "end_logit": -6.15234375,
            "text": "Sox2, Klf4",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 8.140625,
            "end_logit": -6.8515625,
            "text": "Sox2, Klf4, c-Myc) are highly expressed in embryonic stem (ES) cells, and their over-expression can induce pluripotency",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.18359375,
            "end_logit": 7.46484375,
            "text": ", Sox2",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.140625,
            "end_logit": -7.109375,
            "text": "Sox2, Klf4, c-Myc",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.140625,
            "end_logit": -7.19140625,
            "text": "Sox2, Klf4, c-Myc) are highly expressed in embryonic stem (ES) cells, and their over-expression",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.140625,
            "end_logit": -7.19921875,
            "text": "Sox2, Kl",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.140625,
            "end_logit": -7.48046875,
            "text": "Sox2, Klf4, c",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.140625,
            "end_logit": -7.5,
            "text": "Sox2, Klf4, c-Myc)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.140625,
            "end_logit": -7.52734375,
            "text": "Sox2, Klf4, c-Myc) are highly expressed in embryonic stem (ES) cells, and their over-expression can",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.140625,
            "end_logit": -7.53515625,
            "text": "Sox2, Klf4, c-Myc) are highly expressed",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.140625,
            "end_logit": -7.5390625,
            "text": "Sox2, Klf4, c-Myc) are highly expressed in embryonic stem (ES) cells, and their over-",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.0625,
            "end_logit": 7.46484375,
            "text": "Oct3/4, Sox2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.16015625,
            "end_logit": 7.46484375,
            "text": "4, Sox2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 7.46484375,
            "text": "(Oct3/4, Sox2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 7.46484375,
            "text": "factors (Oct3/4, Sox2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.18359375,
            "end_logit": -6.15234375,
            "text": ", Sox2, Klf4",
            "probability": 0.0
        },
        {
            "start_logit": -6.18359375,
            "end_logit": -6.8515625,
            "text": ", Sox2, Klf4, c-Myc) are highly expressed in embryonic stem (ES) cells, and their over-expression can induce pluripotency",
            "probability": 0.0
        },
        {
            "start_logit": -7.0234375,
            "end_logit": -6.15234375,
            "text": "Klf4",
            "probability": 0.0
        },
        {
            "start_logit": -7.0625,
            "end_logit": -6.15234375,
            "text": "Oct3/4, Sox2, Klf4",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_18": [
        {
            "start_logit": 7.8359375,
            "end_logit": 7.8046875,
            "text": "Sox2",
            "probability": 1.0
        },
        {
            "start_logit": -6.49609375,
            "end_logit": 7.8046875,
            "text": "namely Sox2",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -7.4609375,
            "text": "Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 7.8046875,
            "text": "factors, namely Sox2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 7.8046875,
            "text": ", namely Sox2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -7.625,
            "text": "Sox2, Oct3/4 (Pou5f1)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -7.64453125,
            "text": "Sox2, Oct3/4 (Pou5",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -7.6640625,
            "text": "Sox2, Oct3/4 (Pou5f1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -7.66796875,
            "text": "Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc, and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -7.671875,
            "text": "Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc, and the",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -7.671875,
            "text": "Sox2, Oct3/4 (Pou5f1), Klf4, and c",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -7.6953125,
            "text": "Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc, and the Thomson factors, namely Sox2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.49609375,
            "end_logit": -7.4609375,
            "text": "namely Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -6.49609375,
            "end_logit": -7.625,
            "text": "namely Sox2, Oct3/4 (Pou5f1)",
            "probability": 0.0
        },
        {
            "start_logit": -6.49609375,
            "end_logit": -7.64453125,
            "text": "namely Sox2, Oct3/4 (Pou5",
            "probability": 0.0
        },
        {
            "start_logit": -6.49609375,
            "end_logit": -7.6640625,
            "text": "namely Sox2, Oct3/4 (Pou5f1",
            "probability": 0.0
        },
        {
            "start_logit": -6.49609375,
            "end_logit": -7.66796875,
            "text": "namely Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc, and",
            "probability": 0.0
        },
        {
            "start_logit": -6.49609375,
            "end_logit": -7.671875,
            "text": "namely Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc, and the",
            "probability": 0.0
        },
        {
            "start_logit": -6.49609375,
            "end_logit": -7.671875,
            "text": "namely Sox2, Oct3/4 (Pou5f1), Klf4, and c",
            "probability": 0.0
        },
        {
            "start_logit": -7.5859375,
            "end_logit": -6.796875,
            "text": ", and c-Myc, and the Thomson factors, namely Sox2, Oct3, Lin28, and Nanog",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_19": [
        {
            "start_logit": 8.1796875,
            "end_logit": 7.3984375,
            "text": "Sox2",
            "probability": 1.0
        },
        {
            "start_logit": 8.1796875,
            "end_logit": -6.27734375,
            "text": "Sox2, Klf4",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 8.1796875,
            "end_logit": -6.96875,
            "text": "Sox2, Klf4, c-Myc) are highly expressed in embryonic stem (ES) cells, and their over-expression can induce pluripotency",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.27734375,
            "end_logit": 7.3984375,
            "text": ", Sox2",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.1796875,
            "end_logit": -7.1640625,
            "text": "Sox2, Klf4, c-Myc",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.1796875,
            "end_logit": -7.2109375,
            "text": "Sox2, Klf4, c-Myc) are highly expressed in embryonic stem (ES) cells, and their over-expression",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.1796875,
            "end_logit": -7.25,
            "text": "Sox2, Kl",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.1796875,
            "end_logit": -7.48828125,
            "text": "Sox2, Klf4, c",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.1796875,
            "end_logit": -7.515625,
            "text": "Sox2, Klf4, c-Myc)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.1796875,
            "end_logit": -7.53515625,
            "text": "Sox2, Klf4, c-Myc) are highly expressed in embryonic stem (ES) cells, and their over-",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.1796875,
            "end_logit": -7.53515625,
            "text": "Sox2, Klf4, c-Myc) are highly expressed in embryonic stem (ES) cells, and their over-expression can",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.1796875,
            "end_logit": -7.55859375,
            "text": "Sox2, Klf4, c-Myc) are highly expressed",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 7.3984375,
            "text": "Oct3/4, Sox2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 7.3984375,
            "text": "4, Sox2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 7.3984375,
            "text": "(Oct3/4, Sox2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 7.3984375,
            "text": "factors (Oct3/4, Sox2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.27734375,
            "end_logit": -6.27734375,
            "text": ", Sox2, Klf4",
            "probability": 0.0
        },
        {
            "start_logit": -6.27734375,
            "end_logit": -6.96875,
            "text": ", Sox2, Klf4, c-Myc) are highly expressed in embryonic stem (ES) cells, and their over-expression can induce pluripotency",
            "probability": 0.0
        },
        {
            "start_logit": -7.12109375,
            "end_logit": -6.27734375,
            "text": "Klf4",
            "probability": 0.0
        },
        {
            "start_logit": -7.12890625,
            "end_logit": -6.27734375,
            "text": "Oct3/4, Sox2, Klf4",
            "probability": 0.0
        }
    ],
    "53137541e3eabad021000010_20": [
        {
            "start_logit": 8.0859375,
            "end_logit": 7.54296875,
            "text": "Oct4",
            "probability": 1.0
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -6.53125,
            "text": "Oct4, Sox2",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -6.71484375,
            "text": "Oct4, Sox2, Klf4 and cMyc",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -7.3671875,
            "text": "Oct4, Sox2, Klf4 and cMyc (4TF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -7.3671875,
            "text": "Oct4, Sox2, Klf4",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.875,
            "end_logit": 7.54296875,
            "text": "Transcription factors, Oct4",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -7.47265625,
            "text": "Oct4, Sox2, Klf4 and cMyc (4TF, Yamanaka factors) are",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -7.484375,
            "text": "Oct4, Sox2, Klf4 and cMyc (4TF, Yamanaka factors)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -7.484375,
            "text": "Oct4, Sox2, Klf4 and cMyc (",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -7.5390625,
            "text": "Oct4, Sox2, Klf4 and cMyc (4TF, Yamanaka factors) are used",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -7.5390625,
            "text": "Oct4, Sox2, Klf4 and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -7.5546875,
            "text": "Oct4, Sox2, Klf4 and cM",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -7.57421875,
            "text": "Oct4, Sox2, Klf4 and cMyc (4T",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -7.61328125,
            "text": "Oct4,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -7.6328125,
            "text": "Oct4, Sox2, Klf4 and cMyc (4TF, Yamanaka factors) are used as basal conditions to generate iPS",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -7.6484375,
            "text": "Oct4, Sox2, Klf4 and cMyc (4TF, Yamanaka factors) are used as basal conditions to",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -7.6484375,
            "text": "Oct4, Sox2, Klf4 and cMyc (4TF, Yamanaka factors",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -7.65625,
            "text": "Oct4, Sox2, Klf4 and cMyc (4TF,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.1640625,
            "end_logit": 7.54296875,
            "text": ", Oct4",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.17578125,
            "end_logit": 7.54296875,
            "text": "factors, Oct4",
            "probability": 2.384185791015625e-07
        }
    ],
    "53137541e3eabad021000010_21": [
        {
            "start_logit": 8.15625,
            "end_logit": 7.453125,
            "text": "Oct4",
            "probability": 1.0
        },
        {
            "start_logit": -5.51171875,
            "end_logit": 7.453125,
            "text": "transcription factors, Oct4",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 8.15625,
            "end_logit": -6.3203125,
            "text": "Oct4, Sox2, Klf4 and c-Myc",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 8.15625,
            "end_logit": -7.23046875,
            "text": "Oct4, Sox2",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.15625,
            "end_logit": -7.38671875,
            "text": "Oct4, Sox2, Klf4 and c-Myc, also known",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.15625,
            "end_logit": -7.46875,
            "text": "Oct4, Sox2, Klf4",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.15625,
            "end_logit": -7.52734375,
            "text": "Oct4, Sox2, Klf4 and c",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.15625,
            "end_logit": -7.5546875,
            "text": "Oct4, Sox2, Klf4 and c-Myc, also",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.15625,
            "end_logit": -7.5625,
            "text": "Oct4, Sox2, Klf4 and c-Myc, also known as",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.14453125,
            "end_logit": 7.453125,
            "text": "ectopic expression of four transcription factors, Oct4",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.23046875,
            "end_logit": 7.453125,
            "text": ", Oct4",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 7.453125,
            "text": "by ectopic expression of four transcription factors, Oct4",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 7.453125,
            "text": "four transcription factors, Oct4",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 7.453125,
            "text": "induced pluripotent stem (iPS) cells from somatic cells has been successfully achieved by ectopic expression of four transcription factors, Oct4",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 7.453125,
            "text": "of four transcription factors, Oct4",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 7.453125,
            "text": "factors, Oct4",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.51171875,
            "end_logit": -6.3203125,
            "text": "transcription factors, Oct4, Sox2, Klf4 and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -5.51171875,
            "end_logit": -7.10546875,
            "text": "transcription factors",
            "probability": 0.0
        },
        {
            "start_logit": -5.51171875,
            "end_logit": -7.23046875,
            "text": "transcription factors, Oct4, Sox2",
            "probability": 0.0
        },
        {
            "start_logit": -5.51171875,
            "end_logit": -7.38671875,
            "text": "transcription factors, Oct4, Sox2, Klf4 and c-Myc, also known",
            "probability": 0.0
        }
    ],
    "62755c2a56bf9aee6f000001_1": [
        {
            "start_logit": 9.1796875,
            "end_logit": 9.265625,
            "text": "breast cancer",
            "probability": 1.0
        },
        {
            "start_logit": -1.3701171875,
            "end_logit": 9.265625,
            "text": "cancer",
            "probability": 2.6285648345947266e-05
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -1.4072265625,
            "text": "breast",
            "probability": 2.3365020751953125e-05
        },
        {
            "start_logit": -7.109375,
            "end_logit": 9.265625,
            "text": "including breast cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 9.265625,
            "text": "tumors, including breast cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.53125,
            "text": "breast cancer.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 9.265625,
            "text": "transcription factor and proto-oncogene, MYC is known to be deregulated in a variety of tumors, including breast cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6484375,
            "end_logit": 9.265625,
            "text": "variety of tumors, including breast cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.671875,
            "end_logit": 9.265625,
            "text": "proto-oncogene, MYC is known to be deregulated in a variety of tumors, including breast cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 9.265625,
            "text": "MYC is known to be deregulated in a variety of tumors, including breast cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.109375,
            "end_logit": -1.4072265625,
            "text": "including breast",
            "probability": 0.0
        },
        {
            "start_logit": -1.3701171875,
            "end_logit": -7.53125,
            "text": "cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -7.5859375,
            "end_logit": -1.4072265625,
            "text": "tumors, including breast",
            "probability": 0.0
        },
        {
            "start_logit": -7.64453125,
            "end_logit": -1.4072265625,
            "text": "transcription factor and proto-oncogene, MYC is known to be deregulated in a variety of tumors, including breast",
            "probability": 0.0
        },
        {
            "start_logit": -7.6484375,
            "end_logit": -1.4072265625,
            "text": "variety of tumors, including breast",
            "probability": 0.0
        },
        {
            "start_logit": -7.671875,
            "end_logit": -1.4072265625,
            "text": "proto-oncogene, MYC is known to be deregulated in a variety of tumors, including breast",
            "probability": 0.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -1.4072265625,
            "text": "MYC is known to be deregulated in a variety of tumors, including breast",
            "probability": 0.0
        },
        {
            "start_logit": -7.5859375,
            "end_logit": -6.72265625,
            "text": "tumors",
            "probability": 0.0
        },
        {
            "start_logit": -7.64453125,
            "end_logit": -6.72265625,
            "text": "transcription factor and proto-oncogene, MYC is known to be deregulated in a variety of tumors",
            "probability": 0.0
        },
        {
            "start_logit": -7.6484375,
            "end_logit": -6.72265625,
            "text": "variety of tumors",
            "probability": 0.0
        }
    ],
    "62755c2a56bf9aee6f000001_2": [
        {
            "start_logit": 7.4375,
            "end_logit": 8.125,
            "text": "NSCLC",
            "probability": 1.0
        },
        {
            "start_logit": 7.4375,
            "end_logit": -6.078125,
            "text": "NSCLC by",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.38671875,
            "end_logit": 8.125,
            "text": "in NSCLC",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.43359375,
            "end_logit": 8.125,
            "text": "tumor suppressor role of miR-376a in NSCLC",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 8.125,
            "text": "a tumor suppressor role of miR-376a in NSCLC",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 8.125,
            "text": "miR-376a in NSCLC",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.4375,
            "end_logit": -7.48046875,
            "text": "NSCLC by targeting",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.4375,
            "end_logit": -7.58984375,
            "text": "NSCLC by targeting c-Myc",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.4375,
            "end_logit": -7.58984375,
            "text": "NSCLC by targeting c",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.4375,
            "end_logit": -7.62890625,
            "text": "NSCLC by targeting c-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.38671875,
            "end_logit": -6.078125,
            "text": "in NSCLC by",
            "probability": 0.0
        },
        {
            "start_logit": -7.43359375,
            "end_logit": -6.078125,
            "text": "tumor suppressor role of miR-376a in NSCLC by",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -6.078125,
            "text": "a tumor suppressor role of miR-376a in NSCLC by",
            "probability": 0.0
        },
        {
            "start_logit": -7.65234375,
            "end_logit": -6.078125,
            "text": "miR-376a in NSCLC by",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -6.484375,
            "text": "a",
            "probability": 0.0
        },
        {
            "start_logit": -7.43359375,
            "end_logit": -7.27734375,
            "text": "tumor suppressor role",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -7.27734375,
            "text": "a tumor suppressor role",
            "probability": 0.0
        },
        {
            "start_logit": -7.43359375,
            "end_logit": -7.359375,
            "text": "tumor suppressor",
            "probability": 0.0
        },
        {
            "start_logit": -7.38671875,
            "end_logit": -7.48046875,
            "text": "in NSCLC by targeting",
            "probability": 0.0
        },
        {
            "start_logit": -7.43359375,
            "end_logit": -7.4453125,
            "text": "tumor suppressor role of miR-37",
            "probability": 0.0
        }
    ],
    "62755c2a56bf9aee6f000001_3": [
        {
            "start_logit": 7.79296875,
            "end_logit": 7.7578125,
            "text": "PDA",
            "probability": 1.0
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.0546875,
            "text": "PDA.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 7.7578125,
            "text": "of PDA",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.40625,
            "end_logit": 7.7578125,
            "text": "results provide strong justification for eventual clinical evaluation of anti-Myc drugs as potential chemotherapeutic agents for the treatment of PDA",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 7.7578125,
            "text": "potential chemotherapeutic agents for the treatment of PDA",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 7.7578125,
            "text": "strong justification for eventual clinical evaluation of anti-Myc drugs as potential chemotherapeutic agents for the treatment of PDA",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.5625,
            "end_logit": 7.7578125,
            "text": "justification for eventual clinical evaluation of anti-Myc drugs as potential chemotherapeutic agents for the treatment of PDA",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 7.7578125,
            "text": "clinical evaluation of anti-Myc drugs as potential chemotherapeutic agents for the treatment of PDA",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 7.7578125,
            "text": "These results provide strong justification for eventual clinical evaluation of anti-Myc drugs as potential chemotherapeutic agents for the treatment of PDA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.609375,
            "end_logit": 7.7578125,
            "text": "treatment of PDA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 7.7578125,
            "text": "provide strong justification for eventual clinical evaluation of anti-Myc drugs as potential chemotherapeutic agents for the treatment of PDA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.625,
            "end_logit": 7.7578125,
            "text": "evaluation of anti-Myc drugs as potential chemotherapeutic agents for the treatment of PDA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.8359375,
            "end_logit": -7.0546875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.3359375,
            "end_logit": -7.0546875,
            "text": "of PDA.",
            "probability": 0.0
        },
        {
            "start_logit": -7.40625,
            "end_logit": -7.0078125,
            "text": "results provide",
            "probability": 0.0
        },
        {
            "start_logit": -7.40625,
            "end_logit": -7.0546875,
            "text": "results provide strong justification for eventual clinical evaluation of anti-Myc drugs as potential chemotherapeutic agents for the treatment of PDA.",
            "probability": 0.0
        },
        {
            "start_logit": -7.48046875,
            "end_logit": -7.0546875,
            "text": "potential chemotherapeutic agents for the treatment of PDA.",
            "probability": 0.0
        },
        {
            "start_logit": -7.5390625,
            "end_logit": -7.0546875,
            "text": "strong justification for eventual clinical evaluation of anti-Myc drugs as potential chemotherapeutic agents for the treatment of PDA.",
            "probability": 0.0
        },
        {
            "start_logit": -7.6015625,
            "end_logit": -7.0078125,
            "text": "These results provide",
            "probability": 0.0
        },
        {
            "start_logit": -7.5625,
            "end_logit": -7.0546875,
            "text": "justification for eventual clinical evaluation of anti-Myc drugs as potential chemotherapeutic agents for the treatment of PDA.",
            "probability": 0.0
        }
    ],
    "62755c2a56bf9aee6f000001_4": [
        {
            "start_logit": 9.2109375,
            "end_logit": 9.34375,
            "text": "breast cancer",
            "probability": 1.0
        },
        {
            "start_logit": -1.1875,
            "end_logit": 9.34375,
            "text": "cancer",
            "probability": 3.0219554901123047e-05
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -1.2880859375,
            "text": "breast",
            "probability": 2.390146255493164e-05
        },
        {
            "start_logit": -7.265625,
            "end_logit": 9.34375,
            "text": "including breast cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 9.34375,
            "text": "human cancer, including breast cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 9.34375,
            "text": "proto-oncogene c-Myc has a pivotal function in growth control, differentiation, and apoptosis and is frequently affected in human cancer, including breast cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 9.34375,
            "text": "in human cancer, including breast cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 9.34375,
            "text": "growth control, differentiation, and apoptosis and is frequently affected in human cancer, including breast cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6875,
            "end_logit": 9.34375,
            "text": "cancer, including breast cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.265625,
            "end_logit": -1.2880859375,
            "text": "including breast",
            "probability": 0.0
        },
        {
            "start_logit": -7.4765625,
            "end_logit": -1.2880859375,
            "text": "human cancer, including breast",
            "probability": 0.0
        },
        {
            "start_logit": -7.62109375,
            "end_logit": -1.2880859375,
            "text": "proto-oncogene c-Myc has a pivotal function in growth control, differentiation, and apoptosis and is frequently affected in human cancer, including breast",
            "probability": 0.0
        },
        {
            "start_logit": -7.6640625,
            "end_logit": -1.2880859375,
            "text": "in human cancer, including breast",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -1.2880859375,
            "text": "growth control, differentiation, and apoptosis and is frequently affected in human cancer, including breast",
            "probability": 0.0
        },
        {
            "start_logit": -7.6875,
            "end_logit": -1.2880859375,
            "text": "cancer, including breast",
            "probability": 0.0
        },
        {
            "start_logit": -7.4765625,
            "end_logit": -7.265625,
            "text": "human cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.62109375,
            "end_logit": -7.265625,
            "text": "proto-oncogene c-Myc has a pivotal function in growth control, differentiation, and apoptosis and is frequently affected in human cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.6640625,
            "end_logit": -7.265625,
            "text": "in human cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -7.265625,
            "text": "growth control, differentiation, and apoptosis and is frequently affected in human cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.6875,
            "end_logit": -7.265625,
            "text": "cancer",
            "probability": 0.0
        }
    ],
    "62755c2a56bf9aee6f000001_5": [
        {
            "start_logit": 9.25,
            "end_logit": 9.3828125,
            "text": "breast cancer",
            "probability": 1.0
        },
        {
            "start_logit": -1.1083984375,
            "end_logit": 9.3828125,
            "text": "cancer",
            "probability": 3.1948089599609375e-05
        },
        {
            "start_logit": 9.25,
            "end_logit": -1.228515625,
            "text": "breast",
            "probability": 2.485513687133789e-05
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.15625,
            "text": "breast cancer and confers resistance to endocrine therapy in luminal tumours",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.27734375,
            "text": "breast cancer and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.41015625,
            "text": "breast cancer and confers resistance to endocrine therapy in luminal tumours.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 9.3828125,
            "text": "biological subtypes of breast cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.48828125,
            "text": "breast cancer and confers resistance",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.3828125,
            "text": "of breast cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.3828125,
            "text": "MYC functions are specific in biological subtypes of breast cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 9.3828125,
            "text": "subtypes of breast cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.55078125,
            "text": "breast cancer and confers resistance to endocrine therapy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69140625,
            "end_logit": 9.3828125,
            "text": "functions are specific in biological subtypes of breast cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.56640625,
            "text": "breast cancer and confers resistance to endocrine therapy in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.5703125,
            "text": "breast cancer and confers resistance to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.578125,
            "text": "breast cancer and confers resistance to endocrine therapy in luminal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.59765625,
            "text": "breast cancer and confers resistance to endocrine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.64453125,
            "text": "breast cancer and confers",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.1083984375,
            "end_logit": -7.15625,
            "text": "cancer and confers resistance to endocrine therapy in luminal tumours",
            "probability": 0.0
        },
        {
            "start_logit": -1.1083984375,
            "end_logit": -7.27734375,
            "text": "cancer and",
            "probability": 0.0
        }
    ],
    "62755c2a56bf9aee6f000001_6": [
        {
            "start_logit": 9.28125,
            "end_logit": 9.3828125,
            "text": "breast cancer",
            "probability": 1.0
        },
        {
            "start_logit": -1.1142578125,
            "end_logit": 9.3828125,
            "text": "cancer",
            "probability": 3.069639205932617e-05
        },
        {
            "start_logit": 9.28125,
            "end_logit": -1.154296875,
            "text": "breast",
            "probability": 2.6702880859375e-05
        },
        {
            "start_logit": -6.90625,
            "end_logit": 9.3828125,
            "text": "familial breast cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 9.3828125,
            "text": "risk for familial breast cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 9.3828125,
            "text": "increased risk for familial breast cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.41796875,
            "text": "breast cancer.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.578125,
            "end_logit": 9.3828125,
            "text": "for familial breast cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.3828125,
            "text": "associated with increased risk for familial breast cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 9.3828125,
            "text": "MYC Asn11Ser is associated with increased risk for familial breast cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 9.3828125,
            "text": "with increased risk for familial breast cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65625,
            "end_logit": 9.3828125,
            "text": "Asn11Ser is associated with increased risk for familial breast cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.90625,
            "end_logit": -1.154296875,
            "text": "familial breast",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -1.154296875,
            "text": "risk for familial breast",
            "probability": 0.0
        },
        {
            "start_logit": -7.27734375,
            "end_logit": -1.154296875,
            "text": "increased risk for familial breast",
            "probability": 0.0
        },
        {
            "start_logit": -1.1142578125,
            "end_logit": -7.41796875,
            "text": "cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -7.578125,
            "end_logit": -1.154296875,
            "text": "for familial breast",
            "probability": 0.0
        },
        {
            "start_logit": -7.640625,
            "end_logit": -1.154296875,
            "text": "associated with increased risk for familial breast",
            "probability": 0.0
        },
        {
            "start_logit": -7.64453125,
            "end_logit": -1.154296875,
            "text": "MYC Asn11Ser is associated with increased risk for familial breast",
            "probability": 0.0
        },
        {
            "start_logit": -7.65234375,
            "end_logit": -1.154296875,
            "text": "with increased risk for familial breast",
            "probability": 0.0
        }
    ],
    "60281b1c1cb411341a0000f3_1": [
        {
            "start_logit": 7.93359375,
            "end_logit": 7.59765625,
            "text": "schizophrenia",
            "probability": 1.0
        },
        {
            "start_logit": 7.93359375,
            "end_logit": -5.42578125,
            "text": "schizophrenia, autism, mental retardation, ADHD and epilepsy",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 7.93359375,
            "end_logit": -6.95703125,
            "text": "schizophrenia, autism",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.93359375,
            "end_logit": -7.1640625,
            "text": "schizophrenia, autism, mental retardation, ADHD and",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.93359375,
            "end_logit": -7.23046875,
            "text": "schizophrenia, autism, mental retardation, ADHD and epilepsy.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.9609375,
            "end_logit": 7.59765625,
            "text": "as schizophrenia",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.93359375,
            "end_logit": -7.52734375,
            "text": "schizophrenia, autism, mental retardation, ADHD",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.93359375,
            "end_logit": -7.60546875,
            "text": "schizophrenia,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.93359375,
            "end_logit": -7.61328125,
            "text": "schizophrenia, autism, mental retardation",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 7.59765625,
            "text": "implicated in several neuropsychiatric disorders, such as schizophrenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.53125,
            "end_logit": 7.59765625,
            "text": "neuropsychiatric disorders, such as schizophrenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 7.59765625,
            "text": "genomic copy number variants are implicated in several neuropsychiatric disorders, such as schizophrenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 7.59765625,
            "text": "disorders, such as schizophrenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.9609375,
            "end_logit": -5.42578125,
            "text": "as schizophrenia, autism, mental retardation, ADHD and epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -7.51953125,
            "end_logit": -5.42578125,
            "text": "implicated in several neuropsychiatric disorders, such as schizophrenia, autism, mental retardation, ADHD and epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -7.53125,
            "end_logit": -5.42578125,
            "text": "neuropsychiatric disorders, such as schizophrenia, autism, mental retardation, ADHD and epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -7.6640625,
            "end_logit": -5.42578125,
            "text": "genomic copy number variants are implicated in several neuropsychiatric disorders, such as schizophrenia, autism, mental retardation, ADHD and epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -5.42578125,
            "text": "disorders, such as schizophrenia, autism, mental retardation, ADHD and epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -6.9609375,
            "end_logit": -6.95703125,
            "text": "as schizophrenia, autism",
            "probability": 0.0
        },
        {
            "start_logit": -6.9609375,
            "end_logit": -7.1640625,
            "text": "as schizophrenia, autism, mental retardation, ADHD and",
            "probability": 0.0
        }
    ],
    "517a8c918ed59a060a000043_1": [
        {
            "start_logit": 7.77734375,
            "end_logit": 7.86328125,
            "text": "adenovirus",
            "probability": 1.0
        },
        {
            "start_logit": 7.77734375,
            "end_logit": -6.37109375,
            "text": "adenovirus genome",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.16796875,
            "end_logit": 7.86328125,
            "text": "study the adenovirus",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.77734375,
            "end_logit": -7.15234375,
            "text": "adenovirus genome was found to be the most frequent virus genome in explanted heart tissues.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.77734375,
            "end_logit": -7.18359375,
            "text": "adenovirus genome was",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.77734375,
            "end_logit": -7.18359375,
            "text": "adenovirus genome was found to be the most frequent virus",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.77734375,
            "end_logit": -7.19921875,
            "text": "adenovirus genome was found to be the most frequent virus genome",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.77734375,
            "end_logit": -7.22265625,
            "text": "adenovirus genome was found",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.77734375,
            "end_logit": -7.34765625,
            "text": "adenovirus genome was found to be the most frequent virus genome in explanted heart",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 7.86328125,
            "text": "our study the adenovirus",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 7.86328125,
            "text": "n our study the adenovirus",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.77734375,
            "end_logit": -7.41796875,
            "text": "adenovirus genome was found to be the most frequent virus genome in explanted heart tissues",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.77734375,
            "end_logit": -7.4453125,
            "text": "adenovirus genome was found to",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.53125,
            "end_logit": 7.86328125,
            "text": "the adenovirus",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.77734375,
            "end_logit": -7.54296875,
            "text": "adenovirus genome was found to be the",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.77734375,
            "end_logit": -7.5625,
            "text": "adenovirus genome was found to be",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.77734375,
            "end_logit": -7.58203125,
            "text": "adenovirus genome was found to be the most frequent virus genome in explanted",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.16796875,
            "end_logit": -6.37109375,
            "text": "study the adenovirus genome",
            "probability": 0.0
        },
        {
            "start_logit": -7.4765625,
            "end_logit": -6.37109375,
            "text": "our study the adenovirus genome",
            "probability": 0.0
        },
        {
            "start_logit": -7.48046875,
            "end_logit": -6.37109375,
            "text": "n our study the adenovirus genome",
            "probability": 0.0
        }
    ],
    "550e9d2cb305b40c5c000001_1": [
        {
            "start_logit": 7.76171875,
            "end_logit": 7.73828125,
            "text": "Age",
            "probability": 1.0
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -7.0078125,
            "text": "Age and NIHSS-100 (SPAN-100; NRI = 0.175; p = 0.04).",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -7.2265625,
            "text": "Age and NIHSS",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -7.23828125,
            "text": "Age and NIHSS-100 (SPAN-100; NRI = 0.175; p = 0",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -7.25,
            "text": "Age and NIHSS-100 (SPAN-100; NRI = 0.175; p = 0.04",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -7.2578125,
            "text": "Age and NIHSS-100",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -7.2890625,
            "text": "Age and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -7.31640625,
            "text": "Age and NIHSS-100 (SPAN-100; NRI = 0",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -7.3359375,
            "text": "Age and NIHSS-100 (SPAN-100; NRI = 0.175",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -7.37109375,
            "text": "Age and NIH",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -7.375,
            "text": "Age and NIHSS-",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 7.73828125,
            "text": "prediction of outcome by the Stroke Prognostication using Age",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.4375,
            "end_logit": 7.73828125,
            "text": "using Age",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -7.46875,
            "text": "Age and NIHSS-100 (SPAN-100; NRI = 0.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -7.46875,
            "text": "Age and NIHSS-100 (SPAN-100; NRI =",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -7.4765625,
            "text": "Age and NIHSS-100 (SPAN-100; NRI",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.46875,
            "end_logit": 7.73828125,
            "text": "reclassification of patients in the prediction of outcome by the Stroke Prognostication using Age",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -7.49609375,
            "text": "Age and NIHSS-100 (SPAN-100; NRI = 0.175; p = 0.04)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 7.73828125,
            "text": "of outcome by the Stroke Prognostication using Age",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.52734375,
            "end_logit": 7.73828125,
            "text": "Stroke Prognostication using Age",
            "probability": 2.384185791015625e-07
        }
    ],
    "550e9d2cb305b40c5c000001_2": [
        {
            "start_logit": 7.5859375,
            "end_logit": 7.96875,
            "text": "Age",
            "probability": 1.0
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -6.04296875,
            "text": "Age and NIH Stroke Scale",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -6.86328125,
            "end_logit": 7.96875,
            "text": "Stroke Prognostication using Age",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.9296875,
            "end_logit": 7.96875,
            "text": "using Age",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -6.84375,
            "text": "Age and NIH Stroke",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 7.96875,
            "text": "Prognostication using Age",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -7.05859375,
            "text": "Age and NIH Stroke Scale: SPAN-100.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -7.58984375,
            "text": "Age and NIH Stroke Scale:",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -7.62109375,
            "text": "Age and NIH Stroke Scale: SPAN-100",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -7.65234375,
            "text": "Age and NIH",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -7.671875,
            "text": "Age and NIH Stroke Scale: SPAN-",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.140625,
            "end_logit": -6.04296875,
            "text": "NIH Stroke Scale",
            "probability": 0.0
        },
        {
            "start_logit": -6.86328125,
            "end_logit": -6.04296875,
            "text": "Stroke Prognostication using Age and NIH Stroke Scale",
            "probability": 0.0
        },
        {
            "start_logit": -6.9296875,
            "end_logit": -6.04296875,
            "text": "using Age and NIH Stroke Scale",
            "probability": 0.0
        },
        {
            "start_logit": -6.140625,
            "end_logit": -6.84375,
            "text": "NIH Stroke",
            "probability": 0.0
        },
        {
            "start_logit": -6.140625,
            "end_logit": -7.05859375,
            "text": "NIH Stroke Scale: SPAN-100.",
            "probability": 0.0
        },
        {
            "start_logit": -7.26171875,
            "end_logit": -6.04296875,
            "text": "and NIH Stroke Scale",
            "probability": 0.0
        },
        {
            "start_logit": -7.31640625,
            "end_logit": -6.04296875,
            "text": "Prognostication using Age and NIH Stroke Scale",
            "probability": 0.0
        },
        {
            "start_logit": -6.86328125,
            "end_logit": -6.84375,
            "text": "Stroke Prognostication using Age and NIH Stroke",
            "probability": 0.0
        },
        {
            "start_logit": -6.140625,
            "end_logit": -7.58984375,
            "text": "NIH Stroke Scale:",
            "probability": 0.0
        }
    ],
    "550e9d2cb305b40c5c000001_3": [
        {
            "start_logit": 7.88671875,
            "end_logit": 7.671875,
            "text": "Age",
            "probability": 1.0
        },
        {
            "start_logit": 7.88671875,
            "end_logit": -6.78515625,
            "text": "Age and NIH Stroke Scale (SPAN) index by combining age",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.69140625,
            "end_logit": 7.671875,
            "text": "using Age",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.88671875,
            "end_logit": -7.15234375,
            "text": "Age and NIH Stroke Scale (SPAN) index by combining age in years plus NIH Stroke Scale (NIHSS",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.88671875,
            "end_logit": -7.21484375,
            "text": "Age and NIH Stroke Scale (SPAN) index by combining age in years plus NIH Stroke Scale (NIHSS) \u2265100",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.88671875,
            "end_logit": -7.22265625,
            "text": "Age and NIH Stroke Scale (SPAN) index by combining age in years plus NIH Stroke Scale (NIHSS) \u2265100.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.88671875,
            "end_logit": -7.26171875,
            "text": "Age and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.88671875,
            "end_logit": -7.33203125,
            "text": "Age and NIH Stroke Scale",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.88671875,
            "end_logit": -7.40234375,
            "text": "Age and NIH Stroke",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.88671875,
            "end_logit": -7.48828125,
            "text": "Age and NIH Stroke Scale (SPAN) index by combining age in years plus NIH Stroke Scale (NIHSS)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.30859375,
            "end_logit": 7.671875,
            "text": "Stroke Prognostication using Age",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.88671875,
            "end_logit": -7.5546875,
            "text": "Age and NIH Stroke Scale (SPAN) index by combining age in years plus NIH Stroke Scale (NIHSS) \u226510",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.88671875,
            "end_logit": -7.56640625,
            "text": "Age and NIH Stroke Scale (SPAN) index",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.88671875,
            "end_logit": -7.58203125,
            "text": "Age and NIH Stroke Scale (",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.88671875,
            "end_logit": -7.58203125,
            "text": "Age and NIH Stroke Scale (SPAN)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.88671875,
            "end_logit": -7.59375,
            "text": "Age and NIH Stroke Scale (SPAN) index by combining age in years",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.390625,
            "end_logit": 7.671875,
            "text": "the Stroke Prognostication using Age",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.88671875,
            "end_logit": -7.64453125,
            "text": "Age and NIH",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.88671875,
            "end_logit": -7.64453125,
            "text": "Age and NIH Stroke Scale (SPAN) index by combining age in years plus",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 7.671875,
            "text": "We created the Stroke Prognostication using Age",
            "probability": 2.384185791015625e-07
        }
    ],
    "550e9d2cb305b40c5c000001_4": [
        {
            "start_logit": 7.41796875,
            "end_logit": 6.8515625,
            "text": "age",
            "probability": 1.0
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -5.8984375,
            "text": "age and the NIH Stroke Scale",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -6.57421875,
            "text": "age and the NIH Stroke Scale (a 15-item neurological examination scale with scores ranging from 0 to 42, with higher scores indicating more severe strokes",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -6.58984375,
            "text": "age and",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -6.7734375,
            "text": "age and the NIH Stroke",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -6.5546875,
            "end_logit": 6.8515625,
            "text": "if the sum of the age",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -7.3203125,
            "text": "age and the",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -6.83984375,
            "end_logit": 6.8515625,
            "text": "the age",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -7.41796875,
            "text": "age and the NIH Stroke Scale (a 15-item neurological examination scale with scores ranging from 0 to 42",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -7.45703125,
            "text": "age and the NIH Stroke Scale (",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -7.5859375,
            "text": "age and the NIH Stroke Scale (a 15-item neurological examination scale with scores ranging from 0 to 42, with higher scores indicating",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -7.5859375,
            "text": "age and the NIH Stroke Scale (a 15-item neurological examination scale with scores ranging from 0 to 42, with higher scores indicating more severe strokes)",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -7.59765625,
            "text": "age and the NIH Stroke Scale (a 15-item neurological examination scale with scores ranging from 0 to",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.046875,
            "end_logit": 6.8515625,
            "text": "considered positive if the sum of the age",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 6.8515625,
            "text": "the sum of the age",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.3046875,
            "end_logit": 6.8515625,
            "text": "positive if the sum of the age",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.34375,
            "end_logit": 6.8515625,
            "text": "index is considered positive if the sum of the age",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.38671875,
            "end_logit": 6.8515625,
            "text": "sum of the age",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 6.8515625,
            "text": "The SPAN-100 index is considered positive if the sum of the age",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.07421875,
            "end_logit": -5.8984375,
            "text": "NIH Stroke Scale",
            "probability": 0.0
        }
    ],
    "550e9d2cb305b40c5c000001_5": [
        {
            "start_logit": 7.98828125,
            "end_logit": 7.61328125,
            "text": "Age",
            "probability": 1.0
        },
        {
            "start_logit": 7.98828125,
            "end_logit": -7.05859375,
            "text": "Age and",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.1171875,
            "end_logit": 7.61328125,
            "text": "Stroke Prognostication using Age",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.98828125,
            "end_logit": -7.50390625,
            "text": "Age and the",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.98828125,
            "end_logit": -7.54296875,
            "text": "Age and the NIH Stroke Scale",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.98828125,
            "end_logit": -7.5625,
            "text": "Age and the NIH Stroke Scale index",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 7.61328125,
            "text": "The Stroke Prognostication using Age",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.98828125,
            "end_logit": -7.609375,
            "text": "Age and the NIH Stroke",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.98828125,
            "end_logit": -7.6328125,
            "text": "Age and the NIH Stroke Scale index, created by combining age in years plus a National Institutes of Health (NIH) Stroke Scale score of 100 or higher",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 7.61328125,
            "text": "using Age",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.98828125,
            "end_logit": -7.6796875,
            "text": "Age and the NIH Stroke Scale index, created by combining age in years plus a National Institutes of Health (NIH) Stroke Scale score of 100 or",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.98828125,
            "end_logit": -7.69921875,
            "text": "Age and the NIH Stroke Scale index, created",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.98828125,
            "end_logit": -7.71484375,
            "text": "Age and the NIH",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.98828125,
            "end_logit": -7.734375,
            "text": "Age and the NIH Stroke Scale index, created by combining age in years plus a National Institutes of Health (NIH) Stroke Scale score of",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.1171875,
            "end_logit": -7.05859375,
            "text": "Stroke Prognostication using Age and",
            "probability": 0.0
        },
        {
            "start_logit": -7.20703125,
            "end_logit": -7.05859375,
            "text": "The Stroke Prognostication using Age and",
            "probability": 0.0
        },
        {
            "start_logit": -7.26171875,
            "end_logit": -7.05859375,
            "text": "using Age and",
            "probability": 0.0
        },
        {
            "start_logit": -7.1171875,
            "end_logit": -7.50390625,
            "text": "Stroke Prognostication using Age and the",
            "probability": 0.0
        },
        {
            "start_logit": -7.1171875,
            "end_logit": -7.515625,
            "text": "Stroke Prognostication",
            "probability": 0.0
        },
        {
            "start_logit": -7.1171875,
            "end_logit": -7.54296875,
            "text": "Stroke Prognostication using Age and the NIH Stroke Scale",
            "probability": 0.0
        }
    ],
    "601f19d11cb411341a000073_1": [
        {
            "start_logit": 7.74609375,
            "end_logit": 8.5,
            "text": "Emmanuelle Charpentier",
            "probability": 1.0
        },
        {
            "start_logit": -2.505859375,
            "end_logit": 8.5,
            "text": "ier",
            "probability": 3.510713577270508e-05
        },
        {
            "start_logit": 7.74609375,
            "end_logit": -3.47265625,
            "text": "Em",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": -5.92578125,
            "end_logit": 8.5,
            "text": "Charpentier",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -6.59375,
            "end_logit": 8.5,
            "text": "ntier",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.9453125,
            "end_logit": 8.5,
            "text": "to Emmanuelle Charpentier",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.06640625,
            "end_logit": 8.5,
            "text": "le Charpentier",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.74609375,
            "end_logit": -6.49609375,
            "text": "Emmanuelle Charpe",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.30078125,
            "end_logit": 8.5,
            "text": "manuelle Charpentier",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.3125,
            "end_logit": 8.5,
            "text": "in Chemistry awarded to Emmanuelle Charpentier",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 8.5,
            "text": "Prize in Chemistry awarded to Emmanuelle Charpentier",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.74609375,
            "end_logit": -6.79296875,
            "text": "Emmanuelle Charpentier and Jennifer Doudna",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.74609375,
            "end_logit": -6.92578125,
            "text": "Emmanuelle Charpentier and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 8.5,
            "text": "bel Prize in Chemistry awarded to Emmanuelle Charpentier",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.74609375,
            "end_logit": -6.97265625,
            "text": "Emmanuel",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.74609375,
            "end_logit": -7.12890625,
            "text": "Emmanuelle Charpentier and Jennifer Doudna for",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.74609375,
            "end_logit": -7.1484375,
            "text": "Emmanuelle Charpent",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.74609375,
            "end_logit": -7.1484375,
            "text": "Emmanuelle Charpentier and Je",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.74609375,
            "end_logit": -7.15625,
            "text": "Emmanuelle Charpentier and Jennifer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.74609375,
            "end_logit": -7.2265625,
            "text": "Emmanuelle Charpentier and Jennifer Doudna for their discovery of the CRISPR",
            "probability": 1.1920928955078125e-07
        }
    ],
    "601f19d11cb411341a000073_2": [
        {
            "start_logit": 7.5078125,
            "end_logit": 8.4140625,
            "text": "Emmanuelle Charpentier",
            "probability": 1.0
        },
        {
            "start_logit": -2.677734375,
            "end_logit": 8.4140625,
            "text": "ier",
            "probability": 3.7610530853271484e-05
        },
        {
            "start_logit": 7.5078125,
            "end_logit": -3.8359375,
            "text": "Em",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": 7.5078125,
            "end_logit": -5.69140625,
            "text": "Emmanuelle Charpentier and Jennifer Doudna",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.73046875,
            "end_logit": 8.4140625,
            "text": "ers Emmanuelle Charpentier",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.80078125,
            "end_logit": 8.4140625,
            "text": "CRISPR-Cas pioneers Emmanuelle Charpentier",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.86328125,
            "end_logit": 8.4140625,
            "text": "manuelle Charpentier",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.5078125,
            "end_logit": -5.99609375,
            "text": "Emmanuelle Charpentier and Jennifer Doudna, who developed the CRISPR-Cas system to precisely edit genomic DNA.",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.95703125,
            "end_logit": 8.4140625,
            "text": "ntier",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.14453125,
            "end_logit": 8.4140625,
            "text": "to CRISPR-Cas pioneers Emmanuelle Charpentier",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.1875,
            "end_logit": 8.4140625,
            "text": "2020 Nobel Prize in Chemistry was awarded to CRISPR-Cas pioneers Emmanuelle Charpentier",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.2265625,
            "end_logit": 8.4140625,
            "text": "pioneers Emmanuelle Charpentier",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 8.4140625,
            "text": "Charpentier",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.3046875,
            "end_logit": 8.4140625,
            "text": "pentier",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 8.4140625,
            "text": "le Charpentier",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.5078125,
            "end_logit": -6.58984375,
            "text": "Emmanuel",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 8.4140625,
            "text": "Prize in Chemistry was awarded to CRISPR-Cas pioneers Emmanuelle Charpentier",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.546875,
            "end_logit": 8.4140625,
            "text": "in Chemistry was awarded to CRISPR-Cas pioneers Emmanuelle Charpentier",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.5078125,
            "end_logit": -7.02734375,
            "text": "Emmanuelle Charpent",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.5078125,
            "end_logit": -7.078125,
            "text": "Emmanuelle Charpentier and Jennifer Do",
            "probability": 1.7881393432617188e-07
        }
    ],
    "601f19d11cb411341a000073_3": [
        {
            "start_logit": 7.6875,
            "end_logit": 6.75,
            "text": "Emmanuelle Charpentier",
            "probability": 1.0
        },
        {
            "start_logit": 7.6875,
            "end_logit": -3.75,
            "text": "Em",
            "probability": 2.753734588623047e-05
        },
        {
            "start_logit": -4.4296875,
            "end_logit": 6.75,
            "text": "ier",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": 7.6875,
            "end_logit": -5.9140625,
            "text": "Emmanuelle Charpent",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": 7.6875,
            "end_logit": -6.4296875,
            "text": "Emmanuelle Charpe",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 7.6875,
            "end_logit": -6.703125,
            "text": "Emmanuelle Charpentier, PhD, and Jennifer Doudna",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 7.6875,
            "end_logit": -6.80078125,
            "text": "Emmanuelle Char",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 7.6875,
            "end_logit": -6.8203125,
            "text": "Emmanuel",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 7.6875,
            "end_logit": -7.06640625,
            "text": "Emmanuelle",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 7.6875,
            "end_logit": -7.21875,
            "text": "Emmanuelle Charpentier, PhD, and Jennifer",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -6.4296875,
            "end_logit": 6.75,
            "text": "manuelle Charpentier",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 6.75,
            "text": "Charpentier",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -4.4296875,
            "end_logit": -6.703125,
            "text": "ier, PhD, and Jennifer Doudna",
            "probability": 0.0
        },
        {
            "start_logit": -4.4296875,
            "end_logit": -7.078125,
            "text": "ier, PhD, and Jennifer Doudna, PhD, who pioneered the site-specific CRISPR gene-editing",
            "probability": 0.0
        },
        {
            "start_logit": -4.4296875,
            "end_logit": -7.1171875,
            "text": "ier, PhD, and Jennifer Doudna, PhD, who pioneered the site-specific CRISPR gene-editing technology",
            "probability": 0.0
        },
        {
            "start_logit": -4.4296875,
            "end_logit": -7.21875,
            "text": "ier, PhD, and Jennifer",
            "probability": 0.0
        },
        {
            "start_logit": -6.04296875,
            "end_logit": -5.73046875,
            "text": "cancer research and treatment, were awarded the 2020 Nobel Prize in Chemistry.",
            "probability": 0.0
        },
        {
            "start_logit": -6.43359375,
            "end_logit": -5.73046875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.04296875,
            "end_logit": -6.23046875,
            "text": "cancer",
            "probability": 0.0
        },
        {
            "start_logit": -6.4296875,
            "end_logit": -5.9140625,
            "text": "manuelle Charpent",
            "probability": 0.0
        }
    ],
    "601f19d11cb411341a000073_4": [
        {
            "start_logit": 2.373046875,
            "end_logit": 8.1015625,
            "text": "Dr. Emmanuelle Charpentier",
            "probability": 0.72314453125
        },
        {
            "start_logit": 1.3984375,
            "end_logit": 8.1015625,
            "text": "Emmanuelle Charpentier",
            "probability": 0.2724609375
        },
        {
            "start_logit": -3.052734375,
            "end_logit": 8.1015625,
            "text": "ier",
            "probability": 0.003170013427734375
        },
        {
            "start_logit": -5.4140625,
            "end_logit": 8.1015625,
            "text": ", Dr. Emmanuelle Charpentier",
            "probability": 0.0002994537353515625
        },
        {
            "start_logit": -5.9140625,
            "end_logit": 8.1015625,
            "text": "Charpentier",
            "probability": 0.00018167495727539062
        },
        {
            "start_logit": -6.140625,
            "end_logit": 8.1015625,
            "text": "ntier",
            "probability": 0.00014483928680419922
        },
        {
            "start_logit": -6.2578125,
            "end_logit": 8.1015625,
            "text": "pentier",
            "probability": 0.00012886524200439453
        },
        {
            "start_logit": -6.51953125,
            "end_logit": 8.1015625,
            "text": ". Emmanuelle Charpentier",
            "probability": 9.959936141967773e-05
        },
        {
            "start_logit": -6.96875,
            "end_logit": 8.1015625,
            "text": "0, Dr. Emmanuelle Charpentier",
            "probability": 6.330013275146484e-05
        },
        {
            "start_logit": -7.171875,
            "end_logit": 8.1015625,
            "text": "le Charpentier",
            "probability": 5.161762237548828e-05
        },
        {
            "start_logit": -7.21484375,
            "end_logit": 8.1015625,
            "text": "manuelle Charpentier",
            "probability": 4.929304122924805e-05
        },
        {
            "start_logit": 2.373046875,
            "end_logit": -5.8125,
            "text": "Dr. Emmanuelle Charpentier and Dr. Jennifer Doudna",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 2.373046875,
            "end_logit": -6.26171875,
            "text": "Dr. Emmanuelle Charpentier and Dr. Jennifer",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 2.373046875,
            "end_logit": -6.44140625,
            "text": "Dr. Emmanuel",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 1.3984375,
            "end_logit": -5.8125,
            "text": "Emmanuelle Charpentier and Dr. Jennifer Doudna",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 2.373046875,
            "end_logit": -6.9921875,
            "text": "Dr. Emmanuelle Charpentier and Dr. Jenn",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 2.373046875,
            "end_logit": -6.99609375,
            "text": "Dr. Emmanuelle Charpentier and Dr",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 1.3984375,
            "end_logit": -6.26171875,
            "text": "Emmanuelle Charpentier and Dr. Jennifer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 2.373046875,
            "end_logit": -7.28515625,
            "text": "Dr. Emmanuelle Charpentier and Dr. Jennifer Do",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 2.373046875,
            "end_logit": -7.3046875,
            "text": "Dr",
            "probability": 1.1920928955078125e-07
        }
    ],
    "601f19d11cb411341a000073_5": [
        {
            "start_logit": 7.5078125,
            "end_logit": 8.4140625,
            "text": "Emmanuelle Charpentier",
            "probability": 1.0
        },
        {
            "start_logit": -2.677734375,
            "end_logit": 8.4140625,
            "text": "ier",
            "probability": 3.7610530853271484e-05
        },
        {
            "start_logit": 7.5078125,
            "end_logit": -3.8359375,
            "text": "Em",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": 7.5078125,
            "end_logit": -5.69140625,
            "text": "Emmanuelle Charpentier and Jennifer Doudna",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.73046875,
            "end_logit": 8.4140625,
            "text": "ers Emmanuelle Charpentier",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.80078125,
            "end_logit": 8.4140625,
            "text": "CRISPR-Cas pioneers Emmanuelle Charpentier",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.86328125,
            "end_logit": 8.4140625,
            "text": "manuelle Charpentier",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.5078125,
            "end_logit": -5.99609375,
            "text": "Emmanuelle Charpentier and Jennifer Doudna, who developed the CRISPR-Cas system to precisely edit genomic DNA.",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.95703125,
            "end_logit": 8.4140625,
            "text": "ntier",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.14453125,
            "end_logit": 8.4140625,
            "text": "to CRISPR-Cas pioneers Emmanuelle Charpentier",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.1875,
            "end_logit": 8.4140625,
            "text": "2020 Nobel Prize in Chemistry was awarded to CRISPR-Cas pioneers Emmanuelle Charpentier",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.2265625,
            "end_logit": 8.4140625,
            "text": "pioneers Emmanuelle Charpentier",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 8.4140625,
            "text": "Charpentier",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.3046875,
            "end_logit": 8.4140625,
            "text": "pentier",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 8.4140625,
            "text": "le Charpentier",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.5078125,
            "end_logit": -6.58984375,
            "text": "Emmanuel",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 8.4140625,
            "text": "Prize in Chemistry was awarded to CRISPR-Cas pioneers Emmanuelle Charpentier",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.546875,
            "end_logit": 8.4140625,
            "text": "in Chemistry was awarded to CRISPR-Cas pioneers Emmanuelle Charpentier",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.5078125,
            "end_logit": -7.02734375,
            "text": "Emmanuelle Charpent",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.5078125,
            "end_logit": -7.078125,
            "text": "Emmanuelle Charpentier and Jennifer Do",
            "probability": 1.7881393432617188e-07
        }
    ],
    "601f19d11cb411341a000073_6": [
        {
            "start_logit": 7.62890625,
            "end_logit": 7.546875,
            "text": "Emmanuelle Charpentier",
            "probability": 1.0
        },
        {
            "start_logit": 7.62890625,
            "end_logit": -2.306640625,
            "text": "Emmanuelle Charpentier and Jennifer Doudna",
            "probability": 5.269050598144531e-05
        },
        {
            "start_logit": 7.62890625,
            "end_logit": -3.802734375,
            "text": "Em",
            "probability": 1.1861324310302734e-05
        },
        {
            "start_logit": -3.80859375,
            "end_logit": 7.546875,
            "text": "ier",
            "probability": 1.0788440704345703e-05
        },
        {
            "start_logit": -6.06640625,
            "end_logit": 7.546875,
            "text": "ers Emmanuelle Charpentier",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 7.62890625,
            "end_logit": -6.51171875,
            "text": "Emmanuel",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.69140625,
            "end_logit": 7.546875,
            "text": "manuelle Charpentier",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.8125,
            "end_logit": 7.546875,
            "text": "pioneers Emmanuelle Charpentier",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.62890625,
            "end_logit": -6.91015625,
            "text": "Emmanuelle Charpentier and Jennifer Do",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.62890625,
            "end_logit": -6.99609375,
            "text": "Emmanuelle Char",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.62890625,
            "end_logit": -7.01953125,
            "text": "Emmanuelle Charpe",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.62890625,
            "end_logit": -7.03515625,
            "text": "Emmanuelle Charpent",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.62890625,
            "end_logit": -7.04296875,
            "text": "Emmanuelle Charpentier and Jennifer",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.62890625,
            "end_logit": -7.1171875,
            "text": "Emmanuelle",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.62890625,
            "end_logit": -7.14453125,
            "text": "Emmanuelle Charpentier and Jennifer Doud",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.15625,
            "end_logit": 7.546875,
            "text": "ntier",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.62890625,
            "end_logit": -7.26171875,
            "text": "Emmanuelle Charpentier and Jennifer Doudna, who developed the CRISPR-Cas system to",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.62890625,
            "end_logit": -7.265625,
            "text": "Emmanuelle Charpentier and Jennifer Doudna, who developed the CRISPR-Cas",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.62890625,
            "end_logit": -7.28515625,
            "text": "Emmanuelle Charpentier and Jennifer Doudna, who developed the CRISPR-Cas system to precisely edit genomic DNA",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.28125,
            "end_logit": 7.546875,
            "text": "CRISPR-Cas pioneers Emmanuelle Charpentier",
            "probability": 3.5762786865234375e-07
        }
    ],
    "601f19d11cb411341a000073_7": [
        {
            "start_logit": 7.86328125,
            "end_logit": 7.3984375,
            "text": "Emmanuelle Charpentier",
            "probability": 1.0
        },
        {
            "start_logit": 7.86328125,
            "end_logit": -3.505859375,
            "text": "Em",
            "probability": 1.8358230590820312e-05
        },
        {
            "start_logit": -3.810546875,
            "end_logit": 7.3984375,
            "text": "ier",
            "probability": 8.463859558105469e-06
        },
        {
            "start_logit": 7.86328125,
            "end_logit": -5.93359375,
            "text": "Emmanuelle Charpent",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 7.86328125,
            "end_logit": -6.5703125,
            "text": "Emmanuelle Charpe",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 7.86328125,
            "end_logit": -6.59375,
            "text": "Emmanuelle Charpentier, PhD, and Jennifer Doudna",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 7.86328125,
            "end_logit": -6.8515625,
            "text": "Emmanuel",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.5078125,
            "end_logit": 7.3984375,
            "text": "manuelle Charpentier",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.86328125,
            "end_logit": -7.015625,
            "text": "Emmanuelle Char",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.86328125,
            "end_logit": -7.11328125,
            "text": "Emmanuelle",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.86328125,
            "end_logit": -7.2578125,
            "text": "Emmanuelle Charpentier,",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.1640625,
            "end_logit": 7.3984375,
            "text": "Charpentier",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 7.3984375,
            "text": "uelle Charpentier",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -3.810546875,
            "end_logit": -6.59375,
            "text": "ier, PhD, and Jennifer Doudna",
            "probability": 0.0
        },
        {
            "start_logit": -3.810546875,
            "end_logit": -7.06640625,
            "text": "ier, PhD, and Jennifer Doudna, PhD, who pioneered the site-specific CRISPR gene-editing technology",
            "probability": 0.0
        },
        {
            "start_logit": -3.810546875,
            "end_logit": -7.078125,
            "text": "ier, PhD, and Jennifer Doudna, PhD, who pioneered the site-specific CRISPR gene-editing",
            "probability": 0.0
        },
        {
            "start_logit": -3.810546875,
            "end_logit": -7.2578125,
            "text": "ier,",
            "probability": 0.0
        },
        {
            "start_logit": -6.01171875,
            "end_logit": -6.28125,
            "text": "cancer",
            "probability": 0.0
        },
        {
            "start_logit": -6.01171875,
            "end_logit": -6.3046875,
            "text": "cancer research and treatment, were awarded the 2020 Nobel Prize in Chemistry",
            "probability": 0.0
        },
        {
            "start_logit": -6.5078125,
            "end_logit": -5.93359375,
            "text": "manuelle Charpent",
            "probability": 0.0
        }
    ],
    "601f19d11cb411341a000073_8": [
        {
            "start_logit": 8.078125,
            "end_logit": 8.84375,
            "text": "Jean Bennett",
            "probability": 1.0
        },
        {
            "start_logit": -2.24609375,
            "end_logit": 8.84375,
            "text": "t",
            "probability": 3.272294998168945e-05
        },
        {
            "start_logit": -3.35546875,
            "end_logit": 8.84375,
            "text": "Katherine Uyhazi and renowned gene therapy pioneer Jean Bennett",
            "probability": 1.0788440704345703e-05
        },
        {
            "start_logit": 8.078125,
            "end_logit": -3.26953125,
            "text": "Je",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": 8.078125,
            "end_logit": -3.466796875,
            "text": "Jean Ben",
            "probability": 4.470348358154297e-06
        },
        {
            "start_logit": -6.9140625,
            "end_logit": 8.84375,
            "text": "gene therapy pioneer Jean Bennett",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -6.23828125,
            "text": "Jean Bennet",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 8.84375,
            "text": "Uyhazi and renowned gene therapy pioneer Jean Bennett",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.30859375,
            "end_logit": 8.84375,
            "text": "an Bennett",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -6.75,
            "text": "Jean Bennett share",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.609375,
            "end_logit": 8.84375,
            "text": "renowned gene therapy pioneer Jean Bennett",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -6.89453125,
            "text": "Jean",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -7.12890625,
            "text": "Jean Bennett share their perspective on the 2020 Nobel Prize in Chemistry",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -7.2890625,
            "text": "Jean Bennett share their perspective on the 2020 Nobel Prize in Chemistry awarded to Emmanuelle Charpentier",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.35546875,
            "end_logit": -3.26953125,
            "text": "Katherine Uyhazi and renowned gene therapy pioneer Je",
            "probability": 0.0
        },
        {
            "start_logit": -3.35546875,
            "end_logit": -3.466796875,
            "text": "Katherine Uyhazi and renowned gene therapy pioneer Jean Ben",
            "probability": 0.0
        },
        {
            "start_logit": -3.35546875,
            "end_logit": -4.26953125,
            "text": "Katherine Uyhazi",
            "probability": 0.0
        },
        {
            "start_logit": -2.24609375,
            "end_logit": -6.75,
            "text": "t share",
            "probability": 0.0
        },
        {
            "start_logit": -2.24609375,
            "end_logit": -7.12890625,
            "text": "t share their perspective on the 2020 Nobel Prize in Chemistry",
            "probability": 0.0
        },
        {
            "start_logit": -2.24609375,
            "end_logit": -7.2890625,
            "text": "t share their perspective on the 2020 Nobel Prize in Chemistry awarded to Emmanuelle Charpentier",
            "probability": 0.0
        }
    ],
    "601f19d11cb411341a000073_9": [
        {
            "start_logit": 9.3203125,
            "end_logit": 9.390625,
            "text": "Jennifer Doudna",
            "probability": 1.0
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -1.037109375,
            "text": "Je",
            "probability": 2.9325485229492188e-05
        },
        {
            "start_logit": -1.142578125,
            "end_logit": 9.390625,
            "text": "na",
            "probability": 2.8431415557861328e-05
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -3.708984375,
            "text": "Jennifer Do",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -5.8203125,
            "text": "Jennifer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.3359375,
            "end_logit": 9.390625,
            "text": "nnifer Doudna",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -6.30078125,
            "text": "Jennifer Doudna won the Nobel Prize in Chemistry for their pioneering work in precise genome editing using the CRISPR technology.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -6.51953125,
            "text": "Jennifer Doud",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.62109375,
            "end_logit": 9.390625,
            "text": "udna",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -6.71484375,
            "text": "Jennifer Doudna won the Nobel Prize in Chemistry for their pioneering work in precise genome editing",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -6.8046875,
            "text": "Jennifer Doudna w",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9296875,
            "end_logit": 9.390625,
            "text": "ifer Doudna",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.98046875,
            "end_logit": 9.390625,
            "text": "Doudna",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.0625,
            "text": "Jennifer Doudna won the Nobel Prize in Chemistry for their pioneering work in precise genome editing using the CRISPR technology",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.13671875,
            "text": "Jennifer Doudna won the Nobel Prize in Chemistry",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.21484375,
            "text": "Jennifer Doudna won the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.2421875,
            "text": "Jennifer Doudna won the Nobel Prize in Chemistry for",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.26171875,
            "text": "Jennifer Doudna won the Nobel Prize",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.28515625,
            "text": "Jennifer Doudna won",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.3125,
            "text": "Jennifer Doudna won the Nobel Prize in Chemistry for their pioneering work in",
            "probability": 5.960464477539063e-08
        }
    ],
    "601f19d11cb411341a000073_10": [
        {
            "start_logit": 8.421875,
            "end_logit": 9.015625,
            "text": "Jean Bennett",
            "probability": 1.0
        },
        {
            "start_logit": -1.921875,
            "end_logit": 9.015625,
            "text": "t",
            "probability": 3.218650817871094e-05
        },
        {
            "start_logit": 8.421875,
            "end_logit": -2.78125,
            "text": "Je",
            "probability": 7.510185241699219e-06
        },
        {
            "start_logit": 8.421875,
            "end_logit": -3.17578125,
            "text": "Jean Ben",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": -3.791015625,
            "end_logit": 9.015625,
            "text": "Katherine Uyhazi and renowned gene therapy pioneer Jean Bennett",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": 8.421875,
            "end_logit": -6.125,
            "text": "Jean Bennet",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.921875,
            "end_logit": 9.015625,
            "text": "gene therapy pioneer Jean Bennett",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.16796875,
            "end_logit": 9.015625,
            "text": "Uyhazi and renowned gene therapy pioneer Jean Bennett",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.234375,
            "end_logit": 9.015625,
            "text": "an Bennett",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.421875,
            "end_logit": -6.68359375,
            "text": "Jean Bennett share",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.421875,
            "end_logit": -6.94921875,
            "text": "Jean",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 9.015625,
            "text": "er Jean Bennett",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 9.015625,
            "text": "renowned gene therapy pioneer Jean Bennett",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.421875,
            "end_logit": -7.16796875,
            "text": "Jean Bennett share their perspective on the 2020 Nobel Prize in Chemistry",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.421875,
            "end_logit": -7.26953125,
            "text": "Jean Bennett share their perspective on the 2020 Nobel Prize in Chemistry awarded to Emmanuelle Charpentier",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.791015625,
            "end_logit": -2.78125,
            "text": "Katherine Uyhazi and renowned gene therapy pioneer Je",
            "probability": 0.0
        },
        {
            "start_logit": -3.791015625,
            "end_logit": -3.17578125,
            "text": "Katherine Uyhazi and renowned gene therapy pioneer Jean Ben",
            "probability": 0.0
        },
        {
            "start_logit": -3.791015625,
            "end_logit": -4.70703125,
            "text": "Katherine Uyhazi",
            "probability": 0.0
        },
        {
            "start_logit": -1.921875,
            "end_logit": -6.68359375,
            "text": "t share",
            "probability": 0.0
        },
        {
            "start_logit": -1.921875,
            "end_logit": -7.16796875,
            "text": "t share their perspective on the 2020 Nobel Prize in Chemistry",
            "probability": 0.0
        }
    ],
    "52eea509c8da89891000000d_1": [
        {
            "start_logit": 9.3515625,
            "end_logit": 9.40625,
            "text": "KCNQ1",
            "probability": 1.0
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -0.96533203125,
            "text": "KCN",
            "probability": 3.147125244140625e-05
        },
        {
            "start_logit": -1.130859375,
            "end_logit": 9.40625,
            "text": "1",
            "probability": 2.8192996978759766e-05
        },
        {
            "start_logit": -5.49609375,
            "end_logit": 9.40625,
            "text": "Q1",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -5.94921875,
            "text": "KCNQ1 gene",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.1015625,
            "end_logit": 9.40625,
            "text": "mutations in the KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -7.32421875,
            "text": "KCNQ1 gene.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 9.40625,
            "text": "to mutations in the KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.453125,
            "end_logit": 9.40625,
            "text": "LQTS and is linked to mutations in the KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.484375,
            "end_logit": 9.40625,
            "text": "Long QT syndrome (LQTS) 1 is the most common type of inherited LQTS and is linked to mutations in the KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.40625,
            "text": "inherited LQTS and is linked to mutations in the KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6484375,
            "end_logit": 9.40625,
            "text": "linked to mutations in the KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 9.40625,
            "text": "LQTS) 1 is the most common type of inherited LQTS and is linked to mutations in the KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69140625,
            "end_logit": 9.40625,
            "text": "syndrome (LQTS) 1 is the most common type of inherited LQTS and is linked to mutations in the KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6953125,
            "end_logit": 9.40625,
            "text": "1 is the most common type of inherited LQTS and is linked to mutations in the KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.71875,
            "end_logit": 9.40625,
            "text": "and is linked to mutations in the KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.130859375,
            "end_logit": -5.94921875,
            "text": "1 gene",
            "probability": 0.0
        },
        {
            "start_logit": -7.1015625,
            "end_logit": -0.96533203125,
            "text": "mutations in the KCN",
            "probability": 0.0
        },
        {
            "start_logit": -7.44921875,
            "end_logit": -0.96533203125,
            "text": "to mutations in the KCN",
            "probability": 0.0
        },
        {
            "start_logit": -7.453125,
            "end_logit": -0.96533203125,
            "text": "LQTS and is linked to mutations in the KCN",
            "probability": 0.0
        }
    ],
    "52eea509c8da89891000000d_2": [
        {
            "start_logit": 9.3359375,
            "end_logit": 9.578125,
            "text": "KCNQ1",
            "probability": 1.0
        },
        {
            "start_logit": -0.55908203125,
            "end_logit": 9.578125,
            "text": "1",
            "probability": 5.066394805908203e-05
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -1.01953125,
            "text": "KCN",
            "probability": 2.5093555450439453e-05
        },
        {
            "start_logit": -6.28125,
            "end_logit": 9.578125,
            "text": "Q1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -6.4921875,
            "text": "KCNQ",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.046875,
            "end_logit": 9.578125,
            "text": "KQT-like, voltage-gated potassium channel-1 gene (KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -6.89453125,
            "text": "KCNQ1; MIM 607542",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3125,
            "end_logit": 9.578125,
            "text": "single nucleotide mutation in the KQT-like, voltage-gated potassium channel-1 gene (KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3203125,
            "end_logit": 9.578125,
            "text": "nucleotide mutation in the KQT-like, voltage-gated potassium channel-1 gene (KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.12109375,
            "text": "KCNQ1; MIM 607542).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.375,
            "end_logit": 9.578125,
            "text": ", voltage-gated potassium channel-1 gene (KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.15234375,
            "text": "KCNQ1; MIM 6075",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 9.578125,
            "text": "voltage-gated potassium channel-1 gene (KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.21875,
            "text": "KCNQ1; MIM 607542)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 9.578125,
            "text": "by a single nucleotide mutation in the KQT-like, voltage-gated potassium channel-1 gene (KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 9.578125,
            "text": "(KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.30859375,
            "text": "KCNQ1; MIM 60",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.40234375,
            "text": "KCNQ1;",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.55908203125,
            "end_logit": -6.89453125,
            "text": "1; MIM 607542",
            "probability": 0.0
        },
        {
            "start_logit": -0.55908203125,
            "end_logit": -7.12109375,
            "text": "1; MIM 607542).",
            "probability": 0.0
        }
    ],
    "52eea509c8da89891000000d_3": [
        {
            "start_logit": 9.265625,
            "end_logit": 9.34375,
            "text": "KCNQ1",
            "probability": 1.0
        },
        {
            "start_logit": 9.265625,
            "end_logit": -1.2451171875,
            "text": "KCN",
            "probability": 2.5272369384765625e-05
        },
        {
            "start_logit": -1.3271484375,
            "end_logit": 9.34375,
            "text": "1",
            "probability": 2.5093555450439453e-05
        },
        {
            "start_logit": -5.8828125,
            "end_logit": 9.34375,
            "text": "Q1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.01953125,
            "end_logit": 9.34375,
            "text": ", KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.04296875,
            "end_logit": 9.34375,
            "text": "Mutations in a cardiac voltage-gated potassium channel, KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.01953125,
            "text": "KCNQ1, account for the most common form of LQTS",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.078125,
            "text": "KCNQ1,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.16796875,
            "text": "KCNQ1, account",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.2734375,
            "text": "KCNQ1, account for the most common form of LQTS, LQTS1.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.44140625,
            "text": "KCNQ1, account for the most common form of LQ",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.4453125,
            "text": "KCNQ1, account for the most common form of LQTS, LQTS1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.5078125,
            "text": "KCNQ1, account for",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.5078125,
            "text": "KCNQ1, account for the most common form of LQTS, LQTS",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.53125,
            "text": "KCNQ1, account for the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 9.34375,
            "text": "cardiac voltage-gated potassium channel, KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.625,
            "end_logit": 9.34375,
            "text": "voltage-gated potassium channel, KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.55078125,
            "text": "KCNQ1, account for the most common form of LQTS,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 9.34375,
            "text": "channel, KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.5703125,
            "text": "KCNQ1, account for the most common form of",
            "probability": 5.960464477539063e-08
        }
    ],
    "52eea509c8da89891000000d_4": [
        {
            "start_logit": 1.59375,
            "end_logit": 5.12109375,
            "text": "KCNQ1",
            "probability": 0.986328125
        },
        {
            "start_logit": -3.486328125,
            "end_logit": 5.12109375,
            "text": "genes KCNQ1",
            "probability": 0.0061492919921875
        },
        {
            "start_logit": 1.59375,
            "end_logit": -0.60791015625,
            "text": "KCNQ1 and KCNH2",
            "probability": 0.0032024383544921875
        },
        {
            "start_logit": 1.59375,
            "end_logit": -0.880859375,
            "text": "KCNQ1 and KCNH2 (HERG",
            "probability": 0.002445220947265625
        },
        {
            "start_logit": -5.3671875,
            "end_logit": 5.12109375,
            "text": "1",
            "probability": 0.0009355545043945312
        },
        {
            "start_logit": -6.66015625,
            "end_logit": 5.12109375,
            "text": "mutations (using mSSCP and sequencing), genomic DNA was obtained from patients to determine the expression levels of the genes KCNQ1",
            "probability": 0.00025773048400878906
        },
        {
            "start_logit": -7.0234375,
            "end_logit": 5.12109375,
            "text": "patients to determine the expression levels of the genes KCNQ1",
            "probability": 0.0001785755157470703
        },
        {
            "start_logit": -7.03515625,
            "end_logit": 5.12109375,
            "text": ", genomic DNA was obtained from patients to determine the expression levels of the genes KCNQ1",
            "probability": 0.00017714500427246094
        },
        {
            "start_logit": -7.04296875,
            "end_logit": 5.12109375,
            "text": "Q1",
            "probability": 0.00017440319061279297
        },
        {
            "start_logit": -1.6884765625,
            "end_logit": -0.60791015625,
            "text": "KCNH2",
            "probability": 0.00011986494064331055
        },
        {
            "start_logit": -1.6884765625,
            "end_logit": -0.880859375,
            "text": "KCNH2 (HERG",
            "probability": 9.191036224365234e-05
        },
        {
            "start_logit": -3.486328125,
            "end_logit": -0.60791015625,
            "text": "genes KCNQ1 and KCNH2",
            "probability": 1.9848346710205078e-05
        },
        {
            "start_logit": -3.23828125,
            "end_logit": -0.880859375,
            "text": "HERG",
            "probability": 1.9609928131103516e-05
        },
        {
            "start_logit": -3.486328125,
            "end_logit": -0.880859375,
            "text": "genes KCNQ1 and KCNH2 (HERG",
            "probability": 1.52587890625e-05
        },
        {
            "start_logit": 1.59375,
            "end_logit": -6.359375,
            "text": "KCNQ1 and KCNH2 (",
            "probability": 1.0192394256591797e-05
        },
        {
            "start_logit": 1.59375,
            "end_logit": -6.36328125,
            "text": "KCNQ1 and KCNH2 (HERG), involved in the occurrence of clinical signs of disease.",
            "probability": 1.0192394256591797e-05
        },
        {
            "start_logit": 1.59375,
            "end_logit": -6.6484375,
            "text": "KCNQ1 and KCNH2 (HERG)",
            "probability": 7.62939453125e-06
        },
        {
            "start_logit": 1.59375,
            "end_logit": -6.8125,
            "text": "KCNQ1 and KCNH2 (HER",
            "probability": 6.496906280517578e-06
        },
        {
            "start_logit": 1.59375,
            "end_logit": -7.09375,
            "text": "KCNQ",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": -5.3671875,
            "end_logit": -0.60791015625,
            "text": "1 and KCNH2",
            "probability": 3.039836883544922e-06
        }
    ],
    "52eea509c8da89891000000d_5": [
        {
            "start_logit": 1.8134765625,
            "end_logit": 4.265625,
            "text": "KCNJ5",
            "probability": 0.77978515625
        },
        {
            "start_logit": 2.08984375,
            "end_logit": 2.65625,
            "text": "and SCN5A",
            "probability": 0.205810546875
        },
        {
            "start_logit": -0.66796875,
            "end_logit": 2.65625,
            "text": "SCN5A",
            "probability": 0.01305389404296875
        },
        {
            "start_logit": -5.984375,
            "end_logit": 4.265625,
            "text": "5",
            "probability": 0.00032067298889160156
        },
        {
            "start_logit": -4.4765625,
            "end_logit": 2.65625,
            "text": ", KCNH2 (locus name LQT2) and SCN5A",
            "probability": 0.0002894401550292969
        },
        {
            "start_logit": 2.08984375,
            "end_logit": -4.55078125,
            "text": "and SCN5A (locus name LQT3) are the most common. Other, less frequently involved genes are KCNE1",
            "probability": 0.000152587890625
        },
        {
            "start_logit": -5.36328125,
            "end_logit": 2.65625,
            "text": "KCNQ1 (locus name LQT1), KCNH2 (locus name LQT2) and SCN5A",
            "probability": 0.00011974573135375977
        },
        {
            "start_logit": 2.08984375,
            "end_logit": -4.8828125,
            "text": "and",
            "probability": 0.00010907649993896484
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 4.265625,
            "text": "and KCNJ5",
            "probability": 0.00010246038436889648
        },
        {
            "start_logit": -5.99609375,
            "end_logit": 2.65625,
            "text": "KCNH2 (locus name LQT2) and SCN5A",
            "probability": 6.312131881713867e-05
        },
        {
            "start_logit": -6.75,
            "end_logit": 2.65625,
            "text": "which KCNQ1 (locus name LQT1), KCNH2 (locus name LQT2) and SCN5A",
            "probability": 2.9802322387695312e-05
        },
        {
            "start_logit": -6.83203125,
            "end_logit": 2.65625,
            "text": "5A",
            "probability": 2.753734588623047e-05
        },
        {
            "start_logit": 2.08984375,
            "end_logit": -6.56640625,
            "text": "and SCN5A (locus name LQT3) are",
            "probability": 2.0325183868408203e-05
        },
        {
            "start_logit": 2.08984375,
            "end_logit": -6.61328125,
            "text": "and SCN5A (locus name LQT3) are the most common.",
            "probability": 1.9371509552001953e-05
        },
        {
            "start_logit": 1.8134765625,
            "end_logit": -6.43359375,
            "text": "KCNJ",
            "probability": 1.7523765563964844e-05
        },
        {
            "start_logit": 1.8134765625,
            "end_logit": -6.60546875,
            "text": "KCNJ5 (locus name LQT13).",
            "probability": 1.4781951904296875e-05
        },
        {
            "start_logit": -0.66796875,
            "end_logit": -4.55078125,
            "text": "SCN5A (locus name LQT3) are the most common. Other, less frequently involved genes are KCNE1",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": -0.66796875,
            "end_logit": -6.56640625,
            "text": "SCN5A (locus name LQT3) are",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -0.66796875,
            "end_logit": -6.61328125,
            "text": "SCN5A (locus name LQT3) are the most common.",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -4.4765625,
            "end_logit": -4.8828125,
            "text": ", KCNH2 (locus name LQT2) and",
            "probability": 1.1920928955078125e-07
        }
    ],
    "52eea509c8da89891000000d_6": [
        {
            "start_logit": 9.328125,
            "end_logit": 9.4453125,
            "text": "KCNQ1",
            "probability": 1.0
        },
        {
            "start_logit": -1.0234375,
            "end_logit": 9.4453125,
            "text": "1",
            "probability": 3.170967102050781e-05
        },
        {
            "start_logit": 9.328125,
            "end_logit": -1.0361328125,
            "text": "KCN",
            "probability": 2.777576446533203e-05
        },
        {
            "start_logit": -5.67578125,
            "end_logit": 9.4453125,
            "text": "Q1",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -5.68359375,
            "text": "KCNQ1 gene",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.25,
            "end_logit": 9.4453125,
            "text": "mutations in the KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.32421875,
            "end_logit": 9.4453125,
            "text": "LQT1) is caused by mutations in the KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 9.4453125,
            "text": "by mutations in the KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.453125,
            "end_logit": 9.4453125,
            "text": "long-QT syndrome (LQT1) is caused by mutations in the KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.33984375,
            "text": "KCNQ1 gene.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 9.4453125,
            "text": "in the KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 9.4453125,
            "text": "syndrome (LQT1) is caused by mutations in the KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 9.4453125,
            "text": "Type-1 long-QT syndrome (LQT1) is caused by mutations in the KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 9.4453125,
            "text": "caused by mutations in the KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.4453125,
            "text": "-QT syndrome (LQT1) is caused by mutations in the KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 9.4453125,
            "text": "-1 long-QT syndrome (LQT1) is caused by mutations in the KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.57421875,
            "text": "KCNQ",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.0234375,
            "end_logit": -5.68359375,
            "text": "1 gene",
            "probability": 0.0
        },
        {
            "start_logit": -7.25,
            "end_logit": -1.0361328125,
            "text": "mutations in the KCN",
            "probability": 0.0
        },
        {
            "start_logit": -1.0234375,
            "end_logit": -7.33984375,
            "text": "1 gene.",
            "probability": 0.0
        }
    ],
    "52eea509c8da89891000000d_7": [
        {
            "start_logit": 2.09375,
            "end_logit": 3.650390625,
            "text": "KCNQ1",
            "probability": 0.97509765625
        },
        {
            "start_logit": 2.09375,
            "end_logit": -0.56689453125,
            "text": "KCNQ1 (Kv7.1), whereas drug-induced LQTS is a consequence of HERG",
            "probability": 0.01441192626953125
        },
        {
            "start_logit": 2.09375,
            "end_logit": -1.5400390625,
            "text": "KCNQ1 (Kv7.1",
            "probability": 0.0054473876953125
        },
        {
            "start_logit": -4.15234375,
            "end_logit": 3.650390625,
            "text": "mutations in KCNQ1",
            "probability": 0.0018968582153320312
        },
        {
            "start_logit": -0.787109375,
            "end_logit": -0.56689453125,
            "text": "HERG",
            "probability": 0.0008096694946289062
        },
        {
            "start_logit": 2.09375,
            "end_logit": -3.646484375,
            "text": "KCNQ1 (Kv7.1)",
            "probability": 0.0006608963012695312
        },
        {
            "start_logit": -5.90234375,
            "end_logit": 3.650390625,
            "text": "LQTS is most frequently caused by mutations in KCNQ1",
            "probability": 0.00032973289489746094
        },
        {
            "start_logit": -6.1328125,
            "end_logit": 3.650390625,
            "text": "1",
            "probability": 0.0002608299255371094
        },
        {
            "start_logit": -6.2734375,
            "end_logit": 3.650390625,
            "text": "in KCNQ1",
            "probability": 0.00022661685943603516
        },
        {
            "start_logit": -6.58984375,
            "end_logit": 3.650390625,
            "text": "by mutations in KCNQ1",
            "probability": 0.00016582012176513672
        },
        {
            "start_logit": -6.90234375,
            "end_logit": 3.650390625,
            "text": "Congenital LQTS is most frequently caused by mutations in KCNQ1",
            "probability": 0.00012123584747314453
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 3.650390625,
            "text": "caused by mutations in KCNQ1",
            "probability": 7.075071334838867e-05
        },
        {
            "start_logit": 2.09375,
            "end_logit": -6.015625,
            "text": "KCNQ1 (",
            "probability": 6.198883056640625e-05
        },
        {
            "start_logit": 2.09375,
            "end_logit": -6.03515625,
            "text": "KCNQ",
            "probability": 6.0498714447021484e-05
        },
        {
            "start_logit": 2.09375,
            "end_logit": -6.43359375,
            "text": "KCNQ1 (Kv7.",
            "probability": 4.094839096069336e-05
        },
        {
            "start_logit": 2.09375,
            "end_logit": -6.72265625,
            "text": "KCNQ1 (Kv7",
            "probability": 3.039836883544922e-05
        },
        {
            "start_logit": -4.15234375,
            "end_logit": -0.56689453125,
            "text": "mutations in KCNQ1 (Kv7.1), whereas drug-induced LQTS is a consequence of HERG",
            "probability": 2.7894973754882812e-05
        },
        {
            "start_logit": 2.09375,
            "end_logit": -7.04296875,
            "text": "KCN",
            "probability": 2.2292137145996094e-05
        },
        {
            "start_logit": 2.09375,
            "end_logit": -7.0703125,
            "text": "KCNQ1 (Kv7.1), whereas drug-induced LQTS is a consequence of HERG (",
            "probability": 2.1576881408691406e-05
        },
        {
            "start_logit": 2.09375,
            "end_logit": -7.265625,
            "text": "KCNQ1 (Kv7.1), whereas drug-induced LQTS",
            "probability": 1.7702579498291016e-05
        }
    ],
    "52eea509c8da89891000000d_8": [
        {
            "start_logit": 9.265625,
            "end_logit": 9.40625,
            "text": "KCNQ1",
            "probability": 1.0
        },
        {
            "start_logit": -1.154296875,
            "end_logit": 9.40625,
            "text": "1",
            "probability": 2.9802322387695312e-05
        },
        {
            "start_logit": 9.265625,
            "end_logit": -1.2255859375,
            "text": "KCN",
            "probability": 2.4139881134033203e-05
        },
        {
            "start_logit": -6.078125,
            "end_logit": 9.40625,
            "text": "Q1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -6.1796875,
            "text": "KCNQ1 induce the most common form of LQTS",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.8515625,
            "end_logit": 9.40625,
            "text": "Mutations in the voltage-gated potassium channel subunit KCNQ1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.1171875,
            "text": "KCNQ1 induce",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.1796875,
            "text": "KCNQ1 induce the most common form of LQTS.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.359375,
            "end_logit": 9.40625,
            "text": "voltage-gated potassium channel subunit KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 9.40625,
            "text": "subunit KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.2265625,
            "text": "KCNQ1 induce the most common form of LQ",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 9.40625,
            "text": "potassium channel subunit KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.3828125,
            "text": "KCNQ",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 9.40625,
            "text": "channel subunit KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.44921875,
            "text": "KCNQ1 induce the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.49609375,
            "text": "KCNQ1 induce the most common form of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.55859375,
            "text": "KCNQ1 induce the most common",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.56640625,
            "text": "KCNQ1 induce the most common form",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.154296875,
            "end_logit": -6.1796875,
            "text": "1 induce the most common form of LQTS",
            "probability": 0.0
        },
        {
            "start_logit": -6.8515625,
            "end_logit": -1.2255859375,
            "text": "Mutations in the voltage-gated potassium channel subunit KCN",
            "probability": 0.0
        }
    ],
    "52eea509c8da89891000000d_9": [
        {
            "start_logit": 3.396484375,
            "end_logit": 3.1484375,
            "text": "SCN5A",
            "probability": 0.99609375
        },
        {
            "start_logit": -2.556640625,
            "end_logit": 3.1484375,
            "text": "KCNQ1, KCNH2, SCN5A",
            "probability": 0.0025882720947265625
        },
        {
            "start_logit": -5.015625,
            "end_logit": 3.1484375,
            "text": "KCNH2, SCN5A",
            "probability": 0.00022089481353759766
        },
        {
            "start_logit": -5.86328125,
            "end_logit": 3.1484375,
            "text": ", SCN5A",
            "probability": 9.423494338989258e-05
        },
        {
            "start_logit": 3.396484375,
            "end_logit": -6.30859375,
            "text": "SCN5A, KCNE1 and KCNE2 and the accessory protein Ankyrin-B",
            "probability": 7.75456428527832e-05
        },
        {
            "start_logit": 3.396484375,
            "end_logit": -6.71875,
            "text": "SCN5A, KCNE1 and KCNE2 and the accessory protein Ankyrin-B gene, to be responsible for this disorder.",
            "probability": 5.167722702026367e-05
        },
        {
            "start_logit": 3.396484375,
            "end_logit": -6.7265625,
            "text": "SCN5A, KCNE1 and KCNE2",
            "probability": 5.125999450683594e-05
        },
        {
            "start_logit": 3.396484375,
            "end_logit": -6.796875,
            "text": "SCN5A, KCNE1",
            "probability": 4.774332046508789e-05
        },
        {
            "start_logit": -6.640625,
            "end_logit": 3.1484375,
            "text": ", KCNQ1, KCNH2, SCN5A",
            "probability": 4.3511390686035156e-05
        },
        {
            "start_logit": -6.6484375,
            "end_logit": 3.1484375,
            "text": "ion channel genes, KCNQ1, KCNH2, SCN5A",
            "probability": 4.315376281738281e-05
        },
        {
            "start_logit": 3.396484375,
            "end_logit": -6.953125,
            "text": "SCN5A, KCNE1 and KCNE2 and the accessory protein Ankyrin-B gene",
            "probability": 4.082918167114258e-05
        },
        {
            "start_logit": -6.859375,
            "end_logit": 3.1484375,
            "text": "5A",
            "probability": 3.49879264831543e-05
        },
        {
            "start_logit": 3.396484375,
            "end_logit": -7.1640625,
            "text": "SCN",
            "probability": 3.30805778503418e-05
        },
        {
            "start_logit": 3.396484375,
            "end_logit": -7.19140625,
            "text": "SCN5A, KCNE1 and KCN",
            "probability": 3.2067298889160156e-05
        },
        {
            "start_logit": 3.396484375,
            "end_logit": -7.24609375,
            "text": "SCN5A, KCNE1 and",
            "probability": 3.0338764190673828e-05
        },
        {
            "start_logit": -7.0546875,
            "end_logit": 3.1484375,
            "text": "mutations in six ion channel genes, KCNQ1, KCNH2, SCN5A",
            "probability": 2.872943878173828e-05
        },
        {
            "start_logit": 3.396484375,
            "end_logit": -7.3046875,
            "text": "SCN5A, KCNE1 and KCNE2 and",
            "probability": 2.872943878173828e-05
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 3.1484375,
            "text": "identified mutations in six ion channel genes, KCNQ1, KCNH2, SCN5A",
            "probability": 2.658367156982422e-05
        },
        {
            "start_logit": 3.396484375,
            "end_logit": -7.38671875,
            "text": "SCN5A, KCNE1 and KCNE2 and the accessory protein Ankyrin",
            "probability": 2.6345252990722656e-05
        },
        {
            "start_logit": 3.396484375,
            "end_logit": -7.421875,
            "text": "SCN5A, KCNE1 and KCNE2 and the accessory protein Ankyrin-",
            "probability": 2.5570392608642578e-05
        }
    ],
    "52eea509c8da89891000000d_10": [
        {
            "start_logit": 9.28125,
            "end_logit": 9.4453125,
            "text": "KCNQ1",
            "probability": 1.0
        },
        {
            "start_logit": -1.0224609375,
            "end_logit": 9.4453125,
            "text": "1",
            "probability": 3.3736228942871094e-05
        },
        {
            "start_logit": 9.28125,
            "end_logit": -1.177734375,
            "text": "KCN",
            "probability": 2.4497509002685547e-05
        },
        {
            "start_logit": -5.8828125,
            "end_logit": 9.4453125,
            "text": "Q1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.03125,
            "end_logit": 9.4453125,
            "text": "cardiac potassium channel gene KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1640625,
            "end_logit": 9.4453125,
            "text": "gene KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.21484375,
            "end_logit": 9.4453125,
            "text": "potassium channel gene KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3515625,
            "end_logit": 9.4453125,
            "text": "V254M-V417M) in the cardiac potassium channel gene KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.2265625,
            "text": "KCNQ1.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 9.4453125,
            "text": "in the cardiac potassium channel gene KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.296875,
            "text": "KCNQ",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 9.4453125,
            "text": "family members were carriers of two amino acid alterations in cis (V254M-V417M) in the cardiac potassium channel gene KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 9.4453125,
            "text": "channel gene KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 9.4453125,
            "text": "V417M) in the cardiac potassium channel gene KCNQ1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.03125,
            "end_logit": -1.177734375,
            "text": "cardiac potassium channel gene KCN",
            "probability": 0.0
        },
        {
            "start_logit": -1.0224609375,
            "end_logit": -7.2265625,
            "text": "1.",
            "probability": 0.0
        },
        {
            "start_logit": -7.1640625,
            "end_logit": -1.177734375,
            "text": "gene KCN",
            "probability": 0.0
        },
        {
            "start_logit": -7.21484375,
            "end_logit": -1.177734375,
            "text": "potassium channel gene KCN",
            "probability": 0.0
        },
        {
            "start_logit": -7.3515625,
            "end_logit": -1.177734375,
            "text": "V254M-V417M) in the cardiac potassium channel gene KCN",
            "probability": 0.0
        },
        {
            "start_logit": -7.45703125,
            "end_logit": -1.177734375,
            "text": "in the cardiac potassium channel gene KCN",
            "probability": 0.0
        }
    ],
    "52eea509c8da89891000000d_11": [
        {
            "start_logit": 9.2421875,
            "end_logit": 9.328125,
            "text": "KVLQT1",
            "probability": 1.0
        },
        {
            "start_logit": -1.3291015625,
            "end_logit": 9.328125,
            "text": "T1",
            "probability": 2.586841583251953e-05
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -1.248046875,
            "text": "KV",
            "probability": 2.568960189819336e-05
        },
        {
            "start_logit": -2.66015625,
            "end_logit": 9.328125,
            "text": "KCNQ1 (formerly called KVLQT1",
            "probability": 6.854534149169922e-06
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -5.734375,
            "text": "KVLQT1)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.9453125,
            "end_logit": 9.328125,
            "text": "LQT1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.41015625,
            "text": "KVLQT1) is a Shaker-like voltage-gated potassium channel gene responsible for the LQT1 sub-type of LQTS",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.4453125,
            "text": "KVLQT1) is",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.5859375,
            "end_logit": 9.328125,
            "text": "QT1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.6484375,
            "end_logit": 9.328125,
            "text": "called KVLQT1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.8828125,
            "text": "KVLQ",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.04296875,
            "text": "KVLQT1) is a Shaker-like voltage-gated potassium channel gene responsible for the LQT1 sub-type of LQTS.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.16796875,
            "text": "KVLQT1) is a Shaker-like voltage-gated potassium channel gene responsible for the LQT1 sub-type of LQ",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.25,
            "text": "KVLQT1) is a Shaker-like voltage-gated potassium channel gene responsible for the LQT1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.2578125,
            "text": "KVLQT1) is a Shaker-like voltage-gated potassium channel gene responsible",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.33203125,
            "text": "KVLQT1) is a Shaker-like voltage-gated potassium channel gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.4140625,
            "text": "KVLQT1) is a Shaker-like voltage-gated potassium channel gene responsible for the LQT1 sub-type",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.4375,
            "text": "KVLQT1) is a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.453125,
            "text": "KVLQT1) is a Shaker-like voltage-gated potassium channel gene responsible for",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.46875,
            "text": "KVLQT1) is a Shaker-like voltage-gated potassium channel gene responsible for the LQT1 sub",
            "probability": 5.960464477539063e-08
        }
    ],
    "52eea509c8da89891000000d_12": [
        {
            "start_logit": 8.2578125,
            "end_logit": 7.7109375,
            "text": "KCNE1",
            "probability": 0.9970703125
        },
        {
            "start_logit": 2.55078125,
            "end_logit": 7.7109375,
            "text": "SCN5A, KCNE1",
            "probability": 0.003326416015625
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -3.00390625,
            "text": "KCN",
            "probability": 2.205371856689453e-05
        },
        {
            "start_logit": -3.681640625,
            "end_logit": 7.7109375,
            "text": "E1",
            "probability": 6.556510925292969e-06
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -4.640625,
            "text": "KCNE1, and KCNE2",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": -4.296875,
            "end_logit": 7.7109375,
            "text": "HERG, SCN5A, KCNE1",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": 2.55078125,
            "end_logit": 0.79833984375,
            "text": "SCN5A",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": -5.1875,
            "end_logit": 7.7109375,
            "text": ", SCN5A, KCNE1",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -5.54296875,
            "end_logit": 7.7109375,
            "text": "KVLQT1, HERG, SCN5A, KCNE1",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -6.04296875,
            "end_logit": 7.7109375,
            "text": ", KCNE1",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -6.671875,
            "text": "KCNE1, and KCNE2.",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -6.73046875,
            "text": "KCNE1, and KCN",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.796875,
            "end_logit": 7.7109375,
            "text": ": KVLQT1, HERG, SCN5A, KCNE1",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.83203125,
            "end_logit": 7.7109375,
            "text": "LQTS: KVLQT1, HERG, SCN5A, KCNE1",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.8359375,
            "end_logit": 7.7109375,
            "text": ", HERG, SCN5A, KCNE1",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.12109375,
            "end_logit": 7.7109375,
            "text": "5A, KCNE1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.2421875,
            "end_logit": 7.7109375,
            "text": "G, SCN5A, KCNE1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 2.55078125,
            "end_logit": -3.00390625,
            "text": "SCN5A, KCN",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 2.55078125,
            "end_logit": -4.640625,
            "text": "SCN5A, KCNE1, and KCNE2",
            "probability": 0.0
        },
        {
            "start_logit": -4.296875,
            "end_logit": 0.79833984375,
            "text": "HERG, SCN5A",
            "probability": 0.0
        }
    ],
    "52eea509c8da89891000000d_13": [
        {
            "start_logit": 9.328125,
            "end_logit": 9.3984375,
            "text": "KVLQT1",
            "probability": 1.0
        },
        {
            "start_logit": -1.1064453125,
            "end_logit": 9.3984375,
            "text": "T1",
            "probability": 2.956390380859375e-05
        },
        {
            "start_logit": 9.328125,
            "end_logit": -1.044921875,
            "text": "KV",
            "probability": 2.9325485229492188e-05
        },
        {
            "start_logit": -5.89453125,
            "end_logit": 9.3984375,
            "text": "LQT1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.03125,
            "end_logit": 9.3984375,
            "text": "QT1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.8125,
            "end_logit": 9.3984375,
            "text": ". The primary defect in LQT1 is a mutation in KVLQT1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.75390625,
            "text": "KVLQ",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.12109375,
            "text": "KVLQT1, a gene that encodes the pore-forming alpha-subunit of a K+ channel.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.15234375,
            "text": "KVLQT1, a gene that encodes the pore-forming alpha-subunit of a K+ channel",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 9.3984375,
            "text": "LQT1 is a mutation in KVLQT1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46875,
            "end_logit": 9.3984375,
            "text": "in KVLQT1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 9.3984375,
            "text": "mutation in KVLQT1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.4296875,
            "text": "KVLQT1, a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.4375,
            "text": "KVLQT1, a gene that",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.44140625,
            "text": "KVLQT1, a gene that encodes the pore-forming alpha-subunit",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.4765625,
            "text": "KVLQT1, a gene that encodes the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.546875,
            "end_logit": 9.3984375,
            "text": "autosomal dominant trait (Romano-Ward syndrome). The primary defect in LQT1 is a mutation in KVLQT1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.546875,
            "end_logit": 9.3984375,
            "text": "a mutation in KVLQT1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.48046875,
            "text": "KVLQT1, a gene that encodes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69921875,
            "end_logit": 9.3984375,
            "text": "primary defect in LQT1 is a mutation in KVLQT1",
            "probability": 5.960464477539063e-08
        }
    ],
    "52eea509c8da89891000000d_14": [
        {
            "start_logit": 9.125,
            "end_logit": 9.28125,
            "text": "HERG",
            "probability": 1.0
        },
        {
            "start_logit": -1.3828125,
            "end_logit": 9.28125,
            "text": "G",
            "probability": 2.7298927307128906e-05
        },
        {
            "start_logit": 9.125,
            "end_logit": -1.525390625,
            "text": "HER",
            "probability": 2.0325183868408203e-05
        },
        {
            "start_logit": -3.82421875,
            "end_logit": 9.28125,
            "text": "human ether-a-go-go-related gene (HERG",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": 9.125,
            "end_logit": -4.59765625,
            "text": "HERG)",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -6.09765625,
            "end_logit": 9.28125,
            "text": "ether-a-go-go-related gene (HERG",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.7578125,
            "end_logit": 9.28125,
            "text": ". Clinical and genetic analyses revealed that a mutation was linked to the human ether-a-go-go-related gene (HERG",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.7578125,
            "end_logit": 9.28125,
            "text": "mutation was linked to the human ether-a-go-go-related gene (HERG",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.97265625,
            "end_logit": 9.28125,
            "text": "to the human ether-a-go-go-related gene (HERG",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.04296875,
            "end_logit": 9.28125,
            "text": "related gene (HERG",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0859375,
            "end_logit": 9.28125,
            "text": "gene (HERG",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.0078125,
            "text": "HERG).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1640625,
            "end_logit": 9.28125,
            "text": "that a mutation was linked to the human ether-a-go-go-related gene (HERG",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.23828125,
            "end_logit": 9.28125,
            "text": "(HERG",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3046875,
            "end_logit": 9.28125,
            "text": "a mutation was linked to the human ether-a-go-go-related gene (HERG",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 9.28125,
            "text": "Clinical and genetic analyses revealed that a mutation was linked to the human ether-a-go-go-related gene (HERG",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 9.28125,
            "text": "genetic analyses revealed that a mutation was linked to the human ether-a-go-go-related gene (HERG",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.82421875,
            "end_logit": -1.525390625,
            "text": "human ether-a-go-go-related gene (HER",
            "probability": 0.0
        },
        {
            "start_logit": -1.3828125,
            "end_logit": -4.59765625,
            "text": "G)",
            "probability": 0.0
        },
        {
            "start_logit": -6.09765625,
            "end_logit": -1.525390625,
            "text": "ether-a-go-go-related gene (HER",
            "probability": 0.0
        }
    ],
    "52eea509c8da89891000000d_15": [
        {
            "start_logit": 9.125,
            "end_logit": 9.34375,
            "text": "KCNA9",
            "probability": 1.0
        },
        {
            "start_logit": -1.203125,
            "end_logit": 9.34375,
            "text": "9",
            "probability": 3.272294998168945e-05
        },
        {
            "start_logit": 9.125,
            "end_logit": -1.49609375,
            "text": "KCN",
            "probability": 1.9550323486328125e-05
        },
        {
            "start_logit": -4.4921875,
            "end_logit": 9.34375,
            "text": "KVLQT1 (also known as KCNQ1 and KCNA9",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 9.125,
            "end_logit": -5.58984375,
            "text": "KCNA",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.29296875,
            "end_logit": 9.34375,
            "text": "compound heterozygosity for two mutations in the KVLQT1 (also known as KCNQ1 and KCNA9",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.34765625,
            "end_logit": 9.34375,
            "text": "A9",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.46875,
            "end_logit": 9.34375,
            "text": "KCNQ1 and KCNA9",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.7421875,
            "text": "KCNA9)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.125,
            "end_logit": 9.34375,
            "text": "two mutations in the KVLQT1 (also known as KCNQ1 and KCNA9",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2421875,
            "end_logit": 9.34375,
            "text": "with compound heterozygosity for two mutations in the KVLQT1 (also known as KCNQ1 and KCNA9",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 9.34375,
            "text": "and KCNA9",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4375,
            "end_logit": 9.34375,
            "text": "as KCNQ1 and KCNA9",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 9.34375,
            "text": "LQT1 (also known as KCNQ1 and KCNA9",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 9.34375,
            "text": "mutations in the KVLQT1 (also known as KCNQ1 and KCNA9",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.4921875,
            "end_logit": -1.49609375,
            "text": "KVLQT1 (also known as KCNQ1 and KCN",
            "probability": 0.0
        },
        {
            "start_logit": -6.29296875,
            "end_logit": -1.49609375,
            "text": "compound heterozygosity for two mutations in the KVLQT1 (also known as KCNQ1 and KCN",
            "probability": 0.0
        },
        {
            "start_logit": -1.203125,
            "end_logit": -6.7421875,
            "text": "9)",
            "probability": 0.0
        },
        {
            "start_logit": -6.46875,
            "end_logit": -1.49609375,
            "text": "KCNQ1 and KCN",
            "probability": 0.0
        },
        {
            "start_logit": -7.125,
            "end_logit": -1.49609375,
            "text": "two mutations in the KVLQT1 (also known as KCNQ1 and KCN",
            "probability": 0.0
        }
    ],
    "52eea509c8da89891000000d_16": [
        {
            "start_logit": 9.2421875,
            "end_logit": 9.2421875,
            "text": "SCN5A",
            "probability": 1.0
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -1.3046875,
            "text": "SCN",
            "probability": 2.6285648345947266e-05
        },
        {
            "start_logit": -1.4990234375,
            "end_logit": 9.2421875,
            "text": "5A",
            "probability": 2.1636486053466797e-05
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 9.2421875,
            "text": "sodium channel gene, SCN5A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.16796875,
            "text": "SCN5A,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.24609375,
            "text": "SCN5A, is also mutated in some Romano-Ward cases to produce defects in INa, the cardiac inward Na+ current",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.3125,
            "text": "SCN5A, is also mutated in some Romano-Ward cases to produce defects in INa, the cardiac inward Na+ current.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.35546875,
            "text": "SCN5A, is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.36328125,
            "text": "SCN5A, is also mutated in some Romano-Ward cases to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 9.2421875,
            "text": "cardiac sodium channel gene, SCN5A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.3984375,
            "text": "SCN5A, is also",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.44140625,
            "text": "SCN5A, is also mutated in some Romano-Ward cases to produce defects in INa",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 9.2421875,
            "text": ", SCN5A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.4765625,
            "text": "SCN5A, is also mutated",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.53125,
            "text": "SCN5A, is also mutated in some Romano-Ward cases to produce defects in INa, the cardiac inward Na",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.5390625,
            "text": "SCN5A, is also mutated in some Romano-Ward cases to produce defects in INa, the cardiac inward Na+",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.56640625,
            "text": "SCN5A, is also mutated in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.5703125,
            "text": "SCN5A, is also mutated in some Romano-Ward cases to produce defects in INa, the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.12890625,
            "end_logit": -1.3046875,
            "text": "sodium channel gene, SCN",
            "probability": 0.0
        },
        {
            "start_logit": -1.4990234375,
            "end_logit": -7.16796875,
            "text": "5A,",
            "probability": 0.0
        }
    ],
    "52eea509c8da89891000000d_17": [
        {
            "start_logit": 9.3046875,
            "end_logit": 9.359375,
            "text": "KVLQT1",
            "probability": 1.0
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -1.1123046875,
            "text": "KV",
            "probability": 2.86102294921875e-05
        },
        {
            "start_logit": -1.2431640625,
            "end_logit": 9.359375,
            "text": "T1",
            "probability": 2.6464462280273438e-05
        },
        {
            "start_logit": -5.71484375,
            "end_logit": 9.359375,
            "text": "LQT1",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.99609375,
            "end_logit": 9.359375,
            "text": "QT1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -6.9765625,
            "text": "KVLQ",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.21484375,
            "text": "KVLQT1 do",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.25,
            "text": "KVLQT1 do not invariably produce the Jervell and Lange-Nielsen syndrome.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 9.359375,
            "text": "that homozygous mutations on KVLQT1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.40234375,
            "text": "KVLQT1 do not invariably produce",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.4765625,
            "text": "KVLQT1 do not",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.49609375,
            "text": "KVLQT1 do not invariably produce the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 9.359375,
            "text": "homozygous mutations on KVLQT1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 9.359375,
            "text": "and indicate that homozygous mutations on KVLQT1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 9.359375,
            "text": "on KVLQT1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65625,
            "end_logit": 9.359375,
            "text": "findings provide the first evidence for a recessive form of the Romano-Ward long-QT syndrome and indicate that homozygous mutations on KVLQT1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69921875,
            "end_logit": 9.359375,
            "text": "recessive form of the Romano-Ward long-QT syndrome and indicate that homozygous mutations on KVLQT1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 9.359375,
            "text": "syndrome and indicate that homozygous mutations on KVLQT1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.71875,
            "end_logit": 9.359375,
            "text": "for a recessive form of the Romano-Ward long-QT syndrome and indicate that homozygous mutations on KVLQT1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.71875,
            "end_logit": 9.359375,
            "text": "first evidence for a recessive form of the Romano-Ward long-QT syndrome and indicate that homozygous mutations on KVLQT1",
            "probability": 5.960464477539063e-08
        }
    ],
    "602346eb1cb411341a000090_1": [
        {
            "start_logit": 9.109375,
            "end_logit": 9.21875,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": -1.6083984375,
            "end_logit": 9.21875,
            "text": "umab",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": 9.109375,
            "end_logit": -1.6337890625,
            "text": "ate",
            "probability": 1.9371509552001953e-05
        },
        {
            "start_logit": 9.109375,
            "end_logit": -5.27734375,
            "text": "atezolizumab and bevacizumab",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.359375,
            "end_logit": 9.21875,
            "text": "zolizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.51953125,
            "end_logit": 9.21875,
            "text": "lizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.4453125,
            "text": "atezoliz",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.86328125,
            "end_logit": 9.21875,
            "text": "zumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.9296875,
            "text": "atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma has recently been reported.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.1328125,
            "text": "atezoli",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 9.21875,
            "text": "of atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.3984375,
            "text": "atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma has recently been reported",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.42578125,
            "text": "atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 9.21875,
            "text": "combination of atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5625,
            "end_logit": 9.21875,
            "text": "phase III trial for the combination of atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.515625,
            "text": "atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma has",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.515625,
            "text": "atezolizumab and bevacizumab (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69140625,
            "end_logit": 9.21875,
            "text": "the combination of atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 9.21875,
            "text": "successful phase III trial for the combination of atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.6083984375,
            "end_logit": -5.27734375,
            "text": "umab and bevacizumab",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_2": [
        {
            "start_logit": 2.00390625,
            "end_logit": 4.0546875,
            "text": "pembrolizumab",
            "probability": 0.916015625
        },
        {
            "start_logit": -1.1484375,
            "end_logit": 4.0546875,
            "text": "lenvatinib plus pembrolizumab",
            "probability": 0.039154052734375
        },
        {
            "start_logit": 2.00390625,
            "end_logit": 0.87646484375,
            "text": "pembrolizumab and atezolizumab",
            "probability": 0.038177490234375
        },
        {
            "start_logit": -0.1619873046875,
            "end_logit": 0.87646484375,
            "text": "atezolizumab",
            "probability": 0.0043792724609375
        },
        {
            "start_logit": -1.1484375,
            "end_logit": 0.87646484375,
            "text": "lenvatinib plus pembrolizumab and atezolizumab",
            "probability": 0.001628875732421875
        },
        {
            "start_logit": -6.36328125,
            "end_logit": 4.0546875,
            "text": "umab",
            "probability": 0.00021278858184814453
        },
        {
            "start_logit": -1.1484375,
            "end_logit": -1.4443359375,
            "text": "lenvatinib",
            "probability": 0.00015938282012939453
        },
        {
            "start_logit": -7.09375,
            "end_logit": 4.0546875,
            "text": "eed, preliminary results from phase I studies of lenvatinib plus pembrolizumab",
            "probability": 0.00010293722152709961
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 4.0546875,
            "text": "of lenvatinib plus pembrolizumab",
            "probability": 9.369850158691406e-05
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 4.0546875,
            "text": "brolizumab",
            "probability": 8.469820022583008e-05
        },
        {
            "start_logit": -7.37890625,
            "end_logit": 4.0546875,
            "text": "preliminary results from phase I studies of lenvatinib plus pembrolizumab",
            "probability": 7.706880569458008e-05
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 4.0546875,
            "text": "results from phase I studies of lenvatinib plus pembrolizumab",
            "probability": 7.528066635131836e-05
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 4.0546875,
            "text": "olizumab",
            "probability": 7.355213165283203e-05
        },
        {
            "start_logit": 2.00390625,
            "end_logit": -5.66796875,
            "text": "pembrolizumab and atezolizumab plus bevacizumab",
            "probability": 5.507469177246094e-05
        },
        {
            "start_logit": -5.33203125,
            "end_logit": 0.87646484375,
            "text": "and atezolizumab",
            "probability": 2.485513687133789e-05
        },
        {
            "start_logit": 2.00390625,
            "end_logit": -6.48828125,
            "text": "pembrolizumab and atezoli",
            "probability": 2.4080276489257812e-05
        },
        {
            "start_logit": 2.00390625,
            "end_logit": -6.51171875,
            "text": "pembroliz",
            "probability": 2.372264862060547e-05
        },
        {
            "start_logit": 2.00390625,
            "end_logit": -6.6328125,
            "text": "pembrolizumab and atezoliz",
            "probability": 2.092123031616211e-05
        },
        {
            "start_logit": 2.00390625,
            "end_logit": -6.8671875,
            "text": "pembroli",
            "probability": 1.6570091247558594e-05
        },
        {
            "start_logit": 2.00390625,
            "end_logit": -6.94140625,
            "text": "pembrolizumab and atezo",
            "probability": 1.52587890625e-05
        }
    ],
    "602346eb1cb411341a000090_3": [
        {
            "start_logit": 9.0625,
            "end_logit": 8.9609375,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": 9.0625,
            "end_logit": -1.7412109375,
            "text": "ate",
            "probability": 2.2292137145996094e-05
        },
        {
            "start_logit": -2.140625,
            "end_logit": 8.9609375,
            "text": "umab",
            "probability": 1.3530254364013672e-05
        },
        {
            "start_logit": 9.0625,
            "end_logit": -5.796875,
            "text": "atezolizumab plus bevacizumab",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.5390625,
            "end_logit": 8.9609375,
            "text": "zolizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.8125,
            "end_logit": 8.9609375,
            "text": "lizumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0625,
            "end_logit": -6.96875,
            "text": "atezoliz",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0625,
            "end_logit": -7.13671875,
            "text": "atezolizumab plus bevacizumab (atezolizumab-bevacizumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.08203125,
            "end_logit": 8.9609375,
            "text": "either atezolizumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0625,
            "end_logit": -7.203125,
            "text": "atezolizumab plus bevacizumab (atezolizumab-bevacizumab) or sorafenib",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1875,
            "end_logit": 8.9609375,
            "text": "zumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0625,
            "end_logit": -7.41015625,
            "text": "atezolizumab plus bevacizumab (atezolizumab-bevacizumab)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0625,
            "end_logit": -7.43359375,
            "text": "atezolizumab plus bevacizumab (atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0625,
            "end_logit": -7.4453125,
            "text": "atezoli",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0625,
            "end_logit": -7.453125,
            "text": "atezolizumab plus bevacizumab (atezoliz",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0625,
            "end_logit": -7.48046875,
            "text": "atezolizumab plus bevacizumab (atezoli",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0625,
            "end_logit": -7.48828125,
            "text": "atezolizumab plus bevacizumab (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4375,
            "end_logit": 8.9609375,
            "text": "receive either atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.484375,
            "end_logit": 8.9609375,
            "text": ") patients to receive either atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 8.9609375,
            "text": "randomly allocated (2:1) patients to receive either atezolizumab",
            "probability": 5.960464477539063e-08
        }
    ],
    "602346eb1cb411341a000090_4": [
        {
            "start_logit": 8.8671875,
            "end_logit": 9.0390625,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": -1.9814453125,
            "end_logit": 9.0390625,
            "text": "umab",
            "probability": 1.9550323486328125e-05
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -2.14453125,
            "text": "ate",
            "probability": 1.3828277587890625e-05
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -2.42578125,
            "text": "atezolizumab and bevacizumab",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -6.328125,
            "text": "atezoliz",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.5390625,
            "end_logit": 9.0390625,
            "text": "zolizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.65234375,
            "end_logit": 9.0390625,
            "text": "lizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -6.546875,
            "text": "atezolizumab and bevacizumab was successfully used compared to sorafenib in the first-line treatment.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.734375,
            "end_logit": 9.0390625,
            "text": "of atezolizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.91015625,
            "end_logit": 9.0390625,
            "text": "combination of atezolizumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.98046875,
            "end_logit": 9.0390625,
            "text": "zumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.10546875,
            "end_logit": 9.0390625,
            "text": ", the combination of atezolizumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -6.96875,
            "text": "atezoli",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 9.0390625,
            "text": "the combination of atezolizumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -7.16015625,
            "text": "atezolizumab and bevacizumab was successfully used compared to sorafenib",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -7.3984375,
            "text": "atezolizumab and bevacizumab was",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -7.40625,
            "text": "atezolizumab and bevacizumab was successfully used compared to sorafenib in the first-line treatment",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -7.4375,
            "text": "atezolizumab and bevacizumab was successfully used compared",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 9.0390625,
            "text": "study IMbrave150, the combination of atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.9814453125,
            "end_logit": -2.42578125,
            "text": "umab and bevacizumab",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_5": [
        {
            "start_logit": 8.765625,
            "end_logit": 8.7109375,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": 8.765625,
            "end_logit": -2.31640625,
            "text": "ate",
            "probability": 1.6450881958007812e-05
        },
        {
            "start_logit": 8.765625,
            "end_logit": -2.427734375,
            "text": "atezolizumab plus bevacizumab",
            "probability": 1.4603137969970703e-05
        },
        {
            "start_logit": -2.53125,
            "end_logit": 8.7109375,
            "text": "umab",
            "probability": 1.2516975402832031e-05
        },
        {
            "start_logit": 8.765625,
            "end_logit": -6.59765625,
            "text": "atezoliz",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.625,
            "end_logit": 8.7109375,
            "text": "zolizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.8515625,
            "end_logit": 8.7109375,
            "text": "lizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.078125,
            "end_logit": 8.7109375,
            "text": "combination immunotherapy with atezolizumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.08984375,
            "end_logit": 8.7109375,
            "text": "that combination immunotherapy with atezolizumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1171875,
            "end_logit": 8.7109375,
            "text": "zumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.765625,
            "end_logit": -7.17578125,
            "text": "atezoli",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.12109375,
            "end_logit": 8.7109375,
            "text": "with atezolizumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.765625,
            "end_logit": -7.43359375,
            "text": "atezolizumab plus bevacizumab increases overall survival compared with sorafenib therapy; Food and Drug Agency already approved this combination therapy, and worldwide approval is expected",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.765625,
            "end_logit": -7.46875,
            "text": "atezolizumab plus bevacizumab increases overall survival compared with sorafenib therapy; Food and Drug Agency already approved this combination therapy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.765625,
            "end_logit": -7.53515625,
            "text": "atezolizumab plus bevacizumab increases overall survival compared with sorafenib",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.765625,
            "end_logit": -7.5390625,
            "text": "atezolizumab plus bevacizumab increases overall survival compared with sorafenib therapy; Food and Drug Agency already approved",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.765625,
            "end_logit": -7.546875,
            "text": "atezolizumab plus bevacizumab increases overall survival",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 8.7109375,
            "text": "phase III trial (IMbrave150) showed that combination immunotherapy with atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.765625,
            "end_logit": -7.55078125,
            "text": "atezolizumab plus bevacizumab increases overall survival compared with sorafenib therapy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5625,
            "end_logit": 8.7109375,
            "text": "showed that combination immunotherapy with atezolizumab",
            "probability": 5.960464477539063e-08
        }
    ],
    "602346eb1cb411341a000090_6": [
        {
            "start_logit": 5.89453125,
            "end_logit": 6.93359375,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": 5.89453125,
            "end_logit": -2.361328125,
            "text": "atezolizumab (anti-programmed death-ligand 1 [PD-L1]) and bevacizumab",
            "probability": 9.173154830932617e-05
        },
        {
            "start_logit": -4.6953125,
            "end_logit": 6.93359375,
            "text": "umab",
            "probability": 2.5093555450439453e-05
        },
        {
            "start_logit": 5.89453125,
            "end_logit": -5.7109375,
            "text": "ate",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": -6.82421875,
            "end_logit": 6.93359375,
            "text": "zolizumab",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": -6.91015625,
            "end_logit": 6.93359375,
            "text": "lizumab",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": -6.98828125,
            "end_logit": 6.93359375,
            "text": "that combination therapy of atezolizumab",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": -6.98828125,
            "end_logit": 6.93359375,
            "text": "of atezolizumab",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": -7.140625,
            "end_logit": 6.93359375,
            "text": "combination therapy of atezolizumab",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 6.93359375,
            "text": "zumab",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 6.93359375,
            "text": ", the IMbrave150 trial demonstrated that combination therapy of atezolizumab",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 5.89453125,
            "end_logit": -6.7578125,
            "text": "atezoliz",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 5.89453125,
            "end_logit": -6.984375,
            "text": "atezolizumab (anti-programmed death-ligand 1 [PD-L1",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 5.89453125,
            "end_logit": -7.18359375,
            "text": "atezolizumab (anti-programmed death-ligand 1 [PD-L1])",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 5.89453125,
            "end_logit": -7.2109375,
            "text": "atezolizumab (anti-programmed death-ligand 1 [PD-L1]) and bevacizumab (anti-vascular endothelial growth factor [VEGF",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 5.89453125,
            "end_logit": -7.359375,
            "text": "atezoli",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 5.89453125,
            "end_logit": -7.39453125,
            "text": "atezolizumab (anti-programmed",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 5.89453125,
            "end_logit": -7.39453125,
            "text": "atezolizumab (",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 5.89453125,
            "end_logit": -7.43359375,
            "text": "atezolizumab (anti",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 5.89453125,
            "end_logit": -7.453125,
            "text": "atezolizumab (anti-programmed death-ligand 1 [PD-L1]) and bevacizumab (",
            "probability": 5.364418029785156e-07
        }
    ],
    "602346eb1cb411341a000090_7": [
        {
            "start_logit": 8.453125,
            "end_logit": 8.703125,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": 8.453125,
            "end_logit": -0.96630859375,
            "text": "atezolizumab and bevacizumab",
            "probability": 6.300210952758789e-05
        },
        {
            "start_logit": -2.525390625,
            "end_logit": 8.703125,
            "text": "umab",
            "probability": 1.710653305053711e-05
        },
        {
            "start_logit": 8.453125,
            "end_logit": -2.873046875,
            "text": "ate",
            "probability": 9.357929229736328e-06
        },
        {
            "start_logit": 8.453125,
            "end_logit": -6.29296875,
            "text": "atezoliz",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.8515625,
            "end_logit": 8.703125,
            "text": "zolizumab",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.85546875,
            "end_logit": 8.703125,
            "text": "of atezolizumab",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.453125,
            "end_logit": -6.6796875,
            "text": "atezolizumab and bevacizumab over sorafenib as a standard of care in advanced unresectable HCC.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.453125,
            "end_logit": -6.78515625,
            "text": "atezoli",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.046875,
            "end_logit": 8.703125,
            "text": "lizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.1640625,
            "end_logit": 8.703125,
            "text": "combination of atezolizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.3046875,
            "end_logit": 8.703125,
            "text": "zumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 8.703125,
            "text": "favor the combination of atezolizumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.40625,
            "end_logit": 8.703125,
            "text": "the combination of atezolizumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.40625,
            "end_logit": 8.703125,
            "text": "results of a recent Phase III (IMbrave150) trial favor the combination of atezolizumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 8.703125,
            "text": "The results of a recent Phase III (IMbrave150) trial favor the combination of atezolizumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.453125,
            "end_logit": -7.18359375,
            "text": "atezolizumab and bevacizumab over sorafenib",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.453125,
            "end_logit": 8.703125,
            "text": ") trial favor the combination of atezolizumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.453125,
            "end_logit": -7.21484375,
            "text": "atezolizumab and bevacizumab over sorafenib as a standard of care in advanced unresectable HCC",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 8.703125,
            "text": "Phase III (IMbrave150) trial favor the combination of atezolizumab",
            "probability": 1.1920928955078125e-07
        }
    ],
    "602346eb1cb411341a000090_8": [
        {
            "start_logit": 7.67578125,
            "end_logit": 8.96875,
            "text": "lenvatinib",
            "probability": 1.0
        },
        {
            "start_logit": -1.3369140625,
            "end_logit": 8.96875,
            "text": "atezolizumab and bevacizumab over sorafenib as a standard of care in advanced unresectable HCC. While only lenvatinib",
            "probability": 0.00012242794036865234
        },
        {
            "start_logit": -2.076171875,
            "end_logit": 8.96875,
            "text": "tinib",
            "probability": 5.829334259033203e-05
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -3.68359375,
            "text": "len",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": -5.49609375,
            "end_logit": 8.96875,
            "text": "bevacizumab over sorafenib as a standard of care in advanced unresectable HCC. While only lenvatinib",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -6.87890625,
            "end_logit": 8.96875,
            "text": "combination of atezolizumab and bevacizumab over sorafenib as a standard of care in advanced unresectable HCC. While only lenvatinib",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.8984375,
            "end_logit": 8.96875,
            "text": "of atezolizumab and bevacizumab over sorafenib as a standard of care in advanced unresectable HCC. While only lenvatinib",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.93359375,
            "end_logit": 8.96875,
            "text": "While only lenvatinib",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.05859375,
            "end_logit": 8.96875,
            "text": "and bevacizumab over sorafenib as a standard of care in advanced unresectable HCC. While only lenvatinib",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.109375,
            "end_logit": 8.96875,
            "text": "zolizumab and bevacizumab over sorafenib as a standard of care in advanced unresectable HCC. While only lenvatinib",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.1796875,
            "end_logit": 8.96875,
            "text": "only lenvatinib",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 8.96875,
            "text": ". While only lenvatinib",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -6.06640625,
            "text": "lenva",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 8.96875,
            "text": "favor the combination of atezolizumab and bevacizumab over sorafenib as a standard of care in advanced unresectable HCC. While only lenvatinib",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.40625,
            "end_logit": 8.96875,
            "text": "zumab and bevacizumab over sorafenib as a standard of care in advanced unresectable HCC. While only lenvatinib",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.421875,
            "end_logit": 8.96875,
            "text": "lizumab and bevacizumab over sorafenib as a standard of care in advanced unresectable HCC. While only lenvatinib",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 8.96875,
            "text": "the combination of atezolizumab and bevacizumab over sorafenib as a standard of care in advanced unresectable HCC. While only lenvatinib",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -1.3369140625,
            "end_logit": -2.86328125,
            "text": "atezolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -1.3369140625,
            "end_logit": -3.68359375,
            "text": "atezolizumab and bevacizumab over sorafenib as a standard of care in advanced unresectable HCC. While only len",
            "probability": 0.0
        },
        {
            "start_logit": -1.3369140625,
            "end_logit": -4.65234375,
            "text": "atezolizumab and bevacizumab",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_9": [
        {
            "start_logit": 8.921875,
            "end_logit": 9.046875,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": -1.94921875,
            "end_logit": 9.046875,
            "text": "umab",
            "probability": 1.895427703857422e-05
        },
        {
            "start_logit": 8.921875,
            "end_logit": -2.021484375,
            "text": "ate",
            "probability": 1.5556812286376953e-05
        },
        {
            "start_logit": 8.921875,
            "end_logit": -4.2578125,
            "text": "atezolizumab (targeting PD-L1) and bevacizumab",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": -6.2265625,
            "end_logit": 9.046875,
            "text": "zolizumab",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.37890625,
            "end_logit": 9.046875,
            "text": "lizumab",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.5078125,
            "end_logit": 9.046875,
            "text": "with atezolizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.828125,
            "end_logit": 9.046875,
            "text": "zumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -6.73828125,
            "text": "atezolizumab (targeting PD-L1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -6.76171875,
            "text": "atezolizumab (targeting PD-L1) and bevacizumab (targeting VEGF",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -6.9765625,
            "text": "atezoliz",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.13671875,
            "end_logit": 9.046875,
            "text": "treatment with atezolizumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3125,
            "end_logit": 9.046875,
            "text": "ation treatment with atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3203125,
            "end_logit": 9.046875,
            "text": "ion treatment with atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.4140625,
            "text": "atezolizumab (targeting PD-L1)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.421875,
            "text": "atezolizumab (targeting PD-L1) and bevacizumab (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.4765625,
            "text": "atezolizumab (targeting PD-L1) and bevacizumab (targeting VEGF)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.4921875,
            "text": "atezoli",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.49609375,
            "text": "atezolizumab (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.52734375,
            "text": "atezolizumab (targeting PD-L1) and bevacizumab (targeting VEGF) in",
            "probability": 5.960464477539063e-08
        }
    ],
    "602346eb1cb411341a000090_10": [
        {
            "start_logit": 9.234375,
            "end_logit": 9.15625,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": 9.234375,
            "end_logit": -1.30859375,
            "text": "ate",
            "probability": 2.8431415557861328e-05
        },
        {
            "start_logit": -1.7412109375,
            "end_logit": 9.15625,
            "text": "umab",
            "probability": 1.710653305053711e-05
        },
        {
            "start_logit": 9.234375,
            "end_logit": -4.3515625,
            "text": "atezolizumab plus bevacizumab",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -6.40625,
            "end_logit": 9.15625,
            "text": "zolizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.41796875,
            "end_logit": 9.15625,
            "text": "lizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.5703125,
            "end_logit": 9.15625,
            "text": "zumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.1640625,
            "text": "atezoliz",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 9.15625,
            "text": "light of positive efficacy and safety findings from the IMbrave150 trial of atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2578125,
            "end_logit": 9.15625,
            "text": "In light of positive efficacy and safety findings from the IMbrave150 trial of atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 9.15625,
            "text": "of atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.484375,
            "text": "atezoli",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.53125,
            "text": "atezolizumab plus bevacizumab, this novel combination has become",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.54296875,
            "text": "atezolizumab plus bevacizumab, this novel combination has",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.56640625,
            "text": "atezolizumab plus bevacizumab, this novel combination has become the preferred first-line standard of care for patients with unresectable hepatocellular carcinoma (HCC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.609375,
            "end_logit": 9.15625,
            "text": "positive efficacy and safety findings from the IMbrave150 trial of atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.7412109375,
            "end_logit": -4.3515625,
            "text": "umab plus bevacizumab",
            "probability": 0.0
        },
        {
            "start_logit": -7.1484375,
            "end_logit": -1.30859375,
            "text": "light of positive efficacy and safety findings from the IMbrave150 trial of ate",
            "probability": 0.0
        },
        {
            "start_logit": -7.2578125,
            "end_logit": -1.30859375,
            "text": "In light of positive efficacy and safety findings from the IMbrave150 trial of ate",
            "probability": 0.0
        },
        {
            "start_logit": -1.7412109375,
            "end_logit": -6.88671875,
            "text": "umab plus bevacizumab, this novel combination has become the preferred first-line standard of care for patients with unresectable hepatocellular carcinoma (HCC).",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_11": [
        {
            "start_logit": 8.7578125,
            "end_logit": 9.0234375,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": -1.955078125,
            "end_logit": 9.0234375,
            "text": "umab",
            "probability": 2.2292137145996094e-05
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -2.32421875,
            "text": "ate",
            "probability": 1.1861324310302734e-05
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -4.1875,
            "text": "atezolizumab plus bevacizumab",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": -6.75,
            "end_logit": 9.0234375,
            "text": "zolizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -6.5546875,
            "text": "atezoliz",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.87109375,
            "end_logit": 9.0234375,
            "text": "lizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.9609375,
            "end_logit": 9.0234375,
            "text": "that, among patients with previously untreated unresectable HCC, treatment with atezolizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -6.765625,
            "text": "atezolizumab plus bevacizumab resulted in significantly longer overall survival and progression-free survival compared to sorafenib",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0546875,
            "end_logit": 9.0234375,
            "text": "with atezolizumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -6.92578125,
            "text": "atezoli",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 9.0234375,
            "text": "zumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3515625,
            "end_logit": 9.0234375,
            "text": ", treatment with atezolizumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 9.0234375,
            "text": "treatment with atezolizumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 9.0234375,
            "text": ", among patients with previously untreated unresectable HCC, treatment with atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.515625,
            "end_logit": 9.0234375,
            "text": "unresectable HCC, treatment with atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 9.0234375,
            "text": "HCC, treatment with atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -7.31640625,
            "text": "atezolizumab plus bevacizumab resulted",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -7.421875,
            "text": "atezolizumab plus bevacizumab resulted in significantly longer overall survival and progression-free survival compared to sorafenib monotherapy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -7.4453125,
            "text": "atezolizumab plus bevacizumab resulted in significantly longer overall survival and progression-free survival compared",
            "probability": 5.960464477539063e-08
        }
    ],
    "602346eb1cb411341a000090_12": [
        {
            "start_logit": 7.1640625,
            "end_logit": 6.91015625,
            "text": "bevacizumab",
            "probability": 0.96435546875
        },
        {
            "start_logit": 7.1640625,
            "end_logit": 3.599609375,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined with atezolizumab",
            "probability": 0.035125732421875
        },
        {
            "start_logit": 2.080078125,
            "end_logit": 3.599609375,
            "text": "atezolizumab",
            "probability": 0.00021708011627197266
        },
        {
            "start_logit": 7.1640625,
            "end_logit": -6.13671875,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined with atezoliz",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 7.1640625,
            "end_logit": -6.8828125,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined with atezoli",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 6.91015625,
            "text": "of bevacizumab",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.1640625,
            "end_logit": -7.4609375,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.1640625,
            "end_logit": -7.4609375,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.1640625,
            "end_logit": -7.47265625,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.1640625,
            "end_logit": -7.5234375,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.1640625,
            "end_logit": -7.5234375,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.1640625,
            "end_logit": -7.546875,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined with atezo",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.1640625,
            "end_logit": -7.55078125,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.1640625,
            "end_logit": -7.5625,
            "text": "bevacizumab, which",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.1640625,
            "end_logit": -7.57421875,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.1640625,
            "end_logit": -7.578125,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.1640625,
            "end_logit": -7.578125,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.1640625,
            "end_logit": -7.578125,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.1640625,
            "end_logit": -7.59765625,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 6.91015625,
            "text": "direct antitumor effect of bevacizumab",
            "probability": 4.172325134277344e-07
        }
    ],
    "602346eb1cb411341a000090_13": [
        {
            "start_logit": 7.0703125,
            "end_logit": 6.5859375,
            "text": "atezolizumab",
            "probability": 0.9990234375
        },
        {
            "start_logit": 7.0703125,
            "end_logit": -0.75048828125,
            "text": "atezolizumab plus bevacizumab",
            "probability": 0.0006513595581054688
        },
        {
            "start_logit": 7.0703125,
            "end_logit": -4.58984375,
            "text": "ate",
            "probability": 1.4066696166992188e-05
        },
        {
            "start_logit": -4.97265625,
            "end_logit": 6.5859375,
            "text": "umab",
            "probability": 5.841255187988281e-06
        },
        {
            "start_logit": 7.0703125,
            "end_logit": -6.37890625,
            "text": "atezoliz",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": 7.0703125,
            "end_logit": -6.88671875,
            "text": "atezoli",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 7.0703125,
            "end_logit": -7.33984375,
            "text": "atezolizumab plus bevacizumab increases overall survival compared with sorafenib therapy; Food and Drug Agency already approved this combination therapy, and worldwide approval is expected",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -6.87890625,
            "end_logit": 6.5859375,
            "text": "with atezolizumab",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 7.0703125,
            "end_logit": -7.40234375,
            "text": "atezolizumab plus bevacizumab increases overall survival compared with sorafenib therapy; Food and Drug Agency already approved this combination therapy",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -6.93359375,
            "end_logit": 6.5859375,
            "text": "zolizumab",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 7.0703125,
            "end_logit": -7.47265625,
            "text": "atezo",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -7.046875,
            "end_logit": 6.5859375,
            "text": "that combination immunotherapy with atezolizumab",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.0546875,
            "end_logit": 6.5859375,
            "text": "combination immunotherapy with atezolizumab",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.234375,
            "end_logit": 6.5859375,
            "text": "lizumab",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 6.5859375,
            "text": "zumab",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 6.5859375,
            "text": "immunotherapy with atezolizumab",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 6.5859375,
            "text": "I trial (IMbrave150) showed that combination immunotherapy with atezolizumab",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -3.169921875,
            "end_logit": -0.75048828125,
            "text": "bevacizumab",
            "probability": 0.0
        },
        {
            "start_logit": -4.97265625,
            "end_logit": -0.75048828125,
            "text": "umab plus bevacizumab",
            "probability": 0.0
        },
        {
            "start_logit": -6.87890625,
            "end_logit": -0.75048828125,
            "text": "with atezolizumab plus bevacizumab",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_14": [
        {
            "start_logit": 8.8359375,
            "end_logit": 8.8515625,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -2.16796875,
            "text": "ate",
            "probability": 1.6450881958007812e-05
        },
        {
            "start_logit": -2.30859375,
            "end_logit": 8.8515625,
            "text": "umab",
            "probability": 1.4483928680419922e-05
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -3.01171875,
            "text": "atezolizumab + bevacizumab",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": -6.6171875,
            "end_logit": 8.8515625,
            "text": "zolizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.7734375,
            "end_logit": 8.8515625,
            "text": "lizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.78125,
            "end_logit": 8.8515625,
            "text": "assessed atezolizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -6.8828125,
            "text": "atezolizumab + bevacizumab (ATEZO/BEV) versus sorafenib",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.99609375,
            "end_logit": 8.8515625,
            "text": "zumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -7.06640625,
            "text": "atezoliz",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -7.08203125,
            "text": "atezolizumab + bevacizumab (ATEZO",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -7.23046875,
            "text": "atezolizumab + bevacizumab (ATEZO/",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -7.2890625,
            "text": "atezoli",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -7.296875,
            "text": "atezolizumab + bevacizumab (ATEZO/BEV",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.328125,
            "end_logit": 8.8515625,
            "text": "phase III trial that assessed atezolizumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -7.34765625,
            "text": "atezolizumab + bevacizumab (ATEZO/BEV)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -7.35546875,
            "text": "atezolizumab + bevacizumab (ATEZO/BE",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -7.3671875,
            "text": "atezolizumab + bevacizumab (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -7.375,
            "text": "atezolizumab + bevacizumab (ATEZO/BEV) versus sorafenib (SOR)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -7.40625,
            "text": "atezolizumab + bevacizumab (ATEZO/BEV) versus sorafenib (SOR",
            "probability": 5.960464477539063e-08
        }
    ],
    "602346eb1cb411341a000090_15": [
        {
            "start_logit": 9.109375,
            "end_logit": 9.21875,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": -1.6083984375,
            "end_logit": 9.21875,
            "text": "umab",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": 9.109375,
            "end_logit": -1.6337890625,
            "text": "ate",
            "probability": 1.9371509552001953e-05
        },
        {
            "start_logit": 9.109375,
            "end_logit": -5.27734375,
            "text": "atezolizumab and bevacizumab",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.359375,
            "end_logit": 9.21875,
            "text": "zolizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.51953125,
            "end_logit": 9.21875,
            "text": "lizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.4453125,
            "text": "atezoliz",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.86328125,
            "end_logit": 9.21875,
            "text": "zumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.9296875,
            "text": "atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma has recently been reported.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.1328125,
            "text": "atezoli",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 9.21875,
            "text": "of atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.3984375,
            "text": "atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma has recently been reported",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.42578125,
            "text": "atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 9.21875,
            "text": "combination of atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5625,
            "end_logit": 9.21875,
            "text": "phase III trial for the combination of atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.515625,
            "text": "atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma has",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.515625,
            "text": "atezolizumab and bevacizumab (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69140625,
            "end_logit": 9.21875,
            "text": "the combination of atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 9.21875,
            "text": "successful phase III trial for the combination of atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.6083984375,
            "end_logit": -5.27734375,
            "text": "umab and bevacizumab",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_16": [
        {
            "start_logit": 7.52734375,
            "end_logit": 6.87109375,
            "text": "bevacizumab",
            "probability": 1.0
        },
        {
            "start_logit": -3.728515625,
            "end_logit": 6.87109375,
            "text": "atezolizumab plus bevacizumab",
            "probability": 1.2934207916259766e-05
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -7.1328125,
            "text": "bevacizumab versus sorafenib in patients with advanced hepatocellular carcinoma",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -6.57421875,
            "end_logit": 6.87109375,
            "text": "with atezolizumab plus bevacizumab",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -7.30859375,
            "text": "bevacizumab versus sorafenib",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -6.78125,
            "end_logit": 6.87109375,
            "text": "plus bevacizumab",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -7.44140625,
            "text": "bevacizumab versus sorafenib in patients with advanced hepatocellular carcinoma in the IMbrave150 trial, which has already shown significant overall survival and progression-free survival",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -7.44140625,
            "text": "bevacizumab versus sorafenib in patients with advanced hepatocellular carcinoma in the IMbrave150 trial, which has already shown significant overall survival",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -7.4921875,
            "text": "bevacizumab versus sorafenib in patients with advanced hepatocellular carcinoma in",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.171875,
            "end_logit": 6.87109375,
            "text": "patient-reported outcomes (PROs) with atezolizumab plus bevacizumab",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 6.87109375,
            "text": "evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 6.87109375,
            "text": "zolizumab plus bevacizumab",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 6.87109375,
            "text": ". We aimed to evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.46875,
            "end_logit": 6.87109375,
            "text": "outcomes (PROs) with atezolizumab plus bevacizumab",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -3.728515625,
            "end_logit": -4.48828125,
            "text": "atezolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -3.728515625,
            "end_logit": -6.9140625,
            "text": "atezoliz",
            "probability": 0.0
        },
        {
            "start_logit": -3.728515625,
            "end_logit": -6.93359375,
            "text": "atezoli",
            "probability": 0.0
        },
        {
            "start_logit": -3.728515625,
            "end_logit": -7.1328125,
            "text": "atezolizumab plus bevacizumab versus sorafenib in patients with advanced hepatocellular carcinoma",
            "probability": 0.0
        },
        {
            "start_logit": -3.728515625,
            "end_logit": -7.30859375,
            "text": "atezolizumab plus bevacizumab versus sorafenib",
            "probability": 0.0
        },
        {
            "start_logit": -6.57421875,
            "end_logit": -4.48828125,
            "text": "with atezolizumab",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_17": [
        {
            "start_logit": 9.1015625,
            "end_logit": 9.1015625,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -1.6533203125,
            "text": "ate",
            "probability": 2.1457672119140625e-05
        },
        {
            "start_logit": -1.8408203125,
            "end_logit": 9.1015625,
            "text": "umab",
            "probability": 1.7762184143066406e-05
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -5.84375,
            "text": "atezolizumab plus bevacizumab",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.52734375,
            "end_logit": 9.1015625,
            "text": "zolizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.6875,
            "end_logit": 9.1015625,
            "text": "lizumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.921875,
            "text": "atezoliz",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 9.1015625,
            "text": "zumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 9.1015625,
            "text": "of atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.43359375,
            "text": "atezoli",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.48828125,
            "text": "atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.52734375,
            "text": "atezolizumab plus bevacizumab for",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53125,
            "end_logit": 9.1015625,
            "text": "efficacy and safety of atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 9.1015625,
            "text": "the efficacy and safety of atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 9.1015625,
            "text": "indicated the efficacy and safety of atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65625,
            "end_logit": 9.1015625,
            "text": "clinical trial (IMbrave150) indicated the efficacy and safety of atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.703125,
            "end_logit": 9.1015625,
            "text": "safety of atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.8408203125,
            "end_logit": -5.84375,
            "text": "umab plus bevacizumab",
            "probability": 0.0
        },
        {
            "start_logit": -7.41796875,
            "end_logit": -1.6533203125,
            "text": "of ate",
            "probability": 0.0
        },
        {
            "start_logit": -7.53125,
            "end_logit": -1.6533203125,
            "text": "efficacy and safety of ate",
            "probability": 0.0
        }
    ],
    "602346eb1cb411341a000090_18": [
        {
            "start_logit": 7.26953125,
            "end_logit": 8.1640625,
            "text": "bevacizumab",
            "probability": 0.998046875
        },
        {
            "start_logit": 7.26953125,
            "end_logit": 1.912109375,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined with atezolizumab",
            "probability": 0.001911163330078125
        },
        {
            "start_logit": 0.701171875,
            "end_logit": 1.912109375,
            "text": "atezolizumab",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": -6.9765625,
            "end_logit": 8.1640625,
            "text": "of bevacizumab",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.26953125,
            "end_logit": -6.26171875,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined with atezoliz",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 8.1640625,
            "text": "direct antitumor effect of bevacizumab",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.5625,
            "end_logit": 8.1640625,
            "text": "phase 3 IMbrave150 clinical trial was successful because of the direct antitumor effect of bevacizumab",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.26953125,
            "end_logit": -6.703125,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined with atezoli",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 8.1640625,
            "text": "antitumor effect of bevacizumab",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.625,
            "end_logit": 8.1640625,
            "text": "because of the direct antitumor effect of bevacizumab",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 8.1640625,
            "text": "of the direct antitumor effect of bevacizumab",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.26953125,
            "end_logit": -6.95703125,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined with atezolizumab.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.26953125,
            "end_logit": -7.43359375,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.26953125,
            "end_logit": -7.44921875,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.26953125,
            "end_logit": -7.46875,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.26953125,
            "end_logit": -7.4921875,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.26953125,
            "end_logit": -7.51171875,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.26953125,
            "end_logit": -7.53125,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.26953125,
            "end_logit": -7.55078125,
            "text": "bevacizumab, which",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.26953125,
            "end_logit": -7.5546875,
            "text": "bevacizumab, which shifted the suppressive immune microenvironment to a",
            "probability": 1.7881393432617188e-07
        }
    ],
    "602346eb1cb411341a000090_19": [
        {
            "start_logit": 8.7265625,
            "end_logit": 8.84375,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": -2.310546875,
            "end_logit": 8.84375,
            "text": "umab",
            "probability": 1.621246337890625e-05
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -2.36328125,
            "text": "ate",
            "probability": 1.3649463653564453e-05
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -2.912109375,
            "text": "atezolizumab plus bevacizumab",
            "probability": 7.867813110351562e-06
        },
        {
            "start_logit": -5.421875,
            "end_logit": 8.84375,
            "text": ", patients with unresectable HCC treated with atezolizumab",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -6.2578125,
            "end_logit": 8.84375,
            "text": "with atezolizumab",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -6.43359375,
            "text": "atezoliz",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.60546875,
            "end_logit": 8.84375,
            "text": "unresectable HCC treated with atezolizumab",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.7578125,
            "end_logit": 8.84375,
            "text": "HCC treated with atezolizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -6.69921875,
            "text": "atezoli",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.86328125,
            "end_logit": 8.84375,
            "text": "patients with unresectable HCC treated with atezolizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.91796875,
            "end_logit": 8.84375,
            "text": "zolizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.94140625,
            "end_logit": 8.84375,
            "text": "treated with atezolizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.0546875,
            "end_logit": 8.84375,
            "text": "lizumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -6.96484375,
            "text": "atezolizumab plus bevacizumab between",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.12109375,
            "end_logit": 8.84375,
            "text": "zumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.140625,
            "end_logit": 8.84375,
            "text": "with unresectable HCC treated with atezolizumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.21875,
            "end_logit": 8.84375,
            "text": "study, patients with unresectable HCC treated with atezolizumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -7.3359375,
            "text": "atezolizumab plus bevacizumab between October 2020",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -7.34375,
            "text": "atezo",
            "probability": 1.1920928955078125e-07
        }
    ],
    "602346eb1cb411341a000090_20": [
        {
            "start_logit": 0.75439453125,
            "end_logit": 4.75,
            "text": "bevacizumab",
            "probability": 0.7177734375
        },
        {
            "start_logit": -0.3828125,
            "end_logit": 4.75,
            "text": "atezolizumab and bevacizumab",
            "probability": 0.230224609375
        },
        {
            "start_logit": 2.375,
            "end_logit": -0.09014892578125,
            "text": "sorafenib, in the phase III IMbrave150 trial.Areas covered: This article focuses on the mechanism of action of atezolizumab",
            "probability": 0.028717041015625
        },
        {
            "start_logit": 2.375,
            "end_logit": -0.5234375,
            "text": "sorafenib",
            "probability": 0.0186004638671875
        },
        {
            "start_logit": -0.3828125,
            "end_logit": -0.09014892578125,
            "text": "atezolizumab",
            "probability": 0.0018205642700195312
        },
        {
            "start_logit": -5.96484375,
            "end_logit": 4.75,
            "text": "article focuses on the mechanism of action of atezolizumab and bevacizumab",
            "probability": 0.0008668899536132812
        },
        {
            "start_logit": -6.76953125,
            "end_logit": 4.75,
            "text": "and bevacizumab",
            "probability": 0.0003876686096191406
        },
        {
            "start_logit": -7.12109375,
            "end_logit": 4.75,
            "text": "mechanism of action of atezolizumab and bevacizumab",
            "probability": 0.0002727508544921875
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 4.75,
            "text": "zolizumab and bevacizumab",
            "probability": 0.0002334117889404297
        },
        {
            "start_logit": -7.32421875,
            "end_logit": 4.75,
            "text": "focuses on the mechanism of action of atezolizumab and bevacizumab",
            "probability": 0.0002225637435913086
        },
        {
            "start_logit": -7.34375,
            "end_logit": 4.75,
            "text": "of atezolizumab and bevacizumab",
            "probability": 0.00021910667419433594
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 4.75,
            "text": "This article focuses on the mechanism of action of atezolizumab and bevacizumab",
            "probability": 0.00021398067474365234
        },
        {
            "start_logit": -7.38671875,
            "end_logit": 4.75,
            "text": "on the mechanism of action of atezolizumab and bevacizumab",
            "probability": 0.0002090930938720703
        },
        {
            "start_logit": -7.43359375,
            "end_logit": 4.75,
            "text": "Areas covered: This article focuses on the mechanism of action of atezolizumab and bevacizumab",
            "probability": 0.00019943714141845703
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 4.75,
            "text": "lizumab and bevacizumab",
            "probability": 0.00019037723541259766
        },
        {
            "start_logit": 2.375,
            "end_logit": -6.9453125,
            "text": "sorafenib, in the phase III IMbrave150 trial.Areas covered: This article focuses on the mechanism of action of atezoli",
            "probability": 3.0100345611572266e-05
        },
        {
            "start_logit": 2.375,
            "end_logit": -7.01171875,
            "text": "sorafenib, in the phase III IMbrave150 trial.Areas covered: This article focuses on the mechanism of action of atezoliz",
            "probability": 2.8312206268310547e-05
        },
        {
            "start_logit": 2.375,
            "end_logit": -7.17578125,
            "text": "sorafenib, in the phase III IMbrave150 trial.Areas covered: This article focuses",
            "probability": 2.4020671844482422e-05
        },
        {
            "start_logit": 2.375,
            "end_logit": -7.1796875,
            "text": "sorafenib, in the phase III IMbrave150 trial.Areas covered: This article focuses on the mechanism of action",
            "probability": 2.384185791015625e-05
        },
        {
            "start_logit": 2.375,
            "end_logit": -7.30859375,
            "text": "sorafenib,",
            "probability": 2.104043960571289e-05
        }
    ],
    "602346eb1cb411341a000090_21": [
        {
            "start_logit": 9.0234375,
            "end_logit": 9.1875,
            "text": "atezolizumab",
            "probability": 1.0
        },
        {
            "start_logit": -1.6201171875,
            "end_logit": 9.1875,
            "text": "umab",
            "probability": 2.3543834686279297e-05
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -1.80859375,
            "text": "ate",
            "probability": 1.6689300537109375e-05
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -4.62890625,
            "text": "atezolizumab (targeting PD-L1) and bevacizumab",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -6.20703125,
            "end_logit": 9.1875,
            "text": "zolizumab",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.28125,
            "end_logit": 9.1875,
            "text": "lizumab",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.765625,
            "end_logit": 9.1875,
            "text": "zumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -6.6875,
            "text": "atezolizumab (targeting PD-L1) and bevacizumab (targeting VEGF",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -6.7109375,
            "text": "atezolizumab (targeting PD-L1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.88671875,
            "end_logit": 9.1875,
            "text": "with atezolizumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.09375,
            "end_logit": 9.1875,
            "text": "Combination treatment with atezolizumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -6.96875,
            "text": "atezoliz",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4375,
            "end_logit": 9.1875,
            "text": "treatment with atezolizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.32421875,
            "text": "atezolizumab (targeting PD-L1)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.34765625,
            "text": "atezoli",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.41015625,
            "text": "atezolizumab (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.453125,
            "text": "atezolizumab (targeting PD-L1) and bevacizumab (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.46875,
            "text": "atezolizumab (targeting PD-L1) and bevacizumab (targeting VEGF)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.55859375,
            "text": "atezolizumab (targeting PD-L1) and bevacizumab (targeting VEGF) in the recent IMbra",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.5625,
            "text": "atezolizumab (targeting PD-L1) and bevacizumab (targeting VEGF) in the recent IMbrave",
            "probability": 5.960464477539063e-08
        }
    ],
    "5713b0a51174fb175500000e_1": [
        {
            "start_logit": 4.30078125,
            "end_logit": 3.080078125,
            "text": "Charcot-Marie-Tooth disease",
            "probability": 0.96240234375
        },
        {
            "start_logit": 4.30078125,
            "end_logit": -0.377197265625,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome",
            "probability": 0.0302734375
        },
        {
            "start_logit": -1.0302734375,
            "end_logit": 3.080078125,
            "text": "X-linked Charcot-Marie-Tooth disease",
            "probability": 0.004650115966796875
        },
        {
            "start_logit": 4.30078125,
            "end_logit": -3.6640625,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness",
            "probability": 0.0011320114135742188
        },
        {
            "start_logit": 4.30078125,
            "end_logit": -4.20703125,
            "text": "Charcot-Marie-Tooth disease, Arts",
            "probability": 0.0006570816040039062
        },
        {
            "start_logit": -1.0302734375,
            "end_logit": -0.377197265625,
            "text": "X-linked Charcot-Marie-Tooth disease, Arts syndrome",
            "probability": 0.00014662742614746094
        },
        {
            "start_logit": 4.30078125,
            "end_logit": -5.94921875,
            "text": "Charco",
            "probability": 0.00011515617370605469
        },
        {
            "start_logit": 4.30078125,
            "end_logit": -6.375,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form",
            "probability": 7.551908493041992e-05
        },
        {
            "start_logit": -1.775390625,
            "end_logit": -0.377197265625,
            "text": "Arts syndrome",
            "probability": 6.979703903198242e-05
        },
        {
            "start_logit": 4.30078125,
            "end_logit": -7.078125,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual",
            "probability": 3.737211227416992e-05
        },
        {
            "start_logit": 4.30078125,
            "end_logit": -7.09375,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic",
            "probability": 3.6776065826416016e-05
        },
        {
            "start_logit": 4.30078125,
            "end_logit": -7.1484375,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a disease continuum: evidence from a",
            "probability": 3.457069396972656e-05
        },
        {
            "start_logit": 4.30078125,
            "end_logit": -7.2265625,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a",
            "probability": 3.1948089599609375e-05
        },
        {
            "start_logit": 4.30078125,
            "end_logit": -7.33203125,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a disease continuum: evidence",
            "probability": 2.8848648071289062e-05
        },
        {
            "start_logit": 4.30078125,
            "end_logit": -7.3359375,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a disease continuum: evidence from",
            "probability": 2.866983413696289e-05
        },
        {
            "start_logit": 4.30078125,
            "end_logit": -7.34375,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a disease continuum: evidence from a family",
            "probability": 2.866983413696289e-05
        },
        {
            "start_logit": 4.30078125,
            "end_logit": -7.40234375,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a disease continuum: evidence from a family with",
            "probability": 2.6881694793701172e-05
        },
        {
            "start_logit": -6.2421875,
            "end_logit": 3.080078125,
            "text": "disease",
            "probability": 2.5272369384765625e-05
        },
        {
            "start_logit": 4.30078125,
            "end_logit": -7.46875,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-",
            "probability": 2.5272369384765625e-05
        },
        {
            "start_logit": -6.765625,
            "end_logit": 3.080078125,
            "text": "Tooth disease",
            "probability": 1.4960765838623047e-05
        }
    ],
    "5713b0a51174fb175500000e_2": [
        {
            "start_logit": 7.01953125,
            "end_logit": 4.69921875,
            "text": "Charcot-Marie-Tooth disease type 5",
            "probability": 0.97314453125
        },
        {
            "start_logit": 3.392578125,
            "end_logit": 4.69921875,
            "text": "X-linked Charcot-Marie-Tooth disease type 5",
            "probability": 0.02593994140625
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -3.783203125,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX5), Arts syndrome, and non-syndromic sensorineural deafness",
            "probability": 0.00020122528076171875
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -4.0546875,
            "text": "Charco",
            "probability": 0.00015425682067871094
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -4.2109375,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX5)",
            "probability": 0.00013196468353271484
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -4.92578125,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX5",
            "probability": 6.431341171264648e-05
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -5.85546875,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX5), Arts",
            "probability": 2.5331974029541016e-05
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -5.890625,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX5), Arts syndrome, and non-syndromic sensorineural deafness (DFN2",
            "probability": 2.4437904357910156e-05
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -5.96875,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX5), Arts syndrome",
            "probability": 2.2590160369873047e-05
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -6.046875,
            "text": "Charcot-Marie-Tooth disease",
            "probability": 2.086162567138672e-05
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -6.15234375,
            "text": "Charcot-Marie-Tooth disease type 5 (CMT",
            "probability": 1.8835067749023438e-05
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -6.61328125,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -6.71484375,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX5), Arts syndrome, and non-syndromic sensorineural deafness (DF",
            "probability": 1.0728836059570312e-05
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -6.86328125,
            "text": "Charcot-Marie-Tooth disease type 5 (",
            "probability": 9.298324584960938e-06
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -7.01953125,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX5), Arts syndrome, and non-syndromic sensorineural deafness (DFN2)",
            "probability": 7.927417755126953e-06
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -7.07421875,
            "text": "Charcot-Marie-Tooth disease type",
            "probability": 7.510185241699219e-06
        },
        {
            "start_logit": 3.392578125,
            "end_logit": -3.783203125,
            "text": "X-linked Charcot-Marie-Tooth disease type 5 (CMTX5), Arts syndrome, and non-syndromic sensorineural deafness",
            "probability": 5.364418029785156e-06
        },
        {
            "start_logit": 3.392578125,
            "end_logit": -4.0546875,
            "text": "X-linked Charco",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": 3.392578125,
            "end_logit": -4.2109375,
            "text": "X-linked Charcot-Marie-Tooth disease type 5 (CMTX5)",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": -5.75390625,
            "end_logit": 4.69921875,
            "text": "5",
            "probability": 2.8014183044433594e-06
        }
    ],
    "5713b0a51174fb175500000e_3": [
        {
            "start_logit": 6.14453125,
            "end_logit": 6.1171875,
            "text": "Arts syndrome",
            "probability": 1.0
        },
        {
            "start_logit": -3.75390625,
            "end_logit": 6.1171875,
            "text": "CMTX5, Arts syndrome",
            "probability": 4.988908767700195e-05
        },
        {
            "start_logit": 6.14453125,
            "end_logit": -4.9296875,
            "text": "Art",
            "probability": 1.5914440155029297e-05
        },
        {
            "start_logit": 6.14453125,
            "end_logit": -5.12109375,
            "text": "Arts",
            "probability": 1.3113021850585938e-05
        },
        {
            "start_logit": -5.2890625,
            "end_logit": 6.1171875,
            "text": "syndrome",
            "probability": 1.0788440704345703e-05
        },
        {
            "start_logit": -5.5859375,
            "end_logit": 6.1171875,
            "text": "that CMTX5, Arts syndrome",
            "probability": 7.987022399902344e-06
        },
        {
            "start_logit": -6.23046875,
            "end_logit": 6.1171875,
            "text": ", Arts syndrome",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": 6.14453125,
            "end_logit": -6.640625,
            "text": "Arts syndrome and DFN2 are phenotypic clusters on an intrafamilial continuum, including overlapping phenotypes even within individuals.",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": 6.14453125,
            "end_logit": -6.9453125,
            "text": "Arts syndrome and DFN2",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 6.14453125,
            "end_logit": -6.99609375,
            "text": "Arts syndrome and",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": 6.14453125,
            "end_logit": -7.05859375,
            "text": "Arts syndrome and DFN2 are phenotypic clusters on an intrafamilial continuum, including overlapping phenotypes even within individuals. The respective phenotypic presentation seems",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 6.14453125,
            "end_logit": -7.14453125,
            "text": "Arts syndrome and DFN2 are phenotypic clusters on an intrafamilial continuum, including overlapping phenotypes even",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": -7.16796875,
            "end_logit": 6.1171875,
            "text": "findings demonstrate that CMTX5, Arts syndrome",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": -7.2265625,
            "end_logit": 6.1171875,
            "text": "demonstrate that CMTX5, Arts syndrome",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 6.1171875,
            "text": "Our findings demonstrate that CMTX5, Arts syndrome",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -3.75390625,
            "end_logit": -3.46484375,
            "text": "CMTX5",
            "probability": 0.0
        },
        {
            "start_logit": -3.75390625,
            "end_logit": -4.9296875,
            "text": "CMTX5, Art",
            "probability": 0.0
        },
        {
            "start_logit": -3.75390625,
            "end_logit": -5.12109375,
            "text": "CMTX5, Arts",
            "probability": 0.0
        },
        {
            "start_logit": -5.5859375,
            "end_logit": -3.46484375,
            "text": "that CMTX5",
            "probability": 0.0
        },
        {
            "start_logit": -3.75390625,
            "end_logit": -6.640625,
            "text": "CMTX5, Arts syndrome and DFN2 are phenotypic clusters on an intrafamilial continuum, including overlapping phenotypes even within individuals.",
            "probability": 0.0
        }
    ],
    "5713b0a51174fb175500000e_4": [
        {
            "start_logit": 5.16015625,
            "end_logit": 6.83984375,
            "text": "Arts syndrome",
            "probability": 0.9931640625
        },
        {
            "start_logit": 0.1986083984375,
            "end_logit": 6.83984375,
            "text": "X-linked nonsyndromic sensorineural deafness type 2 (DFN2), or in syndromic deafness including Arts syndrome",
            "probability": 0.006961822509765625
        },
        {
            "start_logit": -4.23046875,
            "end_logit": 6.83984375,
            "text": "syndrome",
            "probability": 8.291006088256836e-05
        },
        {
            "start_logit": 5.16015625,
            "end_logit": -3.646484375,
            "text": "Arts",
            "probability": 2.777576446533203e-05
        },
        {
            "start_logit": -5.4140625,
            "end_logit": 6.83984375,
            "text": "deafness including Arts syndrome",
            "probability": 2.5272369384765625e-05
        },
        {
            "start_logit": -5.55859375,
            "end_logit": 6.83984375,
            "text": "nonsyndromic sensorineural deafness type 2 (DFN2), or in syndromic deafness including Arts syndrome",
            "probability": 2.193450927734375e-05
        },
        {
            "start_logit": -5.5625,
            "end_logit": 6.83984375,
            "text": "sensorineural deafness type 2 (DFN2), or in syndromic deafness including Arts syndrome",
            "probability": 2.193450927734375e-05
        },
        {
            "start_logit": -6.08984375,
            "end_logit": 6.83984375,
            "text": "syndromic deafness including Arts syndrome",
            "probability": 1.2934207916259766e-05
        },
        {
            "start_logit": 5.16015625,
            "end_logit": -4.8046875,
            "text": "Art",
            "probability": 8.761882781982422e-06
        },
        {
            "start_logit": -6.80859375,
            "end_logit": 6.83984375,
            "text": "in X-linked nonsyndromic sensorineural deafness type 2 (DFN2), or in syndromic deafness including Arts syndrome",
            "probability": 6.258487701416016e-06
        },
        {
            "start_logit": -6.8671875,
            "end_logit": 6.83984375,
            "text": "s syndrome",
            "probability": 5.900859832763672e-06
        },
        {
            "start_logit": -7.01171875,
            "end_logit": 6.83984375,
            "text": "including Arts syndrome",
            "probability": 5.125999450683594e-06
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 6.83984375,
            "text": "-linked nonsyndromic sensorineural deafness type 2 (DFN2), or in syndromic deafness including Arts syndrome",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 6.83984375,
            "text": "in syndromic deafness including Arts syndrome",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 6.83984375,
            "text": "deafness type 2 (DFN2), or in syndromic deafness including Arts syndrome",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": 5.16015625,
            "end_logit": -6.6640625,
            "text": "Arts syndrome and X-linked Charcot-Marie-Tooth disease-5 (CMT",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 5.16015625,
            "end_logit": -6.6953125,
            "text": "Arts syndrome and",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 5.16015625,
            "end_logit": -6.84375,
            "text": "Arts syndrome and X-linked Charcot-Marie-Tooth disease-5 (CMTX5",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 5.16015625,
            "end_logit": -6.953125,
            "text": "Arts syndrome and X-linked Charcot-Marie-Tooth disease-5 (CMTX",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 5.16015625,
            "end_logit": -6.98046875,
            "text": "Arts syndrome and X",
            "probability": 1.0132789611816406e-06
        }
    ],
    "5713b0a51174fb175500000e_5": [
        {
            "start_logit": 4.29296875,
            "end_logit": 3.490234375,
            "text": "Charcot-Marie-Tooth disease",
            "probability": 0.93701171875
        },
        {
            "start_logit": 4.29296875,
            "end_logit": 0.59619140625,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome",
            "probability": 0.052032470703125
        },
        {
            "start_logit": -0.467041015625,
            "end_logit": 3.490234375,
            "text": "X-linked Charcot-Marie-Tooth disease",
            "probability": 0.0080413818359375
        },
        {
            "start_logit": 4.29296875,
            "end_logit": -3.53125,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness",
            "probability": 0.0008378028869628906
        },
        {
            "start_logit": 4.29296875,
            "end_logit": -3.806640625,
            "text": "Charcot-Marie-Tooth disease, Arts",
            "probability": 0.0006346702575683594
        },
        {
            "start_logit": -0.467041015625,
            "end_logit": 0.59619140625,
            "text": "X-linked Charcot-Marie-Tooth disease, Arts syndrome",
            "probability": 0.0004448890686035156
        },
        {
            "start_logit": -0.67919921875,
            "end_logit": 0.59619140625,
            "text": "Arts syndrome",
            "probability": 0.00036025047302246094
        },
        {
            "start_logit": 4.29296875,
            "end_logit": -5.9453125,
            "text": "Charco",
            "probability": 7.468461990356445e-05
        },
        {
            "start_logit": 4.29296875,
            "end_logit": -6.33203125,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form",
            "probability": 5.0902366638183594e-05
        },
        {
            "start_logit": -6.1171875,
            "end_logit": 3.490234375,
            "text": "disease",
            "probability": 2.8312206268310547e-05
        },
        {
            "start_logit": 4.29296875,
            "end_logit": -7.078125,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual",
            "probability": 2.4259090423583984e-05
        },
        {
            "start_logit": 4.29296875,
            "end_logit": -7.078125,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic",
            "probability": 2.4259090423583984e-05
        },
        {
            "start_logit": 4.29296875,
            "end_logit": -7.24609375,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a",
            "probability": 2.0384788513183594e-05
        },
        {
            "start_logit": 4.29296875,
            "end_logit": -7.28125,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a disease continuum: evidence from a",
            "probability": 1.9788742065429688e-05
        },
        {
            "start_logit": 4.29296875,
            "end_logit": -7.35546875,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a disease continuum: evidence",
            "probability": 1.8298625946044922e-05
        },
        {
            "start_logit": 4.29296875,
            "end_logit": -7.39453125,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a disease continuum: evidence from",
            "probability": 1.7583370208740234e-05
        },
        {
            "start_logit": 4.29296875,
            "end_logit": -7.42578125,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a disease continuum: evidence from a family",
            "probability": 1.704692840576172e-05
        },
        {
            "start_logit": 4.29296875,
            "end_logit": -7.43359375,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a disease continuum: evidence from a family with",
            "probability": 1.6927719116210938e-05
        },
        {
            "start_logit": -6.66015625,
            "end_logit": 3.490234375,
            "text": "t-Marie-Tooth disease",
            "probability": 1.6391277313232422e-05
        },
        {
            "start_logit": -6.8125,
            "end_logit": 3.490234375,
            "text": "Tooth disease",
            "probability": 1.4126300811767578e-05
        }
    ],
    "5713b0a51174fb175500000e_6": [
        {
            "start_logit": 5.11328125,
            "end_logit": 4.98046875,
            "text": "Arts syndrome",
            "probability": 0.97412109375
        },
        {
            "start_logit": 1.462890625,
            "end_logit": 4.98046875,
            "text": "X-linked Charcot-Marie-Tooth disease-5 (CMTX5), Arts syndrome",
            "probability": 0.025360107421875
        },
        {
            "start_logit": 5.11328125,
            "end_logit": -3.994140625,
            "text": "Arts syndrome, and X-linked nonsyndromic sensorineural deafness",
            "probability": 0.00012314319610595703
        },
        {
            "start_logit": -3.92578125,
            "end_logit": 4.98046875,
            "text": "Charcot-Marie-Tooth disease-5 (CMTX5), Arts syndrome",
            "probability": 0.00011563301086425781
        },
        {
            "start_logit": 5.11328125,
            "end_logit": -4.13671875,
            "text": "Arts",
            "probability": 0.00010699033737182617
        },
        {
            "start_logit": 5.11328125,
            "end_logit": -4.62890625,
            "text": "Art",
            "probability": 6.538629531860352e-05
        },
        {
            "start_logit": -5.53125,
            "end_logit": 4.98046875,
            "text": ", Arts syndrome",
            "probability": 2.3305416107177734e-05
        },
        {
            "start_logit": -5.75390625,
            "end_logit": 4.98046875,
            "text": "syndrome",
            "probability": 1.8596649169921875e-05
        },
        {
            "start_logit": 5.11328125,
            "end_logit": -6.359375,
            "text": "Arts syndrome, and X-linked nonsyndromic sensorineural deafness (DFN2",
            "probability": 1.1563301086425781e-05
        },
        {
            "start_logit": 5.11328125,
            "end_logit": -6.4296875,
            "text": "Arts syndrome, and X-linked nonsyndromic sensorineural deafness (DF",
            "probability": 1.0848045349121094e-05
        },
        {
            "start_logit": -6.55078125,
            "end_logit": 4.98046875,
            "text": "CMTX5), Arts syndrome",
            "probability": 8.344650268554688e-06
        },
        {
            "start_logit": -6.55859375,
            "end_logit": 4.98046875,
            "text": "in X-linked Charcot-Marie-Tooth disease-5 (CMTX5), Arts syndrome",
            "probability": 8.285045623779297e-06
        },
        {
            "start_logit": 5.11328125,
            "end_logit": -6.765625,
            "text": "Arts syndrome, and X-linked nonsyndromic sensorineural deafness (DFN2).",
            "probability": 7.68899917602539e-06
        },
        {
            "start_logit": 5.11328125,
            "end_logit": -6.79296875,
            "text": "Arts syndrome, and X-linked nonsyndromic sensorineural deafness (",
            "probability": 7.510185241699219e-06
        },
        {
            "start_logit": 5.11328125,
            "end_logit": -6.88671875,
            "text": "Arts syndrome, and X-linked",
            "probability": 6.854534149169922e-06
        },
        {
            "start_logit": -6.7734375,
            "end_logit": 4.98046875,
            "text": "s syndrome",
            "probability": 6.67572021484375e-06
        },
        {
            "start_logit": 1.462890625,
            "end_logit": -4.13671875,
            "text": "X-linked Charcot-Marie-Tooth disease-5 (CMTX5), Arts",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": 1.462890625,
            "end_logit": -4.37109375,
            "text": "X-linked",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 1.462890625,
            "end_logit": -4.62890625,
            "text": "X-linked Charcot-Marie-Tooth disease-5 (CMTX5), Art",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 1.462890625,
            "end_logit": -5.5703125,
            "text": "X-linked Charcot-Marie-Tooth disease-5 (CMTX5",
            "probability": 6.556510925292969e-07
        }
    ],
    "5713b0a51174fb175500000e_7": [
        {
            "start_logit": 4.3671875,
            "end_logit": 4.4375,
            "text": "Arts syndrome",
            "probability": 0.96337890625
        },
        {
            "start_logit": 1.06640625,
            "end_logit": 4.4375,
            "text": "X-linked Charcot-Marie-Tooth disease-5 (CMTX5), Arts syndrome",
            "probability": 0.0355224609375
        },
        {
            "start_logit": -4.13671875,
            "end_logit": 4.4375,
            "text": "Charcot-Marie-Tooth disease-5 (CMTX5), Arts syndrome",
            "probability": 0.00019598007202148438
        },
        {
            "start_logit": 4.3671875,
            "end_logit": -4.109375,
            "text": "Arts",
            "probability": 0.00018703937530517578
        },
        {
            "start_logit": 4.3671875,
            "end_logit": -4.921875,
            "text": "Arts syndrome, and X-linked nonsyndromic sensorineural deafness",
            "probability": 8.296966552734375e-05
        },
        {
            "start_logit": 4.3671875,
            "end_logit": -5.03515625,
            "text": "Art",
            "probability": 7.43865966796875e-05
        },
        {
            "start_logit": -5.3984375,
            "end_logit": 4.4375,
            "text": ", Arts syndrome",
            "probability": 5.53131103515625e-05
        },
        {
            "start_logit": -5.9765625,
            "end_logit": 4.4375,
            "text": "syndrome",
            "probability": 3.0994415283203125e-05
        },
        {
            "start_logit": 4.3671875,
            "end_logit": -6.4609375,
            "text": "Arts syndrome, and X-linked nonsyndromic sensorineural deafness (DFN2",
            "probability": 1.7821788787841797e-05
        },
        {
            "start_logit": -6.61328125,
            "end_logit": 4.4375,
            "text": "s syndrome",
            "probability": 1.6391277313232422e-05
        },
        {
            "start_logit": 4.3671875,
            "end_logit": -6.58984375,
            "text": "Arts syndrome, and X-linked nonsyndromic sensorineural deafness (DF",
            "probability": 1.5616416931152344e-05
        },
        {
            "start_logit": -6.67578125,
            "end_logit": 4.4375,
            "text": "in X-linked Charcot-Marie-Tooth disease-5 (CMTX5), Arts syndrome",
            "probability": 1.531839370727539e-05
        },
        {
            "start_logit": -6.6953125,
            "end_logit": 4.4375,
            "text": "CMTX5), Arts syndrome",
            "probability": 1.5079975128173828e-05
        },
        {
            "start_logit": 4.3671875,
            "end_logit": -6.91015625,
            "text": "Arts syndrome, and X-linked nonsyndromic sensorineural deafness (",
            "probability": 1.1444091796875e-05
        },
        {
            "start_logit": 4.3671875,
            "end_logit": -7.14453125,
            "text": "Arts syndrome, and X-linked",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": 4.3671875,
            "end_logit": -7.1484375,
            "text": "Arts syndrome, and X-linked nonsyndromic sensorineural deafness (DFN2)",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": 1.06640625,
            "end_logit": -4.109375,
            "text": "X-linked Charcot-Marie-Tooth disease-5 (CMTX5), Arts",
            "probability": 6.973743438720703e-06
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 4.4375,
            "text": "disease-5 (CMTX5), Arts syndrome",
            "probability": 6.854534149169922e-06
        },
        {
            "start_logit": 1.06640625,
            "end_logit": -4.50390625,
            "text": "X-linked",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": 1.06640625,
            "end_logit": -5.03515625,
            "text": "X-linked Charcot-Marie-Tooth disease-5 (CMTX5), Art",
            "probability": 2.7418136596679688e-06
        }
    ],
    "5713b0a51174fb175500000e_8": [
        {
            "start_logit": 7.01953125,
            "end_logit": 4.69921875,
            "text": "Charcot-Marie-Tooth disease type 5",
            "probability": 0.97314453125
        },
        {
            "start_logit": 3.392578125,
            "end_logit": 4.69921875,
            "text": "X-linked Charcot-Marie-Tooth disease type 5",
            "probability": 0.02593994140625
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -3.783203125,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX5), Arts syndrome, and non-syndromic sensorineural deafness",
            "probability": 0.00020122528076171875
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -4.0546875,
            "text": "Charco",
            "probability": 0.00015425682067871094
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -4.2109375,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX5)",
            "probability": 0.00013196468353271484
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -4.92578125,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX5",
            "probability": 6.431341171264648e-05
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -5.85546875,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX5), Arts",
            "probability": 2.5331974029541016e-05
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -5.890625,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX5), Arts syndrome, and non-syndromic sensorineural deafness (DFN2",
            "probability": 2.4437904357910156e-05
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -5.96875,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX5), Arts syndrome",
            "probability": 2.2590160369873047e-05
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -6.046875,
            "text": "Charcot-Marie-Tooth disease",
            "probability": 2.086162567138672e-05
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -6.15234375,
            "text": "Charcot-Marie-Tooth disease type 5 (CMT",
            "probability": 1.8835067749023438e-05
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -6.61328125,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -6.71484375,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX5), Arts syndrome, and non-syndromic sensorineural deafness (DF",
            "probability": 1.0728836059570312e-05
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -6.86328125,
            "text": "Charcot-Marie-Tooth disease type 5 (",
            "probability": 9.298324584960938e-06
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -7.01953125,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX5), Arts syndrome, and non-syndromic sensorineural deafness (DFN2)",
            "probability": 7.927417755126953e-06
        },
        {
            "start_logit": 7.01953125,
            "end_logit": -7.07421875,
            "text": "Charcot-Marie-Tooth disease type",
            "probability": 7.510185241699219e-06
        },
        {
            "start_logit": 3.392578125,
            "end_logit": -3.783203125,
            "text": "X-linked Charcot-Marie-Tooth disease type 5 (CMTX5), Arts syndrome, and non-syndromic sensorineural deafness",
            "probability": 5.364418029785156e-06
        },
        {
            "start_logit": 3.392578125,
            "end_logit": -4.0546875,
            "text": "X-linked Charco",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": 3.392578125,
            "end_logit": -4.2109375,
            "text": "X-linked Charcot-Marie-Tooth disease type 5 (CMTX5)",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": -5.75390625,
            "end_logit": 4.69921875,
            "text": "5",
            "probability": 2.8014183044433594e-06
        }
    ],
    "5713b0a51174fb175500000e_9": [
        {
            "start_logit": 8.96875,
            "end_logit": 7.1953125,
            "text": "Charcot-Marie-Tooth disease type 5",
            "probability": 0.998046875
        },
        {
            "start_logit": 2.65234375,
            "end_logit": 7.1953125,
            "text": "X-linked Charcot-Marie-Tooth disease type 5",
            "probability": 0.0018100738525390625
        },
        {
            "start_logit": 8.96875,
            "end_logit": -1.6591796875,
            "text": "Charco",
            "probability": 0.00014400482177734375
        },
        {
            "start_logit": 8.96875,
            "end_logit": -4.34375,
            "text": "Charcot-Marie-Tooth disease",
            "probability": 9.834766387939453e-06
        },
        {
            "start_logit": 8.96875,
            "end_logit": -5.38671875,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX5)",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": 8.96875,
            "end_logit": -5.5234375,
            "text": "Charcot-Marie-Tooth disease type 5 (CMT",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": 8.96875,
            "end_logit": -5.5390625,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX5",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": -3.85546875,
            "end_logit": 7.1953125,
            "text": "5",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": 8.96875,
            "end_logit": -5.80859375,
            "text": "Charcot-Marie-Tooth disease type 5 (",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": 8.96875,
            "end_logit": -6.17578125,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX5) is",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 8.96875,
            "end_logit": -6.65234375,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.96875,
            "end_logit": -6.97265625,
            "text": "Charcot-Marie-Tooth disease type",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.4140625,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX5) is caused by mutations in the gene encoding phosphoribosyl pyrophosphate synthetase I (",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.42578125,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX5) is caused by mutations in the",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.45703125,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX5) is caused by mutations",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.4609375,
            "text": "Charcot-Marie-Tooth disease type 5 (CMTX5) is caused",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.01953125,
            "end_logit": 7.1953125,
            "text": "t-Marie-Tooth disease type 5",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 2.65234375,
            "end_logit": -1.6591796875,
            "text": "X-linked Charco",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.21875,
            "end_logit": 7.1953125,
            "text": "type 5",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.30078125,
            "end_logit": 7.1953125,
            "text": "Tooth disease type 5",
            "probability": 2.384185791015625e-07
        }
    ],
    "5713b0a51174fb175500000e_10": [
        {
            "start_logit": 5.21875,
            "end_logit": 6.734375,
            "text": "Arts syndrome",
            "probability": 0.97802734375
        },
        {
            "start_logit": 1.3935546875,
            "end_logit": 6.734375,
            "text": "X-linked nonsyndromic sensorineural deafness type 2 (DFN2), or in syndromic deafness including Arts syndrome",
            "probability": 0.021270751953125
        },
        {
            "start_logit": -4.3515625,
            "end_logit": 6.734375,
            "text": "syndrome",
            "probability": 6.824731826782227e-05
        },
        {
            "start_logit": 5.21875,
            "end_logit": -3.474609375,
            "text": "Arts",
            "probability": 3.594160079956055e-05
        },
        {
            "start_logit": -5.12109375,
            "end_logit": 6.734375,
            "text": "nonsyndromic sensorineural deafness type 2 (DFN2), or in syndromic deafness including Arts syndrome",
            "probability": 3.147125244140625e-05
        },
        {
            "start_logit": -5.2890625,
            "end_logit": 6.734375,
            "text": "sensorineural deafness type 2 (DFN2), or in syndromic deafness including Arts syndrome",
            "probability": 2.6702880859375e-05
        },
        {
            "start_logit": -5.40625,
            "end_logit": 6.734375,
            "text": "deafness including Arts syndrome",
            "probability": 2.378225326538086e-05
        },
        {
            "start_logit": -5.90625,
            "end_logit": 6.734375,
            "text": "syndromic deafness including Arts syndrome",
            "probability": 1.4424324035644531e-05
        },
        {
            "start_logit": 5.21875,
            "end_logit": -4.74609375,
            "text": "Art",
            "probability": 1.0073184967041016e-05
        },
        {
            "start_logit": -6.62109375,
            "end_logit": 6.734375,
            "text": "in X-linked nonsyndromic sensorineural deafness type 2 (DFN2), or in syndromic deafness including Arts syndrome",
            "probability": 7.033348083496094e-06
        },
        {
            "start_logit": -7.03125,
            "end_logit": 6.734375,
            "text": "including Arts syndrome",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": -7.05859375,
            "end_logit": 6.734375,
            "text": "s syndrome",
            "probability": 4.5299530029296875e-06
        },
        {
            "start_logit": -7.2421875,
            "end_logit": 6.734375,
            "text": "-linked nonsyndromic sensorineural deafness type 2 (DFN2), or in syndromic deafness including Arts syndrome",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": -7.32421875,
            "end_logit": 6.734375,
            "text": "deafness type 2 (DFN2), or in syndromic deafness including Arts syndrome",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 6.734375,
            "text": "in syndromic deafness including Arts syndrome",
            "probability": 3.3974647521972656e-06
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 6.734375,
            "text": "dromic sensorineural deafness type 2 (DFN2), or in syndromic deafness including Arts syndrome",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": 5.21875,
            "end_logit": -6.62109375,
            "text": "Arts syndrome and X-linked Charcot-Marie-Tooth disease-5 (CMT",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 5.21875,
            "end_logit": -6.72265625,
            "text": "Arts syndrome and",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 5.21875,
            "end_logit": -6.80859375,
            "text": "Arts syndrome and X-linked Charcot-Marie-Tooth disease-5 (CMTX5",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 5.21875,
            "end_logit": -6.8515625,
            "text": "Arts syndrome and X-linked Charcot-Marie-Tooth disease-5 (CMTX5).",
            "probability": 1.2516975402832031e-06
        }
    ],
    "5713b0a51174fb175500000e_11": [
        {
            "start_logit": 8.0234375,
            "end_logit": 8.53125,
            "text": "Arts syndrome",
            "probability": 1.0
        },
        {
            "start_logit": -2.740234375,
            "end_logit": 8.53125,
            "text": "syndrome",
            "probability": 2.092123031616211e-05
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -3.12890625,
            "text": "Art",
            "probability": 8.52346420288086e-06
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -4.29296875,
            "text": "Arts syndrome, Charcot-Marie-Tooth disease-5 (CMTX5) and X-linked non-syndromic sensorineural deafness",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -5.16015625,
            "text": "Arts",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -6.453125,
            "text": "Arts syndrome, Charcot-Marie-Tooth disease-5 (CMTX5) and X-linked",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.0625,
            "end_logit": 8.53125,
            "text": "includes Arts syndrome",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.2734375,
            "end_logit": 8.53125,
            "text": "spectrum of PRPS1-related disorders associated with reduced activity includes Arts syndrome",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -6.859375,
            "text": "Arts syndrome, Charcot-Marie-Tooth disease-5 (CMTX5",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -6.93359375,
            "text": "Arts syndrome, Charcot-Marie-Tooth disease-5 (CMTX5) and X-linked non-syndromic",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 8.53125,
            "text": "disorders associated with reduced activity includes Arts syndrome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 8.53125,
            "text": "s syndrome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -7.0625,
            "text": "Arts syndrome, Charcot-Marie-Tooth disease-5 (CMTX",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -7.06640625,
            "text": "Arts syndrome, Charcot-Marie-Tooth disease-5 (CMTX5)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -7.09765625,
            "text": "Arts syndrome, Charcot-Marie-Tooth disease-5 (CMTX5) and X-linked non-syndromic sensorineural deafness (DF",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -7.16015625,
            "text": "Arts syndrome, Charcot-Marie-Tooth disease-5 (CMTX5) and X-linked non-syndromic sensorineural deafness (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -7.1640625,
            "text": "Arts syndrome, Charcot-Marie-Tooth disease-5 (CMT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -7.26953125,
            "text": "Arts syndrome, Charcot-Marie-Tooth disease-5 (CMTX5) and X-linked non-syndromic sensorineural",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -7.3046875,
            "text": "Arts syndrome, Charcot-Marie-Tooth disease-5 (CMTX5) and X-linked non",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.740234375,
            "end_logit": -4.29296875,
            "text": "syndrome, Charcot-Marie-Tooth disease-5 (CMTX5) and X-linked non-syndromic sensorineural deafness",
            "probability": 0.0
        }
    ],
    "5713b0a51174fb175500000e_12": [
        {
            "start_logit": 4.29296875,
            "end_logit": 3.490234375,
            "text": "Charcot-Marie-Tooth disease",
            "probability": 0.93701171875
        },
        {
            "start_logit": 4.29296875,
            "end_logit": 0.59619140625,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome",
            "probability": 0.052032470703125
        },
        {
            "start_logit": -0.467041015625,
            "end_logit": 3.490234375,
            "text": "X-linked Charcot-Marie-Tooth disease",
            "probability": 0.0080413818359375
        },
        {
            "start_logit": 4.29296875,
            "end_logit": -3.53125,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness",
            "probability": 0.0008378028869628906
        },
        {
            "start_logit": 4.29296875,
            "end_logit": -3.806640625,
            "text": "Charcot-Marie-Tooth disease, Arts",
            "probability": 0.0006346702575683594
        },
        {
            "start_logit": -0.467041015625,
            "end_logit": 0.59619140625,
            "text": "X-linked Charcot-Marie-Tooth disease, Arts syndrome",
            "probability": 0.0004448890686035156
        },
        {
            "start_logit": -0.67919921875,
            "end_logit": 0.59619140625,
            "text": "Arts syndrome",
            "probability": 0.00036025047302246094
        },
        {
            "start_logit": 4.29296875,
            "end_logit": -5.9453125,
            "text": "Charco",
            "probability": 7.468461990356445e-05
        },
        {
            "start_logit": 4.29296875,
            "end_logit": -6.33203125,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form",
            "probability": 5.0902366638183594e-05
        },
        {
            "start_logit": -6.1171875,
            "end_logit": 3.490234375,
            "text": "disease",
            "probability": 2.8312206268310547e-05
        },
        {
            "start_logit": 4.29296875,
            "end_logit": -7.078125,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual",
            "probability": 2.4259090423583984e-05
        },
        {
            "start_logit": 4.29296875,
            "end_logit": -7.078125,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic",
            "probability": 2.4259090423583984e-05
        },
        {
            "start_logit": 4.29296875,
            "end_logit": -7.24609375,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a",
            "probability": 2.0384788513183594e-05
        },
        {
            "start_logit": 4.29296875,
            "end_logit": -7.28125,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a disease continuum: evidence from a",
            "probability": 1.9788742065429688e-05
        },
        {
            "start_logit": 4.29296875,
            "end_logit": -7.35546875,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a disease continuum: evidence",
            "probability": 1.8298625946044922e-05
        },
        {
            "start_logit": 4.29296875,
            "end_logit": -7.39453125,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a disease continuum: evidence from",
            "probability": 1.7583370208740234e-05
        },
        {
            "start_logit": 4.29296875,
            "end_logit": -7.42578125,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a disease continuum: evidence from a family",
            "probability": 1.704692840576172e-05
        },
        {
            "start_logit": 4.29296875,
            "end_logit": -7.43359375,
            "text": "Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a disease continuum: evidence from a family with",
            "probability": 1.6927719116210938e-05
        },
        {
            "start_logit": -6.66015625,
            "end_logit": 3.490234375,
            "text": "t-Marie-Tooth disease",
            "probability": 1.6391277313232422e-05
        },
        {
            "start_logit": -6.8125,
            "end_logit": 3.490234375,
            "text": "Tooth disease",
            "probability": 1.4126300811767578e-05
        }
    ],
    "5543a1b2ee40ea110c000001_1": [
        {
            "start_logit": 3.7734375,
            "end_logit": 4.1484375,
            "text": "chloroplasts",
            "probability": 1.0
        },
        {
            "start_logit": -6.3515625,
            "end_logit": 4.1484375,
            "text": "in chloroplasts",
            "probability": 4.00543212890625e-05
        },
        {
            "start_logit": -6.859375,
            "end_logit": 4.1484375,
            "text": ". PLBs are formed not only in etioplasts but also in chloroplasts",
            "probability": 2.4139881134033203e-05
        },
        {
            "start_logit": 3.7734375,
            "end_logit": -6.70703125,
            "text": "chloroplasts in young developing leaves",
            "probability": 1.9252300262451172e-05
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 4.1484375,
            "text": "etioplasts but also in chloroplasts",
            "probability": 1.6987323760986328e-05
        },
        {
            "start_logit": -7.21875,
            "end_logit": 4.1484375,
            "text": "prolamellar body (PLB) proteome of dark-grown wheat leaves was characterized. PLBs are formed not only in etioplasts but also in chloroplasts",
            "probability": 1.6808509826660156e-05
        },
        {
            "start_logit": -7.26953125,
            "end_logit": 4.1484375,
            "text": "PLBs are formed not only in etioplasts but also in chloroplasts",
            "probability": 1.5914440155029297e-05
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 4.1484375,
            "text": "PLB) proteome of dark-grown wheat leaves was characterized. PLBs are formed not only in etioplasts but also in chloroplasts",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": -7.34375,
            "end_logit": 4.1484375,
            "text": "characterized. PLBs are formed not only in etioplasts but also in chloroplasts",
            "probability": 1.4841556549072266e-05
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 4.1484375,
            "text": "B) proteome of dark-grown wheat leaves was characterized. PLBs are formed not only in etioplasts but also in chloroplasts",
            "probability": 1.430511474609375e-05
        },
        {
            "start_logit": 3.7734375,
            "end_logit": -7.0546875,
            "text": "chloroplasts in young developing leaves during the night",
            "probability": 1.3649463653564453e-05
        },
        {
            "start_logit": 3.7734375,
            "end_logit": -7.05859375,
            "text": "chloroplasts in",
            "probability": 1.3649463653564453e-05
        },
        {
            "start_logit": 3.7734375,
            "end_logit": -7.109375,
            "text": "chloroplasts in young developing leaves during",
            "probability": 1.2934207916259766e-05
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 4.1484375,
            "text": ") proteome of dark-grown wheat leaves was characterized. PLBs are formed not only in etioplasts but also in chloroplasts",
            "probability": 1.2814998626708984e-05
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 4.1484375,
            "text": "in etioplasts but also in chloroplasts",
            "probability": 1.2636184692382812e-05
        },
        {
            "start_logit": -7.515625,
            "end_logit": 4.1484375,
            "text": "oplasts but also in chloroplasts",
            "probability": 1.2516975402832031e-05
        },
        {
            "start_logit": -6.3515625,
            "end_logit": -6.70703125,
            "text": "in chloroplasts in young developing leaves",
            "probability": 0.0
        },
        {
            "start_logit": -6.3515625,
            "end_logit": -7.0546875,
            "text": "in chloroplasts in young developing leaves during the night",
            "probability": 0.0
        },
        {
            "start_logit": -6.3515625,
            "end_logit": -7.05859375,
            "text": "in chloroplasts in",
            "probability": 0.0
        },
        {
            "start_logit": -6.3515625,
            "end_logit": -7.109375,
            "text": "in chloroplasts in young developing leaves during",
            "probability": 0.0
        }
    ],
    "58e0035f6fddd3e83e000009_1": [
        {
            "start_logit": 5.69921875,
            "end_logit": 4.0,
            "text": "microtubules",
            "probability": 0.9921875
        },
        {
            "start_logit": 0.72412109375,
            "end_logit": 4.0,
            "text": "actin filaments, microtubules",
            "probability": 0.006816864013671875
        },
        {
            "start_logit": 0.72412109375,
            "end_logit": 1.955078125,
            "text": "actin filaments",
            "probability": 0.0008840560913085938
        },
        {
            "start_logit": 5.69921875,
            "end_logit": -5.9609375,
            "text": "microtubules, and intermediate filaments",
            "probability": 4.649162292480469e-05
        },
        {
            "start_logit": -5.42578125,
            "end_logit": 4.0,
            "text": ", microtubules",
            "probability": 1.4603137969970703e-05
        },
        {
            "start_logit": 5.69921875,
            "end_logit": -7.42578125,
            "text": "microtubules, and intermediate filaments-",
            "probability": 1.0788440704345703e-05
        },
        {
            "start_logit": 5.69921875,
            "end_logit": -7.44140625,
            "text": "microtubules, and intermediate filaments-are",
            "probability": 1.0669231414794922e-05
        },
        {
            "start_logit": -6.796875,
            "end_logit": 4.0,
            "text": "filaments, microtubules",
            "probability": 3.7550926208496094e-06
        },
        {
            "start_logit": -7.08203125,
            "end_logit": 4.0,
            "text": "-actin filaments, microtubules",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 4.0,
            "text": "Fibrillar polymers-actin filaments, microtubules",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": -7.703125,
            "end_logit": 4.0,
            "text": "polymers-actin filaments, microtubules",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -6.796875,
            "end_logit": 1.955078125,
            "text": "filaments",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.08203125,
            "end_logit": 1.955078125,
            "text": "-actin filaments",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 0.72412109375,
            "end_logit": -5.9609375,
            "text": "actin filaments, microtubules, and intermediate filaments",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 1.955078125,
            "text": "Fibrillar polymers-actin filaments",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.703125,
            "end_logit": 1.955078125,
            "text": "polymers-actin filaments",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 0.72412109375,
            "end_logit": -7.02734375,
            "text": "actin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 0.72412109375,
            "end_logit": -7.42578125,
            "text": "actin filaments, microtubules, and intermediate filaments-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 0.72412109375,
            "end_logit": -7.44140625,
            "text": "actin filaments, microtubules, and intermediate filaments-are",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.42578125,
            "end_logit": -5.9609375,
            "text": ", microtubules, and intermediate filaments",
            "probability": 0.0
        }
    ],
    "5a86ebf2faa1ab7d2e000038_1": [
        {
            "start_logit": 7.86328125,
            "end_logit": 7.7890625,
            "text": "CLOCK",
            "probability": 1.0
        },
        {
            "start_logit": 7.86328125,
            "end_logit": -5.453125,
            "text": "CLOCK and BMAL1",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 7.86328125,
            "end_logit": -6.91015625,
            "text": "CLOCK and BM",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.86328125,
            "end_logit": -6.98046875,
            "text": "CLOCK and BMAL",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.86328125,
            "end_logit": -7.03125,
            "text": "CLOCK and BMAL1 are two members of bHLH-PAS-containing family of transcription factors",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.86328125,
            "end_logit": -7.12890625,
            "text": "CLOCK and BMAL1 are",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.86328125,
            "end_logit": -7.234375,
            "text": "CLOCK and BMAL1 are two members of bHLH",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.86328125,
            "end_logit": -7.3046875,
            "text": "CLOCK and BMAL1 are two members of bHLH-PAS",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.86328125,
            "end_logit": -7.3125,
            "text": "CLOCK and BMAL1 are two",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.86328125,
            "end_logit": -7.40625,
            "text": "CLOCK and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.86328125,
            "end_logit": -7.41796875,
            "text": "CLOCK and BMAL1 are two members of bHLH-PAS-containing",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.86328125,
            "end_logit": -7.45703125,
            "text": "CLOCK and BMAL1 are two members",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.86328125,
            "end_logit": -7.46875,
            "text": "CLOCK and BMAL1 are two members of bHLH-PAS-containing family of transcription factors that represent",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.86328125,
            "end_logit": -7.47265625,
            "text": "CLOCK and BMAL1 are two members of bHLH-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.86328125,
            "end_logit": -7.50390625,
            "text": "CLOCK and BMAL1 are two members of bHLH-PAS-containing family of transcription factors that represent the positive elements of circadian autoregulatory feedback",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.86328125,
            "end_logit": -7.50390625,
            "text": "CLOCK and BMAL1 are two members of bHLH-PAS-containing family of transcription",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.6953125,
            "end_logit": 7.7890625,
            "text": "Mammalian CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.234375,
            "end_logit": -5.453125,
            "text": "BMAL1",
            "probability": 0.0
        },
        {
            "start_logit": -7.3671875,
            "end_logit": -5.453125,
            "text": "and BMAL1",
            "probability": 0.0
        },
        {
            "start_logit": -7.48828125,
            "end_logit": -5.453125,
            "text": "AL1",
            "probability": 0.0
        }
    ],
    "5a86ebf2faa1ab7d2e000038_2": [
        {
            "start_logit": 8.0078125,
            "end_logit": 7.6328125,
            "text": "CLOCK",
            "probability": 1.0
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -5.77734375,
            "text": "CLOCK and BMAL1 proteins. Nuclear/cytoplasm distribution of CLOCK",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -6.51953125,
            "text": "CLOCK and BMAL1",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.05078125,
            "text": "CLOCK and BMAL1 proteins",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.27734375,
            "text": "CLOCK and BMAL1 proteins. Nuclear/cytoplasm distribution",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.28125,
            "text": "CLOCK and BMAL1 proteins. Nuclear/cytoplasm",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.29296875,
            "text": "CLOCK and",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.32421875,
            "text": "CLOCK and BMAL1 proteins. Nuclear/cytoplasm distribution of CLOCK was found to be under circadian regulation",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.33203125,
            "text": "CLOCK and BMAL1 proteins.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.33203125,
            "text": "CLOCK and BMAL1 proteins. Nuclear/cytoplasm distribution of CLOCK was found to be under circadian regulation.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.4453125,
            "text": "CLOCK and BMAL",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.44921875,
            "text": "CLOCK and BMAL1 proteins. Nuclear/cytoplasm distribution of CLOCK was found to be under circadian",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.48046875,
            "text": "CLOCK and BMAL1 proteins. Nuclear/cytoplasm distribution of CLOCK was found",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.546875,
            "text": "CLOCK and BMAL1 proteins. Nuclear/",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.375,
            "end_logit": 7.6328125,
            "text": "abundance, posttranslational modifications, cellular localization of endogenous and ectopically expressed CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 7.6328125,
            "text": ", posttranslational modifications, cellular localization of endogenous and ectopically expressed CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 7.6328125,
            "text": "have examined abundance, posttranslational modifications, cellular localization of endogenous and ectopically expressed CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.578125,
            "end_logit": 7.6328125,
            "text": "examined abundance, posttranslational modifications, cellular localization of endogenous and ectopically expressed CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 7.6328125,
            "text": "endogenous and ectopically expressed CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 7.6328125,
            "text": "We have examined abundance, posttranslational modifications, cellular localization of endogenous and ectopically expressed CLOCK",
            "probability": 1.7881393432617188e-07
        }
    ],
    "5a86ebf2faa1ab7d2e000038_3": [
        {
            "start_logit": 8.1640625,
            "end_logit": 7.4453125,
            "text": "CLOCK",
            "probability": 1.0
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -6.02734375,
            "text": "CLOCK/BMAL1",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -6.46484375,
            "text": "CLOCK/BMAL1 complex following ectopic coexpression of both proteins is followed by their codependent phosphorylation, which is tightly coupled to CLOCK",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -7.06640625,
            "text": "CLOCK/BMAL1 complex following ectopic coexpression of both proteins",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -7.23046875,
            "text": "CLOCK/BMAL1 complex following ectopic coexpression of both proteins is followed by their codependent phosphorylation, which is tightly coupled to CLOCK nuclear translocation",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -7.3203125,
            "text": "CLOCK/BMAL1 complex following ectopic coexpression of both proteins is followed by their codependent phosphorylation, which is tightly coupled to CLOCK nuclear",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -7.35546875,
            "text": "CLOCK/BMAL1 complex",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -7.4921875,
            "text": "CLOCK/BMAL",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -7.49609375,
            "text": "CLOCK/BMAL1 complex following ectopic coexpression of both",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -7.515625,
            "text": "CLOCK/BMAL1 complex following ectopic coexpression of both proteins is followed by their codependent phosphorylation",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -7.52734375,
            "text": "CLOCK/BMAL1 complex following ectopic coexpression of both proteins is",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -7.5625,
            "text": "CLOCK/BMAL1 complex following",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -7.56640625,
            "text": "CLOCK/BMAL1 complex following ectopic coexpression",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -7.57421875,
            "text": "CLOCK/BMAL1 complex following ectopic coexpression of both proteins is followed by their codependent phosphorylation, which is tightly coupled",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -7.5859375,
            "text": "CLOCK/BMAL1 complex following ectopic coexpression of",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 7.4453125,
            "text": "Formation of CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 7.4453125,
            "text": "of CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.265625,
            "end_logit": -6.02734375,
            "text": "BMAL1",
            "probability": 0.0
        },
        {
            "start_logit": -7.44921875,
            "end_logit": -6.02734375,
            "text": "Formation of CLOCK/BMAL1",
            "probability": 0.0
        },
        {
            "start_logit": -7.453125,
            "end_logit": -6.02734375,
            "text": "AL1",
            "probability": 0.0
        }
    ],
    "5a86ebf2faa1ab7d2e000038_4": [
        {
            "start_logit": 8.0078125,
            "end_logit": 7.62109375,
            "text": "CLOCK",
            "probability": 1.0
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -5.69921875,
            "text": "CLOCK/BMAL1",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -6.25,
            "text": "CLOCK/BMAL1 complex",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.1953125,
            "text": "CLOCK/BMAL1 complex.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.25390625,
            "text": "CLOCK/BMAL",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.4921875,
            "text": "CLOCK/BM",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 7.62109375,
            "text": "of CLOCK",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 7.62109375,
            "text": "results provide evidence for an additional level of circadian system control, which is based on regulation of transcriptional activity or/and availability of CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 7.62109375,
            "text": "activity or/and availability of CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 7.62109375,
            "text": "regulation of transcriptional activity or/and availability of CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 7.62109375,
            "text": "level of circadian system control, which is based on regulation of transcriptional activity or/and availability of CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 7.62109375,
            "text": "Altogether, these results provide evidence for an additional level of circadian system control, which is based on regulation of transcriptional activity or/and availability of CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 7.62109375,
            "text": "transcriptional activity or/and availability of CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 7.62109375,
            "text": "an additional level of circadian system control, which is based on regulation of transcriptional activity or/and availability of CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 7.62109375,
            "text": "of transcriptional activity or/and availability of CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 7.62109375,
            "text": "these results provide evidence for an additional level of circadian system control, which is based on regulation of transcriptional activity or/and availability of CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.875,
            "end_logit": -5.69921875,
            "text": "BMAL1",
            "probability": 0.0
        },
        {
            "start_logit": -7.3359375,
            "end_logit": -5.69921875,
            "text": "of CLOCK/BMAL1",
            "probability": 0.0
        },
        {
            "start_logit": -7.390625,
            "end_logit": -5.69921875,
            "text": "AL1",
            "probability": 0.0
        },
        {
            "start_logit": -6.875,
            "end_logit": -6.25,
            "text": "BMAL1 complex",
            "probability": 0.0
        }
    ],
    "5a86ebf2faa1ab7d2e000038_5": [
        {
            "start_logit": 8.0546875,
            "end_logit": 7.51953125,
            "text": "CLOCK",
            "probability": 1.0
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -5.0859375,
            "text": "CLOCK and BMAL1",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.01953125,
            "text": "CLOCK and BMAL",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.11328125,
            "text": "CLOCK and BM",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.26953125,
            "text": "CLOCK and BMAL1, are known to regulate gene expression by interacting with a promoter element termed the E-box (CACGTG",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.3828125,
            "text": "CLOCK and BMAL1, are known to regulate gene expression by interacting with a promoter element termed the E-box (CACGTG)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.40234375,
            "text": "CLOCK and BMAL1, are known to regulate gene expression by interacting with a promoter element termed the E-box (CACGTG).",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.44140625,
            "text": "CLOCK and BMAL1, are known to regulate gene expression by interacting with a promoter element termed the E-box (CACGT",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.47265625,
            "text": "CLOCK and BMAL1, are",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.9609375,
            "end_logit": 7.51953125,
            "text": ", CLOCK",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.515625,
            "text": "CLOCK and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.53125,
            "text": "CLOCK and BMAL1, are known to regulate gene expression",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.15625,
            "end_logit": 7.51953125,
            "text": "basic helix-loop-helix (bHLH) PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.37890625,
            "end_logit": 7.51953125,
            "text": "Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.421875,
            "end_logit": 7.51953125,
            "text": "for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 7.51953125,
            "text": "bHLH) PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 7.51953125,
            "text": "(for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 7.51953125,
            "text": "(bHLH) PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.609375,
            "end_logit": 7.51953125,
            "text": "helix (bHLH) PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 7.51953125,
            "text": "helix-loop-helix (bHLH) PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 1.7881393432617188e-07
        }
    ],
    "5a86ebf2faa1ab7d2e000038_6": [
        {
            "start_logit": 8.2265625,
            "end_logit": 7.26171875,
            "text": "CLOCK",
            "probability": 1.0
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -5.3984375,
            "text": "CLOCK and BMAL1",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -7.17578125,
            "text": "CLOCK and BMAL1.",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -7.22265625,
            "text": "CLOCK and BMAL",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -7.33984375,
            "text": "CLOCK and BM",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -7.53125,
            "text": "CLOCK and",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.10546875,
            "end_logit": 7.26171875,
            "text": "PER and CRY, which inhibit their own transcriptional activators, CLOCK",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.2265625,
            "end_logit": 7.26171875,
            "text": "of PER and CRY, which inhibit their own transcriptional activators, CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.3515625,
            "end_logit": 7.26171875,
            "text": ", CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.40625,
            "end_logit": 7.26171875,
            "text": "and CRY, which inhibit their own transcriptional activators, CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.40625,
            "end_logit": 7.26171875,
            "text": "by oscillations of PER and CRY, which inhibit their own transcriptional activators, CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 7.26171875,
            "text": "activators, CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 7.26171875,
            "text": "transcriptional negative feedback loop that is driven primarily by oscillations of PER and CRY, which inhibit their own transcriptional activators, CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5,
            "end_logit": 7.26171875,
            "text": "negative feedback loop that is driven primarily by oscillations of PER and CRY, which inhibit their own transcriptional activators, CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 7.26171875,
            "text": "oscillations of PER and CRY, which inhibit their own transcriptional activators, CLOCK",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.53125,
            "end_logit": 7.26171875,
            "text": "transcriptional activators, CLOCK",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 7.26171875,
            "text": "a transcriptional negative feedback loop that is driven primarily by oscillations of PER and CRY, which inhibit their own transcriptional activators, CLOCK",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.10546875,
            "end_logit": -5.16015625,
            "text": "PER",
            "probability": 0.0
        },
        {
            "start_logit": -7.2265625,
            "end_logit": -5.16015625,
            "text": "of PER",
            "probability": 0.0
        },
        {
            "start_logit": -7.10546875,
            "end_logit": -5.3984375,
            "text": "PER and CRY, which inhibit their own transcriptional activators, CLOCK and BMAL1",
            "probability": 0.0
        }
    ],
    "5a86ebf2faa1ab7d2e000038_7": [
        {
            "start_logit": 8.28125,
            "end_logit": 7.17578125,
            "text": "CLOCK",
            "probability": 1.0
        },
        {
            "start_logit": 8.28125,
            "end_logit": -5.6328125,
            "text": "CLOCK:BMAL1, while CRY only interacts indirectly; PER2 bridges CRY and CLOCK",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.1171875,
            "text": "CLOCK:BMAL1, while CRY only interacts indirectly; PER2 bridges CRY",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.2578125,
            "text": "CLOCK:BMAL1, while CRY only interacts indirectly; PER2 bridges CRY and CLOCK:BMAL1",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.28125,
            "text": "CLOCK:BMAL1, while CRY only interacts indirectly; PER2 bridges CRY and CLOCK:BMAL1 to drive the circadian negative feedback loop",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.29296875,
            "text": "CLOCK:BMAL1, while CRY",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.34375,
            "text": "CLOCK:BMAL1",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.34765625,
            "text": "CLOCK:BMAL1, while CRY only interacts indirectly; PER2 bridges CRY and CLOCK:BMAL1 to",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.359375,
            "text": "CLOCK:BMAL1, while CRY only interacts indirectly; PER2 bridges CRY and CLOCK:BM",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.43359375,
            "text": "CLOCK:BMAL1, while CRY only interacts indirectly; PER2 bridges CRY and CLOCK:BMAL1 to drive the circadian negative feedback",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.40234375,
            "end_logit": 7.17578125,
            "text": "PER2 directly and rhythmically binds to CLOCK",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.953125,
            "end_logit": 7.17578125,
            "text": "to CLOCK",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.33203125,
            "end_logit": 7.17578125,
            "text": "disparity: PER2 directly and rhythmically binds to CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 7.17578125,
            "text": ": PER2 directly and rhythmically binds to CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 7.17578125,
            "text": "binds to CLOCK",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 7.17578125,
            "text": "elegant mechanism for the disparity: PER2 directly and rhythmically binds to CLOCK",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 7.17578125,
            "text": "Our biochemical evidence supports an elegant mechanism for the disparity: PER2 directly and rhythmically binds to CLOCK",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.40234375,
            "end_logit": -5.6328125,
            "text": "PER2 directly and rhythmically binds to CLOCK:BMAL1, while CRY only interacts indirectly; PER2 bridges CRY and CLOCK",
            "probability": 0.0
        },
        {
            "start_logit": -6.40234375,
            "end_logit": -6.09375,
            "text": "PER2",
            "probability": 0.0
        },
        {
            "start_logit": -6.953125,
            "end_logit": -5.6328125,
            "text": "to CLOCK:BMAL1, while CRY only interacts indirectly; PER2 bridges CRY and CLOCK",
            "probability": 0.0
        }
    ],
    "5a86ebf2faa1ab7d2e000038_8": [
        {
            "start_logit": 8.0546875,
            "end_logit": 7.51953125,
            "text": "CLOCK",
            "probability": 1.0
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -5.0859375,
            "text": "CLOCK and BMAL1",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.01953125,
            "text": "CLOCK and BMAL",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.11328125,
            "text": "CLOCK and BM",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.26953125,
            "text": "CLOCK and BMAL1, are known to regulate gene expression by interacting with a promoter element termed the E-box (CACGTG",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.3828125,
            "text": "CLOCK and BMAL1, are known to regulate gene expression by interacting with a promoter element termed the E-box (CACGTG)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.40234375,
            "text": "CLOCK and BMAL1, are known to regulate gene expression by interacting with a promoter element termed the E-box (CACGTG).",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.44140625,
            "text": "CLOCK and BMAL1, are known to regulate gene expression by interacting with a promoter element termed the E-box (CACGT",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.47265625,
            "text": "CLOCK and BMAL1, are",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.9609375,
            "end_logit": 7.51953125,
            "text": ", CLOCK",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.515625,
            "text": "CLOCK and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.53125,
            "text": "CLOCK and BMAL1, are known to regulate gene expression",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.15625,
            "end_logit": 7.51953125,
            "text": "basic helix-loop-helix (bHLH) PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.37890625,
            "end_logit": 7.51953125,
            "text": "Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.421875,
            "end_logit": 7.51953125,
            "text": "for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 7.51953125,
            "text": "bHLH) PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 7.51953125,
            "text": "(for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 7.51953125,
            "text": "(bHLH) PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.609375,
            "end_logit": 7.51953125,
            "text": "helix (bHLH) PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 7.51953125,
            "text": "helix-loop-helix (bHLH) PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 1.7881393432617188e-07
        }
    ],
    "5a86ebf2faa1ab7d2e000038_9": [
        {
            "start_logit": 7.58984375,
            "end_logit": 6.15234375,
            "text": "CRY proteins in turn inhibit CLOCK",
            "probability": 0.484375
        },
        {
            "start_logit": 7.0078125,
            "end_logit": 6.15234375,
            "text": "CLOCK",
            "probability": 0.26953125
        },
        {
            "start_logit": 7.58984375,
            "end_logit": 5.46875,
            "text": "CRY",
            "probability": 0.2454833984375
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -4.5703125,
            "text": "CRY proteins",
            "probability": 1.0728836059570312e-05
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -6.1875,
            "text": "CRY proteins in turn inhibit CLOCK:BMAL",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 7.0078125,
            "end_logit": -6.1875,
            "text": "CLOCK:BMAL",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -6.90234375,
            "text": "CRY proteins in turn inhibit CLOCK:BMAL-mediated transcription",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -6.9296875,
            "text": "CRY proteins in turn",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -6.93359375,
            "text": "CRY proteins in turn inhibit CLOCK:BMAL-mediated transcription closing the negative feedback loop.",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -7.04296875,
            "text": "CRY proteins in turn inhibit CLOCK:BMAL-",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -7.2109375,
            "text": "CRY proteins in turn inhibit CLOCK:BMAL-mediated transcription closing the negative feedback loop",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -7.29296875,
            "text": "CRY proteins in turn inhibit CLOCK:BMAL-mediated",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -7.34375,
            "text": "CRY proteins in",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -7.41796875,
            "text": "CRY proteins in turn inhibit CLOCK:BMAL-mediated transcription closing",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -7.4375,
            "text": "CRY proteins in turn inhibit CLOCK:BMAL-mediated transcription closing the negative feedback",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -7.46484375,
            "text": "CRY proteins in turn inhibit CLOCK:BM",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.0078125,
            "end_logit": -6.90234375,
            "text": "CLOCK:BMAL-mediated transcription",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.0078125,
            "end_logit": -6.93359375,
            "text": "CLOCK:BMAL-mediated transcription closing the negative feedback loop.",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.0078125,
            "end_logit": -7.04296875,
            "text": "CLOCK:BMAL-",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.0078125,
            "end_logit": -7.2109375,
            "text": "CLOCK:BMAL-mediated transcription closing the negative feedback loop",
            "probability": 4.172325134277344e-07
        }
    ],
    "5a86ebf2faa1ab7d2e000038_10": [
        {
            "start_logit": 8.328125,
            "end_logit": 7.17578125,
            "text": "CLOCK",
            "probability": 1.0
        },
        {
            "start_logit": 8.328125,
            "end_logit": -5.3984375,
            "text": "CLOCK:BMAL heterodimers induce the expression of Cry genes",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": 8.328125,
            "end_logit": -6.23828125,
            "text": "CLOCK:BMAL heterodimers induce the expression of Cry",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 8.328125,
            "end_logit": -6.4453125,
            "text": "CLOCK:BMAL",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 8.328125,
            "end_logit": -6.65234375,
            "text": "CLOCK:BMAL heterodimers",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 8.328125,
            "end_logit": -6.68359375,
            "text": "CLOCK:BMAL heterodimer",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.328125,
            "end_logit": -7.1796875,
            "text": "CLOCK:BMAL heterodimers induce the expression of Cry genes.",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.328125,
            "end_logit": -7.33984375,
            "text": "CLOCK:BMAL heterodimers induce the expression",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.328125,
            "end_logit": -7.53515625,
            "text": "CLOCK:BMAL heterodimers induce",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.328125,
            "end_logit": -7.5625,
            "text": "CLOCK:BMAL heterodimers induce the",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.328125,
            "end_logit": -7.5859375,
            "text": "CLOCK:BM",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 7.17578125,
            "text": ", CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.65625,
            "end_logit": 7.17578125,
            "text": "circadian feedback loop, CLOCK",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.671875,
            "end_logit": 7.17578125,
            "text": "In the vertebrate circadian feedback loop, CLOCK",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.61328125,
            "end_logit": -5.3984375,
            "text": "Cry genes",
            "probability": 0.0
        },
        {
            "start_logit": -6.859375,
            "end_logit": -5.3984375,
            "text": "BMAL heterodimers induce the expression of Cry genes",
            "probability": 0.0
        },
        {
            "start_logit": -7.27734375,
            "end_logit": -5.3984375,
            "text": ", CLOCK:BMAL heterodimers induce the expression of Cry genes",
            "probability": 0.0
        },
        {
            "start_logit": -7.31640625,
            "end_logit": -5.3984375,
            "text": ":BMAL heterodimers induce the expression of Cry genes",
            "probability": 0.0
        },
        {
            "start_logit": -6.61328125,
            "end_logit": -6.23828125,
            "text": "Cry",
            "probability": 0.0
        },
        {
            "start_logit": -7.4765625,
            "end_logit": -5.3984375,
            "text": "expression of Cry genes",
            "probability": 0.0
        }
    ],
    "5a86ebf2faa1ab7d2e000038_11": [
        {
            "start_logit": 8.0546875,
            "end_logit": 7.51953125,
            "text": "CLOCK",
            "probability": 1.0
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -5.0859375,
            "text": "CLOCK and BMAL1",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.01953125,
            "text": "CLOCK and BMAL",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.11328125,
            "text": "CLOCK and BM",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.26953125,
            "text": "CLOCK and BMAL1, are known to regulate gene expression by interacting with a promoter element termed the E-box (CACGTG",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.3828125,
            "text": "CLOCK and BMAL1, are known to regulate gene expression by interacting with a promoter element termed the E-box (CACGTG)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.40234375,
            "text": "CLOCK and BMAL1, are known to regulate gene expression by interacting with a promoter element termed the E-box (CACGTG).",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.44140625,
            "text": "CLOCK and BMAL1, are known to regulate gene expression by interacting with a promoter element termed the E-box (CACGT",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.47265625,
            "text": "CLOCK and BMAL1, are",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.9609375,
            "end_logit": 7.51953125,
            "text": ", CLOCK",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.515625,
            "text": "CLOCK and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.53125,
            "text": "CLOCK and BMAL1, are known to regulate gene expression",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.15625,
            "end_logit": 7.51953125,
            "text": "basic helix-loop-helix (bHLH) PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.37890625,
            "end_logit": 7.51953125,
            "text": "Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.421875,
            "end_logit": 7.51953125,
            "text": "for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 7.51953125,
            "text": "bHLH) PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 7.51953125,
            "text": "(for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 7.51953125,
            "text": "(bHLH) PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.609375,
            "end_logit": 7.51953125,
            "text": "helix (bHLH) PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 7.51953125,
            "text": "helix-loop-helix (bHLH) PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK",
            "probability": 1.7881393432617188e-07
        }
    ],
    "5a86ebf2faa1ab7d2e000038_12": [
        {
            "start_logit": 8.5703125,
            "end_logit": 5.0,
            "text": "clock genes Clock",
            "probability": 0.69921875
        },
        {
            "start_logit": 8.5703125,
            "end_logit": 4.15625,
            "text": "clock",
            "probability": 0.30078125
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -5.28125,
            "text": "clock genes Clock and Bmal1",
            "probability": 2.396106719970703e-05
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -6.8125,
            "text": "clock genes",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -7.03515625,
            "text": "clock genes Clock and Bmal",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -7.2109375,
            "text": "clock genes Clock and Bm",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -7.23828125,
            "text": "clock genes Clock and Bmal1.",
            "probability": 3.3974647521972656e-06
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -7.375,
            "text": "clock genes Clock and",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": -3.83203125,
            "end_logit": 5.0,
            "text": "Clock",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": -5.9375,
            "end_logit": 5.0,
            "text": "genes Clock",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.34375,
            "end_logit": 5.0,
            "text": "Id2 is involved in stabilization of the amplitudes of the circadian oscillations by suppressing transcriptional activation of clock genes Clock",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.34375,
            "end_logit": 4.15625,
            "text": "Id2 is involved in stabilization of the amplitudes of the circadian oscillations by suppressing transcriptional activation of clock",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3125,
            "end_logit": 5.0,
            "text": "that Id2 is involved in stabilization of the amplitudes of the circadian oscillations by suppressing transcriptional activation of clock genes Clock",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 5.0,
            "text": "present study, we demonstrate that Id2 is involved in stabilization of the amplitudes of the circadian oscillations by suppressing transcriptional activation of clock genes Clock",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3203125,
            "end_logit": 5.0,
            "text": "study, we demonstrate that Id2 is involved in stabilization of the amplitudes of the circadian oscillations by suppressing transcriptional activation of clock genes Clock",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 5.0,
            "text": "of clock genes Clock",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.421875,
            "end_logit": 5.0,
            "text": "demonstrate that Id2 is involved in stabilization of the amplitudes of the circadian oscillations by suppressing transcriptional activation of clock genes Clock",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 5.0,
            "text": "suppressing transcriptional activation of clock genes Clock",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 5.0,
            "text": "we demonstrate that Id2 is involved in stabilization of the amplitudes of the circadian oscillations by suppressing transcriptional activation of clock genes Clock",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 5.0,
            "text": "In the present study, we demonstrate that Id2 is involved in stabilization of the amplitudes of the circadian oscillations by suppressing transcriptional activation of clock genes Clock",
            "probability": 5.960464477539063e-08
        }
    ],
    "5a86ebf2faa1ab7d2e000038_13": [
        {
            "start_logit": 9.34375,
            "end_logit": 9.4765625,
            "text": "bmal1",
            "probability": 1.0
        },
        {
            "start_logit": -0.8330078125,
            "end_logit": 9.4765625,
            "text": "1",
            "probability": 3.820657730102539e-05
        },
        {
            "start_logit": 9.34375,
            "end_logit": -0.923828125,
            "text": "bm",
            "probability": 3.069639205932617e-05
        },
        {
            "start_logit": -5.80859375,
            "end_logit": 9.4765625,
            "text": "al1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.953125,
            "end_logit": -5.90234375,
            "text": "intercellular coupling and molecular noise",
            "probability": 0.0
        },
        {
            "start_logit": -5.953125,
            "end_logit": -6.296875,
            "text": "intercellular coupling",
            "probability": 0.0
        },
        {
            "start_logit": -6.6171875,
            "end_logit": -5.68359375,
            "text": "per2",
            "probability": 0.0
        },
        {
            "start_logit": -6.3125,
            "end_logit": -6.046875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.53125,
            "end_logit": -5.90234375,
            "text": "molecular noise",
            "probability": 0.0
        },
        {
            "start_logit": -6.6171875,
            "end_logit": -6.23046875,
            "text": "per",
            "probability": 0.0
        },
        {
            "start_logit": -6.6171875,
            "end_logit": -6.25390625,
            "text": "per2 detected by bioluminescence imaging but could not generate circadian oscillations intrinsically inhibition of intercellular communication",
            "probability": 0.0
        },
        {
            "start_logit": -5.953125,
            "end_logit": -6.94921875,
            "text": "intercellular coupling and molecular noise are",
            "probability": 0.0
        },
        {
            "start_logit": -5.953125,
            "end_logit": -6.96875,
            "text": "intercellular coupling and molecular noise are required for the stochastic rhythms providing a novel biological example of noise",
            "probability": 0.0
        },
        {
            "start_logit": -7.16796875,
            "end_logit": -5.90234375,
            "text": "both intercellular coupling and molecular noise",
            "probability": 0.0
        },
        {
            "start_logit": -7.40625,
            "end_logit": -5.68359375,
            "text": "stochastic oscillations with periods that overlap the circadian range dissociated scn neurons expressed fluctuating levels of per2",
            "probability": 0.0
        },
        {
            "start_logit": -6.6171875,
            "end_logit": -6.58984375,
            "text": "per2 detected by bioluminescence imaging but could not generate circadian oscillations intrinsically inhibition of intercellular communication or cyclic amp signaling",
            "probability": 0.0
        },
        {
            "start_logit": -6.6171875,
            "end_logit": -6.6875,
            "text": "per2 detected",
            "probability": 0.0
        },
        {
            "start_logit": -7.30078125,
            "end_logit": -6.046875,
            "text": "emergence of stochastic circadian oscillations from the scn network in the absence of cell autonomous circadian oscillatory function highlights a previously unrecognized level of circadian organization.",
            "probability": 0.0
        },
        {
            "start_logit": -7.4765625,
            "end_logit": -5.90234375,
            "text": "quasi circadian oscillations that arise as an emergent property of the scn network experimental analysis and mathematical modeling argue that both intercellular coupling and molecular noise",
            "probability": 0.0
        },
        {
            "start_logit": -6.6171875,
            "end_logit": -6.80859375,
            "text": "per2 detected by bioluminescence imaging but could not generate circadian oscillations intrinsically inhibition of intercellular communication or cyclic amp",
            "probability": 0.0
        }
    ],
    "5a86ebf2faa1ab7d2e000038_14": [
        {
            "start_logit": 4.07421875,
            "end_logit": 6.1875,
            "text": "bmal1",
            "probability": 0.9951171875
        },
        {
            "start_logit": 4.07421875,
            "end_logit": 0.6435546875,
            "text": "bmal1 gene mbmal1 and defined the mbmal1 promoter region transcription of mbmal1 was activated by cry1",
            "probability": 0.0038814544677734375
        },
        {
            "start_logit": 4.07421875,
            "end_logit": -1.5322265625,
            "text": "bmal1 gene mbmal1 and defined the mbmal1 promoter region transcription of mbmal1 was activated by cry1 cry",
            "probability": 0.0004405975341796875
        },
        {
            "start_logit": -5.0625,
            "end_logit": 6.1875,
            "text": "1",
            "probability": 0.00010669231414794922
        },
        {
            "start_logit": 4.07421875,
            "end_logit": -3.900390625,
            "text": "bmal1 gene mbmal1 and defined the mbmal1 promoter region transcription of mbmal1 was activated by cry1 cry2",
            "probability": 4.118680953979492e-05
        },
        {
            "start_logit": -0.5302734375,
            "end_logit": 0.6435546875,
            "text": "cry1",
            "probability": 3.8683414459228516e-05
        },
        {
            "start_logit": -6.546875,
            "end_logit": 6.1875,
            "text": "we characterized the genomic structure of the mouse bmal1",
            "probability": 2.4199485778808594e-05
        },
        {
            "start_logit": -0.5302734375,
            "end_logit": 0.03790283203125,
            "text": "cry1 cry2 and per2 and was repressed by bmal1 clock",
            "probability": 2.1159648895263672e-05
        },
        {
            "start_logit": 4.07421875,
            "end_logit": -5.5703125,
            "text": "bmal1 gene mbmal1 and defined the mbmal1 promoter region transcription",
            "probability": 7.68899917602539e-06
        },
        {
            "start_logit": 4.07421875,
            "end_logit": -5.9140625,
            "text": "bm",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": -0.5302734375,
            "end_logit": -1.5322265625,
            "text": "cry1 cry",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": -4.5703125,
            "end_logit": 0.6435546875,
            "text": "activated by cry1",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -4.1015625,
            "end_logit": 0.03790283203125,
            "text": "clock",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -5.0625,
            "end_logit": 0.6435546875,
            "text": "1 gene mbmal1 and defined the mbmal1 promoter region transcription of mbmal1 was activated by cry1",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -0.5302734375,
            "end_logit": -3.8984375,
            "text": "cry1 cry2 and per2 and was repressed by bmal1 clock dimers therefore cry per2 and bmal1 clock",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -0.5302734375,
            "end_logit": -3.900390625,
            "text": "cry1 cry2",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -4.5703125,
            "end_logit": 0.03790283203125,
            "text": "activated by cry1 cry2 and per2 and was repressed by bmal1 clock",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.34765625,
            "end_logit": 0.6435546875,
            "text": "by cry1",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.34765625,
            "end_logit": 0.03790283203125,
            "text": "by cry1 cry2 and per2 and was repressed by bmal1 clock",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -0.5302734375,
            "end_logit": -4.9453125,
            "text": "cry1 cry2 and per2 and was repressed by bmal1 clock dimers therefore cry",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5a86ebf2faa1ab7d2e000038_15": [
        {
            "start_logit": 8.1015625,
            "end_logit": 7.45703125,
            "text": "clock",
            "probability": 1.0
        },
        {
            "start_logit": 8.1015625,
            "end_logit": -6.13671875,
            "text": "clock and bmal1",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 8.1015625,
            "end_logit": -7.0625,
            "text": "clock and bmal1 are",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.1015625,
            "end_logit": -7.08984375,
            "text": "clock and bmal1 are known to regulate gene expression by interacting with a promoter element termed the e box cacgtg",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.1015625,
            "end_logit": -7.1484375,
            "text": "clock and",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.6015625,
            "end_logit": 7.45703125,
            "text": "activators clock",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.1015625,
            "end_logit": -7.25390625,
            "text": "clock and bm",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.1015625,
            "end_logit": -7.26953125,
            "text": "clock and bmal",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.30859375,
            "end_logit": 7.45703125,
            "text": "transcriptional activators clock",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.296875,
            "end_logit": -6.3203125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.6015625,
            "end_logit": -6.13671875,
            "text": "activators clock and bmal1",
            "probability": 0.0
        },
        {
            "start_logit": -6.62109375,
            "end_logit": -6.3203125,
            "text": "study is the minimal required element for the generation of cell autonomous transcriptional oscillation of clock and clock controlled genes.",
            "probability": 0.0
        },
        {
            "start_logit": -7.30859375,
            "end_logit": -6.13671875,
            "text": "transcriptional activators clock and bmal1",
            "probability": 0.0
        },
        {
            "start_logit": -7.234375,
            "end_logit": -6.3203125,
            "text": "minimal required element for the generation of cell autonomous transcriptional oscillation of clock and clock controlled genes.",
            "probability": 0.0
        },
        {
            "start_logit": -7.328125,
            "end_logit": -6.3203125,
            "text": "elements identified in this study is the minimal required element for the generation of cell autonomous transcriptional oscillation of clock and clock controlled genes.",
            "probability": 0.0
        },
        {
            "start_logit": -6.6015625,
            "end_logit": -7.0625,
            "text": "activators clock and bmal1 are",
            "probability": 0.0
        },
        {
            "start_logit": -6.6015625,
            "end_logit": -7.08984375,
            "text": "activators clock and bmal1 are known to regulate gene expression by interacting with a promoter element termed the e box cacgtg",
            "probability": 0.0
        },
        {
            "start_logit": -6.6015625,
            "end_logit": -7.1484375,
            "text": "activators clock and",
            "probability": 0.0
        },
        {
            "start_logit": -6.6015625,
            "end_logit": -7.25390625,
            "text": "activators clock and bm",
            "probability": 0.0
        },
        {
            "start_logit": -6.6015625,
            "end_logit": -7.26953125,
            "text": "activators clock and bmal",
            "probability": 0.0
        }
    ],
    "5a86ebf2faa1ab7d2e000038_16": [
        {
            "start_logit": 8.7890625,
            "end_logit": 9.203125,
            "text": "cryptochrome1a",
            "probability": 1.0
        },
        {
            "start_logit": 8.7890625,
            "end_logit": 0.10791015625,
            "text": "cryptochrome1a gene",
            "probability": 0.00011152029037475586
        },
        {
            "start_logit": -1.5322265625,
            "end_logit": 9.203125,
            "text": "1a",
            "probability": 3.272294998168945e-05
        },
        {
            "start_logit": 8.7890625,
            "end_logit": -1.98046875,
            "text": "crypt",
            "probability": 1.3828277587890625e-05
        },
        {
            "start_logit": -5.125,
            "end_logit": 9.203125,
            "text": "clock bmal independent circadian oscillation of zebrafish cryptochrome1a",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -6.46484375,
            "end_logit": 9.203125,
            "text": "zebrafish cryptochrome1a",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.7890625,
            "end_logit": -6.35546875,
            "text": "cryptochrome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.81640625,
            "end_logit": 9.203125,
            "text": "ochrome1a",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.16015625,
            "end_logit": 9.203125,
            "text": "oscillation of zebrafish cryptochrome1a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 9.203125,
            "text": "of zebrafish cryptochrome1a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.5322265625,
            "end_logit": 0.10791015625,
            "text": "1a gene",
            "probability": 0.0
        },
        {
            "start_logit": -5.125,
            "end_logit": 0.10791015625,
            "text": "clock bmal independent circadian oscillation of zebrafish cryptochrome1a gene",
            "probability": 0.0
        },
        {
            "start_logit": -6.46484375,
            "end_logit": 0.10791015625,
            "text": "zebrafish cryptochrome1a gene",
            "probability": 0.0
        },
        {
            "start_logit": -6.81640625,
            "end_logit": 0.10791015625,
            "text": "ochrome1a gene",
            "probability": 0.0
        },
        {
            "start_logit": -7.16015625,
            "end_logit": 0.10791015625,
            "text": "oscillation of zebrafish cryptochrome1a gene",
            "probability": 0.0
        },
        {
            "start_logit": -5.125,
            "end_logit": -1.98046875,
            "text": "clock bmal independent circadian oscillation of zebrafish crypt",
            "probability": 0.0
        },
        {
            "start_logit": -7.33203125,
            "end_logit": 0.10791015625,
            "text": "gene",
            "probability": 0.0
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 0.10791015625,
            "text": "of zebrafish cryptochrome1a gene",
            "probability": 0.0
        },
        {
            "start_logit": -6.46484375,
            "end_logit": -1.98046875,
            "text": "zebrafish crypt",
            "probability": 0.0
        },
        {
            "start_logit": -7.16015625,
            "end_logit": -1.98046875,
            "text": "oscillation of zebrafish crypt",
            "probability": 0.0
        }
    ],
    "5324cf139b2d7acc7e00001f_1": [
        {
            "start_logit": 8.125,
            "end_logit": 6.1640625,
            "text": "depression",
            "probability": 0.9990234375
        },
        {
            "start_logit": 8.125,
            "end_logit": -1.400390625,
            "text": "depression during childhood and adolescence",
            "probability": 0.0005192756652832031
        },
        {
            "start_logit": 8.125,
            "end_logit": -4.3515625,
            "text": "depression during childhood",
            "probability": 2.7120113372802734e-05
        },
        {
            "start_logit": 8.125,
            "end_logit": -6.83984375,
            "text": "depression during childhood and",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": -6.11328125,
            "end_logit": 6.1640625,
            "text": "with depression",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.2734375,
            "end_logit": 6.1640625,
            "text": "inpatients with depression",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.51953125,
            "end_logit": 6.1640625,
            "text": "present analysis evaluates the prevalence and medication use in inpatients with depression",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.6640625,
            "end_logit": 6.1640625,
            "text": "prevalence and medication use in inpatients with depression",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.671875,
            "end_logit": 6.1640625,
            "text": "analysis evaluates the prevalence and medication use in inpatients with depression",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.74609375,
            "end_logit": 6.1640625,
            "text": "in inpatients with depression",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 6.1640625,
            "text": "medication use in inpatients with depression",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.38671875,
            "end_logit": 6.1640625,
            "text": "the prevalence and medication use in inpatients with depression",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.46875,
            "end_logit": 6.1640625,
            "text": "evaluates the prevalence and medication use in inpatients with depression",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.88671875,
            "end_logit": -1.400390625,
            "text": "during childhood and adolescence",
            "probability": 0.0
        },
        {
            "start_logit": -6.11328125,
            "end_logit": -1.400390625,
            "text": "with depression during childhood and adolescence",
            "probability": 0.0
        },
        {
            "start_logit": -6.2734375,
            "end_logit": -1.400390625,
            "text": "inpatients with depression during childhood and adolescence",
            "probability": 0.0
        },
        {
            "start_logit": -6.51953125,
            "end_logit": -1.400390625,
            "text": "present analysis evaluates the prevalence and medication use in inpatients with depression during childhood and adolescence",
            "probability": 0.0
        },
        {
            "start_logit": -6.6640625,
            "end_logit": -1.400390625,
            "text": "prevalence and medication use in inpatients with depression during childhood and adolescence",
            "probability": 0.0
        },
        {
            "start_logit": -6.671875,
            "end_logit": -1.400390625,
            "text": "analysis evaluates the prevalence and medication use in inpatients with depression during childhood and adolescence",
            "probability": 0.0
        },
        {
            "start_logit": -6.74609375,
            "end_logit": -1.400390625,
            "text": "in inpatients with depression during childhood and adolescence",
            "probability": 0.0
        }
    ],
    "5324cf139b2d7acc7e00001f_2": [
        {
            "start_logit": 6.515625,
            "end_logit": 3.458984375,
            "text": "Premature ejaculation",
            "probability": 0.9970703125
        },
        {
            "start_logit": 6.515625,
            "end_logit": -2.546875,
            "text": "Premature ejaculation (PE)",
            "probability": 0.0024509429931640625
        },
        {
            "start_logit": 6.515625,
            "end_logit": -5.0,
            "text": "Premature",
            "probability": 0.0002110004425048828
        },
        {
            "start_logit": 6.515625,
            "end_logit": -6.3203125,
            "text": "Premature ejaculation (PE",
            "probability": 5.632638931274414e-05
        },
        {
            "start_logit": 6.515625,
            "end_logit": -6.45703125,
            "text": "Premature ejaculation (PE) is a common sexual dysfunction",
            "probability": 4.8995018005371094e-05
        },
        {
            "start_logit": 6.515625,
            "end_logit": -6.60546875,
            "text": "Premature ejaculation (PE) is a common sexual dysfunction affecting 20% to 30% of men",
            "probability": 4.2557716369628906e-05
        },
        {
            "start_logit": 6.515625,
            "end_logit": -6.61328125,
            "text": "Premature ejaculation (PE) is a common sexual dysfunction affecting 20% to 30% of men worldwide",
            "probability": 4.184246063232422e-05
        },
        {
            "start_logit": 6.515625,
            "end_logit": -6.921875,
            "text": "Premature ejaculation (",
            "probability": 3.081560134887695e-05
        },
        {
            "start_logit": 6.515625,
            "end_logit": -7.3203125,
            "text": "Premature ejaculation (PE) is a common sexual dysfunction affecting 20% to 30",
            "probability": 2.0742416381835938e-05
        },
        {
            "start_logit": 6.515625,
            "end_logit": -7.33984375,
            "text": "Premature ejaculation (PE) is",
            "probability": 2.0384788513183594e-05
        },
        {
            "start_logit": 6.515625,
            "end_logit": -7.47265625,
            "text": "Premature ejaculation (PE) is a common sexual dysfunction affecting 20",
            "probability": 1.7702579498291016e-05
        },
        {
            "start_logit": 6.515625,
            "end_logit": -7.49609375,
            "text": "Premature ejaculation (PE) is a common sexual dysfunction affecting 20%",
            "probability": 1.7464160919189453e-05
        },
        {
            "start_logit": -6.7265625,
            "end_logit": 3.458984375,
            "text": "ejaculation",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -6.7265625,
            "end_logit": -2.546875,
            "text": "ejaculation (PE)",
            "probability": 0.0
        },
        {
            "start_logit": -7.23828125,
            "end_logit": -2.546875,
            "text": "PE)",
            "probability": 0.0
        },
        {
            "start_logit": -6.4140625,
            "end_logit": -6.45703125,
            "text": "sexual dysfunction",
            "probability": 0.0
        },
        {
            "start_logit": -6.4140625,
            "end_logit": -6.60546875,
            "text": "sexual dysfunction affecting 20% to 30% of men",
            "probability": 0.0
        },
        {
            "start_logit": -6.4140625,
            "end_logit": -6.61328125,
            "text": "sexual dysfunction affecting 20% to 30% of men worldwide",
            "probability": 0.0
        },
        {
            "start_logit": -6.7265625,
            "end_logit": -6.3203125,
            "text": "ejaculation (PE",
            "probability": 0.0
        },
        {
            "start_logit": -6.7265625,
            "end_logit": -6.45703125,
            "text": "ejaculation (PE) is a common sexual dysfunction",
            "probability": 0.0
        }
    ],
    "5324cf139b2d7acc7e00001f_3": [
        {
            "start_logit": 9.0078125,
            "end_logit": 9.0234375,
            "text": "dapoxetine",
            "probability": 1.0
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -1.7333984375,
            "text": "dap",
            "probability": 2.1278858184814453e-05
        },
        {
            "start_logit": -1.90234375,
            "end_logit": 9.0234375,
            "text": "oxetine",
            "probability": 1.8358230590820312e-05
        },
        {
            "start_logit": -6.15625,
            "end_logit": 9.0234375,
            "text": "and dapoxetine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.86328125,
            "text": "dapoxetine (SSRI",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.953125,
            "end_logit": 9.0234375,
            "text": "other compounds, only 2 treatments have been evaluated in randomized controlled phase 3 clinical trials: PSD502 and dapoxetine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0234375,
            "end_logit": 9.0234375,
            "text": "compounds, only 2 treatments have been evaluated in randomized controlled phase 3 clinical trials: PSD502 and dapoxetine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.0234375,
            "text": "dapoxetine (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.25390625,
            "text": "dapoxetine (SSRI)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.15625,
            "end_logit": -1.7333984375,
            "text": "and dap",
            "probability": 0.0
        },
        {
            "start_logit": -6.8671875,
            "end_logit": -1.7333984375,
            "text": "selective serotonin reuptake inhibitors (SSRIs) and other compounds, only 2 treatments have been evaluated in randomized controlled phase 3 clinical trials: PSD502 and dap",
            "probability": 0.0
        },
        {
            "start_logit": -6.953125,
            "end_logit": -1.7333984375,
            "text": "other compounds, only 2 treatments have been evaluated in randomized controlled phase 3 clinical trials: PSD502 and dap",
            "probability": 0.0
        },
        {
            "start_logit": -7.0234375,
            "end_logit": -1.7333984375,
            "text": "compounds, only 2 treatments have been evaluated in randomized controlled phase 3 clinical trials: PSD502 and dap",
            "probability": 0.0
        },
        {
            "start_logit": -1.90234375,
            "end_logit": -6.86328125,
            "text": "oxetine (SSRI",
            "probability": 0.0
        },
        {
            "start_logit": -1.90234375,
            "end_logit": -7.0234375,
            "text": "oxetine (",
            "probability": 0.0
        },
        {
            "start_logit": -1.90234375,
            "end_logit": -7.25390625,
            "text": "oxetine (SSRI)",
            "probability": 0.0
        },
        {
            "start_logit": -6.15625,
            "end_logit": -6.86328125,
            "text": "and dapoxetine (SSRI",
            "probability": 0.0
        },
        {
            "start_logit": -6.64453125,
            "end_logit": -6.4453125,
            "text": "Treatment of PE typically involves pharmacotherapy, particularly when lifelong.",
            "probability": 0.0
        },
        {
            "start_logit": -6.68359375,
            "end_logit": -6.4453125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.15625,
            "end_logit": -7.0234375,
            "text": "and dapoxetine (",
            "probability": 0.0
        }
    ],
    "5324cf139b2d7acc7e00001f_4": [
        {
            "start_logit": -0.2464599609375,
            "end_logit": -1.9384765625,
            "text": "fibromyalgia syndrome",
            "probability": 0.556640625
        },
        {
            "start_logit": -0.2464599609375,
            "end_logit": -2.970703125,
            "text": "fibromyalgia",
            "probability": 0.1983642578125
        },
        {
            "start_logit": -0.2464599609375,
            "end_logit": -2.98828125,
            "text": "fibromyalgia syndrome. Systematic review, meta-analysis and guideline].",
            "probability": 0.1949462890625
        },
        {
            "start_logit": -0.2464599609375,
            "end_logit": -5.3203125,
            "text": "fibromyalgia syndrome. Systematic review, meta-analysis",
            "probability": 0.0189361572265625
        },
        {
            "start_logit": -0.2464599609375,
            "end_logit": -5.796875,
            "text": "fibromyalgia syndrome. Systematic review, meta-analysis and guideline]",
            "probability": 0.011749267578125
        },
        {
            "start_logit": -0.2464599609375,
            "end_logit": -7.00390625,
            "text": "fibromyalgia syndrome. Systematic review, meta-analysis and",
            "probability": 0.0035228729248046875
        },
        {
            "start_logit": -0.2464599609375,
            "end_logit": -7.046875,
            "text": "fibromyalgia syndrome. Systematic review, meta-analysis and guideline",
            "probability": 0.003360748291015625
        },
        {
            "start_logit": -0.2464599609375,
            "end_logit": -7.16796875,
            "text": "fibromyalgia syndrome. Systematic review, meta-",
            "probability": 0.0029888153076171875
        },
        {
            "start_logit": -0.2464599609375,
            "end_logit": -7.1796875,
            "text": "fibromyalgia syndrome. Systematic review",
            "probability": 0.0029430389404296875
        },
        {
            "start_logit": -4.58984375,
            "end_logit": -2.98828125,
            "text": "meta-analysis and guideline].",
            "probability": 0.002536773681640625
        },
        {
            "start_logit": -6.64453125,
            "end_logit": -1.9384765625,
            "text": "Drug therapy of fibromyalgia syndrome",
            "probability": 0.0009260177612304688
        },
        {
            "start_logit": -5.83203125,
            "end_logit": -2.98828125,
            "text": ".",
            "probability": 0.000732421875
        },
        {
            "start_logit": -7.14453125,
            "end_logit": -1.9384765625,
            "text": "of fibromyalgia syndrome",
            "probability": 0.0005617141723632812
        },
        {
            "start_logit": -6.64453125,
            "end_logit": -2.970703125,
            "text": "Drug therapy of fibromyalgia",
            "probability": 0.00033020973205566406
        },
        {
            "start_logit": -6.64453125,
            "end_logit": -2.98828125,
            "text": "Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline].",
            "probability": 0.0003249645233154297
        },
        {
            "start_logit": -4.58984375,
            "end_logit": -5.3203125,
            "text": "meta-analysis",
            "probability": 0.0002472400665283203
        },
        {
            "start_logit": -6.94140625,
            "end_logit": -2.98828125,
            "text": "Systematic review, meta-analysis and guideline].",
            "probability": 0.0002416372299194336
        },
        {
            "start_logit": -7.14453125,
            "end_logit": -2.970703125,
            "text": "of fibromyalgia",
            "probability": 0.00020039081573486328
        },
        {
            "start_logit": -7.14453125,
            "end_logit": -2.98828125,
            "text": "of fibromyalgia syndrome. Systematic review, meta-analysis and guideline].",
            "probability": 0.0001971721649169922
        },
        {
            "start_logit": -7.24609375,
            "end_logit": -2.98828125,
            "text": "review, meta-analysis and guideline].",
            "probability": 0.00017821788787841797
        }
    ],
    "5324cf139b2d7acc7e00001f_5": [
        {
            "start_logit": 8.15625,
            "end_logit": 7.08203125,
            "text": "depression",
            "probability": 1.0
        },
        {
            "start_logit": 8.15625,
            "end_logit": -5.328125,
            "text": "depression. Insomnia",
            "probability": 4.112720489501953e-06
        },
        {
            "start_logit": 8.15625,
            "end_logit": -6.859375,
            "text": "depression. Insomnia is the most frequent reason for prescription of trazodone. It has also been proven useful in the treatment of anxiety disorders.",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.15625,
            "end_logit": -6.87890625,
            "text": "depression. Insomnia is the most frequent reason for prescription of trazodone. It has also been proven useful in the treatment of anxiety",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.15625,
            "end_logit": -6.96484375,
            "text": "depression.",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.15625,
            "end_logit": -7.046875,
            "text": "depression. Insomnia is the most frequent reason for prescription of trazodone.",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.15625,
            "end_logit": -7.296875,
            "text": "depression. Insomnia is the most frequent reason for prescription of trazodone. It has also been proven useful in the treatment of anxiety disorders",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.56640625,
            "end_logit": 7.08203125,
            "text": "Trazodone is an antidepressant belonging to the class of serotonin receptor antagonists and reuptake inhibitors. It is approved by the FDA for the treatment of depression",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.9609375,
            "end_logit": 7.08203125,
            "text": "treatment of depression",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.23828125,
            "end_logit": 7.08203125,
            "text": "of depression",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.24609375,
            "end_logit": 7.08203125,
            "text": ". It is approved by the FDA for the treatment of depression",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 7.08203125,
            "text": "antidepressant belonging to the class of serotonin receptor antagonists and reuptake inhibitors. It is approved by the FDA for the treatment of depression",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.04296875,
            "end_logit": -5.328125,
            "text": "Insomnia",
            "probability": 0.0
        },
        {
            "start_logit": -5.04296875,
            "end_logit": -6.859375,
            "text": "Insomnia is the most frequent reason for prescription of trazodone. It has also been proven useful in the treatment of anxiety disorders.",
            "probability": 0.0
        },
        {
            "start_logit": -5.04296875,
            "end_logit": -6.87890625,
            "text": "Insomnia is the most frequent reason for prescription of trazodone. It has also been proven useful in the treatment of anxiety",
            "probability": 0.0
        },
        {
            "start_logit": -5.04296875,
            "end_logit": -7.046875,
            "text": "Insomnia is the most frequent reason for prescription of trazodone.",
            "probability": 0.0
        },
        {
            "start_logit": -6.9609375,
            "end_logit": -5.328125,
            "text": "treatment of depression. Insomnia",
            "probability": 0.0
        },
        {
            "start_logit": -5.04296875,
            "end_logit": -7.296875,
            "text": "Insomnia is the most frequent reason for prescription of trazodone. It has also been proven useful in the treatment of anxiety disorders",
            "probability": 0.0
        },
        {
            "start_logit": -7.03515625,
            "end_logit": -5.328125,
            "text": ". Insomnia",
            "probability": 0.0
        },
        {
            "start_logit": -7.23828125,
            "end_logit": -5.328125,
            "text": "of depression. Insomnia",
            "probability": 0.0
        }
    ],
    "5324cf139b2d7acc7e00001f_6": [
        {
            "start_logit": 9.1484375,
            "end_logit": 9.234375,
            "text": "hot flashes",
            "probability": 1.0
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -1.349609375,
            "text": "hot",
            "probability": 2.5451183319091797e-05
        },
        {
            "start_logit": -1.45703125,
            "end_logit": 9.234375,
            "text": "es",
            "probability": 2.5093555450439453e-05
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -2.96875,
            "text": "hot flashes) associated with the menopausal transition",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -6.16015625,
            "text": "hot flashes) associated with the menopausal transition and sex hormone deprivation.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.7265625,
            "end_logit": 9.234375,
            "text": "symptoms of vasomotor dysregulation (hot flashes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -6.6484375,
            "text": "hot flashes)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -6.7265625,
            "text": "hot flashes) associated with the menopausal transition and sex hormone deprivation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.85546875,
            "end_logit": 9.234375,
            "text": "flashes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.91796875,
            "end_logit": 9.234375,
            "text": "vasomotor dysregulation (hot flashes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.05859375,
            "end_logit": 9.234375,
            "text": "(hot flashes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -7.00390625,
            "text": "hot flashes) associated with the menopausal transition and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -7.01953125,
            "text": "hot flash",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -7.0625,
            "text": "hot flashes) associated with the menopausal transition and sex hormone deprivation. Implication of changes in central neurotransmission in the pathogenesis of hot flashes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -7.21875,
            "text": "hot flashes) associated with the menopausal transition and sex hormone deprivation. Implication of changes in central neurotransmission in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -7.37890625,
            "text": "hot flashes) associated with the menopausal transition and sex hormone deprivation. Implication of changes in central neurotransmission",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -7.40234375,
            "text": "hot flashes) associated",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.45703125,
            "end_logit": -2.96875,
            "text": "es) associated with the menopausal transition",
            "probability": 0.0
        },
        {
            "start_logit": -4.4609375,
            "end_logit": -2.96875,
            "text": "menopausal transition",
            "probability": 0.0
        },
        {
            "start_logit": -1.45703125,
            "end_logit": -6.16015625,
            "text": "es) associated with the menopausal transition and sex hormone deprivation.",
            "probability": 0.0
        }
    ],
    "5324cf139b2d7acc7e00001f_7": [
        {
            "start_logit": 8.5,
            "end_logit": 8.1640625,
            "text": "duloxetine",
            "probability": 0.74267578125
        },
        {
            "start_logit": 8.5,
            "end_logit": 6.71875,
            "text": "duloxetine is a possible alternative treatment of postprostatectomy established stress urinary incontinence",
            "probability": 0.1763916015625
        },
        {
            "start_logit": 7.71875,
            "end_logit": 6.71875,
            "text": "stress urinary incontinence",
            "probability": 0.08074951171875
        },
        {
            "start_logit": 8.5,
            "end_logit": -2.720703125,
            "text": "dul",
            "probability": 1.4066696166992188e-05
        },
        {
            "start_logit": 8.5,
            "end_logit": -3.166015625,
            "text": "duloxetine is a possible alternative treatment of postprostatectomy established stress",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": -3.376953125,
            "end_logit": 8.1640625,
            "text": "oxetine",
            "probability": 5.245208740234375e-06
        },
        {
            "start_logit": 7.71875,
            "end_logit": -3.166015625,
            "text": "stress",
            "probability": 4.112720489501953e-06
        },
        {
            "start_logit": -4.80859375,
            "end_logit": 8.1640625,
            "text": "that duloxetine",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -3.376953125,
            "end_logit": 6.71875,
            "text": "oxetine is a possible alternative treatment of postprostatectomy established stress urinary incontinence",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 8.5,
            "end_logit": -6.44140625,
            "text": "duloxetine is a possible alternative treatment of postprostatectomy established stress urinary incontinence.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -4.671875,
            "end_logit": 6.71875,
            "text": "incontinence",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -4.80859375,
            "end_logit": 6.71875,
            "text": "that duloxetine is a possible alternative treatment of postprostatectomy established stress urinary incontinence",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.3671875,
            "end_logit": 8.1640625,
            "text": "results suggest that duloxetine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.5,
            "end_logit": -6.8671875,
            "text": "duloxetine is a possible alternative treatment of postprostatectomy established stress urinary",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.5,
            "end_logit": -6.9140625,
            "text": "duloxetine is a possible alternative treatment of postprostatectomy",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.5,
            "end_logit": -6.9375,
            "text": "duloxetine is",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.5,
            "end_logit": -7.03125,
            "text": "duloxetine is a",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.7421875,
            "end_logit": 8.1640625,
            "text": "suggest that duloxetine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.5,
            "end_logit": -7.1875,
            "text": "duloxetine is a possible alternative treatment",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.71875,
            "end_logit": -6.44140625,
            "text": "stress urinary incontinence.",
            "probability": 1.7881393432617188e-07
        }
    ],
    "5324cf139b2d7acc7e00001f_8": [
        {
            "start_logit": 3.580078125,
            "end_logit": 5.31640625,
            "text": "fibromyalgia",
            "probability": 1.0
        },
        {
            "start_logit": -6.3125,
            "end_logit": 5.31640625,
            "text": "Pharmacological treatment of fibromyalgia",
            "probability": 5.066394805908203e-05
        },
        {
            "start_logit": -6.484375,
            "end_logit": 5.31640625,
            "text": "treatment of fibromyalgia",
            "probability": 4.267692565917969e-05
        },
        {
            "start_logit": 3.580078125,
            "end_logit": -5.39453125,
            "text": "fibromyalgia.",
            "probability": 2.2292137145996094e-05
        },
        {
            "start_logit": -7.15625,
            "end_logit": 5.31640625,
            "text": "of fibromyalgia",
            "probability": 2.1755695343017578e-05
        },
        {
            "start_logit": -6.3125,
            "end_logit": -5.39453125,
            "text": "Pharmacological treatment of fibromyalgia.",
            "probability": 0.0
        },
        {
            "start_logit": -6.484375,
            "end_logit": -5.39453125,
            "text": "treatment of fibromyalgia.",
            "probability": 0.0
        },
        {
            "start_logit": -6.55859375,
            "end_logit": -5.39453125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.15625,
            "end_logit": -5.39453125,
            "text": "of fibromyalgia.",
            "probability": 0.0
        },
        {
            "start_logit": -6.3125,
            "end_logit": -7.296875,
            "text": "Pharmacological",
            "probability": 0.0
        }
    ],
    "5324cf139b2d7acc7e00001f_9": [
        {
            "start_logit": 8.0078125,
            "end_logit": 8.921875,
            "text": "hot flashes",
            "probability": 1.0
        },
        {
            "start_logit": -1.9833984375,
            "end_logit": 8.921875,
            "text": "es",
            "probability": 4.5418739318847656e-05
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -3.087890625,
            "text": "hot",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": -4.15625,
            "end_logit": 8.921875,
            "text": "controlling hot flashes",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": -4.4296875,
            "end_logit": 8.921875,
            "text": "antidepressants, gabapentine and clonidine. The main limits to the use of these drugs in controlling hot flashes",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": -5.0078125,
            "end_logit": 8.921875,
            "text": "drugs in controlling hot flashes",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": -6.4765625,
            "end_logit": 8.921875,
            "text": ", gabapentine and clonidine. The main limits to the use of these drugs in controlling hot flashes",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.55859375,
            "end_logit": 8.921875,
            "text": ". The main limits to the use of these drugs in controlling hot flashes",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -5.93359375,
            "text": "hot flash",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.88671875,
            "end_logit": 8.921875,
            "text": "clonidine. The main limits to the use of these drugs in controlling hot flashes",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.92578125,
            "end_logit": 8.921875,
            "text": "gabapentine and clonidine. The main limits to the use of these drugs in controlling hot flashes",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.94140625,
            "end_logit": 8.921875,
            "text": "use of these drugs in controlling hot flashes",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 8.921875,
            "text": "some antidepressants, gabapentine and clonidine. The main limits to the use of these drugs in controlling hot flashes",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.16015625,
            "end_logit": 8.921875,
            "text": ", some antidepressants, gabapentine and clonidine. The main limits to the use of these drugs in controlling hot flashes",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.171875,
            "end_logit": 8.921875,
            "text": "these drugs in controlling hot flashes",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.265625,
            "end_logit": 8.921875,
            "text": "limits to the use of these drugs in controlling hot flashes",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.06640625,
            "text": "hot flashes are",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.15625,
            "end_logit": -3.087890625,
            "text": "controlling hot",
            "probability": 0.0
        },
        {
            "start_logit": -4.4296875,
            "end_logit": -3.087890625,
            "text": "antidepressants, gabapentine and clonidine. The main limits to the use of these drugs in controlling hot",
            "probability": 0.0
        },
        {
            "start_logit": -5.0078125,
            "end_logit": -3.087890625,
            "text": "drugs in controlling hot",
            "probability": 0.0
        }
    ],
    "5324cf139b2d7acc7e00001f_10": [
        {
            "start_logit": 7.33203125,
            "end_logit": 8.65625,
            "text": "erectile dysfunction",
            "probability": 1.0
        },
        {
            "start_logit": -2.421875,
            "end_logit": 8.65625,
            "text": "dysfunction",
            "probability": 5.829334259033203e-05
        },
        {
            "start_logit": 7.33203125,
            "end_logit": -3.400390625,
            "text": "erectile",
            "probability": 5.841255187988281e-06
        },
        {
            "start_logit": -6.53125,
            "end_logit": 8.65625,
            "text": "with erectile dysfunction",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 7.33203125,
            "end_logit": -5.375,
            "text": "erectile dysfunction.",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -6.83984375,
            "end_logit": 8.65625,
            "text": "ymptomatic therapy for patients with erectile dysfunction",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -6.9453125,
            "end_logit": 8.65625,
            "text": "patients with erectile dysfunction",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 8.65625,
            "text": "for patients with erectile dysfunction",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -2.421875,
            "end_logit": -5.375,
            "text": "dysfunction.",
            "probability": 0.0
        },
        {
            "start_logit": -6.53125,
            "end_logit": -3.400390625,
            "text": "with erectile",
            "probability": 0.0
        },
        {
            "start_logit": -6.83984375,
            "end_logit": -3.400390625,
            "text": "ymptomatic therapy for patients with erectile",
            "probability": 0.0
        },
        {
            "start_logit": -6.9453125,
            "end_logit": -3.400390625,
            "text": "patients with erectile",
            "probability": 0.0
        },
        {
            "start_logit": -7.4609375,
            "end_logit": -3.400390625,
            "text": "for patients with erectile",
            "probability": 0.0
        },
        {
            "start_logit": -6.12890625,
            "end_logit": -5.375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.53125,
            "end_logit": -5.375,
            "text": "with erectile dysfunction.",
            "probability": 0.0
        },
        {
            "start_logit": -6.83984375,
            "end_logit": -5.375,
            "text": "ymptomatic therapy for patients with erectile dysfunction.",
            "probability": 0.0
        },
        {
            "start_logit": -6.9453125,
            "end_logit": -5.375,
            "text": "patients with erectile dysfunction.",
            "probability": 0.0
        },
        {
            "start_logit": -7.4609375,
            "end_logit": -5.375,
            "text": "for patients with erectile dysfunction.",
            "probability": 0.0
        },
        {
            "start_logit": -6.83984375,
            "end_logit": -7.359375,
            "text": "ymptomatic therapy",
            "probability": 0.0
        }
    ],
    "5324cf139b2d7acc7e00001f_11": [
        {
            "start_logit": 9.203125,
            "end_logit": 9.046875,
            "text": "dapoxetine",
            "probability": 1.0
        },
        {
            "start_logit": 9.203125,
            "end_logit": -1.369140625,
            "text": "dap",
            "probability": 2.9981136322021484e-05
        },
        {
            "start_logit": -1.900390625,
            "end_logit": 9.046875,
            "text": "oxetine",
            "probability": 1.5079975128173828e-05
        },
        {
            "start_logit": 9.203125,
            "end_logit": -5.0234375,
            "text": "dapoxetine, as well as other SSRIs in PE",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.18359375,
            "text": "dapoxetine, as well as other SSRIs in PE, is an off-label drug for PE.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.29296875,
            "text": "dapoxetine, as well as other SSRIs in PE, is an off-label drug for PE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.26953125,
            "end_logit": 9.046875,
            "text": ", dapoxetine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.5,
            "text": "dapoxetine, as well as other SSRIs in PE,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.546875,
            "text": "dapoxetine, as well as other SSRIs in PE, is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.63671875,
            "text": "dapoxetine, as well as other SSRIs",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.64453125,
            "text": "dapoxetine, as",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.65234375,
            "text": "dapoxetine, as well as other SSRIs in PE, is an",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 9.046875,
            "text": "Food and Drug Administration approval, dapoxetine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.900390625,
            "end_logit": -5.0234375,
            "text": "oxetine, as well as other SSRIs in PE",
            "probability": 0.0
        },
        {
            "start_logit": -7.26953125,
            "end_logit": -1.369140625,
            "text": ", dap",
            "probability": 0.0
        },
        {
            "start_logit": -7.6015625,
            "end_logit": -1.369140625,
            "text": "Food and Drug Administration approval, dap",
            "probability": 0.0
        },
        {
            "start_logit": -1.900390625,
            "end_logit": -7.18359375,
            "text": "oxetine, as well as other SSRIs in PE, is an off-label drug for PE.",
            "probability": 0.0
        },
        {
            "start_logit": -1.900390625,
            "end_logit": -7.29296875,
            "text": "oxetine, as well as other SSRIs in PE, is an off-label drug for PE",
            "probability": 0.0
        },
        {
            "start_logit": -1.900390625,
            "end_logit": -7.5,
            "text": "oxetine, as well as other SSRIs in PE,",
            "probability": 0.0
        },
        {
            "start_logit": -1.900390625,
            "end_logit": -7.546875,
            "text": "oxetine, as well as other SSRIs in PE, is",
            "probability": 0.0
        }
    ],
    "5324cf139b2d7acc7e00001f_12": [
        {
            "start_logit": 4.35546875,
            "end_logit": 5.85546875,
            "text": "PE",
            "probability": 0.99609375
        },
        {
            "start_logit": -1.177734375,
            "end_logit": 5.85546875,
            "text": "treatment of PE",
            "probability": 0.00394439697265625
        },
        {
            "start_logit": 4.35546875,
            "end_logit": -4.59765625,
            "text": "PE consists of primarily off-label use of oral selective serotonin reuptake inhibitors (SSRIs) via either on-demand or daily delivery",
            "probability": 2.872943878173828e-05
        },
        {
            "start_logit": -6.359375,
            "end_logit": 5.85546875,
            "text": "the treatment of PE",
            "probability": 2.205371856689453e-05
        },
        {
            "start_logit": -6.44140625,
            "end_logit": 5.85546875,
            "text": "of PE",
            "probability": 2.0384788513183594e-05
        },
        {
            "start_logit": 4.35546875,
            "end_logit": -5.31640625,
            "text": "PE consists of primarily off-label use of oral selective serotonin reuptake inhibitors (SSRIs) via either on-demand or daily delivery.",
            "probability": 1.4007091522216797e-05
        },
        {
            "start_logit": 4.35546875,
            "end_logit": -5.734375,
            "text": "PE consists",
            "probability": 9.179115295410156e-06
        },
        {
            "start_logit": 4.35546875,
            "end_logit": -5.96484375,
            "text": "PE consists of primarily off-label use of oral selective serotonin reuptake inhibitors (SSRIs) via either on-demand or",
            "probability": 7.331371307373047e-06
        },
        {
            "start_logit": 4.35546875,
            "end_logit": -6.04296875,
            "text": "PE consists of primarily off-label use of oral selective serotonin reuptake inhibitors",
            "probability": 6.794929504394531e-06
        },
        {
            "start_logit": 4.35546875,
            "end_logit": -6.18359375,
            "text": "PE consists of primarily off-label use of oral selective serotonin reuptake inhibitors (SSRIs) via either on-demand",
            "probability": 5.900859832763672e-06
        },
        {
            "start_logit": 4.35546875,
            "end_logit": -6.90234375,
            "text": "PE consists of primarily off-label use of oral selective serotonin reuptake inhibitors (SSRIs) via either on-demand or daily",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": 4.35546875,
            "end_logit": -6.94140625,
            "text": "PE consists of primarily off-label use of oral selective serotonin reuptake",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": 4.35546875,
            "end_logit": -7.09765625,
            "text": "PE consists of primarily off-label use of oral selective serotonin reuptake inhibitors (SSRIs)",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": 4.35546875,
            "end_logit": -7.203125,
            "text": "PE consists of primarily off-label use of oral selective serotonin",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 4.35546875,
            "end_logit": -7.21875,
            "text": "PE consists of primarily off-label use of oral selective serotonin reuptake inhibitors (SSRIs) via",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 4.35546875,
            "end_logit": -7.32421875,
            "text": "PE consists of primarily off-label use of oral selective serotonin reuptake inhibitors (",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 4.35546875,
            "end_logit": -7.32421875,
            "text": "PE consists of primarily off-label use of oral selective serotonin reuptake inhibitors (SSRIs) via either on-",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 4.35546875,
            "end_logit": -7.37890625,
            "text": "PE consists of",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -1.177734375,
            "end_logit": -4.59765625,
            "text": "treatment of PE consists of primarily off-label use of oral selective serotonin reuptake inhibitors (SSRIs) via either on-demand or daily delivery",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.177734375,
            "end_logit": -5.31640625,
            "text": "treatment of PE consists of primarily off-label use of oral selective serotonin reuptake inhibitors (SSRIs) via either on-demand or daily delivery.",
            "probability": 5.960464477539063e-08
        }
    ],
    "5324cf139b2d7acc7e00001f_13": [
        {
            "start_logit": 8.8984375,
            "end_logit": 8.484375,
            "text": "Duloxetine",
            "probability": 1.0
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -2.021484375,
            "text": "Dul",
            "probability": 2.753734588623047e-05
        },
        {
            "start_logit": -2.91796875,
            "end_logit": 8.484375,
            "text": "oxetine",
            "probability": 7.3909759521484375e-06
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -3.630859375,
            "text": "Duloxetine is effective in men with SUI after prostate surgery",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -4.671875,
            "text": "Duloxetine is effective in men with SUI",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -5.62109375,
            "end_logit": 8.484375,
            "text": "that Duloxetine",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.58203125,
            "text": "Duloxetine is effective in men with SUI after prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.625,
            "text": "Duloxetine is effective in men with SUI after prostate surgery even if standard pelvic floor exercises have failed.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.828125,
            "text": "Duloxetine is effective in men with SUI after prostate surgery even if standard pelvic floor exercises have failed",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.84375,
            "text": "Duloxetine is effective in men with SUI after prostate surgery even if standard pelvic floor exercises",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.0625,
            "text": "Duloxetine is effective in men with SUI after prostate surgery even if standard pelvic floor",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.13671875,
            "text": "Duloxetine is effective in men with SUI after prostate surgery even",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.19140625,
            "text": "Duloxetine is effective in men with SUI after",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.23828125,
            "text": "Duloxetine is effective in men with SUI after prostate surgery even if standard pelvic floor exercises have",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.33984375,
            "text": "Duloxetine is",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.953125,
            "end_logit": 8.484375,
            "text": "show that Duloxetine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4375,
            "end_logit": 8.484375,
            "text": "results of this off-label use show that Duloxetine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 8.484375,
            "text": "The results of this off-label use show that Duloxetine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.5380859375,
            "end_logit": -3.630859375,
            "text": "SUI after prostate surgery",
            "probability": 0.0
        },
        {
            "start_logit": -1.5380859375,
            "end_logit": -4.671875,
            "text": "SUI",
            "probability": 0.0
        }
    ],
    "5324cf139b2d7acc7e00001f_14": [
        {
            "start_logit": 7.53125,
            "end_logit": 7.5703125,
            "text": "insomnia",
            "probability": 1.0
        },
        {
            "start_logit": -0.671875,
            "end_logit": 7.5703125,
            "text": "trazodone, for treating insomnia",
            "probability": 0.00027370452880859375
        },
        {
            "start_logit": -6.5,
            "end_logit": 7.5703125,
            "text": "treating insomnia",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -6.8046875,
            "end_logit": 7.5703125,
            "text": "zodone, for treating insomnia",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.81640625,
            "end_logit": 7.5703125,
            "text": "antidepressants, particularly trazodone, for treating insomnia",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.53125,
            "end_logit": -6.81640625,
            "text": "insomnia.",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.9609375,
            "end_logit": 7.5703125,
            "text": "particularly trazodone, for treating insomnia",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.04296875,
            "end_logit": 7.5703125,
            "text": "1980s there has been a rapid rise in the off-label use of antidepressants, particularly trazodone, for treating insomnia",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.1171875,
            "end_logit": 7.5703125,
            "text": "rapid rise in the off-label use of antidepressants, particularly trazodone, for treating insomnia",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.1875,
            "end_logit": 7.5703125,
            "text": "mid-1980s there has been a rapid rise in the off-label use of antidepressants, particularly trazodone, for treating insomnia",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.43359375,
            "end_logit": 7.5703125,
            "text": "rise in the off-label use of antidepressants, particularly trazodone, for treating insomnia",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 7.5703125,
            "text": "been a rapid rise in the off-label use of antidepressants, particularly trazodone, for treating insomnia",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 7.5703125,
            "text": "a rapid rise in the off-label use of antidepressants, particularly trazodone, for treating insomnia",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 7.5703125,
            "text": "Since the mid-1980s there has been a rapid rise in the off-label use of antidepressants, particularly trazodone, for treating insomnia",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -0.671875,
            "end_logit": -1.26953125,
            "text": "trazodone",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.671875,
            "end_logit": -6.734375,
            "text": "trazod",
            "probability": 0.0
        },
        {
            "start_logit": -0.671875,
            "end_logit": -6.81640625,
            "text": "trazodone, for treating insomnia.",
            "probability": 0.0
        },
        {
            "start_logit": -0.671875,
            "end_logit": -7.19140625,
            "text": "trazodone,",
            "probability": 0.0
        },
        {
            "start_logit": -6.8046875,
            "end_logit": -1.26953125,
            "text": "zodone",
            "probability": 0.0
        },
        {
            "start_logit": -0.671875,
            "end_logit": -7.4140625,
            "text": "trazodone, for",
            "probability": 0.0
        }
    ],
    "5c5f03371a4c55d80b000009_1": [
        {
            "start_logit": 9.34375,
            "end_logit": 9.046875,
            "text": "PARL",
            "probability": 1.0
        },
        {
            "start_logit": 9.34375,
            "end_logit": -0.9453125,
            "text": "PAR",
            "probability": 4.57763671875e-05
        },
        {
            "start_logit": -1.943359375,
            "end_logit": 9.046875,
            "text": "L",
            "probability": 1.2516975402832031e-05
        },
        {
            "start_logit": -5.9921875,
            "end_logit": 9.046875,
            "text": "rhomboid protease PARL",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 9.046875,
            "text": "protease PARL",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.9921875,
            "end_logit": -0.9453125,
            "text": "rhomboid protease PAR",
            "probability": 0.0
        },
        {
            "start_logit": -7.62890625,
            "end_logit": -0.9453125,
            "text": "protease PAR",
            "probability": 0.0
        },
        {
            "start_logit": -5.9921875,
            "end_logit": -6.78515625,
            "text": "rhomboid protease",
            "probability": 0.0
        },
        {
            "start_logit": -5.9921875,
            "end_logit": -6.921875,
            "text": "rhomboid",
            "probability": 0.0
        },
        {
            "start_logit": -5.9921875,
            "end_logit": -7.33984375,
            "text": "rho",
            "probability": 0.0
        },
        {
            "start_logit": -5.9921875,
            "end_logit": -7.34765625,
            "text": "rhomb",
            "probability": 0.0
        },
        {
            "start_logit": -7.62890625,
            "end_logit": -6.78515625,
            "text": "protease",
            "probability": 0.0
        }
    ],
    "5c5f03371a4c55d80b000009_2": [
        {
            "start_logit": 9.2421875,
            "end_logit": 9.34375,
            "text": "Pcp1",
            "probability": 1.0
        },
        {
            "start_logit": -1.2509765625,
            "end_logit": 9.34375,
            "text": "1",
            "probability": 2.753734588623047e-05
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -1.212890625,
            "text": "Pcp",
            "probability": 2.586841583251953e-05
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -5.6953125,
            "text": "Pcp1 protein belongs to the rhomboid-GlpG",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.4140625,
            "text": "Pcp1 protein belongs to the rhomboid",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.69140625,
            "text": "Pcp1 protein belongs",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.85546875,
            "text": "Pcp1 protein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.90234375,
            "text": "Pcp1 protein belongs to the rhomboid-GlpG superfamily of putative intramembrane peptidases",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 9.34375,
            "text": "identified Pcp1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.28125,
            "text": "Pcp1 protein belongs to the rhomboid-GlpG superfamily",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.33203125,
            "text": "Pcp1 protein belongs to the rhomboid-GlpG superfamily of putative intramembrane peptidases.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.359375,
            "text": "Pcp1 protein belongs to the rhomboid-Glp",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 9.34375,
            "text": "newly identified Pcp1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.375,
            "text": "Pcp1 protein belongs to the rhomboid-GlpG superfamily of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.48828125,
            "text": "Pcp1 protein belongs to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.50390625,
            "text": "Pcp1 protein belongs to the rhomboid-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.2509765625,
            "end_logit": -5.6953125,
            "text": "1 protein belongs to the rhomboid-GlpG",
            "probability": 0.0
        },
        {
            "start_logit": -1.2509765625,
            "end_logit": -6.4140625,
            "text": "1 protein belongs to the rhomboid",
            "probability": 0.0
        },
        {
            "start_logit": -1.2509765625,
            "end_logit": -6.69140625,
            "text": "1 protein belongs",
            "probability": 0.0
        },
        {
            "start_logit": -1.2509765625,
            "end_logit": -6.85546875,
            "text": "1 protein",
            "probability": 0.0
        }
    ],
    "5c5f03371a4c55d80b000009_3": [
        {
            "start_logit": 9.2421875,
            "end_logit": 9.3828125,
            "text": "GlpG",
            "probability": 1.0
        },
        {
            "start_logit": -1.1845703125,
            "end_logit": 9.3828125,
            "text": "G",
            "probability": 2.956390380859375e-05
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -1.2119140625,
            "text": "Glp",
            "probability": 2.5093555450439453e-05
        },
        {
            "start_logit": -4.08203125,
            "end_logit": 9.3828125,
            "text": "Escherichia coli GlpG",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": -5.69140625,
            "end_logit": 9.3828125,
            "text": ", Escherichia coli GlpG",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -5.9609375,
            "text": "GlpG (ecGlpG) and Bacillus subtilis (YqgP",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.79296875,
            "text": "GlpG (ecGlpG",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.88671875,
            "text": "GlpG (ecGlpG)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.984375,
            "text": "GlpG (ecGlpG) and Bacillus subtilis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 9.3828125,
            "text": ", (hiGlpG), Escherichia coli GlpG",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.109375,
            "text": "GlpG (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.16796875,
            "text": "GlpG (ecGlpG) and Bacillus subtilis (Y",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.171875,
            "text": "GlpG (ecGlpG) and Bacillus subtilis (YqgP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.1796875,
            "text": "GlpG (ecGlpG) and Bacillus subtilis (Yq",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.23828125,
            "text": "GlpG (ecGlp",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.25390625,
            "text": "GlpG (ecG",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.3359375,
            "text": "GlpG (ecGlpG) and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5,
            "end_logit": 9.3828125,
            "text": "(hiGlpG), Escherichia coli GlpG",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 9.3828125,
            "text": "subjected Haemophilus influenzae, (hiGlpG), Escherichia coli GlpG",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.515625,
            "end_logit": 9.3828125,
            "text": "hiGlpG), Escherichia coli GlpG",
            "probability": 5.960464477539063e-08
        }
    ],
    "5c5f03371a4c55d80b000009_4": [
        {
            "start_logit": 9.3515625,
            "end_logit": 9.3671875,
            "text": "GlpG",
            "probability": 1.0
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -0.9501953125,
            "text": "Glp",
            "probability": 3.2961368560791016e-05
        },
        {
            "start_logit": -1.1650390625,
            "end_logit": 9.3671875,
            "text": "G",
            "probability": 2.7120113372802734e-05
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -6.1953125,
            "text": "GlpG (ecGlpG) rhomboids have revealed a structure with six transmembrane helices and a Ser-His catalytic dyad buried within the membrane",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.6328125,
            "end_logit": 9.3671875,
            "text": "E. coli GlpG",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -6.65234375,
            "text": "GlpG (ecGlpG",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -6.9140625,
            "text": "GlpG (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0234375,
            "end_logit": 9.3671875,
            "text": "and E. coli GlpG",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -7.05078125,
            "text": "GlpG (ecG",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -7.15234375,
            "text": "GlpG (ecGlpG) rhomboids have revealed a structure with six transmembrane helices",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -7.21484375,
            "text": "GlpG (ecGlp",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -7.27734375,
            "text": "GlpG (ecGlpG) rhomboids have revealed a structure with six transmembrane helices and a Ser-His catalytic dyad buried",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -7.359375,
            "text": "GlpG (ecGlpG) rhomboids have revealed a structure with six transmembrane helices and a Ser-His catalytic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -7.3671875,
            "text": "GlpG (ecGlpG) rhomboids have revealed a structure with six transmembrane helices and a Ser-His",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.453125,
            "end_logit": 9.3671875,
            "text": ". coli GlpG",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 9.3671875,
            "text": "hiGlpG) and E. coli GlpG",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -7.46875,
            "text": "GlpG (ecGlpG) rhomboids have revealed a structure with six transmembrane helices and a Ser-His catalytic dyad",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 9.3671875,
            "text": "Crystal structures of H. influenzae (hiGlpG) and E. coli GlpG",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.1650390625,
            "end_logit": -6.1953125,
            "text": "G (ecGlpG) rhomboids have revealed a structure with six transmembrane helices and a Ser-His catalytic dyad buried within the membrane",
            "probability": 0.0
        },
        {
            "start_logit": -6.6328125,
            "end_logit": -0.9501953125,
            "text": "E. coli Glp",
            "probability": 0.0
        }
    ],
    "5c72b6be7c78d69471000072_1": [
        {
            "start_logit": 9.09375,
            "end_logit": 9.6640625,
            "text": "phosphoinositide 3-kinase-\u03b4",
            "probability": 0.994140625
        },
        {
            "start_logit": 9.09375,
            "end_logit": 4.46875,
            "text": "phosphoinositide 3-kinase-\u03b4 (PI3K-\u03b4)",
            "probability": 0.005550384521484375
        },
        {
            "start_logit": 0.35595703125,
            "end_logit": 9.6640625,
            "text": "\u03b4",
            "probability": 0.00016129016876220703
        },
        {
            "start_logit": 9.09375,
            "end_logit": -1.5048828125,
            "text": "phosphoinositide",
            "probability": 1.424551010131836e-05
        },
        {
            "start_logit": 9.09375,
            "end_logit": -3.50390625,
            "text": "phosphoinositide 3-kinase-\u03b4 (",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 9.09375,
            "end_logit": -4.08984375,
            "text": "phosphoinositide 3-kinase-\u03b4 (PI3K-\u03b4",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 0.35595703125,
            "end_logit": 4.46875,
            "text": "\u03b4 (PI3K-\u03b4)",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -6.015625,
            "end_logit": 9.6640625,
            "text": "-\u03b4",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.08203125,
            "end_logit": 9.6640625,
            "text": "kinase-\u03b4",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -5.66796875,
            "text": "phosphoinositide 3-kinase-\u03b4 (PI3K-\u03b4) and PI3K-\u03b3",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.80078125,
            "end_logit": 9.6640625,
            "text": "3-kinase-\u03b4",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 9.6640625,
            "text": "of phosphoinositide 3-kinase-\u03b4",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.98828125,
            "end_logit": 9.6640625,
            "text": "-kinase-\u03b4",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.55859375,
            "text": "phosphoinositide 3-kinase-\u03b4 (PI3K",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.76171875,
            "text": "phosphoinositide 3-kinase-\u03b4 (PI3K-\u03b4) and PI3K",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34375,
            "end_logit": 9.6640625,
            "text": "inhibitor of phosphoinositide 3-kinase-\u03b4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3515625,
            "end_logit": 9.6640625,
            "text": "dual inhibitor of phosphoinositide 3-kinase-\u03b4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.86328125,
            "text": "phosphoinositide 3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 9.6640625,
            "text": "oral dual inhibitor of phosphoinositide 3-kinase-\u03b4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 9.6640625,
            "text": "is an oral dual inhibitor of phosphoinositide 3-kinase-\u03b4",
            "probability": 5.960464477539063e-08
        }
    ],
    "5c72b6be7c78d69471000072_2": [
        {
            "start_logit": 8.8125,
            "end_logit": 8.7734375,
            "text": "phosphoinositide-3 kinase \u03b4/\u03b3",
            "probability": 0.771484375
        },
        {
            "start_logit": 8.8125,
            "end_logit": 7.5625,
            "text": "phosphoinositide-3 kinase \u03b4",
            "probability": 0.2281494140625
        },
        {
            "start_logit": -0.8251953125,
            "end_logit": 8.7734375,
            "text": "\u03b3",
            "probability": 5.0187110900878906e-05
        },
        {
            "start_logit": 8.8125,
            "end_logit": -2.05859375,
            "text": "phosphoinositide",
            "probability": 1.5079975128173828e-05
        },
        {
            "start_logit": -3.64453125,
            "end_logit": 8.7734375,
            "text": "\u03b4/\u03b3",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": 8.8125,
            "end_logit": -4.5078125,
            "text": "phosphoinositide-3 kinase",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 8.8125,
            "end_logit": -4.625,
            "text": "phosphoinositide-3 kinase \u03b4/\u03b3 inhibitor for chronic lymphocytic leukemia",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -3.64453125,
            "end_logit": 7.5625,
            "text": "\u03b4",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -5.76171875,
            "text": "phosphoinositide-3",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.73828125,
            "end_logit": 8.7734375,
            "text": "-3 kinase \u03b4/\u03b3",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.80859375,
            "end_logit": 8.7734375,
            "text": "/\u03b3",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -7.06640625,
            "text": "phosphoinositide-3 kinase \u03b4/\u03b3 inhibitor for chronic lymphocytic leukemia.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -7.28515625,
            "text": "phosphoinositide-3 kinase \u03b4/\u03b3 inhibitor for chronic lymphocytic",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.25,
            "end_logit": 8.7734375,
            "text": "3 kinase \u03b4/\u03b3",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -7.37890625,
            "text": "phosphoinositide-3 kinase \u03b4/\u03b3 inhibitor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.359375,
            "end_logit": 8.7734375,
            "text": "a phosphoinositide-3 kinase \u03b4/\u03b3",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 8.7734375,
            "text": ": a phosphoinositide-3 kinase \u03b4/\u03b3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.75,
            "end_logit": 8.7734375,
            "text": "ib: a phosphoinositide-3 kinase \u03b4/\u03b3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.75390625,
            "end_logit": 8.7734375,
            "text": "kinase \u03b4/\u03b3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 8.7734375,
            "text": "velisib: a phosphoinositide-3 kinase \u03b4/\u03b3",
            "probability": 5.960464477539063e-08
        }
    ],
    "5548da00f35db7552600000b_1": [
        {
            "start_logit": 8.078125,
            "end_logit": 7.859375,
            "text": "myosins-Ibeta",
            "probability": 1.0
        },
        {
            "start_logit": 8.078125,
            "end_logit": -3.232421875,
            "text": "myosin",
            "probability": 1.519918441772461e-05
        },
        {
            "start_logit": -3.259765625,
            "end_logit": 7.859375,
            "text": "eta",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": -4.96484375,
            "end_logit": 7.859375,
            "text": "s-Ibeta",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 8.078125,
            "end_logit": -5.2890625,
            "text": "myosins-Ib",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": 8.078125,
            "end_logit": -6.83984375,
            "text": "myosins-Ibeta, -VI, and -VIIa",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -6.89453125,
            "text": "myosins-Ibeta, -VI, and -VII",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.74609375,
            "end_logit": 7.859375,
            "text": "of myosins-Ibeta",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -7.05859375,
            "text": "myosins-Ibeta,",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -7.1953125,
            "text": "myosins-Ibeta, -VI",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -7.25390625,
            "text": "myosins-Ibeta, -VI, and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.09375,
            "end_logit": 7.859375,
            "text": "amounts of myosins-Ibeta",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -7.32421875,
            "text": "myosins-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -7.48046875,
            "text": "myosins-Ibeta, -VI, and -VIIa are",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -7.58984375,
            "text": "myosins-Ibeta, -VI, and -VIIa are located",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -7.6171875,
            "text": "myosins",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -7.62109375,
            "text": "myosins-Ibeta, -VI, and -",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.4375,
            "end_logit": 7.859375,
            "text": "Substantial amounts of myosins-Ibeta",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 7.859375,
            "text": "-Ibeta",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.74609375,
            "end_logit": -3.232421875,
            "text": "of myosin",
            "probability": 0.0
        }
    ],
    "5548da00f35db7552600000b_2": [
        {
            "start_logit": 7.859375,
            "end_logit": 7.55078125,
            "text": "myosins-Ibeta",
            "probability": 1.0
        },
        {
            "start_logit": 7.859375,
            "end_logit": -3.537109375,
            "text": "myosin",
            "probability": 1.531839370727539e-05
        },
        {
            "start_logit": -3.5703125,
            "end_logit": 7.55078125,
            "text": "eta",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": 7.859375,
            "end_logit": -4.92578125,
            "text": "myosins-Ib",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": -5.5,
            "end_logit": 7.55078125,
            "text": "s-Ibeta",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 7.859375,
            "end_logit": -6.53515625,
            "text": "myosins-Ibeta,",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.37109375,
            "end_logit": 7.55078125,
            "text": "of myosins-Ibeta",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.859375,
            "end_logit": -6.75,
            "text": "myosins-Ibeta, -VI",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.859375,
            "end_logit": -6.80078125,
            "text": "myosins-Ibeta, -VI, and -VIIa",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.859375,
            "end_logit": -6.87890625,
            "text": "myosins-Ibeta, -VI, and -VII",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.859375,
            "end_logit": -7.19140625,
            "text": "myosins-",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.859375,
            "end_logit": -7.265625,
            "text": "myosins-Ibeta, -VI, and",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.859375,
            "end_logit": -7.3203125,
            "text": "myosins-Ibeta, -VI, and -VIIa are",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.0390625,
            "end_logit": 7.55078125,
            "text": "amounts of myosins-Ibeta",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.859375,
            "end_logit": -7.42578125,
            "text": "myosins",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 7.55078125,
            "text": "Substantial amounts of myosins-Ibeta",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.37109375,
            "end_logit": -3.537109375,
            "text": "of myosin",
            "probability": 0.0
        },
        {
            "start_logit": -3.5703125,
            "end_logit": -6.53515625,
            "text": "eta,",
            "probability": 0.0
        },
        {
            "start_logit": -3.5703125,
            "end_logit": -6.75,
            "text": "eta, -VI",
            "probability": 0.0
        },
        {
            "start_logit": -3.5703125,
            "end_logit": -6.80078125,
            "text": "eta, -VI, and -VIIa",
            "probability": 0.0
        }
    ],
    "5548da00f35db7552600000b_3": [
        {
            "start_logit": 9.0234375,
            "end_logit": 9.125,
            "text": "myosin VI",
            "probability": 1.0
        },
        {
            "start_logit": -1.2998046875,
            "end_logit": 9.125,
            "text": "VI",
            "probability": 3.272294998168945e-05
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -1.6640625,
            "text": "myosin",
            "probability": 2.0444393157958984e-05
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -3.5703125,
            "text": "myosin VI and myosin VIIa",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": -6.5234375,
            "end_logit": 9.125,
            "text": "changes of myosin VI",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -6.66796875,
            "text": "myosin VI and myosin VII",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.84765625,
            "end_logit": 9.125,
            "text": "of myosin VI",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -6.765625,
            "text": "myosin VI and myosin VIIa, two unconventional myosins",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -6.88671875,
            "text": "myosin VI and myosin VIIa, two unconventional myosin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.05859375,
            "end_logit": 9.125,
            "text": "study examined the changes of myosin VI",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.22265625,
            "end_logit": 9.125,
            "text": "This study examined the changes of myosin VI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.13671875,
            "text": "myosin VI and myosin VIIa, two unconventional myosins that are critical for normal hair cell formation and function, during hair cell death and regeneration.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.25390625,
            "end_logit": 9.125,
            "text": "the changes of myosin VI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.26953125,
            "end_logit": 9.125,
            "text": "examined the changes of myosin VI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.34765625,
            "text": "myosin VI and myosin VIIa, two unconventional myosins that are critical for normal hair cell formation and function, during hair cell death and regeneration",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.3671875,
            "text": "myosin VI and myosin VIIa, two unconventional myosins that are critical for normal hair cell formation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.44921875,
            "text": "myosin VI and myosin VIIa, two unconventional myosins that are critical",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.48046875,
            "text": "myosin VI and myosin VIIa, two unconventional myosins that are critical for normal hair cell",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.484375,
            "text": "myosin VI and myosin VIIa, two unconventional myosins that are critical for normal hair cell formation and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.4921875,
            "text": "myosin VI and myosin VIIa, two unconventional myosins that are",
            "probability": 5.960464477539063e-08
        }
    ],
    "5548da00f35db7552600000b_4": [
        {
            "start_logit": 7.859375,
            "end_logit": 7.55078125,
            "text": "myosins-Ibeta",
            "probability": 1.0
        },
        {
            "start_logit": 7.859375,
            "end_logit": -3.537109375,
            "text": "myosin",
            "probability": 1.531839370727539e-05
        },
        {
            "start_logit": -3.5703125,
            "end_logit": 7.55078125,
            "text": "eta",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": 7.859375,
            "end_logit": -4.92578125,
            "text": "myosins-Ib",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": -5.5,
            "end_logit": 7.55078125,
            "text": "s-Ibeta",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 7.859375,
            "end_logit": -6.53515625,
            "text": "myosins-Ibeta,",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.37109375,
            "end_logit": 7.55078125,
            "text": "of myosins-Ibeta",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.859375,
            "end_logit": -6.75,
            "text": "myosins-Ibeta, -VI",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.859375,
            "end_logit": -6.80078125,
            "text": "myosins-Ibeta, -VI, and -VIIa",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.859375,
            "end_logit": -6.87890625,
            "text": "myosins-Ibeta, -VI, and -VII",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.859375,
            "end_logit": -7.19140625,
            "text": "myosins-",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.859375,
            "end_logit": -7.265625,
            "text": "myosins-Ibeta, -VI, and",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.859375,
            "end_logit": -7.3203125,
            "text": "myosins-Ibeta, -VI, and -VIIa are",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.0390625,
            "end_logit": 7.55078125,
            "text": "amounts of myosins-Ibeta",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.859375,
            "end_logit": -7.42578125,
            "text": "myosins",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 7.55078125,
            "text": "Substantial amounts of myosins-Ibeta",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.37109375,
            "end_logit": -3.537109375,
            "text": "of myosin",
            "probability": 0.0
        },
        {
            "start_logit": -3.5703125,
            "end_logit": -6.53515625,
            "text": "eta,",
            "probability": 0.0
        },
        {
            "start_logit": -3.5703125,
            "end_logit": -6.75,
            "text": "eta, -VI",
            "probability": 0.0
        },
        {
            "start_logit": -3.5703125,
            "end_logit": -6.80078125,
            "text": "eta, -VI, and -VIIa",
            "probability": 0.0
        }
    ],
    "5548da00f35db7552600000b_5": [
        {
            "start_logit": 7.66015625,
            "end_logit": 7.48046875,
            "text": "myosins-Ibeta",
            "probability": 1.0
        },
        {
            "start_logit": 7.66015625,
            "end_logit": -3.787109375,
            "text": "myosin",
            "probability": 1.2814998626708984e-05
        },
        {
            "start_logit": -3.66015625,
            "end_logit": 7.48046875,
            "text": "eta",
            "probability": 1.2099742889404297e-05
        },
        {
            "start_logit": 7.66015625,
            "end_logit": -5.0234375,
            "text": "myosins-Ib",
            "probability": 3.7550926208496094e-06
        },
        {
            "start_logit": -5.25390625,
            "end_logit": 7.48046875,
            "text": "s-Ibeta",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": 7.66015625,
            "end_logit": -6.69921875,
            "text": "myosins-Ibeta,",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -6.5234375,
            "end_logit": 7.48046875,
            "text": "of myosins-Ibeta",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 7.66015625,
            "end_logit": -6.78515625,
            "text": "myosins-Ibeta, -VI",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.66015625,
            "end_logit": -6.86328125,
            "text": "myosins-Ibeta, -VI, and -VIIa",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.66015625,
            "end_logit": -6.8828125,
            "text": "myosins-Ibeta, -VI, and -VII",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.66015625,
            "end_logit": -7.2265625,
            "text": "myosins-Ibeta, -VI, and",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.66015625,
            "end_logit": -7.23046875,
            "text": "myosins-",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.09765625,
            "end_logit": 7.48046875,
            "text": "amounts of myosins-Ibeta",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.66015625,
            "end_logit": -7.359375,
            "text": "myosins-Ibeta, -VI, and -VIIa are",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.26953125,
            "end_logit": 7.48046875,
            "text": "Substantial amounts of myosins-Ibeta",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.25390625,
            "end_logit": -5.0234375,
            "text": "s-Ib",
            "probability": 0.0
        },
        {
            "start_logit": -6.5234375,
            "end_logit": -3.787109375,
            "text": "of myosin",
            "probability": 0.0
        },
        {
            "start_logit": -3.66015625,
            "end_logit": -6.69921875,
            "text": "eta,",
            "probability": 0.0
        },
        {
            "start_logit": -3.66015625,
            "end_logit": -6.78515625,
            "text": "eta, -VI",
            "probability": 0.0
        },
        {
            "start_logit": -3.66015625,
            "end_logit": -6.86328125,
            "text": "eta, -VI, and -VIIa",
            "probability": 0.0
        }
    ],
    "6278dd4c56bf9aee6f000011_1": [
        {
            "start_logit": 9.0078125,
            "end_logit": 8.859375,
            "text": "MD STARnet",
            "probability": 1.0
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -1.6767578125,
            "text": "MD",
            "probability": 2.6285648345947266e-05
        },
        {
            "start_logit": -2.193359375,
            "end_logit": 8.859375,
            "text": "net",
            "probability": 1.3530254364013672e-05
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -3.8203125,
            "text": "MD STARnet)",
            "probability": 3.0994415283203125e-06
        },
        {
            "start_logit": -4.16015625,
            "end_logit": 8.859375,
            "text": "Using data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -6.5234375,
            "end_logit": 8.859375,
            "text": "STARnet",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.52734375,
            "end_logit": 8.859375,
            "text": "data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.54296875,
            "end_logit": 8.859375,
            "text": "Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.875,
            "end_logit": 8.859375,
            "text": "from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.94921875,
            "end_logit": 8.859375,
            "text": "Research Network (MD STARnet",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.23828125,
            "text": "MD STAR",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.125,
            "end_logit": 8.859375,
            "text": "Surveillance, Tracking, and Research Network (MD STARnet",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.15234375,
            "end_logit": 8.859375,
            "text": "Network (MD STARnet",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.21875,
            "end_logit": 8.859375,
            "text": "(MD STARnet",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.328125,
            "end_logit": 8.859375,
            "text": "and Research Network (MD STARnet",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 8.859375,
            "text": "Dystrophy Surveillance, Tracking, and Research Network (MD STARnet",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37890625,
            "end_logit": 8.859375,
            "text": "Tracking, and Research Network (MD STARnet",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.515625,
            "end_logit": 8.859375,
            "text": ", and Research Network (MD STARnet",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.16015625,
            "end_logit": -1.6767578125,
            "text": "Using data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD",
            "probability": 0.0
        },
        {
            "start_logit": -2.193359375,
            "end_logit": -3.8203125,
            "text": "net)",
            "probability": 0.0
        }
    ],
    "6278dd4c56bf9aee6f000011_2": [
        {
            "start_logit": 5.44921875,
            "end_logit": 5.4375,
            "text": "PRO-DMD-01",
            "probability": 0.9990234375
        },
        {
            "start_logit": -2.3359375,
            "end_logit": 5.4375,
            "text": "and the PRO-DMD-01",
            "probability": 0.00041365623474121094
        },
        {
            "start_logit": -3.90234375,
            "end_logit": 5.4375,
            "text": "01",
            "probability": 8.606910705566406e-05
        },
        {
            "start_logit": 5.44921875,
            "end_logit": -4.4296875,
            "text": "PRO-DMD",
            "probability": 5.137920379638672e-05
        },
        {
            "start_logit": 5.44921875,
            "end_logit": -4.578125,
            "text": "PRO",
            "probability": 4.464387893676758e-05
        },
        {
            "start_logit": 5.44921875,
            "end_logit": -4.89453125,
            "text": "PRO-DMD-01 study",
            "probability": 3.236532211303711e-05
        },
        {
            "start_logit": 5.44921875,
            "end_logit": -5.484375,
            "text": "PRO-DMD-01 study (n = 430 patients, in total).",
            "probability": 1.806020736694336e-05
        },
        {
            "start_logit": -6.5078125,
            "end_logit": 5.4375,
            "text": ", and the PRO-DMD-01",
            "probability": 6.377696990966797e-06
        },
        {
            "start_logit": 5.44921875,
            "end_logit": -6.8828125,
            "text": "PRO-DMD-01 study (n = 430",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": -6.87109375,
            "end_logit": 5.4375,
            "text": "the PRO-DMD-01",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": -6.953125,
            "end_logit": 5.4375,
            "text": "Group, The Cooperative International Neuromuscular Research Group, ImagingDMD, and the PRO-DMD-01",
            "probability": 4.112720489501953e-06
        },
        {
            "start_logit": -6.96875,
            "end_logit": 5.4375,
            "text": ", The Cooperative International Neuromuscular Research Group, ImagingDMD, and the PRO-DMD-01",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": 5.44921875,
            "end_logit": -7.01953125,
            "text": "PRO-DMD-",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": 5.44921875,
            "end_logit": -7.078125,
            "text": "PRO-DMD-01 study (n",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": 5.44921875,
            "end_logit": -7.0859375,
            "text": "PRO-DMD-01 study (n = 430 patients, in total)",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": -7.07421875,
            "end_logit": 5.4375,
            "text": "DMD Italian Group, The Cooperative International Neuromuscular Research Group, ImagingDMD, and the PRO-DMD-01",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 5.4375,
            "text": "-DMD-01",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": -7.21875,
            "end_logit": 5.4375,
            "text": ", ImagingDMD, and the PRO-DMD-01",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": -7.22265625,
            "end_logit": 5.4375,
            "text": "ImagingDMD, and the PRO-DMD-01",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": -7.2421875,
            "end_logit": 5.4375,
            "text": "Leuven, DMD Italian Group, The Cooperative International Neuromuscular Research Group, ImagingDMD, and the PRO-DMD-01",
            "probability": 3.039836883544922e-06
        }
    ],
    "6278dd4c56bf9aee6f000011_3": [
        {
            "start_logit": 3.4609375,
            "end_logit": 7.3359375,
            "text": "GSE38417, GSE3307, and GSE6011",
            "probability": 0.85546875
        },
        {
            "start_logit": 1.546875,
            "end_logit": 7.3359375,
            "text": "GSE6011",
            "probability": 0.1260986328125
        },
        {
            "start_logit": 3.4609375,
            "end_logit": 3.341796875,
            "text": "GSE38417",
            "probability": 0.0157928466796875
        },
        {
            "start_logit": -2.875,
            "end_logit": 7.3359375,
            "text": "microarray datasets, GSE38417, GSE3307, and GSE6011",
            "probability": 0.0015153884887695312
        },
        {
            "start_logit": -3.765625,
            "end_logit": 7.3359375,
            "text": "11",
            "probability": 0.0006222724914550781
        },
        {
            "start_logit": -5.078125,
            "end_logit": 7.3359375,
            "text": "and GSE6011",
            "probability": 0.00016736984252929688
        },
        {
            "start_logit": -5.875,
            "end_logit": 7.3359375,
            "text": "three microarray datasets, GSE38417, GSE3307, and GSE6011",
            "probability": 7.545948028564453e-05
        },
        {
            "start_logit": -6.375,
            "end_logit": 7.3359375,
            "text": "meta-analysis of three microarray datasets, GSE38417, GSE3307, and GSE6011",
            "probability": 4.571676254272461e-05
        },
        {
            "start_logit": -6.421875,
            "end_logit": 7.3359375,
            "text": ", GSE38417, GSE3307, and GSE6011",
            "probability": 4.363059997558594e-05
        },
        {
            "start_logit": -6.4296875,
            "end_logit": 7.3359375,
            "text": ", GSE3307, and GSE6011",
            "probability": 4.3332576751708984e-05
        },
        {
            "start_logit": -6.46875,
            "end_logit": 7.3359375,
            "text": "7, GSE3307, and GSE6011",
            "probability": 4.166364669799805e-05
        },
        {
            "start_logit": -2.875,
            "end_logit": 3.341796875,
            "text": "microarray datasets, GSE38417",
            "probability": 2.8014183044433594e-05
        },
        {
            "start_logit": -6.90234375,
            "end_logit": 7.3359375,
            "text": "a meta-analysis of three microarray datasets, GSE38417, GSE3307, and GSE6011",
            "probability": 2.7120113372802734e-05
        },
        {
            "start_logit": -7.046875,
            "end_logit": 7.3359375,
            "text": "GSE3307, and GSE6011",
            "probability": 2.3365020751953125e-05
        },
        {
            "start_logit": -7.05078125,
            "end_logit": 7.3359375,
            "text": "E38417, GSE3307, and GSE6011",
            "probability": 2.3186206817626953e-05
        },
        {
            "start_logit": 3.4609375,
            "end_logit": -3.234375,
            "text": "GSE38417, GSE3307, and GSE60",
            "probability": 2.199411392211914e-05
        },
        {
            "start_logit": -7.234375,
            "end_logit": 7.3359375,
            "text": "of three microarray datasets, GSE38417, GSE3307, and GSE6011",
            "probability": 1.9371509552001953e-05
        },
        {
            "start_logit": -7.25,
            "end_logit": 7.3359375,
            "text": "conducted a meta-analysis of three microarray datasets, GSE38417, GSE3307, and GSE6011",
            "probability": 1.9073486328125e-05
        },
        {
            "start_logit": 3.4609375,
            "end_logit": -4.74609375,
            "text": "GSE3841",
            "probability": 4.827976226806641e-06
        },
        {
            "start_logit": 1.546875,
            "end_logit": -3.234375,
            "text": "GSE60",
            "probability": 3.2782554626464844e-06
        }
    ],
    "6278dd4c56bf9aee6f000011_4": [
        {
            "start_logit": 2.60546875,
            "end_logit": 4.375,
            "text": "Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet)",
            "probability": 0.94921875
        },
        {
            "start_logit": -0.62255859375,
            "end_logit": 4.375,
            "text": "MD STARnet)",
            "probability": 0.03759765625
        },
        {
            "start_logit": 2.60546875,
            "end_logit": -0.0931396484375,
            "text": "Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet",
            "probability": 0.01087188720703125
        },
        {
            "start_logit": -4.6875,
            "end_logit": 4.375,
            "text": "(MD STARnet)",
            "probability": 0.0006456375122070312
        },
        {
            "start_logit": -4.80078125,
            "end_logit": 4.375,
            "text": "the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet)",
            "probability": 0.0005764961242675781
        },
        {
            "start_logit": -0.62255859375,
            "end_logit": -0.0931396484375,
            "text": "MD STARnet",
            "probability": 0.0004317760467529297
        },
        {
            "start_logit": -5.97265625,
            "end_logit": 4.375,
            "text": ")",
            "probability": 0.0001786947250366211
        },
        {
            "start_logit": -6.23046875,
            "end_logit": 4.375,
            "text": "from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet)",
            "probability": 0.0001380443572998047
        },
        {
            "start_logit": -6.4609375,
            "end_logit": 4.375,
            "text": "Network (MD STARnet)",
            "probability": 0.0001100301742553711
        },
        {
            "start_logit": -6.5546875,
            "end_logit": 4.375,
            "text": "cohort comes from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet)",
            "probability": 0.00010019540786743164
        },
        {
            "start_logit": -6.734375,
            "end_logit": 4.375,
            "text": "Research Network (MD STARnet)",
            "probability": 8.302927017211914e-05
        },
        {
            "start_logit": -6.9921875,
            "end_logit": 4.375,
            "text": "Surveillance, Tracking, and Research Network (MD STARnet)",
            "probability": 6.467103958129883e-05
        },
        {
            "start_logit": -7.01171875,
            "end_logit": 4.375,
            "text": "Dystrophy Surveillance, Tracking, and Research Network (MD STARnet)",
            "probability": 6.318092346191406e-05
        },
        {
            "start_logit": -7.078125,
            "end_logit": 4.375,
            "text": "STARnet)",
            "probability": 5.888938903808594e-05
        },
        {
            "start_logit": 2.60546875,
            "end_logit": -6.4375,
            "text": "Muscular Dystrophy Surveillance, Tracking, and Research Network",
            "probability": 1.913309097290039e-05
        },
        {
            "start_logit": 2.60546875,
            "end_logit": -6.62890625,
            "text": "Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet), a multistate, multiple-source, population-based surveillance system",
            "probability": 1.5854835510253906e-05
        },
        {
            "start_logit": 2.60546875,
            "end_logit": -7.00390625,
            "text": "Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet), a multistate, multiple-source, population-based",
            "probability": 1.0907649993896484e-05
        },
        {
            "start_logit": 2.60546875,
            "end_logit": -7.0546875,
            "text": "Muscular Dystrophy Surveillance,",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": 2.60546875,
            "end_logit": -7.0625,
            "text": "Muscular",
            "probability": 1.0251998901367188e-05
        },
        {
            "start_logit": 2.60546875,
            "end_logit": -7.1015625,
            "text": "Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STAR",
            "probability": 9.834766387939453e-06
        }
    ],
    "6278dd4c56bf9aee6f000011_5": [
        {
            "start_logit": 9.171875,
            "end_logit": 9.3203125,
            "text": "Remudy",
            "probability": 1.0
        },
        {
            "start_logit": -1.3828125,
            "end_logit": 9.3203125,
            "text": "y",
            "probability": 2.586841583251953e-05
        },
        {
            "start_logit": 9.171875,
            "end_logit": -1.4921875,
            "text": "Rem",
            "probability": 1.996755599975586e-05
        },
        {
            "start_logit": -6.00390625,
            "end_logit": 9.3203125,
            "text": "udy",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -6.2109375,
            "text": "Remudy)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.74609375,
            "end_logit": 9.3203125,
            "text": "Japanese Registry of Muscular Dystrophy (Remudy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.265625,
            "end_logit": 9.3203125,
            "text": "data from the Japanese Registry of Muscular Dystrophy (Remudy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 9.3203125,
            "text": "the data from the Japanese Registry of Muscular Dystrophy (Remudy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 9.3203125,
            "text": "used the data from the Japanese Registry of Muscular Dystrophy (Remudy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.43359375,
            "end_logit": 9.3203125,
            "text": "(Remudy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 9.3203125,
            "text": "Dystrophy (Remudy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 9.3203125,
            "text": "from the Japanese Registry of Muscular Dystrophy (Remudy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 9.3203125,
            "text": "We used the data from the Japanese Registry of Muscular Dystrophy (Remudy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 9.3203125,
            "text": "Muscular Dystrophy (Remudy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3828125,
            "end_logit": -6.2109375,
            "text": "y)",
            "probability": 0.0
        },
        {
            "start_logit": -6.74609375,
            "end_logit": -1.4921875,
            "text": "Japanese Registry of Muscular Dystrophy (Rem",
            "probability": 0.0
        },
        {
            "start_logit": -7.265625,
            "end_logit": -1.4921875,
            "text": "data from the Japanese Registry of Muscular Dystrophy (Rem",
            "probability": 0.0
        },
        {
            "start_logit": -7.35546875,
            "end_logit": -1.4921875,
            "text": "the data from the Japanese Registry of Muscular Dystrophy (Rem",
            "probability": 0.0
        },
        {
            "start_logit": -7.4296875,
            "end_logit": -1.4921875,
            "text": "used the data from the Japanese Registry of Muscular Dystrophy (Rem",
            "probability": 0.0
        },
        {
            "start_logit": -7.43359375,
            "end_logit": -1.4921875,
            "text": "(Rem",
            "probability": 0.0
        }
    ],
    "6278dd4c56bf9aee6f000011_6": [
        {
            "start_logit": 9.015625,
            "end_logit": 9.2421875,
            "text": "Remudy",
            "probability": 1.0
        },
        {
            "start_logit": -1.564453125,
            "end_logit": 9.2421875,
            "text": "y",
            "probability": 2.568960189819336e-05
        },
        {
            "start_logit": 9.015625,
            "end_logit": -1.8359375,
            "text": "Rem",
            "probability": 1.5556812286376953e-05
        },
        {
            "start_logit": -5.93359375,
            "end_logit": 9.2421875,
            "text": "udy",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.015625,
            "end_logit": -5.984375,
            "text": "Remudy\"",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.3671875,
            "end_logit": 9.2421875,
            "text": "\"Remudy",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.0546875,
            "end_logit": 9.2421875,
            "text": "national patient registry, \"Remudy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1796875,
            "end_logit": 9.2421875,
            "text": "patient registry, \"Remudy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 9.2421875,
            "text": ", \"Remudy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.38671875,
            "end_logit": 9.2421875,
            "text": "dystrophinopathies mutation dataset in Japan from a national patient registry, \"Remudy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.390625,
            "end_logit": 9.2421875,
            "text": "from a national patient registry, \"Remudy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 9.2421875,
            "text": "a national patient registry, \"Remudy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 9.2421875,
            "text": "largest dystrophinopathies mutation dataset in Japan from a national patient registry, \"Remudy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.546875,
            "end_logit": 9.2421875,
            "text": "mutation dataset in Japan from a national patient registry, \"Remudy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 9.2421875,
            "text": "We report the largest dystrophinopathies mutation dataset in Japan from a national patient registry, \"Remudy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.564453125,
            "end_logit": -5.984375,
            "text": "y\"",
            "probability": 0.0
        },
        {
            "start_logit": -6.3671875,
            "end_logit": -1.8359375,
            "text": "\"Rem",
            "probability": 0.0
        },
        {
            "start_logit": -7.0546875,
            "end_logit": -1.8359375,
            "text": "national patient registry, \"Rem",
            "probability": 0.0
        },
        {
            "start_logit": -7.1796875,
            "end_logit": -1.8359375,
            "text": "patient registry, \"Rem",
            "probability": 0.0
        },
        {
            "start_logit": -7.35546875,
            "end_logit": -1.8359375,
            "text": ", \"Rem",
            "probability": 0.0
        }
    ],
    "6278dd4c56bf9aee6f000011_7": [
        {
            "start_logit": 9.1328125,
            "end_logit": 9.390625,
            "text": "GSE38417",
            "probability": 1.0
        },
        {
            "start_logit": -1.083984375,
            "end_logit": 9.390625,
            "text": "7",
            "probability": 3.618001937866211e-05
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -1.5146484375,
            "text": "GS",
            "probability": 1.817941665649414e-05
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -4.04296875,
            "text": "GSE38417 of DMD was obtained from the Gene Expression Omnibus",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -5.36328125,
            "text": "GSE3841",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.62890625,
            "end_logit": 9.390625,
            "text": "E38417",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.9296875,
            "end_logit": 9.390625,
            "text": "gene expression profile dataset GSE38417",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -6.01171875,
            "text": "GSE38",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.4765625,
            "end_logit": 9.390625,
            "text": "38417",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.50390625,
            "end_logit": 9.390625,
            "text": "417",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -6.42578125,
            "text": "GSE38417 of DMD was obtained from the Gene Expression Omnibus (GEO) database",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -6.703125,
            "text": "GSE38417 of DMD was obtained from the Gene Expression Omnibus (GEO)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.05859375,
            "end_logit": 9.390625,
            "text": "dataset GSE38417",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -6.87109375,
            "text": "GSE38417 of DMD was obtained from the Gene Expression Omnibus (GEO",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1875,
            "end_logit": 9.390625,
            "text": "The gene expression profile dataset GSE38417",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.05859375,
            "text": "GSE38417 of DMD was obtained from the Gene Expression Omnibus (GEO) database.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.18359375,
            "text": "GSE38417 of DMD was obtained",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 9.390625,
            "text": "expression profile dataset GSE38417",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.28515625,
            "text": "GSE38417 of DMD was obtained from the Gene Expression Omnibus (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.3828125,
            "text": "GSE38417 of DMD",
            "probability": 5.960464477539063e-08
        }
    ],
    "6278dd4c56bf9aee6f000011_8": [
        {
            "start_logit": 9.2890625,
            "end_logit": 9.2265625,
            "text": "MD STARnet",
            "probability": 1.0
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -1.138671875,
            "text": "MD",
            "probability": 3.147125244140625e-05
        },
        {
            "start_logit": -1.5205078125,
            "end_logit": 9.2265625,
            "text": "net",
            "probability": 2.014636993408203e-05
        },
        {
            "start_logit": -5.25,
            "end_logit": 9.2265625,
            "text": "STARnet",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -5.8203125,
            "text": "MD STARnet, DuchenneConnect",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -6.9375,
            "text": "MD STARnet, DuchenneConne",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.01171875,
            "end_logit": 9.2265625,
            "text": "patient information (MD STARnet",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.15625,
            "end_logit": 9.2265625,
            "text": "(MD STARnet",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.2578125,
            "text": "MD STARnet, DuchenneConnect, and TREAT-NMD)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.2734375,
            "text": "MD STARnet, DuchenneConnect, and TREAT-NMD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.33203125,
            "end_logit": 9.2265625,
            "text": "Current methods to monitor DMD patient information (MD STARnet",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 9.2265625,
            "text": "DMD patient information (MD STARnet",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.40234375,
            "end_logit": 9.2265625,
            "text": "monitor DMD patient information (MD STARnet",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.484375,
            "text": "MD STARnet, DuchenneCon",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.5078125,
            "text": "MD STARnet, DuchenneConnect, and TREAT",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.5234375,
            "text": "MD STARnet, Duchenne",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 9.2265625,
            "text": "information (MD STARnet",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.5859375,
            "text": "MD STARnet, DuchenneConnect,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.59375,
            "text": "MD STARnet, DuchenneConnect, and TREAT-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.60546875,
            "text": "MD STARnet, DuchenneConnect, and",
            "probability": 5.960464477539063e-08
        }
    ],
    "6278dd4c56bf9aee6f000011_9": [
        {
            "start_logit": -0.9326171875,
            "end_logit": -4.1875,
            "text": "patient registry",
            "probability": 0.33251953125
        },
        {
            "start_logit": -0.9326171875,
            "end_logit": -4.33984375,
            "text": "patient registry is under development for the Muscular Dystrophy Association (MDA) clinic network",
            "probability": 0.28564453125
        },
        {
            "start_logit": -0.9326171875,
            "end_logit": -5.38671875,
            "text": "patient registry is under development for the Muscular Dystrophy Association (MDA",
            "probability": 0.1002197265625
        },
        {
            "start_logit": -0.9326171875,
            "end_logit": -5.9921875,
            "text": "patient registry is under development for the Muscular Dystrophy Association (MDA) clinic network.",
            "probability": 0.054718017578125
        },
        {
            "start_logit": -0.9326171875,
            "end_logit": -6.10546875,
            "text": "patient registry is under development for the Muscular Dystrophy Association (MDA)",
            "probability": 0.048828125
        },
        {
            "start_logit": -0.9326171875,
            "end_logit": -6.1640625,
            "text": "patient registry is",
            "probability": 0.046051025390625
        },
        {
            "start_logit": -0.9326171875,
            "end_logit": -6.6953125,
            "text": "patient registry is under development",
            "probability": 0.027069091796875
        },
        {
            "start_logit": -0.9326171875,
            "end_logit": -6.75390625,
            "text": "patient registry is under",
            "probability": 0.0255279541015625
        },
        {
            "start_logit": -0.9326171875,
            "end_logit": -7.37109375,
            "text": "patient registry is under development for the Muscular Dystrophy Association (",
            "probability": 0.0137786865234375
        },
        {
            "start_logit": -0.9326171875,
            "end_logit": -7.390625,
            "text": "patient registry is under development for",
            "probability": 0.0135650634765625
        },
        {
            "start_logit": -0.9326171875,
            "end_logit": -7.4296875,
            "text": "patient registry is under development for the Muscular Dystrophy",
            "probability": 0.0130462646484375
        },
        {
            "start_logit": -0.9326171875,
            "end_logit": -7.49609375,
            "text": "patient registry is under development for the Muscular Dystrophy Association (MDA) clinic",
            "probability": 0.01215362548828125
        },
        {
            "start_logit": -4.62109375,
            "end_logit": -4.33984375,
            "text": "Muscular Dystrophy Association (MDA) clinic network",
            "probability": 0.00714874267578125
        },
        {
            "start_logit": -5.34765625,
            "end_logit": -4.1875,
            "text": "similar patient registry",
            "probability": 0.004039764404296875
        },
        {
            "start_logit": -5.34765625,
            "end_logit": -4.33984375,
            "text": "similar patient registry is under development for the Muscular Dystrophy Association (MDA) clinic network",
            "probability": 0.0034580230712890625
        },
        {
            "start_logit": -5.5703125,
            "end_logit": -4.1875,
            "text": "A similar patient registry",
            "probability": 0.0032215118408203125
        },
        {
            "start_logit": -5.5703125,
            "end_logit": -4.33984375,
            "text": "A similar patient registry is under development for the Muscular Dystrophy Association (MDA) clinic network",
            "probability": 0.002777099609375
        },
        {
            "start_logit": -4.62109375,
            "end_logit": -5.38671875,
            "text": "Muscular Dystrophy Association (MDA",
            "probability": 0.0025081634521484375
        },
        {
            "start_logit": -5.73046875,
            "end_logit": -4.33984375,
            "text": "MDA) clinic network",
            "probability": 0.0023555755615234375
        },
        {
            "start_logit": -4.62109375,
            "end_logit": -5.9921875,
            "text": "Muscular Dystrophy Association (MDA) clinic network.",
            "probability": 0.0013751983642578125
        }
    ],
    "6278dd4c56bf9aee6f000011_10": [
        {
            "start_logit": 6.671875,
            "end_logit": 8.3671875,
            "text": "Developmental Delay",
            "probability": 0.9990234375
        },
        {
            "start_logit": -0.720703125,
            "end_logit": 8.3671875,
            "text": "4D-DMD study (Detection by Developmental Delay",
            "probability": 0.0006165504455566406
        },
        {
            "start_logit": -2.798828125,
            "end_logit": 8.3671875,
            "text": "Delay",
            "probability": 7.718801498413086e-05
        },
        {
            "start_logit": -6.57421875,
            "end_logit": 8.3671875,
            "text": "case-control 4D-DMD study (Detection by Developmental Delay",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 6.671875,
            "end_logit": -4.88671875,
            "text": "Developmental",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -6.99609375,
            "end_logit": 8.3671875,
            "text": "the case-control 4D-DMD study (Detection by Developmental Delay",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 6.671875,
            "end_logit": -5.66796875,
            "text": "Developmental Delay in Dutch boys with Duchenne Muscular Dystrophy), data on developmental milestones for 76 young males with DMD and 12 41",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 6.671875,
            "end_logit": -6.28515625,
            "text": "Developmental Delay in Dutch boys with Duchenne Muscular Dystrophy), data on developmental milestones for 76 young males with DMD and 12 414",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 6.671875,
            "end_logit": -6.296875,
            "text": "Developmental Delay in Dutch boys with Duchenne Muscular Dystrophy), data on developmental milestones for 76 young males with DMD and 12 414 young males",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 6.671875,
            "end_logit": -6.3359375,
            "text": "Developmental Delay in Dutch boys with Duchenne Muscular Dystrophy), data on developmental milestones for 76 young males with DMD and 12 414 young males from",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 6.671875,
            "end_logit": -6.41796875,
            "text": "Developmental Delay in Dutch boys with Duchenne Muscular Dystrophy), data on developmental milestones for 76 young males with DMD and 12",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 6.671875,
            "end_logit": -6.55078125,
            "text": "Developmental Delay in Dutch",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 6.671875,
            "end_logit": -6.734375,
            "text": "Developmental Delay in Dutch boys with Duchenne Muscular Dystrophy), data on developmental milestones",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -0.720703125,
            "end_logit": -3.71484375,
            "text": "4D-DMD",
            "probability": 0.0
        },
        {
            "start_logit": -0.720703125,
            "end_logit": -4.88671875,
            "text": "4D-DMD study (Detection by Developmental",
            "probability": 0.0
        },
        {
            "start_logit": -0.720703125,
            "end_logit": -5.921875,
            "text": "4D-DMD study",
            "probability": 0.0
        },
        {
            "start_logit": -0.720703125,
            "end_logit": -6.55078125,
            "text": "4D-DMD study (Detection by Developmental Delay in Dutch",
            "probability": 0.0
        },
        {
            "start_logit": -0.720703125,
            "end_logit": -6.734375,
            "text": "4D-DMD study (Detection by Developmental Delay in Dutch boys with Duchenne Muscular Dystrophy), data on developmental milestones",
            "probability": 0.0
        },
        {
            "start_logit": -2.798828125,
            "end_logit": -5.66796875,
            "text": "Delay in Dutch boys with Duchenne Muscular Dystrophy), data on developmental milestones for 76 young males with DMD and 12 41",
            "probability": 0.0
        },
        {
            "start_logit": -2.798828125,
            "end_logit": -6.28515625,
            "text": "Delay in Dutch boys with Duchenne Muscular Dystrophy), data on developmental milestones for 76 young males with DMD and 12 414",
            "probability": 0.0
        }
    ],
    "6278dd4c56bf9aee6f000011_11": [
        {
            "start_logit": 6.78125,
            "end_logit": 1.08203125,
            "text": "Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet)",
            "probability": 0.65576171875
        },
        {
            "start_logit": 6.78125,
            "end_logit": 0.41357421875,
            "text": "Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet",
            "probability": 0.33642578125
        },
        {
            "start_logit": 6.78125,
            "end_logit": -4.734375,
            "text": "Muscular",
            "probability": 0.001953125
        },
        {
            "start_logit": 6.78125,
            "end_logit": -5.24609375,
            "text": "Muscular Dystrophy Surveillance, Tracking, and Research Network",
            "probability": 0.001171112060546875
        },
        {
            "start_logit": 0.429931640625,
            "end_logit": 1.08203125,
            "text": "MD STARnet)",
            "probability": 0.0011444091796875
        },
        {
            "start_logit": 6.78125,
            "end_logit": -5.671875,
            "text": "Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet); Dutch Natural History Survey (DNHS",
            "probability": 0.0007653236389160156
        },
        {
            "start_logit": 0.429931640625,
            "end_logit": 0.41357421875,
            "text": "MD STARnet",
            "probability": 0.0005865097045898438
        },
        {
            "start_logit": 6.78125,
            "end_logit": -5.94140625,
            "text": "Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet); Dutch Natural History Survey",
            "probability": 0.0005841255187988281
        },
        {
            "start_logit": 6.78125,
            "end_logit": -6.7109375,
            "text": "Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet); Dutch Natural History Survey (DNHS)",
            "probability": 0.000270843505859375
        },
        {
            "start_logit": 6.78125,
            "end_logit": -6.90234375,
            "text": "Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet); Dutch Natural History",
            "probability": 0.00022351741790771484
        },
        {
            "start_logit": 6.78125,
            "end_logit": -7.015625,
            "text": "Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet); Dutch Natural History Survey (DN",
            "probability": 0.00020039081573486328
        },
        {
            "start_logit": 6.78125,
            "end_logit": -7.20703125,
            "text": "Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STAR",
            "probability": 0.00016486644744873047
        },
        {
            "start_logit": 6.78125,
            "end_logit": -7.21875,
            "text": "Muscular Dystrophy Surveillance,",
            "probability": 0.00016355514526367188
        },
        {
            "start_logit": 6.78125,
            "end_logit": -7.2265625,
            "text": "Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet); Dutch Natural History Survey (DNHS); and Parent Project",
            "probability": 0.0001609325408935547
        },
        {
            "start_logit": -5.9921875,
            "end_logit": 1.08203125,
            "text": "Surveillance, Tracking, and Research Network (MD STARnet)",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": -6.0234375,
            "end_logit": 1.08203125,
            "text": ", Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet)",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -6.3046875,
            "end_logit": 1.08203125,
            "text": "(MD STARnet)",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 0.429931640625,
            "end_logit": -5.671875,
            "text": "MD STARnet); Dutch Natural History Survey (DNHS",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 0.429931640625,
            "end_logit": -5.73046875,
            "text": "MD STARnet); Dutch Natural History Survey (DNHS); and Parent Project Muscular Dystrophy (PPM",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -6.55859375,
            "end_logit": 1.08203125,
            "text": "Dystrophy Surveillance, Tracking, and Research Network (MD STARnet)",
            "probability": 1.0728836059570312e-06
        }
    ],
    "6278dd4c56bf9aee6f000011_12": [
        {
            "start_logit": 9.2109375,
            "end_logit": 9.34375,
            "text": "GSE64420",
            "probability": 1.0
        },
        {
            "start_logit": -1.205078125,
            "end_logit": 9.34375,
            "text": "0",
            "probability": 2.9802322387695312e-05
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -1.31640625,
            "text": "GS",
            "probability": 2.3186206817626953e-05
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -2.74609375,
            "text": "GSE64",
            "probability": 5.602836608886719e-06
        },
        {
            "start_logit": -3.421875,
            "end_logit": 9.34375,
            "text": "Gene Expression Omnibus (GEO) with the accession number GSE64420",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -5.23828125,
            "text": "GSE6442",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -5.71484375,
            "end_logit": 9.34375,
            "text": "E64420",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.51171875,
            "end_logit": 9.34375,
            "text": "420",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.65234375,
            "end_logit": 9.34375,
            "text": "accession number GSE64420",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.7421875,
            "end_logit": 9.34375,
            "text": "number GSE64420",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.81640625,
            "end_logit": 9.34375,
            "text": "Expression Omnibus (GEO) with the accession number GSE64420",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9921875,
            "end_logit": 9.34375,
            "text": "with the accession number GSE64420",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.08984375,
            "end_logit": 9.34375,
            "text": "Omnibus (GEO) with the accession number GSE64420",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1796875,
            "end_logit": 9.34375,
            "text": "the Gene Expression Omnibus (GEO) with the accession number GSE64420",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.19921875,
            "end_logit": 9.34375,
            "text": "The data have been deposited in the Gene Expression Omnibus (GEO) with the accession number GSE64420",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -7.10546875,
            "text": "GSE64420.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.25390625,
            "end_logit": 9.34375,
            "text": "64420",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 9.34375,
            "text": "the accession number GSE64420",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.328125,
            "end_logit": 9.34375,
            "text": "ibus (GEO) with the accession number GSE64420",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.33984375,
            "end_logit": 9.34375,
            "text": "data have been deposited in the Gene Expression Omnibus (GEO) with the accession number GSE64420",
            "probability": 5.960464477539063e-08
        }
    ],
    "6278dd4c56bf9aee6f000011_13": [
        {
            "start_logit": 8.9296875,
            "end_logit": 8.859375,
            "text": "drisapersen",
            "probability": 1.0
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -1.9609375,
            "text": "dr",
            "probability": 2.014636993408203e-05
        },
        {
            "start_logit": -2.306640625,
            "end_logit": 8.859375,
            "text": "en",
            "probability": 1.329183578491211e-05
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -5.16796875,
            "text": "drisapersen.",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -5.69921875,
            "end_logit": 8.859375,
            "text": "PRO051-02) with drisapersen",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -6.4765625,
            "text": "drisapers",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.60546875,
            "end_logit": 8.859375,
            "text": "with drisapersen",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.671875,
            "end_logit": 8.859375,
            "text": "persen",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.76953125,
            "end_logit": 8.859375,
            "text": "isapersen",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 8.859375,
            "text": "(PRO051-02) with drisapersen",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 8.859375,
            "text": "escalating dose pilot study (PRO051-02) with drisapersen",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.28125,
            "end_logit": 8.859375,
            "text": "02) with drisapersen",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.48046875,
            "text": "drisa",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59375,
            "end_logit": 8.859375,
            "text": "051-02) with drisapersen",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.306640625,
            "end_logit": -5.16796875,
            "text": "en.",
            "probability": 0.0
        },
        {
            "start_logit": -5.69921875,
            "end_logit": -1.9609375,
            "text": "PRO051-02) with dr",
            "probability": 0.0
        },
        {
            "start_logit": -6.60546875,
            "end_logit": -1.9609375,
            "text": "with dr",
            "probability": 0.0
        },
        {
            "start_logit": -7.12890625,
            "end_logit": -1.9609375,
            "text": "(PRO051-02) with dr",
            "probability": 0.0
        },
        {
            "start_logit": -7.18359375,
            "end_logit": -1.9609375,
            "text": "escalating dose pilot study (PRO051-02) with dr",
            "probability": 0.0
        },
        {
            "start_logit": -7.28125,
            "end_logit": -1.9609375,
            "text": "02) with dr",
            "probability": 0.0
        }
    ],
    "6278dd4c56bf9aee6f000011_14": [
        {
            "start_logit": 8.796875,
            "end_logit": 9.0546875,
            "text": "PRO051-02",
            "probability": 1.0
        },
        {
            "start_logit": -1.7734375,
            "end_logit": 9.0546875,
            "text": "02",
            "probability": 2.586841583251953e-05
        },
        {
            "start_logit": 8.796875,
            "end_logit": -2.236328125,
            "text": "PRO",
            "probability": 1.2636184692382812e-05
        },
        {
            "start_logit": -5.84375,
            "end_logit": 9.0546875,
            "text": "051-02",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.359375,
            "end_logit": 9.0546875,
            "text": "(PRO051-02",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.796875,
            "end_logit": -6.1796875,
            "text": "PRO051-02)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.4375,
            "end_logit": 9.0546875,
            "text": "1-02",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.796875,
            "end_logit": -6.69921875,
            "text": "PRO051",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.05859375,
            "end_logit": 9.0546875,
            "text": "-02",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.296875,
            "end_logit": 9.0546875,
            "text": "in the escalating dose pilot study (PRO051-02",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.796875,
            "end_logit": -7.1015625,
            "text": "PRO051-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 9.0546875,
            "text": "the escalating dose pilot study (PRO051-02",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.609375,
            "end_logit": 9.0546875,
            "text": "escalating dose pilot study (PRO051-02",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.7734375,
            "end_logit": -6.1796875,
            "text": "02)",
            "probability": 0.0
        },
        {
            "start_logit": -6.359375,
            "end_logit": -2.236328125,
            "text": "(PRO",
            "probability": 0.0
        },
        {
            "start_logit": -7.296875,
            "end_logit": -2.236328125,
            "text": "in the escalating dose pilot study (PRO",
            "probability": 0.0
        },
        {
            "start_logit": -7.5234375,
            "end_logit": -2.236328125,
            "text": "the escalating dose pilot study (PRO",
            "probability": 0.0
        },
        {
            "start_logit": -7.609375,
            "end_logit": -2.236328125,
            "text": "escalating dose pilot study (PRO",
            "probability": 0.0
        },
        {
            "start_logit": -5.84375,
            "end_logit": -6.1796875,
            "text": "051-02)",
            "probability": 0.0
        },
        {
            "start_logit": -6.359375,
            "end_logit": -6.1796875,
            "text": "(PRO051-02)",
            "probability": 0.0
        }
    ],
    "5a8afbf2fcd1d6a10c00001c_1": [
        {
            "start_logit": 8.2578125,
            "end_logit": 8.8359375,
            "text": "tiger",
            "probability": 0.99609375
        },
        {
            "start_logit": 8.2578125,
            "end_logit": 3.146484375,
            "text": "tiger stifle. SE T1-weighted sequence provided excellent resolution of the subchondral bones of the femur",
            "probability": 0.0033740997314453125
        },
        {
            "start_logit": -2.015625,
            "end_logit": 8.8359375,
            "text": "er",
            "probability": 3.439188003540039e-05
        },
        {
            "start_logit": 2.9140625,
            "end_logit": 3.146484375,
            "text": "femur",
            "probability": 1.615285873413086e-05
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -2.962890625,
            "text": "tig",
            "probability": 7.510185241699219e-06
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -3.513671875,
            "text": "tiger stifle. SE T1-weighted sequence provided excellent resolution of the subchondral bones of the femur, tibia and patella",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -5.65625,
            "text": "tiger stifle. SE T1-weighted sequence provided excellent resolution of the subchondral bones of the femur, tibia",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.69140625,
            "end_logit": 8.8359375,
            "text": "bone, articular cartilage, menisci and ligaments of the normal tiger",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.04296875,
            "end_logit": 8.8359375,
            "text": "menisci and ligaments of the normal tiger",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.08984375,
            "end_logit": 8.8359375,
            "text": "ligaments of the normal tiger",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.125,
            "end_logit": 8.8359375,
            "text": "articular cartilage, menisci and ligaments of the normal tiger",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -6.5625,
            "text": "tiger stifle. SE T1-weighted sequence provided excellent resolution of the subchondral bones",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.15234375,
            "end_logit": 8.8359375,
            "text": "normal tiger",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -6.97265625,
            "text": "tiger stifle",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.015625,
            "end_logit": 3.146484375,
            "text": "er stifle. SE T1-weighted sequence provided excellent resolution of the subchondral bones of the femur",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -7.1796875,
            "text": "tiger stifle. SE T1-weighted sequence provided excellent resolution of the subchondral bones of the femur, tibia and patella compared",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -7.29296875,
            "text": "tiger stifl",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -7.31640625,
            "text": "tiger stifle. SE T1-weighted sequence provided excellent resolution of the subchondral bones of the femur, tibia and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -7.37109375,
            "text": "tiger sti",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 2.9140625,
            "end_logit": -3.513671875,
            "text": "femur, tibia and patella",
            "probability": 0.0
        }
    ],
    "621218fc3a8413c653000014_1": [
        {
            "start_logit": 7.75,
            "end_logit": 7.74609375,
            "text": "B-cell maturation antigen (BCMA)",
            "probability": 0.78271484375
        },
        {
            "start_logit": 7.75,
            "end_logit": 6.46484375,
            "text": "B-cell maturation antigen (BCMA",
            "probability": 0.21728515625
        },
        {
            "start_logit": 7.75,
            "end_logit": -3.1484375,
            "text": "B",
            "probability": 1.4483928680419922e-05
        },
        {
            "start_logit": -3.470703125,
            "end_logit": 7.74609375,
            "text": ")",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": 7.75,
            "end_logit": -3.49609375,
            "text": "B-cell maturation antigen",
            "probability": 1.0192394256591797e-05
        },
        {
            "start_logit": -4.390625,
            "end_logit": 7.74609375,
            "text": "BCMA)",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": -4.4140625,
            "end_logit": 7.74609375,
            "text": "MA)",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": 7.75,
            "end_logit": -4.453125,
            "text": "B-cell maturation antigen (BCMA) and CD3",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": 7.75,
            "end_logit": -5.546875,
            "text": "B-cell maturation antigen (BC",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -4.390625,
            "end_logit": 6.46484375,
            "text": "BCMA",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -4.4140625,
            "end_logit": 6.46484375,
            "text": "MA",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -6.0546875,
            "end_logit": 7.74609375,
            "text": "bsAb (REGN5458) that binds to B-cell maturation antigen (BCMA)",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.0546875,
            "end_logit": 7.74609375,
            "text": "to B-cell maturation antigen (BCMA)",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.2421875,
            "end_logit": 7.74609375,
            "text": "maturation antigen (BCMA)",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.47265625,
            "end_logit": 7.74609375,
            "text": "-cell maturation antigen (BCMA)",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.54296875,
            "end_logit": 7.74609375,
            "text": "(BCMA)",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.89453125,
            "end_logit": 7.74609375,
            "text": "fully human bsAb (REGN5458) that binds to B-cell maturation antigen (BCMA)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.75,
            "end_logit": -6.90234375,
            "text": "B-cell maturation antigen (BCMA) and CD3, and compare its antitumor activities vs those of anti-BCMA CAR T cells to",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.921875,
            "end_logit": 7.74609375,
            "text": "Here we describe a fully human bsAb (REGN5458) that binds to B-cell maturation antigen (BCMA)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.75,
            "end_logit": -6.953125,
            "text": "B-cell maturation antigen (BCMA) and CD3, and compare its antitumor activities vs those of anti-BCMA",
            "probability": 2.980232238769531e-07
        }
    ],
    "58a2fac960087bc10a000009_1": [
        {
            "start_logit": 7.61328125,
            "end_logit": 7.63671875,
            "text": "hepatotoxicity",
            "probability": 1.0
        },
        {
            "start_logit": -7.23828125,
            "end_logit": 7.63671875,
            "text": "adverse effects including hepatotoxicity",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -7.3515625,
            "text": "hepatotoxicity.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 7.63671875,
            "text": "with significant adverse effects including hepatotoxicity",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 7.63671875,
            "text": "including hepatotoxicity",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 7.63671875,
            "text": "associated with significant adverse effects including hepatotoxicity",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 7.63671875,
            "text": "significant adverse effects including hepatotoxicity",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 7.63671875,
            "text": ", the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.97265625,
            "end_logit": -7.3515625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.23828125,
            "end_logit": -7.23828125,
            "text": "adverse effects",
            "probability": 0.0
        },
        {
            "start_logit": -7.23828125,
            "end_logit": -7.3515625,
            "text": "adverse effects including hepatotoxicity.",
            "probability": 0.0
        },
        {
            "start_logit": -7.5078125,
            "end_logit": -7.23828125,
            "text": "with significant adverse effects",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": -7.23828125,
            "text": "associated with significant adverse effects",
            "probability": 0.0
        },
        {
            "start_logit": -7.56640625,
            "end_logit": -7.23828125,
            "text": "significant adverse effects",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": -7.23828125,
            "text": ", the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects",
            "probability": 0.0
        },
        {
            "start_logit": -7.5078125,
            "end_logit": -7.3515625,
            "text": "with significant adverse effects including hepatotoxicity.",
            "probability": 0.0
        },
        {
            "start_logit": -7.53515625,
            "end_logit": -7.3515625,
            "text": "including hepatotoxicity.",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": -7.3515625,
            "text": "associated with significant adverse effects including hepatotoxicity.",
            "probability": 0.0
        },
        {
            "start_logit": -7.56640625,
            "end_logit": -7.3515625,
            "text": "significant adverse effects including hepatotoxicity.",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": -7.3515625,
            "text": ", the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity.",
            "probability": 0.0
        }
    ],
    "58a2fac960087bc10a000009_2": [
        {
            "start_logit": 7.61328125,
            "end_logit": 7.63671875,
            "text": "hepatotoxicity",
            "probability": 1.0
        },
        {
            "start_logit": -7.23828125,
            "end_logit": 7.63671875,
            "text": "adverse effects including hepatotoxicity",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -7.3515625,
            "text": "hepatotoxicity.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 7.63671875,
            "text": "with significant adverse effects including hepatotoxicity",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 7.63671875,
            "text": "including hepatotoxicity",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 7.63671875,
            "text": "associated with significant adverse effects including hepatotoxicity",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 7.63671875,
            "text": "significant adverse effects including hepatotoxicity",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 7.63671875,
            "text": ", the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.97265625,
            "end_logit": -7.3515625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.23828125,
            "end_logit": -7.23828125,
            "text": "adverse effects",
            "probability": 0.0
        },
        {
            "start_logit": -7.23828125,
            "end_logit": -7.3515625,
            "text": "adverse effects including hepatotoxicity.",
            "probability": 0.0
        },
        {
            "start_logit": -7.5078125,
            "end_logit": -7.23828125,
            "text": "with significant adverse effects",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": -7.23828125,
            "text": "associated with significant adverse effects",
            "probability": 0.0
        },
        {
            "start_logit": -7.56640625,
            "end_logit": -7.23828125,
            "text": "significant adverse effects",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": -7.23828125,
            "text": ", the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects",
            "probability": 0.0
        },
        {
            "start_logit": -7.5078125,
            "end_logit": -7.3515625,
            "text": "with significant adverse effects including hepatotoxicity.",
            "probability": 0.0
        },
        {
            "start_logit": -7.53515625,
            "end_logit": -7.3515625,
            "text": "including hepatotoxicity.",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": -7.3515625,
            "text": "associated with significant adverse effects including hepatotoxicity.",
            "probability": 0.0
        },
        {
            "start_logit": -7.56640625,
            "end_logit": -7.3515625,
            "text": "significant adverse effects including hepatotoxicity.",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": -7.3515625,
            "text": ", the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity.",
            "probability": 0.0
        }
    ],
    "58a2fac960087bc10a000009_3": [
        {
            "start_logit": 7.78515625,
            "end_logit": 7.48046875,
            "text": "Nausea",
            "probability": 1.0
        },
        {
            "start_logit": -5.15234375,
            "end_logit": 7.48046875,
            "text": "gastrointestinal side effects of donepezil, rivastigmine, galantamin and tacrine that result from acetylcholinesterase inhibition. Nausea",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": 7.78515625,
            "end_logit": -5.70703125,
            "text": "Nausea, diarrhea",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 7.78515625,
            "end_logit": -6.3828125,
            "text": "Nausea, diarrhea, vomiting, and weight loss",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 7.78515625,
            "end_logit": -6.90625,
            "text": "Nausea, diarrhea, vomiting, and weight loss are the most common side effects of the acetylcholinesterase inhibitors.",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.7421875,
            "end_logit": 7.48046875,
            "text": ". Nausea",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.78515625,
            "end_logit": -7.31640625,
            "text": "Nausea, diarrhea, vomiting, and weight",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 7.48046875,
            "text": "side effects of donepezil, rivastigmine, galantamin and tacrine that result from acetylcholinesterase inhibition. Nausea",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.15234375,
            "end_logit": -5.703125,
            "text": "gastrointestinal side effects",
            "probability": 0.0
        },
        {
            "start_logit": -5.15234375,
            "end_logit": -5.70703125,
            "text": "gastrointestinal side effects of donepezil, rivastigmine, galantamin and tacrine that result from acetylcholinesterase inhibition. Nausea, diarrhea",
            "probability": 0.0
        },
        {
            "start_logit": -6.01953125,
            "end_logit": -5.70703125,
            "text": "diarrhea",
            "probability": 0.0
        },
        {
            "start_logit": -5.15234375,
            "end_logit": -6.9140625,
            "text": "gastrointestinal side effects of donepezil, rivastigmine, galantamin and tacrine that result from acetylcholinesterase inhibition.",
            "probability": 0.0
        },
        {
            "start_logit": -5.15234375,
            "end_logit": -7.0546875,
            "text": "gastrointestinal side effects of donepezil",
            "probability": 0.0
        },
        {
            "start_logit": -5.15234375,
            "end_logit": -7.08984375,
            "text": "gastrointestinal side effects of donepez",
            "probability": 0.0
        },
        {
            "start_logit": -6.62890625,
            "end_logit": -5.703125,
            "text": "hepatotoxicity of tacrine and gastrointestinal side effects",
            "probability": 0.0
        },
        {
            "start_logit": -5.15234375,
            "end_logit": -7.234375,
            "text": "gastrointestinal side effects of donepezil, rivastigmine, galantamin and tacrine that result from acetylcholinesterase inhibition",
            "probability": 0.0
        },
        {
            "start_logit": -6.68359375,
            "end_logit": -5.703125,
            "text": "except hepatotoxicity of tacrine and gastrointestinal side effects",
            "probability": 0.0
        },
        {
            "start_logit": -5.15234375,
            "end_logit": -7.25,
            "text": "gastrointestinal side effects of donepezil, rivastigmine, galantamin",
            "probability": 0.0
        },
        {
            "start_logit": -6.01953125,
            "end_logit": -6.3828125,
            "text": "diarrhea, vomiting, and weight loss",
            "probability": 0.0
        },
        {
            "start_logit": -5.15234375,
            "end_logit": -7.26953125,
            "text": "gastrointestinal side effects of donepe",
            "probability": 0.0
        }
    ],
    "58a2fac960087bc10a000009_4": [
        {
            "start_logit": 8.0234375,
            "end_logit": 7.56640625,
            "text": "diarrhoea",
            "probability": 1.0
        },
        {
            "start_logit": -5.36328125,
            "end_logit": 7.56640625,
            "text": "Gastrointestinal side effects (diarrhoea",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -6.7890625,
            "text": "diarrhoea, anorexia",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -7.37890625,
            "text": "diarrhoea, anorexia, dyspepsia and abdominal pain)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -7.41796875,
            "text": "diarrhoea, anorexia, dyspepsia and abdominal pain",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -7.515625,
            "text": "diarrhoea, anorexia, dyspepsia and abdominal pain) were",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -7.53125,
            "text": "diarrhoea, anorexia, dyspepsia and abdominal pain) were the other major cause of adverse events and for withdrawal, and the odds ratio for withdrawal",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.16796875,
            "end_logit": 7.56640625,
            "text": "(diarrhoea",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 7.56640625,
            "text": "side effects (diarrhoea",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.36328125,
            "end_logit": -6.671875,
            "text": "Gastrointestinal",
            "probability": 0.0
        },
        {
            "start_logit": -5.36328125,
            "end_logit": -6.7890625,
            "text": "Gastrointestinal side effects (diarrhoea, anorexia",
            "probability": 0.0
        },
        {
            "start_logit": -5.36328125,
            "end_logit": -7.1875,
            "text": "Gastrointestinal side effects",
            "probability": 0.0
        },
        {
            "start_logit": -5.36328125,
            "end_logit": -7.37890625,
            "text": "Gastrointestinal side effects (diarrhoea, anorexia, dyspepsia and abdominal pain)",
            "probability": 0.0
        },
        {
            "start_logit": -5.36328125,
            "end_logit": -7.41796875,
            "text": "Gastrointestinal side effects (diarrhoea, anorexia, dyspepsia and abdominal pain",
            "probability": 0.0
        },
        {
            "start_logit": -5.36328125,
            "end_logit": -7.515625,
            "text": "Gastrointestinal side effects (diarrhoea, anorexia, dyspepsia and abdominal pain) were",
            "probability": 0.0
        },
        {
            "start_logit": -6.80078125,
            "end_logit": -6.91796875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.16796875,
            "end_logit": -6.7890625,
            "text": "(diarrhoea, anorexia",
            "probability": 0.0
        },
        {
            "start_logit": -7.5078125,
            "end_logit": -6.7890625,
            "text": "side effects (diarrhoea, anorexia",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -6.91796875,
            "text": "1).",
            "probability": 0.0
        },
        {
            "start_logit": -7.49609375,
            "end_logit": -6.91796875,
            "text": "95%CI 2.8-5.1).",
            "probability": 0.0
        }
    ],
    "58a2fac960087bc10a000009_5": [
        {
            "start_logit": 7.9296875,
            "end_logit": 7.50390625,
            "text": "nausea",
            "probability": 1.0
        },
        {
            "start_logit": 7.9296875,
            "end_logit": -0.12420654296875,
            "text": "nausea, vomiting, diarrhea, anorexia, and dizziness. Tacrine, the leading anticholinesterase, caused frequent hepatic enzyme elevation",
            "probability": 0.00048422813415527344
        },
        {
            "start_logit": 7.9296875,
            "end_logit": -6.75390625,
            "text": "nausea, vomiting, diarrhea, anorexia, and dizziness",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.9296875,
            "end_logit": -7.328125,
            "text": "nausea, vomiting, diarrhea, anorexia",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.9296875,
            "end_logit": -7.42578125,
            "text": "nausea, vomiting, diarrhea, anorexia, and dizziness. Tacrine, the leading anticholinesterase, caused frequent hepatic enzyme elevation and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.9296875,
            "end_logit": -7.43359375,
            "text": "nausea, vomiting, diarrhea, anorexia, and dizziness. Tacrine, the leading anticholinesterase, caused frequent hepatic enzyme elevation and was withdrawn",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.9296875,
            "end_logit": -7.50390625,
            "text": "nausea, vomiting, diarrhea, anorexia, and dizziness. Tacrine, the leading anticholinesterase",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.9296875,
            "end_logit": -7.56640625,
            "text": "nausea, vomiting, diarrhea, anorexia, and dizziness. Tacrine, the leading anticholinesterase, caused frequent hepatic enzyme elevation and was",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.2421875,
            "end_logit": 7.50390625,
            "text": "include nausea",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.390625,
            "end_logit": 7.50390625,
            "text": ", Side effects, in 5% to 15% of cases, include nausea",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.421875,
            "end_logit": 7.50390625,
            "text": "Section (ADAS-Cog), Side effects, in 5% to 15% of cases, include nausea",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -1.6337890625,
            "end_logit": -0.12420654296875,
            "text": "hepatic enzyme elevation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.51171875,
            "end_logit": -0.12420654296875,
            "text": "enzyme elevation",
            "probability": 0.0
        },
        {
            "start_logit": -6.6875,
            "end_logit": -0.12420654296875,
            "text": "diarrhea, anorexia, and dizziness. Tacrine, the leading anticholinesterase, caused frequent hepatic enzyme elevation",
            "probability": 0.0
        },
        {
            "start_logit": -7.09765625,
            "end_logit": -0.12420654296875,
            "text": "dizziness. Tacrine, the leading anticholinesterase, caused frequent hepatic enzyme elevation",
            "probability": 0.0
        },
        {
            "start_logit": -7.2421875,
            "end_logit": -0.12420654296875,
            "text": "include nausea, vomiting, diarrhea, anorexia, and dizziness. Tacrine, the leading anticholinesterase, caused frequent hepatic enzyme elevation",
            "probability": 0.0
        },
        {
            "start_logit": -7.40625,
            "end_logit": -0.12420654296875,
            "text": ", diarrhea, anorexia, and dizziness. Tacrine, the leading anticholinesterase, caused frequent hepatic enzyme elevation",
            "probability": 0.0
        },
        {
            "start_logit": -1.6337890625,
            "end_logit": -7.42578125,
            "text": "hepatic enzyme elevation and",
            "probability": 0.0
        },
        {
            "start_logit": -1.6337890625,
            "end_logit": -7.43359375,
            "text": "hepatic enzyme elevation and was withdrawn",
            "probability": 0.0
        },
        {
            "start_logit": -1.6337890625,
            "end_logit": -7.56640625,
            "text": "hepatic enzyme elevation and was",
            "probability": 0.0
        }
    ],
    "58a2fac960087bc10a000009_6": [
        {
            "start_logit": 7.73046875,
            "end_logit": 7.828125,
            "text": "hepatotoxicity",
            "probability": 1.0
        },
        {
            "start_logit": 7.73046875,
            "end_logit": -6.92578125,
            "text": "hepatotoxicity in 30-50% of patients, as indicated by an increase in transaminase levels",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.73046875,
            "end_logit": -7.33203125,
            "text": "hepatotoxicity in 30-50% of patients, as indicated by an increase in transaminase levels.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.73046875,
            "end_logit": -7.390625,
            "text": "hepatotoxicity in 30-50% of patients, as indicated by an increase in transaminase",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 7.828125,
            "text": "reversible hepatotoxicity",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.5,
            "end_logit": 7.828125,
            "text": "Administration of tacrine (THA) for the treatment of Alzheimer's disease results in a reversible hepatotoxicity",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 7.828125,
            "text": "a reversible hepatotoxicity",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 7.828125,
            "text": "in a reversible hepatotoxicity",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.73046875,
            "end_logit": -7.50390625,
            "text": "hepatotoxicity in 30-50",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.73046875,
            "end_logit": -7.5078125,
            "text": "hepatotoxicity in 30-50% of patients",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.73046875,
            "end_logit": -7.55859375,
            "text": "hepatotoxicity in 30-50% of patients, as",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.73046875,
            "end_logit": -7.56640625,
            "text": "hepatotoxicity in 30-50% of patients, as indicated by an",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.73046875,
            "end_logit": -7.57421875,
            "text": "hepatotoxicity in 30-50% of patients, as indicated",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.73046875,
            "end_logit": -7.578125,
            "text": "hepatotoxicity in 30",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.73046875,
            "end_logit": -7.62109375,
            "text": "hepatotoxicity in 30-50%",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.73046875,
            "end_logit": -7.64453125,
            "text": "hepatotoxicity in",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.73046875,
            "end_logit": -7.66796875,
            "text": "hepatotoxicity in 30-50% of patients, as indicated by",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.98046875,
            "end_logit": -7.33203125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.4609375,
            "end_logit": -6.92578125,
            "text": "increase in transaminase levels",
            "probability": 0.0
        },
        {
            "start_logit": -7.48828125,
            "end_logit": -6.92578125,
            "text": "reversible hepatotoxicity in 30-50% of patients, as indicated by an increase in transaminase levels",
            "probability": 0.0
        }
    ],
    "5c6e01af7c78d69471000048_1": [
        {
            "start_logit": 5.10546875,
            "end_logit": 8.5234375,
            "text": "CMV infection",
            "probability": 1.0
        },
        {
            "start_logit": -2.673828125,
            "end_logit": 8.5234375,
            "text": "infection",
            "probability": 0.0004208087921142578
        },
        {
            "start_logit": -6.3828125,
            "end_logit": 8.5234375,
            "text": "prophylaxis of CMV infection",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -6.44921875,
            "end_logit": 8.5234375,
            "text": "of CMV infection",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 8.5234375,
            "text": "the prophylaxis of CMV infection",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 8.5234375,
            "text": "for the prophylaxis of CMV infection",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": 5.10546875,
            "end_logit": -5.42578125,
            "text": "CMV",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 5.10546875,
            "end_logit": -6.56640625,
            "text": "CMV infection and disease",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 5.10546875,
            "end_logit": -6.8671875,
            "text": "CMV infection and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant (HSCT).",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 5.10546875,
            "end_logit": -6.984375,
            "text": "CMV infection and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 5.10546875,
            "end_logit": -7.046875,
            "text": "CMV infection and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant (HSCT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 5.10546875,
            "end_logit": -7.26171875,
            "text": "CMV infection and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant (HSCT)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.10546875,
            "end_logit": -7.26171875,
            "text": "CMV infection and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.10546875,
            "end_logit": -7.328125,
            "text": "CMV infection and disease in adult CMV-seropositive",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.10546875,
            "end_logit": -7.453125,
            "text": "CMV infection and disease in adult CMV-seropositive recipients",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.10546875,
            "end_logit": -7.46875,
            "text": "CMV infection and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.10546875,
            "end_logit": -7.48046875,
            "text": "CMV infection and disease in adult CMV-seropositive recipients of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.10546875,
            "end_logit": -7.51953125,
            "text": "CMV infection and disease in adult CMV-seropositive recipients of an",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.10546875,
            "end_logit": -7.546875,
            "text": "CMV infection and disease in adult CMV-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.10546875,
            "end_logit": -7.5546875,
            "text": "CMV infection and disease in adult CMV",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5c6e01af7c78d69471000048_2": [
        {
            "start_logit": 9.34375,
            "end_logit": 9.2265625,
            "text": "CMV infection",
            "probability": 1.0
        },
        {
            "start_logit": 9.34375,
            "end_logit": -0.5595703125,
            "text": "CMV",
            "probability": 5.650520324707031e-05
        },
        {
            "start_logit": -1.232421875,
            "end_logit": 9.2265625,
            "text": "infection",
            "probability": 2.568960189819336e-05
        },
        {
            "start_logit": 9.34375,
            "end_logit": -6.51171875,
            "text": "CMV infection and disease in adult CMV-seropositive recipients of an allogeneic HSCT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.34375,
            "end_logit": -6.8671875,
            "text": "CMV infection and disease in adult CMV-seropositive recipients of an allogeneic HSCT.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.34375,
            "end_logit": -6.92578125,
            "text": "CMV infection and disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.00390625,
            "end_logit": 9.2265625,
            "text": "of CMV infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.34375,
            "end_logit": -7.2578125,
            "text": "CMV infection and disease in adult CMV-seropositive",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.34375,
            "end_logit": -7.3515625,
            "text": "CMV infection and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.34375,
            "end_logit": -7.3515625,
            "text": "CMV infection and disease in adult CMV-seropositive recipients",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.34375,
            "end_logit": -7.4296875,
            "text": "CMV infection and disease in adult CMV-seropositive recipients of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.34375,
            "end_logit": -7.484375,
            "text": "CMV infection and disease in adult CMV",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 9.2265625,
            "text": "prophylaxis of CMV infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.609375,
            "end_logit": 9.2265625,
            "text": "summarizes the milestones in the development of letermovir leading to its first global approval in Canada as well as the USA for the prophylaxis of CMV infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.91796875,
            "end_logit": -0.5595703125,
            "text": "article summarizes the milestones in the development of letermovir leading to its first global approval in Canada as well as the USA for the prophylaxis of CMV",
            "probability": 0.0
        },
        {
            "start_logit": -7.00390625,
            "end_logit": -0.5595703125,
            "text": "of CMV",
            "probability": 0.0
        },
        {
            "start_logit": -1.232421875,
            "end_logit": -6.51171875,
            "text": "infection and disease in adult CMV-seropositive recipients of an allogeneic HSCT",
            "probability": 0.0
        },
        {
            "start_logit": -7.44140625,
            "end_logit": -0.5595703125,
            "text": "prophylaxis of CMV",
            "probability": 0.0
        },
        {
            "start_logit": -1.232421875,
            "end_logit": -6.8671875,
            "text": "infection and disease in adult CMV-seropositive recipients of an allogeneic HSCT.",
            "probability": 0.0
        },
        {
            "start_logit": -1.232421875,
            "end_logit": -6.92578125,
            "text": "infection and disease",
            "probability": 0.0
        }
    ],
    "5c6e01af7c78d69471000048_3": [
        {
            "start_logit": 9.3984375,
            "end_logit": 9.3515625,
            "text": "CMV infection",
            "probability": 1.0
        },
        {
            "start_logit": 9.3984375,
            "end_logit": -0.62109375,
            "text": "CMV",
            "probability": 4.684925079345703e-05
        },
        {
            "start_logit": -1.08984375,
            "end_logit": 9.3515625,
            "text": "infection",
            "probability": 2.7954578399658203e-05
        },
        {
            "start_logit": 9.3984375,
            "end_logit": -6.546875,
            "text": "CMV infection and disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.92578125,
            "end_logit": 9.3515625,
            "text": "of CMV infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3984375,
            "end_logit": -7.328125,
            "text": "CMV infection and disease.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3984375,
            "end_logit": -7.33203125,
            "text": "CMV infection and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.296875,
            "end_logit": 9.3515625,
            "text": "prophylaxis of CMV infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.3515625,
            "text": "the prophylaxis of CMV infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.67578125,
            "end_logit": 9.3515625,
            "text": "Letermovir has shown promising clinical efficacy and is generally well tolerated, thus providing a favorable new option in the prophylaxis of CMV infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 9.3515625,
            "text": "favorable new option in the prophylaxis of CMV infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.92578125,
            "end_logit": -0.62109375,
            "text": "of CMV",
            "probability": 0.0
        },
        {
            "start_logit": -1.08984375,
            "end_logit": -6.546875,
            "text": "infection and disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.296875,
            "end_logit": -0.62109375,
            "text": "prophylaxis of CMV",
            "probability": 0.0
        },
        {
            "start_logit": -7.640625,
            "end_logit": -0.62109375,
            "text": "the prophylaxis of CMV",
            "probability": 0.0
        },
        {
            "start_logit": -7.67578125,
            "end_logit": -0.62109375,
            "text": "Letermovir has shown promising clinical efficacy and is generally well tolerated, thus providing a favorable new option in the prophylaxis of CMV",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -0.62109375,
            "text": "favorable new option in the prophylaxis of CMV",
            "probability": 0.0
        },
        {
            "start_logit": -1.08984375,
            "end_logit": -7.328125,
            "text": "infection and disease.",
            "probability": 0.0
        },
        {
            "start_logit": -1.08984375,
            "end_logit": -7.33203125,
            "text": "infection and",
            "probability": 0.0
        },
        {
            "start_logit": -6.92578125,
            "end_logit": -6.546875,
            "text": "of CMV infection and disease",
            "probability": 0.0
        }
    ],
    "5171651e8ed59a060a000009_1": [
        {
            "start_logit": 6.40625,
            "end_logit": 4.234375,
            "text": "kallikrein-related peptidase 3",
            "probability": 1.0
        },
        {
            "start_logit": 6.40625,
            "end_logit": -4.52734375,
            "text": "kallikrein",
            "probability": 0.00015604496002197266
        },
        {
            "start_logit": 6.40625,
            "end_logit": -4.55078125,
            "text": "kallikrein-related peptidase 3, prostate-specific antigen, in the brain",
            "probability": 0.00015354156494140625
        },
        {
            "start_logit": 6.40625,
            "end_logit": -5.55859375,
            "text": "kallikrein-related peptidase",
            "probability": 5.561113357543945e-05
        },
        {
            "start_logit": 6.40625,
            "end_logit": -6.515625,
            "text": "kallikrein-related",
            "probability": 2.1457672119140625e-05
        },
        {
            "start_logit": 6.40625,
            "end_logit": -6.73046875,
            "text": "kallikrein-related peptidase 3, prostate-specific antigen, in the brain.",
            "probability": 1.722574234008789e-05
        },
        {
            "start_logit": 6.40625,
            "end_logit": -6.91796875,
            "text": "kallikrein-related peptidase 3,",
            "probability": 1.430511474609375e-05
        },
        {
            "start_logit": 6.40625,
            "end_logit": -7.23828125,
            "text": "kallikrein-related peptidase 3, prostate-specific antigen,",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": 6.40625,
            "end_logit": -7.25,
            "text": "kallikrein-related peptidase 3, prostate",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": 6.40625,
            "end_logit": -7.28515625,
            "text": "kallikrein-related peptidase 3, prostate-specific antigen, in",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": 6.40625,
            "end_logit": -7.32421875,
            "text": "kallikrein-related peptidase 3, prostate-specific antigen, in the",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": 6.40625,
            "end_logit": -7.42578125,
            "text": "kallikrein-",
            "probability": 8.64267349243164e-06
        },
        {
            "start_logit": -5.5625,
            "end_logit": 4.234375,
            "text": "3",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": -7.02734375,
            "end_logit": 4.234375,
            "text": "human kallikrein-related peptidase 3",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -7.0625,
            "end_logit": 4.234375,
            "text": "Evidence for the novel expression of human kallikrein-related peptidase 3",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -7.1171875,
            "end_logit": 4.234375,
            "text": "expression of human kallikrein-related peptidase 3",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 4.234375,
            "text": "of human kallikrein-related peptidase 3",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 4.234375,
            "text": "-related peptidase 3",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -7.59375,
            "end_logit": 4.234375,
            "text": "related peptidase 3",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -5.5625,
            "end_logit": -4.55078125,
            "text": "3, prostate-specific antigen, in the brain",
            "probability": 0.0
        }
    ],
    "5171651e8ed59a060a000009_2": [
        {
            "start_logit": 1.1318359375,
            "end_logit": 1.8232421875,
            "text": "kallikrein-related peptidase 3 (hK3), also known as prostate-specific antigen (PSA",
            "probability": 0.96142578125
        },
        {
            "start_logit": -2.6328125,
            "end_logit": 1.8232421875,
            "text": "PSA",
            "probability": 0.0222625732421875
        },
        {
            "start_logit": 1.1318359375,
            "end_logit": -3.22265625,
            "text": "kallikrein-related peptidase 3 (hK3)",
            "probability": 0.0061798095703125
        },
        {
            "start_logit": -4.046875,
            "end_logit": 1.8232421875,
            "text": "Human kallikrein-related peptidase 3 (hK3), also known as prostate-specific antigen (PSA",
            "probability": 0.005413055419921875
        },
        {
            "start_logit": 1.1318359375,
            "end_logit": -5.1171875,
            "text": "kallikrein-related peptidase 3",
            "probability": 0.0009336471557617188
        },
        {
            "start_logit": -6.5703125,
            "end_logit": 1.8232421875,
            "text": "as prostate-specific antigen (PSA",
            "probability": 0.00043392181396484375
        },
        {
            "start_logit": -6.94140625,
            "end_logit": 1.8232421875,
            "text": "hK3), also known as prostate-specific antigen (PSA",
            "probability": 0.0003006458282470703
        },
        {
            "start_logit": 1.1318359375,
            "end_logit": -6.265625,
            "text": "kallikrein-related peptidase 3 (hK3), also known as prostate-specific antigen (PSA)",
            "probability": 0.00029587745666503906
        },
        {
            "start_logit": -6.99609375,
            "end_logit": 1.8232421875,
            "text": "antigen (PSA",
            "probability": 0.0002846717834472656
        },
        {
            "start_logit": 1.1318359375,
            "end_logit": -6.33203125,
            "text": "kallikrein-related peptidase 3 (hK3",
            "probability": 0.0002758502960205078
        },
        {
            "start_logit": 1.1318359375,
            "end_logit": -6.34765625,
            "text": "kallikrein-related peptidase",
            "probability": 0.0002715587615966797
        },
        {
            "start_logit": 1.1318359375,
            "end_logit": -6.52734375,
            "text": "kallikrein-related peptidase 3 (hK",
            "probability": 0.0002269744873046875
        },
        {
            "start_logit": 1.1318359375,
            "end_logit": -6.55078125,
            "text": "kallikrein-related",
            "probability": 0.00022172927856445312
        },
        {
            "start_logit": -7.26953125,
            "end_logit": 1.8232421875,
            "text": "3), also known as prostate-specific antigen (PSA",
            "probability": 0.00021648406982421875
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 1.8232421875,
            "text": "3 (hK3), also known as prostate-specific antigen (PSA",
            "probability": 0.00021314620971679688
        },
        {
            "start_logit": -7.2890625,
            "end_logit": 1.8232421875,
            "text": "also known as prostate-specific antigen (PSA",
            "probability": 0.00021159648895263672
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 1.8232421875,
            "text": "(hK3), also known as prostate-specific antigen (PSA",
            "probability": 0.00019872188568115234
        },
        {
            "start_logit": -7.359375,
            "end_logit": 1.8232421875,
            "text": "-related peptidase 3 (hK3), also known as prostate-specific antigen (PSA",
            "probability": 0.0001971721649169922
        },
        {
            "start_logit": 1.1318359375,
            "end_logit": -6.69140625,
            "text": "kallikrein-related peptidase 3 (hK3), also known",
            "probability": 0.00019252300262451172
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 1.8232421875,
            "text": "(PSA",
            "probability": 0.00018095970153808594
        }
    ],
    "626aecc6e764a53204000042_1": [
        {
            "start_logit": 3.60546875,
            "end_logit": 1.9326171875,
            "text": "inotersen",
            "probability": 0.9970703125
        },
        {
            "start_logit": 3.60546875,
            "end_logit": -5.3046875,
            "text": "inoterse",
            "probability": 0.0007166862487792969
        },
        {
            "start_logit": 3.60546875,
            "end_logit": -5.4375,
            "text": "inotersen (brand name Tagsedi), also known as IONIS-TTRRX",
            "probability": 0.0006270408630371094
        },
        {
            "start_logit": 3.60546875,
            "end_logit": -6.3203125,
            "text": "inotersen (brand name Tagsedi), also known as IONIS-TTRRX, has been approved by the United States",
            "probability": 0.0002605915069580078
        },
        {
            "start_logit": 3.60546875,
            "end_logit": -6.46484375,
            "text": "inoter",
            "probability": 0.0002244710922241211
        },
        {
            "start_logit": 3.60546875,
            "end_logit": -6.69140625,
            "text": "inotersen (brand name Tagsedi), also known as IONIS-TTR",
            "probability": 0.00017905235290527344
        },
        {
            "start_logit": 3.60546875,
            "end_logit": -6.91015625,
            "text": "in",
            "probability": 0.0001437664031982422
        },
        {
            "start_logit": 3.60546875,
            "end_logit": -6.95703125,
            "text": "inotersen (brand name Tagsedi), also known as IONIS-TTRRX, has been approved by the United States Food",
            "probability": 0.0001373291015625
        },
        {
            "start_logit": 3.60546875,
            "end_logit": -6.9921875,
            "text": "inotersen (brand name Tagsedi), also known as IONIS",
            "probability": 0.00013303756713867188
        },
        {
            "start_logit": 3.60546875,
            "end_logit": -7.01953125,
            "text": "inotersen (brand name Tagsedi), also known as IONIS-",
            "probability": 0.0001289844512939453
        },
        {
            "start_logit": 3.60546875,
            "end_logit": -7.03515625,
            "text": "inotersen (brand name Tagsedi), also known as IONIS-TTRR",
            "probability": 0.00012695789337158203
        },
        {
            "start_logit": 3.60546875,
            "end_logit": -7.4296875,
            "text": "inotersen (",
            "probability": 8.589029312133789e-05
        },
        {
            "start_logit": 3.60546875,
            "end_logit": -7.46484375,
            "text": "inotersen (brand name Tagsedi)",
            "probability": 8.26120376586914e-05
        },
        {
            "start_logit": 0.1866455078125,
            "end_logit": -4.98828125,
            "text": "United States Food and Drug Agency",
            "probability": 3.2067298889160156e-05
        },
        {
            "start_logit": -6.92578125,
            "end_logit": 1.9326171875,
            "text": "new drug named inotersen",
            "probability": 2.664327621459961e-05
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 1.9326171875,
            "text": "A new drug named inotersen",
            "probability": 1.7464160919189453e-05
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 1.9326171875,
            "text": "otersen",
            "probability": 1.6927719116210938e-05
        },
        {
            "start_logit": -7.40625,
            "end_logit": 1.9326171875,
            "text": "drug named inotersen",
            "probability": 1.6391277313232422e-05
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 1.9326171875,
            "text": "n",
            "probability": 1.615285873413086e-05
        },
        {
            "start_logit": 0.1866455078125,
            "end_logit": -6.3203125,
            "text": "United States",
            "probability": 8.52346420288086e-06
        }
    ],
    "5e31b575fbd6abf43b00004c_1": [
        {
            "start_logit": 9.3203125,
            "end_logit": 9.4375,
            "text": "sensorineural deafness",
            "probability": 1.0
        },
        {
            "start_logit": -0.818359375,
            "end_logit": 9.4375,
            "text": "deafness",
            "probability": 3.975629806518555e-05
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -1.00390625,
            "text": "sensorineural",
            "probability": 2.9325485229492188e-05
        },
        {
            "start_logit": -6.46875,
            "end_logit": 9.4375,
            "text": ", sensorineural deafness",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.5078125,
            "end_logit": 9.4375,
            "text": "nephritic syndrome, sensorineural deafness",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -6.66015625,
            "text": "sensorineural deafness, and ophthalmological alterations",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 9.4375,
            "text": "clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.1875,
            "text": "sensorineural deafness, and ophthalmological alterations.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 9.4375,
            "text": "triad of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.33203125,
            "text": "sensorineural deafness, and ophthalmological",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 9.4375,
            "text": "rare condition characterized by the clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53125,
            "end_logit": 9.4375,
            "text": "syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 9.4375,
            "text": "of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 9.4375,
            "text": "condition characterized by the clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.48046875,
            "text": "sensorineural deafness, and ophthalm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 9.4375,
            "text": ": Alport syndrome is a rare condition characterized by the clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.46875,
            "end_logit": -1.00390625,
            "text": ", sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -0.818359375,
            "end_logit": -6.66015625,
            "text": "deafness, and ophthalmological alterations",
            "probability": 0.0
        },
        {
            "start_logit": -6.5078125,
            "end_logit": -1.00390625,
            "text": "nephritic syndrome, sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -0.818359375,
            "end_logit": -7.1875,
            "text": "deafness, and ophthalmological alterations.",
            "probability": 0.0
        }
    ],
    "5e31b575fbd6abf43b00004c_2": [
        {
            "start_logit": 9.2109375,
            "end_logit": 9.140625,
            "text": "sensorineural deafness",
            "probability": 0.9990234375
        },
        {
            "start_logit": 2.47265625,
            "end_logit": 9.140625,
            "text": "hereditary nephritis, sensorineural deafness",
            "probability": 0.0011882781982421875
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -1.265625,
            "text": "sensorineural",
            "probability": 3.045797348022461e-05
        },
        {
            "start_logit": -1.54296875,
            "end_logit": 9.140625,
            "text": "deafness",
            "probability": 2.1457672119140625e-05
        },
        {
            "start_logit": 2.47265625,
            "end_logit": 4.0234375,
            "text": "hereditary nephritis",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": -5.6796875,
            "end_logit": 9.140625,
            "text": "nephritis, sensorineural deafness",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.70703125,
            "end_logit": 9.140625,
            "text": ", sensorineural deafness",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -7.01953125,
            "text": "sensorineural deafness, and ocular abnormalities",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.14453125,
            "end_logit": 9.140625,
            "text": "of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -7.21875,
            "text": "sensorineural deafness, and ocular abnormalities.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 9.140625,
            "text": "clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -7.41015625,
            "text": "sensorineural deafness, and ocular",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 9.140625,
            "text": "triad of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -7.53515625,
            "text": "sensorineural deafness,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -7.58203125,
            "text": "sensorineural deafness, and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 9.140625,
            "text": ": Alport syndrome refers to the clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 9.140625,
            "text": "BACKGROUND: Alport syndrome refers to the clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 9.140625,
            "text": "syndrome refers to the clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 2.47265625,
            "end_logit": -1.265625,
            "text": "hereditary nephritis, sensorineural",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.6796875,
            "end_logit": 4.0234375,
            "text": "nephritis",
            "probability": 0.0
        }
    ],
    "5e31b575fbd6abf43b00004c_3": [
        {
            "start_logit": 9.3203125,
            "end_logit": 9.4375,
            "text": "sensorineural deafness",
            "probability": 1.0
        },
        {
            "start_logit": -0.818359375,
            "end_logit": 9.4375,
            "text": "deafness",
            "probability": 3.975629806518555e-05
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -1.00390625,
            "text": "sensorineural",
            "probability": 2.9325485229492188e-05
        },
        {
            "start_logit": -6.46875,
            "end_logit": 9.4375,
            "text": ", sensorineural deafness",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.5078125,
            "end_logit": 9.4375,
            "text": "nephritic syndrome, sensorineural deafness",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -6.66015625,
            "text": "sensorineural deafness, and ophthalmological alterations",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 9.4375,
            "text": "clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.1875,
            "text": "sensorineural deafness, and ophthalmological alterations.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 9.4375,
            "text": "triad of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.33203125,
            "text": "sensorineural deafness, and ophthalmological",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 9.4375,
            "text": "rare condition characterized by the clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53125,
            "end_logit": 9.4375,
            "text": "syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 9.4375,
            "text": "of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 9.4375,
            "text": "condition characterized by the clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.48046875,
            "text": "sensorineural deafness, and ophthalm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 9.4375,
            "text": ":  Alport syndrome is a rare condition characterized by the clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.46875,
            "end_logit": -1.00390625,
            "text": ", sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -0.818359375,
            "end_logit": -6.66015625,
            "text": "deafness, and ophthalmological alterations",
            "probability": 0.0
        },
        {
            "start_logit": -6.5078125,
            "end_logit": -1.00390625,
            "text": "nephritic syndrome, sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -0.818359375,
            "end_logit": -7.1875,
            "text": "deafness, and ophthalmological alterations.",
            "probability": 0.0
        }
    ],
    "5e31b575fbd6abf43b00004c_4": [
        {
            "start_logit": 9.2890625,
            "end_logit": 9.2421875,
            "text": "sensorineural deafness",
            "probability": 1.0
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -1.0751953125,
            "text": "sensorineural",
            "probability": 3.2961368560791016e-05
        },
        {
            "start_logit": -1.33203125,
            "end_logit": 9.2421875,
            "text": "deafness",
            "probability": 2.4318695068359375e-05
        },
        {
            "start_logit": -2.646484375,
            "end_logit": 9.2421875,
            "text": "hereditary nephritis, sensorineural deafness",
            "probability": 6.556510925292969e-06
        },
        {
            "start_logit": -6.57421875,
            "end_logit": 9.2421875,
            "text": ", sensorineural deafness",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.05078125,
            "text": "sensorineural deafness, and ocular abnormalities",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 9.2421875,
            "text": "of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.29296875,
            "text": "sensorineural deafness, and ocular abnormalities.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 9.2421875,
            "text": "triad of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.265625,
            "end_logit": 9.2421875,
            "text": "nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2734375,
            "end_logit": 9.2421875,
            "text": "clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.45703125,
            "text": "sensorineural deafness, and ocular",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 9.2421875,
            "text": "BACKGROUND  Alport syndrome refers to the clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.5234375,
            "text": "sensorineural deafness,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.59765625,
            "text": "sensorineural deafness, and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.67578125,
            "end_logit": 9.2421875,
            "text": "syndrome refers to the clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6953125,
            "end_logit": 9.2421875,
            "text": "Alport syndrome refers to the clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.646484375,
            "end_logit": -1.0751953125,
            "text": "hereditary nephritis, sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -2.646484375,
            "end_logit": -1.857421875,
            "text": "hereditary nephritis",
            "probability": 0.0
        },
        {
            "start_logit": -6.57421875,
            "end_logit": -1.0751953125,
            "text": ", sensorineural",
            "probability": 0.0
        }
    ],
    "5e31b575fbd6abf43b00004c_5": [
        {
            "start_logit": 9.2890625,
            "end_logit": 9.2421875,
            "text": "sensorineural deafness",
            "probability": 1.0
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -1.0751953125,
            "text": "sensorineural",
            "probability": 3.2961368560791016e-05
        },
        {
            "start_logit": -1.33203125,
            "end_logit": 9.2421875,
            "text": "deafness",
            "probability": 2.4318695068359375e-05
        },
        {
            "start_logit": -2.646484375,
            "end_logit": 9.2421875,
            "text": "hereditary nephritis, sensorineural deafness",
            "probability": 6.556510925292969e-06
        },
        {
            "start_logit": -6.57421875,
            "end_logit": 9.2421875,
            "text": ", sensorineural deafness",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.05078125,
            "text": "sensorineural deafness, and ocular abnormalities",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 9.2421875,
            "text": "of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.29296875,
            "text": "sensorineural deafness, and ocular abnormalities.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 9.2421875,
            "text": "triad of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.265625,
            "end_logit": 9.2421875,
            "text": "nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2734375,
            "end_logit": 9.2421875,
            "text": "clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.45703125,
            "text": "sensorineural deafness, and ocular",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 9.2421875,
            "text": "BACKGROUND Alport syndrome refers to the clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.5234375,
            "text": "sensorineural deafness,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.59765625,
            "text": "sensorineural deafness, and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.67578125,
            "end_logit": 9.2421875,
            "text": "syndrome refers to the clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6953125,
            "end_logit": 9.2421875,
            "text": "Alport syndrome refers to the clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.646484375,
            "end_logit": -1.0751953125,
            "text": "hereditary nephritis, sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -2.646484375,
            "end_logit": -1.857421875,
            "text": "hereditary nephritis",
            "probability": 0.0
        },
        {
            "start_logit": -6.57421875,
            "end_logit": -1.0751953125,
            "text": ", sensorineural",
            "probability": 0.0
        }
    ],
    "5e31b575fbd6abf43b00004c_6": [
        {
            "start_logit": 9.21875,
            "end_logit": 9.1484375,
            "text": "sensorineural deafness",
            "probability": 1.0
        },
        {
            "start_logit": 9.21875,
            "end_logit": -1.232421875,
            "text": "sensorineural",
            "probability": 3.069639205932617e-05
        },
        {
            "start_logit": -1.421875,
            "end_logit": 9.1484375,
            "text": "hereditary nephritis , sensorineural deafness",
            "probability": 2.372264862060547e-05
        },
        {
            "start_logit": -1.4853515625,
            "end_logit": 9.1484375,
            "text": "deafness",
            "probability": 2.2292137145996094e-05
        },
        {
            "start_logit": -6.734375,
            "end_logit": 9.1484375,
            "text": ", sensorineural deafness",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -6.96484375,
            "text": "sensorineural deafness , and ocular abnormalities",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.08203125,
            "end_logit": 9.1484375,
            "text": "nephritis , sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.109375,
            "end_logit": 9.1484375,
            "text": "of hereditary nephritis , sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.30078125,
            "text": "sensorineural deafness , and ocular",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.23828125,
            "end_logit": 9.1484375,
            "text": "triad of hereditary nephritis , sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.328125,
            "end_logit": 9.1484375,
            "text": "clinical triad of hereditary nephritis , sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.52734375,
            "text": "sensorineural deafness ,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 9.1484375,
            "text": "Alport syndrome refers to the clinical triad of hereditary nephritis , sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.421875,
            "end_logit": -0.489013671875,
            "text": "hereditary nephritis",
            "probability": 0.0
        },
        {
            "start_logit": -1.421875,
            "end_logit": -1.232421875,
            "text": "hereditary nephritis , sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -7.08203125,
            "end_logit": -0.489013671875,
            "text": "nephritis",
            "probability": 0.0
        },
        {
            "start_logit": -7.109375,
            "end_logit": -0.489013671875,
            "text": "of hereditary nephritis",
            "probability": 0.0
        },
        {
            "start_logit": -7.23828125,
            "end_logit": -0.489013671875,
            "text": "triad of hereditary nephritis",
            "probability": 0.0
        },
        {
            "start_logit": -7.328125,
            "end_logit": -0.489013671875,
            "text": "clinical triad of hereditary nephritis",
            "probability": 0.0
        },
        {
            "start_logit": -6.734375,
            "end_logit": -1.232421875,
            "text": ", sensorineural",
            "probability": 0.0
        }
    ],
    "5e31b575fbd6abf43b00004c_7": [
        {
            "start_logit": 9.3203125,
            "end_logit": 9.4375,
            "text": "sensorineural deafness",
            "probability": 1.0
        },
        {
            "start_logit": -0.818359375,
            "end_logit": 9.4375,
            "text": "deafness",
            "probability": 3.975629806518555e-05
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -1.00390625,
            "text": "sensorineural",
            "probability": 2.9325485229492188e-05
        },
        {
            "start_logit": -6.46875,
            "end_logit": 9.4375,
            "text": ", sensorineural deafness",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.5078125,
            "end_logit": 9.4375,
            "text": "nephritic syndrome, sensorineural deafness",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -6.66015625,
            "text": "sensorineural deafness, and ophthalmological alterations",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 9.4375,
            "text": "clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.1875,
            "text": "sensorineural deafness, and ophthalmological alterations.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 9.4375,
            "text": "triad of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.33203125,
            "text": "sensorineural deafness, and ophthalmological",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 9.4375,
            "text": "rare condition characterized by the clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53125,
            "end_logit": 9.4375,
            "text": "syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 9.4375,
            "text": "of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 9.4375,
            "text": "condition characterized by the clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.48046875,
            "text": "sensorineural deafness, and ophthalm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 9.4375,
            "text": ": Alport syndrome is a rare condition characterized by the clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.46875,
            "end_logit": -1.00390625,
            "text": ", sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -0.818359375,
            "end_logit": -6.66015625,
            "text": "deafness, and ophthalmological alterations",
            "probability": 0.0
        },
        {
            "start_logit": -6.5078125,
            "end_logit": -1.00390625,
            "text": "nephritic syndrome, sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -0.818359375,
            "end_logit": -7.1875,
            "text": "deafness, and ophthalmological alterations.",
            "probability": 0.0
        }
    ],
    "5e31b575fbd6abf43b00004c_8": [
        {
            "start_logit": 9.296875,
            "end_logit": 9.4375,
            "text": "sensorineural deafness",
            "probability": 1.0
        },
        {
            "start_logit": -0.818359375,
            "end_logit": 9.4375,
            "text": "deafness",
            "probability": 4.035234451293945e-05
        },
        {
            "start_logit": 9.296875,
            "end_logit": -1.0625,
            "text": "sensorineural",
            "probability": 2.753734588623047e-05
        },
        {
            "start_logit": -6.3515625,
            "end_logit": 9.4375,
            "text": "nephritic syndrome, sensorineural deafness",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.3828125,
            "end_logit": 9.4375,
            "text": ", sensorineural deafness",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -6.63671875,
            "text": "sensorineural deafness, and ophthalmological alterations",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.2109375,
            "end_logit": 9.4375,
            "text": "clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.15625,
            "text": "sensorineural deafness, and ophthalmological alterations.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 9.4375,
            "text": "triad of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.30859375,
            "text": "sensorineural deafness, and ophthalmological",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.484375,
            "end_logit": 9.4375,
            "text": "rare condition characterized by the clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 9.4375,
            "text": "syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 9.4375,
            "text": "of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 9.4375,
            "text": ": Alport syndrome is a rare condition characterized by the clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 9.4375,
            "text": "condition characterized by the clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.53515625,
            "text": "sensorineural deafness, and ophthalm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.5625,
            "text": "sensorineural deafness,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.3515625,
            "end_logit": -1.0625,
            "text": "nephritic syndrome, sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -6.3828125,
            "end_logit": -1.0625,
            "text": ", sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -0.818359375,
            "end_logit": -6.63671875,
            "text": "deafness, and ophthalmological alterations",
            "probability": 0.0
        }
    ],
    "5e31b575fbd6abf43b00004c_9": [
        {
            "start_logit": 9.2109375,
            "end_logit": 9.140625,
            "text": "sensorineural deafness",
            "probability": 0.9990234375
        },
        {
            "start_logit": 2.47265625,
            "end_logit": 9.140625,
            "text": "hereditary nephritis, sensorineural deafness",
            "probability": 0.0011882781982421875
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -1.265625,
            "text": "sensorineural",
            "probability": 3.045797348022461e-05
        },
        {
            "start_logit": -1.54296875,
            "end_logit": 9.140625,
            "text": "deafness",
            "probability": 2.1457672119140625e-05
        },
        {
            "start_logit": 2.47265625,
            "end_logit": 4.0234375,
            "text": "hereditary nephritis",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": -5.6796875,
            "end_logit": 9.140625,
            "text": "nephritis, sensorineural deafness",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.70703125,
            "end_logit": 9.140625,
            "text": ", sensorineural deafness",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -7.01953125,
            "text": "sensorineural deafness, and ocular abnormalities",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.14453125,
            "end_logit": 9.140625,
            "text": "of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -7.21875,
            "text": "sensorineural deafness, and ocular abnormalities.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 9.140625,
            "text": "clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -7.41015625,
            "text": "sensorineural deafness, and ocular",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 9.140625,
            "text": "triad of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -7.53515625,
            "text": "sensorineural deafness,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -7.58203125,
            "text": "sensorineural deafness, and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 9.140625,
            "text": ": Alport syndrome refers to the clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 9.140625,
            "text": "BACKGROUND: Alport syndrome refers to the clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 9.140625,
            "text": "syndrome refers to the clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 2.47265625,
            "end_logit": -1.265625,
            "text": "hereditary nephritis, sensorineural",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.6796875,
            "end_logit": 4.0234375,
            "text": "nephritis",
            "probability": 0.0
        }
    ],
    "5e31b575fbd6abf43b00004c_10": [
        {
            "start_logit": 9.3125,
            "end_logit": 9.296875,
            "text": "sensorineural deafness",
            "probability": 1.0
        },
        {
            "start_logit": 9.3125,
            "end_logit": -1.0166015625,
            "text": "sensorineural",
            "probability": 3.319978713989258e-05
        },
        {
            "start_logit": -1.1943359375,
            "end_logit": 9.296875,
            "text": "deafness",
            "probability": 2.7298927307128906e-05
        },
        {
            "start_logit": -2.146484375,
            "end_logit": 9.296875,
            "text": "hereditary nephritis, sensorineural deafness",
            "probability": 1.055002212524414e-05
        },
        {
            "start_logit": -6.59375,
            "end_logit": 9.296875,
            "text": ", sensorineural deafness",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.0390625,
            "text": "sensorineural deafness, and ocular abnormalities",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0546875,
            "end_logit": 9.296875,
            "text": "nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.14453125,
            "end_logit": 9.296875,
            "text": "of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 9.296875,
            "text": "triad of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.296875,
            "text": "sensorineural deafness, and ocular abnormalities.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.328125,
            "end_logit": 9.296875,
            "text": "clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.4453125,
            "text": "sensorineural deafness, and ocular",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.53125,
            "text": "sensorineural deafness,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.609375,
            "text": "sensorineural deafness, and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6875,
            "end_logit": 9.296875,
            "text": "Alport syndrome refers to the clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69921875,
            "end_logit": 9.296875,
            "text": "syndrome refers to the clinical triad of hereditary nephritis, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.146484375,
            "end_logit": -1.0166015625,
            "text": "hereditary nephritis, sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -2.146484375,
            "end_logit": -1.1474609375,
            "text": "hereditary nephritis",
            "probability": 0.0
        },
        {
            "start_logit": -6.59375,
            "end_logit": -1.0166015625,
            "text": ", sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -7.0546875,
            "end_logit": -1.0166015625,
            "text": "nephritis, sensorineural",
            "probability": 0.0
        }
    ],
    "5e31b575fbd6abf43b00004c_11": [
        {
            "start_logit": 9.3828125,
            "end_logit": 9.3984375,
            "text": "sensorineural deafness",
            "probability": 1.0
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -0.81494140625,
            "text": "sensorineural",
            "probability": 3.6776065826416016e-05
        },
        {
            "start_logit": -1.0009765625,
            "end_logit": 9.3984375,
            "text": "deafness",
            "probability": 3.0934810638427734e-05
        },
        {
            "start_logit": -6.9296875,
            "end_logit": 9.3984375,
            "text": ", sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.03125,
            "end_logit": 9.3984375,
            "text": "nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -7.046875,
            "text": "sensorineural deafness, and ophthalmological alterations",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.21875,
            "end_logit": 9.3984375,
            "text": "clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -7.25,
            "text": "sensorineural deafness, and ophthalmological alterations.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 9.3984375,
            "text": "triad of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 9.3984375,
            "text": "rare condition characterized by the clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -7.5078125,
            "text": "sensorineural deafness, and ophthalmological",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59375,
            "end_logit": 9.3984375,
            "text": "condition characterized by the clinical triad of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 9.3984375,
            "text": "of nephritic syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 9.3984375,
            "text": "syndrome, sensorineural deafness",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -7.609375,
            "text": "sensorineural deafness,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.9296875,
            "end_logit": -0.81494140625,
            "text": ", sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -7.03125,
            "end_logit": -0.81494140625,
            "text": "nephritic syndrome, sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -7.21875,
            "end_logit": -0.81494140625,
            "text": "clinical triad of nephritic syndrome, sensorineural",
            "probability": 0.0
        },
        {
            "start_logit": -1.0009765625,
            "end_logit": -7.046875,
            "text": "deafness, and ophthalmological alterations",
            "probability": 0.0
        },
        {
            "start_logit": -7.3359375,
            "end_logit": -0.81494140625,
            "text": "triad of nephritic syndrome, sensorineural",
            "probability": 0.0
        }
    ],
    "5e92005c2d3121100d000003_1": [
        {
            "start_logit": 9.15625,
            "end_logit": 8.265625,
            "text": "Ebola virus",
            "probability": 1.0
        },
        {
            "start_logit": 9.15625,
            "end_logit": -0.642578125,
            "text": "Ebola",
            "probability": 0.00013554096221923828
        },
        {
            "start_logit": -1.8154296875,
            "end_logit": 8.265625,
            "text": "filoviruses, Ebola virus",
            "probability": 1.722574234008789e-05
        },
        {
            "start_logit": -3.0859375,
            "end_logit": 8.265625,
            "text": "virus",
            "probability": 4.827976226806641e-06
        },
        {
            "start_logit": 9.15625,
            "end_logit": -5.96875,
            "text": "Ebola virus (EBOV)",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 9.15625,
            "end_logit": -6.7734375,
            "text": "Ebola virus (EBOV) and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.15625,
            "end_logit": -6.88671875,
            "text": "Ebola virus (EBOV",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.15625,
            "end_logit": -7.109375,
            "text": "Ebola virus (EBOV) and Marburg virus",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.15625,
            "end_logit": -7.1640625,
            "text": "Ebola virus (EBOV) and Marburg virus (MARV",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.15625,
            "end_logit": -7.17578125,
            "text": "Ebola virus (EBOV) and Marburg",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.15625,
            "end_logit": -7.18359375,
            "text": "Ebola virus (EB",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.15625,
            "end_logit": -7.24609375,
            "text": "Ebola virus (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.15625,
            "end_logit": -7.2734375,
            "text": "Ebola virus (EBOV) and Marburg virus (MAR",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.15625,
            "end_logit": -7.30859375,
            "text": "Ebola virus (EBOV) and Marburg virus (MARV)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.15625,
            "end_logit": -7.359375,
            "text": "Ebola virus (EBOV) and Mar",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.7109375,
            "end_logit": 8.265625,
            "text": ", Ebola virus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 8.265625,
            "text": "The filoviruses, Ebola virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 8.265625,
            "text": "oviruses, Ebola virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.8154296875,
            "end_logit": -0.642578125,
            "text": "filoviruses, Ebola",
            "probability": 0.0
        },
        {
            "start_logit": -1.8154296875,
            "end_logit": -2.962890625,
            "text": "filoviruses",
            "probability": 0.0
        }
    ],
    "5e92005c2d3121100d000003_2": [
        {
            "start_logit": 7.55859375,
            "end_logit": 8.0390625,
            "text": "HIV",
            "probability": 1.0
        },
        {
            "start_logit": 7.55859375,
            "end_logit": -6.9296875,
            "text": "HIV as",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 8.0390625,
            "text": "WHO ranks HIV",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.55859375,
            "end_logit": -7.23828125,
            "text": "HIV as one",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.7421875,
            "end_logit": 8.0390625,
            "text": "s HIV",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.55859375,
            "end_logit": -7.31640625,
            "text": "HIV as one of the deadliest diseases",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.55859375,
            "end_logit": -7.41796875,
            "text": "HIV as one of the",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.55859375,
            "end_logit": -7.43359375,
            "text": "HIV as one of",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.63671875,
            "end_logit": -6.9296875,
            "text": "WHO ranks HIV as",
            "probability": 0.0
        },
        {
            "start_logit": -7.7421875,
            "end_logit": -6.9296875,
            "text": "s HIV as",
            "probability": 0.0
        },
        {
            "start_logit": -7.63671875,
            "end_logit": -7.23828125,
            "text": "WHO ranks HIV as one",
            "probability": 0.0
        },
        {
            "start_logit": -7.63671875,
            "end_logit": -7.31640625,
            "text": "WHO ranks HIV as one of the deadliest diseases",
            "probability": 0.0
        },
        {
            "start_logit": -7.7421875,
            "end_logit": -7.23828125,
            "text": "s HIV as one",
            "probability": 0.0
        },
        {
            "start_logit": -7.63671875,
            "end_logit": -7.3984375,
            "text": "WHO rank",
            "probability": 0.0
        },
        {
            "start_logit": -7.7265625,
            "end_logit": -7.31640625,
            "text": "est diseases",
            "probability": 0.0
        },
        {
            "start_logit": -7.7265625,
            "end_logit": -7.31640625,
            "text": "deadliest diseases",
            "probability": 0.0
        },
        {
            "start_logit": -7.63671875,
            "end_logit": -7.41796875,
            "text": "WHO ranks HIV as one of the",
            "probability": 0.0
        },
        {
            "start_logit": -7.7421875,
            "end_logit": -7.31640625,
            "text": "s HIV as one of the deadliest diseases",
            "probability": 0.0
        },
        {
            "start_logit": -7.63671875,
            "end_logit": -7.43359375,
            "text": "WHO ranks HIV as one of",
            "probability": 0.0
        },
        {
            "start_logit": -7.7421875,
            "end_logit": -7.41796875,
            "text": "s HIV as one of the",
            "probability": 0.0
        }
    ],
    "550312b4e9bde6963400001c_1": [
        {
            "start_logit": 9.25,
            "end_logit": 9.234375,
            "text": "GATA1",
            "probability": 1.0
        },
        {
            "start_logit": 9.25,
            "end_logit": -1.236328125,
            "text": "GATA",
            "probability": 2.8431415557861328e-05
        },
        {
            "start_logit": -1.470703125,
            "end_logit": 9.234375,
            "text": "1",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": -4.5625,
            "end_logit": 9.234375,
            "text": "and GATA1",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.3203125,
            "text": "GATA1 in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 9.234375,
            "text": "26 and GATA1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.41796875,
            "text": "GATA1 in about 60-65",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.5625,
            "end_logit": -1.236328125,
            "text": "and GATA",
            "probability": 0.0
        },
        {
            "start_logit": -7.35546875,
            "end_logit": -1.236328125,
            "text": "26 and GATA",
            "probability": 0.0
        },
        {
            "start_logit": -1.470703125,
            "end_logit": -7.3203125,
            "text": "1 in",
            "probability": 0.0
        },
        {
            "start_logit": -1.470703125,
            "end_logit": -7.41796875,
            "text": "1 in about 60-65",
            "probability": 0.0
        },
        {
            "start_logit": -4.5625,
            "end_logit": -7.3203125,
            "text": "and GATA1 in",
            "probability": 0.0
        },
        {
            "start_logit": -4.5625,
            "end_logit": -7.41796875,
            "text": "and GATA1 in about 60-65",
            "probability": 0.0
        },
        {
            "start_logit": -6.3203125,
            "end_logit": -7.20703125,
            "text": "point mutations and large deletions in ten ribosomal protein (RP) genes RPS19",
            "probability": 0.0
        },
        {
            "start_logit": -6.3203125,
            "end_logit": -7.26953125,
            "text": "point mutations and large deletions in ten ribosomal protein (RP) genes RPS",
            "probability": 0.0
        },
        {
            "start_logit": -6.3203125,
            "end_logit": -7.3046875,
            "text": "point mutations",
            "probability": 0.0
        },
        {
            "start_logit": -6.3203125,
            "end_logit": -7.359375,
            "text": "point mutations and",
            "probability": 0.0
        },
        {
            "start_logit": -6.796875,
            "end_logit": -6.91015625,
            "text": ". The main features of the disease are normochromic and macrocytic anemia, reticulocytopenia, and nearly absent erythroid progenitors in the bone marrow",
            "probability": 0.0
        },
        {
            "start_logit": -6.796875,
            "end_logit": -6.9765625,
            "text": ". The main features of the disease are normochromic and macrocytic anemia, reticulocytopenia, and nearly absent erythroid progenitors in the bone marrow.",
            "probability": 0.0
        },
        {
            "start_logit": -6.796875,
            "end_logit": -6.9765625,
            "text": ".",
            "probability": 0.0
        }
    ],
    "550312b4e9bde6963400001c_2": [
        {
            "start_logit": 0.365234375,
            "end_logit": 4.69140625,
            "text": "RPS19",
            "probability": 0.9384765625
        },
        {
            "start_logit": -3.041015625,
            "end_logit": 4.69140625,
            "text": "genes associated with DBA: RPS19",
            "probability": 0.03118896484375
        },
        {
            "start_logit": -4.1328125,
            "end_logit": 4.69140625,
            "text": "mutations in the nine known genes associated with DBA: RPS19",
            "probability": 0.010467529296875
        },
        {
            "start_logit": -4.15625,
            "end_logit": 4.69140625,
            "text": ": RPS19",
            "probability": 0.010223388671875
        },
        {
            "start_logit": -4.65234375,
            "end_logit": 4.69140625,
            "text": "19",
            "probability": 0.0062255859375
        },
        {
            "start_logit": -5.765625,
            "end_logit": 4.69140625,
            "text": "cases of DBA admitted in our hospital from Dec 2008 to Aug 2012 were screened by PCR for mutations in the nine known genes associated with DBA: RPS19",
            "probability": 0.002044677734375
        },
        {
            "start_logit": -6.2265625,
            "end_logit": 4.69140625,
            "text": "known genes associated with DBA: RPS19",
            "probability": 0.0012903213500976562
        },
        {
            "start_logit": 0.365234375,
            "end_logit": -4.9140625,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11, RPS7, RPL35a, RPS10 and RPS26",
            "probability": 6.347894668579102e-05
        },
        {
            "start_logit": 0.365234375,
            "end_logit": -5.32421875,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11, RPS7, RPL35a",
            "probability": 4.1961669921875e-05
        },
        {
            "start_logit": 0.365234375,
            "end_logit": -6.078125,
            "text": "RPS19, RPS24, RPS17, RPL5",
            "probability": 1.9788742065429688e-05
        },
        {
            "start_logit": 0.365234375,
            "end_logit": -6.49609375,
            "text": "RPS",
            "probability": 1.2993812561035156e-05
        },
        {
            "start_logit": 0.365234375,
            "end_logit": -6.5703125,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11",
            "probability": 1.2159347534179688e-05
        },
        {
            "start_logit": 0.365234375,
            "end_logit": -6.73046875,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11, RPS7, RPL35",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": 0.365234375,
            "end_logit": -6.734375,
            "text": "RPS19, RPS24",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": 0.365234375,
            "end_logit": -6.76171875,
            "text": "RPS19, RPS",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": -3.041015625,
            "end_logit": -3.4609375,
            "text": "genes",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": 0.365234375,
            "end_logit": -6.921875,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11, RPS7, RPL35a, RPS10",
            "probability": 8.52346420288086e-06
        },
        {
            "start_logit": 0.365234375,
            "end_logit": -7.0390625,
            "text": "RPS19,",
            "probability": 7.569789886474609e-06
        },
        {
            "start_logit": -4.1328125,
            "end_logit": -3.4609375,
            "text": "mutations in the nine known genes",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": -3.041015625,
            "end_logit": -5.32421875,
            "text": "genes associated with DBA: RPS19, RPS24, RPS17, RPL5, RPL11, RPS7, RPL35a",
            "probability": 1.3709068298339844e-06
        }
    ],
    "550312b4e9bde6963400001c_3": [
        {
            "start_logit": 5.65625,
            "end_logit": 8.2890625,
            "text": "RPS19",
            "probability": 1.0
        },
        {
            "start_logit": -2.953125,
            "end_logit": 8.2890625,
            "text": "19",
            "probability": 0.0001823902130126953
        },
        {
            "start_logit": 5.65625,
            "end_logit": -0.37841796875,
            "text": "RPS19 mutation was identified in 3 patients, RPS24, RPS7, RPL5, RPL11 and RPL35A",
            "probability": 0.00017130374908447266
        },
        {
            "start_logit": -5.828125,
            "end_logit": 8.2890625,
            "text": "mutations in the genes coding for ribosomal protein, in which RPS19",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -6.1484375,
            "end_logit": 8.2890625,
            "text": "had mutations in the genes coding for ribosomal protein, in which RPS19",
            "probability": 7.450580596923828e-06
        },
        {
            "start_logit": -6.47265625,
            "end_logit": 8.2890625,
            "text": "which RPS19",
            "probability": 5.424022674560547e-06
        },
        {
            "start_logit": -6.73046875,
            "end_logit": 8.2890625,
            "text": "genes coding for ribosomal protein, in which RPS19",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": -6.91015625,
            "end_logit": 8.2890625,
            "text": "that 8 patients (38.1%) with DBA had mutations in the genes coding for ribosomal protein, in which RPS19",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": 5.65625,
            "end_logit": -5.59375,
            "text": "RPS",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 5.65625,
            "end_logit": -6.2734375,
            "text": "RPS19 mutation was identified in 3 patients, RPS24",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 5.65625,
            "end_logit": -6.390625,
            "text": "RPS19 mutation",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 5.65625,
            "end_logit": -6.5,
            "text": "RPS19 mutation was identified in 3 patients, RPS24, RPS7, RPL5, RPL11 and RPL35",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 5.65625,
            "end_logit": -6.53125,
            "text": "RPS19 mutation was identified in 3 patients, RPS24, RPS",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 5.65625,
            "end_logit": -6.78125,
            "text": "RPS19 mutation was identified in 3 patients, RPS24, RPS7, RPL5, RPL",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 5.65625,
            "end_logit": -6.8125,
            "text": "RPS19 mutation was identified in 3 patients, RPS24, RPS7, RPL5, RPL11 and RPL35A mutations",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 5.65625,
            "end_logit": -6.8125,
            "text": "RPS19 mutation was identified in 3 patients, RPS24, RPS7",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 5.65625,
            "end_logit": -6.890625,
            "text": "RPS19 mutation was identified in 3 patients, RPS24, RPS7, RPL",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 5.65625,
            "end_logit": -6.9375,
            "text": "RPS19 mutation was identified in 3 patients, RPS",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 5.65625,
            "end_logit": -6.984375,
            "text": "RPS19 mutation was identified in 3 patients, RPS24, RPS7, RPL5",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 5.65625,
            "end_logit": -7.11328125,
            "text": "RPS19 mutation was identified in 3 patients, RPS24, RPS7, RPL5, RPL11",
            "probability": 1.7881393432617188e-07
        }
    ],
    "550312b4e9bde6963400001c_4": [
        {
            "start_logit": 9.2890625,
            "end_logit": 9.1328125,
            "text": "GATA1",
            "probability": 1.0
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -1.140625,
            "text": "GATA",
            "probability": 3.451108932495117e-05
        },
        {
            "start_logit": -1.7421875,
            "end_logit": 9.1328125,
            "text": "1",
            "probability": 1.621246337890625e-05
        },
        {
            "start_logit": -6.6796875,
            "end_logit": 9.1328125,
            "text": ". We performed exome sequencing on two siblings who had no known pathogenic mutations for DBA and identified a mutation in the gene encoding the hematopoietic transcription factor GATA1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9921875,
            "end_logit": 9.1328125,
            "text": "mutation in the gene encoding the hematopoietic transcription factor GATA1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.04296875,
            "end_logit": 9.1328125,
            "text": "a mutation in the gene encoding the hematopoietic transcription factor GATA1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.08984375,
            "end_logit": 9.1328125,
            "text": "identified a mutation in the gene encoding the hematopoietic transcription factor GATA1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1328125,
            "end_logit": 9.1328125,
            "text": "hematopoietic transcription factor GATA1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.21484375,
            "end_logit": 9.1328125,
            "text": "transcription factor GATA1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 9.1328125,
            "text": "siblings who had no known pathogenic mutations for DBA and identified a mutation in the gene encoding the hematopoietic transcription factor GATA1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.40234375,
            "end_logit": 9.1328125,
            "text": "exome sequencing on two siblings who had no known pathogenic mutations for DBA and identified a mutation in the gene encoding the hematopoietic transcription factor GATA1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.43359375,
            "end_logit": 9.1328125,
            "text": "performed exome sequencing on two siblings who had no known pathogenic mutations for DBA and identified a mutation in the gene encoding the hematopoietic transcription factor GATA1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 9.1328125,
            "text": "who had no known pathogenic mutations for DBA and identified a mutation in the gene encoding the hematopoietic transcription factor GATA1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 9.1328125,
            "text": "two siblings who had no known pathogenic mutations for DBA and identified a mutation in the gene encoding the hematopoietic transcription factor GATA1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 9.1328125,
            "text": "factor GATA1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.6796875,
            "end_logit": -1.140625,
            "text": ". We performed exome sequencing on two siblings who had no known pathogenic mutations for DBA and identified a mutation in the gene encoding the hematopoietic transcription factor GATA",
            "probability": 0.0
        },
        {
            "start_logit": -6.9921875,
            "end_logit": -1.140625,
            "text": "mutation in the gene encoding the hematopoietic transcription factor GATA",
            "probability": 0.0
        },
        {
            "start_logit": -7.04296875,
            "end_logit": -1.140625,
            "text": "a mutation in the gene encoding the hematopoietic transcription factor GATA",
            "probability": 0.0
        },
        {
            "start_logit": -7.08984375,
            "end_logit": -1.140625,
            "text": "identified a mutation in the gene encoding the hematopoietic transcription factor GATA",
            "probability": 0.0
        },
        {
            "start_logit": -7.1328125,
            "end_logit": -1.140625,
            "text": "hematopoietic transcription factor GATA",
            "probability": 0.0
        }
    ],
    "550312b4e9bde6963400001c_5": [
        {
            "start_logit": 8.5546875,
            "end_logit": 9.265625,
            "text": "RPS17",
            "probability": 1.0
        },
        {
            "start_logit": -1.1787109375,
            "end_logit": 9.265625,
            "text": "17",
            "probability": 5.9664249420166016e-05
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -2.541015625,
            "text": "RPS",
            "probability": 7.510185241699219e-06
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -3.552734375,
            "text": "RPS17, RPS19, RPS26, RPL5, RPL11, and RPL35A",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": -5.5625,
            "end_logit": 9.265625,
            "text": "genes that are most frequently mutated in Diamond-Blackfan anemia patients: RPS17",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -5.9296875,
            "end_logit": 9.265625,
            "text": ": RPS17",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -5.63671875,
            "text": "RPS17, RPS19, RPS26, RPL5, RPL11",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -5.83984375,
            "text": "RPS17, RPS19, RPS26, RPL5",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.8359375,
            "end_logit": 9.265625,
            "text": "six genes that are most frequently mutated in Diamond-Blackfan anemia patients: RPS17",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.9140625,
            "end_logit": 9.265625,
            "text": "multiplex ligation-dependent probe amplification assay targeted to screen the six genes that are most frequently mutated in Diamond-Blackfan anemia patients: RPS17",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -6.29296875,
            "text": "RPS17, RPS19",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.23046875,
            "end_logit": 9.265625,
            "text": "screen the six genes that are most frequently mutated in Diamond-Blackfan anemia patients: RPS17",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -6.6796875,
            "text": "RPS17, RPS19, RPS26, RPL5, RPL11, and RPL35",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -6.79296875,
            "text": "RPS17, RPS19, RPS26, RPL5, RPL11, and RPL35A.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -6.8046875,
            "text": "RPS17, RPS19, RPS26, RPL5, RPL",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -7.109375,
            "text": "RPS17, RPS19, RPS26, RPL",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -7.125,
            "text": "RPS17, RPS",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -7.16015625,
            "text": "RPS17, RPS19, RPS26, RPL5, RPL11, and RPL35A. Using this assay we",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5546875,
            "end_logit": -7.28125,
            "text": "RPS17,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.1787109375,
            "end_logit": -3.552734375,
            "text": "17, RPS19, RPS26, RPL5, RPL11, and RPL35A",
            "probability": 0.0
        }
    ],
    "550312b4e9bde6963400001c_6": [
        {
            "start_logit": 3.806640625,
            "end_logit": 6.7265625,
            "text": "RPS19",
            "probability": 0.9990234375
        },
        {
            "start_logit": -4.3359375,
            "end_logit": 6.7265625,
            "text": "19",
            "probability": 0.0002911090850830078
        },
        {
            "start_logit": 3.806640625,
            "end_logit": -1.84765625,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11",
            "probability": 0.0001894235610961914
        },
        {
            "start_logit": 3.806640625,
            "end_logit": -1.87109375,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11, and RPL35A",
            "probability": 0.0001850128173828125
        },
        {
            "start_logit": -5.37109375,
            "end_logit": 6.7265625,
            "text": ": RPS19",
            "probability": 0.00010383129119873047
        },
        {
            "start_logit": -5.72265625,
            "end_logit": 6.7265625,
            "text": "genes associated with Diamond-Blackfan anemia: RPS19",
            "probability": 7.2479248046875e-05
        },
        {
            "start_logit": 3.806640625,
            "end_logit": -3.447265625,
            "text": "RPS19, RPS24, RPS17, RPL5",
            "probability": 3.814697265625e-05
        },
        {
            "start_logit": -6.51953125,
            "end_logit": 6.7265625,
            "text": "for mutations in the six known genes associated with Diamond-Blackfan anemia: RPS19",
            "probability": 3.266334533691406e-05
        },
        {
            "start_logit": -6.578125,
            "end_logit": 6.7265625,
            "text": "known genes associated with Diamond-Blackfan anemia: RPS19",
            "probability": 3.0875205993652344e-05
        },
        {
            "start_logit": -6.9453125,
            "end_logit": 6.7265625,
            "text": "mutations in the six known genes associated with Diamond-Blackfan anemia: RPS19",
            "probability": 2.1457672119140625e-05
        },
        {
            "start_logit": 3.806640625,
            "end_logit": -6.4375,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11, and RPL35",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 3.806640625,
            "end_logit": -6.515625,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11, and RPL35A.",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 3.806640625,
            "end_logit": -6.5390625,
            "text": "RPS19, RPS24",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": 3.806640625,
            "end_logit": -6.57421875,
            "text": "RPS",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": -1.328125,
            "end_logit": -1.84765625,
            "text": "RPL5, RPL11",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -1.328125,
            "end_logit": -1.87109375,
            "text": "RPL5, RPL11, and RPL35A",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 3.806640625,
            "end_logit": -7.08984375,
            "text": "RPS19,",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 3.806640625,
            "end_logit": -7.125,
            "text": "RPS19, RPS24, RPS17",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 3.806640625,
            "end_logit": -7.125,
            "text": "RPS19, RPS",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -1.58203125,
            "end_logit": -1.84765625,
            "text": "RPL11",
            "probability": 8.940696716308594e-07
        }
    ],
    "550312b4e9bde6963400001c_7": [
        {
            "start_logit": 8.8984375,
            "end_logit": 9.171875,
            "text": "RPS19",
            "probability": 1.0
        },
        {
            "start_logit": -1.611328125,
            "end_logit": 9.171875,
            "text": "19",
            "probability": 2.753734588623047e-05
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -2.04296875,
            "text": "RPS",
            "probability": 1.3649463653564453e-05
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -5.0078125,
            "text": "RPS19 gene",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -5.93359375,
            "text": "RPS19 gene, encoding the ribosomal protein S19",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.13671875,
            "text": "RPS19 gene, encoding the ribosomal protein S1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.484375,
            "end_logit": 9.171875,
            "text": "in the RPS19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.515625,
            "end_logit": 9.171875,
            "text": "Defects in the RPS19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.3125,
            "text": "RPS19 gene, encoding the ribosomal protein S19,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.671875,
            "end_logit": 9.171875,
            "text": "the RPS19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.4296875,
            "text": "RPS19 gene, encoding the ribosomal protein S19, are",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.453125,
            "text": "RPS19 gene,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.4765625,
            "text": "RPS19 gene, encoding the ribosomal protein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.5,
            "text": "RPS19 gene, encoding the ribosomal protein S19, are the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.55078125,
            "text": "RPS19 gene, encoding the ribosomal protein S19, are the main known cause of Diamond-Blackfan anemia and account for more than 25",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.578125,
            "text": "RPS19 gene, encoding the ribosomal protein S19, are the main known cause of Diamond-Blackfan anemia and account",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.578125,
            "text": "RPS19 gene, encoding the ribosomal protein S19, are the main known cause of Diamond-Blackfan anemia and account for more",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.611328125,
            "end_logit": -5.0078125,
            "text": "19 gene",
            "probability": 0.0
        },
        {
            "start_logit": -1.611328125,
            "end_logit": -5.93359375,
            "text": "19 gene, encoding the ribosomal protein S19",
            "probability": 0.0
        },
        {
            "start_logit": -1.611328125,
            "end_logit": -7.13671875,
            "text": "19 gene, encoding the ribosomal protein S1",
            "probability": 0.0
        }
    ],
    "550312b4e9bde6963400001c_8": [
        {
            "start_logit": 9.1171875,
            "end_logit": 9.0703125,
            "text": "RPS19",
            "probability": 1.0
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -1.580078125,
            "text": "RPS",
            "probability": 2.372264862060547e-05
        },
        {
            "start_logit": -1.86328125,
            "end_logit": 9.0703125,
            "text": "19",
            "probability": 1.6987323760986328e-05
        },
        {
            "start_logit": -6.62109375,
            "end_logit": 9.0703125,
            "text": "ribosomal protein RPS19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.171875,
            "text": "RPS19 have been identified in 25% of patients with DBA, with resulting impairment of 18S rRNA processing and 40S ribosomal subunit formation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 9.0703125,
            "text": "gene coding for the ribosomal protein RPS19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 9.0703125,
            "text": "Mutations in the gene coding for the ribosomal protein RPS19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.4609375,
            "text": "RPS19 have been identified in 25% of patients with DBA, with resulting impairment of 18S rRNA processing",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 9.0703125,
            "text": "protein RPS19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.55078125,
            "text": "RPS19 have",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.57421875,
            "text": "RPS19 have been identified",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.5859375,
            "text": "RPS19 have been",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.5859375,
            "text": "RPS19 have been identified in 25% of patients with DBA, with resulting impairment of 18S rRNA processing and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.6015625,
            "text": "RPS19 have been identified in 25% of patients with DBA, with resulting impairment of 18S rRNA processing and 40S ribosomal subunit",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.62109375,
            "end_logit": -1.580078125,
            "text": "ribosomal protein RPS",
            "probability": 0.0
        },
        {
            "start_logit": -7.26171875,
            "end_logit": -1.580078125,
            "text": "gene coding for the ribosomal protein RPS",
            "probability": 0.0
        },
        {
            "start_logit": -7.31640625,
            "end_logit": -1.580078125,
            "text": "Mutations in the gene coding for the ribosomal protein RPS",
            "probability": 0.0
        },
        {
            "start_logit": -7.4453125,
            "end_logit": -1.580078125,
            "text": "protein RPS",
            "probability": 0.0
        },
        {
            "start_logit": -1.86328125,
            "end_logit": -7.171875,
            "text": "19 have been identified in 25% of patients with DBA, with resulting impairment of 18S rRNA processing and 40S ribosomal subunit formation",
            "probability": 0.0
        },
        {
            "start_logit": -1.86328125,
            "end_logit": -7.4609375,
            "text": "19 have been identified in 25% of patients with DBA, with resulting impairment of 18S rRNA processing",
            "probability": 0.0
        }
    ],
    "550312b4e9bde6963400001c_9": [
        {
            "start_logit": 1.806640625,
            "end_logit": 3.0234375,
            "text": "RPL11, and RPL35A",
            "probability": 0.72607421875
        },
        {
            "start_logit": -0.020660400390625,
            "end_logit": 3.0234375,
            "text": "RPL35A",
            "probability": 0.116943359375
        },
        {
            "start_logit": 1.806640625,
            "end_logit": 1.083984375,
            "text": "RPL11",
            "probability": 0.1046142578125
        },
        {
            "start_logit": -1.3095703125,
            "end_logit": 3.0234375,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11, and RPL35A",
            "probability": 0.03228759765625
        },
        {
            "start_logit": -2.443359375,
            "end_logit": 3.0234375,
            "text": "RPL5, RPL11, and RPL35A",
            "probability": 0.0103607177734375
        },
        {
            "start_logit": -1.3095703125,
            "end_logit": 1.083984375,
            "text": "RPS19, RPS24, RPS17, RPL5, RPL11",
            "probability": 0.00463104248046875
        },
        {
            "start_logit": -2.443359375,
            "end_logit": 1.083984375,
            "text": "RPL5, RPL11",
            "probability": 0.001491546630859375
        },
        {
            "start_logit": -4.90625,
            "end_logit": 3.0234375,
            "text": "and RPL35A",
            "probability": 0.0008845329284667969
        },
        {
            "start_logit": -1.3095703125,
            "end_logit": -1.037109375,
            "text": "RPS19",
            "probability": 0.0005555152893066406
        },
        {
            "start_logit": -5.5390625,
            "end_logit": 3.0234375,
            "text": ": RPS19, RPS24, RPS17, RPL5, RPL11, and RPL35A",
            "probability": 0.0004696846008300781
        },
        {
            "start_logit": -5.8984375,
            "end_logit": 3.0234375,
            "text": "genes associated with Diamond-Blackfan anemia: RPS19, RPS24, RPS17, RPL5, RPL11, and RPL35A",
            "probability": 0.00032782554626464844
        },
        {
            "start_logit": -5.92578125,
            "end_logit": 3.0234375,
            "text": ", RPL11, and RPL35A",
            "probability": 0.0003190040588378906
        },
        {
            "start_logit": -6.24609375,
            "end_logit": 3.0234375,
            "text": "RPS24, RPS17, RPL5, RPL11, and RPL35A",
            "probability": 0.00023257732391357422
        },
        {
            "start_logit": -6.35546875,
            "end_logit": 3.0234375,
            "text": "A",
            "probability": 0.00020825862884521484
        },
        {
            "start_logit": -6.671875,
            "end_logit": 3.0234375,
            "text": "known genes associated with Diamond-Blackfan anemia: RPS19, RPS24, RPS17, RPL5, RPL11, and RPL35A",
            "probability": 0.0001512765884399414
        },
        {
            "start_logit": -6.7890625,
            "end_logit": 3.0234375,
            "text": ", RPL5, RPL11, and RPL35A",
            "probability": 0.00013458728790283203
        },
        {
            "start_logit": 1.806640625,
            "end_logit": -5.8359375,
            "text": "RPL11, and RPL35",
            "probability": 0.00010317564010620117
        },
        {
            "start_logit": -7.19921875,
            "end_logit": 3.0234375,
            "text": "11, and RPL35A",
            "probability": 8.958578109741211e-05
        },
        {
            "start_logit": -7.265625,
            "end_logit": 3.0234375,
            "text": "RPS17, RPL5, RPL11, and RPL35A",
            "probability": 8.356571197509766e-05
        },
        {
            "start_logit": -5.5390625,
            "end_logit": 1.083984375,
            "text": ": RPS19, RPS24, RPS17, RPL5, RPL11",
            "probability": 6.765127182006836e-05
        }
    ],
    "550312b4e9bde6963400001c_10": [
        {
            "start_logit": 8.71875,
            "end_logit": 8.890625,
            "text": "RPS19",
            "probability": 1.0
        },
        {
            "start_logit": -2.173828125,
            "end_logit": 8.890625,
            "text": "19",
            "probability": 1.8656253814697266e-05
        },
        {
            "start_logit": 8.71875,
            "end_logit": -2.376953125,
            "text": "RPS",
            "probability": 1.2814998626708984e-05
        },
        {
            "start_logit": 8.71875,
            "end_logit": -4.9921875,
            "text": "RPS19 gene",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.71875,
            "end_logit": -6.21875,
            "text": "RPS19 gene, encoding the ribosomal protein S19",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.71875,
            "end_logit": -7.203125,
            "text": "RPS19 gene, encoding the ribosomal protein S1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.71875,
            "end_logit": -7.3359375,
            "text": "RPS19 gene, encoding the ribosomal protein S19,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 8.890625,
            "text": "in the RPS19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5625,
            "end_logit": 8.890625,
            "text": "Defects in the RPS19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.71875,
            "end_logit": -7.4140625,
            "text": "RPS19 gene,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.71875,
            "end_logit": -7.46875,
            "text": "RPS19 gene, encoding the ribosomal protein S19, are",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.71875,
            "end_logit": -7.5234375,
            "text": "RPS19 gene, encoding the ribosomal protein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.71875,
            "end_logit": -7.53125,
            "text": "RPS19 gene, encoding the ribosomal protein S19, are the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.71875,
            "end_logit": -7.58203125,
            "text": "RPS19 gene, encoding the ribosomal protein S19, are the main known cause of Diamond-Blackfan anemia and account for more than 25",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.71875,
            "end_logit": -7.58984375,
            "text": "RPS19 gene, encoding the ribosomal protein S19, are the main known cause of Diamond-Blackfan anemia and account for more",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.71875,
            "end_logit": -7.59765625,
            "text": "RPS19 gene, encoding the ribosomal protein S19, are the main known cause of Diamond-Blackfan anemia and account for",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.71875,
            "end_logit": -7.59765625,
            "text": "RPS19 gene, encoding the ribosomal protein S19, are the main known cause of Diamond-Blackfan anemia and account",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.173828125,
            "end_logit": -4.9921875,
            "text": "19 gene",
            "probability": 0.0
        },
        {
            "start_logit": -2.173828125,
            "end_logit": -6.21875,
            "text": "19 gene, encoding the ribosomal protein S19",
            "probability": 0.0
        },
        {
            "start_logit": -2.173828125,
            "end_logit": -7.203125,
            "text": "19 gene, encoding the ribosomal protein S1",
            "probability": 0.0
        }
    ],
    "550312b4e9bde6963400001c_11": [
        {
            "start_logit": 8.7734375,
            "end_logit": 9.0546875,
            "text": "RPS19",
            "probability": 1.0
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -1.3056640625,
            "text": "RPS19 gene",
            "probability": 3.170967102050781e-05
        },
        {
            "start_logit": -1.8388671875,
            "end_logit": 9.0546875,
            "text": "19",
            "probability": 2.467632293701172e-05
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -2.263671875,
            "text": "RPS",
            "probability": 1.2099742889404297e-05
        },
        {
            "start_logit": -3.927734375,
            "end_logit": 9.0546875,
            "text": "ribosomal protein (RP) gene S19 (RPS19",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": -6.359375,
            "end_logit": 9.0546875,
            "text": "S19 (RPS19",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.39453125,
            "end_logit": 9.0546875,
            "text": "ribosomal gene involved in DBA, ribosomal protein (RP) gene S19 (RPS19",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.5390625,
            "end_logit": 9.0546875,
            "text": "gene S19 (RPS19",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.69140625,
            "end_logit": 9.0546875,
            "text": ", ribosomal protein (RP) gene S19 (RPS19",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -6.62109375,
            "text": "RPS19 gene)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.92578125,
            "end_logit": 9.0546875,
            "text": "(RPS19",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.140625,
            "end_logit": 9.0546875,
            "text": "protein (RP) gene S19 (RPS19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -6.9765625,
            "text": "RPS19 gene), was identified in 1999",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 9.0546875,
            "text": "9 (RPS19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.33203125,
            "end_logit": 9.0546875,
            "text": ") gene S19 (RPS19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.33984375,
            "end_logit": 9.0546875,
            "text": "first ribosomal gene involved in DBA, ribosomal protein (RP) gene S19 (RPS19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.375,
            "end_logit": 9.0546875,
            "text": "gene involved in DBA, ribosomal protein (RP) gene S19 (RPS19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.12890625,
            "text": "RPS19 gene), was",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.1484375,
            "text": "RPS19 gene), was identified",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.3203125,
            "text": "RPS19 gene),",
            "probability": 5.960464477539063e-08
        }
    ],
    "5e46f9683f54159529000010_1": [
        {
            "start_logit": 9.078125,
            "end_logit": 8.6171875,
            "text": "radiation necrosis",
            "probability": 1.0
        },
        {
            "start_logit": 9.078125,
            "end_logit": -1.4052734375,
            "text": "radiation",
            "probability": 4.470348358154297e-05
        },
        {
            "start_logit": -2.548828125,
            "end_logit": 8.6171875,
            "text": "necrosis",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": 9.078125,
            "end_logit": -5.66015625,
            "text": "radiation necrosis, microangiopathy, and progressive leukencephalopathy",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.3984375,
            "end_logit": 8.6171875,
            "text": "include radiation necrosis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.078125,
            "end_logit": -6.9140625,
            "text": "radiation necrosis, microangiopathy, and progressive leukencephalopathy.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.078125,
            "end_logit": -6.94921875,
            "text": "radiation necrosis, microangiopathy, and progressive leukencephal",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.68359375,
            "end_logit": 8.6171875,
            "text": "nervous system are uncommon and include radiation necrosis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.71875,
            "end_logit": 8.6171875,
            "text": "central nervous system are uncommon and include radiation necrosis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.8203125,
            "end_logit": 8.6171875,
            "text": "head or central nervous system are uncommon and include radiation necrosis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.85546875,
            "end_logit": 8.6171875,
            "text": "side effects of radiation therapy on the head or central nervous system are uncommon and include radiation necrosis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.98046875,
            "end_logit": 8.6171875,
            "text": "serious side effects of radiation therapy on the head or central nervous system are uncommon and include radiation necrosis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.078125,
            "end_logit": -7.5859375,
            "text": "radiation necrosis, microangiopathy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.2265625,
            "end_logit": 8.6171875,
            "text": "uncommon and include radiation necrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.3984375,
            "end_logit": -1.4052734375,
            "text": "include radiation",
            "probability": 0.0
        },
        {
            "start_logit": -6.68359375,
            "end_logit": -1.4052734375,
            "text": "nervous system are uncommon and include radiation",
            "probability": 0.0
        },
        {
            "start_logit": -6.71875,
            "end_logit": -1.4052734375,
            "text": "central nervous system are uncommon and include radiation",
            "probability": 0.0
        },
        {
            "start_logit": -2.548828125,
            "end_logit": -5.66015625,
            "text": "necrosis, microangiopathy, and progressive leukencephalopathy",
            "probability": 0.0
        },
        {
            "start_logit": -6.8203125,
            "end_logit": -1.4052734375,
            "text": "head or central nervous system are uncommon and include radiation",
            "probability": 0.0
        },
        {
            "start_logit": -6.85546875,
            "end_logit": -1.4052734375,
            "text": "side effects of radiation therapy on the head or central nervous system are uncommon and include radiation",
            "probability": 0.0
        }
    ],
    "5e46f9683f54159529000010_2": [
        {
            "start_logit": 4.671875,
            "end_logit": 3.453125,
            "text": "meningiomas",
            "probability": 0.931640625
        },
        {
            "start_logit": 4.671875,
            "end_logit": 0.70068359375,
            "text": "meningiomas, followed by radiation-induced gliomas",
            "probability": 0.059326171875
        },
        {
            "start_logit": 2.716796875,
            "end_logit": 0.70068359375,
            "text": "gliomas",
            "probability": 0.00841522216796875
        },
        {
            "start_logit": 4.671875,
            "end_logit": -5.296875,
            "text": "meningiomas, followed by radiation-induced gliomas (RIGs) and sarcomas",
            "probability": 0.0001475811004638672
        },
        {
            "start_logit": 4.671875,
            "end_logit": -6.16015625,
            "text": "meningiomas, followed by radiation-induced gliomas (RIGs)",
            "probability": 6.252527236938477e-05
        },
        {
            "start_logit": 4.671875,
            "end_logit": -6.41796875,
            "text": "meningiomas, followed by radiation-induced gliomas (RIGs",
            "probability": 4.792213439941406e-05
        },
        {
            "start_logit": 4.671875,
            "end_logit": -6.5859375,
            "text": "meningiomas, followed by radiation-induced gliomas (RIG",
            "probability": 4.07099723815918e-05
        },
        {
            "start_logit": 4.671875,
            "end_logit": -6.9921875,
            "text": "meningiomas, followed by radiation-induced gliomas (",
            "probability": 2.7120113372802734e-05
        },
        {
            "start_logit": 4.671875,
            "end_logit": -7.01953125,
            "text": "meningiomas, followed by radiation-induced gliomas (RIGs) and",
            "probability": 2.6464462280273438e-05
        },
        {
            "start_logit": 4.671875,
            "end_logit": -7.03125,
            "text": "meningiomas, followed by radiation-induced gliomas (RIGs) and sarcomas.",
            "probability": 2.6047229766845703e-05
        },
        {
            "start_logit": 2.716796875,
            "end_logit": -5.296875,
            "text": "gliomas (RIGs) and sarcomas",
            "probability": 2.092123031616211e-05
        },
        {
            "start_logit": -6.0546875,
            "end_logit": 3.453125,
            "text": "are meningiomas",
            "probability": 2.0444393157958984e-05
        },
        {
            "start_logit": 4.671875,
            "end_logit": -7.2890625,
            "text": "meningiomas,",
            "probability": 2.014636993408203e-05
        },
        {
            "start_logit": -6.88671875,
            "end_logit": 3.453125,
            "text": "tumors, a majority of which are meningiomas",
            "probability": 8.881092071533203e-06
        },
        {
            "start_logit": 2.716796875,
            "end_logit": -6.16015625,
            "text": "gliomas (RIGs)",
            "probability": 8.761882781982422e-06
        },
        {
            "start_logit": -7.12109375,
            "end_logit": 3.453125,
            "text": "radiation-induced tumors, a majority of which are meningiomas",
            "probability": 6.973743438720703e-06
        },
        {
            "start_logit": 2.716796875,
            "end_logit": -6.41796875,
            "text": "gliomas (RIGs",
            "probability": 6.794929504394531e-06
        },
        {
            "start_logit": 2.716796875,
            "end_logit": -6.5859375,
            "text": "gliomas (RIG",
            "probability": 5.781650543212891e-06
        },
        {
            "start_logit": 2.716796875,
            "end_logit": -6.9921875,
            "text": "gliomas (",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": 2.716796875,
            "end_logit": -7.01953125,
            "text": "gliomas (RIGs) and",
            "probability": 3.6954879760742188e-06
        }
    ],
    "5e46f9683f54159529000010_3": [
        {
            "start_logit": 7.63671875,
            "end_logit": 7.98828125,
            "text": "pneumonitis",
            "probability": 1.0
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 7.98828125,
            "text": "are pneumonitis",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.63671875,
            "end_logit": -7.359375,
            "text": "pneumonitis, disturbance of the blood-brain barrier, radionecrosis of brain tissue, radiogenic liver damage, mucositis",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.63671875,
            "end_logit": -7.40625,
            "text": "pneumonitis, disturbance of the blood-brain barrier, radionecrosis of brain tissue, radiogenic liver damage, mucositis, colitis, osteitis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.63671875,
            "end_logit": -7.51953125,
            "text": "pneumonitis, disturbance of the blood-brain barrier, radionecrosis of brain tissue, radiogenic liver damage, mucositis, colitis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.63671875,
            "end_logit": -7.57421875,
            "text": "pneumonitis, disturbance of the blood-brain barrier, radionecrosis of brain tissue",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.63671875,
            "end_logit": -7.58203125,
            "text": "pneumonitis, disturbance of the blood-brain barrier, radionecrosis of brain tissue, radiogenic liver damage",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.63671875,
            "end_logit": -7.65234375,
            "text": "pneumonitis, disturbance of the blood-brain barrier",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.63671875,
            "end_logit": -7.66015625,
            "text": "pneumonitis, disturbance of the blood-brain barrier, radionecrosis of brain tissue, radiogenic liver damage, mucositis, colitis, oste",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.63671875,
            "end_logit": -7.6640625,
            "text": "pneumonitis, disturbance of the blood-brain barrier, radionecrosis of brain tissue, radiogenic liver damage, mucositis, colitis, osteitis, osteoradi",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.63671875,
            "end_logit": -7.671875,
            "text": "pneumonitis, disturbance of the blood-brain barrier, radionecrosis of brain tissue, radiogenic liver damage, mucositis, colitis, osteitis, oste",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.63671875,
            "end_logit": -7.68359375,
            "text": "pneumonitis, disturbance of the blood-brain barrier, radionecrosis of brain tissue, radiogenic liver",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.0234375,
            "end_logit": -7.23046875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.4609375,
            "end_logit": -7.21484375,
            "text": ", mucositis, colitis, osteitis, osteoradionecrosis and myositis",
            "probability": 0.0
        },
        {
            "start_logit": -7.4609375,
            "end_logit": -7.23046875,
            "text": ", mucositis, colitis, osteitis, osteoradionecrosis and myositis.",
            "probability": 0.0
        },
        {
            "start_logit": -7.484375,
            "end_logit": -7.21484375,
            "text": ", osteitis, osteoradionecrosis and myositis",
            "probability": 0.0
        },
        {
            "start_logit": -7.484375,
            "end_logit": -7.23046875,
            "text": ", osteitis, osteoradionecrosis and myositis.",
            "probability": 0.0
        },
        {
            "start_logit": -7.5,
            "end_logit": -7.21484375,
            "text": ", radiogenic liver damage, mucositis, colitis, osteitis, osteoradionecrosis and myositis",
            "probability": 0.0
        },
        {
            "start_logit": -7.5,
            "end_logit": -7.23046875,
            "text": ", radiogenic liver damage, mucositis, colitis, osteitis, osteoradionecrosis and myositis.",
            "probability": 0.0
        },
        {
            "start_logit": -7.515625,
            "end_logit": -7.21484375,
            "text": "radionecrosis of brain tissue, radiogenic liver damage, mucositis, colitis, osteitis, osteoradionecrosis and myositis",
            "probability": 0.0
        }
    ],
    "5e46f9683f54159529000010_4": [
        {
            "start_logit": 8.515625,
            "end_logit": 8.359375,
            "text": "Radiation-induced fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 8.515625,
            "end_logit": -2.34375,
            "text": "Radiation",
            "probability": 2.2470951080322266e-05
        },
        {
            "start_logit": -2.744140625,
            "end_logit": 8.359375,
            "text": "fibrosis",
            "probability": 1.2934207916259766e-05
        },
        {
            "start_logit": 8.515625,
            "end_logit": -5.5078125,
            "text": "Radiation-induced fibrosis (RIF)",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.515625,
            "end_logit": -6.046875,
            "text": "Radiation-induced fibrosis (RIF",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.515625,
            "end_logit": -6.53125,
            "text": "Radiation-induced fibrosis (RIF) is",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.4140625,
            "end_logit": 8.359375,
            "text": "-induced fibrosis",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.515625,
            "end_logit": -6.703125,
            "text": "Radiation-induced fibrosis (RIF) is one",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.5703125,
            "end_logit": 8.359375,
            "text": "induced fibrosis",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.515625,
            "end_logit": -6.80859375,
            "text": "Radiation-induced fibrosis (",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.1953125,
            "text": "Radiation-induced fibrosis (RIF) is one of the severe long-term",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.4296875,
            "text": "Radiation-induced fibrosis (RIF) is one of the severe long-term side effects",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.44140625,
            "text": "Radiation-induced fibrosis (RIF) is one of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.49609375,
            "text": "Radiation-induced fibrosis (RIF) is one of the severe long-term side effects of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.5,
            "text": "Radiation-induced",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.50390625,
            "text": "Radiation-induced fibrosis (RIF) is one of the severe long-term side effects of radiation therapy (RT)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.51171875,
            "text": "Radiation-induced fibrosis (RIF) is one of the severe long-term side effects of radiation therapy (RT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.515625,
            "text": "Radiation-induced fibrosis (RIF) is one of the severe long-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.744140625,
            "end_logit": -5.5078125,
            "text": "fibrosis (RIF)",
            "probability": 0.0
        },
        {
            "start_logit": -2.744140625,
            "end_logit": -6.046875,
            "text": "fibrosis (RIF",
            "probability": 0.0
        }
    ],
    "5e46f9683f54159529000010_5": [
        {
            "start_logit": 4.65234375,
            "end_logit": 7.41015625,
            "text": "skin reactions",
            "probability": 0.93017578125
        },
        {
            "start_logit": 2.0625,
            "end_logit": 7.41015625,
            "text": "Acute skin reactions",
            "probability": 0.06951904296875
        },
        {
            "start_logit": -4.0546875,
            "end_logit": 7.41015625,
            "text": "reactions",
            "probability": 0.0001544952392578125
        },
        {
            "start_logit": 4.65234375,
            "end_logit": -5.83203125,
            "text": "skin",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 4.65234375,
            "end_logit": -6.65625,
            "text": "skin reactions are",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 4.65234375,
            "end_logit": -7.1484375,
            "text": "skin reactions are one",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 4.65234375,
            "end_logit": -7.390625,
            "text": "skin reactions are one of the",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 4.65234375,
            "end_logit": -7.5,
            "text": "skin reactions are one of the most common side effects",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 4.65234375,
            "end_logit": -7.55078125,
            "text": "skin reactions are one of",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 2.0625,
            "end_logit": -5.83203125,
            "text": "Acute skin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 2.0625,
            "end_logit": -6.65625,
            "text": "Acute skin reactions are",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 2.0625,
            "end_logit": -7.1484375,
            "text": "Acute skin reactions are one",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 2.0625,
            "end_logit": -7.390625,
            "text": "Acute skin reactions are one of the",
            "probability": 0.0
        },
        {
            "start_logit": 2.0625,
            "end_logit": -7.5,
            "text": "Acute skin reactions are one of the most common side effects",
            "probability": 0.0
        },
        {
            "start_logit": 2.0625,
            "end_logit": -7.55078125,
            "text": "Acute skin reactions are one of",
            "probability": 0.0
        },
        {
            "start_logit": -4.0546875,
            "end_logit": -6.65625,
            "text": "reactions are",
            "probability": 0.0
        },
        {
            "start_logit": -4.0546875,
            "end_logit": -7.1484375,
            "text": "reactions are one",
            "probability": 0.0
        },
        {
            "start_logit": -4.0546875,
            "end_logit": -7.390625,
            "text": "reactions are one of the",
            "probability": 0.0
        },
        {
            "start_logit": -4.0546875,
            "end_logit": -7.5,
            "text": "reactions are one of the most common side effects",
            "probability": 0.0
        },
        {
            "start_logit": -4.0546875,
            "end_logit": -7.55078125,
            "text": "reactions are one of",
            "probability": 0.0
        }
    ],
    "56bf487def6e394741000011_1": [
        {
            "start_logit": 9.1640625,
            "end_logit": 9.4375,
            "text": "Aip1",
            "probability": 1.0
        },
        {
            "start_logit": -0.9130859375,
            "end_logit": 9.4375,
            "text": "1",
            "probability": 4.2319297790527344e-05
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -1.330078125,
            "text": "Aip",
            "probability": 2.1278858184814453e-05
        },
        {
            "start_logit": -6.80078125,
            "end_logit": 9.4375,
            "text": ". This approach identifies Aip1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.6015625,
            "text": "Aip1, Ede1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.08984375,
            "end_logit": 9.4375,
            "text": "approach identifies Aip1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.84375,
            "text": "Aip1, Ede1 and Inn1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1640625,
            "end_logit": 9.4375,
            "text": "identifies Aip1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.9609375,
            "text": "Aip1, Ede1 and Inn1 as cytokinetic regulators.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.1171875,
            "text": "Aip1, Ede1 and Inn1 as",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.171875,
            "text": "Aip1, Ede1 and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.21875,
            "text": "Aip1, Ede1 and Inn1 as cytokinetic regulators. Our results suggest that cytokinesis is coordinately controlled by the master cell cycle",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.26171875,
            "text": "Aip1, Ede1 and Inn1 as cytokinetic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.28515625,
            "text": "Aip1, Ed",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.9130859375,
            "end_logit": -6.6015625,
            "text": "1, Ede1",
            "probability": 0.0
        },
        {
            "start_logit": -0.9130859375,
            "end_logit": -6.84375,
            "text": "1, Ede1 and Inn1",
            "probability": 0.0
        },
        {
            "start_logit": -0.9130859375,
            "end_logit": -6.9609375,
            "text": "1, Ede1 and Inn1 as cytokinetic regulators.",
            "probability": 0.0
        },
        {
            "start_logit": -0.9130859375,
            "end_logit": -7.1171875,
            "text": "1, Ede1 and Inn1 as",
            "probability": 0.0
        },
        {
            "start_logit": -0.9130859375,
            "end_logit": -7.171875,
            "text": "1, Ede1 and",
            "probability": 0.0
        },
        {
            "start_logit": -0.9130859375,
            "end_logit": -7.21875,
            "text": "1, Ede1 and Inn1 as cytokinetic regulators. Our results suggest that cytokinesis is coordinately controlled by the master cell cycle",
            "probability": 0.0
        }
    ],
    "5e52900d6d0a277941000041_1": [
        {
            "start_logit": 1.14453125,
            "end_logit": -4.90625,
            "text": "protease-activated receptor1",
            "probability": 0.273193359375
        },
        {
            "start_logit": 1.14453125,
            "end_logit": -5.18359375,
            "text": "protease-activated receptor",
            "probability": 0.20703125
        },
        {
            "start_logit": 1.14453125,
            "end_logit": -5.5625,
            "text": "protease-activated",
            "probability": 0.1417236328125
        },
        {
            "start_logit": 1.14453125,
            "end_logit": -5.59765625,
            "text": "protease-activated receptor1&2 (PAR",
            "probability": 0.1368408203125
        },
        {
            "start_logit": -2.28515625,
            "end_logit": -2.560546875,
            "text": "H349A",
            "probability": 0.09259033203125
        },
        {
            "start_logit": 1.14453125,
            "end_logit": -6.35546875,
            "text": "protease-activated receptor1&",
            "probability": 0.06414794921875
        },
        {
            "start_logit": 1.14453125,
            "end_logit": -6.52734375,
            "text": "protease-activated receptor1&2 (PAR1",
            "probability": 0.053985595703125
        },
        {
            "start_logit": -2.28515625,
            "end_logit": -4.59765625,
            "text": "H349",
            "probability": 0.01204681396484375
        },
        {
            "start_logit": -4.9765625,
            "end_logit": -2.560546875,
            "text": ", H349A",
            "probability": 0.006252288818359375
        },
        {
            "start_logit": -4.9609375,
            "end_logit": -3.546875,
            "text": "Akt",
            "probability": 0.00237274169921875
        },
        {
            "start_logit": -2.28515625,
            "end_logit": -6.2421875,
            "text": "H349A, but not in R352A",
            "probability": 0.0023174285888671875
        },
        {
            "start_logit": -5.171875,
            "end_logit": -3.546875,
            "text": ". This occurs via the association of the pleckstrin homology (PH) domain with Akt",
            "probability": 0.0019216537475585938
        },
        {
            "start_logit": -6.8125,
            "end_logit": -2.560546875,
            "text": "point mutation in PAR2, H349A",
            "probability": 0.0009965896606445312
        },
        {
            "start_logit": -6.8515625,
            "end_logit": -2.560546875,
            "text": "Etk/Bmx. A point mutation in PAR2, H349A",
            "probability": 0.0009589195251464844
        },
        {
            "start_logit": -4.9765625,
            "end_logit": -4.59765625,
            "text": ", H349",
            "probability": 0.0008134841918945312
        },
        {
            "start_logit": -6.171875,
            "end_logit": -3.546875,
            "text": "with Akt",
            "probability": 0.0007071495056152344
        },
        {
            "start_logit": -5.140625,
            "end_logit": -4.83984375,
            "text": ".",
            "probability": 0.0005421638488769531
        },
        {
            "start_logit": -5.171875,
            "end_logit": -4.8671875,
            "text": ".",
            "probability": 0.0005130767822265625
        },
        {
            "start_logit": -6.6953125,
            "end_logit": -3.546875,
            "text": "association of the pleckstrin homology (PH) domain with Akt",
            "probability": 0.0004189014434814453
        },
        {
            "start_logit": -6.7265625,
            "end_logit": -3.546875,
            "text": "pleckstrin homology (PH) domain with Akt",
            "probability": 0.00040602684020996094
        }
    ],
    "5e9208702d3121100d000009_1": [
        {
            "start_logit": 8.921875,
            "end_logit": 5.9375,
            "text": "\u03b1",
            "probability": 0.9970703125
        },
        {
            "start_logit": 8.921875,
            "end_logit": 0.2025146484375,
            "text": "\u03b1 and \u03b2-defensins",
            "probability": 0.003223419189453125
        },
        {
            "start_logit": 8.921875,
            "end_logit": -5.9921875,
            "text": "\u03b1 and \u03b2-defensin",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": 8.921875,
            "end_logit": -6.6640625,
            "text": "\u03b1 and",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": 8.921875,
            "end_logit": -6.7578125,
            "text": "\u03b1 and \u03b2-def",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": -7.34375,
            "end_logit": 5.9375,
            "text": "Human \u03b1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.1875,
            "end_logit": 0.2025146484375,
            "text": "\u03b2-defensins",
            "probability": 0.0
        },
        {
            "start_logit": -7.046875,
            "end_logit": 0.2025146484375,
            "text": "-defensins",
            "probability": 0.0
        },
        {
            "start_logit": -7.32421875,
            "end_logit": 0.2025146484375,
            "text": "defensins",
            "probability": 0.0
        },
        {
            "start_logit": -7.34375,
            "end_logit": 0.2025146484375,
            "text": "Human \u03b1 and \u03b2-defensins",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 0.2025146484375,
            "text": "ensins",
            "probability": 0.0
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 0.2025146484375,
            "text": "and \u03b2-defensins",
            "probability": 0.0
        },
        {
            "start_logit": -3.1875,
            "end_logit": -5.9921875,
            "text": "\u03b2-defensin",
            "probability": 0.0
        },
        {
            "start_logit": -3.1875,
            "end_logit": -6.7578125,
            "text": "\u03b2-def",
            "probability": 0.0
        },
        {
            "start_logit": -7.046875,
            "end_logit": -5.9921875,
            "text": "-defensin",
            "probability": 0.0
        },
        {
            "start_logit": -7.32421875,
            "end_logit": -5.9921875,
            "text": "defensin",
            "probability": 0.0
        },
        {
            "start_logit": -7.34375,
            "end_logit": -5.9921875,
            "text": "Human \u03b1 and \u03b2-defensin",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -5.9921875,
            "text": "ensin",
            "probability": 0.0
        },
        {
            "start_logit": -7.58984375,
            "end_logit": -5.9921875,
            "text": "and \u03b2-defensin",
            "probability": 0.0
        },
        {
            "start_logit": -7.046875,
            "end_logit": -6.7578125,
            "text": "-def",
            "probability": 0.0
        }
    ],
    "5e9208702d3121100d000009_2": [
        {
            "start_logit": 6.77734375,
            "end_logit": 4.55078125,
            "text": "\u03b1- and \u03b2-defensins",
            "probability": 0.9990234375
        },
        {
            "start_logit": 6.77734375,
            "end_logit": -3.509765625,
            "text": "\u03b1",
            "probability": 0.00031495094299316406
        },
        {
            "start_logit": 6.77734375,
            "end_logit": -3.998046875,
            "text": "\u03b1-",
            "probability": 0.0001939535140991211
        },
        {
            "start_logit": -2.541015625,
            "end_logit": 4.55078125,
            "text": "\u03b2-defensins",
            "probability": 8.952617645263672e-05
        },
        {
            "start_logit": 6.77734375,
            "end_logit": -4.921875,
            "text": "\u03b1- and",
            "probability": 7.718801498413086e-05
        },
        {
            "start_logit": 6.77734375,
            "end_logit": -6.23828125,
            "text": "\u03b1- and \u03b2-defensin",
            "probability": 2.0623207092285156e-05
        },
        {
            "start_logit": -4.12109375,
            "end_logit": 4.55078125,
            "text": "antimicrobial peptides that participate in the innate immunity of hosts. Humans constitutively and/or inducibly express \u03b1- and \u03b2-defensins",
            "probability": 1.8477439880371094e-05
        },
        {
            "start_logit": 6.77734375,
            "end_logit": -6.56640625,
            "text": "\u03b1- and \u03b2-def",
            "probability": 1.4841556549072266e-05
        },
        {
            "start_logit": 6.77734375,
            "end_logit": -7.26953125,
            "text": "\u03b1- and \u03b2-defensins, which are known for their antiviral and antibacterial activities.",
            "probability": 7.331371307373047e-06
        },
        {
            "start_logit": 6.77734375,
            "end_logit": -7.2734375,
            "text": "\u03b1- and \u03b2-defensins, which are known for their antiviral and antibacterial activities",
            "probability": 7.271766662597656e-06
        },
        {
            "start_logit": 6.77734375,
            "end_logit": -7.32421875,
            "text": "\u03b1- and \u03b2-defensins, which are known for their antiviral and antibacterial",
            "probability": 6.973743438720703e-06
        },
        {
            "start_logit": 6.77734375,
            "end_logit": -7.46875,
            "text": "\u03b1- and \u03b2-defensins, which are known",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": -5.56640625,
            "end_logit": 4.55078125,
            "text": "s",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": -6.96875,
            "end_logit": 4.55078125,
            "text": "innate immunity of hosts. Humans constitutively and/or inducibly express \u03b1- and \u03b2-defensins",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -7.03125,
            "end_logit": 4.55078125,
            "text": ". Humans constitutively and/or inducibly express \u03b1- and \u03b2-defensins",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 4.55078125,
            "text": "express \u03b1- and \u03b2-defensins",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -7.1875,
            "end_logit": 4.55078125,
            "text": "ensins",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 4.55078125,
            "text": "-defensins",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -7.30078125,
            "end_logit": 4.55078125,
            "text": "are antimicrobial peptides that participate in the innate immunity of hosts. Humans constitutively and/or inducibly express \u03b1- and \u03b2-defensins",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -7.375,
            "end_logit": 4.55078125,
            "text": "defensins",
            "probability": 7.152557373046875e-07
        }
    ],
    "5c658a8f7c78d69471000007_1": [
        {
            "start_logit": 8.125,
            "end_logit": 7.4765625,
            "text": "diarrhea",
            "probability": 1.0
        },
        {
            "start_logit": -6.31640625,
            "end_logit": 7.4765625,
            "text": "elevated bilirubin level, diarrhea",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.125,
            "end_logit": -6.98046875,
            "text": "diarrhea, differentiation syndrome",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.4765625,
            "end_logit": 7.4765625,
            "text": ", diarrhea",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.125,
            "end_logit": -7.46875,
            "text": "diarrhea, differentiation syndrome, decreased potassium and calcium levels etc",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.125,
            "end_logit": -7.484375,
            "text": "diarrhea, differentiation syndrome, decreased potassium and calcium levels etc.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.953125,
            "end_logit": 7.4765625,
            "text": "adverse effects like elevated bilirubin level, diarrhea",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.125,
            "end_logit": -7.609375,
            "text": "diarrhea, differentiation syndrome, decreased potassium and calcium",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.125,
            "end_logit": -7.6328125,
            "text": "diarrhea,",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.125,
            "end_logit": -7.6484375,
            "text": "diarrhea, differentiation syndrome, decreased potassium",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.125,
            "end_logit": -7.65625,
            "text": "diarrhea, differentiation syndrome, decreased potassium and calcium levels",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.17578125,
            "end_logit": 7.4765625,
            "text": "certain adverse effects like elevated bilirubin level, diarrhea",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 7.4765625,
            "text": "like elevated bilirubin level, diarrhea",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.453125,
            "end_logit": 7.4765625,
            "text": "with certain adverse effects like elevated bilirubin level, diarrhea",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5,
            "end_logit": 7.4765625,
            "text": "associated with certain adverse effects like elevated bilirubin level, diarrhea",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 7.4765625,
            "text": "Enasidenib is found to be associated with certain adverse effects like elevated bilirubin level, diarrhea",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.31640625,
            "end_logit": -6.78125,
            "text": "elevated bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": -6.31640625,
            "end_logit": -6.98046875,
            "text": "elevated bilirubin level, diarrhea, differentiation syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -6.4765625,
            "end_logit": -6.98046875,
            "text": ", diarrhea, differentiation syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -6.31640625,
            "end_logit": -7.296875,
            "text": "elevated bilirubin level",
            "probability": 0.0
        }
    ],
    "532b15ecd6d3ac6a34000014_1": [
        {
            "start_logit": 8.09375,
            "end_logit": 7.52734375,
            "text": "bortezomib",
            "probability": 1.0
        },
        {
            "start_logit": 8.09375,
            "end_logit": -7.0,
            "text": "bortezomib with topoisomerase I and II inhibitors",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -7.015625,
            "text": "bortezomib with topoisomerase I",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -7.09765625,
            "text": "bortezomib with topoisomerase I and II inhibitors increased the therapeutic potency in U-CH2 and patient-derived primary cultures.",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -7.265625,
            "text": "bortezomib with topoisomerase I and II inhibitors increased the therapeutic potency in U-CH2",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -7.28515625,
            "text": "bortezomib with",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -7.31640625,
            "text": "bortezomib with topoisomerase I and II",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -7.32421875,
            "text": "bortezomib with topoisomerase",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.7578125,
            "end_logit": 7.52734375,
            "text": "combination treatment of bortezomib",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -7.37109375,
            "text": "bortezomib with topoisomerase I and",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -7.41015625,
            "text": "bortezomib with topoisomerase I and II inhibitors increased",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.9140625,
            "end_logit": 7.52734375,
            "text": "of bortezomib",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -7.5546875,
            "text": "bortezomib with topoisomerase I and II inhibitors increased the therapeutic potency",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -7.57421875,
            "text": "bortezomib with topoisomerase I and II inhibitors increased the therapeutic potency in U-CH2 and patient-derived primary cultures",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -7.6328125,
            "text": "bortezomib with topoisomerase I and II inhibitors increased the therapeutic potency in U-CH2 and patient-derived",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -7.63671875,
            "text": "bortezomib with topoisomerase I and II inhibitors increased the therapeutic potency in U-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -7.640625,
            "text": "bortezomib with topoisomerase I and II inhibitors increased the therapeutic potency in U-CH2 and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -7.66015625,
            "text": "bortezomib with topoisomerase I and II inhibitors increased the therapeutic potency in U-CH2 and patient-derived primary",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -7.66015625,
            "text": "bortezomib with topoisomerase I and II inhibitors increased the",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 7.52734375,
            "text": "The combination treatment of bortezomib",
            "probability": 1.7881393432617188e-07
        }
    ],
    "532b15ecd6d3ac6a34000014_2": [
        {
            "start_logit": 8.1875,
            "end_logit": 7.18359375,
            "text": "Vincristine",
            "probability": 1.0
        },
        {
            "start_logit": 8.1875,
            "end_logit": -3.61328125,
            "text": "Vincristine, doxorubicin",
            "probability": 2.0444393157958984e-05
        },
        {
            "start_logit": 8.1875,
            "end_logit": -6.14453125,
            "text": "Vincristine, doxorubicin, etoposide, cisplatin, and fludarabine",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 8.1875,
            "end_logit": -6.74609375,
            "text": "Vincristine, doxorubicin, etoposide, cisplatin, and fludarabin",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.1875,
            "end_logit": -6.94140625,
            "text": "Vincristine, doxorubicin, etoposide, cisplatin",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.1875,
            "end_logit": -7.08203125,
            "text": "Vincristine, doxorubicin, etoposide, cisplatin, and fludara",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.1875,
            "end_logit": -7.2578125,
            "text": "Vincristine, doxorubicin, etoposide",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.1875,
            "end_logit": -7.484375,
            "text": "Vincristine, doxorubicin, etoposide, cisplatin, and fluda",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -4.38671875,
            "end_logit": -3.61328125,
            "text": "doxorubicin",
            "probability": 0.0
        },
        {
            "start_logit": -6.69140625,
            "end_logit": -3.61328125,
            "text": ", doxorubicin",
            "probability": 0.0
        },
        {
            "start_logit": -4.38671875,
            "end_logit": -6.14453125,
            "text": "doxorubicin, etoposide, cisplatin, and fludarabine",
            "probability": 0.0
        },
        {
            "start_logit": -4.38671875,
            "end_logit": -6.74609375,
            "text": "doxorubicin, etoposide, cisplatin, and fludarabin",
            "probability": 0.0
        },
        {
            "start_logit": -4.38671875,
            "end_logit": -6.94140625,
            "text": "doxorubicin, etoposide, cisplatin",
            "probability": 0.0
        },
        {
            "start_logit": -4.38671875,
            "end_logit": -7.08203125,
            "text": "doxorubicin, etoposide, cisplatin, and fludara",
            "probability": 0.0
        },
        {
            "start_logit": -4.38671875,
            "end_logit": -7.2578125,
            "text": "doxorubicin, etoposide",
            "probability": 0.0
        },
        {
            "start_logit": -4.38671875,
            "end_logit": -7.484375,
            "text": "doxorubicin, etoposide, cisplatin, and fluda",
            "probability": 0.0
        },
        {
            "start_logit": -6.6484375,
            "end_logit": -6.14453125,
            "text": "fludarabine",
            "probability": 0.0
        },
        {
            "start_logit": -6.69140625,
            "end_logit": -6.14453125,
            "text": ", doxorubicin, etoposide, cisplatin, and fludarabine",
            "probability": 0.0
        },
        {
            "start_logit": -6.6484375,
            "end_logit": -6.74609375,
            "text": "fludarabin",
            "probability": 0.0
        },
        {
            "start_logit": -6.69140625,
            "end_logit": -6.74609375,
            "text": ", doxorubicin, etoposide, cisplatin, and fludarabin",
            "probability": 0.0
        }
    ],
    "532b15ecd6d3ac6a34000014_3": [
        {
            "start_logit": 9.234375,
            "end_logit": 8.390625,
            "text": "pingyangmycin",
            "probability": 1.0
        },
        {
            "start_logit": 9.234375,
            "end_logit": -1.322265625,
            "text": "pin",
            "probability": 6.0617923736572266e-05
        },
        {
            "start_logit": 9.234375,
            "end_logit": -3.125,
            "text": "pingyangmycin lipiodol",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": -3.109375,
            "end_logit": 8.390625,
            "text": "cin",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": 9.234375,
            "end_logit": -6.25,
            "text": "pingyangmycin lipiodol emulsion",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -5.82421875,
            "end_logit": 8.390625,
            "text": "gyangmycin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -6.7109375,
            "text": "pingyangmy",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -6.96875,
            "text": "pingyangmycin lip",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.33203125,
            "text": "pingyang",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.375,
            "text": "pingyangmycin lipiod",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.41796875,
            "text": "pingyangmycin lipiodol emulsion for",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.5,
            "text": "pingyangmycin lipiodol emulsion for the treatment of recurrent sacrococc",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.7265625,
            "end_logit": 8.390625,
            "text": "angmycin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0234375,
            "end_logit": 8.390625,
            "text": "with pingyangmycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.19921875,
            "end_logit": 8.390625,
            "text": "mycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 8.390625,
            "text": "Percutaneous intratumoral injection with pingyangmycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 8.390625,
            "text": "injection with pingyangmycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 8.390625,
            "text": "intratumoral injection with pingyangmycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.109375,
            "end_logit": -3.125,
            "text": "cin lipiodol",
            "probability": 0.0
        },
        {
            "start_logit": -7.0234375,
            "end_logit": -1.322265625,
            "text": "with pin",
            "probability": 0.0
        }
    ],
    "532b15ecd6d3ac6a34000014_4": [
        {
            "start_logit": 9.171875,
            "end_logit": 9.1328125,
            "text": "pingyangmycin",
            "probability": 1.0
        },
        {
            "start_logit": 9.171875,
            "end_logit": -1.4775390625,
            "text": "pin",
            "probability": 2.4497509002685547e-05
        },
        {
            "start_logit": -1.75390625,
            "end_logit": 9.1328125,
            "text": "cin",
            "probability": 1.7762184143066406e-05
        },
        {
            "start_logit": 9.171875,
            "end_logit": -5.2109375,
            "text": "pingyangmycin lipiodol",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -5.171875,
            "end_logit": 9.1328125,
            "text": "gyangmycin",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -6.01171875,
            "text": "pingyangmycin lipiodol emulsion",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.46875,
            "end_logit": 9.1328125,
            "text": "with pingyangmycin",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -6.55859375,
            "text": "pingyangmycin lipiodol emulsion under fluoroscopic guidance",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.58203125,
            "end_logit": 9.1328125,
            "text": "angmycin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.76953125,
            "end_logit": 9.1328125,
            "text": "mycin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -6.83984375,
            "text": "pingyangmycin lipiodol emulsion under fluoroscopic guidance is effective and safe and may be considered as a treatment option.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.02734375,
            "text": "pingyangmy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.109375,
            "end_logit": 9.1328125,
            "text": "PIIT with pingyangmycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 9.1328125,
            "text": "that PIIT with pingyangmycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.234375,
            "text": "pingyangmycin lipiodol emulsion under",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.296875,
            "text": "pingyangmycin lipiodol emulsion under fluoroscopic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 9.1328125,
            "text": "IT with pingyangmycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.328125,
            "text": "pingyang",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.4296875,
            "text": "pingyangmycin lipiod",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 9.1328125,
            "text": "Preliminary results showed that PIIT with pingyangmycin",
            "probability": 5.960464477539063e-08
        }
    ],
    "532b15ecd6d3ac6a34000014_5": [
        {
            "start_logit": 9.2421875,
            "end_logit": 8.6484375,
            "text": "pingyangmycin",
            "probability": 1.0
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -1.2939453125,
            "text": "pin",
            "probability": 4.83393669128418e-05
        },
        {
            "start_logit": -2.71875,
            "end_logit": 8.6484375,
            "text": "cin",
            "probability": 6.377696990966797e-06
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -3.533203125,
            "text": "pingyangmycin lipiodol",
            "probability": 5.125999450683594e-06
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.1484375,
            "text": "pingyangmycin lipiodol emulsion",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.8203125,
            "end_logit": 8.6484375,
            "text": "gyangmycin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.6796875,
            "text": "pingyangmy",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.03515625,
            "text": "pingyangmycin lip",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.7109375,
            "end_logit": 8.6484375,
            "text": "angmycin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.3125,
            "text": "pingyang",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.3671875,
            "text": "pingyangmycin lipiod",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.48046875,
            "text": "pingyangmycin lipiodol emulsion for",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.48828125,
            "text": "pingyangmycin lipiodol emulsion for treatment of recurrent sacrococc",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.140625,
            "end_logit": 8.6484375,
            "text": "with pingyangmycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 8.6484375,
            "text": "mycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.33203125,
            "end_logit": 8.6484375,
            "text": "Percutaneous intratumoral injection with pingyangmycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 8.6484375,
            "text": "intratumoral injection with pingyangmycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.71875,
            "end_logit": -3.533203125,
            "text": "cin lipiodol",
            "probability": 0.0
        },
        {
            "start_logit": -7.140625,
            "end_logit": -1.2939453125,
            "text": "with pin",
            "probability": 0.0
        },
        {
            "start_logit": -7.33203125,
            "end_logit": -1.2939453125,
            "text": "Percutaneous intratumoral injection with pin",
            "probability": 0.0
        }
    ],
    "5e80caeb835f4e477700002b_1": [
        {
            "start_logit": 0.677734375,
            "end_logit": 4.2578125,
            "text": "malaria",
            "probability": 0.9853515625
        },
        {
            "start_logit": -3.740234375,
            "end_logit": 4.2578125,
            "text": "Chloroquine (CQ) has been used for decades as the primary chemotherapeutic drug for the treatment of malaria",
            "probability": 0.01183319091796875
        },
        {
            "start_logit": -6.7109375,
            "end_logit": 4.2578125,
            "text": "treatment of malaria",
            "probability": 0.0006079673767089844
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 4.2578125,
            "text": "chemotherapeutic drug for the treatment of malaria",
            "probability": 0.0003790855407714844
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 4.2578125,
            "text": "CQ) has been used for decades as the primary chemotherapeutic drug for the treatment of malaria",
            "probability": 0.0002696514129638672
        },
        {
            "start_logit": -7.578125,
            "end_logit": 4.2578125,
            "text": "of malaria",
            "probability": 0.00025534629821777344
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 4.2578125,
            "text": "as the primary chemotherapeutic drug for the treatment of malaria",
            "probability": 0.00025343894958496094
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 4.2578125,
            "text": "the treatment of malaria",
            "probability": 0.00024175643920898438
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 4.2578125,
            "text": "decades as the primary chemotherapeutic drug for the treatment of malaria",
            "probability": 0.00024175643920898438
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 4.2578125,
            "text": "primary chemotherapeutic drug for the treatment of malaria",
            "probability": 0.00023818016052246094
        },
        {
            "start_logit": 0.677734375,
            "end_logit": -6.66796875,
            "text": "malaria.",
            "probability": 1.7702579498291016e-05
        },
        {
            "start_logit": -3.740234375,
            "end_logit": -3.779296875,
            "text": "Chloroquine",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": -3.740234375,
            "end_logit": -5.31640625,
            "text": "Chloroquine (CQ",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -3.740234375,
            "end_logit": -6.390625,
            "text": "Chloroquine (CQ)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -3.740234375,
            "end_logit": -6.62109375,
            "text": "Chloroquine (CQ) has been used for decades as the primary chemotherapeutic drug",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -3.740234375,
            "end_logit": -6.66796875,
            "text": "Chloroquine (CQ) has been used for decades as the primary chemotherapeutic drug for the treatment of malaria.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -3.740234375,
            "end_logit": -6.96484375,
            "text": "Chloroquine (CQ) has",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -3.740234375,
            "end_logit": -7.11328125,
            "text": "Chloroquine (CQ) has been used for decades as",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.740234375,
            "end_logit": -7.1171875,
            "text": "Chloroquine (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.740234375,
            "end_logit": -7.1171875,
            "text": "Chloroquine (CQ) has been used for",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5e80caeb835f4e477700002b_2": [
        {
            "start_logit": -0.88818359375,
            "end_logit": 4.81640625,
            "text": "malaria",
            "probability": 0.93505859375
        },
        {
            "start_logit": -3.73828125,
            "end_logit": 4.81640625,
            "text": "chloroquine was used to treat the most deadly form of malaria",
            "probability": 0.054107666015625
        },
        {
            "start_logit": -7.04296875,
            "end_logit": 4.81640625,
            "text": "Historically chloroquine was used to treat the most deadly form of malaria",
            "probability": 0.001983642578125
        },
        {
            "start_logit": -7.1640625,
            "end_logit": 4.81640625,
            "text": "most deadly form of malaria",
            "probability": 0.0017633438110351562
        },
        {
            "start_logit": -7.17578125,
            "end_logit": 4.81640625,
            "text": "deadly form of malaria",
            "probability": 0.0017366409301757812
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 4.81640625,
            "text": "treat the most deadly form of malaria",
            "probability": 0.0015077590942382812
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 4.81640625,
            "text": "form of malaria",
            "probability": 0.001373291015625
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 4.81640625,
            "text": "of malaria",
            "probability": 0.0012903213500976562
        },
        {
            "start_logit": -7.515625,
            "end_logit": 4.81640625,
            "text": "to treat the most deadly form of malaria",
            "probability": 0.0012407302856445312
        },
        {
            "start_logit": -0.88818359375,
            "end_logit": -6.125,
            "text": "malaria, caused by the parasite Plasmodium falciparum",
            "probability": 1.6629695892333984e-05
        },
        {
            "start_logit": -0.88818359375,
            "end_logit": -6.73828125,
            "text": "malaria, caused by the parasite Plasmodium falciparum.",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": -0.88818359375,
            "end_logit": -6.9453125,
            "text": "malaria, caused by the parasite Plasmodium",
            "probability": 7.331371307373047e-06
        },
        {
            "start_logit": -3.73828125,
            "end_logit": -4.15625,
            "text": "chloroquine",
            "probability": 6.854534149169922e-06
        },
        {
            "start_logit": -3.73828125,
            "end_logit": -6.125,
            "text": "chloroquine was used to treat the most deadly form of malaria, caused by the parasite Plasmodium falciparum",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -3.73828125,
            "end_logit": -6.73828125,
            "text": "chloroquine was used to treat the most deadly form of malaria, caused by the parasite Plasmodium falciparum.",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -3.73828125,
            "end_logit": -6.78515625,
            "text": "chloroquine was",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -3.73828125,
            "end_logit": -6.9453125,
            "text": "chloroquine was used to treat the most deadly form of malaria, caused by the parasite Plasmodium",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -3.73828125,
            "end_logit": -7.1953125,
            "text": "chloroquine was used to treat the most deadly",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -3.73828125,
            "end_logit": -7.4296875,
            "text": "chloroquine was used",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -3.73828125,
            "end_logit": -7.43359375,
            "text": "chloroquine was used to treat the most deadly form",
            "probability": 2.980232238769531e-07
        }
    ],
    "5e80caeb835f4e477700002b_3": [
        {
            "start_logit": -3.962890625,
            "end_logit": -3.412109375,
            "text": "4-aminoquinolone antimalarial",
            "probability": 0.2403564453125
        },
        {
            "start_logit": -2.697265625,
            "end_logit": -5.25390625,
            "text": "lupus erythematosus",
            "probability": 0.1348876953125
        },
        {
            "start_logit": -4.78125,
            "end_logit": -3.412109375,
            "text": "antimalarial",
            "probability": 0.1058349609375
        },
        {
            "start_logit": -2.697265625,
            "end_logit": -5.90234375,
            "text": "lupus",
            "probability": 0.07049560546875
        },
        {
            "start_logit": -2.697265625,
            "end_logit": -5.9453125,
            "text": "lupus erythematosus (SLE",
            "probability": 0.06781005859375
        },
        {
            "start_logit": -3.962890625,
            "end_logit": -5.140625,
            "text": "4-aminoquinolone",
            "probability": 0.042755126953125
        },
        {
            "start_logit": -3.962890625,
            "end_logit": -5.25390625,
            "text": "4-aminoquinolone antimalarial, is regarded as the oral therapy of choice for cutaneous and systemic lupus erythematosus",
            "probability": 0.03802490234375
        },
        {
            "start_logit": -2.697265625,
            "end_logit": -6.5703125,
            "text": "lupus erythematosus (SLE). It is also licensed for rheumatoid",
            "probability": 0.036285400390625
        },
        {
            "start_logit": -2.697265625,
            "end_logit": -6.6875,
            "text": "lupus erythematosus (SLE). It is also licensed for rheumatoid arthritis (RA).",
            "probability": 0.03228759765625
        },
        {
            "start_logit": -2.697265625,
            "end_logit": -6.69140625,
            "text": "lupus erythematosus (SLE).",
            "probability": 0.032012939453125
        },
        {
            "start_logit": -2.697265625,
            "end_logit": -6.76953125,
            "text": "lupus erythematosus (SLE). It is also licensed for rheumatoid arthritis",
            "probability": 0.0296173095703125
        },
        {
            "start_logit": -2.697265625,
            "end_logit": -6.828125,
            "text": "lupus erythematosus (SLE)",
            "probability": 0.0280303955078125
        },
        {
            "start_logit": -3.962890625,
            "end_logit": -5.90234375,
            "text": "4-aminoquinolone antimalarial, is regarded as the oral therapy of choice for cutaneous and systemic lupus",
            "probability": 0.0198822021484375
        },
        {
            "start_logit": -3.962890625,
            "end_logit": -5.9453125,
            "text": "4-aminoquinolone antimalarial, is regarded as the oral therapy of choice for cutaneous and systemic lupus erythematosus (SLE",
            "probability": 0.019134521484375
        },
        {
            "start_logit": -2.697265625,
            "end_logit": -7.21484375,
            "text": "lupus erythematosus (",
            "probability": 0.0189666748046875
        },
        {
            "start_logit": -2.697265625,
            "end_logit": -7.2890625,
            "text": "lupus erythematosus (SLE). It is also licensed for",
            "probability": 0.0177001953125
        },
        {
            "start_logit": -2.697265625,
            "end_logit": -7.3046875,
            "text": "lupus erythematosus (SLE). It is also",
            "probability": 0.0174102783203125
        },
        {
            "start_logit": -2.697265625,
            "end_logit": -7.3125,
            "text": "lupus erythematosus (SLE). It is also licensed for rheumatoid arthritis (RA",
            "probability": 0.0172882080078125
        },
        {
            "start_logit": -4.78125,
            "end_logit": -5.25390625,
            "text": "antimalarial, is regarded as the oral therapy of choice for cutaneous and systemic lupus erythematosus",
            "probability": 0.016876220703125
        },
        {
            "start_logit": -6.76953125,
            "end_logit": -3.412109375,
            "text": "aminoquinolone antimalarial",
            "probability": 0.01454925537109375
        }
    ],
    "5e80caeb835f4e477700002b_4": [
        {
            "start_logit": -3.2578125,
            "end_logit": -1.5712890625,
            "text": "Chloroquine is a potent inhibitor of SARS coronavirus infection",
            "probability": 0.391845703125
        },
        {
            "start_logit": -3.314453125,
            "end_logit": -1.5712890625,
            "text": "SARS coronavirus infection",
            "probability": 0.369384765625
        },
        {
            "start_logit": -3.2578125,
            "end_logit": -2.517578125,
            "text": "Chloroquine",
            "probability": 0.1522216796875
        },
        {
            "start_logit": -6.37890625,
            "end_logit": -1.5712890625,
            "text": "inhibitor of SARS coronavirus infection",
            "probability": 0.01727294921875
        },
        {
            "start_logit": -6.62890625,
            "end_logit": -1.5712890625,
            "text": "potent inhibitor of SARS coronavirus infection",
            "probability": 0.01340484619140625
        },
        {
            "start_logit": -3.2578125,
            "end_logit": -5.265625,
            "text": "Chloroquine is a potent inhibitor of SARS coronavirus",
            "probability": 0.00972747802734375
        },
        {
            "start_logit": -3.314453125,
            "end_logit": -5.265625,
            "text": "SARS coronavirus",
            "probability": 0.00920867919921875
        },
        {
            "start_logit": -3.2578125,
            "end_logit": -5.6640625,
            "text": "Chloroquine is a potent inhibitor of SARS coronavirus infection and spread",
            "probability": 0.006534576416015625
        },
        {
            "start_logit": -3.314453125,
            "end_logit": -5.6640625,
            "text": "SARS coronavirus infection and spread",
            "probability": 0.00618743896484375
        },
        {
            "start_logit": -7.65234375,
            "end_logit": -1.5712890625,
            "text": "of SARS coronavirus infection",
            "probability": 0.004817962646484375
        },
        {
            "start_logit": -7.6953125,
            "end_logit": -1.5712890625,
            "text": "a potent inhibitor of SARS coronavirus infection",
            "probability": 0.00463104248046875
        },
        {
            "start_logit": -3.2578125,
            "end_logit": -6.50390625,
            "text": "Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.",
            "probability": 0.0028095245361328125
        },
        {
            "start_logit": -3.314453125,
            "end_logit": -6.50390625,
            "text": "SARS coronavirus infection and spread.",
            "probability": 0.0026607513427734375
        },
        {
            "start_logit": -3.2578125,
            "end_logit": -6.76953125,
            "text": "Chloroquine is",
            "probability": 0.002155303955078125
        },
        {
            "start_logit": -3.2578125,
            "end_logit": -7.140625,
            "text": "Chloroquine is a potent inhibitor of SARS coronavirus infection and",
            "probability": 0.0014925003051757812
        },
        {
            "start_logit": -3.314453125,
            "end_logit": -7.140625,
            "text": "SARS coronavirus infection and",
            "probability": 0.0014133453369140625
        },
        {
            "start_logit": -3.2578125,
            "end_logit": -7.28125,
            "text": "Chloroquine is a potent inhibitor of SARS",
            "probability": 0.0012960433959960938
        },
        {
            "start_logit": -3.2578125,
            "end_logit": -7.28515625,
            "text": "Chloroquine is a",
            "probability": 0.0012865066528320312
        },
        {
            "start_logit": -3.314453125,
            "end_logit": -7.28125,
            "text": "SARS",
            "probability": 0.0012273788452148438
        },
        {
            "start_logit": -6.37890625,
            "end_logit": -5.265625,
            "text": "inhibitor of SARS coronavirus",
            "probability": 0.00043082237243652344
        }
    ],
    "5a86c938faa1ab7d2e000034_1": [
        {
            "start_logit": 1.1376953125,
            "end_logit": 7.26953125,
            "text": "SCFTIR1-IAA6",
            "probability": 0.7421875
        },
        {
            "start_logit": -0.22412109375,
            "end_logit": 7.26953125,
            "text": "IAA6",
            "probability": 0.1905517578125
        },
        {
            "start_logit": -1.3671875,
            "end_logit": 7.26953125,
            "text": "auxin sensing by SCFTIR1-IAA6",
            "probability": 0.060699462890625
        },
        {
            "start_logit": -3.8359375,
            "end_logit": 7.26953125,
            "text": "6",
            "probability": 0.005138397216796875
        },
        {
            "start_logit": -6.2578125,
            "end_logit": 7.26953125,
            "text": "-IAA6",
            "probability": 0.00045609474182128906
        },
        {
            "start_logit": -6.6171875,
            "end_logit": 7.26953125,
            "text": "TIR1-IAA6",
            "probability": 0.0003185272216796875
        },
        {
            "start_logit": -7.09375,
            "end_logit": 7.26953125,
            "text": "dissect auxin sensing by SCFTIR1-IAA6",
            "probability": 0.00019693374633789062
        },
        {
            "start_logit": -7.26953125,
            "end_logit": 7.26953125,
            "text": "by SCFTIR1-IAA6",
            "probability": 0.00016582012176513672
        },
        {
            "start_logit": -7.359375,
            "end_logit": 7.26953125,
            "text": "systematically dissect auxin sensing by SCFTIR1-IAA6",
            "probability": 0.00015103816986083984
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 7.26953125,
            "text": "we systematically dissect auxin sensing by SCFTIR1-IAA6",
            "probability": 0.00014984607696533203
        },
        {
            "start_logit": 1.1376953125,
            "end_logit": -6.0703125,
            "text": "SCFTIR1-IAA6 and",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -1.3671875,
            "end_logit": -3.57421875,
            "text": "auxin",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 1.1376953125,
            "end_logit": -6.14453125,
            "text": "SCFTIR1-IAA6 and SCFTIR1-IAA19 co-receptor complexes, and assess IAA6/IAA19 ubiquitylation",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 1.1376953125,
            "end_logit": -6.6171875,
            "text": "SCFTIR1",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 1.1376953125,
            "end_logit": -6.69921875,
            "text": "SCFTIR1-IAA6 and SCFTIR1-IAA19 co-receptor complexes",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 1.1376953125,
            "end_logit": -6.71484375,
            "text": "SCFTIR1-IAA6 and SCFTIR1-IAA19 co-receptor",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 1.1376953125,
            "end_logit": -6.79296875,
            "text": "SCFTIR1-IAA6 and SCFTIR1-IAA19",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 1.1376953125,
            "end_logit": -6.8515625,
            "text": "SCFTIR1-IAA6 and SCFTIR1-IAA19 co-receptor complexes, and assess IAA6",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 1.1376953125,
            "end_logit": -6.90234375,
            "text": "SCFTIR1-IAA6 and SCFTIR1-IAA19 co",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 1.1376953125,
            "end_logit": -6.96484375,
            "text": "SCFTIR1-IAA6 and SCF",
            "probability": 4.76837158203125e-07
        }
    ],
    "5a86c938faa1ab7d2e000034_2": [
        {
            "start_logit": -0.95947265625,
            "end_logit": 4.66015625,
            "text": "BDL",
            "probability": 0.89501953125
        },
        {
            "start_logit": -3.599609375,
            "end_logit": 4.66015625,
            "text": "SHY2/IAA3 and BDL",
            "probability": 0.06378173828125
        },
        {
            "start_logit": -4.60546875,
            "end_logit": 4.66015625,
            "text": "and BDL",
            "probability": 0.023345947265625
        },
        {
            "start_logit": -6.19921875,
            "end_logit": 4.66015625,
            "text": "proteins SHY2/IAA3 and BDL",
            "probability": 0.004734039306640625
        },
        {
            "start_logit": -6.38671875,
            "end_logit": 4.66015625,
            "text": "L",
            "probability": 0.0039215087890625
        },
        {
            "start_logit": -0.95947265625,
            "end_logit": -1.314453125,
            "text": "BDL/IAA12",
            "probability": 0.002269744873046875
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 4.66015625,
            "text": "SCF(TIR1)-mediated ubiquitination of the Aux/IAA proteins SHY2/IAA3 and BDL",
            "probability": 0.0016107559204101562
        },
        {
            "start_logit": -7.33984375,
            "end_logit": 4.66015625,
            "text": "evidence for SCF(TIR1)-mediated ubiquitination of the Aux/IAA proteins SHY2/IAA3 and BDL",
            "probability": 0.0015125274658203125
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 4.66015625,
            "text": "3 and BDL",
            "probability": 0.0014104843139648438
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 4.66015625,
            "text": "Aux/IAA proteins SHY2/IAA3 and BDL",
            "probability": 0.0011692047119140625
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 4.66015625,
            "text": "IAA3 and BDL",
            "probability": 0.0011243820190429688
        },
        {
            "start_logit": -3.599609375,
            "end_logit": -1.314453125,
            "text": "SHY2/IAA3 and BDL/IAA12",
            "probability": 0.00016200542449951172
        },
        {
            "start_logit": -4.60546875,
            "end_logit": -1.314453125,
            "text": "and BDL/IAA12",
            "probability": 5.91278076171875e-05
        },
        {
            "start_logit": -0.95947265625,
            "end_logit": -6.4296875,
            "text": "BDL/IAA",
            "probability": 1.3589859008789062e-05
        },
        {
            "start_logit": -0.95947265625,
            "end_logit": -6.52734375,
            "text": "BDL/",
            "probability": 1.239776611328125e-05
        },
        {
            "start_logit": -6.19921875,
            "end_logit": -1.314453125,
            "text": "proteins SHY2/IAA3 and BDL/IAA12",
            "probability": 1.1980533599853516e-05
        },
        {
            "start_logit": -6.38671875,
            "end_logit": -1.314453125,
            "text": "L/IAA12",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": -3.599609375,
            "end_logit": -4.6328125,
            "text": "SHY2",
            "probability": 5.841255187988281e-06
        },
        {
            "start_logit": -7.27734375,
            "end_logit": -1.314453125,
            "text": "SCF(TIR1)-mediated ubiquitination of the Aux/IAA proteins SHY2/IAA3 and BDL/IAA12",
            "probability": 4.112720489501953e-06
        },
        {
            "start_logit": -7.33984375,
            "end_logit": -1.314453125,
            "text": "evidence for SCF(TIR1)-mediated ubiquitination of the Aux/IAA proteins SHY2/IAA3 and BDL/IAA12",
            "probability": 3.814697265625e-06
        }
    ],
    "5a86c938faa1ab7d2e000034_3": [
        {
            "start_logit": 8.9765625,
            "end_logit": 9.1328125,
            "text": "IAA9",
            "probability": 1.0
        },
        {
            "start_logit": -1.6201171875,
            "end_logit": 9.1328125,
            "text": "9",
            "probability": 2.5093555450439453e-05
        },
        {
            "start_logit": 8.9765625,
            "end_logit": -1.775390625,
            "text": "IAA",
            "probability": 1.8358230590820312e-05
        },
        {
            "start_logit": 8.9765625,
            "end_logit": -6.3203125,
            "text": "IAA9 is",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9765625,
            "end_logit": -6.48828125,
            "text": "IAA9 is involved in fruit development",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9765625,
            "end_logit": -6.83203125,
            "text": "IAA9 is involved in fruit",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9765625,
            "end_logit": -6.8359375,
            "text": "IAA9 is involved in fruit development and leaf morphogenesis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0859375,
            "end_logit": 9.1328125,
            "text": "transcription factor IAA9",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9765625,
            "end_logit": -6.9921875,
            "text": "IAA9 is involved",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9765625,
            "end_logit": -7.26953125,
            "text": "IAA9 is involved in fruit development and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9765625,
            "end_logit": -7.29296875,
            "text": "IAA9 is involved in fruit development and leaf",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 9.1328125,
            "text": "factor IAA9",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 9.1328125,
            "text": "tomato Aux/IAA transcription factor IAA9",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 9.1328125,
            "text": "Aux/IAA transcription factor IAA9",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9765625,
            "end_logit": -7.4140625,
            "text": "IAA9 is involved in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.6201171875,
            "end_logit": -6.3203125,
            "text": "9 is",
            "probability": 0.0
        },
        {
            "start_logit": -1.6201171875,
            "end_logit": -6.48828125,
            "text": "9 is involved in fruit development",
            "probability": 0.0
        },
        {
            "start_logit": -1.6201171875,
            "end_logit": -6.83203125,
            "text": "9 is involved in fruit",
            "probability": 0.0
        },
        {
            "start_logit": -1.6201171875,
            "end_logit": -6.8359375,
            "text": "9 is involved in fruit development and leaf morphogenesis",
            "probability": 0.0
        },
        {
            "start_logit": -1.6201171875,
            "end_logit": -6.9921875,
            "text": "9 is involved",
            "probability": 0.0
        }
    ],
    "5a86c938faa1ab7d2e000034_4": [
        {
            "start_logit": 7.65625,
            "end_logit": 8.96875,
            "text": "IAA9",
            "probability": 1.0
        },
        {
            "start_logit": -1.7900390625,
            "end_logit": 8.96875,
            "text": "9",
            "probability": 7.903575897216797e-05
        },
        {
            "start_logit": 7.65625,
            "end_logit": -3.583984375,
            "text": "IAA",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 8.96875,
            "text": "the downregulation of IAA9",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.171875,
            "end_logit": 8.96875,
            "text": "downregulation of IAA9",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.19921875,
            "end_logit": 8.96875,
            "text": "that the downregulation of IAA9",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 8.96875,
            "text": "of IAA9",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.5,
            "end_logit": 8.96875,
            "text": "here that the downregulation of IAA9",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.65625,
            "end_logit": -7.05078125,
            "text": "IAA9, a tomato (Solanum lycopersicum) gene from",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.65625,
            "end_logit": -7.26953125,
            "text": "IAA9, a tomato (Solanum lycopersicum) gene from a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.65625,
            "end_logit": -7.375,
            "text": "IAA9, a tomato (Solanum lycopersicum) gene from a distinct subfamily of Aux/IAA genes, results in a pleiotropic phenotype",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.65625,
            "end_logit": -7.37890625,
            "text": "IAA9, a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.65625,
            "end_logit": -7.41015625,
            "text": "IAA9, a tomato (Solanum lycopersicum) gene from a distinct subfamily of Aux/IAA genes, results",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.65625,
            "end_logit": -7.4453125,
            "text": "IAA9, a tomato (Solanum lycopersicum) gene from a distinct subfamily of Aux/IAA genes,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.65625,
            "end_logit": -7.4453125,
            "text": "IAA9, a tomato (Solanum lycopersicum) gene from a distinct subfamily of Aux/IAA genes, results in a pleiotropic phenotype, consistent",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.65625,
            "end_logit": -7.453125,
            "text": "IAA9,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.65625,
            "end_logit": -7.46484375,
            "text": "IAA9, a tomato (Solanum lycopersicum) gene from a distinct",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.65625,
            "end_logit": -7.47265625,
            "text": "IAA9, a tomato (Solanum lycopersicum) gene from a distinct subfamily of Aux/IAA genes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.65625,
            "end_logit": -7.5,
            "text": "IAA9, a tomato (Solanum lycopersicum) gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.7900390625,
            "end_logit": -7.05078125,
            "text": "9, a tomato (Solanum lycopersicum) gene from",
            "probability": 0.0
        }
    ],
    "5a86c938faa1ab7d2e000034_5": [
        {
            "start_logit": 9.1328125,
            "end_logit": 9.515625,
            "text": "IAA9",
            "probability": 1.0
        },
        {
            "start_logit": -0.55517578125,
            "end_logit": 9.515625,
            "text": "9",
            "probability": 6.157159805297852e-05
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -1.2548828125,
            "text": "IAA",
            "probability": 2.0802021026611328e-05
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -4.23046875,
            "text": "IAA9 downregulated lines were hypersensitive to auxin, although the only early auxin-responsive gene that was found to be upregulated in the antisense lines was IAA3",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -5.82421875,
            "text": "IAA9 downregulated lines were hypersensitive to auxin, although the only early auxin-responsive gene that was found to be upregulated in the antisense lines was IAA",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.2890625,
            "end_logit": 9.515625,
            "text": "that IAA9",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -6.921875,
            "text": "IAA9 downregulated",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.515625,
            "end_logit": 9.515625,
            "text": "Auxin dose-response assays revealed that IAA9",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.16015625,
            "text": "IAA9 downregulated lines were",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.234375,
            "text": "IAA9 downregulated lines",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.26171875,
            "text": "IAA9 downregulated lines were hypersensitive to auxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.28125,
            "text": "IAA9 downregulated lines were hypersensitive",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.28515625,
            "text": "IAA9 downregulated lines were hypersensitive to auxin, although the only early auxin-responsive gene that was found to be upregulated in the antisense",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.3125,
            "text": "IAA9 downregulated lines were hypersensitive to auxin, although the only early auxin-responsive gene that was found to be upregulated in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.37109375,
            "text": "IAA9 downregulated lines were hypersensitive to auxin, although the only early auxin-responsive gene that was found to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.39453125,
            "text": "IAA9 downregulated lines were hypersensitive to auxin, although the only early auxin-responsive gene that was found to be upregulated in the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.3984375,
            "text": "IAA9 downregulated lines were hypersensitive to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.40625,
            "text": "IAA9 downregulated lines were hypersensitive to auxin, although the only early auxin-responsive",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.55517578125,
            "end_logit": -4.23046875,
            "text": "9 downregulated lines were hypersensitive to auxin, although the only early auxin-responsive gene that was found to be upregulated in the antisense lines was IAA3",
            "probability": 0.0
        },
        {
            "start_logit": -0.55517578125,
            "end_logit": -5.82421875,
            "text": "9 downregulated lines were hypersensitive to auxin, although the only early auxin-responsive gene that was found to be upregulated in the antisense lines was IAA",
            "probability": 0.0
        }
    ],
    "5a86c938faa1ab7d2e000034_6": [
        {
            "start_logit": 8.890625,
            "end_logit": 9.3515625,
            "text": "IAA9",
            "probability": 1.0
        },
        {
            "start_logit": -1.0068359375,
            "end_logit": 9.3515625,
            "text": "9",
            "probability": 4.988908767700195e-05
        },
        {
            "start_logit": 8.890625,
            "end_logit": -1.7802734375,
            "text": "IAA",
            "probability": 1.4483928680419922e-05
        },
        {
            "start_logit": 8.890625,
            "end_logit": -3.072265625,
            "text": "IAA9 antisense genetic background, indicating that IAA9 acts in planta as a transcriptional repressor of auxin signaling",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": 8.890625,
            "end_logit": -5.24609375,
            "text": "IAA9 antisense genetic background, indicating that IAA9",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.890625,
            "end_logit": -5.40234375,
            "text": "IAA9 antisense genetic background, indicating that IAA9 acts in planta as a transcriptional repressor of auxin",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.890625,
            "end_logit": -6.1015625,
            "text": "IAA9 antisense genetic background, indicating that IAA9 acts in planta as a transcriptional repressor of auxin signaling.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.9921875,
            "end_logit": 9.3515625,
            "text": "IAA3 promoter was stimulated in the IAA9",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.890625,
            "end_logit": -6.6484375,
            "text": "IAA9 antisense genetic background, indicating that IAA9 acts",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.890625,
            "end_logit": -6.76171875,
            "text": "IAA9 antisense genetic background, indicating that IAA9 acts in planta as a transcriptional repressor of auxin signaling. While no mutation in any",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.890625,
            "end_logit": -6.87109375,
            "text": "IAA9 antisense genetic background, indicating that IAA9 acts in planta as a transcriptional repressor of auxin signaling. While no mutation in any member",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.890625,
            "end_logit": -6.890625,
            "text": "IAA9 antisense genetic background, indicating that IAA9 acts in planta as a transcriptional repressor of auxin signaling. While no mutation in any member of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.890625,
            "end_logit": -6.9296875,
            "text": "IAA9 antisense",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.0068359375,
            "end_logit": -3.072265625,
            "text": "9 antisense genetic background, indicating that IAA9 acts in planta as a transcriptional repressor of auxin signaling",
            "probability": 0.0
        },
        {
            "start_logit": -1.0068359375,
            "end_logit": -5.24609375,
            "text": "9 antisense genetic background, indicating that IAA9",
            "probability": 0.0
        },
        {
            "start_logit": -1.0068359375,
            "end_logit": -5.40234375,
            "text": "9 antisense genetic background, indicating that IAA9 acts in planta as a transcriptional repressor of auxin",
            "probability": 0.0
        },
        {
            "start_logit": -1.0068359375,
            "end_logit": -6.0234375,
            "text": "9 antisense genetic background, indicating that IAA9 acts in planta as a transcriptional repressor of auxin signaling. While no mutation in any member of subfamily IV",
            "probability": 0.0
        },
        {
            "start_logit": -1.0068359375,
            "end_logit": -6.1015625,
            "text": "9 antisense genetic background, indicating that IAA9 acts in planta as a transcriptional repressor of auxin signaling.",
            "probability": 0.0
        },
        {
            "start_logit": -1.0068359375,
            "end_logit": -6.6484375,
            "text": "9 antisense genetic background, indicating that IAA9 acts",
            "probability": 0.0
        },
        {
            "start_logit": -1.0068359375,
            "end_logit": -6.76171875,
            "text": "9 antisense genetic background, indicating that IAA9 acts in planta as a transcriptional repressor of auxin signaling. While no mutation in any",
            "probability": 0.0
        }
    ],
    "5a86c938faa1ab7d2e000034_7": [
        {
            "start_logit": 8.2734375,
            "end_logit": 9.21875,
            "text": "axr3",
            "probability": 0.9453125
        },
        {
            "start_logit": 8.2734375,
            "end_logit": 6.3671875,
            "text": "axr3 1",
            "probability": 0.05419921875
        },
        {
            "start_logit": -1.1474609375,
            "end_logit": 9.21875,
            "text": "r3",
            "probability": 7.593631744384766e-05
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -2.8359375,
            "text": "ax",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": -1.1474609375,
            "end_logit": 6.3671875,
            "text": "r3 1",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": -6.7265625,
            "end_logit": 9.21875,
            "text": "gain of function axr3",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -6.3125,
            "text": "axr3 1 iaa",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -4.62109375,
            "end_logit": 6.3671875,
            "text": "1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.7265625,
            "end_logit": 6.3671875,
            "text": "gain of function axr3 1",
            "probability": 0.0
        },
        {
            "start_logit": -1.1474609375,
            "end_logit": -6.3125,
            "text": "r3 1 iaa",
            "probability": 0.0
        },
        {
            "start_logit": -4.29296875,
            "end_logit": -3.783203125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -4.34765625,
            "end_logit": -4.15234375,
            "text": "iaa8",
            "probability": 0.0
        },
        {
            "start_logit": -4.34765625,
            "end_logit": -4.45703125,
            "text": "iaa8 1 iaa9 1 or iaa5",
            "probability": 0.0
        },
        {
            "start_logit": -6.7265625,
            "end_logit": -2.8359375,
            "text": "gain of function ax",
            "probability": 0.0
        },
        {
            "start_logit": -6.5703125,
            "end_logit": -3.783203125,
            "text": "axr3 iaa17 protein severely alters the molecular phenotype resulting in developmental defects.",
            "probability": 0.0
        },
        {
            "start_logit": -4.34765625,
            "end_logit": -6.3671875,
            "text": "iaa8 1 iaa9 1 or iaa5 1",
            "probability": 0.0
        },
        {
            "start_logit": -6.6171875,
            "end_logit": -4.15234375,
            "text": "genes such as iaa8",
            "probability": 0.0
        },
        {
            "start_logit": -4.34765625,
            "end_logit": -6.44140625,
            "text": "iaa8 1 iaa9 1 or",
            "probability": 0.0
        },
        {
            "start_logit": -4.62109375,
            "end_logit": -6.3125,
            "text": "1 iaa",
            "probability": 0.0
        },
        {
            "start_logit": -6.5546875,
            "end_logit": -4.45703125,
            "text": "1 or iaa5",
            "probability": 0.0
        }
    ],
    "5a86c938faa1ab7d2e000034_8": [
        {
            "start_logit": 8.28125,
            "end_logit": 7.83203125,
            "text": "osrsp3",
            "probability": 1.0
        },
        {
            "start_logit": -1.8994140625,
            "end_logit": 7.83203125,
            "text": "overexpression of tanac69 1 in wheat roots using osrsp3",
            "probability": 3.820657730102539e-05
        },
        {
            "start_logit": 8.28125,
            "end_logit": -2.9453125,
            "text": "os",
            "probability": 2.092123031616211e-05
        },
        {
            "start_logit": -3.345703125,
            "end_logit": 7.83203125,
            "text": "p3",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": 8.28125,
            "end_logit": -5.5703125,
            "text": "osrsp3 essentially root specific and ospip2 3 root predominant promoters",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 8.28125,
            "end_logit": -5.9375,
            "text": "osrsp3 essentially root specific and ospip2",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -5.70703125,
            "end_logit": 7.83203125,
            "text": "using osrsp3",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -6.19921875,
            "end_logit": 7.83203125,
            "text": "rsp3",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.8125,
            "end_logit": 7.83203125,
            "text": "stage overexpression of tanac69 1 in wheat roots using osrsp3",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 0.85595703125,
            "end_logit": -1.287109375,
            "text": "tanac69 1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 0.85595703125,
            "end_logit": -1.373046875,
            "text": "tanac69",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 0.85595703125,
            "end_logit": -2.1640625,
            "text": "tanac",
            "probability": 0.0
        },
        {
            "start_logit": -1.8994140625,
            "end_logit": -2.9453125,
            "text": "overexpression of tanac69 1 in wheat roots using os",
            "probability": 0.0
        },
        {
            "start_logit": 0.85595703125,
            "end_logit": -5.83984375,
            "text": "tan",
            "probability": 0.0
        },
        {
            "start_logit": -5.796875,
            "end_logit": -1.287109375,
            "text": "drought up regulated triticum aestivum nac69 1 tanac69 1",
            "probability": 0.0
        },
        {
            "start_logit": -5.796875,
            "end_logit": -1.373046875,
            "text": "drought up regulated triticum aestivum nac69 1 tanac69",
            "probability": 0.0
        },
        {
            "start_logit": -1.8994140625,
            "end_logit": -5.5703125,
            "text": "overexpression of tanac69 1 in wheat roots using osrsp3 essentially root specific and ospip2 3 root predominant promoters",
            "probability": 0.0
        },
        {
            "start_logit": -1.8994140625,
            "end_logit": -5.9375,
            "text": "overexpression of tanac69 1 in wheat roots using osrsp3 essentially root specific and ospip2",
            "probability": 0.0
        },
        {
            "start_logit": -6.5859375,
            "end_logit": -1.287109375,
            "text": "role of a drought up regulated triticum aestivum nac69 1 tanac69 1",
            "probability": 0.0
        },
        {
            "start_logit": -6.62109375,
            "end_logit": -1.287109375,
            "text": "1 tanac69 1",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_1": [
        {
            "start_logit": 9.265625,
            "end_logit": 9.2265625,
            "text": "LigandScout",
            "probability": 1.0
        },
        {
            "start_logit": 9.265625,
            "end_logit": -1.2412109375,
            "text": "LigandS",
            "probability": 2.8192996978759766e-05
        },
        {
            "start_logit": -1.587890625,
            "end_logit": 9.2265625,
            "text": "ut",
            "probability": 1.9252300262451172e-05
        },
        {
            "start_logit": -5.90625,
            "end_logit": 9.2265625,
            "text": "cout",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -6.18359375,
            "text": "LigandScout program",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 9.2265625,
            "text": "using the LigandScout",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 9.2265625,
            "text": "Pharmacophore models based on thermolysin binding modes and activity profiles were generated using the LigandScout",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.2265625,
            "text": "the LigandScout",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 9.2265625,
            "text": "activity profiles were generated using the LigandScout",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.703125,
            "end_logit": 9.2265625,
            "text": "thermolysin binding modes and activity profiles were generated using the LigandScout",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.734375,
            "end_logit": 9.2265625,
            "text": "on thermolysin binding modes and activity profiles were generated using the LigandScout",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.587890625,
            "end_logit": -6.18359375,
            "text": "ut program",
            "probability": 0.0
        },
        {
            "start_logit": -7.31640625,
            "end_logit": -1.2412109375,
            "text": "using the LigandS",
            "probability": 0.0
        },
        {
            "start_logit": -7.4765625,
            "end_logit": -1.2412109375,
            "text": "Pharmacophore models based on thermolysin binding modes and activity profiles were generated using the LigandS",
            "probability": 0.0
        },
        {
            "start_logit": -7.640625,
            "end_logit": -1.2412109375,
            "text": "the LigandS",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -1.2412109375,
            "text": "activity profiles were generated using the LigandS",
            "probability": 0.0
        },
        {
            "start_logit": -7.703125,
            "end_logit": -1.2412109375,
            "text": "thermolysin binding modes and activity profiles were generated using the LigandS",
            "probability": 0.0
        },
        {
            "start_logit": -7.734375,
            "end_logit": -1.2412109375,
            "text": "on thermolysin binding modes and activity profiles were generated using the LigandS",
            "probability": 0.0
        },
        {
            "start_logit": -5.90625,
            "end_logit": -6.18359375,
            "text": "cout program",
            "probability": 0.0
        },
        {
            "start_logit": -7.31640625,
            "end_logit": -6.18359375,
            "text": "using the LigandScout program",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_2": [
        {
            "start_logit": 9.328125,
            "end_logit": 9.296875,
            "text": "Discovery Studio",
            "probability": 1.0
        },
        {
            "start_logit": 9.328125,
            "end_logit": -1.0478515625,
            "text": "Discovery",
            "probability": 3.218650817871094e-05
        },
        {
            "start_logit": -1.39453125,
            "end_logit": 9.296875,
            "text": "io",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": -5.1796875,
            "end_logit": 9.296875,
            "text": "Studio",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.4609375,
            "text": "Discovery Studio program",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 9.296875,
            "text": "study, pharmacophore hypotheses based on known inhibitors were generated using common feature pharmacophore generation protocol available in Discovery Studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 9.296875,
            "text": "common feature pharmacophore generation protocol available in Discovery Studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 9.296875,
            "text": "in Discovery Studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 9.296875,
            "text": "pharmacophore hypotheses based on known inhibitors were generated using common feature pharmacophore generation protocol available in Discovery Studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 9.296875,
            "text": "this study, pharmacophore hypotheses based on known inhibitors were generated using common feature pharmacophore generation protocol available in Discovery Studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 9.296875,
            "text": ", pharmacophore hypotheses based on known inhibitors were generated using common feature pharmacophore generation protocol available in Discovery Studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 9.296875,
            "text": "using common feature pharmacophore generation protocol available in Discovery Studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 9.296875,
            "text": "feature pharmacophore generation protocol available in Discovery Studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 9.296875,
            "text": "In this study, pharmacophore hypotheses based on known inhibitors were generated using common feature pharmacophore generation protocol available in Discovery Studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.73828125,
            "end_logit": 9.296875,
            "text": "on known inhibitors were generated using common feature pharmacophore generation protocol available in Discovery Studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.39453125,
            "end_logit": -6.4609375,
            "text": "io program",
            "probability": 0.0
        },
        {
            "start_logit": -7.49609375,
            "end_logit": -1.0478515625,
            "text": "study, pharmacophore hypotheses based on known inhibitors were generated using common feature pharmacophore generation protocol available in Discovery",
            "probability": 0.0
        },
        {
            "start_logit": -7.54296875,
            "end_logit": -1.0478515625,
            "text": "common feature pharmacophore generation protocol available in Discovery",
            "probability": 0.0
        },
        {
            "start_logit": -7.56640625,
            "end_logit": -1.0478515625,
            "text": "in Discovery",
            "probability": 0.0
        },
        {
            "start_logit": -7.5703125,
            "end_logit": -1.0478515625,
            "text": "pharmacophore hypotheses based on known inhibitors were generated using common feature pharmacophore generation protocol available in Discovery",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_3": [
        {
            "start_logit": 5.63671875,
            "end_logit": 9.203125,
            "text": "Catalyst",
            "probability": 1.0
        },
        {
            "start_logit": -6.26953125,
            "end_logit": 9.203125,
            "text": "program Catalyst",
            "probability": 6.735324859619141e-06
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 9.203125,
            "text": "using the program Catalyst",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 9.203125,
            "text": "A pharmacophore-based screening was then carried out using the program Catalyst",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 9.203125,
            "text": "pharmacophore-based screening was then carried out using the program Catalyst",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -7.72265625,
            "end_logit": 9.203125,
            "text": "the program Catalyst",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -7.5234375,
            "end_logit": -7.13671875,
            "text": "A pharmacophore-based screening was",
            "probability": 0.0
        },
        {
            "start_logit": -7.5234375,
            "end_logit": -7.18359375,
            "text": "A pharmacophore-based screening was then carried out",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": -7.13671875,
            "text": "pharmacophore-based screening was",
            "probability": 0.0
        },
        {
            "start_logit": -7.36328125,
            "end_logit": -7.40234375,
            "text": "using the",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": -7.18359375,
            "text": "pharmacophore-based screening was then carried out",
            "probability": 0.0
        },
        {
            "start_logit": -7.5234375,
            "end_logit": -7.32421875,
            "text": "A pharmacophore-based screening was then carried",
            "probability": 0.0
        },
        {
            "start_logit": -7.5234375,
            "end_logit": -7.359375,
            "text": "A",
            "probability": 0.0
        },
        {
            "start_logit": -7.5234375,
            "end_logit": -7.40234375,
            "text": "A pharmacophore-based screening was then carried out using the",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": -7.32421875,
            "text": "pharmacophore-based screening was then carried",
            "probability": 0.0
        },
        {
            "start_logit": -7.5234375,
            "end_logit": -7.41015625,
            "text": "A pharmacophore-based screening",
            "probability": 0.0
        },
        {
            "start_logit": -7.5234375,
            "end_logit": -7.4296875,
            "text": "A pharmacophore-",
            "probability": 0.0
        },
        {
            "start_logit": -7.36328125,
            "end_logit": -7.61328125,
            "text": "using",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": -7.40234375,
            "text": "pharmacophore-based screening was then carried out using the",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": -7.41015625,
            "text": "pharmacophore-based screening",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_4": [
        {
            "start_logit": 9.1953125,
            "end_logit": 9.4609375,
            "text": "PharmaGist",
            "probability": 1.0
        },
        {
            "start_logit": -0.89892578125,
            "end_logit": 9.4609375,
            "text": "ist",
            "probability": 4.1365623474121094e-05
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -1.388671875,
            "text": "Pharm",
            "probability": 1.9371509552001953e-05
        },
        {
            "start_logit": -5.46875,
            "end_logit": 9.4609375,
            "text": "aGist",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.1953125,
            "end_logit": 9.4609375,
            "text": "The PharmaGist",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.2734375,
            "text": "PharmaGist employed algorithm to identify the best pharmacophores by computing multiple flexible alignments between the input ligands.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.453125,
            "text": "PharmaGist employed algorithm to identify the best pharmacophores",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.45703125,
            "text": "PharmaGist employed",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.5,
            "text": "PharmaGist employed algorithm to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.53515625,
            "text": "PharmaGist employed algorithm to identify the best pharmacophores by computing multiple flexible alignments",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.54296875,
            "text": "PharmaGist employed algorithm to identify the best pharmacophores by computing multiple flexible alignments between the input ligands. The multiple alignments are",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.54296875,
            "text": "PharmaGist employed algorithm to identify the best pharmacophores by",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.55859375,
            "text": "PharmaGist employed algorithm to identify the best pharmacophores by computing multiple flexible alignments between",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.89892578125,
            "end_logit": -7.2734375,
            "text": "ist employed algorithm to identify the best pharmacophores by computing multiple flexible alignments between the input ligands.",
            "probability": 0.0
        },
        {
            "start_logit": -0.89892578125,
            "end_logit": -7.453125,
            "text": "ist employed algorithm to identify the best pharmacophores",
            "probability": 0.0
        },
        {
            "start_logit": -0.89892578125,
            "end_logit": -7.45703125,
            "text": "ist employed",
            "probability": 0.0
        },
        {
            "start_logit": -0.89892578125,
            "end_logit": -7.5,
            "text": "ist employed algorithm to",
            "probability": 0.0
        },
        {
            "start_logit": -0.89892578125,
            "end_logit": -7.53515625,
            "text": "ist employed algorithm to identify the best pharmacophores by computing multiple flexible alignments",
            "probability": 0.0
        },
        {
            "start_logit": -0.89892578125,
            "end_logit": -7.54296875,
            "text": "ist employed algorithm to identify the best pharmacophores by computing multiple flexible alignments between the input ligands. The multiple alignments are",
            "probability": 0.0
        },
        {
            "start_logit": -0.89892578125,
            "end_logit": -7.54296875,
            "text": "ist employed algorithm to identify the best pharmacophores by",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_5": [
        {
            "start_logit": 9.296875,
            "end_logit": 9.453125,
            "text": "Discovery studio",
            "probability": 1.0
        },
        {
            "start_logit": -0.97509765625,
            "end_logit": 9.453125,
            "text": "io",
            "probability": 3.451108932495117e-05
        },
        {
            "start_logit": 9.296875,
            "end_logit": -1.123046875,
            "text": "Discovery",
            "probability": 2.5451183319091797e-05
        },
        {
            "start_logit": -5.578125,
            "end_logit": 9.453125,
            "text": "studio",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -6.90625,
            "text": "Discovery studio program package",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -6.9609375,
            "text": "Discovery studio program",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.375,
            "end_logit": 9.453125,
            "text": "using HypoGen algorithm implemented in Discovery studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 9.453125,
            "text": "HypoGen algorithm implemented in Discovery studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 9.453125,
            "text": "Pharmacophore models of c-Met kinase inhibitors have been developed based on 22 diverse compounds by using HypoGen algorithm implemented in Discovery studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.52734375,
            "end_logit": 9.453125,
            "text": "in Discovery studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 9.453125,
            "text": "diverse compounds by using HypoGen algorithm implemented in Discovery studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.42578125,
            "text": "Discovery studio program package.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 9.453125,
            "text": "kinase inhibitors have been developed based on 22 diverse compounds by using HypoGen algorithm implemented in Discovery studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.453125,
            "text": "on 22 diverse compounds by using HypoGen algorithm implemented in Discovery studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.671875,
            "end_logit": 9.453125,
            "text": "of c-Met kinase inhibitors have been developed based on 22 diverse compounds by using HypoGen algorithm implemented in Discovery studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6953125,
            "end_logit": 9.453125,
            "text": "c-Met kinase inhibitors have been developed based on 22 diverse compounds by using HypoGen algorithm implemented in Discovery studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.71875,
            "end_logit": 9.453125,
            "text": "22 diverse compounds by using HypoGen algorithm implemented in Discovery studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.97509765625,
            "end_logit": -6.90625,
            "text": "io program package",
            "probability": 0.0
        },
        {
            "start_logit": -0.97509765625,
            "end_logit": -6.9609375,
            "text": "io program",
            "probability": 0.0
        },
        {
            "start_logit": -0.97509765625,
            "end_logit": -7.42578125,
            "text": "io program package.",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_6": [
        {
            "start_logit": 7.31640625,
            "end_logit": 8.25,
            "text": "Catalyst",
            "probability": 1.0
        },
        {
            "start_logit": -5.55078125,
            "end_logit": 8.25,
            "text": "HypoGen module within Catalyst",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 8.25,
            "text": "with the aid of HypoGen module within Catalyst",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 8.25,
            "text": "pharmacophore models of MMP-1, MMP-8 and MMP-13 inhibitors have been developed with the aid of HypoGen module within Catalyst",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.609375,
            "end_logit": 8.25,
            "text": "the aid of HypoGen module within Catalyst",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.625,
            "end_logit": 8.25,
            "text": ", MMP-8 and MMP-13 inhibitors have been developed with the aid of HypoGen module within Catalyst",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 8.25,
            "text": "feature based pharmacophore models of MMP-1, MMP-8 and MMP-13 inhibitors have been developed with the aid of HypoGen module within Catalyst",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.671875,
            "end_logit": 8.25,
            "text": "MMP-1, MMP-8 and MMP-13 inhibitors have been developed with the aid of HypoGen module within Catalyst",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 8.25,
            "text": "developed with the aid of HypoGen module within Catalyst",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.6953125,
            "end_logit": 8.25,
            "text": "been developed with the aid of HypoGen module within Catalyst",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.703125,
            "end_logit": 8.25,
            "text": "of MMP-1, MMP-8 and MMP-13 inhibitors have been developed with the aid of HypoGen module within Catalyst",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.31640625,
            "end_logit": -6.84765625,
            "text": "Catalyst program",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.31640625,
            "end_logit": -6.89453125,
            "text": "Catalyst program package",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.55078125,
            "end_logit": -4.7421875,
            "text": "HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -7.33984375,
            "end_logit": -4.7421875,
            "text": "chemical feature based pharmacophore models of MMP-1, MMP-8 and MMP-13 inhibitors have been developed with the aid of HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -7.47265625,
            "end_logit": -4.7421875,
            "text": "with the aid of HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -7.51953125,
            "end_logit": -4.7421875,
            "text": "pharmacophore models of MMP-1, MMP-8 and MMP-13 inhibitors have been developed with the aid of HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -7.609375,
            "end_logit": -4.7421875,
            "text": "the aid of HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -7.625,
            "end_logit": -4.7421875,
            "text": ", MMP-8 and MMP-13 inhibitors have been developed with the aid of HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -5.55078125,
            "end_logit": -6.84765625,
            "text": "HypoGen module within Catalyst program",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_7": [
        {
            "start_logit": 9.1328125,
            "end_logit": 8.96875,
            "text": "GASP",
            "probability": 1.0
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -1.4248046875,
            "text": "GAS",
            "probability": 3.069639205932617e-05
        },
        {
            "start_logit": -2.05859375,
            "end_logit": 8.96875,
            "text": "P",
            "probability": 1.3828277587890625e-05
        },
        {
            "start_logit": -4.890625,
            "end_logit": 8.96875,
            "text": "Genetic Algorithm Similarity Program (GASP",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -6.19921875,
            "text": "GASP)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.14453125,
            "text": "GASP) was used to derive a 3D pharmacophore model",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.171875,
            "text": "GASP) was",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.25390625,
            "text": "GASP) was used to derive a 3D pharmacophore",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.26953125,
            "text": "GASP) was used to derive a 3D pharmacophore model which was used in effective alignment of data set.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.375,
            "text": "GASP) was used to derive a 3D pharmacophore model which was used in effective alignment of data set",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.3828125,
            "text": "GASP) was used",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.4140625,
            "text": "GASP) was used to derive a 3D pharmacophore model which was used",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.46484375,
            "text": "GASP) was used to derive a 3D pharmacophore model which",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.46875,
            "text": "GASP) was used to derive a 3D pharmacophore model which was",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.484375,
            "text": "GASP) was used to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 8.96875,
            "text": "(GASP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 8.96875,
            "text": "Similarity Program (GASP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.890625,
            "end_logit": -1.4248046875,
            "text": "Genetic Algorithm Similarity Program (GAS",
            "probability": 0.0
        },
        {
            "start_logit": -2.05859375,
            "end_logit": -6.19921875,
            "text": "P)",
            "probability": 0.0
        },
        {
            "start_logit": -7.34765625,
            "end_logit": -1.4248046875,
            "text": "(GAS",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_8": [
        {
            "start_logit": 9.3046875,
            "end_logit": 9.375,
            "text": "Discovery studio",
            "probability": 1.0
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -1.1142578125,
            "text": "Discovery",
            "probability": 2.753734588623047e-05
        },
        {
            "start_logit": -1.23828125,
            "end_logit": 9.375,
            "text": "io",
            "probability": 2.6285648345947266e-05
        },
        {
            "start_logit": -5.75,
            "end_logit": 9.375,
            "text": "studio",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.80859375,
            "end_logit": 9.375,
            "text": "A training set of 20 compounds with known experimental activity was used to generate pharmacophore hypotheses using 3D QSAR Pharmacophore Generation module available in Discovery studio",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.265625,
            "end_logit": 9.375,
            "text": "in Discovery studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.38671875,
            "end_logit": 9.375,
            "text": "training set of 20 compounds with known experimental activity was used to generate pharmacophore hypotheses using 3D QSAR Pharmacophore Generation module available in Discovery studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.32421875,
            "text": "Discovery studio.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 9.375,
            "text": "20 compounds with known experimental activity was used to generate pharmacophore hypotheses using 3D QSAR Pharmacophore Generation module available in Discovery studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 9.375,
            "text": "3D QSAR Pharmacophore Generation module available in Discovery studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 9.375,
            "text": "of 20 compounds with known experimental activity was used to generate pharmacophore hypotheses using 3D QSAR Pharmacophore Generation module available in Discovery studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 9.375,
            "text": "pharmacophore hypotheses using 3D QSAR Pharmacophore Generation module available in Discovery studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 9.375,
            "text": "using 3D QSAR Pharmacophore Generation module available in Discovery studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.75,
            "end_logit": 9.375,
            "text": "QSAR Pharmacophore Generation module available in Discovery studio",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.80859375,
            "end_logit": -1.1142578125,
            "text": "A training set of 20 compounds with known experimental activity was used to generate pharmacophore hypotheses using 3D QSAR Pharmacophore Generation module available in Discovery",
            "probability": 0.0
        },
        {
            "start_logit": -7.265625,
            "end_logit": -1.1142578125,
            "text": "in Discovery",
            "probability": 0.0
        },
        {
            "start_logit": -7.38671875,
            "end_logit": -1.1142578125,
            "text": "training set of 20 compounds with known experimental activity was used to generate pharmacophore hypotheses using 3D QSAR Pharmacophore Generation module available in Discovery",
            "probability": 0.0
        },
        {
            "start_logit": -1.23828125,
            "end_logit": -7.32421875,
            "text": "io.",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": -1.1142578125,
            "text": "20 compounds with known experimental activity was used to generate pharmacophore hypotheses using 3D QSAR Pharmacophore Generation module available in Discovery",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": -1.1142578125,
            "text": "3D QSAR Pharmacophore Generation module available in Discovery",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_9": [
        {
            "start_logit": 1.6962890625,
            "end_logit": 9.2109375,
            "text": "CATALYST HypoRefine",
            "probability": 0.6572265625
        },
        {
            "start_logit": 0.9658203125,
            "end_logit": 9.2109375,
            "text": "HypoRefine",
            "probability": 0.31787109375
        },
        {
            "start_logit": -1.6298828125,
            "end_logit": 9.2109375,
            "text": "ine",
            "probability": 0.0236663818359375
        },
        {
            "start_logit": -5.6796875,
            "end_logit": 9.2109375,
            "text": "Refine",
            "probability": 0.00041174888610839844
        },
        {
            "start_logit": -6.97265625,
            "end_logit": 9.2109375,
            "text": "using CATALYST HypoRefine",
            "probability": 0.00011259317398071289
        },
        {
            "start_logit": -7.25,
            "end_logit": 9.2109375,
            "text": "CCR3 antagonists, using CATALYST HypoRefine",
            "probability": 8.565187454223633e-05
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 9.2109375,
            "text": "a training data set of 22 CCR3 antagonists, using CATALYST HypoRefine",
            "probability": 7.158517837524414e-05
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 9.2109375,
            "text": ", on a training data set of 22 CCR3 antagonists, using CATALYST HypoRefine",
            "probability": 6.937980651855469e-05
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 9.2109375,
            "text": "on a training data set of 22 CCR3 antagonists, using CATALYST HypoRefine",
            "probability": 6.937980651855469e-05
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 9.2109375,
            "text": "Pharmacophore model was developed for the first time, on a training data set of 22 CCR3 antagonists, using CATALYST HypoRefine",
            "probability": 6.121397018432617e-05
        },
        {
            "start_logit": -7.625,
            "end_logit": 9.2109375,
            "text": "training data set of 22 CCR3 antagonists, using CATALYST HypoRefine",
            "probability": 5.888938903808594e-05
        },
        {
            "start_logit": -7.734375,
            "end_logit": 9.2109375,
            "text": "first time, on a training data set of 22 CCR3 antagonists, using CATALYST HypoRefine",
            "probability": 5.27501106262207e-05
        },
        {
            "start_logit": -7.7421875,
            "end_logit": 9.2109375,
            "text": ", using CATALYST HypoRefine",
            "probability": 5.239248275756836e-05
        },
        {
            "start_logit": 1.6962890625,
            "end_logit": -4.7734375,
            "text": "CATALYST HypoRefine program",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 0.9658203125,
            "end_logit": -4.7734375,
            "text": "HypoRefine program",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 1.6962890625,
            "end_logit": -6.36328125,
            "text": "CATALYST",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 1.6962890625,
            "end_logit": -7.1953125,
            "text": "CATALYST HypoRefine program.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 0.9658203125,
            "end_logit": -7.1953125,
            "text": "HypoRefine program.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.6298828125,
            "end_logit": -4.7734375,
            "text": "ine program",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.6298828125,
            "end_logit": -7.1953125,
            "text": "ine program.",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_10": [
        {
            "start_logit": 7.265625,
            "end_logit": 8.3203125,
            "text": "catalyst",
            "probability": 1.0
        },
        {
            "start_logit": 7.265625,
            "end_logit": -5.96484375,
            "text": "catalyst program",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 8.3203125,
            "text": "using catalyst",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 8.3203125,
            "text": "with HCV NS3 protease hypothesis using catalyst",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.53125,
            "end_logit": 8.3203125,
            "text": "designed molecules (10a-g), with HCV NS3 protease hypothesis using catalyst",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.59375,
            "end_logit": 8.3203125,
            "text": "10a-g), with HCV NS3 protease hypothesis using catalyst",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 8.3203125,
            "text": "hypothesis using catalyst",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.609375,
            "end_logit": 8.3203125,
            "text": "3D-pharmacophore model of the designed molecules (10a-g), with HCV NS3 protease hypothesis using catalyst",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 8.3203125,
            "text": ", including fitting to a 3D-pharmacophore model of the designed molecules (10a-g), with HCV NS3 protease hypothesis using catalyst",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 8.3203125,
            "text": "fitting to a 3D-pharmacophore model of the designed molecules (10a-g), with HCV NS3 protease hypothesis using catalyst",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.625,
            "end_logit": 8.3203125,
            "text": ", with HCV NS3 protease hypothesis using catalyst",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 8.3203125,
            "text": "-pharmacophore model of the designed molecules (10a-g), with HCV NS3 protease hypothesis using catalyst",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 8.3203125,
            "text": "HCV NS3 protease hypothesis using catalyst",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.6484375,
            "end_logit": 8.3203125,
            "text": "to a 3D-pharmacophore model of the designed molecules (10a-g), with HCV NS3 protease hypothesis using catalyst",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.265625,
            "end_logit": -7.38671875,
            "text": "catalyst program was fulfilled.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.265625,
            "end_logit": -7.55859375,
            "text": "catalyst program was",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.265625,
            "end_logit": -7.59765625,
            "text": "catalyst program was fulfilled",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4296875,
            "end_logit": -5.96484375,
            "text": "using catalyst program",
            "probability": 0.0
        },
        {
            "start_logit": -7.49609375,
            "end_logit": -5.96484375,
            "text": "with HCV NS3 protease hypothesis using catalyst program",
            "probability": 0.0
        },
        {
            "start_logit": -7.53125,
            "end_logit": -5.96484375,
            "text": "designed molecules (10a-g), with HCV NS3 protease hypothesis using catalyst program",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_11": [
        {
            "start_logit": 7.56640625,
            "end_logit": 7.98828125,
            "text": "Catalyst",
            "probability": 1.0
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -2.27734375,
            "text": "Catalyst/HypoGen",
            "probability": 3.4809112548828125e-05
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -6.07421875,
            "text": "Catalyst/HypoGen program",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.9140625,
            "end_logit": 7.98828125,
            "text": "using Catalyst",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 7.98828125,
            "text": "pharmacophore model (Hypo1) with a well prediction capacity for CysLT(1) antagonists was developed using Catalyst",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 7.98828125,
            "text": "CysLT(1) antagonists was developed using Catalyst",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 7.98828125,
            "text": "Hypo1) with a well prediction capacity for CysLT(1) antagonists was developed using Catalyst",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -7.2421875,
            "text": "Catalyst/HypoGen program.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 7.98828125,
            "text": "for CysLT(1) antagonists was developed using Catalyst",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 7.98828125,
            "text": "well prediction capacity for CysLT(1) antagonists was developed using Catalyst",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 7.98828125,
            "text": "was developed using Catalyst",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.71875,
            "end_logit": 7.98828125,
            "text": "developed using Catalyst",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -7.41015625,
            "text": "Catalyst/",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -4.78125,
            "end_logit": -2.27734375,
            "text": "HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -6.9140625,
            "end_logit": -2.27734375,
            "text": "using Catalyst/HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -7.4453125,
            "end_logit": -2.27734375,
            "text": "pharmacophore model (Hypo1) with a well prediction capacity for CysLT(1) antagonists was developed using Catalyst/HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -7.53515625,
            "end_logit": -2.27734375,
            "text": "CysLT(1) antagonists was developed using Catalyst/HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": -2.27734375,
            "text": "Hypo1) with a well prediction capacity for CysLT(1) antagonists was developed using Catalyst/HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -7.6328125,
            "end_logit": -2.27734375,
            "text": "/HypoGen",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -2.27734375,
            "text": "for CysLT(1) antagonists was developed using Catalyst/HypoGen",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_12": [
        {
            "start_logit": 7.17578125,
            "end_logit": 5.6171875,
            "text": "Catalyst/HypoGen",
            "probability": 0.63330078125
        },
        {
            "start_logit": 7.17578125,
            "end_logit": 5.0703125,
            "text": "Catalyst",
            "probability": 0.366455078125
        },
        {
            "start_logit": -2.55859375,
            "end_logit": 5.6171875,
            "text": "HypoGen",
            "probability": 3.74913215637207e-05
        },
        {
            "start_logit": 7.17578125,
            "end_logit": -6.82421875,
            "text": "Catalyst/HypoGen program",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": -5.71484375,
            "end_logit": 5.6171875,
            "text": "en",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": -6.77734375,
            "end_logit": 5.6171875,
            "text": "/HypoGen",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.25,
            "end_logit": 5.6171875,
            "text": "by the Catalyst/HypoGen",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 5.6171875,
            "text": "the Catalyst/HypoGen",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 5.6171875,
            "text": "Three pharmacophore models of opioid agonists were generated by the Catalyst/HypoGen",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 5.6171875,
            "text": "pharmacophore models of opioid agonists were generated by the Catalyst/HypoGen",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.25,
            "end_logit": 5.0703125,
            "text": "by the Catalyst",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 5.0703125,
            "text": "the Catalyst",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 5.0703125,
            "text": "Three pharmacophore models of opioid agonists were generated by the Catalyst",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 5.0703125,
            "text": "pharmacophore models of opioid agonists were generated by the Catalyst",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -2.55859375,
            "end_logit": -6.82421875,
            "text": "HypoGen program",
            "probability": 0.0
        },
        {
            "start_logit": -5.71484375,
            "end_logit": -6.82421875,
            "text": "en program",
            "probability": 0.0
        },
        {
            "start_logit": -6.77734375,
            "end_logit": -6.82421875,
            "text": "/HypoGen program",
            "probability": 0.0
        },
        {
            "start_logit": -7.25,
            "end_logit": -6.82421875,
            "text": "by the Catalyst/HypoGen program",
            "probability": 0.0
        },
        {
            "start_logit": -7.45703125,
            "end_logit": -6.82421875,
            "text": "the Catalyst/HypoGen program",
            "probability": 0.0
        },
        {
            "start_logit": -7.61328125,
            "end_logit": -6.82421875,
            "text": "Three pharmacophore models of opioid agonists were generated by the Catalyst/HypoGen program",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_13": [
        {
            "start_logit": 6.5625,
            "end_logit": 6.7109375,
            "text": "MOE-package",
            "probability": 1.0
        },
        {
            "start_logit": 6.5625,
            "end_logit": -3.26953125,
            "text": "MOE-",
            "probability": 4.6133995056152344e-05
        },
        {
            "start_logit": 6.5625,
            "end_logit": -3.576171875,
            "text": "MOE",
            "probability": 3.3974647521972656e-05
        },
        {
            "start_logit": 6.5625,
            "end_logit": -4.6015625,
            "text": "MO",
            "probability": 1.2218952178955078e-05
        },
        {
            "start_logit": -4.9453125,
            "end_logit": 6.7109375,
            "text": "package",
            "probability": 1.0073184967041016e-05
        },
        {
            "start_logit": -5.0390625,
            "end_logit": 6.7109375,
            "text": "tool Pharmacophore Elucidation (MOE-package",
            "probability": 9.179115295410156e-06
        },
        {
            "start_logit": -6.55859375,
            "end_logit": 6.7109375,
            "text": "with the tool Pharmacophore Elucidation (MOE-package",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -7.0546875,
            "end_logit": 6.7109375,
            "text": "(MOE-package",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -7.0625,
            "end_logit": 6.7109375,
            "text": "superposition of the ligands was performed with the tool Pharmacophore Elucidation (MOE-package",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 6.7109375,
            "text": "Pharmacophore Elucidation (MOE-package",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 6.7109375,
            "text": "Elucidation (MOE-package",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 6.7109375,
            "text": "The superposition of the ligands was performed with the tool Pharmacophore Elucidation (MOE-package",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 6.7109375,
            "text": "the tool Pharmacophore Elucidation (MOE-package",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 6.7109375,
            "text": "ligands was performed with the tool Pharmacophore Elucidation (MOE-package",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 6.7109375,
            "text": "the ligands was performed with the tool Pharmacophore Elucidation (MOE-package",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.671875,
            "end_logit": 6.7109375,
            "text": "ophore Elucidation (MOE-package",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -5.0390625,
            "end_logit": -3.26953125,
            "text": "tool Pharmacophore Elucidation (MOE-",
            "probability": 0.0
        },
        {
            "start_logit": -5.0390625,
            "end_logit": -3.576171875,
            "text": "tool Pharmacophore Elucidation (MOE",
            "probability": 0.0
        },
        {
            "start_logit": -5.0390625,
            "end_logit": -4.6015625,
            "text": "tool Pharmacophore Elucidation (MO",
            "probability": 0.0
        },
        {
            "start_logit": -6.55859375,
            "end_logit": -3.26953125,
            "text": "with the tool Pharmacophore Elucidation (MOE-",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_14": [
        {
            "start_logit": 5.0625,
            "end_logit": 8.4609375,
            "text": "HipHop",
            "probability": 0.994140625
        },
        {
            "start_logit": -0.18798828125,
            "end_logit": 8.4609375,
            "text": "Catalyst/HipHop",
            "probability": 0.005218505859375
        },
        {
            "start_logit": -2.990234375,
            "end_logit": 8.4609375,
            "text": "p",
            "probability": 0.00031566619873046875
        },
        {
            "start_logit": -5.796875,
            "end_logit": 8.4609375,
            "text": "program Catalyst/HipHop",
            "probability": 1.913309097290039e-05
        },
        {
            "start_logit": -6.7421875,
            "end_logit": 8.4609375,
            "text": "Hop",
            "probability": 7.3909759521484375e-06
        },
        {
            "start_logit": -7.1171875,
            "end_logit": 8.4609375,
            "text": "using the program Catalyst/HipHop",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": -7.390625,
            "end_logit": 8.4609375,
            "text": "/HipHop",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 8.4609375,
            "text": "on highly selective AT1 and ET(A) antagonists using the program Catalyst/HipHop",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": -7.69921875,
            "end_logit": 8.4609375,
            "text": "highly selective AT1 and ET(A) antagonists using the program Catalyst/HipHop",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 8.4609375,
            "text": "for AT1 and ET(A) receptors based on highly selective AT1 and ET(A) antagonists using the program Catalyst/HipHop",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": 5.0625,
            "end_logit": -5.97265625,
            "text": "Hip",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -0.18798828125,
            "end_logit": -1.5986328125,
            "text": "Catalyst",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 5.0625,
            "end_logit": -7.43359375,
            "text": "HipHo",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -0.18798828125,
            "end_logit": -5.97265625,
            "text": "Catalyst/Hip",
            "probability": 0.0
        },
        {
            "start_logit": -5.796875,
            "end_logit": -1.5986328125,
            "text": "program Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -0.18798828125,
            "end_logit": -7.27734375,
            "text": "Catalyst/",
            "probability": 0.0
        },
        {
            "start_logit": -0.18798828125,
            "end_logit": -7.43359375,
            "text": "Catalyst/HipHo",
            "probability": 0.0
        },
        {
            "start_logit": -7.1171875,
            "end_logit": -1.5986328125,
            "text": "using the program Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -7.52734375,
            "end_logit": -1.5986328125,
            "text": "pharmacophore models were generated for AT1 and ET(A) receptors based on highly selective AT1 and ET(A) antagonists using the program Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -7.64453125,
            "end_logit": -1.5986328125,
            "text": "on highly selective AT1 and ET(A) antagonists using the program Catalyst",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_15": [
        {
            "start_logit": 7.36328125,
            "end_logit": 8.234375,
            "text": "Catalyst",
            "probability": 1.0
        },
        {
            "start_logit": -6.1796875,
            "end_logit": 8.234375,
            "text": "HipHop and HypoGen modules within Catalyst",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -7.28125,
            "end_logit": 8.234375,
            "text": "study, chemical feature based pharmacophore models of inhibitors of 5-LOX have been developed with the aid of HipHop and HypoGen modules within Catalyst",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 8.234375,
            "text": "with the aid of HipHop and HypoGen modules within Catalyst",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 8.234375,
            "text": "chemical feature based pharmacophore models of inhibitors of 5-LOX have been developed with the aid of HipHop and HypoGen modules within Catalyst",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 8.234375,
            "text": "Hop and HypoGen modules within Catalyst",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.515625,
            "end_logit": 8.234375,
            "text": ", chemical feature based pharmacophore models of inhibitors of 5-LOX have been developed with the aid of HipHop and HypoGen modules within Catalyst",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 8.234375,
            "text": "HypoGen modules within Catalyst",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 8.234375,
            "text": "pharmacophore models of inhibitors of 5-LOX have been developed with the aid of HipHop and HypoGen modules within Catalyst",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 8.234375,
            "text": "the aid of HipHop and HypoGen modules within Catalyst",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 8.234375,
            "text": "inhibitors of 5-LOX have been developed with the aid of HipHop and HypoGen modules within Catalyst",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 8.234375,
            "text": "feature based pharmacophore models of inhibitors of 5-LOX have been developed with the aid of HipHop and HypoGen modules within Catalyst",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.36328125,
            "end_logit": -6.984375,
            "text": "Catalyst program",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.36328125,
            "end_logit": -7.06640625,
            "text": "Catalyst program package",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.1796875,
            "end_logit": -5.1640625,
            "text": "HipHop",
            "probability": 0.0
        },
        {
            "start_logit": -7.28125,
            "end_logit": -5.1640625,
            "text": "study, chemical feature based pharmacophore models of inhibitors of 5-LOX have been developed with the aid of HipHop",
            "probability": 0.0
        },
        {
            "start_logit": -7.37109375,
            "end_logit": -5.1640625,
            "text": "with the aid of HipHop",
            "probability": 0.0
        },
        {
            "start_logit": -7.37109375,
            "end_logit": -5.1640625,
            "text": "chemical feature based pharmacophore models of inhibitors of 5-LOX have been developed with the aid of HipHop",
            "probability": 0.0
        },
        {
            "start_logit": -7.5078125,
            "end_logit": -5.1640625,
            "text": "this study, chemical feature based pharmacophore models of inhibitors of 5-LOX have been developed with the aid of HipHop",
            "probability": 0.0
        },
        {
            "start_logit": -7.5078125,
            "end_logit": -5.1640625,
            "text": "Hop",
            "probability": 0.0
        }
    ],
    "532c0d7fd6d3ac6a3400001c_16": [
        {
            "start_logit": 8.9453125,
            "end_logit": 9.0859375,
            "text": "HypoGen",
            "probability": 1.0
        },
        {
            "start_logit": -1.859375,
            "end_logit": 9.0859375,
            "text": "en",
            "probability": 2.0325183868408203e-05
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -1.94921875,
            "text": "HypoG",
            "probability": 1.621246337890625e-05
        },
        {
            "start_logit": -3.205078125,
            "end_logit": 9.0859375,
            "text": "Catalyst/HypoGen",
            "probability": 5.304813385009766e-06
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -6.3359375,
            "text": "HypoGen program",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.83984375,
            "end_logit": 9.0859375,
            "text": "A data set consisting of 24 inhibitors was selected on the basis of the information content of the structures and activity data as required by the Catalyst/HypoGen",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -7.09375,
            "text": "HypoGen program.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 9.0859375,
            "text": "by the Catalyst/HypoGen",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 9.0859375,
            "text": "/HypoGen",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 9.0859375,
            "text": "of 24 inhibitors was selected on the basis of the information content of the structures and activity data as required by the Catalyst/HypoGen",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 9.0859375,
            "text": "of the information content of the structures and activity data as required by the Catalyst/HypoGen",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 9.0859375,
            "text": "basis of the information content of the structures and activity data as required by the Catalyst/HypoGen",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 9.0859375,
            "text": "24 inhibitors was selected on the basis of the information content of the structures and activity data as required by the Catalyst/HypoGen",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.67578125,
            "end_logit": 9.0859375,
            "text": "data set consisting of 24 inhibitors was selected on the basis of the information content of the structures and activity data as required by the Catalyst/HypoGen",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 9.0859375,
            "text": "the Catalyst/HypoGen",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.205078125,
            "end_logit": -1.046875,
            "text": "Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -3.205078125,
            "end_logit": -1.94921875,
            "text": "Catalyst/HypoG",
            "probability": 0.0
        },
        {
            "start_logit": -6.83984375,
            "end_logit": -1.046875,
            "text": "A data set consisting of 24 inhibitors was selected on the basis of the information content of the structures and activity data as required by the Catalyst",
            "probability": 0.0
        },
        {
            "start_logit": -1.859375,
            "end_logit": -6.3359375,
            "text": "en program",
            "probability": 0.0
        },
        {
            "start_logit": -7.4453125,
            "end_logit": -1.046875,
            "text": "by the Catalyst",
            "probability": 0.0
        }
    ],
    "58962ed178275d0c4a000006_1": [
        {
            "start_logit": 9.1953125,
            "end_logit": 9.4453125,
            "text": "sacubitril",
            "probability": 1.0
        },
        {
            "start_logit": -1.01953125,
            "end_logit": 9.4453125,
            "text": "il",
            "probability": 3.647804260253906e-05
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -1.3984375,
            "text": "sac",
            "probability": 1.9550323486328125e-05
        },
        {
            "start_logit": -5.4453125,
            "end_logit": 9.4453125,
            "text": "ubitril",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.4375,
            "end_logit": 9.4453125,
            "text": "itril",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.2734375,
            "end_logit": 9.4453125,
            "text": "with sacubitril",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.43359375,
            "end_logit": 9.4453125,
            "text": "cardiovascular outcomes with sacubitril",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.23828125,
            "text": "sacubitril/valsartan (Entresto\u00ae, Novartis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.25,
            "text": "sacubitril/valsartan",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.546875,
            "end_logit": 9.4453125,
            "text": "improved cardiovascular outcomes with sacubitril",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 9.4453125,
            "text": "large outcome trial in heart failure and reduced ejection fraction (HFrEF), has recently shown improved cardiovascular outcomes with sacubitril",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 9.4453125,
            "text": "outcome trial in heart failure and reduced ejection fraction (HFrEF), has recently shown improved cardiovascular outcomes with sacubitril",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.390625,
            "text": "sacubitril/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.3984375,
            "text": "sacubitril/valsartan (Entresto\u00ae, Novartis), still commonly referred to as LCZ696",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.44921875,
            "text": "sacubitril/valsartan (Entresto\u00ae, Novartis), still commonly referred to as LCZ69",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.45703125,
            "text": "sacubitril/vals",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.484375,
            "text": "sacubitr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.5078125,
            "text": "sacubitril/valsartan (Entresto\u00ae, Novartis)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.578125,
            "text": "sacubitril/valsartan (Entresto\u00ae, Novart",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.609375,
            "text": "sacubitril/valsartan (Entresto\u00ae",
            "probability": 5.960464477539063e-08
        }
    ],
    "58962ed178275d0c4a000006_2": [
        {
            "start_logit": 9.3203125,
            "end_logit": 9.390625,
            "text": "sacubitril",
            "probability": 1.0
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -1.060546875,
            "text": "sac",
            "probability": 2.86102294921875e-05
        },
        {
            "start_logit": -1.1845703125,
            "end_logit": 9.390625,
            "text": "il",
            "probability": 2.7120113372802734e-05
        },
        {
            "start_logit": -5.1953125,
            "end_logit": 9.390625,
            "text": "ubitril",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.37890625,
            "end_logit": 9.390625,
            "text": "itril",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 9.390625,
            "text": "article reviews the background, current knowledge and data supporting the use of sacubitril",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.3359375,
            "text": "sacubitril/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.35546875,
            "text": "sacubitril/valsartan",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.421875,
            "text": "sacubitr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 9.390625,
            "text": "background, current knowledge and data supporting the use of sacubitril",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 9.390625,
            "text": "current knowledge and data supporting the use of sacubitril",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.578125,
            "end_logit": 9.390625,
            "text": "reviews the background, current knowledge and data supporting the use of sacubitril",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.51953125,
            "text": "sacubitril/vals",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 9.390625,
            "text": "of sacubitril",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 9.390625,
            "text": "This article reviews the background, current knowledge and data supporting the use of sacubitril",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 9.390625,
            "text": "the background, current knowledge and data supporting the use of sacubitril",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.5703125,
            "text": "sacubitril/valsartan (Entresto(\u00ae) )",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6484375,
            "end_logit": 9.390625,
            "text": "knowledge and data supporting the use of sacubitril",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.5859375,
            "text": "sacubitril/valsartan (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.59765625,
            "text": "sacubitril/valsartan (Entresto(\u00ae) ), the newly FDA-approved",
            "probability": 5.960464477539063e-08
        }
    ],
    "58962ed178275d0c4a000006_3": [
        {
            "start_logit": 9.2578125,
            "end_logit": 9.4140625,
            "text": "Sacubitril",
            "probability": 1.0
        },
        {
            "start_logit": -1.10546875,
            "end_logit": 9.4140625,
            "text": "il",
            "probability": 3.170967102050781e-05
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -1.240234375,
            "text": "Sac",
            "probability": 2.3543834686279297e-05
        },
        {
            "start_logit": -5.5703125,
            "end_logit": 9.4140625,
            "text": "ubitril",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.74609375,
            "end_logit": 9.4140625,
            "text": "itril",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -6.85546875,
            "text": "Sacubitr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.26171875,
            "text": "Sacubitril valsartan",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.2734375,
            "text": "Sacubitril valsartan (Entresto-Novartis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.3046875,
            "text": "Sacubitril vals",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.37890625,
            "text": "Sacubitril valsartan (Entresto-Novartis)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 9.4140625,
            "text": "\u25bc Sacubitril",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.49609375,
            "text": "Sacubitril valsartan (Entresto-Novartis) is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.5546875,
            "text": "Sacubitril valsartan (Entresto-Novartis) is a new oral drug licensed",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.5625,
            "text": "Sacubitril valsartan (Entresto-Novartis) is a new oral drug licensed for the treatment of symptomatic chronic heart failure",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.57421875,
            "text": "Sacubitril valsartan (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.5859375,
            "text": "Sacubitril valsartan (Entresto-Novart",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.59765625,
            "text": "Sacubitril valsartan (Entresto-Nov",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.10546875,
            "end_logit": -7.26171875,
            "text": "il valsartan",
            "probability": 0.0
        },
        {
            "start_logit": -1.10546875,
            "end_logit": -7.2734375,
            "text": "il valsartan (Entresto-Novartis",
            "probability": 0.0
        },
        {
            "start_logit": -1.10546875,
            "end_logit": -7.3046875,
            "text": "il vals",
            "probability": 0.0
        }
    ],
    "58962ed178275d0c4a000006_4": [
        {
            "start_logit": 9.25,
            "end_logit": 9.328125,
            "text": "Sacubitril",
            "probability": 1.0
        },
        {
            "start_logit": 9.25,
            "end_logit": -1.244140625,
            "text": "Sac",
            "probability": 2.568960189819336e-05
        },
        {
            "start_logit": -1.32421875,
            "end_logit": 9.328125,
            "text": "il",
            "probability": 2.5451183319091797e-05
        },
        {
            "start_logit": -1.8291015625,
            "end_logit": 9.328125,
            "text": "Atorvastatin and Sacubitril",
            "probability": 1.5437602996826172e-05
        },
        {
            "start_logit": -5.33984375,
            "end_logit": 9.328125,
            "text": "ubitril",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.7265625,
            "end_logit": 9.328125,
            "text": "itril",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.02734375,
            "text": "Sacubitr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.125,
            "text": "Sacubitril/Valsartan (Entresto\u2122) in a 63-Year-Old Woman.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.1796875,
            "text": "Sacubitril/Valsartan",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.19140625,
            "text": "Sacubitril/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.27734375,
            "text": "Sacubitril/Valsartan (Entresto\u2122)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.33203125,
            "text": "Sacubitril/Valsartan (Entresto\u2122",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.43359375,
            "text": "Sacubitril/Valsartan (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.46484375,
            "text": "Sacubitril/Vals",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.47265625,
            "text": "Sacubitril/Valsartan (Entresto\u2122) in a 63-Year",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.4765625,
            "text": "Sacubitril/Valsartan (Entresto\u2122) in a 63-Year-Old Woman",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.625,
            "end_logit": 9.328125,
            "text": "Rhabdomyolysis After Coadministration of Atorvastatin and Sacubitril",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.55078125,
            "text": "Sacubitril/Valsartan (Entresto",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.67578125,
            "end_logit": 9.328125,
            "text": "of Atorvastatin and Sacubitril",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.72265625,
            "end_logit": 9.328125,
            "text": "Coadministration of Atorvastatin and Sacubitril",
            "probability": 5.960464477539063e-08
        }
    ],
    "58962ed178275d0c4a000006_5": [
        {
            "start_logit": 8.8828125,
            "end_logit": 9.3671875,
            "text": "sacubitril",
            "probability": 1.0
        },
        {
            "start_logit": -1.0927734375,
            "end_logit": 9.3671875,
            "text": "il",
            "probability": 4.649162292480469e-05
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -1.9306640625,
            "text": "sac",
            "probability": 1.239776611328125e-05
        },
        {
            "start_logit": -5.984375,
            "end_logit": 9.3671875,
            "text": "ubitril",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.9453125,
            "end_logit": 9.3671875,
            "text": "enalapril 20 mg twice daily for heart failure developed rhabdomyolysis 26 days after enalapril was stopped and sacubitril",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -6.46484375,
            "text": "sacubitril/valsartan (Entresto\u2122) started.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -6.5625,
            "text": "sacubitril/valsartan",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.2265625,
            "end_logit": 9.3671875,
            "text": "itril",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -6.76171875,
            "text": "sacubitr",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 9.3671875,
            "text": "and sacubitril",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 9.3671875,
            "text": "and enalapril 20 mg twice daily for heart failure developed rhabdomyolysis 26 days after enalapril was stopped and sacubitril",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 9.3671875,
            "text": "days after enalapril was stopped and sacubitril",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -7.29296875,
            "text": "sacubitril/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -7.30859375,
            "text": "sacubitril/vals",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.0927734375,
            "end_logit": -6.46484375,
            "text": "il/valsartan (Entresto\u2122) started.",
            "probability": 0.0
        },
        {
            "start_logit": -1.0927734375,
            "end_logit": -6.5625,
            "text": "il/valsartan",
            "probability": 0.0
        },
        {
            "start_logit": -1.0927734375,
            "end_logit": -7.29296875,
            "text": "il/",
            "probability": 0.0
        },
        {
            "start_logit": -1.0927734375,
            "end_logit": -7.30859375,
            "text": "il/vals",
            "probability": 0.0
        },
        {
            "start_logit": -6.9453125,
            "end_logit": -1.9306640625,
            "text": "enalapril 20 mg twice daily for heart failure developed rhabdomyolysis 26 days after enalapril was stopped and sac",
            "probability": 0.0
        },
        {
            "start_logit": -7.47265625,
            "end_logit": -1.9306640625,
            "text": "and sac",
            "probability": 0.0
        }
    ],
    "58962ed178275d0c4a000006_6": [
        {
            "start_logit": 9.2421875,
            "end_logit": 9.3828125,
            "text": "Sacubitril",
            "probability": 1.0
        },
        {
            "start_logit": -1.193359375,
            "end_logit": 9.3828125,
            "text": "il",
            "probability": 2.9325485229492188e-05
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -1.2490234375,
            "text": "Sac",
            "probability": 2.4139881134033203e-05
        },
        {
            "start_logit": -5.7734375,
            "end_logit": 9.3828125,
            "text": "ubitril",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.6796875,
            "end_logit": 9.3828125,
            "text": "itril",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.04296875,
            "text": "Sacubitr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.39453125,
            "text": "Sacubitril/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.45703125,
            "text": "Sacubitril/valsartan",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.4765625,
            "text": "Sacubitril/valsartan [LCZ696 (Entresto), Novartis Pharmaceuticals Corp",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.50390625,
            "text": "Sacubitril/valsartan [LCZ696 (Entresto), Novartis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.515625,
            "text": "Sacubitril/valsartan [LCZ696",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.53515625,
            "text": "Sacubitril/valsartan [LCZ696 (Entresto), Novartis Pharmaceuticals",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.5390625,
            "text": "Sacubitril/vals",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.55078125,
            "text": "Sacubitril/valsartan [LCZ696 (Entresto), Novartis Pharmaceuticals Corp.] is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.58203125,
            "text": "Sacubitril/valsartan [LCZ696 (Entresto), Novartis Pharmaceuticals Corp.]",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.5859375,
            "text": "Sacubitril/valsartan [LCZ696 (Entresto), Novartis Pharmaceuticals Corp.] is the first in a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.193359375,
            "end_logit": -7.39453125,
            "text": "il/",
            "probability": 0.0
        },
        {
            "start_logit": -1.193359375,
            "end_logit": -7.45703125,
            "text": "il/valsartan",
            "probability": 0.0
        },
        {
            "start_logit": -1.193359375,
            "end_logit": -7.4765625,
            "text": "il/valsartan [LCZ696 (Entresto), Novartis Pharmaceuticals Corp",
            "probability": 0.0
        },
        {
            "start_logit": -1.193359375,
            "end_logit": -7.50390625,
            "text": "il/valsartan [LCZ696 (Entresto), Novartis",
            "probability": 0.0
        }
    ],
    "58962ed178275d0c4a000006_7": [
        {
            "start_logit": 8.046875,
            "end_logit": 8.8046875,
            "text": "Valsartan",
            "probability": 1.0
        },
        {
            "start_logit": -2.353515625,
            "end_logit": 8.8046875,
            "text": "artan",
            "probability": 3.069639205932617e-05
        },
        {
            "start_logit": 8.046875,
            "end_logit": -1.6572265625,
            "text": "Valsartan/sacubitril",
            "probability": 2.8848648071289062e-05
        },
        {
            "start_logit": 8.046875,
            "end_logit": -3.5390625,
            "text": "Vals",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": -7.0390625,
            "end_logit": 8.8046875,
            "text": ": Valsartan",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -6.640625,
            "text": "Valsartan/sacubitr",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -6.765625,
            "text": "Valsartan/sacubitril (formerly known as LCZ696 and currently marketed by Novartis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.52734375,
            "end_logit": 8.8046875,
            "text": "class of drugs for the treatment of heart failure: Valsartan",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5625,
            "end_logit": 8.8046875,
            "text": "US Food and Drug Administration approved the first of a new class of drugs for the treatment of heart failure: Valsartan",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.59375,
            "end_logit": 8.8046875,
            "text": "heart failure: Valsartan",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 8.8046875,
            "text": "treatment of heart failure: Valsartan",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.171875,
            "text": "Valsartan/sacub",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.24609375,
            "text": "Valsartan/sacubitril (formerly known as LCZ696",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.25390625,
            "text": "Valsartan/sacubitril (formerly known as LCZ696 and currently marketed by Novartis as",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.34765625,
            "end_logit": -1.6572265625,
            "text": "sacubitril",
            "probability": 0.0
        },
        {
            "start_logit": -2.353515625,
            "end_logit": -1.6572265625,
            "text": "artan/sacubitril",
            "probability": 0.0
        },
        {
            "start_logit": -7.0390625,
            "end_logit": -1.6572265625,
            "text": ": Valsartan/sacubitril",
            "probability": 0.0
        },
        {
            "start_logit": -2.34765625,
            "end_logit": -6.49609375,
            "text": "sacubitril (formerly known as LCZ696 and currently marketed by Novartis as Entresto) combines the angiotensin receptor blocker",
            "probability": 0.0
        },
        {
            "start_logit": -2.34765625,
            "end_logit": -6.640625,
            "text": "sacubitr",
            "probability": 0.0
        },
        {
            "start_logit": -2.353515625,
            "end_logit": -6.640625,
            "text": "artan/sacubitr",
            "probability": 0.0
        }
    ],
    "58962ed178275d0c4a000006_8": [
        {
            "start_logit": 9.265625,
            "end_logit": 9.453125,
            "text": "Sacubitril",
            "probability": 1.0
        },
        {
            "start_logit": -0.9716796875,
            "end_logit": 9.453125,
            "text": "il",
            "probability": 3.594160079956055e-05
        },
        {
            "start_logit": 9.265625,
            "end_logit": -1.203125,
            "text": "Sac",
            "probability": 2.3543834686279297e-05
        },
        {
            "start_logit": -5.6953125,
            "end_logit": 9.453125,
            "text": "ubitril",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.5546875,
            "end_logit": 9.453125,
            "text": "itril",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -6.99609375,
            "text": "Sacubitr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.09765625,
            "text": "Sacubitril/valsartan (Entresto) for chronic heart failure",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.46875,
            "text": "Sacubitril/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.48828125,
            "text": "Sacubitril/valsartan (Entresto) for chronic heart",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.4921875,
            "text": "Sacubitril/valsartan",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.9716796875,
            "end_logit": -7.09765625,
            "text": "il/valsartan (Entresto) for chronic heart failure",
            "probability": 0.0
        },
        {
            "start_logit": -0.9716796875,
            "end_logit": -7.46875,
            "text": "il/",
            "probability": 0.0
        },
        {
            "start_logit": -0.9716796875,
            "end_logit": -7.48828125,
            "text": "il/valsartan (Entresto) for chronic heart",
            "probability": 0.0
        },
        {
            "start_logit": -0.9716796875,
            "end_logit": -7.4921875,
            "text": "il/valsartan",
            "probability": 0.0
        },
        {
            "start_logit": -6.96484375,
            "end_logit": -5.5,
            "text": "lumacaftor",
            "probability": 0.0
        },
        {
            "start_logit": -5.6953125,
            "end_logit": -6.99609375,
            "text": "ubitr",
            "probability": 0.0
        },
        {
            "start_logit": -5.6953125,
            "end_logit": -7.09765625,
            "text": "ubitril/valsartan (Entresto) for chronic heart failure",
            "probability": 0.0
        },
        {
            "start_logit": -7.48828125,
            "end_logit": -5.5,
            "text": "chronic heart failure; brexpiprazole (Rexulti) for major depressive disorder and schizophrenia; and lumacaftor",
            "probability": 0.0
        },
        {
            "start_logit": -7.515625,
            "end_logit": -5.5,
            "text": "; and lumacaftor",
            "probability": 0.0
        },
        {
            "start_logit": -7.515625,
            "end_logit": -5.5,
            "text": "and lumacaftor",
            "probability": 0.0
        }
    ],
    "58962ed178275d0c4a000006_9": [
        {
            "start_logit": 9.3046875,
            "end_logit": 9.3671875,
            "text": "sacubitril",
            "probability": 1.0
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -1.1298828125,
            "text": "sac",
            "probability": 2.753734588623047e-05
        },
        {
            "start_logit": -1.2333984375,
            "end_logit": 9.3671875,
            "text": "il",
            "probability": 2.6464462280273438e-05
        },
        {
            "start_logit": -5.3828125,
            "end_logit": 9.3671875,
            "text": "ubitril",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.3359375,
            "end_logit": 9.3671875,
            "text": "itril",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.40234375,
            "text": "sacubitr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 9.3671875,
            "text": "molecular combination of sacubitril",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 9.3671875,
            "text": "of sacubitril",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 9.3671875,
            "text": "combination of sacubitril",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.51171875,
            "text": "sacubitril and valsartan",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.5703125,
            "text": "sacubitril and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 9.3671875,
            "text": "The molecular combination of sacubitril",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.6171875,
            "text": "sacubitril and valsartan (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.62890625,
            "text": "sacubitril and valsartan (Entresto)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.6328125,
            "text": "sacubitril and vals",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.640625,
            "text": "sacubitril and valsartan (Entresto) is a new drug for reducing the risk of cardiovascular death and hospitalization for heart failure",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.640625,
            "text": "sacubitril and valsartan (Entresto) is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.67578125,
            "text": "sacubitril and valsartan (Entresto) is a new drug for reducing the risk of cardiovascular death and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.68359375,
            "text": "sacubitril and valsartan (Entresto) is a new drug for reducing the risk of cardiovascular death",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51953125,
            "end_logit": -1.1298828125,
            "text": "molecular combination of sac",
            "probability": 0.0
        }
    ],
    "58962ed178275d0c4a000006_10": [
        {
            "start_logit": 9.140625,
            "end_logit": 9.2578125,
            "text": "Sacubitril",
            "probability": 1.0
        },
        {
            "start_logit": -1.474609375,
            "end_logit": 9.2578125,
            "text": "il",
            "probability": 2.4318695068359375e-05
        },
        {
            "start_logit": 9.140625,
            "end_logit": -1.541015625,
            "text": "Sac",
            "probability": 2.0325183868408203e-05
        },
        {
            "start_logit": -6.015625,
            "end_logit": 9.2578125,
            "text": "ubitril",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.8125,
            "end_logit": 9.2578125,
            "text": "itril",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.23828125,
            "text": "Sacubitril valsartan",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.26171875,
            "text": "Sacubitril vals",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.3984375,
            "text": "Sacubitr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.40234375,
            "text": "Sacubitril valsartan (Entresto-Novartis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.421875,
            "text": "Sacubitril valsartan (Entresto-Novartis) is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.474609375,
            "end_logit": -7.23828125,
            "text": "il valsartan",
            "probability": 0.0
        },
        {
            "start_logit": -1.474609375,
            "end_logit": -7.26171875,
            "text": "il vals",
            "probability": 0.0
        },
        {
            "start_logit": -1.474609375,
            "end_logit": -7.40234375,
            "text": "il valsartan (Entresto-Novartis",
            "probability": 0.0
        },
        {
            "start_logit": -1.474609375,
            "end_logit": -7.421875,
            "text": "il valsartan (Entresto-Novartis) is",
            "probability": 0.0
        },
        {
            "start_logit": -6.015625,
            "end_logit": -7.23828125,
            "text": "ubitril valsartan",
            "probability": 0.0
        },
        {
            "start_logit": -6.015625,
            "end_logit": -7.26171875,
            "text": "ubitril vals",
            "probability": 0.0
        },
        {
            "start_logit": -6.015625,
            "end_logit": -7.3984375,
            "text": "ubitr",
            "probability": 0.0
        },
        {
            "start_logit": -6.015625,
            "end_logit": -7.40234375,
            "text": "ubitril valsartan (Entresto-Novartis",
            "probability": 0.0
        },
        {
            "start_logit": -6.015625,
            "end_logit": -7.421875,
            "text": "ubitril valsartan (Entresto-Novartis) is",
            "probability": 0.0
        },
        {
            "start_logit": -6.78125,
            "end_logit": -6.90625,
            "text": ".",
            "probability": 0.0
        }
    ],
    "5e92015b2d3121100d000004_1": [
        {
            "start_logit": 8.2578125,
            "end_logit": 8.2421875,
            "text": "chronic lymphocytic leukemia",
            "probability": 0.77392578125
        },
        {
            "start_logit": 6.98828125,
            "end_logit": 8.2421875,
            "text": "Decreased B-cell activating factor levels may denote nascent chronic lymphocytic leukemia",
            "probability": 0.21826171875
        },
        {
            "start_logit": 3.392578125,
            "end_logit": 8.2421875,
            "text": "B-cell activating factor levels may denote nascent chronic lymphocytic leukemia",
            "probability": 0.005954742431640625
        },
        {
            "start_logit": 6.98828125,
            "end_logit": 2.818359375,
            "text": "Decreased B-cell activating factor",
            "probability": 0.000957489013671875
        },
        {
            "start_logit": 0.91845703125,
            "end_logit": 8.2421875,
            "text": "immune activation precedes non-Hodgkin lymphoma diagnosis by several years. Decreased B-cell activating factor levels may denote nascent chronic lymphocytic leukemia",
            "probability": 0.0005044937133789062
        },
        {
            "start_logit": 3.392578125,
            "end_logit": 2.818359375,
            "text": "B-cell activating factor",
            "probability": 2.6285648345947266e-05
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -2.8125,
            "text": "chronic",
            "probability": 1.2218952178955078e-05
        },
        {
            "start_logit": -2.869140625,
            "end_logit": 8.2421875,
            "text": "leukemia",
            "probability": 1.138448715209961e-05
        },
        {
            "start_logit": 6.98828125,
            "end_logit": -2.8125,
            "text": "Decreased B-cell activating factor levels may denote nascent chronic",
            "probability": 3.3974647521972656e-06
        },
        {
            "start_logit": 0.91845703125,
            "end_logit": 2.818359375,
            "text": "immune activation precedes non-Hodgkin lymphoma diagnosis by several years. Decreased B-cell activating factor",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 6.98828125,
            "end_logit": -4.4921875,
            "text": "Decreased",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.10546875,
            "end_logit": 8.2421875,
            "text": "activating factor levels may denote nascent chronic lymphocytic leukemia",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.2890625,
            "end_logit": 8.2421875,
            "text": "nascent chronic lymphocytic leukemia",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.2890625,
            "end_logit": 8.2421875,
            "text": "factor levels may denote nascent chronic lymphocytic leukemia",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -6.49609375,
            "text": "chronic lymphocytic",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.54296875,
            "end_logit": 8.2421875,
            "text": ". Decreased B-cell activating factor levels may denote nascent chronic lymphocytic leukemia",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.78125,
            "end_logit": 8.2421875,
            "text": "-cell activating factor levels may denote nascent chronic lymphocytic leukemia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.81640625,
            "end_logit": 8.2421875,
            "text": "lymphocytic leukemia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -6.88671875,
            "text": "chronic lymphocytic leukemia many years pre-diagnosis.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -7.08203125,
            "text": "chronic lymphocytic leukemia many years pre",
            "probability": 1.7881393432617188e-07
        }
    ],
    "5e92015b2d3121100d000004_2": [
        {
            "start_logit": 1.27734375,
            "end_logit": 2.83984375,
            "text": "CD30",
            "probability": 0.73681640625
        },
        {
            "start_logit": 0.1513671875,
            "end_logit": 2.83984375,
            "text": "Soluble interleukin-2 receptor-\u03b1, CXC chemokine ligand 13, soluble CD30",
            "probability": 0.2392578125
        },
        {
            "start_logit": -2.59765625,
            "end_logit": 2.83984375,
            "text": "interleukin-2 receptor-\u03b1, CXC chemokine ligand 13, soluble CD30",
            "probability": 0.015289306640625
        },
        {
            "start_logit": 0.1513671875,
            "end_logit": -0.79931640625,
            "text": "Soluble interleukin-2",
            "probability": 0.0062713623046875
        },
        {
            "start_logit": -5.515625,
            "end_logit": 2.83984375,
            "text": "soluble CD30",
            "probability": 0.0008263587951660156
        },
        {
            "start_logit": -2.59765625,
            "end_logit": -0.79931640625,
            "text": "interleukin-2",
            "probability": 0.0004012584686279297
        },
        {
            "start_logit": -6.67578125,
            "end_logit": 2.83984375,
            "text": "CXC chemokine ligand 13, soluble CD30",
            "probability": 0.00025916099548339844
        },
        {
            "start_logit": -6.8828125,
            "end_logit": 2.83984375,
            "text": "0",
            "probability": 0.00021123886108398438
        },
        {
            "start_logit": -7.171875,
            "end_logit": 2.83984375,
            "text": ", soluble CD30",
            "probability": 0.0001571178436279297
        },
        {
            "start_logit": -7.24609375,
            "end_logit": 2.83984375,
            "text": ", CXC chemokine ligand 13, soluble CD30",
            "probability": 0.00014638900756835938
        },
        {
            "start_logit": 0.1513671875,
            "end_logit": -5.74609375,
            "text": "Soluble interleukin-2 receptor-\u03b1",
            "probability": 4.464387893676758e-05
        },
        {
            "start_logit": 0.1513671875,
            "end_logit": -5.76953125,
            "text": "Soluble interleukin-2 receptor",
            "probability": 4.363059997558594e-05
        },
        {
            "start_logit": 1.27734375,
            "end_logit": -7.296875,
            "text": "CD30, and soluble tumor necrosis",
            "probability": 2.9087066650390625e-05
        },
        {
            "start_logit": 1.27734375,
            "end_logit": -7.3515625,
            "text": "CD30, and soluble tumor necrosis factor receptor",
            "probability": 2.771615982055664e-05
        },
        {
            "start_logit": 1.27734375,
            "end_logit": -7.35546875,
            "text": "CD3",
            "probability": 2.753734588623047e-05
        },
        {
            "start_logit": 1.27734375,
            "end_logit": -7.3671875,
            "text": "CD30, and soluble tumor necrosis factor",
            "probability": 2.7298927307128906e-05
        },
        {
            "start_logit": 1.27734375,
            "end_logit": -7.4296875,
            "text": "CD30, and soluble tumor necrosis factor receptor-2 were individually positively associated, and B-cell activating factor of the tumor necrosis factor family inversely",
            "probability": 2.562999725341797e-05
        },
        {
            "start_logit": 0.1513671875,
            "end_logit": -6.73828125,
            "text": "Soluble interleukin-2 receptor-\u03b1, CXC chemokine ligand 13",
            "probability": 1.6570091247558594e-05
        },
        {
            "start_logit": 0.1513671875,
            "end_logit": -7.00390625,
            "text": "Soluble interleukin-",
            "probability": 1.2695789337158203e-05
        },
        {
            "start_logit": 0.1513671875,
            "end_logit": -7.22265625,
            "text": "Soluble interleukin-2 receptor-\u03b1, CXC chemokine ligand",
            "probability": 1.0192394256591797e-05
        }
    ],
    "5e92015b2d3121100d000004_3": [
        {
            "start_logit": 9.28125,
            "end_logit": 9.3671875,
            "text": "GALECTIN-3",
            "probability": 1.0
        },
        {
            "start_logit": -1.080078125,
            "end_logit": 9.3671875,
            "text": "3",
            "probability": 3.147125244140625e-05
        },
        {
            "start_logit": 9.28125,
            "end_logit": -1.1767578125,
            "text": "GALECTIN",
            "probability": 2.6047229766845703e-05
        },
        {
            "start_logit": -5.76171875,
            "end_logit": 9.3671875,
            "text": "-3",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.93359375,
            "text": "GALECTIN-3 AS",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.3671875,
            "text": "GALECTIN-3 AS A PROGNOSTIC BIOMARKER",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.5,
            "text": "GALECTIN-3 AS A PROGNOSTIC BIOMARKER IN PATIENTS WITH NON-HODGKIN LYMPHOMA.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.5234375,
            "text": "GALECTIN-3 AS A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.55078125,
            "text": "GALECTIN-3 AS A PROGNOSTIC BIOMARKER IN PATIENTS WITH NON-HODGKIN LYMPHOMA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.080078125,
            "end_logit": -6.93359375,
            "text": "3 AS",
            "probability": 0.0
        },
        {
            "start_logit": -1.080078125,
            "end_logit": -7.3671875,
            "text": "3 AS A PROGNOSTIC BIOMARKER",
            "probability": 0.0
        },
        {
            "start_logit": -1.080078125,
            "end_logit": -7.5,
            "text": "3 AS A PROGNOSTIC BIOMARKER IN PATIENTS WITH NON-HODGKIN LYMPHOMA.",
            "probability": 0.0
        },
        {
            "start_logit": -1.080078125,
            "end_logit": -7.5234375,
            "text": "3 AS A",
            "probability": 0.0
        },
        {
            "start_logit": -1.080078125,
            "end_logit": -7.55078125,
            "text": "3 AS A PROGNOSTIC BIOMARKER IN PATIENTS WITH NON-HODGKIN LYMPHOMA",
            "probability": 0.0
        },
        {
            "start_logit": -5.76171875,
            "end_logit": -6.93359375,
            "text": "-3 AS",
            "probability": 0.0
        },
        {
            "start_logit": -5.76171875,
            "end_logit": -7.3671875,
            "text": "-3 AS A PROGNOSTIC BIOMARKER",
            "probability": 0.0
        },
        {
            "start_logit": -5.76171875,
            "end_logit": -7.5,
            "text": "-3 AS A PROGNOSTIC BIOMARKER IN PATIENTS WITH NON-HODGKIN LYMPHOMA.",
            "probability": 0.0
        },
        {
            "start_logit": -5.76171875,
            "end_logit": -7.5234375,
            "text": "-3 AS A",
            "probability": 0.0
        },
        {
            "start_logit": -5.76171875,
            "end_logit": -7.55078125,
            "text": "-3 AS A PROGNOSTIC BIOMARKER IN PATIENTS WITH NON-HODGKIN LYMPHOMA",
            "probability": 0.0
        },
        {
            "start_logit": -6.9140625,
            "end_logit": -6.93359375,
            "text": "AS",
            "probability": 0.0
        }
    ],
    "5333f728d6d3ac6a34000041_1": [
        {
            "start_logit": 8.890625,
            "end_logit": 8.7265625,
            "text": "na\u00efve Bayes",
            "probability": 0.994140625
        },
        {
            "start_logit": 8.890625,
            "end_logit": 3.501953125,
            "text": "na\u00efve Bayes classifier",
            "probability": 0.005298614501953125
        },
        {
            "start_logit": 8.890625,
            "end_logit": -1.8603515625,
            "text": "na\u00efve",
            "probability": 2.4974346160888672e-05
        },
        {
            "start_logit": -2.115234375,
            "end_logit": 8.7265625,
            "text": "Bayes",
            "probability": 1.633167266845703e-05
        },
        {
            "start_logit": -6.92578125,
            "end_logit": 8.7265625,
            "text": ". This method learns the parameters of the features, which are embedded in the na\u00efve Bayes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.109375,
            "end_logit": 8.7265625,
            "text": "parameters of the features, which are embedded in the na\u00efve Bayes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 8.7265625,
            "text": "the na\u00efve Bayes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.23828125,
            "end_logit": 8.7265625,
            "text": "supervised-learning method for the prediction of heterodimeric protein complexes. This method learns the parameters of the features, which are embedded in the na\u00efve Bayes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.2734375,
            "end_logit": 8.7265625,
            "text": "in the na\u00efve Bayes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 8.7265625,
            "text": "features, which are embedded in the na\u00efve Bayes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.115234375,
            "end_logit": 3.501953125,
            "text": "Bayes classifier",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.92578125,
            "end_logit": 3.501953125,
            "text": "classifier",
            "probability": 0.0
        },
        {
            "start_logit": -6.92578125,
            "end_logit": 3.501953125,
            "text": ". This method learns the parameters of the features, which are embedded in the na\u00efve Bayes classifier",
            "probability": 0.0
        },
        {
            "start_logit": -7.109375,
            "end_logit": 3.501953125,
            "text": "parameters of the features, which are embedded in the na\u00efve Bayes classifier",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 3.501953125,
            "text": "the na\u00efve Bayes classifier",
            "probability": 0.0
        },
        {
            "start_logit": -7.2734375,
            "end_logit": 3.501953125,
            "text": "in the na\u00efve Bayes classifier",
            "probability": 0.0
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 3.501953125,
            "text": "features, which are embedded in the na\u00efve Bayes classifier",
            "probability": 0.0
        },
        {
            "start_logit": -6.92578125,
            "end_logit": -1.8603515625,
            "text": ". This method learns the parameters of the features, which are embedded in the na\u00efve",
            "probability": 0.0
        },
        {
            "start_logit": -7.109375,
            "end_logit": -1.8603515625,
            "text": "parameters of the features, which are embedded in the na\u00efve",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -1.8603515625,
            "text": "the na\u00efve",
            "probability": 0.0
        }
    ],
    "5333f728d6d3ac6a34000041_2": [
        {
            "start_logit": 9.2578125,
            "end_logit": 9.4140625,
            "text": "Negatome",
            "probability": 1.0
        },
        {
            "start_logit": -1.1142578125,
            "end_logit": 9.4140625,
            "text": "me",
            "probability": 3.11732292175293e-05
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -1.2744140625,
            "text": "Neg",
            "probability": 2.282857894897461e-05
        },
        {
            "start_logit": -5.53515625,
            "end_logit": 9.4140625,
            "text": "PPIs) and for assessing the false positive rates of PPI detection efforts. We present the second version of Negatome",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.59375,
            "end_logit": 9.4140625,
            "text": "atome",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.89453125,
            "end_logit": 9.4140625,
            "text": "interactions (PPIs) and for assessing the false positive rates of PPI detection efforts. We present the second version of Negatome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.109375,
            "end_logit": 9.4140625,
            "text": ". We present the second version of Negatome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37890625,
            "end_logit": 9.4140625,
            "text": "predict protein-protein interactions (PPIs) and for assessing the false positive rates of PPI detection efforts. We present the second version of Negatome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.26953125,
            "text": "Negatome,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 9.4140625,
            "text": "to predict protein-protein interactions (PPIs) and for assessing the false positive rates of PPI detection efforts. We present the second version of Negatome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 9.4140625,
            "text": "second version of Negatome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.609375,
            "end_logit": 9.4140625,
            "text": "protein-protein interactions (PPIs) and for assessing the false positive rates of PPI detection efforts. We present the second version of Negatome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 9.4140625,
            "text": "present the second version of Negatome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.53515625,
            "end_logit": -1.2744140625,
            "text": "PPIs) and for assessing the false positive rates of PPI detection efforts. We present the second version of Neg",
            "probability": 0.0
        },
        {
            "start_logit": -6.89453125,
            "end_logit": -1.2744140625,
            "text": "interactions (PPIs) and for assessing the false positive rates of PPI detection efforts. We present the second version of Neg",
            "probability": 0.0
        },
        {
            "start_logit": -1.1142578125,
            "end_logit": -7.26953125,
            "text": "me,",
            "probability": 0.0
        },
        {
            "start_logit": -7.109375,
            "end_logit": -1.2744140625,
            "text": ". We present the second version of Neg",
            "probability": 0.0
        },
        {
            "start_logit": -7.3125,
            "end_logit": -1.2744140625,
            "text": "algorithms to predict protein-protein interactions (PPIs) and for assessing the false positive rates of PPI detection efforts. We present the second version of Neg",
            "probability": 0.0
        },
        {
            "start_logit": -7.37890625,
            "end_logit": -1.2744140625,
            "text": "predict protein-protein interactions (PPIs) and for assessing the false positive rates of PPI detection efforts. We present the second version of Neg",
            "probability": 0.0
        },
        {
            "start_logit": -7.5,
            "end_logit": -1.2744140625,
            "text": "the algorithms to predict protein-protein interactions (PPIs) and for assessing the false positive rates of PPI detection efforts. We present the second version of Neg",
            "probability": 0.0
        }
    ],
    "5333f728d6d3ac6a34000041_3": [
        {
            "start_logit": 9.2734375,
            "end_logit": 9.3984375,
            "text": "Negatome",
            "probability": 1.0
        },
        {
            "start_logit": -1.1533203125,
            "end_logit": 9.3984375,
            "text": "me",
            "probability": 2.956390380859375e-05
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -1.2109375,
            "text": "Neg",
            "probability": 2.467632293701172e-05
        },
        {
            "start_logit": -5.50390625,
            "end_logit": 9.3984375,
            "text": "atome",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.0625,
            "text": "Negatome is derived by manual curation of literature",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.1640625,
            "text": "Negatome is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.30078125,
            "text": "Negatome is derived by manual curation of literature and by analyzing three-dimensional structures",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.30859375,
            "text": "Negatome is derived by manual curation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.36328125,
            "text": "Negatome is derived",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.42578125,
            "text": "Negatome is derived by manual curation of literature and by analyzing three-dimensional",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.4296875,
            "text": "Negatome is derived by manual cur",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.44921875,
            "text": "Negatome is derived by manual curation of literature and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.46875,
            "text": "Negatome is derived by manual curation of literature and by analyzing three-dimensional structures of protein complexes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.47265625,
            "text": "Negatome is derived by manual curation of literature and by analyzing three-dimensional structures of protein complexes.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.52734375,
            "text": "Negatome is derived by manual",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.55859375,
            "text": "Negatome is derived by manual curation of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.1533203125,
            "end_logit": -7.0625,
            "text": "me is derived by manual curation of literature",
            "probability": 0.0
        },
        {
            "start_logit": -1.1533203125,
            "end_logit": -7.1640625,
            "text": "me is",
            "probability": 0.0
        },
        {
            "start_logit": -1.1533203125,
            "end_logit": -7.30078125,
            "text": "me is derived by manual curation of literature and by analyzing three-dimensional structures",
            "probability": 0.0
        },
        {
            "start_logit": -1.1533203125,
            "end_logit": -7.30859375,
            "text": "me is derived by manual curation",
            "probability": 0.0
        }
    ],
    "5333f728d6d3ac6a34000041_4": [
        {
            "start_logit": 4.1875,
            "end_logit": 4.61328125,
            "text": "Support Vector Machine",
            "probability": 0.97265625
        },
        {
            "start_logit": 4.1875,
            "end_logit": 0.466064453125,
            "text": "Support Vector Machine (SVM)",
            "probability": 0.01541900634765625
        },
        {
            "start_logit": 4.1875,
            "end_logit": 0.11309814453125,
            "text": "Support Vector Machine (SVM",
            "probability": 0.0108489990234375
        },
        {
            "start_logit": 1.0205078125,
            "end_logit": 0.466064453125,
            "text": "SVM)",
            "probability": 0.00064849853515625
        },
        {
            "start_logit": 1.0205078125,
            "end_logit": 0.11309814453125,
            "text": "SVM",
            "probability": 0.0004565715789794922
        },
        {
            "start_logit": -5.28125,
            "end_logit": 4.61328125,
            "text": "Machine",
            "probability": 7.510185241699219e-05
        },
        {
            "start_logit": 4.1875,
            "end_logit": -5.6640625,
            "text": "Support Vector Machine (",
            "probability": 3.355741500854492e-05
        },
        {
            "start_logit": 4.1875,
            "end_logit": -5.80859375,
            "text": "Support",
            "probability": 2.8967857360839844e-05
        },
        {
            "start_logit": 4.1875,
            "end_logit": -5.91796875,
            "text": "Support Vector Machine (SVM) is",
            "probability": 2.5987625122070312e-05
        },
        {
            "start_logit": 4.1875,
            "end_logit": -6.48828125,
            "text": "Support Vector Machine (SVM) is used to cluster the pockets that are most likely to bind ligands with the attributes of geometric characteristics",
            "probability": 1.4781951904296875e-05
        },
        {
            "start_logit": 4.1875,
            "end_logit": -6.640625,
            "text": "Support Vector Machine (SVM) is used to cluster the pockets",
            "probability": 1.2636184692382812e-05
        },
        {
            "start_logit": 4.1875,
            "end_logit": -6.9375,
            "text": "Support Vector Machine (SVM) is used to cluster the pockets that are most likely to bind ligands with the attributes of geometric characteristics, interaction potential",
            "probability": 9.417533874511719e-06
        },
        {
            "start_logit": 4.1875,
            "end_logit": -6.94140625,
            "text": "Support Vector Machine (SVM) is used",
            "probability": 9.417533874511719e-06
        },
        {
            "start_logit": 4.1875,
            "end_logit": -7.0078125,
            "text": "Support Vector",
            "probability": 8.761882781982422e-06
        },
        {
            "start_logit": 4.1875,
            "end_logit": -7.3359375,
            "text": "Support Vector Machine (SVM) is used to cluster the pockets that are most likely to bind ligands",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": -5.28125,
            "end_logit": 0.466064453125,
            "text": "Machine (SVM)",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 1.0205078125,
            "end_logit": -5.91796875,
            "text": "SVM) is",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -5.28125,
            "end_logit": 0.11309814453125,
            "text": "Machine (SVM",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 1.0205078125,
            "end_logit": -6.48828125,
            "text": "SVM) is used to cluster the pockets that are most likely to bind ligands with the attributes of geometric characteristics",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 1.0205078125,
            "end_logit": -6.640625,
            "text": "SVM) is used to cluster the pockets",
            "probability": 5.364418029785156e-07
        }
    ],
    "5333f728d6d3ac6a34000041_5": [
        {
            "start_logit": 9.46875,
            "end_logit": 9.28125,
            "text": "PEWCC",
            "probability": 1.0
        },
        {
            "start_logit": 9.46875,
            "end_logit": -0.5908203125,
            "text": "PE",
            "probability": 5.143880844116211e-05
        },
        {
            "start_logit": -1.4658203125,
            "end_logit": 9.28125,
            "text": "CC",
            "probability": 1.7762184143066406e-05
        },
        {
            "start_logit": -5.73828125,
            "end_logit": 9.28125,
            "text": "graph mining algorithm (PEWCC",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.46875,
            "end_logit": -5.9453125,
            "text": "PEWCC) to identify such protein complexes. Firstly, the algorithm assesses the reliability of the interaction data",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.46875,
            "end_logit": -5.953125,
            "text": "PEWCC)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.28515625,
            "end_logit": 9.28125,
            "text": "WCC",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.61328125,
            "end_logit": 9.28125,
            "text": "novel graph mining algorithm (PEWCC",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.46875,
            "end_logit": -6.8359375,
            "text": "PEWCC) to identify such protein complexes.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.46875,
            "end_logit": -7.20703125,
            "text": "PEWCC) to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.46875,
            "end_logit": -7.25,
            "text": "PEWCC) to identify such protein complexes. Firstly, the algorithm assesses the reliability of the interaction data, then predicts protein complexes based",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.73828125,
            "end_logit": -0.5908203125,
            "text": "graph mining algorithm (PE",
            "probability": 0.0
        },
        {
            "start_logit": -6.61328125,
            "end_logit": -0.5908203125,
            "text": "novel graph mining algorithm (PE",
            "probability": 0.0
        },
        {
            "start_logit": -1.4658203125,
            "end_logit": -5.9453125,
            "text": "CC) to identify such protein complexes. Firstly, the algorithm assesses the reliability of the interaction data",
            "probability": 0.0
        },
        {
            "start_logit": -1.4658203125,
            "end_logit": -5.953125,
            "text": "CC)",
            "probability": 0.0
        },
        {
            "start_logit": -1.4658203125,
            "end_logit": -6.8359375,
            "text": "CC) to identify such protein complexes.",
            "probability": 0.0
        },
        {
            "start_logit": -1.4658203125,
            "end_logit": -7.20703125,
            "text": "CC) to",
            "probability": 0.0
        },
        {
            "start_logit": -1.4658203125,
            "end_logit": -7.25,
            "text": "CC) to identify such protein complexes. Firstly, the algorithm assesses the reliability of the interaction data, then predicts protein complexes based",
            "probability": 0.0
        },
        {
            "start_logit": -5.515625,
            "end_logit": -5.41015625,
            "text": "performance of PEWCC was compared to several methods",
            "probability": 0.0
        },
        {
            "start_logit": -5.69921875,
            "end_logit": -5.41015625,
            "text": "methods",
            "probability": 0.0
        }
    ],
    "5333f728d6d3ac6a34000041_6": [
        {
            "start_logit": 8.875,
            "end_logit": 9.0078125,
            "text": "iPTMClust",
            "probability": 1.0
        },
        {
            "start_logit": -2.05078125,
            "end_logit": 9.0078125,
            "text": "st",
            "probability": 1.806020736694336e-05
        },
        {
            "start_logit": 8.875,
            "end_logit": -2.001953125,
            "text": "iPT",
            "probability": 1.6689300537109375e-05
        },
        {
            "start_logit": 8.875,
            "end_logit": -6.3671875,
            "text": "iPTMClust, which extends a recently introduced PTM refinement algorithm PTMClust",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.51171875,
            "end_logit": 9.0078125,
            "text": "MClust",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.6953125,
            "end_logit": 9.0078125,
            "text": ", iPTMClust",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.875,
            "end_logit": -6.57421875,
            "text": "iPTMClust, which extends a recently introduced PTM refinement algorithm PTMClust and uses a non-parametric Bayesian model",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.78125,
            "end_logit": 9.0078125,
            "text": "lust",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.875,
            "end_logit": -6.796875,
            "text": "iPTMClu",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.03125,
            "end_logit": 9.0078125,
            "text": "PTM refinement algorithm, iPTMClust",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.875,
            "end_logit": -6.91796875,
            "text": "iPTMClust, which extends a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.875,
            "end_logit": -7.00390625,
            "text": "iPTMClust, which extends a recently introduced PTM refinement algorithm PTMClust and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.234375,
            "end_logit": 9.0078125,
            "text": "novel PTM refinement algorithm, iPTMClust",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.875,
            "end_logit": -7.11328125,
            "text": "iPTMClust,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.875,
            "end_logit": -7.1171875,
            "text": "iPTMClust, which extends a recently introduced PTM refinement algorithm PTMClu",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.875,
            "end_logit": -7.12109375,
            "text": "iPTMClust, which extends a recently introduced PTM refinement algorithm PTMClust and uses a non-parametric Bayesian",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.05078125,
            "end_logit": -6.3671875,
            "text": "st, which extends a recently introduced PTM refinement algorithm PTMClust",
            "probability": 0.0
        },
        {
            "start_logit": -2.05078125,
            "end_logit": -6.57421875,
            "text": "st, which extends a recently introduced PTM refinement algorithm PTMClust and uses a non-parametric Bayesian model",
            "probability": 0.0
        },
        {
            "start_logit": -6.6953125,
            "end_logit": -2.001953125,
            "text": ", iPT",
            "probability": 0.0
        },
        {
            "start_logit": -2.05078125,
            "end_logit": -6.91796875,
            "text": "st, which extends a",
            "probability": 0.0
        }
    ],
    "5333f728d6d3ac6a34000041_7": [
        {
            "start_logit": 9.125,
            "end_logit": 9.1640625,
            "text": "NDComplex",
            "probability": 1.0
        },
        {
            "start_logit": 9.125,
            "end_logit": -1.6044921875,
            "text": "ND",
            "probability": 2.110004425048828e-05
        },
        {
            "start_logit": -1.7392578125,
            "end_logit": 9.1640625,
            "text": "plex",
            "probability": 1.9252300262451172e-05
        },
        {
            "start_logit": -6.13671875,
            "end_logit": 9.1640625,
            "text": "Complex",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.96875,
            "end_logit": 9.1640625,
            "text": "program NDComplex",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.09765625,
            "end_logit": 9.1640625,
            "text": "software program NDComplex",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 9.1640625,
            "text": ". A software program NDComplex",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.22265625,
            "end_logit": 9.1640625,
            "text": "existing algorithms. A software program NDComplex",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.30078125,
            "end_logit": 9.1640625,
            "text": "few yeast protein interaction networks, and show that our algorithm is able to identify complexes more accurately than existing algorithms. A software program NDComplex",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.359375,
            "end_logit": 9.1640625,
            "text": "yeast protein interaction networks, and show that our algorithm is able to identify complexes more accurately than existing algorithms. A software program NDComplex",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 9.1640625,
            "text": "A software program NDComplex",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.43359375,
            "end_logit": 9.1640625,
            "text": "on a few yeast protein interaction networks, and show that our algorithm is able to identify complexes more accurately than existing algorithms. A software program NDComplex",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.96875,
            "end_logit": -1.6044921875,
            "text": "program ND",
            "probability": 0.0
        },
        {
            "start_logit": -7.09765625,
            "end_logit": -1.6044921875,
            "text": "software program ND",
            "probability": 0.0
        },
        {
            "start_logit": -7.12890625,
            "end_logit": -1.6044921875,
            "text": ". A software program ND",
            "probability": 0.0
        },
        {
            "start_logit": -7.22265625,
            "end_logit": -1.6044921875,
            "text": "existing algorithms. A software program ND",
            "probability": 0.0
        },
        {
            "start_logit": -7.30078125,
            "end_logit": -1.6044921875,
            "text": "few yeast protein interaction networks, and show that our algorithm is able to identify complexes more accurately than existing algorithms. A software program ND",
            "probability": 0.0
        },
        {
            "start_logit": -7.359375,
            "end_logit": -1.6044921875,
            "text": "yeast protein interaction networks, and show that our algorithm is able to identify complexes more accurately than existing algorithms. A software program ND",
            "probability": 0.0
        },
        {
            "start_logit": -7.39453125,
            "end_logit": -1.6044921875,
            "text": "A software program ND",
            "probability": 0.0
        },
        {
            "start_logit": -7.43359375,
            "end_logit": -1.6044921875,
            "text": "on a few yeast protein interaction networks, and show that our algorithm is able to identify complexes more accurately than existing algorithms. A software program ND",
            "probability": 0.0
        }
    ],
    "5333f728d6d3ac6a34000041_8": [
        {
            "start_logit": 9.3046875,
            "end_logit": 9.4296875,
            "text": "PROCOMOSS",
            "probability": 1.0
        },
        {
            "start_logit": -1.0556640625,
            "end_logit": 9.4296875,
            "text": "OSS",
            "probability": 3.170967102050781e-05
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -1.138671875,
            "text": "PROC",
            "probability": 2.568960189819336e-05
        },
        {
            "start_logit": -5.16015625,
            "end_logit": 9.4296875,
            "text": "algorithm PROCOMOSS",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -5.12109375,
            "text": "PROCOMOSS (Protein Complex Detection using Multi-objective Evolutionary Approach based on Semantic Similarity",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -5.83203125,
            "end_logit": 9.4296875,
            "text": "OMOSS",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -6.74609375,
            "text": "PROCOMOSS (Protein Complex Detection using Multi-objective Evolutionary Approach based on Semantic Similarity) for partitioning the whole PPI network",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.00390625,
            "text": "PROCOMOSS (Protein Complex Detection using Multi-objective Evolutionary Approach based on Semantic Similarity)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1328125,
            "end_logit": 9.4296875,
            "text": "an algorithm PROCOMOSS",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.15625,
            "text": "PROCOMOSS (Protein Complex Detection using Multi-objective Evolutionary",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.26953125,
            "text": "PROCOMOSS (Protein Complex Detection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.2734375,
            "text": "PROCOMOSS (Protein Complex Detection using Multi-objective Evolutionary Approach",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.296875,
            "text": "PROCOMOSS (Protein Complex Detection using Multi-objective Evolutionary Approach based on Semantic Similarity) for partitioning the whole PPI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.43359375,
            "end_logit": 9.4296875,
            "text": "developed an algorithm PROCOMOSS",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.4140625,
            "text": "PROCOMOSS (Protein Complex Detection using Multi-objective Evolutionary Approach based on Semantic Similarity) for partitioning the whole PPI network into clusters",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.4140625,
            "text": "PROCOMOSS (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.42578125,
            "text": "PROCOMOSS (Protein Complex Detection using Multi-objective Evolutionary Approach based on Semantic Similarity) for",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.46484375,
            "text": "PROCOMOSS (Protein Complex Detection using Multi-objective Evolutionary Approach based on Semantic Similarity) for partitioning the whole PPI network into",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.484375,
            "text": "PROCOMOSS (Protein Complex Detection using Multi-objective Evolutionary Approach based",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.58203125,
            "text": "PROCOMOSS (Protein Complex Detection using Multi-objective",
            "probability": 5.960464477539063e-08
        }
    ],
    "5333f728d6d3ac6a34000041_9": [
        {
            "start_logit": 8.8125,
            "end_logit": 9.265625,
            "text": "metaPIS",
            "probability": 1.0
        },
        {
            "start_logit": -1.46484375,
            "end_logit": 9.265625,
            "text": "IS",
            "probability": 3.427267074584961e-05
        },
        {
            "start_logit": 8.8125,
            "end_logit": -2.19921875,
            "text": "metaP",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": -6.91015625,
            "end_logit": 9.265625,
            "text": "'metaPIS",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -6.74609375,
            "text": "metaPIS'",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -7.00390625,
            "text": "metaPIS' web-server",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8125,
            "end_logit": -7.0625,
            "text": "metaPIS' web-server was implemented for meta-prediction",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8125,
            "end_logit": -7.171875,
            "text": "metaPIS' web-server was implemented for meta-prediction.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8125,
            "end_logit": -7.19140625,
            "text": "metaPIS' web-server was",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8125,
            "end_logit": -7.2890625,
            "text": "metaPIS' web-server was implemented for meta-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8125,
            "end_logit": -7.32421875,
            "text": "metaPIS' web-server was implemented for meta",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8125,
            "end_logit": -7.3671875,
            "text": "metaPIS' web-server was implemented",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8125,
            "end_logit": -7.3828125,
            "text": "metaPIS' web-server was implemented for",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8125,
            "end_logit": -7.48828125,
            "text": "metaPIS' web-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.46484375,
            "end_logit": -6.74609375,
            "text": "IS'",
            "probability": 0.0
        },
        {
            "start_logit": -1.46484375,
            "end_logit": -7.00390625,
            "text": "IS' web-server",
            "probability": 0.0
        },
        {
            "start_logit": -1.46484375,
            "end_logit": -7.0625,
            "text": "IS' web-server was implemented for meta-prediction",
            "probability": 0.0
        },
        {
            "start_logit": -1.46484375,
            "end_logit": -7.171875,
            "text": "IS' web-server was implemented for meta-prediction.",
            "probability": 0.0
        },
        {
            "start_logit": -1.46484375,
            "end_logit": -7.19140625,
            "text": "IS' web-server was",
            "probability": 0.0
        },
        {
            "start_logit": -1.46484375,
            "end_logit": -7.2890625,
            "text": "IS' web-server was implemented for meta-",
            "probability": 0.0
        }
    ],
    "5333f728d6d3ac6a34000041_10": [
        {
            "start_logit": 9.125,
            "end_logit": 8.890625,
            "text": "EPOF",
            "probability": 1.0
        },
        {
            "start_logit": 9.125,
            "end_logit": -1.5185546875,
            "text": "EPO",
            "probability": 3.0219554901123047e-05
        },
        {
            "start_logit": -2.251953125,
            "end_logit": 8.890625,
            "text": "F",
            "probability": 1.150369644165039e-05
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.23046875,
            "text": "EPOF, is proposed, using essential proteins and the local metric of vertex fitness",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.84765625,
            "text": "EPOF, is proposed, using essential proteins and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.05078125,
            "text": "EPOF,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.16015625,
            "text": "EPOF, is",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.24609375,
            "text": "EPOF, is proposed",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.3125,
            "text": "EPOF, is proposed, using essential proteins and the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.09375,
            "end_logit": 8.890625,
            "text": "named EPOF",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.33984375,
            "text": "EPOF, is proposed, using essential proteins",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.10546875,
            "end_logit": 8.890625,
            "text": "paper, a novel protein complex identifying method, named EPOF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.39453125,
            "text": "EPOF, is proposed, using essential proteins and the local metric",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.5,
            "text": "EPOF, is proposed,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.515625,
            "text": "EPOF, is proposed, using essential proteins and the local metric of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 8.890625,
            "text": "novel protein complex identifying method, named EPOF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.43359375,
            "end_logit": 8.890625,
            "text": ", a novel protein complex identifying method, named EPOF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5,
            "end_logit": 8.890625,
            "text": "protein complex identifying method, named EPOF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.52734375,
            "end_logit": 8.890625,
            "text": "identifying method, named EPOF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.52734375,
            "end_logit": 8.890625,
            "text": "this paper, a novel protein complex identifying method, named EPOF",
            "probability": 5.960464477539063e-08
        }
    ],
    "5333f728d6d3ac6a34000041_11": [
        {
            "start_logit": 9.1484375,
            "end_logit": 9.421875,
            "text": "EAGLE",
            "probability": 1.0
        },
        {
            "start_logit": -1.0771484375,
            "end_logit": 9.421875,
            "text": "E",
            "probability": 3.647804260253906e-05
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -1.529296875,
            "text": "EA",
            "probability": 1.7642974853515625e-05
        },
        {
            "start_logit": -6.4140625,
            "end_logit": 9.421875,
            "text": "GLE",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.91796875,
            "end_logit": 9.421875,
            "text": "EPOF to other ten previous algorithms, including EAGLE",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.08984375,
            "end_logit": 9.421875,
            "text": "algorithms, including EAGLE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.09375,
            "end_logit": 9.421875,
            "text": "previous algorithms, including EAGLE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1796875,
            "end_logit": 9.421875,
            "text": "compare the performances of EPOF to other ten previous algorithms, including EAGLE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -6.9140625,
            "text": "EAGLE, NFC, MCODE, DPClus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.22265625,
            "end_logit": 9.421875,
            "text": "performances of EPOF to other ten previous algorithms, including EAGLE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.22265625,
            "end_logit": 9.421875,
            "text": "including EAGLE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -7.05859375,
            "text": "EAGLE, NFC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 9.421875,
            "text": "We compare the performances of EPOF to other ten previous algorithms, including EAGLE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -7.1796875,
            "text": "EAGL",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 9.421875,
            "text": "the performances of EPOF to other ten previous algorithms, including EAGLE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.484375,
            "end_logit": 9.421875,
            "text": "of EPOF to other ten previous algorithms, including EAGLE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -7.2890625,
            "text": "EAGLE, NFC, MCODE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -7.37109375,
            "text": "EAGLE, NFC, MCODE, DPClus, IPCA, CPM, MCL, CMC, SPICi, and Core-Attachment",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -7.46484375,
            "text": "EAGLE, NFC, MCODE, DPClu",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -7.4921875,
            "text": "EAGLE, NFC, MC",
            "probability": 5.960464477539063e-08
        }
    ],
    "5333f728d6d3ac6a34000041_12": [
        {
            "start_logit": 8.90625,
            "end_logit": 8.4375,
            "text": "ProRank",
            "probability": 0.822265625
        },
        {
            "start_logit": 8.90625,
            "end_logit": 6.84375,
            "text": "ProRank to some of the well known protein complex prediction methods (ClusterONE",
            "probability": 0.1671142578125
        },
        {
            "start_logit": 6.15625,
            "end_logit": 6.84375,
            "text": "ClusterONE",
            "probability": 0.01068115234375
        },
        {
            "start_logit": 8.90625,
            "end_logit": -1.890625,
            "text": "Pro",
            "probability": 2.6941299438476562e-05
        },
        {
            "start_logit": -3.0390625,
            "end_logit": 8.4375,
            "text": "k",
            "probability": 5.364418029785156e-06
        },
        {
            "start_logit": -3.0390625,
            "end_logit": 6.84375,
            "text": "k to some of the well known protein complex prediction methods (ClusterONE",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 8.90625,
            "end_logit": -5.4140625,
            "text": "ProRank to some of the well known protein complex prediction methods (Cluster",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -4.69140625,
            "end_logit": 6.84375,
            "text": "ONE",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -7.01953125,
            "text": "ProRank to",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.73828125,
            "end_logit": 8.4375,
            "text": "Rank",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -7.34375,
            "text": "ProRank to some of the well known protein complex prediction methods (ClusterONE, CMC, CFinder, MCL, MCode and Core)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -7.42578125,
            "text": "ProRank to some of the well known protein complex prediction methods (ClusterONE, CMC, CFinder, MCL, MCode and Core",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -7.4296875,
            "text": "ProRank to some",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -7.4375,
            "text": "ProRank to some of the well known protein complex prediction methods (ClusterONE, CMC, CFinder, MCL, MCode and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -7.4609375,
            "text": "ProRank to some of the well known protein complex prediction methods (ClusterONE, CMC",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -7.4921875,
            "text": "ProRank to some of the well known protein complex prediction methods",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -7.5,
            "text": "ProRank to some of the well known protein complex prediction methods (ClusterONE, CMC, CFinder",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -7.53515625,
            "text": "ProRank to some of the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -7.55859375,
            "text": "ProRank to some of the well known protein complex prediction methods (ClusterONE, CMC, CFinder, MCL, MCode",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -7.55859375,
            "text": "ProRank to some of the well known protein complex prediction methods (ClusterONE, CMC, CFinder, MCL, MCode and Core) in",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5333f728d6d3ac6a34000041_13": [
        {
            "start_logit": 8.125,
            "end_logit": 7.45703125,
            "text": "MCL",
            "probability": 1.0
        },
        {
            "start_logit": 8.125,
            "end_logit": -6.40625,
            "text": "MCL, Spectral",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.125,
            "end_logit": -6.4453125,
            "text": "MCL, Spectral, RNSC and Affinity Propagation algorithms",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -5.921875,
            "end_logit": 7.45703125,
            "text": "clustering algorithms using six different interaction datasets. We parameterized the MCL",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.125,
            "end_logit": -7.1171875,
            "text": "MCL, Spectral, RNSC and Affinity Propagation algorithms and applied them to six PPI datasets",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.125,
            "end_logit": -7.15234375,
            "text": "MCL, Spectral, RNSC and Affinity Propagation",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.125,
            "end_logit": -7.15625,
            "text": "MCL, Spectral, RNSC",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.125,
            "end_logit": -7.23046875,
            "text": "MCL,",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.125,
            "end_logit": -7.2890625,
            "text": "MCL, Spectral, RNSC and Affinity Propagation algorithms and applied them to six PPI",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.125,
            "end_logit": -7.31640625,
            "text": "MCL, Spectral, RNSC and Affinity Propagation algorithms and applied them to six PPI datasets produced",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.125,
            "end_logit": -7.3203125,
            "text": "MCL, Spectral, RNSC and",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.7421875,
            "end_logit": 7.45703125,
            "text": "evaluated four different clustering algorithms using six different interaction datasets. We parameterized the MCL",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.05078125,
            "end_logit": 7.45703125,
            "text": ". We parameterized the MCL",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.16796875,
            "end_logit": 7.45703125,
            "text": "different clustering algorithms using six different interaction datasets. We parameterized the MCL",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 7.45703125,
            "text": "paper we evaluated four different clustering algorithms using six different interaction datasets. We parameterized the MCL",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.3125,
            "end_logit": 7.45703125,
            "text": "the MCL",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.390625,
            "end_logit": 7.45703125,
            "text": "we evaluated four different clustering algorithms using six different interaction datasets. We parameterized the MCL",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 7.45703125,
            "text": "using six different interaction datasets. We parameterized the MCL",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 7.45703125,
            "text": "four different clustering algorithms using six different interaction datasets. We parameterized the MCL",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 7.45703125,
            "text": "We parameterized the MCL",
            "probability": 1.7881393432617188e-07
        }
    ],
    "5333f728d6d3ac6a34000041_14": [
        {
            "start_logit": 9.1328125,
            "end_logit": 9.234375,
            "text": "HKC",
            "probability": 1.0
        },
        {
            "start_logit": -1.44921875,
            "end_logit": 9.234375,
            "text": "C",
            "probability": 2.5093555450439453e-05
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -1.455078125,
            "text": "HK",
            "probability": 2.2649765014648438e-05
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -6.25,
            "text": "HKC, to detect protein complexes in genome-scale PPI networks",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -6.28515625,
            "text": "HKC, to detect protein complexes in genome-scale PPI networks. HKC",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.64453125,
            "end_logit": 9.234375,
            "text": "algorithm, HKC",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.8359375,
            "end_logit": 9.234375,
            "text": ", HKC",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.83984375,
            "end_logit": 9.234375,
            "text": "present a new topology-based algorithm, HKC",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.90234375,
            "end_logit": 9.234375,
            "text": "topology-based algorithm, HKC",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.94921875,
            "end_logit": 9.234375,
            "text": "new topology-based algorithm, HKC",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -6.890625,
            "text": "HKC, to detect protein complexes in genome-scale PPI networks. HKC mainly uses the concepts of highest k-core",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -6.91796875,
            "text": "HKC, to detect protein complexes in genome-scale PPI networks. HK",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -6.94921875,
            "text": "HKC, to detect protein complexes in genome-scale PPI networks. HKC mainly uses the concepts of highest k-core and cohesion",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0625,
            "end_logit": 9.234375,
            "text": "paper, we present a new topology-based algorithm, HKC",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.00390625,
            "text": "HKC,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.171875,
            "text": "HKC, to detect protein complexes in genome-scale PPI networks.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.24609375,
            "text": "HKC, to detect protein complexes in genome-scale PPI networks. HKC mainly uses the concepts of highest k-core and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.25390625,
            "text": "HKC, to detect protein complexes in genome-scale PPI networks. HKC mainly uses the concepts of highest k-core and cohesion to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.33984375,
            "text": "HKC, to detect protein complexes in genome-scale PPI networks. HKC mainly uses the concepts of highest k-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.359375,
            "text": "HKC, to detect protein complexes in genome-scale PPI networks. HKC mainly uses",
            "probability": 5.960464477539063e-08
        }
    ],
    "5333f728d6d3ac6a34000041_15": [
        {
            "start_logit": 8.8046875,
            "end_logit": 9.09375,
            "text": "RRW",
            "probability": 1.0
        },
        {
            "start_logit": -1.7236328125,
            "end_logit": 9.09375,
            "text": "W",
            "probability": 2.6702880859375e-05
        },
        {
            "start_logit": 8.8046875,
            "end_logit": -2.1484375,
            "text": "RR",
            "probability": 1.2993812561035156e-05
        },
        {
            "start_logit": -5.55859375,
            "end_logit": 9.09375,
            "text": "Macropol et al. proposed a protein complex prediction algorithm, called RRW",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.30078125,
            "end_logit": 9.09375,
            "text": "called RRW",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.55859375,
            "end_logit": -2.1484375,
            "text": "Macropol et al. proposed a protein complex prediction algorithm, called RR",
            "probability": 0.0
        },
        {
            "start_logit": -6.30078125,
            "end_logit": -2.1484375,
            "text": "called RR",
            "probability": 0.0
        },
        {
            "start_logit": -5.55859375,
            "end_logit": -6.6953125,
            "text": "Macropol",
            "probability": 0.0
        },
        {
            "start_logit": -5.55859375,
            "end_logit": -7.14453125,
            "text": "Macropol et al",
            "probability": 0.0
        },
        {
            "start_logit": -6.80859375,
            "end_logit": -6.57421875,
            "text": ". The resulting algorithm is called NW",
            "probability": 0.0
        },
        {
            "start_logit": -6.87109375,
            "end_logit": -6.57421875,
            "text": "NW",
            "probability": 0.0
        },
        {
            "start_logit": -6.67578125,
            "end_logit": -6.87109375,
            "text": ". In the cluster expansion, all the proteins within the cluster",
            "probability": 0.0
        },
        {
            "start_logit": -6.67578125,
            "end_logit": -6.9140625,
            "text": ". In the cluster expansion, all the proteins within the cluster have equal influences",
            "probability": 0.0
        },
        {
            "start_logit": -6.66796875,
            "end_logit": -6.93359375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.67578125,
            "end_logit": -6.9375,
            "text": ". In the cluster expansion, all the proteins within the cluster have equal influences on determination of newly added protein to the cluster.",
            "probability": 0.0
        },
        {
            "start_logit": -6.67578125,
            "end_logit": -6.9375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.68359375,
            "end_logit": -6.9375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.69140625,
            "end_logit": -6.93359375,
            "text": "Node-Weighted Expansion of clusters of proteins).",
            "probability": 0.0
        },
        {
            "start_logit": -7.0625,
            "end_logit": -6.57421875,
            "text": "resulting algorithm is called NW",
            "probability": 0.0
        },
        {
            "start_logit": -6.67578125,
            "end_logit": -7.0234375,
            "text": ". In the cluster expansion, all the proteins within the cluster have",
            "probability": 0.0
        }
    ],
    "5333f728d6d3ac6a34000041_16": [
        {
            "start_logit": 6.89453125,
            "end_logit": 8.5390625,
            "text": "CPM",
            "probability": 1.0
        },
        {
            "start_logit": -6.40625,
            "end_logit": 8.5390625,
            "text": "algorithm CPM",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 6.89453125,
            "end_logit": -5.33203125,
            "text": "CPM and introduced distance restriction, and develop a novel algorithm called CP-DR",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -7.2734375,
            "end_logit": 8.5390625,
            "text": "paper, we propose a new topological model by extending the definition of k-clique community of algorithm CPM",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 8.5390625,
            "text": "propose a new topological model by extending the definition of k-clique community of algorithm CPM",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.46875,
            "end_logit": 8.5390625,
            "text": "we propose a new topological model by extending the definition of k-clique community of algorithm CPM",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 8.5390625,
            "text": "k-clique community of algorithm CPM",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.53125,
            "end_logit": 8.5390625,
            "text": "of algorithm CPM",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 6.89453125,
            "end_logit": -7.0078125,
            "text": "CPM and introduced distance restriction",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.89453125,
            "end_logit": -7.07421875,
            "text": "CPM and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.89453125,
            "end_logit": -7.13671875,
            "text": "CPM and introduced distance restriction, and develop a novel algorithm called CP-DR based on the new topological model",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.89453125,
            "end_logit": -7.1484375,
            "text": "CPM and introduced distance restriction, and develop a novel algorithm called CP-DR based",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.89453125,
            "end_logit": -7.171875,
            "text": "CPM and introduced distance restriction, and develop a novel algorithm called CP",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.89453125,
            "end_logit": -7.37890625,
            "text": "CPM and introduced distance restriction, and develop a novel algorithm called CP-DR based on the new topological model for",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.89453125,
            "end_logit": -7.4375,
            "text": "CPM and introduced distance restriction, and develop a novel algorithm called CP-DR based on",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.89453125,
            "end_logit": -7.47265625,
            "text": "CPM and introduced distance restriction, and develop a novel algorithm called CP-DR based on the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.89453125,
            "end_logit": -7.53515625,
            "text": "CPM and introduced distance restriction, and develop a novel algorithm called CP-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.91015625,
            "end_logit": -5.33203125,
            "text": "CP-DR",
            "probability": 0.0
        },
        {
            "start_logit": -6.3828125,
            "end_logit": -5.33203125,
            "text": "algorithm called CP-DR",
            "probability": 0.0
        },
        {
            "start_logit": -6.40625,
            "end_logit": -5.33203125,
            "text": "algorithm CPM and introduced distance restriction, and develop a novel algorithm called CP-DR",
            "probability": 0.0
        }
    ],
    "5333f728d6d3ac6a34000041_17": [
        {
            "start_logit": 9.3203125,
            "end_logit": 9.09375,
            "text": "PIPE",
            "probability": 1.0
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -1.064453125,
            "text": "PIP",
            "probability": 3.916025161743164e-05
        },
        {
            "start_logit": -1.8369140625,
            "end_logit": 9.09375,
            "text": "E",
            "probability": 1.4424324035644531e-05
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.03125,
            "text": "PIPE.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.1015625,
            "text": "PIPE. This tool",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.26171875,
            "text": "PIPE. This tool is capable of predicting protein-protein interactions for any target pair",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.26953125,
            "text": "PIPE. This tool is capable of predicting protein-protein interactions for any target pair of the yeast Saccharomyces cerevisiae proteins from their primary structure",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.30078125,
            "text": "PIPE. This tool is capable",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.33203125,
            "text": "PIPE. This tool is capable of predicting protein-protein interactions for any",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.15234375,
            "end_logit": 9.09375,
            "text": "termed PIPE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.41015625,
            "text": "PIPE. This tool is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.4140625,
            "text": "PIPE. This tool is capable of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.41796875,
            "text": "PIPE. This tool is capable of predicting protein-protein interactions for any target pair of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 9.09375,
            "text": "development and implementation of a novel Protein-Protein Interaction Prediction Engine termed PIPE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.44921875,
            "text": "PIPE. This tool is capable of predicting protein-protein interactions for any target pair of the yeast Saccharomyces cerevisiae proteins from",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.28125,
            "end_logit": 9.09375,
            "text": "Here we explain the development and implementation of a novel Protein-Protein Interaction Prediction Engine termed PIPE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 9.09375,
            "text": "implementation of a novel Protein-Protein Interaction Prediction Engine termed PIPE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53125,
            "end_logit": 9.09375,
            "text": "Interaction Prediction Engine termed PIPE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53125,
            "end_logit": 9.09375,
            "text": "explain the development and implementation of a novel Protein-Protein Interaction Prediction Engine termed PIPE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.15234375,
            "end_logit": -1.064453125,
            "text": "termed PIP",
            "probability": 0.0
        }
    ],
    "60321aad1cb411341a000134_1": [
        {
            "start_logit": 9.0,
            "end_logit": 8.6640625,
            "text": "cytolysin A",
            "probability": 1.0
        },
        {
            "start_logit": 9.0,
            "end_logit": -1.728515625,
            "text": "cyto",
            "probability": 3.0934810638427734e-05
        },
        {
            "start_logit": -2.197265625,
            "end_logit": 8.6640625,
            "text": "A",
            "probability": 1.3828277587890625e-05
        },
        {
            "start_logit": 9.0,
            "end_logit": -3.677734375,
            "text": "cytolysin",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": -6.12109375,
            "end_logit": 8.6640625,
            "text": "lysin A",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -6.64453125,
            "text": "cytolysin A)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -6.6875,
            "text": "cytolysin A) and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -6.83203125,
            "text": "cytolysin A) and \u03b2-PFT (\u03b1-hemolysin",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.06640625,
            "text": "cytolysin A) and \u03b2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.16015625,
            "text": "cytolysin A) and \u03b2-PFT (\u03b1-hem",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.234375,
            "text": "cytolysin A) and \u03b2-PFT (\u03b1-hemolysin)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.28515625,
            "text": "cytolysin A) and \u03b2-PF",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.296875,
            "text": "cytolysin A) and \u03b2-PFT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.33984375,
            "text": "cytolysin A) and \u03b2-PFT (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.23828125,
            "end_logit": 8.6640625,
            "text": "Application of this algorithm to prototypical \u03b1-PFT (cytolysin A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3125,
            "end_logit": 8.6640625,
            "text": "(cytolysin A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4375,
            "end_logit": 8.6640625,
            "text": "T (cytolysin A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 8.6640625,
            "text": "to prototypical \u03b1-PFT (cytolysin A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.609375,
            "end_logit": 8.6640625,
            "text": "in A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6953125,
            "end_logit": 8.6640625,
            "text": "this algorithm to prototypical \u03b1-PFT (cytolysin A",
            "probability": 5.960464477539063e-08
        }
    ],
    "60321aad1cb411341a000134_2": [
        {
            "start_logit": 9.3203125,
            "end_logit": 9.390625,
            "text": "Streptolysin O",
            "probability": 1.0
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -1.0263671875,
            "text": "Strept",
            "probability": 2.9802322387695312e-05
        },
        {
            "start_logit": -1.126953125,
            "end_logit": 9.390625,
            "text": "O",
            "probability": 2.8848648071289062e-05
        },
        {
            "start_logit": -6.11328125,
            "end_logit": 9.390625,
            "text": "olysin O",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -6.47265625,
            "text": "Streptolysin O (SLO)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -6.5078125,
            "text": "Streptolysin O (SL",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -6.80859375,
            "text": "Streptolysin O (SLO",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -6.94140625,
            "text": "Streptolysin O (SLO) is a bacterial pore-forming toxin that is employed to permeabilize cell membranes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.125,
            "text": "Streptolysin O (SLO) is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.19140625,
            "text": "Streptolysin O (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.3046875,
            "text": "Streptolysin O (SLO) is a bacterial pore-forming toxin that is employed to permeabilize cell membranes in some biological experiments.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.328125,
            "text": "Streptolysin O (SLO) is a bacterial pore",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.33203125,
            "text": "Streptolysin O (SLO) is a bacterial pore-forming toxin that is employed to permeabilize cell membranes in some biological experiments",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.36328125,
            "text": "Streptolysin O (SLO) is a bacterial pore-forming toxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.3671875,
            "text": "Streptolysin O (SLO) is a bacterial pore-forming toxin that is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.38671875,
            "text": "Streptolysin O (SLO) is a bacterial pore-forming toxin that is employed to permeabilize cell membranes in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.41015625,
            "text": "Streptolysin O (SLO) is a bacterial pore-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.126953125,
            "end_logit": -6.47265625,
            "text": "O (SLO)",
            "probability": 0.0
        },
        {
            "start_logit": -1.126953125,
            "end_logit": -6.5078125,
            "text": "O (SL",
            "probability": 0.0
        },
        {
            "start_logit": -1.126953125,
            "end_logit": -6.80859375,
            "text": "O (SLO",
            "probability": 0.0
        }
    ],
    "60321aad1cb411341a000134_3": [
        {
            "start_logit": 6.51953125,
            "end_logit": 5.73046875,
            "text": "pneumolysin",
            "probability": 1.0
        },
        {
            "start_logit": 6.51953125,
            "end_logit": -4.6953125,
            "text": "pneum",
            "probability": 2.9802322387695312e-05
        },
        {
            "start_logit": -3.943359375,
            "end_logit": 5.73046875,
            "text": "S. pneumoniae pneumolysin",
            "probability": 2.86102294921875e-05
        },
        {
            "start_logit": -5.5703125,
            "end_logit": 5.73046875,
            "text": "olysin",
            "probability": 5.602836608886719e-06
        },
        {
            "start_logit": -6.8515625,
            "end_logit": 5.73046875,
            "text": "pneumoniae pneumolysin",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -6.9296875,
            "end_logit": 5.73046875,
            "text": ". pneumoniae pneumolysin",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -3.943359375,
            "end_logit": -4.6953125,
            "text": "S. pneumoniae pneum",
            "probability": 0.0
        },
        {
            "start_logit": -3.943359375,
            "end_logit": -5.90625,
            "text": "S. pneumoniae",
            "probability": 0.0
        },
        {
            "start_logit": -3.943359375,
            "end_logit": -7.3046875,
            "text": "S",
            "probability": 0.0
        },
        {
            "start_logit": -6.8515625,
            "end_logit": -4.6953125,
            "text": "pneumoniae pneum",
            "probability": 0.0
        },
        {
            "start_logit": -6.9296875,
            "end_logit": -4.6953125,
            "text": ". pneumoniae pneum",
            "probability": 0.0
        },
        {
            "start_logit": -6.8515625,
            "end_logit": -5.90625,
            "text": "pneumoniae",
            "probability": 0.0
        },
        {
            "start_logit": -6.9296875,
            "end_logit": -5.90625,
            "text": ". pneumoniae",
            "probability": 0.0
        }
    ],
    "60321aad1cb411341a000134_4": [
        {
            "start_logit": 7.16015625,
            "end_logit": 7.80859375,
            "text": "streptolysin O",
            "probability": 0.9912109375
        },
        {
            "start_logit": 7.16015625,
            "end_logit": 3.03515625,
            "text": "streptolysin O (SLO)-type and listeriolysin",
            "probability": 0.0083770751953125
        },
        {
            "start_logit": 3.42578125,
            "end_logit": 3.03515625,
            "text": "listeriolysin",
            "probability": 0.00020015239715576172
        },
        {
            "start_logit": -3.509765625,
            "end_logit": 7.80859375,
            "text": "O",
            "probability": 2.300739288330078e-05
        },
        {
            "start_logit": 7.16015625,
            "end_logit": -3.80078125,
            "text": "strept",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": 7.16015625,
            "end_logit": -6.07421875,
            "text": "streptolysin O (SLO)-type and listeriolys",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -7.03125,
            "end_logit": 7.80859375,
            "text": "olysin O",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 7.16015625,
            "end_logit": -6.8125,
            "text": "streptolysin O (SLO)-type and lister",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.16015625,
            "end_logit": -6.85546875,
            "text": "streptolysin O (SLO",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.16015625,
            "end_logit": -6.890625,
            "text": "streptolysin O (SLO)-type",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.16015625,
            "end_logit": -6.95703125,
            "text": "streptolysin O (SLO)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.16015625,
            "end_logit": -6.9765625,
            "text": "streptolysin O (",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.16015625,
            "end_logit": -6.98828125,
            "text": "streptolysin",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.16015625,
            "end_logit": -7.03125,
            "text": "streptolysin O (SL",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.16015625,
            "end_logit": -7.06640625,
            "text": "streptolysin O (SLO)-",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -3.509765625,
            "end_logit": 3.03515625,
            "text": "O (SLO)-type and listeriolysin",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 3.42578125,
            "end_logit": -6.07421875,
            "text": "listeriolys",
            "probability": 0.0
        },
        {
            "start_logit": -6.40625,
            "end_logit": 3.03515625,
            "text": "and listeriolysin",
            "probability": 0.0
        },
        {
            "start_logit": 3.42578125,
            "end_logit": -6.8125,
            "text": "lister",
            "probability": 0.0
        },
        {
            "start_logit": -6.75,
            "end_logit": 3.03515625,
            "text": "iolysin",
            "probability": 0.0
        }
    ],
    "60321aad1cb411341a000134_5": [
        {
            "start_logit": 9.125,
            "end_logit": 8.796875,
            "text": "leukocidin",
            "probability": 1.0
        },
        {
            "start_logit": 9.125,
            "end_logit": -1.5263671875,
            "text": "leuk",
            "probability": 3.272294998168945e-05
        },
        {
            "start_logit": -2.501953125,
            "end_logit": 8.796875,
            "text": "din",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": -5.96484375,
            "end_logit": 8.796875,
            "text": "ocidin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.8046875,
            "end_logit": 8.796875,
            "text": ", leukocidin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0078125,
            "end_logit": 8.796875,
            "text": "structures of a staphylococcal pore-forming cytotoxin, leukocidin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 8.796875,
            "text": "cytotoxin, leukocidin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 8.796875,
            "text": "the structures of a staphylococcal pore-forming cytotoxin, leukocidin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 8.796875,
            "text": "report the structures of a staphylococcal pore-forming cytotoxin, leukocidin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 8.796875,
            "text": "e we report the structures of a staphylococcal pore-forming cytotoxin, leukocidin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7578125,
            "end_logit": 8.796875,
            "text": "staphylococcal pore-forming cytotoxin, leukocidin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.76171875,
            "end_logit": 8.796875,
            "text": "of a staphylococcal pore-forming cytotoxin, leukocidin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.78515625,
            "end_logit": 8.796875,
            "text": "ere we report the structures of a staphylococcal pore-forming cytotoxin, leukocidin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.828125,
            "end_logit": 8.796875,
            "text": "we report the structures of a staphylococcal pore-forming cytotoxin, leukocidin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8046875,
            "end_logit": -1.5263671875,
            "text": ", leuk",
            "probability": 0.0
        },
        {
            "start_logit": -7.0078125,
            "end_logit": -1.5263671875,
            "text": "structures of a staphylococcal pore-forming cytotoxin, leuk",
            "probability": 0.0
        },
        {
            "start_logit": -7.44921875,
            "end_logit": -1.5263671875,
            "text": "cytotoxin, leuk",
            "probability": 0.0
        },
        {
            "start_logit": -7.60546875,
            "end_logit": -1.5263671875,
            "text": "the structures of a staphylococcal pore-forming cytotoxin, leuk",
            "probability": 0.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -1.5263671875,
            "text": "report the structures of a staphylococcal pore-forming cytotoxin, leuk",
            "probability": 0.0
        },
        {
            "start_logit": -7.73046875,
            "end_logit": -1.5263671875,
            "text": "e we report the structures of a staphylococcal pore-forming cytotoxin, leuk",
            "probability": 0.0
        }
    ],
    "56cdf3745795f9a73e000039_1": [
        {
            "start_logit": 8.390625,
            "end_logit": 7.6875,
            "text": "mTOR kinase controls cell growth, proliferation, and survival through two distinct multiprotein complexes, mTORC1 and mTORC2. mTOR",
            "probability": 0.5791015625
        },
        {
            "start_logit": 7.9453125,
            "end_logit": 7.6875,
            "text": "mTOR",
            "probability": 0.37109375
        },
        {
            "start_logit": 8.390625,
            "end_logit": 5.234375,
            "text": "mTOR",
            "probability": 0.0498046875
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -5.51171875,
            "text": "mTOR and mLST8 are in both complexes, while raptor and rictor",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -6.265625,
            "text": "mTOR and mLST8 are in both complexes, while raptor",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.390625,
            "end_logit": -7.1171875,
            "text": "mTOR kinase",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.390625,
            "end_logit": -7.328125,
            "text": "mTOR kinase controls cell growth, proliferation, and survival through two distinct multiprotein complexes, mTORC1 and mTORC2. mTOR and mLST8",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.390625,
            "end_logit": -7.37890625,
            "text": "mTOR kinase controls cell growth, proliferation, and survival through two distinct multiprotein complexes, mTORC1 and mTORC2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.390625,
            "end_logit": -7.4140625,
            "text": "mTOR kinase controls cell growth, proliferation, and survival through two distinct multiprotein complexes, mTORC1 and mTORC2.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -6.96875,
            "text": "mTOR and mLST8 are in both complexes, while raptor and rictor are",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -7.01171875,
            "text": "mTOR and mLST8 are in both complexes, while raptor and rict",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -7.11328125,
            "text": "mTOR and mLST8 are in both complexes, while raptor and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -7.18359375,
            "text": "mTOR and mLST8 are in both complexes, while rap",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.953125,
            "end_logit": 7.6875,
            "text": ". mTOR",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -7.23046875,
            "text": "mTOR and mLST8 are in both complexes, while raptor and rictor are part of only mTORC1 and mTORC2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -7.2890625,
            "text": "mTOR and mLST8 are in both complexes, while raptor and rictor are part of only mTORC1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -7.31640625,
            "text": "mTOR and mLST8 are in both",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -7.328125,
            "text": "mTOR and mLST8",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -7.34375,
            "text": "mTOR and mLST8 are in both complexes, while raptor and rictor are part of only mTORC1 and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -7.35546875,
            "text": "mTOR and mLST8 are in both complexes, while raptor and ri",
            "probability": 1.1920928955078125e-07
        }
    ],
    "56cdf3745795f9a73e000039_2": [
        {
            "start_logit": 5.21875,
            "end_logit": 0.414794921875,
            "text": "mTOR",
            "probability": 0.7646484375
        },
        {
            "start_logit": 5.21875,
            "end_logit": -1.10546875,
            "text": "mTOR (mammalian target of rapamycin) protein kinase is an important regulator of cell growth. Two complexes of mTOR",
            "probability": 0.1673583984375
        },
        {
            "start_logit": 0.37744140625,
            "end_logit": 2.0390625,
            "text": "regulatory associated protein of mTOR",
            "probability": 0.0306396484375
        },
        {
            "start_logit": 0.37451171875,
            "end_logit": 2.0390625,
            "text": "mTOR have been identified: complex 1, consisting of mTOR-Raptor (regulatory associated protein of mTOR",
            "probability": 0.0305938720703125
        },
        {
            "start_logit": 5.21875,
            "end_logit": -5.04296875,
            "text": "mTOR (mammalian target of rapamycin",
            "probability": 0.003261566162109375
        },
        {
            "start_logit": 0.37451171875,
            "end_logit": -1.10546875,
            "text": "mTOR",
            "probability": 0.0013179779052734375
        },
        {
            "start_logit": 5.21875,
            "end_logit": -6.703125,
            "text": "mTOR (mammalian target of rapamycin) protein kinase",
            "probability": 0.0006203651428222656
        },
        {
            "start_logit": 5.21875,
            "end_logit": -6.78515625,
            "text": "mTOR (mammalian target of rapamycin) protein kinase is an important regulator of cell growth.",
            "probability": 0.0005712509155273438
        },
        {
            "start_logit": -4.82421875,
            "end_logit": 2.0390625,
            "text": "mTOR-Raptor (regulatory associated protein of mTOR",
            "probability": 0.00016832351684570312
        },
        {
            "start_logit": -5.44921875,
            "end_logit": 2.0390625,
            "text": "mTOR",
            "probability": 9.006261825561523e-05
        },
        {
            "start_logit": -3.1015625,
            "end_logit": -1.10546875,
            "text": "mammalian target of rapamycin) protein kinase is an important regulator of cell growth. Two complexes of mTOR",
            "probability": 4.0590763092041016e-05
        },
        {
            "start_logit": -6.51171875,
            "end_logit": 2.0390625,
            "text": "of mTOR",
            "probability": 3.1113624572753906e-05
        },
        {
            "start_logit": -6.5390625,
            "end_logit": 2.0390625,
            "text": "of mTOR-Raptor (regulatory associated protein of mTOR",
            "probability": 3.039836883544922e-05
        },
        {
            "start_logit": -6.5546875,
            "end_logit": 2.0390625,
            "text": "Raptor (regulatory associated protein of mTOR",
            "probability": 2.9921531677246094e-05
        },
        {
            "start_logit": -6.56640625,
            "end_logit": 2.0390625,
            "text": "associated protein of mTOR",
            "probability": 2.9742717742919922e-05
        },
        {
            "start_logit": -6.59375,
            "end_logit": 2.0390625,
            "text": ". Two complexes of mTOR have been identified: complex 1, consisting of mTOR-Raptor (regulatory associated protein of mTOR",
            "probability": 2.8789043426513672e-05
        },
        {
            "start_logit": -6.6328125,
            "end_logit": 2.0390625,
            "text": "complexes of mTOR have been identified: complex 1, consisting of mTOR-Raptor (regulatory associated protein of mTOR",
            "probability": 2.765655517578125e-05
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 2.0390625,
            "text": "of mTOR have been identified: complex 1, consisting of mTOR-Raptor (regulatory associated protein of mTOR",
            "probability": 1.9788742065429688e-05
        },
        {
            "start_logit": -7.07421875,
            "end_logit": 2.0390625,
            "text": "consisting of mTOR-Raptor (regulatory associated protein of mTOR",
            "probability": 1.7702579498291016e-05
        },
        {
            "start_logit": 0.37744140625,
            "end_logit": -5.48046875,
            "text": "regulatory associated protein of mTOR)",
            "probability": 1.6629695892333984e-05
        }
    ],
    "56cdf3745795f9a73e000039_3": [
        {
            "start_logit": 8.1328125,
            "end_logit": 7.3671875,
            "text": "mTOR",
            "probability": 1.0
        },
        {
            "start_logit": -4.73828125,
            "end_logit": 7.3671875,
            "text": "raptor, mTOR",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": 8.1328125,
            "end_logit": -7.19921875,
            "text": "mTOR, and GbetaL",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.1328125,
            "end_logit": -7.421875,
            "text": "mTOR, and GbetaL)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.1328125,
            "end_logit": -7.484375,
            "text": "mTOR, and Gb",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.9921875,
            "end_logit": 7.3671875,
            "text": "(raptor, mTOR",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.078125,
            "end_logit": 7.3671875,
            "text": ", mTOR",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 7.3671875,
            "text": "composition of mTORC1 (raptor, mTOR",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 7.3671875,
            "text": "mTORC1 (raptor, mTOR",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 7.3671875,
            "text": "C1 (raptor, mTOR",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.59375,
            "end_logit": 7.3671875,
            "text": "of mTORC1 (raptor, mTOR",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.73828125,
            "end_logit": -5.171875,
            "text": "raptor",
            "probability": 0.0
        },
        {
            "start_logit": -4.73828125,
            "end_logit": -6.8828125,
            "text": "rap",
            "probability": 0.0
        },
        {
            "start_logit": -4.73828125,
            "end_logit": -7.19921875,
            "text": "raptor, mTOR, and GbetaL",
            "probability": 0.0
        },
        {
            "start_logit": -4.73828125,
            "end_logit": -7.421875,
            "text": "raptor, mTOR, and GbetaL)",
            "probability": 0.0
        },
        {
            "start_logit": -6.9921875,
            "end_logit": -5.171875,
            "text": "(raptor",
            "probability": 0.0
        },
        {
            "start_logit": -4.73828125,
            "end_logit": -7.484375,
            "text": "raptor, mTOR, and Gb",
            "probability": 0.0
        },
        {
            "start_logit": -7.5078125,
            "end_logit": -5.171875,
            "text": "composition of mTORC1 (raptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.53515625,
            "end_logit": -5.171875,
            "text": "mTORC1 (raptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": -5.171875,
            "text": "C1 (raptor",
            "probability": 0.0
        }
    ],
    "56cdf3745795f9a73e000039_4": [
        {
            "start_logit": 8.1953125,
            "end_logit": 7.1875,
            "text": "mTOR",
            "probability": 0.9990234375
        },
        {
            "start_logit": 8.1953125,
            "end_logit": 0.1712646484375,
            "text": "mTOR) is part of two distinct complexes, mTORC1, containing raptor",
            "probability": 0.0008969306945800781
        },
        {
            "start_logit": -3.646484375,
            "end_logit": 7.1875,
            "text": "mammalian target of rapamycin (mTOR",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -5.95703125,
            "text": "mTOR)",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -6.734375,
            "text": "mTOR) is part of two distinct complexes, mTORC1, containing raptor and mLST8",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -6.9765625,
            "text": "mTOR) is part of two distinct complexes, mTORC1, containing raptor and mLST8, and mTORC2, containing rictor",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -7.0625,
            "text": "mTOR) is",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -7.171875,
            "text": "mTOR) is part of two distinct complexes, mTORC1, containing raptor and mLST",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -7.234375,
            "text": "mTOR) is part of two distinct complexes, mTORC1, containing raptor and",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -7.3828125,
            "text": "mTOR) is part of two distinct complexes, mTORC1, containing raptor and mLST8, and mTORC2",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -7.40625,
            "text": "mTOR) is part",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 0.61279296875,
            "end_logit": 0.1712646484375,
            "text": "raptor",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -7.45703125,
            "text": "mTOR) is part of two distinct complexes, mTORC1, containing raptor and mLST8, and mTORC2, containing rict",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 7.1875,
            "text": "The mammalian target of rapamycin (mTOR",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.2109375,
            "end_logit": 7.1875,
            "text": "target of rapamycin (mTOR",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -3.646484375,
            "end_logit": 0.1712646484375,
            "text": "mammalian target of rapamycin (mTOR) is part of two distinct complexes, mTORC1, containing raptor",
            "probability": 0.0
        },
        {
            "start_logit": 0.61279296875,
            "end_logit": -6.734375,
            "text": "raptor and mLST8",
            "probability": 0.0
        },
        {
            "start_logit": 0.61279296875,
            "end_logit": -6.9765625,
            "text": "raptor and mLST8, and mTORC2, containing rictor",
            "probability": 0.0
        },
        {
            "start_logit": 0.61279296875,
            "end_logit": -7.171875,
            "text": "raptor and mLST",
            "probability": 0.0
        },
        {
            "start_logit": 0.61279296875,
            "end_logit": -7.234375,
            "text": "raptor and",
            "probability": 0.0
        }
    ],
    "56cdf3745795f9a73e000039_5": [
        {
            "start_logit": 7.984375,
            "end_logit": 7.68359375,
            "text": "mTOR",
            "probability": 1.0
        },
        {
            "start_logit": 7.984375,
            "end_logit": -6.4765625,
            "text": "mTOR, raptor, mLST8/GbetaL and PRAS40",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 7.984375,
            "end_logit": -7.04296875,
            "text": "mTOR, raptor",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.984375,
            "end_logit": -7.140625,
            "text": "mTOR, raptor, mLST8/GbetaL and PRAS",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.984375,
            "end_logit": -7.34375,
            "text": "mTOR, rap",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.984375,
            "end_logit": -7.34375,
            "text": "mTOR, raptor, mLST8/GbetaL and PRAS40.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.984375,
            "end_logit": -7.4140625,
            "text": "mTOR, raptor, mLST8/GbetaL and PRA",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.984375,
            "end_logit": -7.50390625,
            "text": "mTOR, raptor, mLST8/GbetaL and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.984375,
            "end_logit": -7.515625,
            "text": "mTOR, raptor, mLST8",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.2890625,
            "end_logit": 7.68359375,
            "text": "of mTOR",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.984375,
            "end_logit": -7.6015625,
            "text": "mTOR, raptor, mLST8/GbetaL",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.984375,
            "end_logit": -7.61328125,
            "text": "mTOR, raptor, mLST",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.984375,
            "end_logit": -7.625,
            "text": "mTOR,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.984375,
            "end_logit": -7.625,
            "text": "mTOR, raptor, mLST8/",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 7.68359375,
            "text": "C1 protein kinase complex consists of mTOR",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 7.68359375,
            "text": "mTORC1 protein kinase complex consists of mTOR",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 7.68359375,
            "text": "complex consists of mTOR",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.2890625,
            "end_logit": -6.4765625,
            "text": "of mTOR, raptor, mLST8/GbetaL and PRAS40",
            "probability": 0.0
        },
        {
            "start_logit": -7.484375,
            "end_logit": -6.4765625,
            "text": "raptor, mLST8/GbetaL and PRAS40",
            "probability": 0.0
        },
        {
            "start_logit": -7.5078125,
            "end_logit": -6.4765625,
            "text": "mLST8/GbetaL and PRAS40",
            "probability": 0.0
        }
    ],
    "56cdf3745795f9a73e000039_6": [
        {
            "start_logit": 8.1484375,
            "end_logit": 7.3984375,
            "text": "mTOR",
            "probability": 0.998046875
        },
        {
            "start_logit": 6.80859375,
            "end_logit": 2.23828125,
            "text": "mTOR",
            "probability": 0.0015001296997070312
        },
        {
            "start_logit": 8.1484375,
            "end_logit": -5.84375,
            "text": "mTOR, Raptor (regulatory associated protein of mTOR",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 8.1484375,
            "end_logit": -6.80078125,
            "text": "mTOR, Raptor",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.1484375,
            "end_logit": -7.13671875,
            "text": "mTOR, Rap",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.1484375,
            "end_logit": -7.18359375,
            "text": "mTOR, Raptor (regulatory associated protein of mTOR)",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.1484375,
            "end_logit": -7.20703125,
            "text": "mTOR, Raptor (regulatory associated protein of mTOR) and mLST8 (mammalian lethal with SEC13 protein 8) and complex 2 (mTORC2",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.1484375,
            "end_logit": -7.29296875,
            "text": "mTOR, Raptor (regulatory associated protein of mTOR) and",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.58203125,
            "end_logit": 7.3984375,
            "text": "of mTOR",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.9140625,
            "end_logit": 7.3984375,
            "text": ". Two complexes of mTOR have been identified: complex 1 (mTORC1), consisting of mTOR",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.33203125,
            "end_logit": 7.3984375,
            "text": "consisting of mTOR",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.484375,
            "end_logit": 7.3984375,
            "text": "C1), consisting of mTOR",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 7.3984375,
            "text": "complexes of mTOR have been identified: complex 1 (mTORC1), consisting of mTOR",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 7.3984375,
            "text": "of mTOR have been identified: complex 1 (mTORC1), consisting of mTOR",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.80859375,
            "end_logit": -7.0390625,
            "text": "mTOR (mammalian target of rapamycin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.80859375,
            "end_logit": -7.08203125,
            "text": "mTOR (mammalian target of rapamycin) protein kinase is an important regulator of cell growth and is a key target for therapeutic intervention in cancer.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.80859375,
            "end_logit": -7.1484375,
            "text": "mTOR (mammalian target of rapamycin) protein kinase",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.58203125,
            "end_logit": -5.84375,
            "text": "of mTOR, Raptor (regulatory associated protein of mTOR",
            "probability": 0.0
        },
        {
            "start_logit": -6.9140625,
            "end_logit": -5.84375,
            "text": ". Two complexes of mTOR have been identified: complex 1 (mTORC1), consisting of mTOR, Raptor (regulatory associated protein of mTOR",
            "probability": 0.0
        },
        {
            "start_logit": -6.69921875,
            "end_logit": -6.12109375,
            "text": "mammalian target of rapamycin) protein kinase is an important regulator of cell growth and is a key target for therapeutic intervention in cancer. Two complexes of mTOR",
            "probability": 0.0
        }
    ],
    "5e2f906ffbd6abf43b00002c_1": [
        {
            "start_logit": 8.171875,
            "end_logit": 7.27734375,
            "text": "lidocaine",
            "probability": 1.0
        },
        {
            "start_logit": 8.171875,
            "end_logit": -5.140625,
            "text": "lidocaine/ antacid",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": 8.171875,
            "end_logit": -6.79296875,
            "text": "lidocaine/ antacid \u00b1 anticholinergic",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.171875,
            "end_logit": -7.08203125,
            "text": "lidocaine/ antacid \u00b1 anticholinergic)",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.3125,
            "end_logit": 7.27734375,
            "text": "viscous lidocaine",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.171875,
            "end_logit": -7.21484375,
            "text": "lidocaine/ antacid \u00b1 anticholinergic) to standard diagnostic protocols (serial electrocardiograms (ECGs), serial biomarkers",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.34375,
            "end_logit": 7.27734375,
            "text": "systematic review of the literature was conducted to locate and evaluate clinical trials comparing the use of an oral gastrointestinal (GI) cocktail (oral viscous lidocaine",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.171875,
            "end_logit": -7.2734375,
            "text": "lidocaine/ antacid \u00b1",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.171875,
            "end_logit": -7.27734375,
            "text": "lidocaine/ antacid \u00b1 anticholinergic) to standard diagnostic protocols (serial electrocardiograms (ECGs), serial biomarkers, imaging and/",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.171875,
            "end_logit": -7.3125,
            "text": "lidocaine/ antacid \u00b1 anticholinergic) to standard diagnostic protocols (serial electrocardiograms (ECGs)",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.171875,
            "end_logit": -7.3515625,
            "text": "lidocaine/ antacid \u00b1 anticholinergic) to standard diagnostic protocols (serial electrocardiograms (ECG",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.81640625,
            "end_logit": 7.27734375,
            "text": "oral viscous lidocaine",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.03125,
            "end_logit": 7.27734375,
            "text": "A systematic review of the literature was conducted to locate and evaluate clinical trials comparing the use of an oral gastrointestinal (GI) cocktail (oral viscous lidocaine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.328125,
            "end_logit": 7.27734375,
            "text": "oral gastrointestinal (GI) cocktail (oral viscous lidocaine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.3515625,
            "end_logit": 7.27734375,
            "text": "(oral viscous lidocaine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.37890625,
            "end_logit": 7.27734375,
            "text": "clinical trials comparing the use of an oral gastrointestinal (GI) cocktail (oral viscous lidocaine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.390625,
            "end_logit": 7.27734375,
            "text": "evaluate clinical trials comparing the use of an oral gastrointestinal (GI) cocktail (oral viscous lidocaine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.36328125,
            "end_logit": -5.140625,
            "text": "antacid",
            "probability": 0.0
        },
        {
            "start_logit": -6.3125,
            "end_logit": -5.140625,
            "text": "viscous lidocaine/ antacid",
            "probability": 0.0
        },
        {
            "start_logit": -6.81640625,
            "end_logit": -5.140625,
            "text": "oral viscous lidocaine/ antacid",
            "probability": 0.0
        }
    ],
    "5e2f906ffbd6abf43b00002c_2": [
        {
            "start_logit": 9.3203125,
            "end_logit": 9.4140625,
            "text": "Benzocaine",
            "probability": 1.0
        },
        {
            "start_logit": -1.095703125,
            "end_logit": 9.4140625,
            "text": "ine",
            "probability": 2.9981136322021484e-05
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -1.060546875,
            "text": "Benzo",
            "probability": 2.8192996978759766e-05
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -3.396484375,
            "text": "Benzocaine or viscous Lidocaine in addition to 30 cc of Maalox",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -5.63671875,
            "text": "Benzocaine or viscous Lidocaine",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -5.7890625,
            "text": "Benzocaine or viscous Lidocaine in addition to 30 cc of Maalox and 10 cc of Donnatal",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.91015625,
            "end_logit": 9.4140625,
            "text": "caine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.79296875,
            "end_logit": 9.4140625,
            "text": "equivalent doses of either Benzocaine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.87109375,
            "end_logit": 9.4140625,
            "text": "either Benzocaine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.953125,
            "end_logit": 9.4140625,
            "text": "to equivalent doses of either Benzocaine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -6.90625,
            "text": "Benzocaine or viscous Lidocaine in addition to 30 cc of Maalox and 10 cc of Donnatal.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.04296875,
            "end_logit": 9.4140625,
            "text": "doses of either Benzocaine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.10546875,
            "text": "Benzocaine or",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.12109375,
            "text": "Benzocaine or viscous Lidocaine in addition to 30 cc of Maalox and 10 cc of Donnat",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.265625,
            "end_logit": 9.4140625,
            "text": "of either Benzocaine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.25390625,
            "text": "Benzocaine or viscous Lidocaine in addition to 30 cc of Maalox and 10 cc of Don",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.32421875,
            "text": "Benzocaine or viscous Lidocaine in addition to 30 cc of Maalo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.4296875,
            "text": "Benzoca",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.44140625,
            "text": "Benzocaine or viscous Lidocaine in addition to 30 cc of Maalox and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.546875,
            "text": "Benzocaine or viscous Lidocaine in addition",
            "probability": 5.960464477539063e-08
        }
    ],
    "5e2f906ffbd6abf43b00002c_3": [
        {
            "start_logit": 9.453125,
            "end_logit": 9.328125,
            "text": "Donnatal",
            "probability": 1.0
        },
        {
            "start_logit": 9.453125,
            "end_logit": -0.5908203125,
            "text": "Don",
            "probability": 4.9114227294921875e-05
        },
        {
            "start_logit": -1.328125,
            "end_logit": 9.328125,
            "text": "al",
            "probability": 2.0802021026611328e-05
        },
        {
            "start_logit": -3.345703125,
            "end_logit": 9.328125,
            "text": "antacid (group 1); antacid + Donnatal",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": 9.453125,
            "end_logit": -6.35546875,
            "text": "Donnatal (group 2); antacid + Donnatal + viscous lidocaine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.453125,
            "end_logit": -6.38671875,
            "text": "Donnatal (group 2); antacid + Donnatal",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.29296875,
            "end_logit": 9.328125,
            "text": "; antacid + Donnatal",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.390625,
            "end_logit": 9.328125,
            "text": "comparing antacid (group 1); antacid + Donnatal",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.39453125,
            "end_logit": 9.328125,
            "text": ". The study was a prospective, randomized, double-blinded trial comparing antacid (group 1); antacid + Donnatal",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.6484375,
            "end_logit": 9.328125,
            "text": "natal",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.453125,
            "end_logit": -6.796875,
            "text": "Donnat",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.453125,
            "end_logit": -6.859375,
            "text": "Donnatal (group 2); antacid + Donnatal + viscous lidocaine (group 3) for acute treatment of dyspepsia in the ED.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.453125,
            "end_logit": -7.12890625,
            "text": "Donnatal (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.125,
            "end_logit": 9.328125,
            "text": "+ Donnatal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.14453125,
            "end_logit": 9.328125,
            "text": "study was a prospective, randomized, double-blinded trial comparing antacid (group 1); antacid + Donnatal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.453125,
            "end_logit": -7.31640625,
            "text": "Donnatal (group 2); antacid + Donnatal + viscous lidocaine (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.19921875,
            "end_logit": 9.328125,
            "text": "antacid + Donnatal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.453125,
            "end_logit": -7.375,
            "text": "Donnatal (group 2); antacid + Donnat",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.453125,
            "end_logit": -7.44140625,
            "text": "Donnatal (group 2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.345703125,
            "end_logit": -0.5908203125,
            "text": "antacid (group 1); antacid + Don",
            "probability": 0.0
        }
    ],
    "5e2f906ffbd6abf43b00002c_4": [
        {
            "start_logit": 2.037109375,
            "end_logit": 0.9921875,
            "text": "antacid",
            "probability": 0.4853515625
        },
        {
            "start_logit": 2.037109375,
            "end_logit": 0.58154296875,
            "text": "antacid, viscous lidocaine",
            "probability": 0.322021484375
        },
        {
            "start_logit": 2.037109375,
            "end_logit": -0.50732421875,
            "text": "antacid, viscous lidocaine, and an anticholinergic",
            "probability": 0.1082763671875
        },
        {
            "start_logit": 0.311279296875,
            "end_logit": 0.58154296875,
            "text": "lidocaine",
            "probability": 0.057281494140625
        },
        {
            "start_logit": 0.311279296875,
            "end_logit": -0.50732421875,
            "text": "lidocaine, and an anticholinergic",
            "probability": 0.0193023681640625
        },
        {
            "start_logit": -1.1923828125,
            "end_logit": -0.50732421875,
            "text": "anticholinergic",
            "probability": 0.004299163818359375
        },
        {
            "start_logit": -3.564453125,
            "end_logit": 0.58154296875,
            "text": "viscous lidocaine",
            "probability": 0.0011882781982421875
        },
        {
            "start_logit": -3.564453125,
            "end_logit": -0.50732421875,
            "text": "viscous lidocaine, and an anticholinergic",
            "probability": 0.0003998279571533203
        },
        {
            "start_logit": 2.037109375,
            "end_logit": -6.74609375,
            "text": "antacid, viscous lidocaine, and an anticholinergic)",
            "probability": 0.00021064281463623047
        },
        {
            "start_logit": 2.037109375,
            "end_logit": -7.0703125,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department",
            "probability": 0.00015294551849365234
        },
        {
            "start_logit": 2.037109375,
            "end_logit": -7.109375,
            "text": "ant",
            "probability": 0.00014710426330566406
        },
        {
            "start_logit": 2.037109375,
            "end_logit": -7.203125,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a single hospital and the responses and final dispositions",
            "probability": 0.00013387203216552734
        },
        {
            "start_logit": -6.25,
            "end_logit": 0.9921875,
            "text": "liquid antacid",
            "probability": 0.00012195110321044922
        },
        {
            "start_logit": 2.037109375,
            "end_logit": -7.37890625,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a single hospital and the responses and final dispositions of patients who received the",
            "probability": 0.0001118779182434082
        },
        {
            "start_logit": 2.037109375,
            "end_logit": -7.3984375,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a single hospital and the responses and final dispositions of patients who received",
            "probability": 0.00011014938354492188
        },
        {
            "start_logit": 2.037109375,
            "end_logit": -7.4140625,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a",
            "probability": 0.00010848045349121094
        },
        {
            "start_logit": 2.037109375,
            "end_logit": -7.453125,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a single hospital and the responses and final dispositions of",
            "probability": 0.0001043081283569336
        },
        {
            "start_logit": -6.25,
            "end_logit": 0.58154296875,
            "text": "liquid antacid, viscous lidocaine",
            "probability": 8.124113082885742e-05
        },
        {
            "start_logit": 0.311279296875,
            "end_logit": -5.9921875,
            "text": "lidocaine, and an anticholinergic) in the emergency department in a single hospital and the responses and final dispositions of patients who received the cocktails.",
            "probability": 7.992982864379883e-05
        },
        {
            "start_logit": -6.73828125,
            "end_logit": 0.9921875,
            "text": "determine practice patterns regarding administration of the \"GI cocktail\" (a mixture of liquid antacid",
            "probability": 7.510185241699219e-05
        }
    ],
    "5e2f906ffbd6abf43b00002c_5": [
        {
            "start_logit": 5.8671875,
            "end_logit": 6.140625,
            "text": "antacid",
            "probability": 0.83740234375
        },
        {
            "start_logit": 5.8671875,
            "end_logit": 4.4765625,
            "text": "antacid (Mylanta II), or 30 mL of antacid plus 15 mL of 2% viscous lidocaine",
            "probability": 0.1585693359375
        },
        {
            "start_logit": 2.16015625,
            "end_logit": 4.4765625,
            "text": "lidocaine",
            "probability": 0.0038928985595703125
        },
        {
            "start_logit": -5.45703125,
            "end_logit": 6.140625,
            "text": "acid",
            "probability": 1.0073184967041016e-05
        },
        {
            "start_logit": 5.8671875,
            "end_logit": -5.44140625,
            "text": "ant",
            "probability": 7.808208465576172e-06
        },
        {
            "start_logit": -6.59375,
            "end_logit": 6.140625,
            "text": "of antacid",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": -7.0234375,
            "end_logit": 6.140625,
            "text": "receive 30 mL of antacid",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -5.45703125,
            "end_logit": 4.4765625,
            "text": "acid (Mylanta II), or 30 mL of antacid plus 15 mL of 2% viscous lidocaine",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -7.140625,
            "end_logit": 6.140625,
            "text": "mL of antacid",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 6.140625,
            "text": "30 mL of antacid",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 6.140625,
            "text": "randomized to receive 30 mL of antacid",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": -7.234375,
            "end_logit": 6.140625,
            "text": "Patients presenting to the ED with dyspeptic symptoms were randomized to receive 30 mL of antacid",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 6.140625,
            "text": "to receive 30 mL of antacid",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 5.8671875,
            "end_logit": -7.12109375,
            "text": "antacid (Mylanta",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 5.8671875,
            "end_logit": -7.14453125,
            "text": "antacid (Mylant",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 5.8671875,
            "end_logit": -7.16015625,
            "text": "antacid (Mylanta II), or 30 mL of antacid plus 15 mL of 2% viscous lidocaine (GI cocktail).",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 5.8671875,
            "end_logit": -7.296875,
            "text": "antacid (Mylanta II), or 30 mL of antacid plus 15 mL of 2%",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 5.8671875,
            "end_logit": -7.30859375,
            "text": "antacid (Mylanta II",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -5.9453125,
            "end_logit": 4.4765625,
            "text": "viscous lidocaine",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 5.8671875,
            "end_logit": -7.359375,
            "text": "antacid (Mylanta II)",
            "probability": 1.1324882507324219e-06
        }
    ],
    "5e2f906ffbd6abf43b00002c_6": [
        {
            "start_logit": 4.9921875,
            "end_logit": 5.6484375,
            "text": "antacid",
            "probability": 0.9990234375
        },
        {
            "start_logit": 4.9921875,
            "end_logit": -1.9130859375,
            "text": "antacid, viscous lidocaine",
            "probability": 0.0005192756652832031
        },
        {
            "start_logit": 4.9921875,
            "end_logit": -2.23828125,
            "text": "antacid, viscous lidocaine, and an anticholinergic",
            "probability": 0.0003752708435058594
        },
        {
            "start_logit": -5.44140625,
            "end_logit": 5.6484375,
            "text": "acid",
            "probability": 2.9325485229492188e-05
        },
        {
            "start_logit": -6.4296875,
            "end_logit": 5.6484375,
            "text": "liquid antacid",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": 4.9921875,
            "end_logit": -5.83203125,
            "text": "ant",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -6.63671875,
            "end_logit": 5.6484375,
            "text": "determine practice patterns regarding administration of the \"GI cocktail\" (a mixture of liquid antacid",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": -6.83203125,
            "end_logit": 5.6484375,
            "text": "mixture of liquid antacid",
            "probability": 7.271766662597656e-06
        },
        {
            "start_logit": -6.95703125,
            "end_logit": 5.6484375,
            "text": "a mixture of liquid antacid",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": -7.11328125,
            "end_logit": 5.6484375,
            "text": "practice patterns regarding administration of the \"GI cocktail\" (a mixture of liquid antacid",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": -7.17578125,
            "end_logit": 5.6484375,
            "text": "cocktail\" (a mixture of liquid antacid",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": 4.9921875,
            "end_logit": -6.84375,
            "text": "antacid, viscous lidocaine, and an anticholinergic)",
            "probability": 3.7550926208496094e-06
        },
        {
            "start_logit": 4.9921875,
            "end_logit": -7.1796875,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": 4.9921875,
            "end_logit": -7.3515625,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a single hospital and the responses and final dispositions",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": 4.9921875,
            "end_logit": -7.3828125,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 4.9921875,
            "end_logit": -7.40625,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a single hospital and the responses and final dispositions of patients who received",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 4.9921875,
            "end_logit": -7.4140625,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a single hospital and the responses and final dispositions of patients who received the",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 4.9921875,
            "end_logit": -7.48828125,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a single hospital and the responses and final dispositions of",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": 4.9921875,
            "end_logit": -7.4921875,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a single hospital",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -2.017578125,
            "end_logit": -1.9130859375,
            "text": "lidocaine",
            "probability": 4.76837158203125e-07
        }
    ],
    "5e2f906ffbd6abf43b00002c_7": [
        {
            "start_logit": 4.9921875,
            "end_logit": 5.6484375,
            "text": "antacid",
            "probability": 0.9990234375
        },
        {
            "start_logit": 4.9921875,
            "end_logit": -1.9130859375,
            "text": "antacid, viscous lidocaine",
            "probability": 0.0005192756652832031
        },
        {
            "start_logit": 4.9921875,
            "end_logit": -2.23828125,
            "text": "antacid, viscous lidocaine, and an anticholinergic",
            "probability": 0.0003752708435058594
        },
        {
            "start_logit": -5.44140625,
            "end_logit": 5.6484375,
            "text": "acid",
            "probability": 2.9325485229492188e-05
        },
        {
            "start_logit": -6.4296875,
            "end_logit": 5.6484375,
            "text": "liquid antacid",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": 4.9921875,
            "end_logit": -5.83203125,
            "text": "ant",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -6.63671875,
            "end_logit": 5.6484375,
            "text": "determine practice patterns regarding administration of the \"GI cocktail\" (a mixture of liquid antacid",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": -6.83203125,
            "end_logit": 5.6484375,
            "text": "mixture of liquid antacid",
            "probability": 7.271766662597656e-06
        },
        {
            "start_logit": -6.95703125,
            "end_logit": 5.6484375,
            "text": "a mixture of liquid antacid",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": -7.11328125,
            "end_logit": 5.6484375,
            "text": "practice patterns regarding administration of the \"GI cocktail\" (a mixture of liquid antacid",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": -7.17578125,
            "end_logit": 5.6484375,
            "text": "cocktail\" (a mixture of liquid antacid",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": 4.9921875,
            "end_logit": -6.84375,
            "text": "antacid, viscous lidocaine, and an anticholinergic)",
            "probability": 3.7550926208496094e-06
        },
        {
            "start_logit": 4.9921875,
            "end_logit": -7.1796875,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": 4.9921875,
            "end_logit": -7.3515625,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a single hospital and the responses and final dispositions",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": 4.9921875,
            "end_logit": -7.3828125,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 4.9921875,
            "end_logit": -7.40625,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a single hospital and the responses and final dispositions of patients who received",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 4.9921875,
            "end_logit": -7.4140625,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a single hospital and the responses and final dispositions of patients who received the",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 4.9921875,
            "end_logit": -7.48828125,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a single hospital and the responses and final dispositions of",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": 4.9921875,
            "end_logit": -7.4921875,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a single hospital",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -2.017578125,
            "end_logit": -1.9130859375,
            "text": "lidocaine",
            "probability": 4.76837158203125e-07
        }
    ],
    "5e2f906ffbd6abf43b00002c_8": [
        {
            "start_logit": 5.1015625,
            "end_logit": 5.8359375,
            "text": "antacid",
            "probability": 0.9990234375
        },
        {
            "start_logit": 5.1015625,
            "end_logit": -1.88671875,
            "text": "antacid, viscous lidocaine",
            "probability": 0.00044226646423339844
        },
        {
            "start_logit": 5.1015625,
            "end_logit": -2.267578125,
            "text": "antacid, viscous lidocaine, and an anticholinergic",
            "probability": 0.0003027915954589844
        },
        {
            "start_logit": -5.29296875,
            "end_logit": 5.8359375,
            "text": "acid",
            "probability": 3.063678741455078e-05
        },
        {
            "start_logit": -6.421875,
            "end_logit": 5.8359375,
            "text": "liquid antacid",
            "probability": 9.894371032714844e-06
        },
        {
            "start_logit": 5.1015625,
            "end_logit": -5.76171875,
            "text": "ant",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": -6.75390625,
            "end_logit": 5.8359375,
            "text": "determine practice patterns regarding administration of the \"GI cocktail\" (a mixture of liquid antacid",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": -6.84765625,
            "end_logit": 5.8359375,
            "text": "mixture of liquid antacid",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": -6.88671875,
            "end_logit": 5.8359375,
            "text": "a mixture of liquid antacid",
            "probability": 6.258487701416016e-06
        },
        {
            "start_logit": -6.93359375,
            "end_logit": 5.8359375,
            "text": "To determine practice patterns regarding administration of the \"GI cocktail\" (a mixture of liquid antacid",
            "probability": 5.9604644775390625e-06
        },
        {
            "start_logit": -7.109375,
            "end_logit": 5.8359375,
            "text": "practice patterns regarding administration of the \"GI cocktail\" (a mixture of liquid antacid",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": 5.1015625,
            "end_logit": -6.8671875,
            "text": "antacid, viscous lidocaine, and an anticholinergic)",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": 5.1015625,
            "end_logit": -7.171875,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": 5.1015625,
            "end_logit": -7.34375,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a single hospital and the responses and final dispositions",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 5.1015625,
            "end_logit": -7.390625,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a single hospital and the responses and final dispositions of patients who received the",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 5.1015625,
            "end_logit": -7.41796875,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a single hospital and the responses and final dispositions of patients who received",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 5.1015625,
            "end_logit": -7.44140625,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": 5.1015625,
            "end_logit": -7.46484375,
            "text": "antacid, viscous lidocaine, and an anticholinergic) in the emergency department in a single hospital and the responses and final dispositions of",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": -1.9873046875,
            "end_logit": -1.88671875,
            "text": "lidocaine",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -1.9873046875,
            "end_logit": -2.267578125,
            "text": "lidocaine, and an anticholinergic",
            "probability": 2.384185791015625e-07
        }
    ],
    "5895e9977d9090f353000013_1": [
        {
            "start_logit": 9.1171875,
            "end_logit": 9.4296875,
            "text": "Hypotrichosis",
            "probability": 1.0
        },
        {
            "start_logit": -0.984375,
            "end_logit": 9.4296875,
            "text": "osis",
            "probability": 4.100799560546875e-05
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -1.4443359375,
            "text": "Hypot",
            "probability": 1.895427703857422e-05
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -1.6591796875,
            "text": "Hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia",
            "probability": 1.519918441772461e-05
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -4.10546875,
            "text": "Hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrodactyly",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -5.23046875,
            "text": "Hypotrichosis with juvenile macular dystrophy",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.0625,
            "end_logit": 9.4296875,
            "text": "richosis",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.04296875,
            "text": "Hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrodactyly and macular dystrophy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.203125,
            "text": "Hypotrichosis with juvenile macular dystrophy (HJMD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.2265625,
            "text": "Hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrodactyly and macular dystrophy (EEM) are",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.30859375,
            "text": "Hypotrichosis with juvenile macular dystrophy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.3203125,
            "text": "Hypotrichosis with juvenile macular",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.34765625,
            "text": "Hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrodactyly and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.3515625,
            "text": "Hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.3515625,
            "text": "Hypotrichosis with",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.375,
            "text": "Hypotrichosis with juvenile macular dystrophy (HJMD)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.44921875,
            "text": "Hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrod",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.47265625,
            "text": "Hypotrichosis with juvenile macular dystrophy (HJ",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.48828125,
            "text": "Hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrodactyly and macular dystrophy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.984375,
            "end_logit": -1.6591796875,
            "text": "osis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia",
            "probability": 0.0
        }
    ],
    "5895e9977d9090f353000013_2": [
        {
            "start_logit": 5.2890625,
            "end_logit": 2.98828125,
            "text": "hypotrichosis",
            "probability": 0.82958984375
        },
        {
            "start_logit": 5.2890625,
            "end_logit": 1.0380859375,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia",
            "probability": 0.11773681640625
        },
        {
            "start_logit": 3.984375,
            "end_logit": 1.0380859375,
            "text": "ectodermal dysplasia",
            "probability": 0.03192138671875
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -1.2470703125,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrodactyly",
            "probability": 0.0119781494140625
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -2.287109375,
            "text": "hypotrichosis with juvenile macular dystrophy",
            "probability": 0.00421905517578125
        },
        {
            "start_logit": 3.984375,
            "end_logit": -1.2470703125,
            "text": "ectodermal dysplasia, ectrodactyly",
            "probability": 0.0032482147216796875
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -5.3671875,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrodactyly, and macular dystrophy",
            "probability": 0.00019443035125732422
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -5.765625,
            "text": "hypot",
            "probability": 0.00013053417205810547
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -6.6328125,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD) and ectoderm",
            "probability": 5.4776668548583984e-05
        },
        {
            "start_logit": 3.984375,
            "end_logit": -5.3671875,
            "text": "ectodermal dysplasia, ectrodactyly, and macular dystrophy",
            "probability": 5.27501106262207e-05
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -7.02734375,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD",
            "probability": 3.707408905029297e-05
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -7.0546875,
            "text": "hypotrichosis with",
            "probability": 3.594160079956055e-05
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -7.06640625,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrodactyly, and macular dystrophy (EEM) syndromes.",
            "probability": 3.540515899658203e-05
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -7.1875,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD)",
            "probability": 3.147125244140625e-05
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -7.19921875,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrodactyly, and macular dystrophy (",
            "probability": 3.123283386230469e-05
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -7.24609375,
            "text": "hypotrich",
            "probability": 2.9802322387695312e-05
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -7.3046875,
            "text": "hypotrichosis with juvenile macular dystrophy (HJ",
            "probability": 2.8014183044433594e-05
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -7.33203125,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrod",
            "probability": 2.7179718017578125e-05
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -7.39453125,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrodactyly, and macular dystrophy (EEM",
            "probability": 2.5451183319091797e-05
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -7.40625,
            "text": "hypotrichosis with juvenile macular dystrophy (",
            "probability": 2.5272369384765625e-05
        }
    ],
    "5895e9977d9090f353000013_3": [
        {
            "start_logit": 3.490234375,
            "end_logit": 2.19921875,
            "text": "hypotrichosis",
            "probability": 0.6943359375
        },
        {
            "start_logit": 3.724609375,
            "end_logit": 0.501953125,
            "text": "ectodermal dysplasia",
            "probability": 0.1611328125
        },
        {
            "start_logit": 3.490234375,
            "end_logit": 0.501953125,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia",
            "probability": 0.12744140625
        },
        {
            "start_logit": 3.724609375,
            "end_logit": -2.5546875,
            "text": "ectodermal dysplasia, ectrodactyly",
            "probability": 0.007595062255859375
        },
        {
            "start_logit": 3.490234375,
            "end_logit": -2.5546875,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrodactyly",
            "probability": 0.006008148193359375
        },
        {
            "start_logit": 3.490234375,
            "end_logit": -3.701171875,
            "text": "hypotrichosis with juvenile macular dystrophy",
            "probability": 0.0019054412841796875
        },
        {
            "start_logit": 3.724609375,
            "end_logit": -5.58203125,
            "text": "ectodermal dysplasia, ectrodactyly, macular dystrophy",
            "probability": 0.00036644935607910156
        },
        {
            "start_logit": 3.490234375,
            "end_logit": -5.58203125,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrodactyly, macular dystrophy",
            "probability": 0.0002899169921875
        },
        {
            "start_logit": 3.724609375,
            "end_logit": -6.69921875,
            "text": "ectoderm",
            "probability": 0.00011992454528808594
        },
        {
            "start_logit": 3.490234375,
            "end_logit": -6.69921875,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD) and ectoderm",
            "probability": 9.483098983764648e-05
        },
        {
            "start_logit": 3.490234375,
            "end_logit": -6.86328125,
            "text": "hypot",
            "probability": 8.046627044677734e-05
        },
        {
            "start_logit": 3.724609375,
            "end_logit": -7.109375,
            "text": "ectodermal dysplasia, ectrodactyly, macular dystrophy (EEM syndrome).",
            "probability": 7.987022399902344e-05
        },
        {
            "start_logit": 3.724609375,
            "end_logit": -7.25390625,
            "text": "ectodermal dysplasia, ectrodactyly, macular",
            "probability": 6.884336471557617e-05
        },
        {
            "start_logit": 3.724609375,
            "end_logit": -7.27734375,
            "text": "ectodermal dysplasia, ectrod",
            "probability": 6.723403930664062e-05
        },
        {
            "start_logit": 3.490234375,
            "end_logit": -7.0546875,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD",
            "probability": 6.669759750366211e-05
        },
        {
            "start_logit": 3.724609375,
            "end_logit": -7.3125,
            "text": "ectodermal dysplasia, ectrodactyly, macular dystrophy (",
            "probability": 6.514787673950195e-05
        },
        {
            "start_logit": 3.490234375,
            "end_logit": -7.109375,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrodactyly, macular dystrophy (EEM syndrome).",
            "probability": 6.318092346191406e-05
        },
        {
            "start_logit": 3.490234375,
            "end_logit": -7.17578125,
            "text": "hypotrichosis with",
            "probability": 5.888938903808594e-05
        },
        {
            "start_logit": 3.490234375,
            "end_logit": -7.19140625,
            "text": "hypotrich",
            "probability": 5.799531936645508e-05
        },
        {
            "start_logit": 3.490234375,
            "end_logit": -7.1953125,
            "text": "hypotrichosis with juvenile macular dystrophy (HJMD)",
            "probability": 5.799531936645508e-05
        }
    ],
    "5895e9977d9090f353000013_4": [
        {
            "start_logit": 9.1640625,
            "end_logit": 9.375,
            "text": "ectodermal dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": -1.060546875,
            "end_logit": 9.375,
            "text": "dysplasia",
            "probability": 3.647804260253906e-05
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -1.427734375,
            "text": "ectoderm",
            "probability": 2.0444393157958984e-05
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -2.6796875,
            "text": "ectodermal dysplasia, ectrodactyly",
            "probability": 5.841255187988281e-06
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -5.875,
            "text": "ectodermal dysplasia, ectrodactyly and macular dystrophy",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.3203125,
            "end_logit": 9.375,
            "text": "al dysplasia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.01171875,
            "end_logit": 9.375,
            "text": "by ectodermal dysplasia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.25,
            "text": "ectodermal dysplasia, ectrodactyly and macular dystrophy.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.36328125,
            "text": "ectodermal dysplasia, ectrod",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.625,
            "end_logit": 9.375,
            "text": "rare condition characterised by ectodermal dysplasia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.4296875,
            "text": "ectodermal dysplasia, ectrodactyly and macular",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.4921875,
            "text": "ectodermal dysplasia, ectrodactyly and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.5,
            "text": "ectodermal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.060546875,
            "end_logit": -2.6796875,
            "text": "dysplasia, ectrodactyly",
            "probability": 0.0
        },
        {
            "start_logit": -4.13671875,
            "end_logit": -2.6796875,
            "text": "ectrodactyly",
            "probability": 0.0
        },
        {
            "start_logit": -1.060546875,
            "end_logit": -5.875,
            "text": "dysplasia, ectrodactyly and macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -1.060546875,
            "end_logit": -7.25,
            "text": "dysplasia, ectrodactyly and macular dystrophy.",
            "probability": 0.0
        },
        {
            "start_logit": -1.060546875,
            "end_logit": -7.36328125,
            "text": "dysplasia, ectrod",
            "probability": 0.0
        },
        {
            "start_logit": -7.01171875,
            "end_logit": -1.427734375,
            "text": "by ectoderm",
            "probability": 0.0
        },
        {
            "start_logit": -1.060546875,
            "end_logit": -7.4296875,
            "text": "dysplasia, ectrodactyly and macular",
            "probability": 0.0
        }
    ],
    "5895e9977d9090f353000013_5": [
        {
            "start_logit": 9.21875,
            "end_logit": 9.21875,
            "text": "ectrodactyly",
            "probability": 1.0
        },
        {
            "start_logit": 9.21875,
            "end_logit": -1.2978515625,
            "text": "ect",
            "probability": 2.7120113372802734e-05
        },
        {
            "start_logit": -1.5771484375,
            "end_logit": 9.21875,
            "text": "actyly",
            "probability": 2.0444393157958984e-05
        },
        {
            "start_logit": 9.21875,
            "end_logit": -4.3359375,
            "text": "ectrodactyly, and macular dystrophy",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -5.58203125,
            "end_logit": 9.21875,
            "text": "ectodermal dysplasia, ectrodactyly",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.015625,
            "end_logit": 9.21875,
            "text": "rodactyly",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.96875,
            "end_logit": 9.21875,
            "text": ", ectrodactyly",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.01171875,
            "text": "ectrodactyly, and macular dystrophy.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.02734375,
            "end_logit": 9.21875,
            "text": "association of ectodermal dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.12890625,
            "text": "ectrodactyly, and macular",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.296875,
            "end_logit": 9.21875,
            "text": "of ectodermal dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.32421875,
            "end_logit": 9.21875,
            "text": ": EEM syndrome is the rare association of ectodermal dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 9.21875,
            "text": "rare association of ectodermal dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 9.21875,
            "text": "is the rare association of ectodermal dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.5,
            "text": "ectrodactyly,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 9.21875,
            "text": "BACKGROUND: EEM syndrome is the rare association of ectodermal dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65625,
            "end_logit": 9.21875,
            "text": "syndrome is the rare association of ectodermal dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.5771484375,
            "end_logit": -4.3359375,
            "text": "actyly, and macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -5.58203125,
            "end_logit": -1.2978515625,
            "text": "ectodermal dysplasia, ect",
            "probability": 0.0
        },
        {
            "start_logit": -6.96875,
            "end_logit": -1.2978515625,
            "text": ", ect",
            "probability": 0.0
        }
    ],
    "5895e9977d9090f353000013_6": [
        {
            "start_logit": 9.1875,
            "end_logit": 9.28125,
            "text": "ectrodactyly",
            "probability": 0.9990234375
        },
        {
            "start_logit": 2.3671875,
            "end_logit": 9.28125,
            "text": "ectodermal dysplasia, ectrodactyly",
            "probability": 0.0010900497436523438
        },
        {
            "start_logit": -1.375,
            "end_logit": 9.28125,
            "text": "actyly",
            "probability": 2.586841583251953e-05
        },
        {
            "start_logit": 9.1875,
            "end_logit": -1.392578125,
            "text": "ect",
            "probability": 2.3186206817626953e-05
        },
        {
            "start_logit": 9.1875,
            "end_logit": -5.06640625,
            "text": "ectrodactyly, macular dystrophy",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 2.3671875,
            "end_logit": 1.15625,
            "text": "ectodermal dysplasia",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.95703125,
            "end_logit": 9.28125,
            "text": "rodactyly",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.0234375,
            "end_logit": 9.28125,
            "text": ", ectrodactyly",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0625,
            "end_logit": 9.28125,
            "text": "al dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.26171875,
            "text": "ectrodactyly, macular dystrophy (EEM syndrome).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.34765625,
            "text": "ectrodactyly, macular dystrophy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.37890625,
            "text": "ectrodactyly, macular",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 9.28125,
            "text": "dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.46875,
            "text": "ectrodactyly, macular dystrophy (EEM syndrome)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 9.28125,
            "text": "cause ectodermal dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 9.28125,
            "text": "Distinct CDH3 mutations cause ectodermal dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 2.3671875,
            "end_logit": -1.392578125,
            "text": "ectodermal dysplasia, ect",
            "probability": 0.0
        },
        {
            "start_logit": 2.3671875,
            "end_logit": -5.06640625,
            "text": "ectodermal dysplasia, ectrodactyly, macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": 2.3671875,
            "end_logit": -7.26171875,
            "text": "ectodermal dysplasia, ectrodactyly, macular dystrophy (EEM syndrome).",
            "probability": 0.0
        },
        {
            "start_logit": 2.3671875,
            "end_logit": -7.28515625,
            "text": "ectodermal",
            "probability": 0.0
        }
    ],
    "5895e9977d9090f353000013_7": [
        {
            "start_logit": 9.328125,
            "end_logit": 9.40625,
            "text": "ectrodactyly",
            "probability": 1.0
        },
        {
            "start_logit": 9.328125,
            "end_logit": -1.03515625,
            "text": "ect",
            "probability": 2.9325485229492188e-05
        },
        {
            "start_logit": -1.1064453125,
            "end_logit": 9.40625,
            "text": "actyly",
            "probability": 2.9325485229492188e-05
        },
        {
            "start_logit": 9.328125,
            "end_logit": -4.6875,
            "text": "ectrodactyly and macular dystrophy",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -5.26953125,
            "end_logit": 9.40625,
            "text": "Ectodermal dysplasia, ectrodactyly",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -5.953125,
            "end_logit": 9.40625,
            "text": "rodactyly",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.00390625,
            "end_logit": 9.40625,
            "text": ", ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.00390625,
            "text": "ectrodactyly and macular",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.0625,
            "text": "ectrodactyly and macular dystrophy (EEM syndrome) in siblings.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.24609375,
            "text": "ectrodactyly and macular dystrophy (EEM syndrome) in siblings",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.34375,
            "text": "ectrodactyly and macular dystrophy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.4765625,
            "text": "ectrodactyly and macular dystrophy (EEM syndrome)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.1064453125,
            "end_logit": -4.6875,
            "text": "actyly and macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -5.26953125,
            "end_logit": -1.03515625,
            "text": "Ectodermal dysplasia, ect",
            "probability": 0.0
        },
        {
            "start_logit": -7.00390625,
            "end_logit": -1.03515625,
            "text": ", ect",
            "probability": 0.0
        },
        {
            "start_logit": -1.1064453125,
            "end_logit": -7.00390625,
            "text": "actyly and macular",
            "probability": 0.0
        },
        {
            "start_logit": -1.1064453125,
            "end_logit": -7.0625,
            "text": "actyly and macular dystrophy (EEM syndrome) in siblings.",
            "probability": 0.0
        },
        {
            "start_logit": -1.1064453125,
            "end_logit": -7.24609375,
            "text": "actyly and macular dystrophy (EEM syndrome) in siblings",
            "probability": 0.0
        },
        {
            "start_logit": -1.1064453125,
            "end_logit": -7.34375,
            "text": "actyly and macular dystrophy (",
            "probability": 0.0
        },
        {
            "start_logit": -1.1064453125,
            "end_logit": -7.4765625,
            "text": "actyly and macular dystrophy (EEM syndrome)",
            "probability": 0.0
        }
    ],
    "5895e9977d9090f353000013_8": [
        {
            "start_logit": 9.3671875,
            "end_logit": 9.4375,
            "text": "ectrodactyly",
            "probability": 1.0
        },
        {
            "start_logit": 9.3671875,
            "end_logit": -0.91943359375,
            "text": "ect",
            "probability": 3.147125244140625e-05
        },
        {
            "start_logit": -1.044921875,
            "end_logit": 9.4375,
            "text": "actyly",
            "probability": 2.9802322387695312e-05
        },
        {
            "start_logit": -6.07421875,
            "end_logit": 9.4375,
            "text": "rodactyly",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.3671875,
            "end_logit": -6.4140625,
            "text": "ectrodactyly, and macular dystrophy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.50390625,
            "end_logit": 9.4375,
            "text": "ectodermal dysplasia, ectrodactyly",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.59765625,
            "end_logit": 9.4375,
            "text": "Association of ectodermal dysplasia, ectrodactyly",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3671875,
            "end_logit": -7.140625,
            "text": "ectrodactyly, and macular dystrophy: the EEM syndrome.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 9.4375,
            "text": "of ectodermal dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.38671875,
            "end_logit": 9.4375,
            "text": ", ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3671875,
            "end_logit": -7.47265625,
            "text": "ectrodactyly, and macular",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.50390625,
            "end_logit": -0.91943359375,
            "text": "ectodermal dysplasia, ect",
            "probability": 0.0
        },
        {
            "start_logit": -1.044921875,
            "end_logit": -6.4140625,
            "text": "actyly, and macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -6.59765625,
            "end_logit": -0.91943359375,
            "text": "Association of ectodermal dysplasia, ect",
            "probability": 0.0
        },
        {
            "start_logit": -1.044921875,
            "end_logit": -7.140625,
            "text": "actyly, and macular dystrophy: the EEM syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": -7.37109375,
            "end_logit": -0.91943359375,
            "text": "of ectodermal dysplasia, ect",
            "probability": 0.0
        },
        {
            "start_logit": -7.38671875,
            "end_logit": -0.91943359375,
            "text": ", ect",
            "probability": 0.0
        },
        {
            "start_logit": -1.044921875,
            "end_logit": -7.47265625,
            "text": "actyly, and macular",
            "probability": 0.0
        },
        {
            "start_logit": -6.07421875,
            "end_logit": -6.4140625,
            "text": "rodactyly, and macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -6.50390625,
            "end_logit": -6.38671875,
            "text": "ectodermal dysplasia",
            "probability": 0.0
        }
    ],
    "5895e9977d9090f353000013_9": [
        {
            "start_logit": 9.3515625,
            "end_logit": 9.4375,
            "text": "ectrodactyly",
            "probability": 1.0
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -0.962890625,
            "text": "ect",
            "probability": 3.069639205932617e-05
        },
        {
            "start_logit": -1.0517578125,
            "end_logit": 9.4375,
            "text": "actyly",
            "probability": 3.045797348022461e-05
        },
        {
            "start_logit": -6.09375,
            "end_logit": 9.4375,
            "text": "rodactyly",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -6.08984375,
            "text": "ectrodactyly and macular dystrophy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.55078125,
            "end_logit": 9.4375,
            "text": "ectodermal dysplasia, ectrodactyly",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.6328125,
            "end_logit": 9.4375,
            "text": "Association of ectodermal dysplasia, ectrodactyly",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -6.890625,
            "text": "ectrodactyly and macular dystrophy: EEM syndrome (case report",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -7.0078125,
            "text": "ectrodactyly and macular dystrophy: EEM syndrome (case report).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -7.2109375,
            "text": "ectrodactyly and macular dystrophy: EEM syndrome (case report)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3203125,
            "end_logit": 9.4375,
            "text": "of ectodermal dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.32421875,
            "end_logit": 9.4375,
            "text": ", ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -7.32421875,
            "text": "ectrodactyly and macular",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.0517578125,
            "end_logit": -6.08984375,
            "text": "actyly and macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -6.55078125,
            "end_logit": -0.962890625,
            "text": "ectodermal dysplasia, ect",
            "probability": 0.0
        },
        {
            "start_logit": -6.6328125,
            "end_logit": -0.962890625,
            "text": "Association of ectodermal dysplasia, ect",
            "probability": 0.0
        },
        {
            "start_logit": -1.0517578125,
            "end_logit": -6.890625,
            "text": "actyly and macular dystrophy: EEM syndrome (case report",
            "probability": 0.0
        },
        {
            "start_logit": -1.0517578125,
            "end_logit": -7.0078125,
            "text": "actyly and macular dystrophy: EEM syndrome (case report).",
            "probability": 0.0
        },
        {
            "start_logit": -1.0517578125,
            "end_logit": -7.2109375,
            "text": "actyly and macular dystrophy: EEM syndrome (case report)",
            "probability": 0.0
        },
        {
            "start_logit": -7.3203125,
            "end_logit": -0.962890625,
            "text": "of ectodermal dysplasia, ect",
            "probability": 0.0
        }
    ],
    "5895e9977d9090f353000013_10": [
        {
            "start_logit": 9.2578125,
            "end_logit": 9.3046875,
            "text": "ectrodactyly",
            "probability": 1.0
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -1.216796875,
            "text": "ect",
            "probability": 2.6881694793701172e-05
        },
        {
            "start_logit": -1.3828125,
            "end_logit": 9.3046875,
            "text": "actyly",
            "probability": 2.390146255493164e-05
        },
        {
            "start_logit": -5.12109375,
            "end_logit": 9.3046875,
            "text": "ectodermal dysplasia, ectrodactyly",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -5.5,
            "text": "ectrodactyly, and macular dystrophy",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.7265625,
            "end_logit": 9.3046875,
            "text": "rodactyly",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.0390625,
            "end_logit": 9.3046875,
            "text": ", ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1171875,
            "end_logit": 9.3046875,
            "text": "association of ectodermal dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.171875,
            "text": "ectrodactyly, and macular dystrophy.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.25,
            "text": "ectrodactyly, and macular",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3203125,
            "end_logit": 9.3046875,
            "text": "rare association of ectodermal dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.33984375,
            "end_logit": 9.3046875,
            "text": "of ectodermal dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4375,
            "end_logit": 9.3046875,
            "text": "is the rare association of ectodermal dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.453125,
            "text": "ectrodactyly,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 9.3046875,
            "text": "syndrome is the rare association of ectodermal dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.12109375,
            "end_logit": -1.216796875,
            "text": "ectodermal dysplasia, ect",
            "probability": 0.0
        },
        {
            "start_logit": -1.3828125,
            "end_logit": -5.5,
            "text": "actyly, and macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -7.0390625,
            "end_logit": -1.216796875,
            "text": ", ect",
            "probability": 0.0
        },
        {
            "start_logit": -7.1171875,
            "end_logit": -1.216796875,
            "text": "association of ectodermal dysplasia, ect",
            "probability": 0.0
        },
        {
            "start_logit": -7.3203125,
            "end_logit": -1.216796875,
            "text": "rare association of ectodermal dysplasia, ect",
            "probability": 0.0
        }
    ],
    "5895e9977d9090f353000013_11": [
        {
            "start_logit": 8.96875,
            "end_logit": 8.671875,
            "text": "ectrodactyly",
            "probability": 1.0
        },
        {
            "start_logit": 8.96875,
            "end_logit": -1.802734375,
            "text": "ect",
            "probability": 2.8192996978759766e-05
        },
        {
            "start_logit": -1.7470703125,
            "end_logit": 8.671875,
            "text": "ectodermal dysplasia, ectrodactyly",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": -2.619140625,
            "end_logit": 8.671875,
            "text": "actyly",
            "probability": 9.298324584960938e-06
        },
        {
            "start_logit": -6.0078125,
            "end_logit": 8.671875,
            "text": "rodactyly",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.96875,
            "end_logit": -6.67578125,
            "text": "ectrodactyly, and macular dystrophy",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.7421875,
            "end_logit": 8.671875,
            "text": "with ectodermal dysplasia, ectrodactyly",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.1953125,
            "text": "ectrodactyly, and macular dystrophy (the EEM syndrome).",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.3125,
            "text": "ectrodactyly, and macular",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.3515625,
            "text": "ectrodactyly, and macular dystrophy (the EEM syndrome)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.3828125,
            "text": "ectrodactyly, and macular dystrophy (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.41796875,
            "text": "ectrodactyly,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.15625,
            "end_logit": 8.671875,
            "text": "brother and sister with ectodermal dysplasia, ectrodactyly",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.50390625,
            "text": "ectrodactyly, and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 8.671875,
            "text": ", ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.328125,
            "end_logit": 8.671875,
            "text": "a brother and sister with ectodermal dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37890625,
            "end_logit": 8.671875,
            "text": "al dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 8.671875,
            "text": "report a brother and sister with ectodermal dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 8.671875,
            "text": "We report a brother and sister with ectodermal dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.640625,
            "end_logit": 8.671875,
            "text": "sister with ectodermal dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        }
    ],
    "5895e9977d9090f353000013_12": [
        {
            "start_logit": 9.328125,
            "end_logit": 9.40625,
            "text": "ectrodactyly",
            "probability": 1.0
        },
        {
            "start_logit": 9.328125,
            "end_logit": -1.03515625,
            "text": "ect",
            "probability": 2.9325485229492188e-05
        },
        {
            "start_logit": -1.1064453125,
            "end_logit": 9.40625,
            "text": "actyly",
            "probability": 2.9325485229492188e-05
        },
        {
            "start_logit": 9.328125,
            "end_logit": -4.6875,
            "text": "ectrodactyly and macular dystrophy",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -5.26953125,
            "end_logit": 9.40625,
            "text": "Ectodermal dysplasia, ectrodactyly",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -5.953125,
            "end_logit": 9.40625,
            "text": "rodactyly",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.00390625,
            "end_logit": 9.40625,
            "text": ", ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.00390625,
            "text": "ectrodactyly and macular",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.0625,
            "text": "ectrodactyly and macular dystrophy (EEM syndrome) in siblings.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.24609375,
            "text": "ectrodactyly and macular dystrophy (EEM syndrome) in siblings",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.34375,
            "text": "ectrodactyly and macular dystrophy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.4765625,
            "text": "ectrodactyly and macular dystrophy (EEM syndrome)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.1064453125,
            "end_logit": -4.6875,
            "text": "actyly and macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": -5.26953125,
            "end_logit": -1.03515625,
            "text": "Ectodermal dysplasia, ect",
            "probability": 0.0
        },
        {
            "start_logit": -7.00390625,
            "end_logit": -1.03515625,
            "text": ", ect",
            "probability": 0.0
        },
        {
            "start_logit": -1.1064453125,
            "end_logit": -7.00390625,
            "text": "actyly and macular",
            "probability": 0.0
        },
        {
            "start_logit": -1.1064453125,
            "end_logit": -7.0625,
            "text": "actyly and macular dystrophy (EEM syndrome) in siblings.",
            "probability": 0.0
        },
        {
            "start_logit": -1.1064453125,
            "end_logit": -7.24609375,
            "text": "actyly and macular dystrophy (EEM syndrome) in siblings",
            "probability": 0.0
        },
        {
            "start_logit": -1.1064453125,
            "end_logit": -7.34375,
            "text": "actyly and macular dystrophy (",
            "probability": 0.0
        },
        {
            "start_logit": -1.1064453125,
            "end_logit": -7.4765625,
            "text": "actyly and macular dystrophy (EEM syndrome)",
            "probability": 0.0
        }
    ],
    "5895e9977d9090f353000013_13": [
        {
            "start_logit": 9.1875,
            "end_logit": 9.28125,
            "text": "ectrodactyly",
            "probability": 0.9990234375
        },
        {
            "start_logit": 2.3671875,
            "end_logit": 9.28125,
            "text": "ectodermal dysplasia, ectrodactyly",
            "probability": 0.0010900497436523438
        },
        {
            "start_logit": -1.375,
            "end_logit": 9.28125,
            "text": "actyly",
            "probability": 2.586841583251953e-05
        },
        {
            "start_logit": 9.1875,
            "end_logit": -1.392578125,
            "text": "ect",
            "probability": 2.3186206817626953e-05
        },
        {
            "start_logit": 9.1875,
            "end_logit": -5.06640625,
            "text": "ectrodactyly, macular dystrophy",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 2.3671875,
            "end_logit": 1.15625,
            "text": "ectodermal dysplasia",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.95703125,
            "end_logit": 9.28125,
            "text": "rodactyly",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.0234375,
            "end_logit": 9.28125,
            "text": ", ectrodactyly",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0625,
            "end_logit": 9.28125,
            "text": "al dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.26171875,
            "text": "ectrodactyly, macular dystrophy (EEM syndrome).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.34765625,
            "text": "ectrodactyly, macular dystrophy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.37890625,
            "text": "ectrodactyly, macular",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 9.28125,
            "text": "dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.46875,
            "text": "ectrodactyly, macular dystrophy (EEM syndrome)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 9.28125,
            "text": "cause ectodermal dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 9.28125,
            "text": "Distinct CDH3 mutations cause ectodermal dysplasia, ectrodactyly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 2.3671875,
            "end_logit": -1.392578125,
            "text": "ectodermal dysplasia, ect",
            "probability": 0.0
        },
        {
            "start_logit": 2.3671875,
            "end_logit": -5.06640625,
            "text": "ectodermal dysplasia, ectrodactyly, macular dystrophy",
            "probability": 0.0
        },
        {
            "start_logit": 2.3671875,
            "end_logit": -7.26171875,
            "text": "ectodermal dysplasia, ectrodactyly, macular dystrophy (EEM syndrome).",
            "probability": 0.0
        },
        {
            "start_logit": 2.3671875,
            "end_logit": -7.28515625,
            "text": "ectodermal",
            "probability": 0.0
        }
    ],
    "56e460d051531f7e33000019_1": [
        {
            "start_logit": 1.3603515625,
            "end_logit": 1.4189453125,
            "text": "Csnk1e in regulating not only the timing of sleep",
            "probability": 0.49560546875
        },
        {
            "start_logit": 1.3603515625,
            "end_logit": 0.318115234375,
            "text": "Csnk1e in regulating not only the timing of sleep, but also the REM sleep",
            "probability": 0.1649169921875
        },
        {
            "start_logit": -0.0770263671875,
            "end_logit": 1.4189453125,
            "text": "a role for Csnk1e in regulating not only the timing of sleep",
            "probability": 0.11773681640625
        },
        {
            "start_logit": 1.3603515625,
            "end_logit": -0.09564208984375,
            "text": "Csnk1e",
            "probability": 0.10894775390625
        },
        {
            "start_logit": -0.0770263671875,
            "end_logit": 0.318115234375,
            "text": "a role for Csnk1e in regulating not only the timing of sleep, but also the REM sleep",
            "probability": 0.03912353515625
        },
        {
            "start_logit": -0.357666015625,
            "end_logit": 0.318115234375,
            "text": "REM sleep",
            "probability": 0.0295867919921875
        },
        {
            "start_logit": -0.0770263671875,
            "end_logit": -0.09564208984375,
            "text": "a role for Csnk1e",
            "probability": 0.025909423828125
        },
        {
            "start_logit": 1.3603515625,
            "end_logit": -3.5,
            "text": "Csnk1e in regulating not only the timing of sleep, but also the REM sleep amount and NREM sleep architecture",
            "probability": 0.0036106109619140625
        },
        {
            "start_logit": -3.6171875,
            "end_logit": 1.4189453125,
            "text": "timing of sleep",
            "probability": 0.00341796875
        },
        {
            "start_logit": -4.171875,
            "end_logit": 1.4189453125,
            "text": "sleep",
            "probability": 0.0019626617431640625
        },
        {
            "start_logit": -0.0770263671875,
            "end_logit": -2.810546875,
            "text": "a",
            "probability": 0.0017185211181640625
        },
        {
            "start_logit": 1.3603515625,
            "end_logit": -4.4921875,
            "text": "Csnk1",
            "probability": 0.001338958740234375
        },
        {
            "start_logit": -3.6171875,
            "end_logit": 0.318115234375,
            "text": "timing of sleep, but also the REM sleep",
            "probability": 0.00113677978515625
        },
        {
            "start_logit": -0.0770263671875,
            "end_logit": -3.5,
            "text": "a role for Csnk1e in regulating not only the timing of sleep, but also the REM sleep amount and NREM sleep architecture",
            "probability": 0.0008611679077148438
        },
        {
            "start_logit": 1.3603515625,
            "end_logit": -5.109375,
            "text": "Csnk1e in regulating not only the timing of sleep, but also the REM sleep amount",
            "probability": 0.0007224082946777344
        },
        {
            "start_logit": -5.18359375,
            "end_logit": 1.4189453125,
            "text": "role for Csnk1e in regulating not only the timing of sleep",
            "probability": 0.0007109642028808594
        },
        {
            "start_logit": -4.171875,
            "end_logit": 0.318115234375,
            "text": "sleep, but also the REM sleep",
            "probability": 0.000652313232421875
        },
        {
            "start_logit": -0.357666015625,
            "end_logit": -3.5,
            "text": "REM sleep amount and NREM sleep architecture",
            "probability": 0.0006499290466308594
        },
        {
            "start_logit": 1.3603515625,
            "end_logit": -5.2265625,
            "text": "Csnk1e in regulating not only the timing of sleep, but also the REM sleep amount and NREM sleep",
            "probability": 0.0006422996520996094
        },
        {
            "start_logit": -0.0770263671875,
            "end_logit": -4.4921875,
            "text": "a role for Csnk1",
            "probability": 0.0003180503845214844
        }
    ],
    "56e460d051531f7e33000019_2": [
        {
            "start_logit": 3.62890625,
            "end_logit": 1.1494140625,
            "text": "breast cancer",
            "probability": 0.97265625
        },
        {
            "start_logit": 3.62890625,
            "end_logit": -3.2890625,
            "text": "breast cancer can suppress Wnt/beta-catenin",
            "probability": 0.01149749755859375
        },
        {
            "start_logit": -2.755859375,
            "end_logit": 2.337890625,
            "text": "cell adhesion and migration",
            "probability": 0.005390167236328125
        },
        {
            "start_logit": 3.62890625,
            "end_logit": -4.7109375,
            "text": "breast cancer can suppress Wnt/beta-catenin as",
            "probability": 0.0027751922607421875
        },
        {
            "start_logit": 3.62890625,
            "end_logit": -4.99609375,
            "text": "breast cancer can suppress Wnt",
            "probability": 0.002086639404296875
        },
        {
            "start_logit": 3.62890625,
            "end_logit": -5.41796875,
            "text": "breast cancer can suppress Wnt/beta-catenin as well as promote the Wnt/Rac-1/JNK and Wnt/NFAT",
            "probability": 0.0013675689697265625
        },
        {
            "start_logit": 3.62890625,
            "end_logit": -5.81640625,
            "text": "breast cancer can",
            "probability": 0.0009183883666992188
        },
        {
            "start_logit": 0.779296875,
            "end_logit": -3.2890625,
            "text": "suppress Wnt/beta-catenin",
            "probability": 0.0006642341613769531
        },
        {
            "start_logit": 3.62890625,
            "end_logit": -6.4765625,
            "text": "breast cancer can suppress Wnt/beta-catenin as well as promote the Wnt/Rac-1/JNK and Wnt/NFAT pathways",
            "probability": 0.00047469139099121094
        },
        {
            "start_logit": 3.62890625,
            "end_logit": -6.9375,
            "text": "breast",
            "probability": 0.00029921531677246094
        },
        {
            "start_logit": 3.62890625,
            "end_logit": -6.984375,
            "text": "breast cancer can suppress Wnt/",
            "probability": 0.0002856254577636719
        },
        {
            "start_logit": 3.62890625,
            "end_logit": -6.9921875,
            "text": "breast cancer can suppress Wnt/beta-catenin as well",
            "probability": 0.00028324127197265625
        },
        {
            "start_logit": 3.62890625,
            "end_logit": -7.01953125,
            "text": "breast cancer can suppress Wnt/beta-catenin as well as promote the Wnt/Rac-1/JNK and Wnt",
            "probability": 0.000274658203125
        },
        {
            "start_logit": 3.62890625,
            "end_logit": -7.11328125,
            "text": "breast cancer can suppress Wnt/beta",
            "probability": 0.00025010108947753906
        },
        {
            "start_logit": 3.62890625,
            "end_logit": -7.1484375,
            "text": "breast cancer can suppress Wnt/beta-catenin as well as",
            "probability": 0.00024247169494628906
        },
        {
            "start_logit": 3.62890625,
            "end_logit": -7.2265625,
            "text": "breast cancer can suppress Wnt/beta-catenin as well as promote the Wnt/Rac-1/JNK",
            "probability": 0.00022423267364501953
        },
        {
            "start_logit": -6.13671875,
            "end_logit": 2.337890625,
            "text": "JNK and Wnt/NFAT pathways, thus contributing to breast cancer development via effects on cell adhesion and migration",
            "probability": 0.00018310546875
        },
        {
            "start_logit": 0.779296875,
            "end_logit": -4.7109375,
            "text": "suppress Wnt/beta-catenin as",
            "probability": 0.00016021728515625
        },
        {
            "start_logit": 0.779296875,
            "end_logit": -4.99609375,
            "text": "suppress Wnt",
            "probability": 0.00011998414993286133
        },
        {
            "start_logit": -6.828125,
            "end_logit": 2.337890625,
            "text": "development via effects on cell adhesion and migration",
            "probability": 9.196996688842773e-05
        }
    ],
    "56e460d051531f7e33000019_3": [
        {
            "start_logit": 5.703125,
            "end_logit": 8.046875,
            "text": "short circadian period",
            "probability": 0.9990234375
        },
        {
            "start_logit": -2.03125,
            "end_logit": 8.046875,
            "text": "period",
            "probability": 0.00043702125549316406
        },
        {
            "start_logit": 5.703125,
            "end_logit": 0.288330078125,
            "text": "short circadian period, abnormal entrainment to light cycles",
            "probability": 0.00042700767517089844
        },
        {
            "start_logit": -3.33984375,
            "end_logit": 8.046875,
            "text": "circadian period",
            "probability": 0.0001176595687866211
        },
        {
            "start_logit": -4.01171875,
            "end_logit": 8.046875,
            "text": "a short circadian period",
            "probability": 6.008148193359375e-05
        },
        {
            "start_logit": 2.0546875,
            "end_logit": 0.288330078125,
            "text": "abnormal entrainment to light cycles",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": -6.2578125,
            "end_logit": 8.046875,
            "text": "in a short circadian period",
            "probability": 6.377696990966797e-06
        },
        {
            "start_logit": 5.703125,
            "end_logit": -4.2109375,
            "text": "short circadian period, abnormal entrainment",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": -6.73828125,
            "end_logit": 8.046875,
            "text": "results in a short circadian period",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": 5.703125,
            "end_logit": -4.8984375,
            "text": "short circadian period, abnormal entrainment to light cycles, and potentiated resetting responses to light.",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": 5.703125,
            "end_logit": -5.37890625,
            "text": "short circadian period, abnormal entrainment to light cycles, and potentiated resetting responses to light",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 5.703125,
            "end_logit": -5.6328125,
            "text": "short",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 5.703125,
            "end_logit": -6.34765625,
            "text": "short circadian period, abnormal entrainment to light cycles,",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 5.703125,
            "end_logit": -6.51171875,
            "text": "short circadian period, abnormal entrainment to light",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 5.703125,
            "end_logit": -6.74609375,
            "text": "short circadian period, abnormal",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 5.703125,
            "end_logit": -6.75,
            "text": "short circadian period, abnormal entrainment to light cycles, and potentiated resetting responses",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -2.03125,
            "end_logit": 0.288330078125,
            "text": "period, abnormal entrainment to light cycles",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 2.0546875,
            "end_logit": -4.2109375,
            "text": "abnormal entrainment",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 2.0546875,
            "end_logit": -4.8984375,
            "text": "abnormal entrainment to light cycles, and potentiated resetting responses to light.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.33984375,
            "end_logit": 0.288330078125,
            "text": "circadian period, abnormal entrainment to light cycles",
            "probability": 5.960464477539063e-08
        }
    ],
    "62008130c9dfcb9c0900001c_1": [
        {
            "start_logit": 8.96875,
            "end_logit": 8.84375,
            "text": "Leukocytosis",
            "probability": 0.9990234375
        },
        {
            "start_logit": 8.96875,
            "end_logit": 1.3369140625,
            "text": "Leukocytosis (1 point), Tachycardia (1 point), and age",
            "probability": 0.0005483627319335938
        },
        {
            "start_logit": 8.96875,
            "end_logit": -1.7099609375,
            "text": "Leuk",
            "probability": 2.6047229766845703e-05
        },
        {
            "start_logit": -2.07421875,
            "end_logit": 8.84375,
            "text": "ocytosis",
            "probability": 1.5914440155029297e-05
        },
        {
            "start_logit": 8.96875,
            "end_logit": -4.3828125,
            "text": "Leukocytosis (1 point), Tachycardia (1 point), and age \u226570",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -5.75,
            "end_logit": 8.84375,
            "text": ", Leukocytosis",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.01171875,
            "text": "Leukocytosis (1 point), Tachycardia (1 point), and age \u2265",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.0859375,
            "text": "Leukocytosis (1 point), Tachycardia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9765625,
            "end_logit": 8.84375,
            "text": ": Asymmetry (3 points), Leukocytosis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.1640625,
            "text": "Leukocytosis (1 point), Tachycardia (1 point), and age \u226570 (2 points).",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.05078125,
            "end_logit": 8.84375,
            "text": "points system to create the ALT-70 cellulitis score as follows: Asymmetry (3 points), Leukocytosis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.109375,
            "end_logit": 8.84375,
            "text": "Asymmetry (3 points), Leukocytosis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.46875,
            "text": "Leukocytosis (1 point), Tachycardia (1 point), and age \u226570 (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 8.84375,
            "text": "as follows: Asymmetry (3 points), Leukocytosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 8.84375,
            "text": "variables into a points system to create the ALT-70 cellulitis score as follows: Asymmetry (3 points), Leukocytosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.484375,
            "text": "Leukocytosis (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.4921875,
            "text": "Leukocytosis (1 point), Tachycardia (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37890625,
            "end_logit": 8.84375,
            "text": "follows: Asymmetry (3 points), Leukocytosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.51953125,
            "text": "Leukocytosis (1 point)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.54296875,
            "text": "Leukocytosis (1 point), Tachycardia (1 point)",
            "probability": 5.960464477539063e-08
        }
    ],
    "5e493bc06d0a277941000003_1": [
        {
            "start_logit": 7.51953125,
            "end_logit": 8.0,
            "text": "glioblastoma",
            "probability": 1.0
        },
        {
            "start_logit": 7.51953125,
            "end_logit": -7.140625,
            "text": "glioblastoma.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.65625,
            "end_logit": 8.0,
            "text": "in glioblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.7578125,
            "end_logit": 8.0,
            "text": "peptide encoded by circular form of LINC-PINT suppresses oncogenic transcriptional elongation in glioblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.046875,
            "end_logit": -7.140625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.65625,
            "end_logit": -7.140625,
            "text": "in glioblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": -7.140625,
            "text": "peptide encoded by circular form of LINC-PINT suppresses oncogenic transcriptional elongation in glioblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": -7.21875,
            "text": "peptide encoded by circular form of LINC-PINT suppresses oncogenic transcriptional elongation",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": -7.31640625,
            "text": "peptide encoded by circular form of LINC-PINT suppresses oncogenic transcriptional",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": -7.3203125,
            "text": "peptide encoded by circular form of LINC-PINT suppresses",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": -7.375,
            "text": "peptide encoded by circular form",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": -7.3984375,
            "text": "peptide encoded by circular form of LINC-PINT",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": -7.48046875,
            "text": "peptide encoded by circular form of LINC-PIN",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": -7.5,
            "text": "peptide encoded",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": -7.51953125,
            "text": "peptide encoded by",
            "probability": 0.0
        }
    ],
    "5e493bc06d0a277941000003_2": [
        {
            "start_logit": 8.4453125,
            "end_logit": 6.87109375,
            "text": "glioblastoma",
            "probability": 1.0
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -5.125,
            "text": "glioblastoma cell proliferation",
            "probability": 6.198883056640625e-06
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -6.921875,
            "text": "glioblastoma cell proliferation in vitro and in vivo.",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -7.09375,
            "text": "glioblastoma cell proliferation in vitro and in vivo",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -7.20703125,
            "text": "glioblastoma cell",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.34765625,
            "end_logit": 6.87109375,
            "text": "circular form of the long intergenic non-protein-coding RNA p53-induced transcript (LINC-PINT) that suppresses glioblastoma",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.92578125,
            "end_logit": 6.87109375,
            "text": "suppresses glioblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -3.1328125,
            "end_logit": -4.83984375,
            "text": "glioblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -3.087890625,
            "end_logit": -5.63671875,
            "text": "glioblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -3.1328125,
            "end_logit": -5.63671875,
            "text": "glioblastoma compared with the levels in normal tissues. Our results establish the existence of peptides encoded by circRNAs and demonstrate their potential functions in glioblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -3.087890625,
            "end_logit": -6.19140625,
            "text": "glioblastoma tumorigenesis",
            "probability": 0.0
        },
        {
            "start_logit": -3.1328125,
            "end_logit": -6.19140625,
            "text": "glioblastoma compared with the levels in normal tissues. Our results establish the existence of peptides encoded by circRNAs and demonstrate their potential functions in glioblastoma tumorigenesis",
            "probability": 0.0
        },
        {
            "start_logit": -4.58203125,
            "end_logit": -4.83984375,
            "text": "expression of this peptide and its corresponding circRNA are decreased in glioblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -3.1328125,
            "end_logit": -6.62109375,
            "text": "glioblastoma compared with the levels in normal tissues. Our results establish the existence of peptides encoded by circRNAs",
            "probability": 0.0
        },
        {
            "start_logit": -3.087890625,
            "end_logit": -6.91796875,
            "text": "glioblastoma tumorigenesis.",
            "probability": 0.0
        },
        {
            "start_logit": -3.1328125,
            "end_logit": -6.91796875,
            "text": "glioblastoma compared with the levels in normal tissues. Our results establish the existence of peptides encoded by circRNAs and demonstrate their potential functions in glioblastoma tumorigenesis.",
            "probability": 0.0
        },
        {
            "start_logit": -3.1328125,
            "end_logit": -6.921875,
            "text": "glioblastoma compared with the levels in normal tissues.",
            "probability": 0.0
        },
        {
            "start_logit": -3.1328125,
            "end_logit": -7.0859375,
            "text": "glioblastoma compared",
            "probability": 0.0
        },
        {
            "start_logit": -5.79296875,
            "end_logit": -4.83984375,
            "text": "peptide and its corresponding circRNA are decreased in glioblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -6.40234375,
            "end_logit": -4.83984375,
            "text": "in glioblastoma",
            "probability": 0.0
        }
    ],
    "5e493bc06d0a277941000003_3": [
        {
            "start_logit": 8.984375,
            "end_logit": 9.34375,
            "text": "Breast cancer",
            "probability": 1.0
        },
        {
            "start_logit": -1.0380859375,
            "end_logit": 9.34375,
            "text": "cancer",
            "probability": 4.4345855712890625e-05
        },
        {
            "start_logit": 8.984375,
            "end_logit": -1.7939453125,
            "text": "Breast",
            "probability": 1.4483928680419922e-05
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.625,
            "text": "Breast cancer is a heterogeneous and polygenic disease that can be divided into different molecular subtypes based on histological and genomic features.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.125,
            "text": "Breast cancer is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.21484375,
            "text": "Breast cancer is a heterogeneous and polygenic disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.0380859375,
            "end_logit": -6.625,
            "text": "cancer is a heterogeneous and polygenic disease that can be divided into different molecular subtypes based on histological and genomic features.",
            "probability": 0.0
        },
        {
            "start_logit": -1.0380859375,
            "end_logit": -7.125,
            "text": "cancer is",
            "probability": 0.0
        },
        {
            "start_logit": -1.0380859375,
            "end_logit": -7.21484375,
            "text": "cancer is a heterogeneous and polygenic disease",
            "probability": 0.0
        },
        {
            "start_logit": -6.41015625,
            "end_logit": -6.6171875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.421875,
            "end_logit": -6.625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.671875,
            "end_logit": -6.84765625,
            "text": "cohort of 3,036 breast cancer",
            "probability": 0.0
        },
        {
            "start_logit": -6.421875,
            "end_logit": -7.20703125,
            "text": ". To date, numerous susceptibility loci of breast",
            "probability": 0.0
        },
        {
            "start_logit": -7.078125,
            "end_logit": -6.671875,
            "text": "and",
            "probability": 0.0
        },
        {
            "start_logit": -7.1015625,
            "end_logit": -6.671875,
            "text": "48) and",
            "probability": 0.0
        },
        {
            "start_logit": -6.96875,
            "end_logit": -6.84765625,
            "text": "breast cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.21875,
            "end_logit": -6.671875,
            "text": ") and",
            "probability": 0.0
        },
        {
            "start_logit": -7.296875,
            "end_logit": -6.6171875,
            "text": "and 10q26.1/FGFR2 (rs35054928) was associated with Luminal B.",
            "probability": 0.0
        },
        {
            "start_logit": -6.96875,
            "end_logit": -7.0078125,
            "text": "breast cancer patients (2,935 samples matched molecular subtypes) and 3,036 healthy controls.RESULTS: Through a stratification analysis, 5q11",
            "probability": 0.0
        },
        {
            "start_logit": -7.078125,
            "end_logit": -6.91015625,
            "text": "and 7q32",
            "probability": 0.0
        }
    ],
    "5e493bc06d0a277941000003_4": [
        {
            "start_logit": 9.375,
            "end_logit": 9.3359375,
            "text": "pancreatic cancer",
            "probability": 1.0
        },
        {
            "start_logit": 9.375,
            "end_logit": -0.89599609375,
            "text": "pancreatic",
            "probability": 3.5643577575683594e-05
        },
        {
            "start_logit": -1.201171875,
            "end_logit": 9.3359375,
            "text": "cancer",
            "probability": 2.5272369384765625e-05
        },
        {
            "start_logit": 9.375,
            "end_logit": -7.34375,
            "text": "pancreatic cancer.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 9.3359375,
            "text": "for pancreatic cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 9.3359375,
            "text": "diagnostic and prognostic biomarkers for pancreatic cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 9.3359375,
            "text": "Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 9.3359375,
            "text": "Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.73828125,
            "end_logit": 9.3359375,
            "text": "tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7421875,
            "end_logit": 9.3359375,
            "text": "and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55078125,
            "end_logit": -0.89599609375,
            "text": "for pancreatic",
            "probability": 0.0
        },
        {
            "start_logit": -1.201171875,
            "end_logit": -7.34375,
            "text": "cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -7.66015625,
            "end_logit": -0.89599609375,
            "text": "diagnostic and prognostic biomarkers for pancreatic",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -0.89599609375,
            "text": "Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic",
            "probability": 0.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -0.89599609375,
            "text": "Linc-pint are diagnostic and prognostic biomarkers for pancreatic",
            "probability": 0.0
        },
        {
            "start_logit": -7.73828125,
            "end_logit": -0.89599609375,
            "text": "tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic",
            "probability": 0.0
        },
        {
            "start_logit": -7.7421875,
            "end_logit": -0.89599609375,
            "text": "and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic",
            "probability": 0.0
        },
        {
            "start_logit": -6.984375,
            "end_logit": -7.34375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": -7.34375,
            "text": "for pancreatic cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -7.66015625,
            "end_logit": -7.34375,
            "text": "diagnostic and prognostic biomarkers for pancreatic cancer.",
            "probability": 0.0
        }
    ],
    "5e493bc06d0a277941000003_5": [
        {
            "start_logit": 9.40625,
            "end_logit": 9.3671875,
            "text": "pancreatic cancer",
            "probability": 1.0
        },
        {
            "start_logit": 9.40625,
            "end_logit": -0.58349609375,
            "text": "pancreatic",
            "probability": 4.7206878662109375e-05
        },
        {
            "start_logit": -0.80322265625,
            "end_logit": 9.3671875,
            "text": "cancer",
            "probability": 3.647804260253906e-05
        },
        {
            "start_logit": 9.40625,
            "end_logit": -5.23828125,
            "text": "pancreatic cancer (PCa",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.63671875,
            "end_logit": 9.3671875,
            "text": ". We used qRT-PCR and RNA FISH analysis to evaluate Linc-pint levels in the plasma and tumor tissues of pancreatic cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.015625,
            "text": "pancreatic cancer (PCa) patients.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.02734375,
            "text": "pancreatic cancer (PCa)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.03515625,
            "text": "pancreatic cancer (PCa) patients. Our data demonstrate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.1171875,
            "text": "pancreatic cancer (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 9.3671875,
            "text": "of pancreatic cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3046875,
            "end_logit": 9.3671875,
            "text": "plasma and tumor tissues of pancreatic cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3125,
            "end_logit": 9.3671875,
            "text": "evaluate Linc-pint levels in the plasma and tumor tissues of pancreatic cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.80322265625,
            "end_logit": -5.23828125,
            "text": "cancer (PCa",
            "probability": 0.0
        },
        {
            "start_logit": -6.63671875,
            "end_logit": -0.58349609375,
            "text": ". We used qRT-PCR and RNA FISH analysis to evaluate Linc-pint levels in the plasma and tumor tissues of pancreatic",
            "probability": 0.0
        },
        {
            "start_logit": -0.80322265625,
            "end_logit": -7.015625,
            "text": "cancer (PCa) patients.",
            "probability": 0.0
        },
        {
            "start_logit": -0.80322265625,
            "end_logit": -7.02734375,
            "text": "cancer (PCa)",
            "probability": 0.0
        },
        {
            "start_logit": -0.80322265625,
            "end_logit": -7.03515625,
            "text": "cancer (PCa) patients. Our data demonstrate",
            "probability": 0.0
        },
        {
            "start_logit": -7.28515625,
            "end_logit": -0.58349609375,
            "text": "of pancreatic",
            "probability": 0.0
        },
        {
            "start_logit": -7.3046875,
            "end_logit": -0.58349609375,
            "text": "plasma and tumor tissues of pancreatic",
            "probability": 0.0
        },
        {
            "start_logit": -7.3125,
            "end_logit": -0.58349609375,
            "text": "evaluate Linc-pint levels in the plasma and tumor tissues of pancreatic",
            "probability": 0.0
        }
    ],
    "601d31df1cb411341a00002e_1": [
        {
            "start_logit": 8.140625,
            "end_logit": 9.3203125,
            "text": "THOC1",
            "probability": 1.0
        },
        {
            "start_logit": -0.9609375,
            "end_logit": 9.3203125,
            "text": "1",
            "probability": 0.000110626220703125
        },
        {
            "start_logit": 8.140625,
            "end_logit": -2.93359375,
            "text": "TH",
            "probability": 4.708766937255859e-06
        },
        {
            "start_logit": -6.40625,
            "end_logit": 9.3203125,
            "text": ", THOC1",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.4375,
            "end_logit": 9.3203125,
            "text": "OC1",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.08984375,
            "end_logit": 9.3203125,
            "text": "., THOC1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.140625,
            "end_logit": -5.9921875,
            "text": "THOC1, THOC2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -0.9609375,
            "end_logit": -5.9921875,
            "text": "1, THOC2",
            "probability": 0.0
        },
        {
            "start_logit": -4.65234375,
            "end_logit": -4.17578125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -4.67578125,
            "end_logit": -4.19140625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.40625,
            "end_logit": -2.93359375,
            "text": ", TH",
            "probability": 0.0
        },
        {
            "start_logit": -7.08984375,
            "end_logit": -2.93359375,
            "text": "., TH",
            "probability": 0.0
        },
        {
            "start_logit": -4.67578125,
            "end_logit": -6.5703125,
            "text": ". We previously implicated missense and splicing-defective THOC2",
            "probability": 0.0
        },
        {
            "start_logit": -7.15234375,
            "end_logit": -4.17578125,
            "text": "has severe-profound ID, persistent hypotonia and respiratory abnormalities. Further investigations to elucidate the pathophysiological basis for this severe phenotype are warranted.",
            "probability": 0.0
        },
        {
            "start_logit": -5.7734375,
            "end_logit": -6.0703125,
            "text": "to language disorder",
            "probability": 0.0
        },
        {
            "start_logit": -5.91015625,
            "end_logit": -6.0703125,
            "text": "language disorder",
            "probability": 0.0
        },
        {
            "start_logit": -5.7734375,
            "end_logit": -6.28125,
            "text": "to language",
            "probability": 0.0
        },
        {
            "start_logit": -6.3125,
            "end_logit": -5.80859375,
            "text": "variant (p.Arg",
            "probability": 0.0
        },
        {
            "start_logit": -5.7734375,
            "end_logit": -6.41015625,
            "text": "to language disorder and/or ID",
            "probability": 0.0
        },
        {
            "start_logit": -5.91015625,
            "end_logit": -6.28125,
            "text": "language",
            "probability": 0.0
        }
    ],
    "6238a32a3a8413c6530000b9_1": [
        {
            "start_logit": 5.91796875,
            "end_logit": 7.2265625,
            "text": "postural headaches",
            "probability": 1.0
        },
        {
            "start_logit": -2.470703125,
            "end_logit": 7.2265625,
            "text": "cause postural headaches",
            "probability": 0.00022876262664794922
        },
        {
            "start_logit": -3.6328125,
            "end_logit": 7.2265625,
            "text": "headaches",
            "probability": 7.140636444091797e-05
        },
        {
            "start_logit": 5.91796875,
            "end_logit": -4.984375,
            "text": "postural",
            "probability": 5.0067901611328125e-06
        },
        {
            "start_logit": -7.515625,
            "end_logit": 7.2265625,
            "text": "Incidental durotomy can cause postural headaches",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 5.91796875,
            "end_logit": -6.50390625,
            "text": "postural headaches, nausea, vomiting, dizziness, photophobia, tinnitus, and vertigo",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 5.91796875,
            "end_logit": -6.87890625,
            "text": "postural headaches, nausea",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 5.91796875,
            "end_logit": -7.02734375,
            "text": "postural headaches, nausea, vomiting, dizziness, photophobia",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 5.91796875,
            "end_logit": -7.2265625,
            "text": "postural headaches, nausea, vomiting, dizziness, photophobia, tinnitus, and vertigo.",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 5.91796875,
            "end_logit": -7.26953125,
            "text": "postural headaches, nausea, vomiting, dizziness, photophobia, tinnitus",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 5.91796875,
            "end_logit": -7.390625,
            "text": "postural headaches, nausea, vomiting",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 5.91796875,
            "end_logit": -7.40234375,
            "text": "postural headaches,",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 5.91796875,
            "end_logit": -7.42578125,
            "text": "postural headaches, nausea, vomiting, dizziness",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 5.91796875,
            "end_logit": -7.44140625,
            "text": "postural headaches, nausea, vomiting, dizziness, photophobia, tinnitus, and",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 5.91796875,
            "end_logit": -7.55078125,
            "text": "postural headaches, nausea, vomiting, dizziness, photopho",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 5.91796875,
            "end_logit": -7.62109375,
            "text": "postural headaches, nausea, vomiting, dizziness, photop",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 5.91796875,
            "end_logit": -7.6328125,
            "text": "postural headaches, nausea,",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -2.470703125,
            "end_logit": -4.984375,
            "text": "cause postural",
            "probability": 0.0
        },
        {
            "start_logit": -2.470703125,
            "end_logit": -6.50390625,
            "text": "cause postural headaches, nausea, vomiting, dizziness, photophobia, tinnitus, and vertigo",
            "probability": 0.0
        },
        {
            "start_logit": -2.470703125,
            "end_logit": -6.87890625,
            "text": "cause postural headaches, nausea",
            "probability": 0.0
        }
    ],
    "6238a32a3a8413c6530000b9_2": [
        {
            "start_logit": 6.66796875,
            "end_logit": 7.73046875,
            "text": "postural headaches",
            "probability": 1.0
        },
        {
            "start_logit": -2.96484375,
            "end_logit": 7.73046875,
            "text": "headaches",
            "probability": 6.556510925292969e-05
        },
        {
            "start_logit": -3.060546875,
            "end_logit": 7.73046875,
            "text": "cause postural headaches",
            "probability": 5.9664249420166016e-05
        },
        {
            "start_logit": 6.66796875,
            "end_logit": -4.24609375,
            "text": "postural",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": 6.66796875,
            "end_logit": -5.79296875,
            "text": "postural headaches, nausea",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -7.0234375,
            "end_logit": 7.73046875,
            "text": "ATA: Incidental durotomy can cause postural headaches",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -7.21875,
            "end_logit": 7.73046875,
            "text": "Incidental durotomy can cause postural headaches",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -7.2734375,
            "end_logit": 7.73046875,
            "text": "can cause postural headaches",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 7.73046875,
            "text": ": Incidental durotomy can cause postural headaches",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -7.421875,
            "end_logit": 7.73046875,
            "text": "durotomy can cause postural headaches",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 6.66796875,
            "end_logit": -6.76171875,
            "text": "postural headaches, nausea, vomiting, dizziness, photophobia, tinnitus, and vertigo",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 6.66796875,
            "end_logit": -7.1484375,
            "text": "postural headaches, nausea, vomiting, dizziness, photophobia, tinnitus, and vertigo.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 6.66796875,
            "end_logit": -7.18359375,
            "text": "postural headaches, nausea, vomiting, dizziness, photophobia",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 6.66796875,
            "end_logit": -7.30078125,
            "text": "postural headaches, nausea, vomiting, dizziness, photophobia, tinnitus",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 6.66796875,
            "end_logit": -7.34375,
            "text": "postural headaches, nausea, vomiting, dizziness",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 6.66796875,
            "end_logit": -7.3828125,
            "text": "postural headaches, nausea, vomiting",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 6.66796875,
            "end_logit": -7.40625,
            "text": "postural headaches, nausea, vomiting, dizziness, photophobia, tinnitus, and vertigo. These symptoms",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 6.66796875,
            "end_logit": -7.41015625,
            "text": "postural headaches, nausea, vomiting, dizziness, photophobia, tinnitus, and vertigo. These symptoms are",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 6.66796875,
            "end_logit": -7.44140625,
            "text": "postural headaches, nausea, vomiting, dizziness, photophobia, tinnitus, and vertigo. These symptoms are believed",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 6.66796875,
            "end_logit": -7.46484375,
            "text": "postural headaches,",
            "probability": 2.384185791015625e-07
        }
    ],
    "5c928958ecadf2e73f000017_1": [
        {
            "start_logit": -0.9765625,
            "end_logit": 3.162109375,
            "text": "four-channel single-reaction multiplexing",
            "probability": 0.89208984375
        },
        {
            "start_logit": -4.5,
            "end_logit": 3.162109375,
            "text": "(i) four-channel single-reaction multiplexing",
            "probability": 0.02630615234375
        },
        {
            "start_logit": -4.72265625,
            "end_logit": 3.162109375,
            "text": ") four-channel single-reaction multiplexing",
            "probability": 0.02105712890625
        },
        {
            "start_logit": -4.921875,
            "end_logit": 3.162109375,
            "text": "single-reaction multiplexing",
            "probability": 0.0172576904296875
        },
        {
            "start_logit": -4.9296875,
            "end_logit": 3.162109375,
            "text": "SHERLOCK version 2 (SHERLOCKv2) (i) four-channel single-reaction multiplexing",
            "probability": 0.017120361328125
        },
        {
            "start_logit": -4.97265625,
            "end_logit": 3.162109375,
            "text": "multiplexing",
            "probability": 0.0164031982421875
        },
        {
            "start_logit": -6.22265625,
            "end_logit": 3.162109375,
            "text": "i) four-channel single-reaction multiplexing",
            "probability": 0.00469970703125
        },
        {
            "start_logit": -6.9609375,
            "end_logit": 3.162109375,
            "text": "ing",
            "probability": 0.0022449493408203125
        },
        {
            "start_logit": -7.046875,
            "end_logit": 3.162109375,
            "text": "-channel single-reaction multiplexing",
            "probability": 0.0020599365234375
        },
        {
            "start_logit": -0.9765625,
            "end_logit": -4.15234375,
            "text": "four-channel single-reaction multiplexing with orthogonal CRISPR enzymes",
            "probability": 0.0005950927734375
        },
        {
            "start_logit": -0.9765625,
            "end_logit": -6.55859375,
            "text": "four-channel single-reaction multiplexing with orthogonal CRISPR enzymes; (ii) quantitative measurement of input as low as 2 attomolar",
            "probability": 5.364418029785156e-05
        },
        {
            "start_logit": -0.9765625,
            "end_logit": -6.75390625,
            "text": "four-channel single-reaction multiplexing with orthogonal CRISPR enzymes; (ii) quantitative measurement of input as low as 2 attomol",
            "probability": 4.410743713378906e-05
        },
        {
            "start_logit": -0.9765625,
            "end_logit": -7.10546875,
            "text": "four-channel single-reaction multiplexing with orthogonal CRISPR enzymes; (ii) quantitative measurement of input as low",
            "probability": 3.1054019927978516e-05
        },
        {
            "start_logit": -4.5,
            "end_logit": -4.15234375,
            "text": "(i) four-channel single-reaction multiplexing with orthogonal CRISPR enzymes",
            "probability": 1.7464160919189453e-05
        },
        {
            "start_logit": -4.72265625,
            "end_logit": -4.15234375,
            "text": ") four-channel single-reaction multiplexing with orthogonal CRISPR enzymes",
            "probability": 1.4007091522216797e-05
        },
        {
            "start_logit": -4.921875,
            "end_logit": -4.15234375,
            "text": "single-reaction multiplexing with orthogonal CRISPR enzymes",
            "probability": 1.1444091796875e-05
        },
        {
            "start_logit": -4.9296875,
            "end_logit": -4.15234375,
            "text": "SHERLOCK version 2 (SHERLOCKv2) (i) four-channel single-reaction multiplexing with orthogonal CRISPR enzymes",
            "probability": 1.1444091796875e-05
        },
        {
            "start_logit": -4.97265625,
            "end_logit": -4.15234375,
            "text": "multiplexing with orthogonal CRISPR enzymes",
            "probability": 1.0907649993896484e-05
        },
        {
            "start_logit": -4.9296875,
            "end_logit": -4.9921875,
            "text": "SHERLOCK",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": -6.21875,
            "end_logit": -4.15234375,
            "text": "CRISPR enzymes",
            "probability": 3.159046173095703e-06
        }
    ],
    "60314ce01cb411341a00012f_1": [
        {
            "start_logit": 8.5234375,
            "end_logit": 6.9375,
            "text": "thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.5234375,
            "end_logit": -6.875,
            "text": "thrombocytopenia, anasarca",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 8.5234375,
            "end_logit": -6.91796875,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.5234375,
            "end_logit": -7.32421875,
            "text": "thrombocytopenia, anasarca, fever",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.5234375,
            "end_logit": -7.38671875,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (TAFRO)",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.5234375,
            "end_logit": -7.453125,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (TAFRO) syndrome",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.5234375,
            "end_logit": -7.45703125,
            "text": "thrombocytopenia, anasar",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.5234375,
            "end_logit": -7.49609375,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (TAFRO) syndrome was first described",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.5234375,
            "end_logit": -7.49609375,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (TAFRO) syndrome was",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.5234375,
            "end_logit": -7.51953125,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (TAFRO) syndrome was first described as a variant of idiopathic multicentric",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.5234375,
            "end_logit": -7.53515625,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (TAFRO) syndrome was first described as a",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.5234375,
            "end_logit": -7.57421875,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.5234375,
            "end_logit": -7.59765625,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (TAFRO) syndrome was first described as",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.5234375,
            "end_logit": -7.60546875,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (TAFRO) syndrome was first described as a variant of",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.5234375,
            "end_logit": -7.62109375,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (TAFRO) syndrome was first",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.01171875,
            "end_logit": 6.9375,
            "text": "Although thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 6.9375,
            "text": ": Although thrombocytopenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.84765625,
            "end_logit": -6.875,
            "text": "anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -6.84375,
            "end_logit": -6.91796875,
            "text": "fever, reticulin fibrosis and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -6.84765625,
            "end_logit": -6.91796875,
            "text": "anasarca, fever, reticulin fibrosis and organomegaly",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_2": [
        {
            "start_logit": 8.5390625,
            "end_logit": 6.9375,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.5390625,
            "end_logit": -6.58984375,
            "text": "Thrombocytopenia, anasarca",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 8.5390625,
            "end_logit": -7.12109375,
            "text": "Thrombocytopenia, anasarca, myelofibrosis",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.5390625,
            "end_logit": -7.34375,
            "text": "Thrombocytopenia, anasar",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.5390625,
            "end_logit": -7.40234375,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.5390625,
            "end_logit": -7.43359375,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.5390625,
            "end_logit": -7.5,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is a severe subtype of idiopathic multicentric",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.5390625,
            "end_logit": -7.54296875,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.5390625,
            "end_logit": -7.5703125,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.5390625,
            "end_logit": -7.5703125,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.5390625,
            "end_logit": -7.59375,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (TAFRO)",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.05078125,
            "end_logit": -6.1953125,
            "text": "fever",
            "probability": 0.0
        },
        {
            "start_logit": -6.83984375,
            "end_logit": -6.58984375,
            "text": "anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -6.94140625,
            "end_logit": -6.58984375,
            "text": ", anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -7.46484375,
            "end_logit": -6.1953125,
            "text": ", fever",
            "probability": 0.0
        },
        {
            "start_logit": -7.46875,
            "end_logit": -6.1953125,
            "text": "by thrombocytopenia, anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -7.35546875,
            "end_logit": -6.49609375,
            "text": "renal dysfunction, and organomegaly (TAFRO) syndrome is a severe subtype of idiopathic multicentric Castleman's disease, characterized by thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": -7.45703125,
            "end_logit": -6.49609375,
            "text": ", renal dysfunction, and organomegaly (TAFRO) syndrome is a severe subtype of idiopathic multicentric Castleman's disease, characterized by thrombocytopenia",
            "probability": 0.0
        },
        {
            "start_logit": -6.83984375,
            "end_logit": -7.12109375,
            "text": "anasarca, myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.46875,
            "end_logit": -6.49609375,
            "text": "by thrombocytopenia",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_3": [
        {
            "start_logit": 8.2109375,
            "end_logit": 7.3984375,
            "text": "thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.21875,
            "text": "thrombocytopenia, anasarca, myelofibrosis",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.2265625,
            "text": "thrombocytopenia, anasarca",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.484375,
            "text": "thrombocytopenia, anasar",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.484375,
            "text": "thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.54296875,
            "text": "thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly) is an atypical manifestation of multicentric Castleman",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.57421875,
            "text": "thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly) is",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.6171875,
            "text": "thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly) is an atypical manifestation of multicentric Castleman'",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.6484375,
            "text": "thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly) is an atypical manifestation of multicentric",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.67578125,
            "text": "thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly) is an",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.6796875,
            "text": "thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly) is an atypical manifestation of",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.68359375,
            "text": "thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly) is an atypical manifestation of multicentric Cast",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.68359375,
            "text": "thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly) is an atypical manifestation of multicentric Castlem",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.7109375,
            "text": "thrombocytopenia, anasarca, myelofibrosis, renal dysfunction",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.7109375,
            "text": "thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly) is an atypical manifestation",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.71875,
            "text": "thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly) is an atypical manifestation of multicentric Castleman's",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 7.3984375,
            "text": "syndrome (thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 7.3984375,
            "text": "RO syndrome (thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 7.3984375,
            "text": "TAFRO syndrome (thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.03125,
            "end_logit": -7.36328125,
            "text": ".",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_4": [
        {
            "start_logit": 8.7421875,
            "end_logit": 6.484375,
            "text": "thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.7421875,
            "end_logit": -6.6015625,
            "text": "thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 8.7421875,
            "end_logit": -6.73828125,
            "text": "thrombocytopenia, ascites (anasarca",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 8.7421875,
            "end_logit": -6.828125,
            "text": "thrombocytopenia, ascites",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 8.7421875,
            "end_logit": -7.14453125,
            "text": "thrombocytopenia, ascites (anasar",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 8.7421875,
            "end_logit": -7.21875,
            "text": "thrombocytopenia, ascites (anasarca)",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 8.7421875,
            "end_logit": -7.484375,
            "text": "thrombocytopenia, ascites (anasa",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 8.7421875,
            "end_logit": -7.54296875,
            "text": "thrombocytopenia, ascites (anasarca), microcytic anemia",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 8.7421875,
            "end_logit": -7.5625,
            "text": "thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.7421875,
            "end_logit": -7.5625,
            "text": "thrombocytopenia, ascites (",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.7421875,
            "end_logit": -7.58203125,
            "text": "thrombocytopenia, ascites (anasarca), microcytic anemia, myelofib",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.671875,
            "end_logit": 6.484375,
            "text": "syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.76953125,
            "end_logit": 6.484375,
            "text": "disease (TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.0703125,
            "end_logit": 6.484375,
            "text": ", thrombocytopenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.30859375,
            "end_logit": 6.484375,
            "text": "TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.38671875,
            "end_logit": 6.484375,
            "text": "RO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 6.484375,
            "text": "Castleman-Kojima disease (TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 6.484375,
            "text": "constellation of symptoms, namely, thrombocytopenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.671875,
            "end_logit": -6.73828125,
            "text": "syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -6.671875,
            "end_logit": -6.828125,
            "text": "syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_5": [
        {
            "start_logit": 8.2734375,
            "end_logit": 7.19921875,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -5.23046875,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -6.91796875,
            "text": "Thrombocytopenia, Anasarca",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -7.1171875,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and histopathology pattern",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -7.24609375,
            "text": "Thrombocytopenia, Anasar",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -7.37109375,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -7.3828125,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and histopathology pattern of atypical Castleman",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -7.51171875,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and histopathology pattern of",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -7.52734375,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and histopathology pattern of atypical Castleman'",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -7.5625,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and histopathology pattern of atypical",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -7.5625,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and histopathology pattern of atypical Cast",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.87109375,
            "end_logit": 7.19921875,
            "text": "by Thrombocytopenia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 7.19921875,
            "text": "Syndrome) is characterized by Thrombocytopenia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.0078125,
            "end_logit": 7.19921875,
            "text": "disease (TAFRO Syndrome) is characterized by Thrombocytopenia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.34375,
            "end_logit": 7.19921875,
            "text": "characterized by Thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.359375,
            "end_logit": 7.19921875,
            "text": ": Castleman-Kojima disease (TAFRO Syndrome) is characterized by Thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 7.19921875,
            "text": "TAFRO Syndrome) is characterized by Thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 7.19921875,
            "text": "jima disease (TAFRO Syndrome) is characterized by Thrombocytopenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.1484375,
            "end_logit": -5.23046875,
            "text": "lymphadenopathy",
            "probability": 0.0
        },
        {
            "start_logit": -6.87109375,
            "end_logit": -5.23046875,
            "text": "by Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_6": [
        {
            "start_logit": 8.0703125,
            "end_logit": 7.5625,
            "text": "thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -6.81640625,
            "text": "thrombocytopenia, anasarca",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -7.20703125,
            "text": "thrombocytopenia, anasarca, fever",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -7.32421875,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis, and organomegaly",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -7.36328125,
            "text": "thrombocytopenia, anasar",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -7.37109375,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis, and organomegaly) syndrome, was recently proposed in Japan.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -7.49609375,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis, and organomegaly) syndrome, was",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -7.50390625,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis, and organomegaly) syndrome, was recently proposed in Japan",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -7.515625,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -7.5390625,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis, and organomegaly) syndrome, was recently proposed",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -7.5703125,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis, and organomegaly) syndrome, was recently",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -7.64453125,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis, and organomegaly) syndrome",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -7.64453125,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis, and organomegaly)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.265625,
            "end_logit": 7.5625,
            "text": ", thrombocytopenia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 7.5625,
            "text": "., thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 7.5625,
            "text": "unique clinicopathologic variant of multicentric Castleman's disease, TAFRO (i.e., thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.4375,
            "end_logit": 7.5625,
            "text": "i.e., thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 7.5625,
            "text": "clinicopathologic variant of multicentric Castleman's disease, TAFRO (i.e., thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 7.5625,
            "text": ", TAFRO (i.e., thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 7.5625,
            "text": "TAFRO (i.e., thrombocytopenia",
            "probability": 1.7881393432617188e-07
        }
    ],
    "60314ce01cb411341a00012f_7": [
        {
            "start_logit": 8.4609375,
            "end_logit": 6.7734375,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -5.62109375,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -6.2421875,
            "text": "Thrombocytopenia, Anasarca",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.08203125,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and a histopathological pattern",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.08984375,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.15625,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and a histopathological pattern of atypical Castleman",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.1875,
            "text": "Thrombocytopenia, Anasar",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.40234375,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and a histopathological pattern of atypical Castleman'",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.45703125,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.48046875,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and a histopathological pattern of atypical Cast",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.4921875,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and a histopathological pattern of",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.49609375,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and a histopathological pattern of atypical",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.5,
            "text": "Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and a histopathological pattern of atypical Castlem",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.62890625,
            "end_logit": 6.7734375,
            "text": "by Thrombocytopenia",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.72265625,
            "end_logit": 6.7734375,
            "text": "syndrome is a novel disease concept characterized by Thrombocytopenia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.30078125,
            "end_logit": 6.7734375,
            "text": "RO syndrome is a novel disease concept characterized by Thrombocytopenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.32421875,
            "end_logit": -5.62109375,
            "text": "Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy",
            "probability": 0.0
        },
        {
            "start_logit": -6.453125,
            "end_logit": -5.62109375,
            "text": "lymphadenopathy",
            "probability": 0.0
        },
        {
            "start_logit": -6.62890625,
            "end_logit": -5.62109375,
            "text": "by Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy",
            "probability": 0.0
        },
        {
            "start_logit": -6.72265625,
            "end_logit": -5.62109375,
            "text": "syndrome is a novel disease concept characterized by Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_8": [
        {
            "start_logit": 8.2578125,
            "end_logit": 7.33203125,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -6.0390625,
            "text": "Thrombocytopenia (T), anasarca",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -7.171875,
            "text": "Thrombocytopenia (T), anasarca (A), myelofibrosis",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -7.35546875,
            "text": "Thrombocytopenia (T), anasar",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -7.55078125,
            "text": "Thrombocytopenia (T)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -7.56640625,
            "text": "Thrombocytopenia (",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -7.6015625,
            "text": "Thrombocytopenia (T), anasarca (",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -7.62109375,
            "text": "Thrombocytopenia (T), anasarca (A",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.2578125,
            "end_logit": -7.63671875,
            "text": "Thrombocytopenia (T",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.33203125,
            "end_logit": -6.0390625,
            "text": "anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -7.36328125,
            "end_logit": -6.0390625,
            "text": "sarca",
            "probability": 0.0
        },
        {
            "start_logit": -7.39453125,
            "end_logit": -6.0390625,
            "text": ", anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -6.33203125,
            "end_logit": -7.171875,
            "text": "anasarca (A), myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -6.33203125,
            "end_logit": -7.35546875,
            "text": "anasar",
            "probability": 0.0
        },
        {
            "start_logit": -6.33203125,
            "end_logit": -7.6015625,
            "text": "anasarca (",
            "probability": 0.0
        },
        {
            "start_logit": -6.33203125,
            "end_logit": -7.62109375,
            "text": "anasarca (A",
            "probability": 0.0
        },
        {
            "start_logit": -7.03125,
            "end_logit": -7.171875,
            "text": "myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -6.9375,
            "end_logit": -7.3515625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.36328125,
            "end_logit": -7.171875,
            "text": "sarca (A), myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.39453125,
            "end_logit": -7.171875,
            "text": ", anasarca (A), myelofibrosis",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_9": [
        {
            "start_logit": 8.3125,
            "end_logit": 7.26171875,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.3125,
            "end_logit": -6.78515625,
            "text": "Thrombocytopenia, anasarca",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.3125,
            "end_logit": -7.38671875,
            "text": "Thrombocytopenia, anasar",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.3125,
            "end_logit": -7.390625,
            "text": "Thrombocytopenia, anasarca, myelofibrosis",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.3125,
            "end_logit": -7.5078125,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.3125,
            "end_logit": -7.51171875,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.3125,
            "end_logit": -7.54296875,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is a severe subtype of idiopathic multicentric",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.3125,
            "end_logit": -7.5703125,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (TAFRO)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.3125,
            "end_logit": -7.5859375,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.3125,
            "end_logit": -7.6015625,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.3125,
            "end_logit": -7.609375,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.37890625,
            "end_logit": 7.26171875,
            "text": ": Thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 7.26171875,
            "text": "Introduction: Thrombocytopenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.046875,
            "end_logit": -6.78515625,
            "text": "anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -7.37109375,
            "end_logit": -6.78515625,
            "text": ", anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -7.5,
            "end_logit": -6.65625,
            "text": "fever",
            "probability": 0.0
        },
        {
            "start_logit": -7.5,
            "end_logit": -6.65625,
            "text": "by thrombocytopenia, anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -7.37890625,
            "end_logit": -6.78515625,
            "text": ": Thrombocytopenia, anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -7.53515625,
            "end_logit": -6.65625,
            "text": "characterized by thrombocytopenia, anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -7.54296875,
            "end_logit": -6.65625,
            "text": ", fever",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_10": [
        {
            "start_logit": 8.1953125,
            "end_logit": 7.42578125,
            "text": "thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -6.79296875,
            "text": "thrombocytopenia, anasarca",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -7.32421875,
            "text": "thrombocytopenia, anasarca, fever",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -7.37890625,
            "text": "thrombocytopenia, anasar",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -7.4921875,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis and organomegaly",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -7.54296875,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis and organomegaly) syndrome, has been identified in Japan",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -7.625,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis and organomegaly) syndrome",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -7.62890625,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis and organomegaly) syndrome, has been identified",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -7.6484375,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -7.6484375,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -7.65234375,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis and organomegaly) syndrome, has",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -7.66015625,
            "text": "thrombocytopenia, anasarca, fever, renal failure",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -7.6796875,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis and organomegaly)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -7.68359375,
            "text": "thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis and organ",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.1953125,
            "end_logit": -7.6953125,
            "text": "thrombocytopenia, anasarca, fever, renal",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.16796875,
            "end_logit": 7.42578125,
            "text": ". thrombocytopenia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 7.42578125,
            "text": "i.e. thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 7.42578125,
            "text": "unique clinicopathologic variant of multicentric Castleman disease, TAFRO (i.e. thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.484375,
            "end_logit": 7.42578125,
            "text": "Recently, a unique clinicopathologic variant of multicentric Castleman disease, TAFRO (i.e. thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 7.42578125,
            "text": "TAFRO (i.e. thrombocytopenia",
            "probability": 1.7881393432617188e-07
        }
    ],
    "60314ce01cb411341a00012f_11": [
        {
            "start_logit": 8.4765625,
            "end_logit": 7.01953125,
            "text": "thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.23046875,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.3046875,
            "text": "thrombocytopenia, anasarca",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.46875,
            "text": "thrombocytopenia, anasarca, fever",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.53515625,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (TAFRO) syndrome was first described as a",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.53515625,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (TAFRO) syndrome",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.546875,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (TAFRO) syndrome was first described",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.5546875,
            "text": "thrombocytopenia, anasar",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.55859375,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (TAFRO)",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.578125,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.5859375,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (TAFRO) syndrome was",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.5859375,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (TAFRO) syndrome was first described as a variant of idiopathic multicentric",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.609375,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (TAFRO) syndrome was first described as",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.6328125,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (TAFRO) syndrome was first described as a variant of",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 7.01953125,
            "text": "Although thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 7.01953125,
            "text": ": Although thrombocytopenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1484375,
            "end_logit": -7.23046875,
            "text": "fever, reticulin fibrosis and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -7.16015625,
            "end_logit": -7.23046875,
            "text": "anasarca, fever, reticulin fibrosis and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -7.18359375,
            "end_logit": -7.23046875,
            "text": "Although thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -7.16015625,
            "end_logit": -7.3046875,
            "text": "anasarca",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_12": [
        {
            "start_logit": 8.4765625,
            "end_logit": 7.01953125,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -5.41796875,
            "text": "Thrombocytopenia, anasarca",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -6.71875,
            "text": "Thrombocytopenia, anasarca, fever",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.33984375,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.375,
            "text": "Thrombocytopenia, anasar",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.578125,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly (",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.60546875,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly (TAFRO) syndrome is a unique clinicopathologic subtype of multicentric Castleman",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.63671875,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly (TAFRO)",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.65234375,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly (TAFRO) syndrome is",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.66796875,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly (TAFRO) syndrome is a unique clinicopathologic subtype of multicentric",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.12890625,
            "end_logit": -5.41796875,
            "text": "anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -6.921875,
            "end_logit": -5.41796875,
            "text": ", anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -7.27734375,
            "end_logit": -5.41796875,
            "text": "sarca",
            "probability": 0.0
        },
        {
            "start_logit": -6.12890625,
            "end_logit": -6.71875,
            "text": "anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -7.4765625,
            "end_logit": -5.41796875,
            "text": "rca",
            "probability": 0.0
        },
        {
            "start_logit": -6.51953125,
            "end_logit": -6.71875,
            "text": "fever",
            "probability": 0.0
        },
        {
            "start_logit": -6.12890625,
            "end_logit": -7.33984375,
            "text": "anasarca, fever, reticulin fibrosis, organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -6.12890625,
            "end_logit": -7.375,
            "text": "anasar",
            "probability": 0.0
        },
        {
            "start_logit": -6.921875,
            "end_logit": -6.71875,
            "text": ", anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -6.12890625,
            "end_logit": -7.578125,
            "text": "anasarca, fever, reticulin fibrosis, organomegaly (",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_13": [
        {
            "start_logit": 8.59375,
            "end_logit": 6.8046875,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.59375,
            "end_logit": -5.4140625,
            "text": "Thrombocytopenia, anasarca",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": 8.59375,
            "end_logit": -6.79296875,
            "text": "Thrombocytopenia, anasarca, fever",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 8.59375,
            "end_logit": -6.97265625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 8.59375,
            "end_logit": -7.421875,
            "text": "Thrombocytopenia, anasar",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.59375,
            "end_logit": -7.51953125,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.59375,
            "end_logit": -7.61328125,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO)",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.59375,
            "end_logit": -7.62890625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome is",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.59375,
            "end_logit": -7.66015625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome is a unique clinicopathologic variant of multicentric",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.59375,
            "end_logit": -7.68359375,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -5.92578125,
            "end_logit": -5.4140625,
            "text": "anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -6.74609375,
            "end_logit": -5.4140625,
            "text": ", anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -7.25390625,
            "end_logit": -5.4140625,
            "text": "sarca",
            "probability": 0.0
        },
        {
            "start_logit": -5.92578125,
            "end_logit": -6.79296875,
            "text": "anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -7.453125,
            "end_logit": -5.4140625,
            "text": "rca",
            "probability": 0.0
        },
        {
            "start_logit": -5.92578125,
            "end_logit": -6.97265625,
            "text": "anasarca, fever, reticulin fibrosis, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -6.1640625,
            "end_logit": -6.79296875,
            "text": "fever",
            "probability": 0.0
        },
        {
            "start_logit": -6.1640625,
            "end_logit": -6.97265625,
            "text": "fever, reticulin fibrosis, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -5.92578125,
            "end_logit": -7.421875,
            "text": "anasar",
            "probability": 0.0
        },
        {
            "start_logit": -5.92578125,
            "end_logit": -7.51953125,
            "text": "anasarca, fever, reticulin fibrosis, and organomegaly (",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_14": [
        {
            "start_logit": 8.046875,
            "end_logit": 7.56640625,
            "text": "thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.046875,
            "end_logit": -6.47265625,
            "text": "thrombocytopenia (T), anasarca (A), fever",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.41796875,
            "text": "thrombocytopenia (T), anasarca",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.484375,
            "text": "thrombocytopenia (T), anasar",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.546875,
            "text": "thrombocytopenia (T)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.625,
            "text": "thrombocytopenia (T), anasarca (A",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.6484375,
            "text": "thrombocytopenia (T), anasarca (A), fever (",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.65234375,
            "text": "thrombocytopenia (T), anasarca (A), fever (F",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.66015625,
            "text": "thrombocytopenia (T), anasarca (A), fever (F)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.2109375,
            "end_logit": 7.56640625,
            "text": "syndrome is a newly recognized variant of idiopathic multicentric Castleman disease (iMCD) that involves a constellation of syndromes: thrombocytopenia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.390625,
            "end_logit": 7.56640625,
            "text": "constellation of syndromes: thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 7.56640625,
            "text": "newly recognized variant of idiopathic multicentric Castleman disease (iMCD) that involves a constellation of syndromes: thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 7.56640625,
            "text": ": thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5,
            "end_logit": 7.56640625,
            "text": "TAFRO syndrome is a newly recognized variant of idiopathic multicentric Castleman disease (iMCD) that involves a constellation of syndromes: thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.390625,
            "end_logit": -6.47265625,
            "text": "constellation of syndromes: thrombocytopenia (T), anasarca (A), fever",
            "probability": 0.0
        },
        {
            "start_logit": -7.4765625,
            "end_logit": -6.47265625,
            "text": ": thrombocytopenia (T), anasarca (A), fever",
            "probability": 0.0
        },
        {
            "start_logit": -7.48046875,
            "end_logit": -6.47265625,
            "text": "fever",
            "probability": 0.0
        },
        {
            "start_logit": -7.2109375,
            "end_logit": -7.515625,
            "text": "syndrome is a newly recognized variant of idiopathic multicentric Castleman disease (iMCD)",
            "probability": 0.0
        },
        {
            "start_logit": -7.2109375,
            "end_logit": -7.546875,
            "text": "syndrome is a newly recognized variant of idiopathic multicentric Castleman disease (iMCD) that involves a constellation of syndromes: thrombocytopenia (T)",
            "probability": 0.0
        },
        {
            "start_logit": -7.2109375,
            "end_logit": -7.578125,
            "text": "syndrome is",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_15": [
        {
            "start_logit": 8.5078125,
            "end_logit": 6.98828125,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.5078125,
            "end_logit": -6.04296875,
            "text": "Thrombocytopenia, anasarca",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 8.5078125,
            "end_logit": -6.53515625,
            "text": "Thrombocytopenia, anasarca, myelofibrosis",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 8.5078125,
            "end_logit": -7.27734375,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction and organomegaly",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.5078125,
            "end_logit": -7.359375,
            "text": "Thrombocytopenia, anasar",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.5078125,
            "end_logit": -7.51953125,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction and organomegaly (",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.5078125,
            "end_logit": -7.55859375,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction and organomegaly (TAFRO) syndrome is",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.5078125,
            "end_logit": -7.56640625,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction and organomegaly (TAFRO)",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.5078125,
            "end_logit": -7.58203125,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction and organomegaly (TAFRO) syndrome",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.5078125,
            "end_logit": -7.59765625,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction and organomegaly (TAFRO) syndrome is a",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.5078125,
            "end_logit": -7.6015625,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction and organomegaly (TAFRO) syndrome is a variant of Castleman",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.5078125,
            "end_logit": -7.609375,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction and organomegaly (TAFRO",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.5078125,
            "end_logit": -7.6328125,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.5078125,
            "end_logit": -7.640625,
            "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction and organomegaly (TAFRO) syndrome is a variant of Castleman'",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.421875,
            "end_logit": -6.04296875,
            "text": "anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -6.421875,
            "end_logit": -6.53515625,
            "text": "anasarca, myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -6.60546875,
            "end_logit": -6.53515625,
            "text": "myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.09765625,
            "end_logit": -6.04296875,
            "text": ", anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -7.4765625,
            "end_logit": -6.04296875,
            "text": "sarca",
            "probability": 0.0
        },
        {
            "start_logit": -7.09765625,
            "end_logit": -6.53515625,
            "text": ", anasarca, myelofibrosis",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_16": [
        {
            "start_logit": 8.1171875,
            "end_logit": 6.85546875,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.1171875,
            "end_logit": -4.48828125,
            "text": "Thrombocytopenia, anasarca, fever",
            "probability": 1.1861324310302734e-05
        },
        {
            "start_logit": 8.1171875,
            "end_logit": -6.2890625,
            "text": "Thrombocytopenia, anasarca",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": 8.1171875,
            "end_logit": -7.28125,
            "text": "Thrombocytopenia, anasar",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.1171875,
            "end_logit": -7.4609375,
            "text": "Thrombocytopenia, anasarca, fever, renal insufficiency",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.1171875,
            "end_logit": -7.53125,
            "text": "Thrombocytopenia, anasarca, fever, renal insufficiency, and organomegaly",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.1171875,
            "end_logit": -7.58984375,
            "text": "Thrombocytopenia, anasarca, fever, renal insufficiency, and organomegaly constitute TAFRO syndrome, a variant of Castleman",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.1171875,
            "end_logit": -7.59765625,
            "text": "Thrombocytopenia, anasarca, fever, renal insufficiency, and organomegaly constitute TAFRO syndrome, a",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.1171875,
            "end_logit": -7.640625,
            "text": "Thrombocytopenia, anasarca, fever, renal insufficiency, and organomegaly constitute TAFRO syndrome, a variant of Castleman disease",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.1171875,
            "end_logit": -7.640625,
            "text": "Thrombocytopenia, anasarca, fever, renal",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.1171875,
            "end_logit": -7.6640625,
            "text": "Thrombocytopenia, anasarca, fever, renal insufficiency, and organomegaly constitute TAFRO syndrome",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.1171875,
            "end_logit": -7.66796875,
            "text": "Thrombocytopenia, anasarca, fever, renal insufficiency, and organomegaly constitute",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.1171875,
            "end_logit": -7.69140625,
            "text": "Thrombocytopenia, anasarca, fever, renal insufficiency, and organomegaly constitute TAFRO syndrome, a variant of",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.1171875,
            "end_logit": -7.6953125,
            "text": "Thrombocytopenia, anasarca, fever, renal insufficiency, and organomegaly constitute TAFRO syndrome,",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -4.77734375,
            "end_logit": -4.48828125,
            "text": "fever",
            "probability": 0.0
        },
        {
            "start_logit": -7.01171875,
            "end_logit": -4.48828125,
            "text": "anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -7.01171875,
            "end_logit": -4.48828125,
            "text": ", fever",
            "probability": 0.0
        },
        {
            "start_logit": -7.41015625,
            "end_logit": -4.48828125,
            "text": ", anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -4.77734375,
            "end_logit": -7.4609375,
            "text": "fever, renal insufficiency",
            "probability": 0.0
        },
        {
            "start_logit": -4.77734375,
            "end_logit": -7.53125,
            "text": "fever, renal insufficiency, and organomegaly",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_17": [
        {
            "start_logit": 8.546875,
            "end_logit": 6.875,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.546875,
            "end_logit": -5.44921875,
            "text": "Thrombocytopenia, anasarca",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": 8.546875,
            "end_logit": -6.921875,
            "text": "Thrombocytopenia, anasarca, fever",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 8.546875,
            "end_logit": -7.00390625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -7.421875,
            "text": "Thrombocytopenia, anasar",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -7.50390625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -7.5546875,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome is",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -7.63671875,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO)",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -7.65234375,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome is considered",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -7.66796875,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -7.671875,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -7.6875,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome is considered as a",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -5.89453125,
            "end_logit": -5.44921875,
            "text": "anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -6.82421875,
            "end_logit": -5.44921875,
            "text": ", anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -7.26953125,
            "end_logit": -5.44921875,
            "text": "sarca",
            "probability": 0.0
        },
        {
            "start_logit": -5.89453125,
            "end_logit": -6.921875,
            "text": "anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -5.89453125,
            "end_logit": -7.00390625,
            "text": "anasarca, fever, reticulin fibrosis, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -7.47265625,
            "end_logit": -5.44921875,
            "text": "rca",
            "probability": 0.0
        },
        {
            "start_logit": -5.89453125,
            "end_logit": -7.421875,
            "text": "anasar",
            "probability": 0.0
        },
        {
            "start_logit": -5.89453125,
            "end_logit": -7.50390625,
            "text": "anasarca, fever, reticulin fibrosis, and organomegaly (",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_18": [
        {
            "start_logit": 8.4609375,
            "end_logit": 7.07421875,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.12890625,
            "text": "Thrombocytopenia, ascites, myelofibrosis",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.1484375,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.2109375,
            "text": "Thrombocytopenia, ascites",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.44921875,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.4765625,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (TAFRO)",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.52734375,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is a newly recognized",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.53515625,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.58984375,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.6328125,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (TAFRO",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.65234375,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is a newly recognized and rare",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.65625,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is a",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.69921875,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is a newly recognized and rare clinical subtype of",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.70703125,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.7109375,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is a newly",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -7.71484375,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is a newly recognized and rare clinical",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 7.07421875,
            "text": ": Thrombocytopenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 7.07421875,
            "text": "INTRODUCTION: Thrombocytopenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.94140625,
            "end_logit": -7.12890625,
            "text": "myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -6.94140625,
            "end_logit": -7.1484375,
            "text": "myelofibrosis, renal dysfunction, and organomegaly",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_19": [
        {
            "start_logit": 8.28125,
            "end_logit": 7.2890625,
            "text": "thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.28125,
            "end_logit": -5.94921875,
            "text": "thrombocytopenia, anasarca",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.05078125,
            "text": "thrombocytopenia, anasarca, fever",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.36328125,
            "text": "thrombocytopenia, anasar",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.4296875,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly)",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.48828125,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly), which is thought to be a variant of multicentric",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.48828125,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly), which is thought to be a variant of multicentric Castleman",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.55078125,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly), which is thought to be a variant of",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.57421875,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly), which is thought to be a variant of multicentric Cast",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.578125,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.5859375,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly), which is thought to be a",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.59375,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly), which is thought to",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.62109375,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly), which is thought",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.96875,
            "end_logit": 7.2890625,
            "text": "pathophysiology and comorbidities of TAFRO syndrome (thrombocytopenia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 7.2890625,
            "text": "The pathophysiology and comorbidities of TAFRO syndrome (thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.32421875,
            "end_logit": 7.2890625,
            "text": "syndrome (thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 7.2890625,
            "text": "comorbidities of TAFRO syndrome (thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 7.2890625,
            "text": "(thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.27734375,
            "end_logit": -5.94921875,
            "text": "anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -6.96875,
            "end_logit": -5.94921875,
            "text": "pathophysiology and comorbidities of TAFRO syndrome (thrombocytopenia, anasarca",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_20": [
        {
            "start_logit": 8.5703125,
            "end_logit": 6.83984375,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -5.01171875,
            "text": "Thrombocytopenia, anasarca",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -6.85546875,
            "text": "Thrombocytopenia, anasarca, fever",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -6.91796875,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -7.36328125,
            "text": "Thrombocytopenia, anasar",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -7.45703125,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -7.515625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome is",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -7.609375,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome is considered",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -7.625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO)",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -7.65625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome is considered as a",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -7.671875,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -7.67578125,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -5.375,
            "end_logit": -5.01171875,
            "text": "anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -6.7109375,
            "end_logit": -5.01171875,
            "text": ", anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -7.16015625,
            "end_logit": -5.01171875,
            "text": "sarca",
            "probability": 0.0
        },
        {
            "start_logit": -5.375,
            "end_logit": -6.85546875,
            "text": "anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -5.375,
            "end_logit": -6.91796875,
            "text": "anasarca, fever, reticulin fibrosis, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -7.40234375,
            "end_logit": -5.01171875,
            "text": "rca",
            "probability": 0.0
        },
        {
            "start_logit": -5.375,
            "end_logit": -7.36328125,
            "text": "anasar",
            "probability": 0.0
        },
        {
            "start_logit": -5.375,
            "end_logit": -7.45703125,
            "text": "anasarca, fever, reticulin fibrosis, and organomegaly (",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_21": [
        {
            "start_logit": 8.53125,
            "end_logit": 6.9375,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.53125,
            "end_logit": -4.890625,
            "text": "Thrombocytopenia, anasarca",
            "probability": 7.271766662597656e-06
        },
        {
            "start_logit": 8.53125,
            "end_logit": -6.6953125,
            "text": "Thrombocytopenia, anasarca, fever",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 8.53125,
            "end_logit": -7.234375,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.53125,
            "end_logit": -7.26171875,
            "text": "Thrombocytopenia, anasar",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.53125,
            "end_logit": -7.51953125,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly (",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.53125,
            "end_logit": -7.546875,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly (TAFRO) syndrome is a unique clinicopathologic subtype of multicentric Castleman",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.53125,
            "end_logit": -7.62109375,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly (TAFRO)",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.53125,
            "end_logit": -7.625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly (TAFRO) syndrome is",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.53125,
            "end_logit": -7.65625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly (TAFRO) syndrome is a unique clinicopathologic subtype of multicentric",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -5.5078125,
            "end_logit": -4.890625,
            "text": "anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -6.703125,
            "end_logit": -4.890625,
            "text": ", anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -7.12109375,
            "end_logit": -4.890625,
            "text": "sarca",
            "probability": 0.0
        },
        {
            "start_logit": -5.5078125,
            "end_logit": -6.6953125,
            "text": "anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -7.40625,
            "end_logit": -4.890625,
            "text": "rca",
            "probability": 0.0
        },
        {
            "start_logit": -5.5078125,
            "end_logit": -7.234375,
            "text": "anasarca, fever, reticulin fibrosis, organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -5.5078125,
            "end_logit": -7.26171875,
            "text": "anasar",
            "probability": 0.0
        },
        {
            "start_logit": -6.30859375,
            "end_logit": -6.6953125,
            "text": "fever",
            "probability": 0.0
        },
        {
            "start_logit": -5.5078125,
            "end_logit": -7.51953125,
            "text": "anasarca, fever, reticulin fibrosis, organomegaly (",
            "probability": 0.0
        },
        {
            "start_logit": -5.5078125,
            "end_logit": -7.546875,
            "text": "anasarca, fever, reticulin fibrosis, organomegaly (TAFRO) syndrome is a unique clinicopathologic subtype of multicentric Castleman",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_22": [
        {
            "start_logit": 8.5859375,
            "end_logit": 6.8125,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -4.828125,
            "text": "Thrombocytopenia, anasarca",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -6.7421875,
            "text": "Thrombocytopenia, anasarca, fever",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -6.88671875,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.3203125,
            "text": "Thrombocytopenia, anasar",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.4453125,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.58203125,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome is",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.62109375,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO)",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.6484375,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome is a unique clinicopathologic variant of multicentric",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.6640625,
            "text": "Thrombocytopenia, anasarca, fever, reticulin fibrosis",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -5.2265625,
            "end_logit": -4.828125,
            "text": "anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -6.61328125,
            "end_logit": -4.828125,
            "text": ", anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -7.12890625,
            "end_logit": -4.828125,
            "text": "sarca",
            "probability": 0.0
        },
        {
            "start_logit": -5.2265625,
            "end_logit": -6.7421875,
            "text": "anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": -5.2265625,
            "end_logit": -6.88671875,
            "text": "anasarca, fever, reticulin fibrosis, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -7.3828125,
            "end_logit": -4.828125,
            "text": "rca",
            "probability": 0.0
        },
        {
            "start_logit": -5.2265625,
            "end_logit": -7.3203125,
            "text": "anasar",
            "probability": 0.0
        },
        {
            "start_logit": -5.859375,
            "end_logit": -6.7421875,
            "text": "fever",
            "probability": 0.0
        },
        {
            "start_logit": -5.2265625,
            "end_logit": -7.4453125,
            "text": "anasarca, fever, reticulin fibrosis, and organomegaly (",
            "probability": 0.0
        },
        {
            "start_logit": -5.2265625,
            "end_logit": -7.5078125,
            "text": "anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome is a unique clinicopathologic variant of multicentric Castleman",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_23": [
        {
            "start_logit": 8.359375,
            "end_logit": 7.21875,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.359375,
            "end_logit": -7.0859375,
            "text": "Thrombocytopenia, ascites",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -7.1171875,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -7.125,
            "text": "Thrombocytopenia, ascites, myelofibrosis",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -7.46875,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -7.5078125,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (TAFRO)",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -7.546875,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is a newly recognized",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -7.55859375,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -7.59765625,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -7.63671875,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (TAFRO",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -7.66015625,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is a",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -7.6640625,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is a newly recognized and rare",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -7.6875,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.359375,
            "end_logit": -7.7265625,
            "text": "Thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is a newly recognized and rare clinical",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 7.21875,
            "text": ": Thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 7.21875,
            "text": "INTRODUCTION: Thrombocytopenia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9375,
            "end_logit": -7.1171875,
            "text": "myelofibrosis, renal dysfunction, and organomegaly",
            "probability": 0.0
        },
        {
            "start_logit": -6.9375,
            "end_logit": -7.125,
            "text": "myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.14453125,
            "end_logit": -7.0859375,
            "text": "ascites",
            "probability": 0.0
        },
        {
            "start_logit": -7.14453125,
            "end_logit": -7.1171875,
            "text": "ascites, myelofibrosis, renal dysfunction, and organomegaly",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_24": [
        {
            "start_logit": 8.078125,
            "end_logit": 7.51953125,
            "text": "Thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.078125,
            "end_logit": -4.91796875,
            "text": "Thrombocytopenia, Anasarca",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": 8.078125,
            "end_logit": -6.28515625,
            "text": "Thrombocytopenia, Anasarca, MyeloFibrosis",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 8.078125,
            "end_logit": -6.84375,
            "text": "Thrombocytopenia, Anasar",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -7.04296875,
            "text": "Thrombocytopenia, Anasarca, MyeloFibrosis, Renal failure, Organomegaly).",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.48828125,
            "end_logit": 7.51953125,
            "text": "constellation of symptoms (Thrombocytopenia",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -7.41796875,
            "text": "Thrombocytopenia, Anasarca, MyeloFibrosis, Renal failure, Organomegaly)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -7.484375,
            "text": "Thrombocytopenia, Anasarca, MyeloFib",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -7.4921875,
            "text": "Thrombocytopenia, Anasa",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -7.51171875,
            "text": "Thrombocytopenia, Anasarca, MyeloFibrosis, Renal failure",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -7.58984375,
            "text": "Thrombocytopenia, Anasarca, MyeloFibrosis, Renal failure, Organomegaly",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.109375,
            "end_logit": 7.51953125,
            "text": "(Thrombocytopenia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 7.51953125,
            "text": "TAFRO represents the constellation of symptoms (Thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 7.51953125,
            "text": "represents the constellation of symptoms (Thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -4.828125,
            "end_logit": -4.91796875,
            "text": "Anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -4.828125,
            "end_logit": -6.28515625,
            "text": "Anasarca, MyeloFibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -6.48828125,
            "end_logit": -4.91796875,
            "text": "constellation of symptoms (Thrombocytopenia, Anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -4.828125,
            "end_logit": -6.84375,
            "text": "Anasar",
            "probability": 0.0
        },
        {
            "start_logit": -4.828125,
            "end_logit": -7.04296875,
            "text": "Anasarca, MyeloFibrosis, Renal failure, Organomegaly).",
            "probability": 0.0
        },
        {
            "start_logit": -7.109375,
            "end_logit": -4.91796875,
            "text": "(Thrombocytopenia, Anasarca",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_25": [
        {
            "start_logit": 8.0546875,
            "end_logit": 7.43359375,
            "text": "thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -5.59375,
            "text": "thrombocytopenia (T), anasarca (A), fever",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -6.6796875,
            "text": "thrombocytopenia (T), anasarca",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.21875,
            "text": "thrombocytopenia (T), anasar",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.8359375,
            "end_logit": 7.43359375,
            "text": "syndrome is a newly recognized variant of idiopathic multicentric Castleman disease (iMCD) that involves a constellation of syndromes: thrombocytopenia",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.5546875,
            "text": "thrombocytopenia (T)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.5703125,
            "text": "thrombocytopenia (T), anasarca (A",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.59765625,
            "text": "thrombocytopenia (T), anasarca (A), fever (F",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.6015625,
            "text": "thrombocytopenia (T), anasarca (A), fever (",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.6015625,
            "text": "thrombocytopenia (T), anasarca (",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0546875,
            "end_logit": -7.60546875,
            "text": "thrombocytopenia (T), anasarca (A), fever (F)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.0859375,
            "end_logit": 7.43359375,
            "text": "constellation of syndromes: thrombocytopenia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 7.43359375,
            "text": ": thrombocytopenia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.3125,
            "end_logit": 7.43359375,
            "text": "newly recognized variant of idiopathic multicentric Castleman disease (iMCD) that involves a constellation of syndromes: thrombocytopenia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.46875,
            "end_logit": 7.43359375,
            "text": "TAFRO syndrome is a newly recognized variant of idiopathic multicentric Castleman disease (iMCD) that involves a constellation of syndromes: thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 7.43359375,
            "text": "idiopathic multicentric Castleman disease (iMCD) that involves a constellation of syndromes: thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 7.43359375,
            "text": "variant of idiopathic multicentric Castleman disease (iMCD) that involves a constellation of syndromes: thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 7.43359375,
            "text": "RO syndrome is a newly recognized variant of idiopathic multicentric Castleman disease (iMCD) that involves a constellation of syndromes: thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.859375,
            "end_logit": -5.59375,
            "text": "fever",
            "probability": 0.0
        },
        {
            "start_logit": -6.91015625,
            "end_logit": -5.59375,
            "text": "anasarca (A), fever",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_26": [
        {
            "start_logit": 8.0703125,
            "end_logit": 7.4140625,
            "text": "thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -6.5546875,
            "text": "thrombocytopenia, anasarca",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -6.77734375,
            "text": "thrombocytopenia, anasarca, fever",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -7.08203125,
            "text": "thrombocytopenia, anasarca, fever, reticulin myelofibrosis, renal dysfunction, and organomegaly.",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.55078125,
            "end_logit": 7.4140625,
            "text": "syndrome is a newly identified disorder of unknown etiology characterized by thrombocytopenia",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -7.23046875,
            "text": "thrombocytopenia, anasar",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -7.42578125,
            "text": "thrombocytopenia, anasarca, fever, reticulin myelofibrosis",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -7.53515625,
            "text": "thrombocytopenia, anasarca, fever, reticulin myelofib",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.91796875,
            "end_logit": 7.4140625,
            "text": "by thrombocytopenia",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -7.5859375,
            "text": "thrombocytopenia, anasarca, fever, reticulin myelofibrosis, renal dysfunction, and organomegaly",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -7.5859375,
            "text": "thrombocytopenia, anasa",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.15234375,
            "end_logit": 7.4140625,
            "text": "unknown etiology characterized by thrombocytopenia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.25390625,
            "end_logit": 7.4140625,
            "text": "RO syndrome is a newly identified disorder of unknown etiology characterized by thrombocytopenia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 7.4140625,
            "text": "TAFRO syndrome is a newly identified disorder of unknown etiology characterized by thrombocytopenia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 7.4140625,
            "text": "newly identified disorder of unknown etiology characterized by thrombocytopenia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 7.4140625,
            "text": "disorder of unknown etiology characterized by thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.55078125,
            "end_logit": -5.984375,
            "text": "syndrome is a newly identified disorder of unknown etiology",
            "probability": 0.0
        },
        {
            "start_logit": -6.55078125,
            "end_logit": -6.5546875,
            "text": "syndrome is a newly identified disorder of unknown etiology characterized by thrombocytopenia, anasarca",
            "probability": 0.0
        },
        {
            "start_logit": -7.15234375,
            "end_logit": -5.984375,
            "text": "unknown etiology",
            "probability": 0.0
        },
        {
            "start_logit": -6.625,
            "end_logit": -6.5546875,
            "text": "anasarca",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_27": [
        {
            "start_logit": 8.0859375,
            "end_logit": 7.53515625,
            "text": "thrombocytopenia",
            "probability": 1.0
        },
        {
            "start_logit": -5.12109375,
            "end_logit": 7.53515625,
            "text": "TAFRO syndrome, an acronym for thrombocytopenia",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -6.95703125,
            "text": "thrombocytopenia, ascites",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -7.24609375,
            "text": "thrombocytopenia, ascites, myelofibrosis",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -7.25390625,
            "text": "thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -7.56640625,
            "text": "thrombocytopenia, ascites, myelofib",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -7.60546875,
            "text": "thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.21484375,
            "end_logit": 7.53515625,
            "text": "RO syndrome, an acronym for thrombocytopenia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.2890625,
            "end_logit": 7.53515625,
            "text": "named TAFRO syndrome, an acronym for thrombocytopenia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 7.53515625,
            "text": "syndrome, an acronym for thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 7.53515625,
            "text": "acronym for thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 7.53515625,
            "text": "Recently, a new variant of the disease was reported and named TAFRO syndrome, an acronym for thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.12109375,
            "end_logit": -6.13671875,
            "text": "TAFRO syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -5.12109375,
            "end_logit": -6.95703125,
            "text": "TAFRO syndrome, an acronym for thrombocytopenia, ascites",
            "probability": 0.0
        },
        {
            "start_logit": -5.12109375,
            "end_logit": -7.24609375,
            "text": "TAFRO syndrome, an acronym for thrombocytopenia, ascites, myelofibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -5.12109375,
            "end_logit": -7.25390625,
            "text": "TAFRO syndrome, an acronym for thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly.",
            "probability": 0.0
        },
        {
            "start_logit": -5.12109375,
            "end_logit": -7.32421875,
            "text": "TAFRO syndrome, an acronym",
            "probability": 0.0
        },
        {
            "start_logit": -5.12109375,
            "end_logit": -7.56640625,
            "text": "TAFRO syndrome, an acronym for thrombocytopenia, ascites, myelofib",
            "probability": 0.0
        },
        {
            "start_logit": -5.12109375,
            "end_logit": -7.58984375,
            "text": "TAFRO syndrome, an acronym for",
            "probability": 0.0
        },
        {
            "start_logit": -5.12109375,
            "end_logit": -7.60546875,
            "text": "TAFRO syndrome, an acronym for thrombocytopenia, ascites, myelofibrosis, renal dysfunction, and organomegaly",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_28": [
        {
            "start_logit": 2.2578125,
            "end_logit": 1.123046875,
            "text": "fever",
            "probability": 0.990234375
        },
        {
            "start_logit": -3.109375,
            "end_logit": 1.123046875,
            "text": "anasarca (A), fever",
            "probability": 0.004619598388671875
        },
        {
            "start_logit": 2.2578125,
            "end_logit": -5.14453125,
            "text": "fever (F), reticulin fibrosis (R), and organomegaly (O) has been described as TAFRO syndrome",
            "probability": 0.0018825531005859375
        },
        {
            "start_logit": -4.703125,
            "end_logit": 1.123046875,
            "text": "thrombocytopenia (T), anasarca (A), fever",
            "probability": 0.0009393692016601562
        },
        {
            "start_logit": 2.2578125,
            "end_logit": -5.94921875,
            "text": "fever (F), reticulin fibrosis (R), and organomegaly (O) has been described as TAFRO",
            "probability": 0.0008420944213867188
        },
        {
            "start_logit": 2.2578125,
            "end_logit": -6.9921875,
            "text": "fever (F), reticulin fibrosis (R), and organomegaly (O) has been described as TAFRO syndrome.",
            "probability": 0.00029540061950683594
        },
        {
            "start_logit": 2.2578125,
            "end_logit": -7.39453125,
            "text": "fever (",
            "probability": 0.0001983642578125
        },
        {
            "start_logit": 2.2578125,
            "end_logit": -7.40234375,
            "text": "fever (F), reticulin fibrosis",
            "probability": 0.00019681453704833984
        },
        {
            "start_logit": -6.578125,
            "end_logit": 1.123046875,
            "text": ", fever",
            "probability": 0.00014400482177734375
        },
        {
            "start_logit": -6.6015625,
            "end_logit": 1.123046875,
            "text": "constellation of clinical features, including thrombocytopenia (T), anasarca (A), fever",
            "probability": 0.00014066696166992188
        },
        {
            "start_logit": -6.64453125,
            "end_logit": 1.123046875,
            "text": ", anasarca (A), fever",
            "probability": 0.0001342296600341797
        },
        {
            "start_logit": -7.015625,
            "end_logit": 1.123046875,
            "text": "including thrombocytopenia (T), anasarca (A), fever",
            "probability": 9.298324584960938e-05
        },
        {
            "start_logit": -7.1171875,
            "end_logit": 1.123046875,
            "text": "iMCD cases in Japan sharing a constellation of clinical features, including thrombocytopenia (T), anasarca (A), fever",
            "probability": 8.398294448852539e-05
        },
        {
            "start_logit": -3.109375,
            "end_logit": -2.93359375,
            "text": "anasarca",
            "probability": 8.016824722290039e-05
        },
        {
            "start_logit": -7.17578125,
            "end_logit": 1.123046875,
            "text": "sharing a constellation of clinical features, including thrombocytopenia (T), anasarca (A), fever",
            "probability": 7.891654968261719e-05
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 1.123046875,
            "text": "series of iMCD cases in Japan sharing a constellation of clinical features, including thrombocytopenia (T), anasarca (A), fever",
            "probability": 7.647275924682617e-05
        },
        {
            "start_logit": -7.234375,
            "end_logit": 1.123046875,
            "text": "sarca (A), fever",
            "probability": 7.474422454833984e-05
        },
        {
            "start_logit": -4.703125,
            "end_logit": -2.93359375,
            "text": "thrombocytopenia (T), anasarca",
            "probability": 1.627206802368164e-05
        },
        {
            "start_logit": -3.341796875,
            "end_logit": -5.14453125,
            "text": "TAFRO syndrome",
            "probability": 6.973743438720703e-06
        },
        {
            "start_logit": -3.341796875,
            "end_logit": -5.94921875,
            "text": "TAFRO",
            "probability": 3.0994415283203125e-06
        }
    ],
    "60314ce01cb411341a00012f_29": [
        {
            "start_logit": 7.99609375,
            "end_logit": 7.140625,
            "text": "thrombocytopenia",
            "probability": 0.9970703125
        },
        {
            "start_logit": 2.001953125,
            "end_logit": 7.140625,
            "text": "TAFRO syndrome, named from thrombocytopenia",
            "probability": 0.002471923828125
        },
        {
            "start_logit": 2.001953125,
            "end_logit": 1.6943359375,
            "text": "TAFRO syndrome",
            "probability": 1.0669231414794922e-05
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -4.59375,
            "text": "thrombocytopenia, anasarca",
            "probability": 7.987022399902344e-06
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -6.4296875,
            "text": "thrombocytopenia, anasarca, fever",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -6.9609375,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly.",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -7.08984375,
            "text": "thrombocytopenia, anasar",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -7.44140625,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -7.5703125,
            "text": "thrombocytopenia, anasarca, fever, reticulin fibrosis",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -7.5859375,
            "text": "thrombocytopenia, anasa",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.9375,
            "end_logit": 7.140625,
            "text": ", TAFRO syndrome, named from thrombocytopenia",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.10546875,
            "end_logit": 7.140625,
            "text": "from thrombocytopenia",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.15625,
            "end_logit": 7.140625,
            "text": "RO syndrome, named from thrombocytopenia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 7.140625,
            "text": "reported a new disease concept, TAFRO syndrome, named from thrombocytopenia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.2734375,
            "end_logit": 7.140625,
            "text": "new disease concept, TAFRO syndrome, named from thrombocytopenia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 7.140625,
            "text": "syndrome, named from thrombocytopenia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.421875,
            "end_logit": 7.140625,
            "text": "a new disease concept, TAFRO syndrome, named from thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 2.001953125,
            "end_logit": -4.59375,
            "text": "TAFRO syndrome, named from thrombocytopenia, anasarca",
            "probability": 0.0
        },
        {
            "start_logit": 2.001953125,
            "end_logit": -6.4296875,
            "text": "TAFRO syndrome, named from thrombocytopenia, anasarca, fever",
            "probability": 0.0
        },
        {
            "start_logit": 2.001953125,
            "end_logit": -6.8828125,
            "text": "TAF",
            "probability": 0.0
        }
    ],
    "60314ce01cb411341a00012f_30": [
        {
            "start_logit": 1.7421875,
            "end_logit": -6.3125,
            "text": "idiopathic multicentric",
            "probability": 0.161376953125
        },
        {
            "start_logit": -2.958984375,
            "end_logit": -1.662109375,
            "text": "thrombocytopenia",
            "probability": 0.1534423828125
        },
        {
            "start_logit": 1.7421875,
            "end_logit": -6.609375,
            "text": "idiopathic multicentric Cast",
            "probability": 0.11993408203125
        },
        {
            "start_logit": 1.7421875,
            "end_logit": -6.99609375,
            "text": "idiopathic multicentric Castleman disease with TAFRO syndrome (iMCD",
            "probability": 0.08148193359375
        },
        {
            "start_logit": 1.7421875,
            "end_logit": -7.16796875,
            "text": "idiopathic multicentric Castleman disease",
            "probability": 0.068603515625
        },
        {
            "start_logit": 1.7421875,
            "end_logit": -7.23046875,
            "text": "idiopathic multicentric Castleman disease with TAFRO syndrome",
            "probability": 0.064453125
        },
        {
            "start_logit": 1.7421875,
            "end_logit": -7.296875,
            "text": "idiopathic multicentric Castleman disease with TAFRO syndrome (iMCD-TAFRO)",
            "probability": 0.060333251953125
        },
        {
            "start_logit": 1.7421875,
            "end_logit": -7.3046875,
            "text": "idiopathic multicentric Castleman disease with TAFRO syndrome (iMCD-",
            "probability": 0.059844970703125
        },
        {
            "start_logit": 1.7421875,
            "end_logit": -7.3828125,
            "text": "idiopathic multicentric Castleman disease with TAFRO syndrome (iMCD-TAF",
            "probability": 0.05535888671875
        },
        {
            "start_logit": 1.7421875,
            "end_logit": -7.421875,
            "text": "idiopathic multicentric Castleman",
            "probability": 0.053253173828125
        },
        {
            "start_logit": 1.7421875,
            "end_logit": -7.44921875,
            "text": "idiopathic multicentric Castleman disease with TAFRO syndrome (iM",
            "probability": 0.051788330078125
        },
        {
            "start_logit": 1.7421875,
            "end_logit": -7.453125,
            "text": "idiopathic multicentric Castleman disease with TAFRO syndrome (",
            "probability": 0.05157470703125
        },
        {
            "start_logit": -2.958984375,
            "end_logit": -5.015625,
            "text": "thrombocytopenia (T), anasarca (A), fever",
            "probability": 0.0053558349609375
        },
        {
            "start_logit": -2.958984375,
            "end_logit": -5.296875,
            "text": "thrombocytopenia (T), anasarca",
            "probability": 0.0040435791015625
        },
        {
            "start_logit": -6.94921875,
            "end_logit": -1.662109375,
            "text": "syndrome (iMCD-TAFRO), is a recently recognized systemic inflammatory disorder with a characteristic series of clinical symptoms, including thrombocytopenia",
            "probability": 0.002841949462890625
        },
        {
            "start_logit": -7.31640625,
            "end_logit": -1.662109375,
            "text": "including thrombocytopenia",
            "probability": 0.0019683837890625
        },
        {
            "start_logit": -7.4140625,
            "end_logit": -1.662109375,
            "text": "clinical symptoms, including thrombocytopenia",
            "probability": 0.0017795562744140625
        },
        {
            "start_logit": -2.958984375,
            "end_logit": -6.6796875,
            "text": "thrombocytopenia (T), anasar",
            "probability": 0.0010137557983398438
        },
        {
            "start_logit": -5.0546875,
            "end_logit": -5.015625,
            "text": "anasarca (A), fever",
            "probability": 0.0006594657897949219
        },
        {
            "start_logit": -5.0546875,
            "end_logit": -5.296875,
            "text": "anasarca",
            "probability": 0.0004978179931640625
        }
    ],
    "60322b501cb411341a000137_1": [
        {
            "start_logit": 9.1640625,
            "end_logit": 9.125,
            "text": "LGALS7",
            "probability": 1.0
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -1.4599609375,
            "text": "LG",
            "probability": 2.5451183319091797e-05
        },
        {
            "start_logit": -1.6982421875,
            "end_logit": 9.125,
            "text": "7",
            "probability": 1.9252300262451172e-05
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -4.41015625,
            "text": "LGALS7, ASPN",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -6.54296875,
            "end_logit": 9.125,
            "text": "ALS7",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.65625,
            "text": "LGALS7, ASPN, HSP90AA1 and HSP90AB1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.9609375,
            "text": "LGALS",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.05078125,
            "text": "LGALS7, ASPN, HSP90AA1 and HSP90AB1.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.07421875,
            "text": "LGALS7, ASPN, HSP90AA1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.2109375,
            "text": "LGALS7, ASPN, HSP90",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.26953125,
            "text": "LGALS7, ASPN, HSP90AA1 and HSP90AB",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.3125,
            "text": "LGALS7, ASPN, HSP90AA1 and HSP90",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.33203125,
            "text": "LGALS7, ASPN, HSP90AA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.37109375,
            "text": "LGALS7, ASPN, HSP90AA1 and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.6982421875,
            "end_logit": -4.41015625,
            "text": "7, ASPN",
            "probability": 0.0
        },
        {
            "start_logit": -1.6982421875,
            "end_logit": -6.65625,
            "text": "7, ASPN, HSP90AA1 and HSP90AB1",
            "probability": 0.0
        },
        {
            "start_logit": -1.6982421875,
            "end_logit": -7.05078125,
            "text": "7, ASPN, HSP90AA1 and HSP90AB1.",
            "probability": 0.0
        },
        {
            "start_logit": -1.6982421875,
            "end_logit": -7.07421875,
            "text": "7, ASPN, HSP90AA1",
            "probability": 0.0
        },
        {
            "start_logit": -1.6982421875,
            "end_logit": -7.2109375,
            "text": "7, ASPN, HSP90",
            "probability": 0.0
        },
        {
            "start_logit": -1.6982421875,
            "end_logit": -7.26953125,
            "text": "7, ASPN, HSP90AA1 and HSP90AB",
            "probability": 0.0
        }
    ],
    "60322b501cb411341a000137_2": [
        {
            "start_logit": 7.65625,
            "end_logit": 5.66015625,
            "text": "TAGLN",
            "probability": 0.99609375
        },
        {
            "start_logit": 1.9794921875,
            "end_logit": 5.66015625,
            "text": "COL1A1, SCGB1A1, TAGLN",
            "probability": 0.0034275054931640625
        },
        {
            "start_logit": 1.9794921875,
            "end_logit": 2.2734375,
            "text": "COL1A1",
            "probability": 0.00011545419692993164
        },
        {
            "start_logit": 7.65625,
            "end_logit": -3.755859375,
            "text": "TAG",
            "probability": 8.124113082885742e-05
        },
        {
            "start_logit": 7.65625,
            "end_logit": -7.2265625,
            "text": "TAGLN, PSEN2, TSPAN1",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": 7.65625,
            "end_logit": -7.32421875,
            "text": "TAGLN, PSEN2, TSPAN1, CTSB, AGR2, CSP",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": 7.65625,
            "end_logit": -7.375,
            "text": "TAGLN, PSEN2",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 7.65625,
            "end_logit": -7.41796875,
            "text": "TAGLN, PSEN2, TSPAN1, CTS",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 7.65625,
            "end_logit": -7.44140625,
            "text": "TAGLN, PSEN2, TSPAN1, CTSB",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 7.65625,
            "end_logit": -7.45703125,
            "text": "TAGLN, PSEN2, TSPAN",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": -5.70703125,
            "end_logit": 5.66015625,
            "text": "N",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -6.33984375,
            "end_logit": 5.66015625,
            "text": "LN",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -6.3671875,
            "end_logit": 5.66015625,
            "text": "SCGB1A1, TAGLN",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 1.9794921875,
            "end_logit": -3.755859375,
            "text": "COL1A1, SCGB1A1, TAG",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 5.66015625,
            "text": ", TAGLN",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 5.66015625,
            "text": "1A1, SCGB1A1, TAGLN",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 1.9794921875,
            "end_logit": -5.53515625,
            "text": "COL1A1, SCGB1A1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.9794921875,
            "end_logit": -6.01953125,
            "text": "COL1A1, SCGB1",
            "probability": 0.0
        },
        {
            "start_logit": 1.9794921875,
            "end_logit": -6.91796875,
            "text": "COL1A1,",
            "probability": 0.0
        },
        {
            "start_logit": 1.9794921875,
            "end_logit": -7.1796875,
            "text": "COL1A1, SCG",
            "probability": 0.0
        }
    ],
    "60322b501cb411341a000137_3": [
        {
            "start_logit": 8.203125,
            "end_logit": 8.8515625,
            "text": "emilin-1",
            "probability": 0.9990234375
        },
        {
            "start_logit": 8.203125,
            "end_logit": 1.3212890625,
            "text": "emilin-1 and fibronectin",
            "probability": 0.0005311965942382812
        },
        {
            "start_logit": -2.197265625,
            "end_logit": 8.8515625,
            "text": "1",
            "probability": 3.0219554901123047e-05
        },
        {
            "start_logit": 8.203125,
            "end_logit": -2.98828125,
            "text": "em",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": -4.98828125,
            "end_logit": 8.8515625,
            "text": "cell adhesion proteins such as emilin-1",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": -5.65625,
            "end_logit": 8.8515625,
            "text": "adhesion proteins such as emilin-1",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -6.05078125,
            "end_logit": 8.8515625,
            "text": "ilin-1",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.49609375,
            "end_logit": 8.8515625,
            "text": "as emilin-1",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.7421875,
            "end_logit": 8.8515625,
            "text": "production of cell adhesion proteins such as emilin-1",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.86328125,
            "end_logit": 8.8515625,
            "text": "remodeling of the scaffold was characterized by an initial phase with cell proliferation and high production of cell adhesion proteins such as emilin-1",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.87890625,
            "end_logit": 8.8515625,
            "text": "of cell adhesion proteins such as emilin-1",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.046875,
            "end_logit": 8.8515625,
            "text": "high production of cell adhesion proteins such as emilin-1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.07421875,
            "end_logit": 8.8515625,
            "text": "-1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.09765625,
            "end_logit": 8.8515625,
            "text": "cell proliferation and high production of cell adhesion proteins such as emilin-1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.16015625,
            "end_logit": 8.8515625,
            "text": "an initial phase with cell proliferation and high production of cell adhesion proteins such as emilin-1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 8.8515625,
            "text": "with cell proliferation and high production of cell adhesion proteins such as emilin-1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.203125,
            "end_logit": -6.8359375,
            "text": "emilin-1 and fibronectin.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.203125,
            "end_logit": -6.90234375,
            "text": "emilin-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.197265625,
            "end_logit": 1.3212890625,
            "text": "1 and fibronectin",
            "probability": 0.0
        },
        {
            "start_logit": -4.34765625,
            "end_logit": 1.3212890625,
            "text": "fibronectin",
            "probability": 0.0
        }
    ],
    "60322b501cb411341a000137_4": [
        {
            "start_logit": 8.734375,
            "end_logit": 9.109375,
            "text": "versican",
            "probability": 1.0
        },
        {
            "start_logit": -1.7431640625,
            "end_logit": 9.109375,
            "text": "ican",
            "probability": 2.8192996978759766e-05
        },
        {
            "start_logit": 8.734375,
            "end_logit": -2.275390625,
            "text": "vers",
            "probability": 1.138448715209961e-05
        },
        {
            "start_logit": 8.734375,
            "end_logit": -4.46484375,
            "text": "versican and decorin",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -5.80859375,
            "end_logit": 9.109375,
            "text": "f proteoglycans, such as versican",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.921875,
            "end_logit": 9.109375,
            "text": "proteoglycans, such as versican",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.734375,
            "end_logit": -6.859375,
            "text": "versican and dec",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 9.109375,
            "text": "as versican",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.734375,
            "end_logit": -7.171875,
            "text": "versican and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 9.109375,
            "text": ", such as versican",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 9.109375,
            "text": "such as versican",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.7431640625,
            "end_logit": -4.46484375,
            "text": "ican and decorin",
            "probability": 0.0
        },
        {
            "start_logit": -5.80859375,
            "end_logit": -2.275390625,
            "text": "f proteoglycans, such as vers",
            "probability": 0.0
        },
        {
            "start_logit": -1.7431640625,
            "end_logit": -6.859375,
            "text": "ican and dec",
            "probability": 0.0
        },
        {
            "start_logit": -1.7431640625,
            "end_logit": -7.171875,
            "text": "ican and",
            "probability": 0.0
        },
        {
            "start_logit": -6.921875,
            "end_logit": -2.275390625,
            "text": "proteoglycans, such as vers",
            "probability": 0.0
        },
        {
            "start_logit": -7.41015625,
            "end_logit": -2.275390625,
            "text": "as vers",
            "probability": 0.0
        },
        {
            "start_logit": -7.6015625,
            "end_logit": -2.275390625,
            "text": ", such as vers",
            "probability": 0.0
        },
        {
            "start_logit": -7.76953125,
            "end_logit": -2.275390625,
            "text": "such as vers",
            "probability": 0.0
        },
        {
            "start_logit": -5.79296875,
            "end_logit": -4.46484375,
            "text": "decorin",
            "probability": 0.0
        }
    ],
    "601ec1fb1cb411341a000061_1": [
        {
            "start_logit": 8.765625,
            "end_logit": 9.375,
            "text": "Alobar",
            "probability": 1.0
        },
        {
            "start_logit": -1.0185546875,
            "end_logit": 9.375,
            "text": "r",
            "probability": 5.650520324707031e-05
        },
        {
            "start_logit": 8.765625,
            "end_logit": -2.169921875,
            "text": "Al",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": -5.125,
            "end_logit": 9.375,
            "text": ": Alobar",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -5.234375,
            "end_logit": 9.375,
            "text": "types: Alobar",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -6.31640625,
            "end_logit": 9.375,
            "text": "obar",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.765625,
            "end_logit": -5.8984375,
            "text": "Alobar, Semilobar, Lobar and Middle interhemispheric fusion",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.765625,
            "end_logit": -6.03515625,
            "text": "Alobar, Semilobar",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.73828125,
            "end_logit": 9.375,
            "text": ". Depending on the degree of involvement, it is classified into 4 types: Alobar",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.9765625,
            "end_logit": 9.375,
            "text": "classified into 4 types: Alobar",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.765625,
            "end_logit": -6.46484375,
            "text": "Aloba",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.22265625,
            "end_logit": 9.375,
            "text": ", it is classified into 4 types: Alobar",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.2578125,
            "end_logit": 9.375,
            "text": "degree of involvement, it is classified into 4 types: Alobar",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.765625,
            "end_logit": -6.90625,
            "text": "Alobar, Semilobar, Lobar and Middle interhemispheric fusion variant",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.765625,
            "end_logit": -7.0078125,
            "text": "Alobar, Semilo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.765625,
            "end_logit": -7.0703125,
            "text": "Alobar, Semilobar, Lobar and Middle interhemispheric fusion variant.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.765625,
            "end_logit": -7.265625,
            "text": "Alobar, Semilobar, Lobar",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.765625,
            "end_logit": -7.47265625,
            "text": "Alobar, Semilobar, Lobar and Middle interhemispheric",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.0185546875,
            "end_logit": -5.8984375,
            "text": "r, Semilobar, Lobar and Middle interhemispheric fusion",
            "probability": 0.0
        },
        {
            "start_logit": -1.0185546875,
            "end_logit": -6.03515625,
            "text": "r, Semilobar",
            "probability": 0.0
        }
    ],
    "5166f41a298dcd4e5100005b_1": [
        {
            "start_logit": 9.25,
            "end_logit": 9.359375,
            "text": "BIX-01294",
            "probability": 1.0
        },
        {
            "start_logit": -1.236328125,
            "end_logit": 9.359375,
            "text": "94",
            "probability": 2.7954578399658203e-05
        },
        {
            "start_logit": 9.25,
            "end_logit": -1.2626953125,
            "text": "BI",
            "probability": 2.4318695068359375e-05
        },
        {
            "start_logit": -6.4765625,
            "end_logit": 9.359375,
            "text": "-01294",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.65625,
            "end_logit": 9.359375,
            "text": "01294",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.75,
            "end_logit": 9.359375,
            "text": "X-01294",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -6.7421875,
            "text": "BIX-01294)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -6.87890625,
            "text": "BIX-01294) of the human G9a histone methyltransferase. Two compounds, BIX-01294 and its derivative TM2-115",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -6.9453125,
            "text": "BIX-012",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.015625,
            "text": "BIX-01294) of the human G9a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.01953125,
            "text": "BIX-01294) of the human G9a histone methyltransferase.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.234375,
            "end_logit": 9.359375,
            "text": "(BIX-01294",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.21875,
            "text": "BIX-01294) of the human G9a histone methyltransferase. Two compounds, BIX-01294 and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 9.359375,
            "text": "a compound library based upon a known specific inhibitor (BIX-01294",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 9.359375,
            "text": "synthesized a compound library based upon a known specific inhibitor (BIX-01294",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.2734375,
            "text": "BIX",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.3125,
            "text": "BIX-01294) of the human G9a histone methyltransferase. Two compounds, BIX",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 9.359375,
            "text": "compound library based upon a known specific inhibitor (BIX-01294",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 9.359375,
            "text": "known specific inhibitor (BIX-01294",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 9.359375,
            "text": "specific inhibitor (BIX-01294",
            "probability": 5.960464477539063e-08
        }
    ],
    "5166f41a298dcd4e5100005b_2": [
        {
            "start_logit": 9.265625,
            "end_logit": 9.5703125,
            "text": "BIX-01294",
            "probability": 1.0
        },
        {
            "start_logit": -0.60400390625,
            "end_logit": 9.5703125,
            "text": "94",
            "probability": 5.143880844116211e-05
        },
        {
            "start_logit": 9.265625,
            "end_logit": -1.2099609375,
            "text": "BI",
            "probability": 2.0623207092285156e-05
        },
        {
            "start_logit": -6.04296875,
            "end_logit": 9.5703125,
            "text": "that BIX-01294",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -5.8828125,
            "text": "BIX-01294 and TM2-115",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.23828125,
            "end_logit": 9.5703125,
            "text": "X-01294",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.53125,
            "end_logit": 9.5703125,
            "text": "-01294",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.65625,
            "end_logit": 9.5703125,
            "text": "01294",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -6.40234375,
            "text": "BIX-012",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.02734375,
            "end_logit": 9.5703125,
            "text": "Together, these results suggest that BIX-01294",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.265625,
            "end_logit": 9.5703125,
            "text": "suggest that BIX-01294",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 9.5703125,
            "text": "results suggest that BIX-01294",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.109375,
            "text": "BIX-01294 and TM",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.21484375,
            "text": "BIX-01294 and TM2-115 inhibit malaria parasite histone methyltransferases, resulting in rapid and irreversible parasite death",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.21875,
            "text": "BIX-01294 and TM2-115 inhibit malaria parasite histone methyltransferases, resulting in rapid and irreversible parasite death.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.23046875,
            "text": "BIX-01294 and TM2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.609375,
            "end_logit": 9.5703125,
            "text": "these results suggest that BIX-01294",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.33984375,
            "text": "BIX-01294 and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.46484375,
            "text": "BIX-01294 and TM2-115 inhibit malaria parasite",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.46875,
            "text": "BIX-01294 and TM2-",
            "probability": 5.960464477539063e-08
        }
    ],
    "5166f41a298dcd4e5100005b_3": [
        {
            "start_logit": 9.0625,
            "end_logit": 9.2890625,
            "text": "BIX-01294",
            "probability": 1.0
        },
        {
            "start_logit": -1.31640625,
            "end_logit": 9.2890625,
            "text": "94",
            "probability": 3.11732292175293e-05
        },
        {
            "start_logit": 9.0625,
            "end_logit": -1.6396484375,
            "text": "BI",
            "probability": 1.806020736694336e-05
        },
        {
            "start_logit": 9.0625,
            "end_logit": -6.14453125,
            "text": "BIX-012",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.88671875,
            "end_logit": 9.2890625,
            "text": "; BIX-01294",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9453125,
            "end_logit": 9.2890625,
            "text": "01294",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.046875,
            "end_logit": 9.2890625,
            "text": "X-01294",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0625,
            "end_logit": -6.84375,
            "text": "BIX-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0625,
            "end_logit": -6.95703125,
            "text": "BIX",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 9.2890625,
            "text": "dimethylation; BIX-01294",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0625,
            "end_logit": -7.30078125,
            "text": "BIX-01294 has",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 9.2890625,
            "text": "EHMT2; also known as G9a) has been shown to be a primary mediator of H3K9 dimethylation; BIX-01294",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0625,
            "end_logit": -7.33984375,
            "text": "BIX-01294 has been shown",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0625,
            "end_logit": -7.3671875,
            "text": "BIX-01294 has been shown to be a specific inhibitor of EHMT2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.88671875,
            "end_logit": -1.6396484375,
            "text": "; BI",
            "probability": 0.0
        },
        {
            "start_logit": -1.31640625,
            "end_logit": -7.30078125,
            "text": "94 has",
            "probability": 0.0
        },
        {
            "start_logit": -1.31640625,
            "end_logit": -7.33984375,
            "text": "94 has been shown",
            "probability": 0.0
        },
        {
            "start_logit": -1.31640625,
            "end_logit": -7.3671875,
            "text": "94 has been shown to be a specific inhibitor of EHMT2",
            "probability": 0.0
        },
        {
            "start_logit": -7.43359375,
            "end_logit": -1.6396484375,
            "text": "methyltransferase 2 (EHMT2; also known as G9a) has been shown to be a primary mediator of H3K9 dimethylation; BI",
            "probability": 0.0
        },
        {
            "start_logit": -7.51953125,
            "end_logit": -1.6396484375,
            "text": "dimethylation; BI",
            "probability": 0.0
        }
    ],
    "5166f41a298dcd4e5100005b_4": [
        {
            "start_logit": 9.2578125,
            "end_logit": 9.4453125,
            "text": "BIX-01294",
            "probability": 1.0
        },
        {
            "start_logit": -1.009765625,
            "end_logit": 9.4453125,
            "text": "94",
            "probability": 3.4809112548828125e-05
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -1.244140625,
            "text": "BI",
            "probability": 2.282857894897461e-05
        },
        {
            "start_logit": -5.79296875,
            "end_logit": 9.4453125,
            "text": "X-01294",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.67578125,
            "end_logit": 9.4453125,
            "text": "-01294",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -6.5078125,
            "text": "BIX-01294 would result in reduced levels of H3K9 dimethylation and compromised embryo development",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.72265625,
            "end_logit": 9.4453125,
            "text": "01294",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.76171875,
            "end_logit": 9.4453125,
            "text": "EHMT2 by BIX-01294",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.859375,
            "end_logit": 9.4453125,
            "text": "by BIX-01294",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -6.6796875,
            "text": "BIX-012",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -6.83203125,
            "text": "BIX-01294 would result in reduced levels of H3K9 dimethylation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.03125,
            "end_logit": 9.4453125,
            "text": "that inhibition of EHMT2 by BIX-01294",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.25390625,
            "text": "BIX-01294 would",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.2734375,
            "text": "BIX-01294 would result in reduced levels of H3K9 dimethylation and compromised embryo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.27734375,
            "text": "BIX-01294 would result in reduced levels of H3K9 dimethylation and compromised embryo development.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.328125,
            "text": "BIX-01294 would result in reduced levels of H3K9 dimethylation and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 9.4453125,
            "text": "hypothesised that inhibition of EHMT2 by BIX-01294",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.34375,
            "text": "BIX-01294 would result in reduced levels of H3K9",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.35546875,
            "text": "BIX-01294 would result in reduced levels of H3K9 dimethyl",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 9.4453125,
            "text": "We hypothesised that inhibition of EHMT2 by BIX-01294",
            "probability": 5.960464477539063e-08
        }
    ],
    "5166f41a298dcd4e5100005b_5": [
        {
            "start_logit": 8.1171875,
            "end_logit": 8.7421875,
            "text": "KDM4C",
            "probability": 0.54248046875
        },
        {
            "start_logit": 8.640625,
            "end_logit": 8.0390625,
            "text": "2,4-pyridinedicarboxylic acid",
            "probability": 0.45703125
        },
        {
            "start_logit": -0.77685546875,
            "end_logit": 8.7421875,
            "text": "acid (2,4-PDCA) with a potency similar to that reported for the HDM KDM4C",
            "probability": 7.474422454833984e-05
        },
        {
            "start_logit": -0.77685546875,
            "end_logit": 8.0390625,
            "text": "acid",
            "probability": 3.695487976074219e-05
        },
        {
            "start_logit": 8.640625,
            "end_logit": -1.3974609375,
            "text": "2",
            "probability": 3.612041473388672e-05
        },
        {
            "start_logit": -2.3671875,
            "end_logit": 8.7421875,
            "text": "C",
            "probability": 1.519918441772461e-05
        },
        {
            "start_logit": 8.640625,
            "end_logit": -2.33984375,
            "text": "2,4-pyridinedicarboxylic acid (2,4-PDCA",
            "probability": 1.4066696166992188e-05
        },
        {
            "start_logit": 8.640625,
            "end_logit": -3.19921875,
            "text": "2,4-pyridinedicarboxylic acid (2,4-PDCA) with a potency similar to that reported for the HDM KD",
            "probability": 5.9604644775390625e-06
        },
        {
            "start_logit": 8.1171875,
            "end_logit": -3.19921875,
            "text": "KD",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": 8.1171875,
            "end_logit": -3.943359375,
            "text": "KDM4",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": -5.5546875,
            "end_logit": 8.7421875,
            "text": "pyridinedicarboxylic acid (2,4-PDCA) with a potency similar to that reported for the HDM KDM4C",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -5.7890625,
            "end_logit": 8.7421875,
            "text": "-pyridinedicarboxylic acid (2,4-PDCA) with a potency similar to that reported for the HDM KDM4C",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.09375,
            "end_logit": 8.7421875,
            "text": "ic acid (2,4-PDCA) with a potency similar to that reported for the HDM KDM4C",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.09375,
            "end_logit": 8.7421875,
            "text": "PDCA) with a potency similar to that reported for the HDM KDM4C",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.40625,
            "end_logit": 8.0390625,
            "text": ",4-pyridinedicarboxylic acid",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.52734375,
            "end_logit": 8.0390625,
            "text": "4-pyridinedicarboxylic acid",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.25390625,
            "end_logit": 8.7421875,
            "text": "2,4-PDCA) with a potency similar to that reported for the HDM KDM4C",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.5546875,
            "end_logit": 8.0390625,
            "text": "pyridinedicarboxylic acid",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.640625,
            "end_logit": -6.328125,
            "text": "2,4-pyridinedicarboxylic acid (",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.4453125,
            "end_logit": 8.7421875,
            "text": "oxylic acid (2,4-PDCA) with a potency similar to that reported for the HDM KDM4C",
            "probability": 2.384185791015625e-07
        }
    ],
    "5166f41a298dcd4e5100005b_6": [
        {
            "start_logit": 8.875,
            "end_logit": 8.9296875,
            "text": "3-deazaneplanocin A",
            "probability": 0.50390625
        },
        {
            "start_logit": 8.9453125,
            "end_logit": 8.8515625,
            "text": "trichostatin A",
            "probability": 0.49609375
        },
        {
            "start_logit": 8.875,
            "end_logit": -0.60546875,
            "text": "3-deazaneplanocin A (DZNep), an inhibitor of H3K27me3",
            "probability": 3.600120544433594e-05
        },
        {
            "start_logit": -1.4697265625,
            "end_logit": 8.9296875,
            "text": "A",
            "probability": 1.609325408935547e-05
        },
        {
            "start_logit": 8.875,
            "end_logit": -1.4560546875,
            "text": "3",
            "probability": 1.5497207641601562e-05
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -1.6494140625,
            "text": "trich",
            "probability": 1.3649463653564453e-05
        },
        {
            "start_logit": -2.18359375,
            "end_logit": 8.8515625,
            "text": "A",
            "probability": 7.271766662597656e-06
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -4.34765625,
            "text": "trichostatin A (TSA",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -4.6171875,
            "end_logit": 8.9296875,
            "text": "deazaneplanocin A",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.875,
            "end_logit": -5.88671875,
            "text": "3-deazaneplanocin A (DZNep",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.875,
            "end_logit": -5.91796875,
            "text": "3-deazaneplanocin A (DZNep)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.875,
            "end_logit": -6.03515625,
            "text": "3-deazaneplanocin A (DZNep), an inhibitor of H3K27me3 and H4K20me3",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.2265625,
            "end_logit": 8.9296875,
            "text": "azaneplanocin A",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.24609375,
            "end_logit": 8.9296875,
            "text": "-deazaneplanocin A",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.875,
            "end_logit": -6.27734375,
            "text": "3-deazaneplanocin A (DZNe",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.375,
            "end_logit": 8.9296875,
            "text": "anocin A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.44921875,
            "end_logit": 8.8515625,
            "text": "HDAC inhibitor, trichostatin A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.546875,
            "end_logit": 8.9296875,
            "text": "cin A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -6.58984375,
            "text": "trichostatin A (TSA)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -6.67578125,
            "text": "trichostatin A (",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5166f41a298dcd4e5100005b_7": [
        {
            "start_logit": 9.328125,
            "end_logit": 9.421875,
            "text": "DZNep",
            "probability": 1.0
        },
        {
            "start_logit": -1.0712890625,
            "end_logit": 9.421875,
            "text": "p",
            "probability": 3.045797348022461e-05
        },
        {
            "start_logit": 9.328125,
            "end_logit": -1.0302734375,
            "text": "DZ",
            "probability": 2.8848648071289062e-05
        },
        {
            "start_logit": -5.37890625,
            "end_logit": 9.421875,
            "text": "Nep",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.52734375,
            "text": "DZNep, a pharmacologic inhibitor of KMT6",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.9140625,
            "text": "DZNep, a pharmacologic inhibitor of KMT6 expression",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.1171875,
            "text": "DZNep, a pharmacologic inhibitor of KMT",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.15234375,
            "text": "DZNep, a pharmacologic inhibitor of KMT6 expression, recapitulated the effects of KMT6 knockdown",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.19921875,
            "text": "DZNep, a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.24609375,
            "text": "DZNep, a pharmacologic inhibitor of KMT6 expression,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.3046875,
            "text": "DZNep, a pharmacologic inhibitor of KMT6 expression, recapit",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.33984375,
            "text": "DZNep, a pharmacologic inhibitor of KMT6 expression, recapitulated",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.37890625,
            "text": "DZNep, a pharmacologic inhibitor of KMT6 expression, recapitulated the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.390625,
            "text": "DZNep, a pharmacologic inhibitor of KMT6 expression, recapitulated the effects of KMT6 knockdown.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.4140625,
            "text": "DZNep, a pharmacologic inhibitor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.421875,
            "text": "DZNep, a pharmacologic inhibitor of KM",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.44140625,
            "text": "DZNep, a pharmacologic inhibitor of KMT6 expression, recapitulated the effects of KMT6",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.46484375,
            "text": "DZNep, a pharmacologic inhibitor of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.4921875,
            "text": "DZNep, a pharmacologic inhibitor of KMT6 expression, recapitulated the effects of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.5,
            "text": "DZNep, a pharmacologic inhibitor of KMT6 expression, recapitulated the effects of KMT",
            "probability": 5.960464477539063e-08
        }
    ],
    "5166f41a298dcd4e5100005b_8": [
        {
            "start_logit": 8.09375,
            "end_logit": 8.59375,
            "text": "3-deazaneplanocin A",
            "probability": 0.994140625
        },
        {
            "start_logit": 8.09375,
            "end_logit": 3.458984375,
            "text": "3-deazaneplanocin A (DZNep) modulate chromatin through indirect inhibition of histone methyltransferases including EZH2",
            "probability": 0.00586700439453125
        },
        {
            "start_logit": -0.374267578125,
            "end_logit": 8.59375,
            "text": "A",
            "probability": 0.00020873546600341797
        },
        {
            "start_logit": 8.09375,
            "end_logit": -0.8525390625,
            "text": "3-deazaneplanocin A (DZNep",
            "probability": 7.855892181396484e-05
        },
        {
            "start_logit": 3.20703125,
            "end_logit": 3.458984375,
            "text": "EZH2",
            "probability": 4.410743713378906e-05
        },
        {
            "start_logit": 8.09375,
            "end_logit": -2.1796875,
            "text": "3",
            "probability": 2.0802021026611328e-05
        },
        {
            "start_logit": -4.73046875,
            "end_logit": 8.59375,
            "text": "S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors (AHI) such as 3-deazaneplanocin A",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": -4.84375,
            "end_logit": 8.59375,
            "text": "deazaneplanocin A",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": -5.2421875,
            "end_logit": 8.59375,
            "text": "-deazaneplanocin A",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": -0.374267578125,
            "end_logit": 3.458984375,
            "text": "A (DZNep) modulate chromatin through indirect inhibition of histone methyltransferases including EZH2",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -5.6171875,
            "end_logit": 8.59375,
            "text": "that S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors (AHI) such as 3-deazaneplanocin A",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 8.09375,
            "end_logit": -5.37890625,
            "text": "3-deazaneplanocin A (DZNe",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -5.984375,
            "end_logit": 8.59375,
            "text": "as 3-deazaneplanocin A",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.12109375,
            "end_logit": 8.59375,
            "text": "cin A",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -5.9296875,
            "text": "3-deazane",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -6.09375,
            "text": "3-deazanepl",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -6.19140625,
            "text": "3-deazaneplanocin A (DZNep) modulate chromatin through indirect inhibition of histone methyltransferases including EZH2.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -6.203125,
            "text": "3-deazaneplanocin A (DZNep) modulate chromatin through indirect inhibition of histone methyltransferases including EZ",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.09375,
            "end_logit": -6.390625,
            "text": "3-deazaneplanocin A (DZ",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -3.201171875,
            "end_logit": 3.458984375,
            "text": "DZNep) modulate chromatin through indirect inhibition of histone methyltransferases including EZH2",
            "probability": 5.960464477539063e-08
        }
    ],
    "5166f41a298dcd4e5100005b_9": [
        {
            "start_logit": 9.3203125,
            "end_logit": 9.265625,
            "text": "psammaplin A",
            "probability": 1.0
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -1.01171875,
            "text": "psa",
            "probability": 3.427267074584961e-05
        },
        {
            "start_logit": -1.384765625,
            "end_logit": 9.265625,
            "text": "A",
            "probability": 2.2292137145996094e-05
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -2.39453125,
            "text": "psammaplin A (PsA",
            "probability": 8.52346420288086e-06
        },
        {
            "start_logit": -4.86328125,
            "end_logit": 9.265625,
            "text": "histone deacetylase and DNA methyltransferase inhibitor, psammaplin A",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -5.515625,
            "text": "psammaplin A (PsA)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.3203125,
            "end_logit": 9.265625,
            "text": "mmaplin A",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.578125,
            "end_logit": 9.265625,
            "text": "in A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -6.94140625,
            "text": "psammaplin A (PsA), in mice.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -6.953125,
            "text": "psammaplin A (PsA), in mice",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.90625,
            "end_logit": 9.265625,
            "text": "aplin A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -6.984375,
            "text": "psammaplin A (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.00390625,
            "text": "psammaplin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.10546875,
            "text": "psammapl",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.15234375,
            "text": "psammaplin A (PsA),",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.109375,
            "end_logit": 9.265625,
            "text": ", psammaplin A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 9.265625,
            "text": "DNA methyltransferase inhibitor, psammaplin A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2109375,
            "end_logit": 9.265625,
            "text": "study reports the pharmacokinetics and tissue distribution of a novel histone deacetylase and DNA methyltransferase inhibitor, psammaplin A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3046875,
            "end_logit": 9.265625,
            "text": "pharmacokinetics and tissue distribution of a novel histone deacetylase and DNA methyltransferase inhibitor, psammaplin A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34375,
            "end_logit": 9.265625,
            "text": "This study reports the pharmacokinetics and tissue distribution of a novel histone deacetylase and DNA methyltransferase inhibitor, psammaplin A",
            "probability": 5.960464477539063e-08
        }
    ],
    "5166f41a298dcd4e5100005b_10": [
        {
            "start_logit": 9.203125,
            "end_logit": 9.3203125,
            "text": "sulforaphane",
            "probability": 1.0
        },
        {
            "start_logit": -1.294921875,
            "end_logit": 9.3203125,
            "text": "ne",
            "probability": 2.7298927307128906e-05
        },
        {
            "start_logit": 9.203125,
            "end_logit": -1.3564453125,
            "text": "sulfo",
            "probability": 2.282857894897461e-05
        },
        {
            "start_logit": -5.8203125,
            "end_logit": 9.3203125,
            "text": "raphane",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -6.0625,
            "text": "sulforaphane (SFN",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -6.15234375,
            "text": "sulforaphane (SFN)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.33203125,
            "end_logit": 9.3203125,
            "text": "phane",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -6.62109375,
            "text": "sulforaphane (SF",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9375,
            "end_logit": 9.3203125,
            "text": "histone deacetylase (HDAC) inhibitors, such as the bioactive component sulforaphane",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -6.859375,
            "text": "sulforapha",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.203125,
            "text": "sulforaphane (SFN), whose epigenetic effects on MSTN gene in satellite cells are unknown.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.24609375,
            "text": "sulforaphane (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 9.3203125,
            "text": "as the bioactive component sulforaphane",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46875,
            "end_logit": 9.3203125,
            "text": "bioactive component sulforaphane",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 9.3203125,
            "text": "Human diet contains many histone deacetylase (HDAC) inhibitors, such as the bioactive component sulforaphane",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 9.3203125,
            "text": "component sulforaphane",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.4375,
            "text": "sulforaphane (SFN), whose epigenetic effects on MSTN gene in satellite cells",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.44921875,
            "text": "sulforaphane (SFN), whose epigenetic effects on MSTN gene in satellite cells are unknown",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.609375,
            "end_logit": 9.3203125,
            "text": "HDAC) inhibitors, such as the bioactive component sulforaphane",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.294921875,
            "end_logit": -6.0625,
            "text": "ne (SFN",
            "probability": 0.0
        }
    ],
    "5166f41a298dcd4e5100005b_11": [
        {
            "start_logit": 9.078125,
            "end_logit": 9.0390625,
            "text": "5-Aza-2'-deoxycytidine",
            "probability": 0.8984375
        },
        {
            "start_logit": 9.078125,
            "end_logit": 6.83984375,
            "text": "5-Aza-2'-deoxycytidine) and histone deacetylase inhibitor (trichostatin A",
            "probability": 0.0992431640625
        },
        {
            "start_logit": 5.46875,
            "end_logit": 6.83984375,
            "text": "trichostatin A",
            "probability": 0.002685546875
        },
        {
            "start_logit": 9.078125,
            "end_logit": -1.5439453125,
            "text": "5",
            "probability": 2.2530555725097656e-05
        },
        {
            "start_logit": -1.5439453125,
            "end_logit": 9.0390625,
            "text": "cytidine",
            "probability": 2.181529998779297e-05
        },
        {
            "start_logit": -1.5439453125,
            "end_logit": 6.83984375,
            "text": "cytidine) and histone deacetylase inhibitor (trichostatin A",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": -4.93359375,
            "end_logit": 9.0390625,
            "text": "-Aza-2'-deoxycytidine",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -5.75,
            "end_logit": 9.0390625,
            "text": "deoxycytidine",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.078125,
            "end_logit": -5.79296875,
            "text": "5-Aza-2'-deoxycytidine) and histone deacetylase inhibitor (trich",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.078125,
            "end_logit": -5.9765625,
            "text": "5-Aza-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.078125,
            "end_logit": -6.109375,
            "text": "5-Aza",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.078125,
            "end_logit": -6.11328125,
            "text": "5-Aza-2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.26171875,
            "end_logit": 9.0390625,
            "text": "-deoxycytidine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.078125,
            "end_logit": -6.32421875,
            "text": "5-Aza-2'-deoxycytidine)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.671875,
            "end_logit": 9.0390625,
            "text": "DNA methyltransferase inhibitor (5-Aza-2'-deoxycytidine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.078125,
            "end_logit": -6.95703125,
            "text": "5-Aza-2'-deoxycytidine) and histone deacetylase",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.74609375,
            "end_logit": 6.83984375,
            "text": "A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.01171875,
            "end_logit": 9.0390625,
            "text": "Aza-2'-deoxycytidine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.078125,
            "end_logit": -7.09765625,
            "text": "5-Aza-2'-deoxycytidine) and histone deacetylase inhibitor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.078125,
            "end_logit": -7.109375,
            "text": "5-Aza-2'-deoxycytidine) and histone deacetylase inhibitor (trichostatin A) reduced leptin receptor expression.",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5166f41a298dcd4e5100005b_12": [
        {
            "start_logit": 9.2421875,
            "end_logit": 9.3359375,
            "text": "trichostatin A",
            "probability": 1.0
        },
        {
            "start_logit": -1.244140625,
            "end_logit": 9.3359375,
            "text": "A",
            "probability": 2.7954578399658203e-05
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -1.1875,
            "text": "trichostatin A (TSA) and sodium butyrate",
            "probability": 2.6881694793701172e-05
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -1.1962890625,
            "text": "trich",
            "probability": 2.6702880859375e-05
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -5.61328125,
            "text": "trichostatin A (TSA",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.88671875,
            "end_logit": 9.3359375,
            "text": "ostatin A",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.40234375,
            "text": "trichostatin A (TSA)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.40625,
            "text": "trichostatin A (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.90625,
            "text": "trichostatin A (TSA) and sodium butyrate (NaBt",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.01953125,
            "text": "trichostatin A (TSA) and sodium butyrate (NaBt)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.05859375,
            "text": "trichostatin A (TSA) and sodium butyrate (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.0703125,
            "text": "trichostatin A (TSA) and sodium butyrate (NaB",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 9.3359375,
            "text": "However, histone deacetylase (HDAC) inhibitors trichostatin A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.375,
            "end_logit": 9.3359375,
            "text": "histone deacetylase (HDAC) inhibitors trichostatin A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.32421875,
            "text": "trichostatin A (TSA) and sodium butyrate (NaBt) significantly increased Wnt5a mRNA expression in SW620.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 9.3359375,
            "text": "inhibitors trichostatin A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.3828125,
            "text": "trichostatin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.3984375,
            "text": "trichostatin A (TSA) and sodium butyrate (NaBt) significantly increased Wnt5a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 9.3359375,
            "text": ", histone deacetylase (HDAC) inhibitors trichostatin A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.453125,
            "text": "trichostatin A (TSA) and sodium butyrate (NaBt) significantly increased Wnt",
            "probability": 5.960464477539063e-08
        }
    ],
    "5162c8a8298dcd4e51000047_1": [
        {
            "start_logit": 9.015625,
            "end_logit": 8.96875,
            "text": "PARN",
            "probability": 1.0
        },
        {
            "start_logit": 9.015625,
            "end_logit": -1.5810546875,
            "text": "PAR",
            "probability": 2.6285648345947266e-05
        },
        {
            "start_logit": -2.06640625,
            "end_logit": 8.96875,
            "text": "N",
            "probability": 1.5437602996826172e-05
        },
        {
            "start_logit": 9.015625,
            "end_logit": -3.556640625,
            "text": "PARN)",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": -3.90625,
            "end_logit": 8.96875,
            "text": "poly(A)-specific ribonuclease (PARN",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": 9.015625,
            "end_logit": -6.8828125,
            "text": "PARN) is",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0390625,
            "end_logit": 8.96875,
            "text": ", poly(A)-specific ribonuclease (PARN",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.16796875,
            "end_logit": 8.96875,
            "text": "ribonuclease (PARN",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.3046875,
            "text": "PARN) is unique in its domain composition, which contains three potential RNA-binding domains: the catalytic nuclease domain, the R3H domain and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.3125,
            "text": "PARN) is unique",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.30859375,
            "end_logit": 8.96875,
            "text": "specific ribonuclease (PARN",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 8.96875,
            "text": "family, poly(A)-specific ribonuclease (PARN",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.515625,
            "end_logit": 8.96875,
            "text": "(PARN",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 8.96875,
            "text": "A)-specific ribonuclease (PARN",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.578125,
            "end_logit": 8.96875,
            "text": "Among the deadenylase family, poly(A)-specific ribonuclease (PARN",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59375,
            "end_logit": 8.96875,
            "text": "deadenylase family, poly(A)-specific ribonuclease (PARN",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.90625,
            "end_logit": -1.5810546875,
            "text": "poly(A)-specific ribonuclease (PAR",
            "probability": 0.0
        },
        {
            "start_logit": -2.06640625,
            "end_logit": -3.556640625,
            "text": "N)",
            "probability": 0.0
        },
        {
            "start_logit": -3.90625,
            "end_logit": -3.556640625,
            "text": "poly(A)-specific ribonuclease (PARN)",
            "probability": 0.0
        },
        {
            "start_logit": -7.0390625,
            "end_logit": -1.5810546875,
            "text": ", poly(A)-specific ribonuclease (PAR",
            "probability": 0.0
        }
    ],
    "5162c8a8298dcd4e51000047_2": [
        {
            "start_logit": 9.1875,
            "end_logit": 9.296875,
            "text": "CCR4",
            "probability": 1.0
        },
        {
            "start_logit": -1.3603515625,
            "end_logit": 9.296875,
            "text": "4",
            "probability": 2.6285648345947266e-05
        },
        {
            "start_logit": 9.1875,
            "end_logit": -1.369140625,
            "text": "CCR",
            "probability": 2.3365020751953125e-05
        },
        {
            "start_logit": 9.1875,
            "end_logit": -6.34375,
            "text": "CCR4 family proteins",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.171875,
            "text": "CCR4 family proteins are",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.23046875,
            "text": "CCR4 family proteins are 3'-5'-deadenylases",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34375,
            "end_logit": 9.296875,
            "text": "The CCR4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.4296875,
            "text": "CCR4 family proteins are 3'-5'-deadenylases that function in the first step of the degradation of poly(A) mRNA.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.4296875,
            "text": "CCR4 family proteins are 3'-5",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.4765625,
            "text": "CCR4 family proteins are 3'-5'-deadenylases that",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.48046875,
            "text": "CCR4 family proteins are 3'-5'-deadenylases that function in the first step of the degradation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.4921875,
            "text": "CCR4 family proteins are 3'-5'-deadenylases that function in the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.5078125,
            "text": "CCR4 family proteins are 3'-5'-deadenylases that function",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.515625,
            "text": "CCR4 family proteins are 3'-5'-deadenyl",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.515625,
            "text": "CCR4 family proteins are 3'-5'-deadenylases that function in the first step of the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.51953125,
            "text": "CCR4 family proteins are 3'-5'",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.53125,
            "text": "CCR4 family proteins are 3'-5'-deadenylases that function in the first step of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.55078125,
            "text": "CCR4 family proteins are 3'-5'-deadenylases that function in the first step of the degradation of poly(A) mRNA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.55859375,
            "text": "CCR4 family proteins are 3'-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3603515625,
            "end_logit": -6.34375,
            "text": "4 family proteins",
            "probability": 0.0
        }
    ],
    "5162c8a8298dcd4e51000047_3": [
        {
            "start_logit": 9.2265625,
            "end_logit": 9.0390625,
            "text": "CCR4",
            "probability": 1.0
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -1.2412109375,
            "text": "CCR",
            "probability": 3.427267074584961e-05
        },
        {
            "start_logit": -1.919921875,
            "end_logit": 9.0390625,
            "text": "4",
            "probability": 1.4424324035644531e-05
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.8671875,
            "text": "CCR4, an evolutionarily conserved member of the CCR4-NOT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.1484375,
            "text": "CCR4, an evolutionarily conserved member of the CCR4",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.1640625,
            "text": "CCR4, an evolutionarily conserved member of the CCR4-NOT complex",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.2734375,
            "text": "CCR4, an evolutionarily conserved member of the CCR4-NOT complex,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.2890625,
            "text": "CCR4, an evolutionarily conserved member of the CCR4-NOT complex, is the main cytoplasmic deadenylase.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.41796875,
            "text": "CCR4, an evolutionarily conserved member of the CCR4-NOT complex, is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.421875,
            "text": "CCR4, an evolutionarily conserved member of the CCR4-NOT complex, is the main cytoplasmic deadenylase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.48828125,
            "text": "CCR4, an evolutionarily conserved member of the CCR4-NOT complex, is the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.68359375,
            "end_logit": -3.849609375,
            "text": "EEP",
            "probability": 0.0
        },
        {
            "start_logit": -1.919921875,
            "end_logit": -6.8671875,
            "text": "4, an evolutionarily conserved member of the CCR4-NOT",
            "probability": 0.0
        },
        {
            "start_logit": -1.919921875,
            "end_logit": -7.1484375,
            "text": "4, an evolutionarily conserved member of the CCR4",
            "probability": 0.0
        },
        {
            "start_logit": -1.919921875,
            "end_logit": -7.1640625,
            "text": "4, an evolutionarily conserved member of the CCR4-NOT complex",
            "probability": 0.0
        },
        {
            "start_logit": -1.919921875,
            "end_logit": -7.2734375,
            "text": "4, an evolutionarily conserved member of the CCR4-NOT complex,",
            "probability": 0.0
        },
        {
            "start_logit": -1.919921875,
            "end_logit": -7.2890625,
            "text": "4, an evolutionarily conserved member of the CCR4-NOT complex, is the main cytoplasmic deadenylase.",
            "probability": 0.0
        },
        {
            "start_logit": -1.919921875,
            "end_logit": -7.41796875,
            "text": "4, an evolutionarily conserved member of the CCR4-NOT complex, is",
            "probability": 0.0
        },
        {
            "start_logit": -1.919921875,
            "end_logit": -7.421875,
            "text": "4, an evolutionarily conserved member of the CCR4-NOT complex, is the main cytoplasmic deadenylase",
            "probability": 0.0
        },
        {
            "start_logit": -1.919921875,
            "end_logit": -7.48828125,
            "text": "4, an evolutionarily conserved member of the CCR4-NOT complex, is the",
            "probability": 0.0
        }
    ],
    "5162c8a8298dcd4e51000047_4": [
        {
            "start_logit": 9.1640625,
            "end_logit": 9.265625,
            "text": "Caf1",
            "probability": 1.0
        },
        {
            "start_logit": -1.46484375,
            "end_logit": 9.265625,
            "text": "1",
            "probability": 2.390146255493164e-05
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -1.4140625,
            "text": "Caf",
            "probability": 2.282857894897461e-05
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -5.48828125,
            "text": "Caf1 family",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.1015625,
            "end_logit": 9.265625,
            "text": "Pop2 protein, belonging to the eukaryotic Caf1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.93359375,
            "text": "Caf1 family, is required for mRNA deadenylation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.9609375,
            "text": "Caf1 family, is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.0390625,
            "text": "Caf1 family, is required",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.0625,
            "text": "Caf1 family,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 9.265625,
            "text": "yeast Pop2 protein, belonging to the eukaryotic Caf1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.35546875,
            "text": "Caf1 family, is required for mRNA deadenylation in vivo.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.39453125,
            "text": "Caf1 family, is required for",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.4453125,
            "text": "Caf1 family, is required for mRNA deadenylation in vivo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.4921875,
            "text": "Caf1 family, is required for mRNA deadenyl",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 9.265625,
            "text": "eukaryotic Caf1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 9.265625,
            "text": "belonging to the eukaryotic Caf1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69140625,
            "end_logit": 9.265625,
            "text": "The yeast Pop2 protein, belonging to the eukaryotic Caf1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.46484375,
            "end_logit": -5.48828125,
            "text": "1 family",
            "probability": 0.0
        },
        {
            "start_logit": -6.1015625,
            "end_logit": -1.4140625,
            "text": "Pop2 protein, belonging to the eukaryotic Caf",
            "probability": 0.0
        },
        {
            "start_logit": -1.46484375,
            "end_logit": -6.93359375,
            "text": "1 family, is required for mRNA deadenylation",
            "probability": 0.0
        }
    ],
    "5162c8a8298dcd4e51000047_5": [
        {
            "start_logit": 7.24609375,
            "end_logit": 8.9140625,
            "text": "CAF1",
            "probability": 0.9892578125
        },
        {
            "start_logit": 7.24609375,
            "end_logit": 4.2890625,
            "text": "CAF1 protein belongs to the DEDDh",
            "probability": 0.00969696044921875
        },
        {
            "start_logit": 4.875,
            "end_logit": 4.2890625,
            "text": "DEDDh",
            "probability": 0.0009093284606933594
        },
        {
            "start_logit": -2.1484375,
            "end_logit": 8.9140625,
            "text": "1",
            "probability": 8.26120376586914e-05
        },
        {
            "start_logit": 7.24609375,
            "end_logit": -4.13671875,
            "text": "CAF",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 7.24609375,
            "end_logit": -4.88671875,
            "text": "CAF1 protein belongs to the DEDDh family of RNases, CCR4",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 7.24609375,
            "end_logit": -4.890625,
            "text": "CAF1 protein belongs to the DEDDh family of RNases",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -2.1484375,
            "end_logit": 4.2890625,
            "text": "1 protein belongs to the DEDDh",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -7.03125,
            "end_logit": 8.9140625,
            "text": "Although CAF1",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.24609375,
            "end_logit": -5.953125,
            "text": "CAF1 protein belongs to the DEDDh family of RNases, CCR",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.24609375,
            "end_logit": -5.96484375,
            "text": "CAF1 protein belongs to the DED",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.24609375,
            "end_logit": -6.48828125,
            "text": "CAF1 protein belongs to the DEDDh family of RNases, CCR4 appears",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.24609375,
            "end_logit": -6.5078125,
            "text": "CAF1 protein belongs to the DEDDh family",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.24609375,
            "end_logit": -6.8515625,
            "text": "CAF1 protein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.24609375,
            "end_logit": -7.05078125,
            "text": "CAF1 protein belongs to the DEDDh family of RNase",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.24609375,
            "end_logit": -7.125,
            "text": "CAF1 protein belongs to the DEDDh family of RNases, CCR4 appears to be the principle deadenylase of the CCR4",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.24609375,
            "end_logit": -7.13671875,
            "text": "CAF1 protein belongs to the DEDDh family of RNases, CCR4 appears to be the principle deadenylase of the CCR4-NOT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.24609375,
            "end_logit": -7.21484375,
            "text": "CAF1 protein belongs to the DEDDh family of RNases, CCR4 appears to be the principle deadenylase of the CCR4-NOT complex",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 4.875,
            "end_logit": -4.88671875,
            "text": "DEDDh family of RNases, CCR4",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 4.875,
            "end_logit": -4.890625,
            "text": "DEDDh family of RNases",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5162c8a8298dcd4e51000047_6": [
        {
            "start_logit": 9.375,
            "end_logit": 9.3828125,
            "text": "CCR4",
            "probability": 1.0
        },
        {
            "start_logit": 9.375,
            "end_logit": -0.6826171875,
            "text": "CCR",
            "probability": 4.297494888305664e-05
        },
        {
            "start_logit": -1.0205078125,
            "end_logit": 9.3828125,
            "text": "4",
            "probability": 3.069639205932617e-05
        },
        {
            "start_logit": 9.375,
            "end_logit": -5.39453125,
            "text": "CCR4, increased length of RNA substrates converted mCAF1 into a processive enzyme. In contrast to two other DEDD",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.39453125,
            "end_logit": 9.3828125,
            "text": "Like CCR4",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.375,
            "end_logit": -6.5,
            "text": "CCR4, increased length of RNA substrates converted mCAF1 into a processive enzyme. In contrast to two other DEDD family",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.375,
            "end_logit": -6.6015625,
            "text": "CCR4, increased length of RNA substrates converted mCAF1 into a processive enzyme. In contrast to two other DEDD family members, PAN2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.375,
            "end_logit": -6.734375,
            "text": "CCR4, increased length of RNA substrates converted mCAF1 into a processive enzyme. In contrast to two other DEDD family members, PAN",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.375,
            "end_logit": -6.984375,
            "text": "CCR4, increased length of RNA substrates converted mCAF1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.375,
            "end_logit": -7.234375,
            "text": "CCR4, increased length of RNA substrates converted mCAF1 into a processive enzyme.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.375,
            "end_logit": -7.3046875,
            "text": "CCR4, increased length of RNA substrates converted mCAF1 into a processive",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.375,
            "end_logit": -7.3359375,
            "text": "CCR4, increased length of RNA substrates",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.375,
            "end_logit": -7.3984375,
            "text": "CCR4, increased length of RNA substrates converted mCAF1 into a processive enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.375,
            "end_logit": -7.4375,
            "text": "CCR4, increased length of RNA substrates converted mCAF1 into a processive enzyme. In contrast to two other DEDD family members",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.0205078125,
            "end_logit": -5.39453125,
            "text": "4, increased length of RNA substrates converted mCAF1 into a processive enzyme. In contrast to two other DEDD",
            "probability": 0.0
        },
        {
            "start_logit": -3.97265625,
            "end_logit": -3.029296875,
            "text": "PARN",
            "probability": 0.0
        },
        {
            "start_logit": -6.39453125,
            "end_logit": -0.6826171875,
            "text": "Like CCR",
            "probability": 0.0
        },
        {
            "start_logit": -1.0205078125,
            "end_logit": -6.5,
            "text": "4, increased length of RNA substrates converted mCAF1 into a processive enzyme. In contrast to two other DEDD family",
            "probability": 0.0
        },
        {
            "start_logit": -1.0205078125,
            "end_logit": -6.6015625,
            "text": "4, increased length of RNA substrates converted mCAF1 into a processive enzyme. In contrast to two other DEDD family members, PAN2",
            "probability": 0.0
        },
        {
            "start_logit": -1.0205078125,
            "end_logit": -6.734375,
            "text": "4, increased length of RNA substrates converted mCAF1 into a processive enzyme. In contrast to two other DEDD family members, PAN",
            "probability": 0.0
        }
    ],
    "5162c8a8298dcd4e51000047_7": [
        {
            "start_logit": 9.046875,
            "end_logit": 9.1953125,
            "text": "CCR4",
            "probability": 1.0
        },
        {
            "start_logit": -1.6025390625,
            "end_logit": 9.1953125,
            "text": "4",
            "probability": 2.3543834686279297e-05
        },
        {
            "start_logit": 9.046875,
            "end_logit": -1.7080078125,
            "text": "CCR",
            "probability": 1.8358230590820312e-05
        },
        {
            "start_logit": 9.046875,
            "end_logit": -6.8984375,
            "text": "CCR4 protein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.046875,
            "end_logit": -7.1015625,
            "text": "CCR4 protein, which is part of the cytoplasmic deadenylase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 9.1953125,
            "text": "evolutionarily conserved CCR4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.046875,
            "end_logit": -7.34765625,
            "text": "CCR4 protein, which is part of the cytoplasmic deadenylase,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.046875,
            "end_logit": -7.4609375,
            "text": "CCR4 protein, which is part of the cytoplasmic deadenyl",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 9.1953125,
            "text": "conserved CCR4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.046875,
            "end_logit": -7.4765625,
            "text": "CCR4 protein, which is part of the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.046875,
            "end_logit": -7.4765625,
            "text": "CCR4 protein, which is part of the cytoplasmic deadenylase, contains",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.046875,
            "end_logit": -7.4765625,
            "text": "CCR4 protein,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.046875,
            "end_logit": -7.5234375,
            "text": "CCR4 protein, which is part",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.046875,
            "end_logit": -7.53125,
            "text": "CCR4 protein, which is part of the cytoplasmic deadenylase, contains a C-terminal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.046875,
            "end_logit": -7.5390625,
            "text": "CCR4 protein, which is part of the cytoplasmic deadenylase, contains a C-terminal domain that displays homology to an Mg2+-dependent",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.046875,
            "end_logit": -7.5546875,
            "text": "CCR4 protein, which is part of the cytoplasmic dead",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.6025390625,
            "end_logit": -6.8984375,
            "text": "4 protein",
            "probability": 0.0
        },
        {
            "start_logit": -1.6025390625,
            "end_logit": -7.1015625,
            "text": "4 protein, which is part of the cytoplasmic deadenylase",
            "probability": 0.0
        },
        {
            "start_logit": -1.6025390625,
            "end_logit": -7.34765625,
            "text": "4 protein, which is part of the cytoplasmic deadenylase,",
            "probability": 0.0
        },
        {
            "start_logit": -1.6025390625,
            "end_logit": -7.4609375,
            "text": "4 protein, which is part of the cytoplasmic deadenyl",
            "probability": 0.0
        }
    ],
    "5162c8a8298dcd4e51000047_8": [
        {
            "start_logit": 9.265625,
            "end_logit": 9.3203125,
            "text": "CCR4",
            "probability": 1.0
        },
        {
            "start_logit": 9.265625,
            "end_logit": -1.1923828125,
            "text": "CCR",
            "probability": 2.6881694793701172e-05
        },
        {
            "start_logit": -1.33984375,
            "end_logit": 9.3203125,
            "text": "4",
            "probability": 2.467632293701172e-05
        },
        {
            "start_logit": 9.265625,
            "end_logit": -5.921875,
            "text": "CCR4 and most probably other members of a widely distributed CCR4",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.16015625,
            "end_logit": 9.3203125,
            "text": "that CCR4",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -6.22265625,
            "text": "CCR4 and most probably other members of a widely distributed CCR4-like family of proteins constitute",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -6.8203125,
            "text": "CCR4 and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -6.828125,
            "text": "CCR4 and most probably other members of a widely distributed CCR4-like family of proteins",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -6.9453125,
            "text": "CCR4 and most probably other members of a widely distributed CCR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.0234375,
            "text": "CCR4 and most probably other members of a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.05859375,
            "text": "CCR4 and most probably other members of a widely distributed CCR4-like family of proteins constitute a novel class of RNA-DNA exonucleases",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.10546875,
            "text": "CCR4 and most probably other members of a widely distributed CCR4-like family of proteins constitute a novel",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.23828125,
            "text": "CCR4 and most probably other members of a widely distributed CCR4-like family of proteins constitute a novel class of RNA-DNA exonucleases.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.296875,
            "text": "CCR4 and most probably other members of a widely distributed CCR4-like family of proteins constitute a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 9.3203125,
            "text": "establish that CCR4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.3203125,
            "text": "CCR4 and most probably other members of a widely distributed CCR4-like",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.33984375,
            "text": "CCR4 and most probably other members of a widely distributed CCR4-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.359375,
            "text": "CCR4 and most probably other members of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 9.3203125,
            "text": "results establish that CCR4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.44140625,
            "text": "CCR4 and most probably other members of a widely distributed CCR4-like family",
            "probability": 5.960464477539063e-08
        }
    ],
    "5162c8a8298dcd4e51000047_9": [
        {
            "start_logit": 9.296875,
            "end_logit": 9.296875,
            "text": "PARN",
            "probability": 1.0
        },
        {
            "start_logit": 9.296875,
            "end_logit": -1.1474609375,
            "text": "PAR",
            "probability": 2.9087066650390625e-05
        },
        {
            "start_logit": -1.361328125,
            "end_logit": 9.296875,
            "text": "N",
            "probability": 2.3543834686279297e-05
        },
        {
            "start_logit": 9.296875,
            "end_logit": -6.625,
            "text": "PARN, Nocturnin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -6.8828125,
            "text": "PARN, Nocturnin and Angel",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.15625,
            "text": "PARN, Nocturnin and Angel are three of the multiple deadenylases",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.24609375,
            "text": "PARN, Nocturnin and Ang",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.24609375,
            "text": "PARN, Nocturn",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.30078125,
            "text": "PARN, Nocturnin and Angel are",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.34375,
            "text": "PARN, Nocturnin and Angel are three",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.3828125,
            "text": "PARN, Nocturnin and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.41015625,
            "text": "PARN, Nocturnin and Angel are three of the multiple deadenylases that have been described in eukaryotic cells.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.453125,
            "text": "PARN, Nocturnin and Angel are three of the multiple deadenylases that have been described in eukaryotic cells",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.4921875,
            "text": "PARN, Nocturnin and Angel are three of the multiple deadenyl",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.50390625,
            "text": "PARN, Nocturnin and Angel are three of the multiple deadenylases that have been described",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.51953125,
            "text": "PARN, Nocturnin and Angel are three of the multiple deadenylases that have",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.52734375,
            "text": "PARN, Nocturnin and Angel are three of the multiple deadenylases that have been",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.54296875,
            "text": "PARN, Nocturnin and Angel are three of the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.361328125,
            "end_logit": -6.625,
            "text": "N, Nocturnin",
            "probability": 0.0
        },
        {
            "start_logit": -1.361328125,
            "end_logit": -6.8828125,
            "text": "N, Nocturnin and Angel",
            "probability": 0.0
        }
    ],
    "515db20e298dcd4e51000014_1": [
        {
            "start_logit": 7.0546875,
            "end_logit": 7.26171875,
            "text": "CBT",
            "probability": 1.0
        },
        {
            "start_logit": -3.333984375,
            "end_logit": 7.26171875,
            "text": "group cognitive-behavioral treatment (CBT",
            "probability": 3.0934810638427734e-05
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -4.73828125,
            "text": "CBT)",
            "probability": 6.139278411865234e-06
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -5.640625,
            "text": "CBT) for anxiety disorders with African-American adolescents. METHODS: Twelve adolescents (mean age = 15.6",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -5.84375,
            "text": "CBT) for anxiety disorders with African-American adolescents.",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -5.85546875,
            "text": "CBT) for anxiety disorders with African-American adolescents. METHODS: Twelve adolescents (mean age = 15",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": -6.06640625,
            "end_logit": 7.26171875,
            "text": "(CBT",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": -6.0703125,
            "end_logit": 7.26171875,
            "text": "cognitive-behavioral treatment (CBT",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -6.125,
            "end_logit": 7.26171875,
            "text": "effectiveness of a school-based group cognitive-behavioral treatment (CBT",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -6.3671875,
            "end_logit": 7.26171875,
            "text": "school-based group cognitive-behavioral treatment (CBT",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -6.484375,
            "text": "CBT) for anxiety disorders with African-American adolescents. METHODS: Twelve adolescents (mean age",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -6.62890625,
            "text": "CBT) for anxiety disorders with African-American adolescents. METHODS: Twelve adolescents (mean age = 15.6 years",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -6.8828125,
            "end_logit": 7.26171875,
            "text": "feasibility and effectiveness of a school-based group cognitive-behavioral treatment (CBT",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -7.02734375,
            "end_logit": 7.26171875,
            "text": "treatment (CBT",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -6.828125,
            "text": "CBT) for anxiety disorders with African-American adolescents. METHODS: Twelve adolescents (mean age = 15.6 years) with anxiety disorders were randomly assigned",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -6.91015625,
            "text": "CBT) for anxiety disorders with African-American",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.12109375,
            "end_logit": 7.26171875,
            "text": "a school-based group cognitive-behavioral treatment (CBT",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.15625,
            "end_logit": 7.26171875,
            "text": "the feasibility and effectiveness of a school-based group cognitive-behavioral treatment (CBT",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.16015625,
            "end_logit": 7.26171875,
            "text": "To evaluate the feasibility and effectiveness of a school-based group cognitive-behavioral treatment (CBT",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -3.333984375,
            "end_logit": -4.73828125,
            "text": "group cognitive-behavioral treatment (CBT)",
            "probability": 0.0
        }
    ],
    "515db20e298dcd4e51000014_2": [
        {
            "start_logit": 7.53125,
            "end_logit": 7.94921875,
            "text": "CBT",
            "probability": 1.0
        },
        {
            "start_logit": -6.01171875,
            "end_logit": 7.94921875,
            "text": "in CBT",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 7.53125,
            "end_logit": -6.59765625,
            "text": "CBT no longer met diagnostic criteria for their primary anxiety disorder, compared with 1/5 in AS-Control.",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.234375,
            "end_logit": 7.94921875,
            "text": "among those who attended more than one treatment session, 3/4 adolescents in CBT",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.23828125,
            "end_logit": 7.94921875,
            "text": ", 3/4 adolescents in CBT",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 7.94921875,
            "text": "4 adolescents in CBT",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.390625,
            "end_logit": 7.94921875,
            "text": "At posttreatment and among those who attended more than one treatment session, 3/4 adolescents in CBT",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 7.94921875,
            "text": "adolescents in CBT",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 7.94921875,
            "text": "/4 adolescents in CBT",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.53125,
            "end_logit": -7.26953125,
            "text": "CBT no longer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.53125,
            "end_logit": -7.28515625,
            "text": "CBT no",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.53125,
            "end_logit": -7.3359375,
            "text": "CBT no longer met diagnostic criteria for their primary anxiety disorder, compared with 1/5 in AS-Control",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.53125,
            "end_logit": -7.359375,
            "text": "CBT no longer met diagnostic criteria for their primary anxiety disorder, compared with 1/5 in AS",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.53125,
            "end_logit": -7.46484375,
            "text": "CBT no longer met diagnostic criteria",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.53125,
            "end_logit": -7.4921875,
            "text": "CBT no longer met diagnostic criteria for",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.53125,
            "end_logit": -7.50390625,
            "text": "CBT no longer met diagnostic criteria for their primary anxiety disorder, compared with 1/5 in",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.53125,
            "end_logit": -7.5078125,
            "text": "CBT no longer met",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.01171875,
            "end_logit": -6.59765625,
            "text": "in CBT no longer met diagnostic criteria for their primary anxiety disorder, compared with 1/5 in AS-Control.",
            "probability": 0.0
        },
        {
            "start_logit": -6.39453125,
            "end_logit": -6.27734375,
            "text": ". Clinician ratings of impairment and self-report levels of overall anxiety were significantly lower at posttreatment in CBT",
            "probability": 0.0
        },
        {
            "start_logit": -6.39453125,
            "end_logit": -6.59765625,
            "text": ".",
            "probability": 0.0
        }
    ],
    "515db20e298dcd4e51000014_3": [
        {
            "start_logit": 0.65380859375,
            "end_logit": 0.7275390625,
            "text": "group treatment",
            "probability": 0.61083984375
        },
        {
            "start_logit": -0.5947265625,
            "end_logit": 0.7275390625,
            "text": "individual and group treatment",
            "probability": 0.17529296875
        },
        {
            "start_logit": 0.220947265625,
            "end_logit": -0.11334228515625,
            "text": "group treatment",
            "probability": 0.1708984375
        },
        {
            "start_logit": -1.642578125,
            "end_logit": -0.11334228515625,
            "text": "individual versus 41% in the group treatment",
            "probability": 0.026519775390625
        },
        {
            "start_logit": -4.14453125,
            "end_logit": 0.7275390625,
            "text": ". Regression analyses showed no significant difference in outcome between individual and group treatment",
            "probability": 0.005039215087890625
        },
        {
            "start_logit": 0.220947265625,
            "end_logit": -3.72265625,
            "text": "group treatment were free of any anxiety disorder at post-treatment; 62% versus 54% were free of their primary anxiety disorder.",
            "probability": 0.004627227783203125
        },
        {
            "start_logit": 0.65380859375,
            "end_logit": -5.30078125,
            "text": "group",
            "probability": 0.0014677047729492188
        },
        {
            "start_logit": -4.875,
            "end_logit": -0.11334228515625,
            "text": "versus 41% in the group treatment",
            "probability": 0.0010480880737304688
        },
        {
            "start_logit": -6.51953125,
            "end_logit": 0.7275390625,
            "text": "versus 54% were free of their primary anxiety disorder. Regression analyses showed no significant difference in outcome between individual and group treatment",
            "probability": 0.0004687309265136719
        },
        {
            "start_logit": -0.5947265625,
            "end_logit": -5.30078125,
            "text": "individual and group",
            "probability": 0.00042366981506347656
        },
        {
            "start_logit": -6.640625,
            "end_logit": 0.7275390625,
            "text": "difference in outcome between individual and group treatment",
            "probability": 0.00041365623474121094
        },
        {
            "start_logit": -6.66796875,
            "end_logit": 0.7275390625,
            "text": "outcome between individual and group treatment",
            "probability": 0.00040411949157714844
        },
        {
            "start_logit": 0.220947265625,
            "end_logit": -6.2109375,
            "text": "group",
            "probability": 0.0003857612609863281
        },
        {
            "start_logit": -0.5947265625,
            "end_logit": -5.45703125,
            "text": "individual and",
            "probability": 0.00036215782165527344
        },
        {
            "start_logit": 0.220947265625,
            "end_logit": -6.29296875,
            "text": "group treatment were",
            "probability": 0.0003540515899658203
        },
        {
            "start_logit": -6.0703125,
            "end_logit": -0.11334228515625,
            "text": "Forty-eight percent of the children in the individual versus 41% in the group treatment",
            "probability": 0.0003173351287841797
        },
        {
            "start_logit": -6.9140625,
            "end_logit": 0.7275390625,
            "text": "; 62% versus 54% were free of their primary anxiety disorder. Regression analyses showed no significant difference in outcome between individual and group treatment",
            "probability": 0.0003147125244140625
        },
        {
            "start_logit": -6.96875,
            "end_logit": 0.7275390625,
            "text": "no significant difference in outcome between individual and group treatment",
            "probability": 0.0002980232238769531
        },
        {
            "start_logit": -6.99609375,
            "end_logit": 0.7275390625,
            "text": "between individual and group treatment",
            "probability": 0.0002911090850830078
        },
        {
            "start_logit": 0.220947265625,
            "end_logit": -6.76171875,
            "text": "group treatment were free of any anxiety disorder at post-treatment; 62% versus",
            "probability": 0.00022137165069580078
        }
    ],
    "5e3c841148dab47f26000002_1": [
        {
            "start_logit": 9.109375,
            "end_logit": 9.2734375,
            "text": "multiple sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": -1.3642578125,
            "end_logit": 9.2734375,
            "text": "sclerosis",
            "probability": 2.8431415557861328e-05
        },
        {
            "start_logit": 9.109375,
            "end_logit": -1.603515625,
            "text": "multiple",
            "probability": 1.9073486328125e-05
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.28515625,
            "text": "multiple sclerosis by induction of inflammation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.2890625,
            "text": "multiple sclerosis by",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 9.2734375,
            "text": "in multiple sclerosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.4140625,
            "text": "multiple sclerosis by induction of inflammation and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.46875,
            "text": "multiple sclerosis by induction of inflammation and aggregation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6953125,
            "end_logit": 9.2734375,
            "text": "hypothetical roles of arsenic in multiple sclerosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.703125,
            "end_logit": 9.2734375,
            "text": "roles of arsenic in multiple sclerosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.60546875,
            "text": "multiple sclerosis by induction",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3642578125,
            "end_logit": -7.28515625,
            "text": "sclerosis by induction of inflammation",
            "probability": 0.0
        },
        {
            "start_logit": -1.3642578125,
            "end_logit": -7.2890625,
            "text": "sclerosis by",
            "probability": 0.0
        },
        {
            "start_logit": -1.3642578125,
            "end_logit": -7.4140625,
            "text": "sclerosis by induction of inflammation and",
            "probability": 0.0
        },
        {
            "start_logit": -1.3642578125,
            "end_logit": -7.46875,
            "text": "sclerosis by induction of inflammation and aggregation",
            "probability": 0.0
        },
        {
            "start_logit": -1.3642578125,
            "end_logit": -7.60546875,
            "text": "sclerosis by induction",
            "probability": 0.0
        },
        {
            "start_logit": -7.4921875,
            "end_logit": -1.603515625,
            "text": "in multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.6953125,
            "end_logit": -1.603515625,
            "text": "hypothetical roles of arsenic in multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.703125,
            "end_logit": -1.603515625,
            "text": "roles of arsenic in multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.4921875,
            "end_logit": -7.28515625,
            "text": "in multiple sclerosis by induction of inflammation",
            "probability": 0.0
        }
    ],
    "5e3c841148dab47f26000002_2": [
        {
            "start_logit": 7.7421875,
            "end_logit": 8.515625,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": -2.13671875,
            "end_logit": 8.515625,
            "text": "disease",
            "probability": 5.143880844116211e-05
        },
        {
            "start_logit": 7.7421875,
            "end_logit": -2.080078125,
            "text": "Alzheimer",
            "probability": 2.5272369384765625e-05
        },
        {
            "start_logit": 7.7421875,
            "end_logit": -3.478515625,
            "text": "Alzheimer's disease (AD",
            "probability": 6.258487701416016e-06
        },
        {
            "start_logit": 7.7421875,
            "end_logit": -5.46875,
            "text": "Alzheimer's disease (AD)",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 7.7421875,
            "end_logit": -5.84375,
            "text": "Alzheimer's disease (AD) is the most common cause of progressive dementia",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.77734375,
            "end_logit": 8.515625,
            "text": "s disease",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.7421875,
            "end_logit": -6.640625,
            "text": "Alzheimer'",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.7421875,
            "end_logit": -6.7421875,
            "text": "Alzheimer's",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.7421875,
            "end_logit": -6.765625,
            "text": "Alzheimer's disease (AD) is",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.7421875,
            "end_logit": -6.83203125,
            "text": "Alzheimer's disease (AD) is the most common cause of progressive dementia in the elderly",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.7421875,
            "end_logit": -6.90234375,
            "text": "Alzheimer's disease (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.7421875,
            "end_logit": -7.24609375,
            "text": "Alzheimer's disease (AD) is the most common cause of progressive dementia in the elderly.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.7421875,
            "end_logit": -7.4609375,
            "text": "Alzheimer's disease (AD) is the most common cause of progressive dementia in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.13671875,
            "end_logit": -3.478515625,
            "text": "disease (AD",
            "probability": 0.0
        },
        {
            "start_logit": -2.13671875,
            "end_logit": -5.46875,
            "text": "disease (AD)",
            "probability": 0.0
        },
        {
            "start_logit": -2.13671875,
            "end_logit": -5.84375,
            "text": "disease (AD) is the most common cause of progressive dementia",
            "probability": 0.0
        },
        {
            "start_logit": -2.13671875,
            "end_logit": -6.765625,
            "text": "disease (AD) is",
            "probability": 0.0
        },
        {
            "start_logit": -2.13671875,
            "end_logit": -6.83203125,
            "text": "disease (AD) is the most common cause of progressive dementia in the elderly",
            "probability": 0.0
        },
        {
            "start_logit": -2.13671875,
            "end_logit": -6.90234375,
            "text": "disease (",
            "probability": 0.0
        }
    ],
    "5e3c841148dab47f26000002_3": [
        {
            "start_logit": 9.234375,
            "end_logit": 9.1015625,
            "text": "multiple sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": 9.234375,
            "end_logit": -0.830078125,
            "text": "multiple sclerosis (MS",
            "probability": 4.83393669128418e-05
        },
        {
            "start_logit": 9.234375,
            "end_logit": -1.267578125,
            "text": "multiple",
            "probability": 3.11732292175293e-05
        },
        {
            "start_logit": -1.66015625,
            "end_logit": 9.1015625,
            "text": "sclerosis",
            "probability": 1.8358230590820312e-05
        },
        {
            "start_logit": 9.234375,
            "end_logit": -5.80078125,
            "text": "multiple sclerosis (MS)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -6.93359375,
            "text": "multiple sclerosis (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1640625,
            "end_logit": 9.1015625,
            "text": "of multiple sclerosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.40625,
            "text": "multiple sclerosis (MS).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.66015625,
            "end_logit": -0.830078125,
            "text": "sclerosis (MS",
            "probability": 0.0
        },
        {
            "start_logit": -3.130859375,
            "end_logit": -0.830078125,
            "text": "MS",
            "probability": 0.0
        },
        {
            "start_logit": -1.66015625,
            "end_logit": -5.80078125,
            "text": "sclerosis (MS)",
            "probability": 0.0
        },
        {
            "start_logit": -7.1640625,
            "end_logit": -0.830078125,
            "text": "of multiple sclerosis (MS",
            "probability": 0.0
        },
        {
            "start_logit": -7.1640625,
            "end_logit": -1.267578125,
            "text": "of multiple",
            "probability": 0.0
        },
        {
            "start_logit": -1.66015625,
            "end_logit": -6.93359375,
            "text": "sclerosis (",
            "probability": 0.0
        },
        {
            "start_logit": -3.130859375,
            "end_logit": -5.80078125,
            "text": "MS)",
            "probability": 0.0
        },
        {
            "start_logit": -1.66015625,
            "end_logit": -7.40625,
            "text": "sclerosis (MS).",
            "probability": 0.0
        },
        {
            "start_logit": -3.130859375,
            "end_logit": -7.40625,
            "text": "MS).",
            "probability": 0.0
        },
        {
            "start_logit": -7.1640625,
            "end_logit": -5.80078125,
            "text": "of multiple sclerosis (MS)",
            "probability": 0.0
        },
        {
            "start_logit": -7.1640625,
            "end_logit": -6.93359375,
            "text": "of multiple sclerosis (",
            "probability": 0.0
        },
        {
            "start_logit": -7.05078125,
            "end_logit": -7.40625,
            "text": ".",
            "probability": 0.0
        }
    ],
    "5e3c841148dab47f26000002_4": [
        {
            "start_logit": 7.71484375,
            "end_logit": 8.9140625,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": -1.748046875,
            "end_logit": 8.9140625,
            "text": "disease",
            "probability": 7.784366607666016e-05
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -2.5703125,
            "text": "Alzheimer",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -6.91015625,
            "end_logit": 8.9140625,
            "text": "s disease",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -5.8671875,
            "text": "Alzheimer's disease (AD",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.30078125,
            "end_logit": 8.9140625,
            "text": "'s disease",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -6.65625,
            "text": "Alzheimer's",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -6.86328125,
            "text": "Alzheimer'",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -6.90625,
            "text": "Alzheimer's disease (AD)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -7.12890625,
            "text": "Alzheimer's disease (AD), progressive supranuclear palsy (PSP",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -7.1953125,
            "text": "Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -7.28515625,
            "text": "Alzheimer's disease (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -7.30078125,
            "text": "Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -7.34765625,
            "text": "Alzheimer's disease (AD), progressive supranuclear palsy (PSP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.748046875,
            "end_logit": -5.8671875,
            "text": "disease (AD",
            "probability": 0.0
        },
        {
            "start_logit": -1.748046875,
            "end_logit": -6.90625,
            "text": "disease (AD)",
            "probability": 0.0
        },
        {
            "start_logit": -1.748046875,
            "end_logit": -7.12890625,
            "text": "disease (AD), progressive supranuclear palsy (PSP",
            "probability": 0.0
        },
        {
            "start_logit": -1.748046875,
            "end_logit": -7.1953125,
            "text": "disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP",
            "probability": 0.0
        },
        {
            "start_logit": -1.748046875,
            "end_logit": -7.28515625,
            "text": "disease (",
            "probability": 0.0
        },
        {
            "start_logit": -1.748046875,
            "end_logit": -7.30078125,
            "text": "disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia",
            "probability": 0.0
        }
    ],
    "5e3c841148dab47f26000002_5": [
        {
            "start_logit": 4.65625,
            "end_logit": 0.82080078125,
            "text": "Alzheimer's and Parkinson's diseases",
            "probability": 0.9853515625
        },
        {
            "start_logit": 4.65625,
            "end_logit": -3.908203125,
            "text": "Alzheimer's",
            "probability": 0.00872802734375
        },
        {
            "start_logit": 4.65625,
            "end_logit": -5.31640625,
            "text": "Alzheimer",
            "probability": 0.002132415771484375
        },
        {
            "start_logit": 4.65625,
            "end_logit": -6.359375,
            "text": "Alzheimer's and Parkinson",
            "probability": 0.0007510185241699219
        },
        {
            "start_logit": 4.65625,
            "end_logit": -6.59375,
            "text": "Alzheimer'",
            "probability": 0.0005941390991210938
        },
        {
            "start_logit": 4.65625,
            "end_logit": -6.96875,
            "text": "Alzheimer's and Parkinson's",
            "probability": 0.000408172607421875
        },
        {
            "start_logit": 4.65625,
            "end_logit": -6.99609375,
            "text": "Alzheimer's and Parkinson'",
            "probability": 0.0003974437713623047
        },
        {
            "start_logit": 4.65625,
            "end_logit": -7.328125,
            "text": "Alzheimer's and Parkinson's diseases, there is a hyperphosphorylation",
            "probability": 0.0002849102020263672
        },
        {
            "start_logit": 4.65625,
            "end_logit": -7.37890625,
            "text": "Alzheimer's and",
            "probability": 0.0002696514129638672
        },
        {
            "start_logit": 4.65625,
            "end_logit": -7.46875,
            "text": "Alzheimer's and Parkinson's diseases, there is a hyperphosph",
            "probability": 0.00024771690368652344
        },
        {
            "start_logit": 4.65625,
            "end_logit": -7.51171875,
            "text": "Alzheimer's and Parkinson's diseases, there is a",
            "probability": 0.00023818016052246094
        },
        {
            "start_logit": 4.65625,
            "end_logit": -7.52734375,
            "text": "Alzheimer's and Parkinson's diseases, there is a hyperphosphorylation of tau that leads",
            "probability": 0.00023436546325683594
        },
        {
            "start_logit": 4.65625,
            "end_logit": -7.5546875,
            "text": "Alzheimer's and Parkinson's diseases,",
            "probability": 0.00022721290588378906
        },
        {
            "start_logit": -5.88671875,
            "end_logit": 0.82080078125,
            "text": "Parkinson's diseases",
            "probability": 2.5928020477294922e-05
        },
        {
            "start_logit": -6.29296875,
            "end_logit": 0.82080078125,
            "text": "and Parkinson's diseases",
            "probability": 1.728534698486328e-05
        },
        {
            "start_logit": -6.65625,
            "end_logit": 0.82080078125,
            "text": "In Alzheimer's and Parkinson's diseases",
            "probability": 1.2040138244628906e-05
        },
        {
            "start_logit": -6.7421875,
            "end_logit": 0.82080078125,
            "text": "diseases",
            "probability": 1.1026859283447266e-05
        },
        {
            "start_logit": -7.53125,
            "end_logit": 0.82080078125,
            "text": "s diseases",
            "probability": 5.0067901611328125e-06
        },
        {
            "start_logit": -6.65625,
            "end_logit": -3.908203125,
            "text": "In Alzheimer's",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.65625,
            "end_logit": -5.31640625,
            "text": "In Alzheimer",
            "probability": 0.0
        }
    ],
    "58da5dc58acda34529000016_1": [
        {
            "start_logit": 0.6123046875,
            "end_logit": 0.5263671875,
            "text": "acute worsening of heart function (acute heart failure-acute coronary syndrome",
            "probability": 0.94287109375
        },
        {
            "start_logit": -3.552734375,
            "end_logit": 0.5263671875,
            "text": "acute heart failure-acute coronary syndrome",
            "probability": 0.01465606689453125
        },
        {
            "start_logit": -3.65234375,
            "end_logit": 0.5263671875,
            "text": "heart failure-acute coronary syndrome",
            "probability": 0.01324462890625
        },
        {
            "start_logit": 0.6123046875,
            "end_logit": -3.748046875,
            "text": "acute worsening of heart function (acute heart failure",
            "probability": 0.0131378173828125
        },
        {
            "start_logit": -5.2421875,
            "end_logit": 0.5263671875,
            "text": "CRS type 1 = acute worsening of heart function (acute heart failure-acute coronary syndrome",
            "probability": 0.002712249755859375
        },
        {
            "start_logit": -5.45703125,
            "end_logit": 0.5263671875,
            "text": "subtypes: CRS type 1 = acute worsening of heart function (acute heart failure-acute coronary syndrome",
            "probability": 0.002178192138671875
        },
        {
            "start_logit": -5.69921875,
            "end_logit": 0.5263671875,
            "text": "acute coronary syndrome",
            "probability": 0.0017099380493164062
        },
        {
            "start_logit": -6.1796875,
            "end_logit": 0.5263671875,
            "text": "coronary syndrome",
            "probability": 0.0010623931884765625
        },
        {
            "start_logit": -6.28125,
            "end_logit": 0.5263671875,
            "text": ": CRS type 1 = acute worsening of heart function (acute heart failure-acute coronary syndrome",
            "probability": 0.0009593963623046875
        },
        {
            "start_logit": -6.29296875,
            "end_logit": 0.5263671875,
            "text": "= acute worsening of heart function (acute heart failure-acute coronary syndrome",
            "probability": 0.0009441375732421875
        },
        {
            "start_logit": -6.375,
            "end_logit": 0.5263671875,
            "text": "type 1 = acute worsening of heart function (acute heart failure-acute coronary syndrome",
            "probability": 0.0008730888366699219
        },
        {
            "start_logit": -6.56640625,
            "end_logit": 0.5263671875,
            "text": "five subtypes: CRS type 1 = acute worsening of heart function (acute heart failure-acute coronary syndrome",
            "probability": 0.0007185935974121094
        },
        {
            "start_logit": 0.6123046875,
            "end_logit": -6.69921875,
            "text": "acute worsening of heart function (acute heart failure-acute coronary",
            "probability": 0.0006856918334960938
        },
        {
            "start_logit": -6.66015625,
            "end_logit": 0.5263671875,
            "text": "syndrome",
            "probability": 0.0006542205810546875
        },
        {
            "start_logit": -6.703125,
            "end_logit": 0.5263671875,
            "text": "definition has been expanded into five subtypes: CRS type 1 = acute worsening of heart function (acute heart failure-acute coronary syndrome",
            "probability": 0.0006289482116699219
        },
        {
            "start_logit": 0.6123046875,
            "end_logit": -6.80859375,
            "text": "acute worsening of heart function (acute heart failure-acute coronary syndrome)",
            "probability": 0.0006146430969238281
        },
        {
            "start_logit": -6.73828125,
            "end_logit": 0.5263671875,
            "text": "into five subtypes: CRS type 1 = acute worsening of heart function (acute heart failure-acute coronary syndrome",
            "probability": 0.0006051063537597656
        },
        {
            "start_logit": 0.6123046875,
            "end_logit": -6.828125,
            "text": "acute worsening of heart function (acute heart failure-",
            "probability": 0.0006051063537597656
        },
        {
            "start_logit": 0.6123046875,
            "end_logit": -7.1015625,
            "text": "acute worsening",
            "probability": 0.0004601478576660156
        },
        {
            "start_logit": 0.6123046875,
            "end_logit": -7.12109375,
            "text": "acute worsening of heart function (acute heart failure-acute coronary syndrome) leading to kidney injury and/or dysfunction; CRS type 2 = chronic abnormalities",
            "probability": 0.0004496574401855469
        }
    ],
    "58da5dc58acda34529000016_2": [
        {
            "start_logit": 8.875,
            "end_logit": 5.6328125,
            "text": "heart failure",
            "probability": 0.9990234375
        },
        {
            "start_logit": 8.875,
            "end_logit": -1.4140625,
            "text": "heart",
            "probability": 0.0008692741394042969
        },
        {
            "start_logit": -2.662109375,
            "end_logit": 5.6328125,
            "text": "CRS type 1 most commonly occurs in the setting of acutely decompensated heart failure",
            "probability": 9.715557098388672e-06
        },
        {
            "start_logit": 8.875,
            "end_logit": -6.7578125,
            "text": "heart failure where approximately 25% of patients develop a rise in serum creatinine and a reduction of urine output after the first several doses of intravenous diuretics",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": 8.875,
            "end_logit": -6.828125,
            "text": "heart failure where approximately 25% of patients develop a rise in serum creatinine and a reduction of urine output after the first several doses of intravenous diuretics.",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": 8.875,
            "end_logit": -6.87109375,
            "text": "heart failure where approximately 25% of patients develop a rise in serum creatinine and a reduction of urine output",
            "probability": 3.7550926208496094e-06
        },
        {
            "start_logit": -3.9765625,
            "end_logit": 5.6328125,
            "text": "type 1 most commonly occurs in the setting of acutely decompensated heart failure",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 8.875,
            "end_logit": -7.22265625,
            "text": "heart failure where",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 8.875,
            "end_logit": -7.3828125,
            "text": "heart failure where approximately 25% of patients develop a rise in serum creatinine",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 8.875,
            "end_logit": -7.453125,
            "text": "heart failure where approximately 25% of patients develop a",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -5.5625,
            "end_logit": 5.6328125,
            "text": "failure",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.6875,
            "end_logit": 5.6328125,
            "text": "setting of acutely decompensated heart failure",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.80859375,
            "end_logit": 5.6328125,
            "text": "acutely decompensated heart failure",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.85546875,
            "end_logit": 5.6328125,
            "text": ". CRS type 1 most commonly occurs in the setting of acutely decompensated heart failure",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.921875,
            "end_logit": 5.6328125,
            "text": "decompensated heart failure",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.03515625,
            "end_logit": 5.6328125,
            "text": "into five distinct entities, each with different major pathophysiologic mechanisms. CRS type 1 most commonly occurs in the setting of acutely decompensated heart failure",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.328125,
            "end_logit": 5.6328125,
            "text": "entities, each with different major pathophysiologic mechanisms. CRS type 1 most commonly occurs in the setting of acutely decompensated heart failure",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.34375,
            "end_logit": 5.6328125,
            "text": "1 most commonly occurs in the setting of acutely decompensated heart failure",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 5.6328125,
            "text": "classified into five distinct entities, each with different major pathophysiologic mechanisms. CRS type 1 most commonly occurs in the setting of acutely decompensated heart failure",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 5.6328125,
            "text": "recently classified into five distinct entities, each with different major pathophysiologic mechanisms. CRS type 1 most commonly occurs in the setting of acutely decompensated heart failure",
            "probability": 5.960464477539063e-08
        }
    ],
    "58da5dc58acda34529000016_3": [
        {
            "start_logit": 8.8671875,
            "end_logit": 8.28125,
            "text": "heart failure",
            "probability": 1.0
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -1.8935546875,
            "text": "heart",
            "probability": 3.7610530853271484e-05
        },
        {
            "start_logit": -2.982421875,
            "end_logit": 8.28125,
            "text": "failure",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": -4.55859375,
            "end_logit": 8.28125,
            "text": "type 2 is the hastened progression of chronic kidney disease (CKD) in the setting of chronic heart failure",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -4.99609375,
            "end_logit": 8.28125,
            "text": "CRS type 2 is the hastened progression of chronic kidney disease (CKD) in the setting of chronic heart failure",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -6.12890625,
            "end_logit": 8.28125,
            "text": "chronic heart failure",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -6.95703125,
            "text": "heart failure.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.6171875,
            "end_logit": 8.28125,
            "text": "chronic kidney disease (CKD) in the setting of chronic heart failure",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.03125,
            "end_logit": 8.28125,
            "text": "setting of chronic heart failure",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1796875,
            "end_logit": 8.28125,
            "text": "hastened progression of chronic kidney disease (CKD) in the setting of chronic heart failure",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.328125,
            "end_logit": 8.28125,
            "text": "progression of chronic kidney disease (CKD) in the setting of chronic heart failure",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 8.28125,
            "text": "in the setting of chronic heart failure",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5,
            "end_logit": 8.28125,
            "text": "kidney disease (CKD) in the setting of chronic heart failure",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53125,
            "end_logit": 8.28125,
            "text": "of chronic heart failure",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.55859375,
            "end_logit": -1.8935546875,
            "text": "type 2 is the hastened progression of chronic kidney disease (CKD) in the setting of chronic heart",
            "probability": 0.0
        },
        {
            "start_logit": -4.99609375,
            "end_logit": -1.8935546875,
            "text": "CRS type 2 is the hastened progression of chronic kidney disease (CKD) in the setting of chronic heart",
            "probability": 0.0
        },
        {
            "start_logit": -6.12890625,
            "end_logit": -1.8935546875,
            "text": "chronic heart",
            "probability": 0.0
        },
        {
            "start_logit": -6.6171875,
            "end_logit": -1.8935546875,
            "text": "chronic kidney disease (CKD) in the setting of chronic heart",
            "probability": 0.0
        },
        {
            "start_logit": -7.03125,
            "end_logit": -1.8935546875,
            "text": "setting of chronic heart",
            "probability": 0.0
        },
        {
            "start_logit": -7.1796875,
            "end_logit": -1.8935546875,
            "text": "hastened progression of chronic kidney disease (CKD) in the setting of chronic heart",
            "probability": 0.0
        }
    ],
    "58da5dc58acda34529000016_4": [
        {
            "start_logit": 9.1796875,
            "end_logit": 8.7578125,
            "text": "heart failure",
            "probability": 1.0
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -1.25390625,
            "text": "heart",
            "probability": 4.470348358154297e-05
        },
        {
            "start_logit": -2.435546875,
            "end_logit": 8.7578125,
            "text": "failure",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": -6.3203125,
            "end_logit": 8.7578125,
            "text": "is acutely decompensated heart failure",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.3828125,
            "end_logit": 8.7578125,
            "text": "type 3 is acutely decompensated heart failure",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.08984375,
            "text": "heart failure after acute kidney injury",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.18359375,
            "text": "heart failure after acute kidney injury from inflammatory, toxic, or ischemic insults.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.23046875,
            "text": "heart failure after acute kidney injury from inflammatory, toxic, or ischemic insults",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.359375,
            "text": "heart failure after acute kidney injury from",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9609375,
            "end_logit": 8.7578125,
            "text": "CRS type 3 is acutely decompensated heart failure",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.00390625,
            "end_logit": 8.7578125,
            "text": "acutely decompensated heart failure",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.43359375,
            "text": "heart failure after acute kidney injury from inflammatory, toxic, or ischemic",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.4609375,
            "text": "heart failure after",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.49609375,
            "text": "heart failure after acute kidney injury from inflammatory, toxic, or",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.51171875,
            "text": "heart failure after acute kidney injury from inflammatory, toxic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 8.7578125,
            "text": "decompensated heart failure",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.3203125,
            "end_logit": -1.25390625,
            "text": "is acutely decompensated heart",
            "probability": 0.0
        },
        {
            "start_logit": -6.3828125,
            "end_logit": -1.25390625,
            "text": "type 3 is acutely decompensated heart",
            "probability": 0.0
        },
        {
            "start_logit": -6.9609375,
            "end_logit": -1.25390625,
            "text": "CRS type 3 is acutely decompensated heart",
            "probability": 0.0
        },
        {
            "start_logit": -7.00390625,
            "end_logit": -1.25390625,
            "text": "acutely decompensated heart",
            "probability": 0.0
        }
    ],
    "58da5dc58acda34529000016_5": [
        {
            "start_logit": 4.5625,
            "end_logit": 1.642578125,
            "text": "heart failure",
            "probability": 0.69091796875
        },
        {
            "start_logit": 4.5625,
            "end_logit": 0.796875,
            "text": "heart failure in the setting of CKD. Cardiac myocyte dysfunction and fibrosis, so-called 'CKD cardiomyopathy",
            "probability": 0.297119140625
        },
        {
            "start_logit": 0.68017578125,
            "end_logit": 0.796875,
            "text": "CKD cardiomyopathy",
            "probability": 0.0061187744140625
        },
        {
            "start_logit": -1.2998046875,
            "end_logit": 2.083984375,
            "text": "sepsis",
            "probability": 0.0030651092529296875
        },
        {
            "start_logit": 4.5625,
            "end_logit": -5.0078125,
            "text": "heart failure in the setting of CKD. Cardiac myocyte dysfunction and fibrosis, so-called 'CKD",
            "probability": 0.0008955001831054688
        },
        {
            "start_logit": 4.5625,
            "end_logit": -5.7734375,
            "text": "heart",
            "probability": 0.0004165172576904297
        },
        {
            "start_logit": 4.5625,
            "end_logit": -6.15625,
            "text": "heart failure in the setting of CKD",
            "probability": 0.00028395652770996094
        },
        {
            "start_logit": 4.5625,
            "end_logit": -6.5703125,
            "text": "heart failure in the setting of CKD. Cardiac myocyte dysfunction and fibrosis, so-called 'CKD cardiomyopathy'",
            "probability": 0.0001876354217529297
        },
        {
            "start_logit": -3.763671875,
            "end_logit": 1.642578125,
            "text": "chronic heart failure",
            "probability": 0.00016701221466064453
        },
        {
            "start_logit": 4.5625,
            "end_logit": -6.765625,
            "text": "heart failure in the setting of CKD. Cardiac myocyte dysfunction and fibrosis",
            "probability": 0.0001544952392578125
        },
        {
            "start_logit": -3.90234375,
            "end_logit": 1.642578125,
            "text": "type 4 is manifested by the acceleration of the progression of chronic heart failure",
            "probability": 0.0001461505889892578
        },
        {
            "start_logit": 4.5625,
            "end_logit": -6.9609375,
            "text": "heart failure in the setting of CKD. Cardiac myocyte dysfunction and fibrosis, so-called 'CKD cardiomyopathy', is",
            "probability": 0.00012695789337158203
        },
        {
            "start_logit": 4.5625,
            "end_logit": -7.08203125,
            "text": "heart failure in the setting of CKD. Cardiac myocyte dysfunction and fibrosis, so-called 'CKD cardiomyopathy',",
            "probability": 0.00011295080184936523
        },
        {
            "start_logit": 4.5625,
            "end_logit": -7.09375,
            "text": "heart failure in",
            "probability": 0.0001112222671508789
        },
        {
            "start_logit": 4.5625,
            "end_logit": -7.11328125,
            "text": "heart failure in the setting of CKD. Cardiac myocyte dysfunction and fibrosis, so-called 'CKD cardiomyopathy', is believed",
            "probability": 0.00010949373245239258
        },
        {
            "start_logit": -3.763671875,
            "end_logit": 0.796875,
            "text": "chronic heart failure in the setting of CKD. Cardiac myocyte dysfunction and fibrosis, so-called 'CKD cardiomyopathy",
            "probability": 7.18235969543457e-05
        },
        {
            "start_logit": -4.66796875,
            "end_logit": 1.642578125,
            "text": "CRS type 4 is manifested by the acceleration of the progression of chronic heart failure",
            "probability": 6.80088996887207e-05
        },
        {
            "start_logit": -4.8359375,
            "end_logit": 1.642578125,
            "text": "4 is manifested by the acceleration of the progression of chronic heart failure",
            "probability": 5.7220458984375e-05
        },
        {
            "start_logit": -5.95703125,
            "end_logit": 2.083984375,
            "text": "renal injury in the setting of an overwhelming systemic insult such as sepsis",
            "probability": 2.8967857360839844e-05
        },
        {
            "start_logit": -4.96484375,
            "end_logit": 0.796875,
            "text": "'CKD cardiomyopathy",
            "probability": 2.1517276763916016e-05
        }
    ],
    "58da5dc58acda34529000016_6": [
        {
            "start_logit": 8.140625,
            "end_logit": 5.36328125,
            "text": "renocardiac syndrome",
            "probability": 0.67578125
        },
        {
            "start_logit": 8.140625,
            "end_logit": 4.625,
            "text": "renocardiac",
            "probability": 0.32421875
        },
        {
            "start_logit": 8.140625,
            "end_logit": -3.166015625,
            "text": "ren",
            "probability": 0.00013434886932373047
        },
        {
            "start_logit": 8.140625,
            "end_logit": -6.4375,
            "text": "renocardi",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": 8.140625,
            "end_logit": -6.99609375,
            "text": "renocardiac syndrome).",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": 8.140625,
            "end_logit": -7.17578125,
            "text": "renocardiac syndrome)",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": -4.625,
            "end_logit": 5.36328125,
            "text": "type 1 (acute cardiorenal syndrome) and type 3 (acute renocardiac syndrome",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -4.625,
            "end_logit": 4.625,
            "text": "type 1 (acute cardiorenal syndrome) and type 3 (acute renocardiac",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -5.6484375,
            "end_logit": 5.36328125,
            "text": "syndrome",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.2109375,
            "end_logit": 5.36328125,
            "text": "ac syndrome",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.74609375,
            "end_logit": 5.36328125,
            "text": "acute renocardiac syndrome",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.8515625,
            "end_logit": 5.36328125,
            "text": "CRS type 1 (acute cardiorenal syndrome) and type 3 (acute renocardiac syndrome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.2109375,
            "end_logit": 4.625,
            "text": "ac",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.15625,
            "end_logit": 5.36328125,
            "text": "and type 3 (acute renocardiac syndrome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 5.36328125,
            "text": "ocardiac syndrome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 5.36328125,
            "text": "are CRS type 1 (acute cardiorenal syndrome) and type 3 (acute renocardiac syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 5.36328125,
            "text": "Of particular interest to the critical care specialist are CRS type 1 (acute cardiorenal syndrome) and type 3 (acute renocardiac syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 5.36328125,
            "text": "type 3 (acute renocardiac syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.74609375,
            "end_logit": 4.625,
            "text": "acute renocardiac",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 5.36328125,
            "text": "critical care specialist are CRS type 1 (acute cardiorenal syndrome) and type 3 (acute renocardiac syndrome",
            "probability": 1.1920928955078125e-07
        }
    ],
    "58da5dc58acda34529000016_7": [
        {
            "start_logit": 0.6123046875,
            "end_logit": 0.5263671875,
            "text": "acute worsening of heart function (acute heart failure-acute coronary syndrome",
            "probability": 0.94287109375
        },
        {
            "start_logit": -3.552734375,
            "end_logit": 0.5263671875,
            "text": "acute heart failure-acute coronary syndrome",
            "probability": 0.01465606689453125
        },
        {
            "start_logit": -3.65234375,
            "end_logit": 0.5263671875,
            "text": "heart failure-acute coronary syndrome",
            "probability": 0.01324462890625
        },
        {
            "start_logit": 0.6123046875,
            "end_logit": -3.748046875,
            "text": "acute worsening of heart function (acute heart failure",
            "probability": 0.0131378173828125
        },
        {
            "start_logit": -5.2421875,
            "end_logit": 0.5263671875,
            "text": "CRS type 1 = acute worsening of heart function (acute heart failure-acute coronary syndrome",
            "probability": 0.002712249755859375
        },
        {
            "start_logit": -5.45703125,
            "end_logit": 0.5263671875,
            "text": "subtypes: CRS type 1 = acute worsening of heart function (acute heart failure-acute coronary syndrome",
            "probability": 0.002178192138671875
        },
        {
            "start_logit": -5.69921875,
            "end_logit": 0.5263671875,
            "text": "acute coronary syndrome",
            "probability": 0.0017099380493164062
        },
        {
            "start_logit": -6.1796875,
            "end_logit": 0.5263671875,
            "text": "coronary syndrome",
            "probability": 0.0010623931884765625
        },
        {
            "start_logit": -6.28125,
            "end_logit": 0.5263671875,
            "text": ": CRS type 1 = acute worsening of heart function (acute heart failure-acute coronary syndrome",
            "probability": 0.0009593963623046875
        },
        {
            "start_logit": -6.29296875,
            "end_logit": 0.5263671875,
            "text": "= acute worsening of heart function (acute heart failure-acute coronary syndrome",
            "probability": 0.0009441375732421875
        },
        {
            "start_logit": -6.375,
            "end_logit": 0.5263671875,
            "text": "type 1 = acute worsening of heart function (acute heart failure-acute coronary syndrome",
            "probability": 0.0008730888366699219
        },
        {
            "start_logit": -6.56640625,
            "end_logit": 0.5263671875,
            "text": "five subtypes: CRS type 1 = acute worsening of heart function (acute heart failure-acute coronary syndrome",
            "probability": 0.0007185935974121094
        },
        {
            "start_logit": 0.6123046875,
            "end_logit": -6.69921875,
            "text": "acute worsening of heart function (acute heart failure-acute coronary",
            "probability": 0.0006856918334960938
        },
        {
            "start_logit": -6.66015625,
            "end_logit": 0.5263671875,
            "text": "syndrome",
            "probability": 0.0006542205810546875
        },
        {
            "start_logit": -6.703125,
            "end_logit": 0.5263671875,
            "text": "definition has been expanded into five subtypes: CRS type 1 = acute worsening of heart function (acute heart failure-acute coronary syndrome",
            "probability": 0.0006289482116699219
        },
        {
            "start_logit": 0.6123046875,
            "end_logit": -6.80859375,
            "text": "acute worsening of heart function (acute heart failure-acute coronary syndrome)",
            "probability": 0.0006146430969238281
        },
        {
            "start_logit": -6.73828125,
            "end_logit": 0.5263671875,
            "text": "into five subtypes: CRS type 1 = acute worsening of heart function (acute heart failure-acute coronary syndrome",
            "probability": 0.0006051063537597656
        },
        {
            "start_logit": 0.6123046875,
            "end_logit": -6.828125,
            "text": "acute worsening of heart function (acute heart failure-",
            "probability": 0.0006051063537597656
        },
        {
            "start_logit": 0.6123046875,
            "end_logit": -7.1015625,
            "text": "acute worsening",
            "probability": 0.0004601478576660156
        },
        {
            "start_logit": 0.6123046875,
            "end_logit": -7.12109375,
            "text": "acute worsening of heart function (acute heart failure-acute coronary syndrome) leading to kidney injury and/or dysfunction; CRS type 2 = chronic abnormalities",
            "probability": 0.0004496574401855469
        }
    ],
    "58da5dc58acda34529000016_8": [
        {
            "start_logit": 1.73046875,
            "end_logit": -2.74609375,
            "text": "acute worsening of heart function",
            "probability": 0.6728515625
        },
        {
            "start_logit": 1.73046875,
            "end_logit": -4.0390625,
            "text": "acute worsening of heart",
            "probability": 0.1845703125
        },
        {
            "start_logit": 1.73046875,
            "end_logit": -5.98046875,
            "text": "acute worsening of heart function leading to kidney",
            "probability": 0.0265045166015625
        },
        {
            "start_logit": -1.8310546875,
            "end_logit": -2.74609375,
            "text": "heart function",
            "probability": 0.0190887451171875
        },
        {
            "start_logit": 1.73046875,
            "end_logit": -6.62109375,
            "text": "acute worsening of heart function leading to kidney injury",
            "probability": 0.0139617919921875
        },
        {
            "start_logit": 1.73046875,
            "end_logit": -6.98828125,
            "text": "acute worsening of heart function leading to kidney injury and/or dysfunction; CRS type 2 = chronic abnormalities",
            "probability": 0.009674072265625
        },
        {
            "start_logit": 1.73046875,
            "end_logit": -7.01953125,
            "text": "acute worsening of heart function leading to kidney injury and",
            "probability": 0.00937652587890625
        },
        {
            "start_logit": 1.73046875,
            "end_logit": -7.07421875,
            "text": "acute worsening of heart function leading to kidney injury and/",
            "probability": 0.00887298583984375
        },
        {
            "start_logit": 1.73046875,
            "end_logit": -7.1171875,
            "text": "acute worsening of heart function leading",
            "probability": 0.0084991455078125
        },
        {
            "start_logit": 1.73046875,
            "end_logit": -7.13671875,
            "text": "acute worsening of heart function leading to kidney injury and/or dysfunction; CRS type 2 = chronic abnormalities in heart",
            "probability": 0.00833892822265625
        },
        {
            "start_logit": 1.73046875,
            "end_logit": -7.171875,
            "text": "acute",
            "probability": 0.00804901123046875
        },
        {
            "start_logit": 1.73046875,
            "end_logit": -7.23046875,
            "text": "acute worsening of heart function leading to kidney injury and/or dysfunction; CRS",
            "probability": 0.00759124755859375
        },
        {
            "start_logit": 1.73046875,
            "end_logit": -7.24609375,
            "text": "acute worsening",
            "probability": 0.007472991943359375
        },
        {
            "start_logit": 1.73046875,
            "end_logit": -7.25,
            "text": "acute worsening of heart function leading to kidney injury and/or dysfunction; CRS type 2 = chronic abnormalities in heart function",
            "probability": 0.007442474365234375
        },
        {
            "start_logit": -1.8310546875,
            "end_logit": -4.0390625,
            "text": "heart",
            "probability": 0.005237579345703125
        },
        {
            "start_logit": -1.8310546875,
            "end_logit": -5.98046875,
            "text": "heart function leading to kidney",
            "probability": 0.0007519721984863281
        },
        {
            "start_logit": -5.4609375,
            "end_logit": -2.74609375,
            "text": "type 1 = acute worsening of heart function",
            "probability": 0.0005083084106445312
        },
        {
            "start_logit": -1.8310546875,
            "end_logit": -6.62109375,
            "text": "heart function leading to kidney injury",
            "probability": 0.0003962516784667969
        },
        {
            "start_logit": -5.7265625,
            "end_logit": -2.74609375,
            "text": "CRS type 1 = acute worsening of heart function",
            "probability": 0.00039005279541015625
        },
        {
            "start_logit": -5.921875,
            "end_logit": -2.74609375,
            "text": "worsening of heart function",
            "probability": 0.00031828880310058594
        }
    ],
    "5523e47f7b523f2123000004_1": [
        {
            "start_logit": 9.0546875,
            "end_logit": 9.28125,
            "text": "dsRed",
            "probability": 1.0
        },
        {
            "start_logit": -1.404296875,
            "end_logit": 9.28125,
            "text": "Red",
            "probability": 2.8431415557861328e-05
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -1.7138671875,
            "text": "ds",
            "probability": 1.6689300537109375e-05
        },
        {
            "start_logit": -4.3046875,
            "end_logit": 9.28125,
            "text": "red fluorescent protein, dsRed",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -6.05078125,
            "end_logit": 9.28125,
            "text": "DsRed1-E5, is a mutant of the red fluorescent protein, dsRed",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.5078125,
            "end_logit": 9.28125,
            "text": "Fluorescent Timer, or DsRed1-E5, is a mutant of the red fluorescent protein, dsRed",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.57421875,
            "end_logit": 9.28125,
            "text": "mutant of the red fluorescent protein, dsRed",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.8515625,
            "end_logit": 9.28125,
            "text": "fluorescent protein, dsRed",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.06640625,
            "end_logit": 9.28125,
            "text": "Timer, or DsRed1-E5, is a mutant of the red fluorescent protein, dsRed",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.0546875,
            "text": "dsRed, in which fluorescence shifts over time from green to red",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2890625,
            "end_logit": 9.28125,
            "text": ", dsRed",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.109375,
            "text": "dsRed, in which fluorescence shifts over time from green to red as the protein matures",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.1484375,
            "text": "dsRed, in which fluorescence shifts over time from green",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.19921875,
            "text": "dsRed,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.2265625,
            "text": "dsRed, in which fluorescence shifts over time from green to red as the protein matures.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.23046875,
            "text": "dsRed, in which fluorescence shifts over time from green to red as the protein mature",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.3046875,
            "end_logit": -1.7138671875,
            "text": "red fluorescent protein, ds",
            "probability": 0.0
        },
        {
            "start_logit": -6.05078125,
            "end_logit": -1.7138671875,
            "text": "DsRed1-E5, is a mutant of the red fluorescent protein, ds",
            "probability": 0.0
        },
        {
            "start_logit": -6.5078125,
            "end_logit": -1.7138671875,
            "text": "Fluorescent Timer, or DsRed1-E5, is a mutant of the red fluorescent protein, ds",
            "probability": 0.0
        },
        {
            "start_logit": -6.57421875,
            "end_logit": -1.7138671875,
            "text": "mutant of the red fluorescent protein, ds",
            "probability": 0.0
        }
    ],
    "5523e47f7b523f2123000004_2": [
        {
            "start_logit": 9.0234375,
            "end_logit": 9.1796875,
            "text": "green fluorescent protein",
            "probability": 1.0
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -1.1689453125,
            "text": "green",
            "probability": 3.218650817871094e-05
        },
        {
            "start_logit": -1.333984375,
            "end_logit": 9.1796875,
            "text": "protein",
            "probability": 3.170967102050781e-05
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -3.3359375,
            "text": "green fluorescent protein (Gfp",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -5.01953125,
            "text": "green fluorescent protein (Gfp)",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -6.5234375,
            "text": "green fluorescent",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.68359375,
            "end_logit": 9.1796875,
            "text": "fluorescent protein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -1.333984375,
            "end_logit": -3.3359375,
            "text": "protein (Gfp",
            "probability": 0.0
        },
        {
            "start_logit": -1.333984375,
            "end_logit": -5.01953125,
            "text": "protein (Gfp)",
            "probability": 0.0
        },
        {
            "start_logit": -5.81640625,
            "end_logit": -3.3359375,
            "text": "Gfp",
            "probability": 0.0
        },
        {
            "start_logit": -6.68359375,
            "end_logit": -3.3359375,
            "text": "fluorescent protein (Gfp",
            "probability": 0.0
        },
        {
            "start_logit": -5.81640625,
            "end_logit": -5.01953125,
            "text": "Gfp)",
            "probability": 0.0
        },
        {
            "start_logit": -7.5078125,
            "end_logit": -3.3359375,
            "text": "(Gfp",
            "probability": 0.0
        },
        {
            "start_logit": -6.68359375,
            "end_logit": -5.01953125,
            "text": "fluorescent protein (Gfp)",
            "probability": 0.0
        },
        {
            "start_logit": -7.5078125,
            "end_logit": -5.01953125,
            "text": "(Gfp)",
            "probability": 0.0
        },
        {
            "start_logit": -6.68359375,
            "end_logit": -6.5234375,
            "text": "fluorescent",
            "probability": 0.0
        }
    ],
    "5523e47f7b523f2123000004_3": [
        {
            "start_logit": 9.1953125,
            "end_logit": 9.1484375,
            "text": "mCherry",
            "probability": 1.0
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -1.40625,
            "text": "mCh",
            "probability": 2.6047229766845703e-05
        },
        {
            "start_logit": -1.720703125,
            "end_logit": 9.1484375,
            "text": "erry",
            "probability": 1.817941665649414e-05
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -6.68359375,
            "text": "mCherry was employed as a reporter protein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.720703125,
            "end_logit": -6.68359375,
            "text": "erry was employed as a reporter protein",
            "probability": 0.0
        },
        {
            "start_logit": -7.33984375,
            "end_logit": -6.68359375,
            "text": "reporter protein",
            "probability": 0.0
        },
        {
            "start_logit": -7.44140625,
            "end_logit": -6.68359375,
            "text": "was employed as a reporter protein",
            "probability": 0.0
        },
        {
            "start_logit": -7.48046875,
            "end_logit": -6.68359375,
            "text": "a reporter protein",
            "probability": 0.0
        },
        {
            "start_logit": -7.671875,
            "end_logit": -6.68359375,
            "text": "employed as a reporter protein",
            "probability": 0.0
        },
        {
            "start_logit": -7.734375,
            "end_logit": -6.68359375,
            "text": "as a reporter protein",
            "probability": 0.0
        }
    ],
    "5523e47f7b523f2123000004_4": [
        {
            "start_logit": 9.234375,
            "end_logit": 8.8984375,
            "text": "yellow fluorescent protein",
            "probability": 1.0
        },
        {
            "start_logit": 9.234375,
            "end_logit": -0.947265625,
            "text": "yellow",
            "probability": 5.346536636352539e-05
        },
        {
            "start_logit": -2.177734375,
            "end_logit": 8.8984375,
            "text": "protein",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": -6.3046875,
            "end_logit": 8.8984375,
            "text": "fluorescent protein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -6.93359375,
            "text": "yellow fluorescent",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.3046875,
            "end_logit": -6.93359375,
            "text": "fluorescent",
            "probability": 0.0
        }
    ],
    "5523e47f7b523f2123000004_5": [
        {
            "start_logit": 5.66015625,
            "end_logit": 4.84765625,
            "text": "enhanced green fluorescent reporter protein",
            "probability": 1.0
        },
        {
            "start_logit": 5.66015625,
            "end_logit": -5.0703125,
            "text": "enhanced green fluorescent",
            "probability": 4.9114227294921875e-05
        },
        {
            "start_logit": 5.66015625,
            "end_logit": -5.296875,
            "text": "enhanced green fluorescent reporter",
            "probability": 3.9458274841308594e-05
        },
        {
            "start_logit": 5.66015625,
            "end_logit": -5.6953125,
            "text": "enhanced",
            "probability": 2.6285648345947266e-05
        },
        {
            "start_logit": 5.66015625,
            "end_logit": -6.40625,
            "text": "enhanced green",
            "probability": 1.2993812561035156e-05
        },
        {
            "start_logit": -5.734375,
            "end_logit": 4.84765625,
            "text": "green fluorescent reporter protein",
            "probability": 1.1324882507324219e-05
        },
        {
            "start_logit": -5.7421875,
            "end_logit": 4.84765625,
            "text": "protein",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 4.84765625,
            "text": "reporter protein",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": -5.734375,
            "end_logit": -5.0703125,
            "text": "green fluorescent",
            "probability": 0.0
        },
        {
            "start_logit": -5.734375,
            "end_logit": -5.296875,
            "text": "green fluorescent reporter",
            "probability": 0.0
        },
        {
            "start_logit": -5.734375,
            "end_logit": -6.40625,
            "text": "green",
            "probability": 0.0
        },
        {
            "start_logit": -7.54296875,
            "end_logit": -5.296875,
            "text": "reporter",
            "probability": 0.0
        }
    ],
    "5523e47f7b523f2123000004_6": [
        {
            "start_logit": 9.1953125,
            "end_logit": 9.296875,
            "text": "green fluorescent protein",
            "probability": 1.0
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -0.55224609375,
            "text": "green fluorescent protein (GFP",
            "probability": 5.227327346801758e-05
        },
        {
            "start_logit": -1.134765625,
            "end_logit": 9.296875,
            "text": "protein",
            "probability": 3.24249267578125e-05
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -1.0712890625,
            "text": "green",
            "probability": 3.11732292175293e-05
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -5.5859375,
            "text": "green fluorescent protein (GFP) and DsRed2",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -6.1015625,
            "text": "green fluorescent protein (GFP)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.609375,
            "end_logit": 9.296875,
            "text": "fluorescent protein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -6.84375,
            "text": "green fluorescent protein (GFP) and DsRed",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.97265625,
            "end_logit": 9.296875,
            "text": "[green fluorescent protein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.09765625,
            "text": "green fluorescent",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.234375,
            "text": "green fluorescent protein (GFP) and Ds",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.28125,
            "text": "green fluorescent protein (GFP) and DsRed2]",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 9.296875,
            "text": "fluorescent reporter protein [green fluorescent protein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.44921875,
            "text": "green fluorescent protein (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 9.296875,
            "text": "protein [green fluorescent protein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6484375,
            "end_logit": 9.296875,
            "text": "reporter protein [green fluorescent protein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.134765625,
            "end_logit": -0.55224609375,
            "text": "protein (GFP",
            "probability": 0.0
        },
        {
            "start_logit": -2.119140625,
            "end_logit": -0.55224609375,
            "text": "GFP",
            "probability": 0.0
        },
        {
            "start_logit": -1.134765625,
            "end_logit": -5.5859375,
            "text": "protein (GFP) and DsRed2",
            "probability": 0.0
        },
        {
            "start_logit": -6.609375,
            "end_logit": -0.55224609375,
            "text": "fluorescent protein (GFP",
            "probability": 0.0
        }
    ],
    "5523e47f7b523f2123000004_7": [
        {
            "start_logit": 7.7578125,
            "end_logit": 7.80078125,
            "text": "coral",
            "probability": 1.0
        },
        {
            "start_logit": 7.7578125,
            "end_logit": -3.888671875,
            "text": "coral fluorescent reporter protein",
            "probability": 8.344650268554688e-06
        },
        {
            "start_logit": 7.7578125,
            "end_logit": -6.52734375,
            "text": "coral fluorescent",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.7578125,
            "end_logit": -7.06640625,
            "text": "coral fluorescent reporter",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.26953125,
            "end_logit": -3.888671875,
            "text": "fluorescent reporter protein",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -3.888671875,
            "text": "reporter protein",
            "probability": 0.0
        },
        {
            "start_logit": -6.26953125,
            "end_logit": -6.52734375,
            "text": "fluorescent",
            "probability": 0.0
        },
        {
            "start_logit": -6.26953125,
            "end_logit": -7.06640625,
            "text": "fluorescent reporter",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -7.06640625,
            "text": "reporter",
            "probability": 0.0
        }
    ],
    "5523e47f7b523f2123000004_8": [
        {
            "start_logit": 7.32421875,
            "end_logit": 7.984375,
            "text": "GFP",
            "probability": 1.0
        },
        {
            "start_logit": 7.32421875,
            "end_logit": -6.984375,
            "text": "GFP as a fluorescent reporter protein",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.32421875,
            "end_logit": -7.30078125,
            "text": "GFP as",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.32421875,
            "end_logit": -7.45703125,
            "text": "GFP as a",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.39453125,
            "end_logit": -6.984375,
            "text": "fluorescent reporter protein",
            "probability": 0.0
        }
    ],
    "5523e47f7b523f2123000004_9": [
        {
            "start_logit": 8.2265625,
            "end_logit": 8.8359375,
            "text": "eqFP611",
            "probability": 1.0
        },
        {
            "start_logit": -1.89453125,
            "end_logit": 8.8359375,
            "text": "red fluorescent protein eqFP611",
            "probability": 4.00543212890625e-05
        },
        {
            "start_logit": -2.37109375,
            "end_logit": 8.8359375,
            "text": "1",
            "probability": 2.5093555450439453e-05
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -3.00390625,
            "text": "eq",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": -6.50390625,
            "end_logit": 8.8359375,
            "text": "FP611",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.63671875,
            "end_logit": 8.8359375,
            "text": "fluorescent protein eqFP611",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.9296875,
            "end_logit": 8.8359375,
            "text": "611",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -6.3515625,
            "text": "eqFP61",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.43359375,
            "end_logit": 8.8359375,
            "text": "protein eqFP611",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.4375,
            "end_logit": 8.8359375,
            "text": "The red fluorescent protein eqFP611",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -1.89453125,
            "end_logit": -3.00390625,
            "text": "red fluorescent protein eq",
            "probability": 0.0
        },
        {
            "start_logit": -1.89453125,
            "end_logit": -5.51171875,
            "text": "red fluorescent protein",
            "probability": 0.0
        },
        {
            "start_logit": -1.89453125,
            "end_logit": -6.3515625,
            "text": "red fluorescent protein eqFP61",
            "probability": 0.0
        },
        {
            "start_logit": -1.89453125,
            "end_logit": -6.41015625,
            "text": "red fluorescent",
            "probability": 0.0
        },
        {
            "start_logit": -1.89453125,
            "end_logit": -6.4140625,
            "text": "red",
            "probability": 0.0
        },
        {
            "start_logit": -6.63671875,
            "end_logit": -3.00390625,
            "text": "fluorescent protein eq",
            "probability": 0.0
        },
        {
            "start_logit": -7.43359375,
            "end_logit": -3.00390625,
            "text": "protein eq",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -3.00390625,
            "text": "The red fluorescent protein eq",
            "probability": 0.0
        },
        {
            "start_logit": -6.63671875,
            "end_logit": -5.51171875,
            "text": "fluorescent protein",
            "probability": 0.0
        },
        {
            "start_logit": -6.50390625,
            "end_logit": -6.3515625,
            "text": "FP61",
            "probability": 0.0
        }
    ],
    "5523e47f7b523f2123000004_10": [
        {
            "start_logit": 9.390625,
            "end_logit": 9.359375,
            "text": "beta-phycoerythrin",
            "probability": 1.0
        },
        {
            "start_logit": 9.390625,
            "end_logit": -0.7509765625,
            "text": "beta",
            "probability": 4.07099723815918e-05
        },
        {
            "start_logit": -1.1845703125,
            "end_logit": 9.359375,
            "text": "in",
            "probability": 2.5451183319091797e-05
        },
        {
            "start_logit": 9.390625,
            "end_logit": -5.25390625,
            "text": "beta-phycoerythrin, a fluorescent reporter protein derived from algae",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -5.52734375,
            "end_logit": 9.359375,
            "text": "-phycoerythrin",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.66796875,
            "end_logit": 9.359375,
            "text": "phycoerythrin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.390625,
            "end_logit": -6.046875,
            "text": "beta-phycoerythrin, a fluorescent reporter protein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.3828125,
            "end_logit": 9.359375,
            "text": "rythrin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.46875,
            "end_logit": 9.359375,
            "text": "ycoerythrin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.4921875,
            "end_logit": 9.359375,
            "text": "oerythrin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.49609375,
            "end_logit": 9.359375,
            "text": "thrin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.390625,
            "end_logit": -6.83984375,
            "text": "beta-phycoerythrin, a fluorescent reporter protein derived",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.390625,
            "end_logit": -7.05078125,
            "text": "beta-phycoerythr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.1845703125,
            "end_logit": -5.25390625,
            "text": "in, a fluorescent reporter protein derived from algae",
            "probability": 0.0
        },
        {
            "start_logit": -1.1845703125,
            "end_logit": -6.046875,
            "text": "in, a fluorescent reporter protein",
            "probability": 0.0
        },
        {
            "start_logit": -1.1845703125,
            "end_logit": -6.83984375,
            "text": "in, a fluorescent reporter protein derived",
            "probability": 0.0
        },
        {
            "start_logit": -5.52734375,
            "end_logit": -5.25390625,
            "text": "-phycoerythrin, a fluorescent reporter protein derived from algae",
            "probability": 0.0
        },
        {
            "start_logit": -5.66796875,
            "end_logit": -5.25390625,
            "text": "phycoerythrin, a fluorescent reporter protein derived from algae",
            "probability": 0.0
        },
        {
            "start_logit": -5.52734375,
            "end_logit": -6.046875,
            "text": "-phycoerythrin, a fluorescent reporter protein",
            "probability": 0.0
        },
        {
            "start_logit": -6.3828125,
            "end_logit": -5.25390625,
            "text": "rythrin, a fluorescent reporter protein derived from algae",
            "probability": 0.0
        }
    ],
    "5523e47f7b523f2123000004_11": [
        {
            "start_logit": 9.015625,
            "end_logit": 9.140625,
            "text": "Timer",
            "probability": 1.0
        },
        {
            "start_logit": -1.7265625,
            "end_logit": 9.140625,
            "text": "r",
            "probability": 2.1636486053466797e-05
        },
        {
            "start_logit": 9.015625,
            "end_logit": -1.7783203125,
            "text": "Time",
            "probability": 1.806020736694336e-05
        },
        {
            "start_logit": -6.9375,
            "end_logit": 9.140625,
            "text": ", Timer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.171875,
            "end_logit": 9.140625,
            "text": "live-cell fluorescent reporter protein, Timer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 9.140625,
            "text": "reporter protein, Timer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 9.140625,
            "text": "fluorescent reporter protein, Timer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 9.140625,
            "text": "-cell fluorescent reporter protein, Timer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 9.140625,
            "text": "protein, Timer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.9375,
            "end_logit": -1.7783203125,
            "text": ", Time",
            "probability": 0.0
        },
        {
            "start_logit": -7.171875,
            "end_logit": -1.7783203125,
            "text": "live-cell fluorescent reporter protein, Time",
            "probability": 0.0
        },
        {
            "start_logit": -7.48828125,
            "end_logit": -1.7783203125,
            "text": "reporter protein, Time",
            "probability": 0.0
        },
        {
            "start_logit": -7.63671875,
            "end_logit": -1.7783203125,
            "text": "fluorescent reporter protein, Time",
            "probability": 0.0
        },
        {
            "start_logit": -7.64453125,
            "end_logit": -1.7783203125,
            "text": "-cell fluorescent reporter protein, Time",
            "probability": 0.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -1.7783203125,
            "text": "protein, Time",
            "probability": 0.0
        },
        {
            "start_logit": -7.171875,
            "end_logit": -7.37109375,
            "text": "live-cell",
            "probability": 0.0
        },
        {
            "start_logit": -7.64453125,
            "end_logit": -7.37109375,
            "text": "-cell",
            "probability": 0.0
        }
    ],
    "602823e61cb411341a0000f9_1": [
        {
            "start_logit": 7.64453125,
            "end_logit": 5.08203125,
            "text": "irinotecan",
            "probability": 0.9990234375
        },
        {
            "start_logit": 0.84423828125,
            "end_logit": 5.08203125,
            "text": "bevacizumab (FOLFOX/Bev) than those with high TS (TS-H) expression and that combined irinotecan",
            "probability": 0.0011119842529296875
        },
        {
            "start_logit": 0.84423828125,
            "end_logit": 3.076171875,
            "text": "bevacizumab",
            "probability": 0.0001499652862548828
        },
        {
            "start_logit": 7.64453125,
            "end_logit": -6.5234375,
            "text": "irinotecan and oxaliplatin (IROX) plus bevacizumab",
            "probability": 9.059906005859375e-06
        },
        {
            "start_logit": 7.64453125,
            "end_logit": -7.2265625,
            "text": "irinotecan and oxaliplatin",
            "probability": 4.470348358154297e-06
        },
        {
            "start_logit": 7.64453125,
            "end_logit": -7.39453125,
            "text": "irinotecan and oxaliplatin (IROX) plus bevacizumab (IROX/Bev) would",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": 7.64453125,
            "end_logit": -7.484375,
            "text": "irinotecan and oxaliplatin (IROX) plus bevacizumab (",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": -5.875,
            "end_logit": 5.08203125,
            "text": "plus bevacizumab (FOLFOX/Bev) than those with high TS (TS-H) expression and that combined irinotecan",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -6.53515625,
            "end_logit": 5.08203125,
            "text": "combined irinotecan",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -6.83203125,
            "end_logit": 5.08203125,
            "text": "that combined irinotecan",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.19921875,
            "end_logit": 5.08203125,
            "text": "and that combined irinotecan",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.7109375,
            "end_logit": 3.076171875,
            "text": "5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) plus bevacizumab",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.875,
            "end_logit": 3.076171875,
            "text": "plus bevacizumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.640625,
            "end_logit": 3.076171875,
            "text": "combined 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) plus bevacizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.01953125,
            "end_logit": 3.076171875,
            "text": "-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) plus bevacizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1796875,
            "end_logit": 3.076171875,
            "text": "to combined 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) plus bevacizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2109375,
            "end_logit": 3.076171875,
            "text": "leucovorin, and oxaliplatin (FOLFOX) plus bevacizumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 0.84423828125,
            "end_logit": -7.2265625,
            "text": "bevacizumab (FOLFOX/Bev) than those with high TS (TS-H) expression and that combined irinotecan and oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": 0.84423828125,
            "end_logit": -7.4375,
            "text": "bevacizumab (",
            "probability": 0.0
        },
        {
            "start_logit": -5.7109375,
            "end_logit": -6.1015625,
            "text": "5-fluorouracil",
            "probability": 0.0
        }
    ],
    "602823e61cb411341a0000f9_2": [
        {
            "start_logit": 1.3681640625,
            "end_logit": 4.5625,
            "text": "raltitrexed",
            "probability": 0.9853515625
        },
        {
            "start_logit": 1.525390625,
            "end_logit": 0.016510009765625,
            "text": "capecitabine",
            "probability": 0.01226043701171875
        },
        {
            "start_logit": -5.84765625,
            "end_logit": 4.5625,
            "text": "ed",
            "probability": 0.0007252693176269531
        },
        {
            "start_logit": -6.27734375,
            "end_logit": 4.5625,
            "text": "irinotecan + oxaliplatin (IROX), raltitrexed",
            "probability": 0.0004718303680419922
        },
        {
            "start_logit": -6.6171875,
            "end_logit": 4.5625,
            "text": ", raltitrexed",
            "probability": 0.000335693359375
        },
        {
            "start_logit": -6.6640625,
            "end_logit": 4.5625,
            "text": "FF), irinotecan + oxaliplatin (IROX), raltitrexed",
            "probability": 0.0003204345703125
        },
        {
            "start_logit": -6.81640625,
            "end_logit": 4.5625,
            "text": "T), folinic acid + 5-fluorouracil (FF), irinotecan + oxaliplatin (IROX), raltitrexed",
            "probability": 0.0002739429473876953
        },
        {
            "start_logit": -6.9296875,
            "end_logit": 4.5625,
            "text": ", irinotecan + oxaliplatin (IROX), raltitrexed",
            "probability": 0.00024580955505371094
        },
        {
            "start_logit": 1.525390625,
            "end_logit": -6.47265625,
            "text": "capecitabine.",
            "probability": 1.8656253814697266e-05
        },
        {
            "start_logit": 1.3681640625,
            "end_logit": -6.453125,
            "text": "ral",
            "probability": 1.621246337890625e-05
        },
        {
            "start_logit": 1.3681640625,
            "end_logit": -6.74609375,
            "text": "raltitrex",
            "probability": 1.2040138244628906e-05
        },
        {
            "start_logit": 1.3681640625,
            "end_logit": -7.1328125,
            "text": "raltit",
            "probability": 8.225440979003906e-06
        },
        {
            "start_logit": -5.84765625,
            "end_logit": 0.016510009765625,
            "text": "ed + oxaliplatin (TOMOX), folinic acid + tegafur-uracil (FTU), raltitrexed, and capecitabine",
            "probability": 7.62939453125e-06
        },
        {
            "start_logit": -6.515625,
            "end_logit": 0.016510009765625,
            "text": "and capecitabine",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": -2.498046875,
            "end_logit": -4.26171875,
            "text": "folinic acid",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": -2.73046875,
            "end_logit": -4.1015625,
            "text": "gemcitabine (FFG), folinic acid + 5-fluorouracil + trimetrexate",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": -2.73046875,
            "end_logit": -4.23828125,
            "text": "gemcitabine",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": -2.73046875,
            "end_logit": -5.23046875,
            "text": "gemcitabine (FFG), folinic acid + 5-fluorouracil + trimetrex",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -2.498046875,
            "end_logit": -5.76171875,
            "text": "folinic acid + 5-fluorouracil",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -5.20703125,
            "end_logit": -4.1015625,
            "text": "trimetrexate",
            "probability": 2.384185791015625e-07
        }
    ],
    "602823e61cb411341a0000f9_3": [
        {
            "start_logit": 8.3515625,
            "end_logit": 7.015625,
            "text": "fluorouracil",
            "probability": 1.0
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -5.65625,
            "text": "fluorouracil [FU] + irinotecan",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -6.08984375,
            "text": "fluorouracil [FU] + irinotecan [IRN]), FOLFOX",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -6.30859375,
            "text": "fluorouracil [FU] + irinotecan [IRN]), FOLFOX (FU + oxaliplatin",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -6.9453125,
            "text": "fluorouracil [FU] + irinotecan [IRN]",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -7.0390625,
            "text": "fluorouracil [FU] + irinotecan [IRN",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -7.07421875,
            "text": "fluorouracil [FU",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -7.078125,
            "text": "fluorouracil [FU] + irinotecan [IRN]), FOLFO",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -7.1171875,
            "text": "fluorouracil [FU] + irinotecan [IRN]), FOLFOX (FU + oxaliplatin), and IROX (IRN + oxaliplatin",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -7.1328125,
            "text": "fluorouracil [FU]",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -7.375,
            "text": "fluorouracil [FU] + irinotecan [IRN]), FOLFOX (FU + oxaliplatin)",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -7.3828125,
            "text": "fluorouracil [FU] + irinotecan [IRN])",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -7.3828125,
            "text": "fluorouracil [",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -7.44921875,
            "text": "fluorouracil [FU] + irinotecan [IR",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.75390625,
            "end_logit": 7.015625,
            "text": ". Three study arms were evaluated: IFL (fluorouracil",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.9765625,
            "end_logit": 7.015625,
            "text": "IFL (fluorouracil",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 7.015625,
            "text": "patients on the North American Gastrointestinal Intergroup N9741 study. Three study arms were evaluated: IFL (fluorouracil",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 7.015625,
            "text": ": Germline DNA was extracted from 520 patients on the North American Gastrointestinal Intergroup N9741 study. Three study arms were evaluated: IFL (fluorouracil",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.74609375,
            "end_logit": -5.65625,
            "text": "irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": -6.75390625,
            "end_logit": -5.65625,
            "text": ". Three study arms were evaluated: IFL (fluorouracil [FU] + irinotecan",
            "probability": 0.0
        }
    ],
    "602823e61cb411341a0000f9_4": [
        {
            "start_logit": 7.6484375,
            "end_logit": 7.875,
            "text": "capecitabine",
            "probability": 1.0
        },
        {
            "start_logit": 7.6484375,
            "end_logit": -6.39453125,
            "text": "capecitabine and developed HFS",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.75390625,
            "end_logit": 7.875,
            "text": "irinotecan/oxaliplatin) and irinotecan/cetuximab regimens. He was started on gemcitabine/capecitabine",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.6484375,
            "end_logit": -6.62109375,
            "text": "capecitabine and developed HFS again, which was controlled with aggressive skin care and vitamin B6",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.84765625,
            "end_logit": 7.875,
            "text": ". He was started on gemcitabine/capecitabine",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.94921875,
            "end_logit": 7.875,
            "text": "oxaliplatin) and irinotecan/cetuximab regimens. He was started on gemcitabine/capecitabine",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.17578125,
            "end_logit": 7.875,
            "text": "on gemcitabine/capecitabine",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.6484375,
            "end_logit": -6.984375,
            "text": "capecitabine and developed HFS again, which was controlled with aggressive skin care and vitamin B6 treatment.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.23046875,
            "end_logit": 7.875,
            "text": "(irinotecan/oxaliplatin) and irinotecan/cetuximab regimens. He was started on gemcitabine/capecitabine",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 7.875,
            "text": "/capecitabine",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.421875,
            "end_logit": 7.875,
            "text": "on IROX (irinotecan/oxaliplatin) and irinotecan/cetuximab regimens. He was started on gemcitabine/capecitabine",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.4375,
            "end_logit": 7.875,
            "text": "patient had progression of disease on IROX (irinotecan/oxaliplatin) and irinotecan/cetuximab regimens. He was started on gemcitabine/capecitabine",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 7.875,
            "text": "He was started on gemcitabine/capecitabine",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.6484375,
            "end_logit": -7.25390625,
            "text": "capecitabine and developed HFS again, which was controlled with aggressive skin care and vitamin B6 treatment",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.6484375,
            "end_logit": -7.28125,
            "text": "capecitabine and developed HFS again",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.6484375,
            "end_logit": -7.4921875,
            "text": "capecitabine and developed HFS again, which was controlled with aggressive skin care and vitamin",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.6484375,
            "end_logit": -7.5390625,
            "text": "capecitabine and developed HFS again, which was controlled with aggressive skin care and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.6484375,
            "end_logit": -7.578125,
            "text": "capecitabine and developed HFS again, which was controlled with aggressive skin care",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.6484375,
            "end_logit": -7.59375,
            "text": "capecitabine and developed HFS again, which was controlled",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.6484375,
            "end_logit": -7.62109375,
            "text": "capecitabine and developed HFS again, which",
            "probability": 1.7881393432617188e-07
        }
    ],
    "602823e61cb411341a0000f9_5": [
        {
            "start_logit": 8.234375,
            "end_logit": 7.30859375,
            "text": "irinotecan",
            "probability": 1.0
        },
        {
            "start_logit": 8.234375,
            "end_logit": -5.578125,
            "text": "irinotecan plus oxaliplatin",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": 8.234375,
            "end_logit": -6.79296875,
            "text": "irinotecan plus oxaliplatin (IROX) is more efficacious than irinotecan alone after fluoropyrimidine",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.234375,
            "end_logit": -7.2734375,
            "text": "irinotecan plus oxaliplatin (IROX) is more efficacious than irinotecan alone after fluoropyrimidine failure in advanced colorectal cancer.",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.234375,
            "end_logit": -7.54296875,
            "text": "irinotecan plus oxaliplatin (",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.234375,
            "end_logit": -7.5625,
            "text": "irinotecan plus oxaliplatin (IROX) is more efficacious than irinotecan alone after fluoropyrimidine failure",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.234375,
            "end_logit": -7.609375,
            "text": "irinotecan plus oxaliplatin (IROX)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.234375,
            "end_logit": -7.65625,
            "text": "irinotecan plus oxaliplatin (IROX",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.234375,
            "end_logit": -7.6796875,
            "text": "irinotecan plus oxaliplatin (IROX) is more efficacious than irinotecan",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.2265625,
            "end_logit": 7.30859375,
            "text": "that irinotecan",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 7.30859375,
            "text": "Haller et al. demonstrated that irinotecan",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.2265625,
            "end_logit": -5.578125,
            "text": "that irinotecan plus oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -7.3046875,
            "end_logit": -5.578125,
            "text": "oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -7.42578125,
            "end_logit": -5.578125,
            "text": "Haller et al. demonstrated that irinotecan plus oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -7.44921875,
            "end_logit": -5.578125,
            "text": "plus oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -7.2265625,
            "end_logit": -6.79296875,
            "text": "that irinotecan plus oxaliplatin (IROX) is more efficacious than irinotecan alone after fluoropyrimidine",
            "probability": 0.0
        },
        {
            "start_logit": -7.26953125,
            "end_logit": -6.79296875,
            "text": "fluoropyrimidine",
            "probability": 0.0
        },
        {
            "start_logit": -7.3046875,
            "end_logit": -6.79296875,
            "text": "oxaliplatin (IROX) is more efficacious than irinotecan alone after fluoropyrimidine",
            "probability": 0.0
        },
        {
            "start_logit": -6.88671875,
            "end_logit": -7.2734375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.42578125,
            "end_logit": -6.79296875,
            "text": "Haller et al. demonstrated that irinotecan plus oxaliplatin (IROX) is more efficacious than irinotecan alone after fluoropyrimidine",
            "probability": 0.0
        }
    ],
    "602823e61cb411341a0000f9_6": [
        {
            "start_logit": 8.21875,
            "end_logit": 7.359375,
            "text": "irinotecan",
            "probability": 1.0
        },
        {
            "start_logit": 8.21875,
            "end_logit": -3.251953125,
            "text": "irinotecan plus oxaliplatin (IROX) is superior to irinotecan alone in patients with metastatic colorectal cancer (CRC) previously treated with single-agent fluoropyrimidine",
            "probability": 2.467632293701172e-05
        },
        {
            "start_logit": 8.21875,
            "end_logit": -6.1640625,
            "text": "irinotecan plus oxaliplatin",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 8.21875,
            "end_logit": -7.6015625,
            "text": "irinotecan plus oxaliplatin (",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.03125,
            "end_logit": 7.359375,
            "text": "whether irinotecan",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 7.359375,
            "text": "determine whether irinotecan",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.53125,
            "end_logit": 7.359375,
            "text": "To determine whether irinotecan",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.5390625,
            "end_logit": -3.251953125,
            "text": "fluoropyrimidine",
            "probability": 0.0
        },
        {
            "start_logit": -2.5390625,
            "end_logit": -3.96484375,
            "text": "fluoropyrimidines",
            "probability": 0.0
        },
        {
            "start_logit": -2.5390625,
            "end_logit": -7.3125,
            "text": "fluoropyrimidines.",
            "probability": 0.0
        },
        {
            "start_logit": -7.01171875,
            "end_logit": -3.251953125,
            "text": "pyrimidine",
            "probability": 0.0
        },
        {
            "start_logit": -7.359375,
            "end_logit": -3.251953125,
            "text": "oxaliplatin (IROX) is superior to irinotecan alone in patients with metastatic colorectal cancer (CRC) previously treated with single-agent fluoropyrimidine",
            "probability": 0.0
        },
        {
            "start_logit": -7.3671875,
            "end_logit": -3.251953125,
            "text": "with single-agent fluoropyrimidine",
            "probability": 0.0
        },
        {
            "start_logit": -7.41015625,
            "end_logit": -3.251953125,
            "text": "plus oxaliplatin (IROX) is superior to irinotecan alone in patients with metastatic colorectal cancer (CRC) previously treated with single-agent fluoropyrimidine",
            "probability": 0.0
        },
        {
            "start_logit": -7.4296875,
            "end_logit": -3.251953125,
            "text": "to irinotecan alone in patients with metastatic colorectal cancer (CRC) previously treated with single-agent fluoropyrimidine",
            "probability": 0.0
        },
        {
            "start_logit": -7.4453125,
            "end_logit": -3.251953125,
            "text": "with metastatic colorectal cancer (CRC) previously treated with single-agent fluoropyrimidine",
            "probability": 0.0
        },
        {
            "start_logit": -7.47265625,
            "end_logit": -3.251953125,
            "text": "patients with metastatic colorectal cancer (CRC) previously treated with single-agent fluoropyrimidine",
            "probability": 0.0
        },
        {
            "start_logit": -7.49609375,
            "end_logit": -3.251953125,
            "text": "in patients with metastatic colorectal cancer (CRC) previously treated with single-agent fluoropyrimidine",
            "probability": 0.0
        },
        {
            "start_logit": -7.01171875,
            "end_logit": -3.96484375,
            "text": "pyrimidines",
            "probability": 0.0
        },
        {
            "start_logit": -7.359375,
            "end_logit": -3.96484375,
            "text": "oxaliplatin (IROX) is superior to irinotecan alone in patients with metastatic colorectal cancer (CRC) previously treated with single-agent fluoropyrimidines",
            "probability": 0.0
        }
    ],
    "602823e61cb411341a0000f9_7": [
        {
            "start_logit": 1.3681640625,
            "end_logit": 4.5625,
            "text": "raltitrexed",
            "probability": 0.9853515625
        },
        {
            "start_logit": 1.525390625,
            "end_logit": 0.016510009765625,
            "text": "capecitabine",
            "probability": 0.01226043701171875
        },
        {
            "start_logit": -5.84765625,
            "end_logit": 4.5625,
            "text": "ed",
            "probability": 0.0007252693176269531
        },
        {
            "start_logit": -6.27734375,
            "end_logit": 4.5625,
            "text": "irinotecan + oxaliplatin (IROX), raltitrexed",
            "probability": 0.0004718303680419922
        },
        {
            "start_logit": -6.6171875,
            "end_logit": 4.5625,
            "text": ", raltitrexed",
            "probability": 0.000335693359375
        },
        {
            "start_logit": -6.6640625,
            "end_logit": 4.5625,
            "text": "FF), irinotecan + oxaliplatin (IROX), raltitrexed",
            "probability": 0.0003204345703125
        },
        {
            "start_logit": -6.81640625,
            "end_logit": 4.5625,
            "text": "T), folinic acid + 5-fluorouracil (FF), irinotecan + oxaliplatin (IROX), raltitrexed",
            "probability": 0.0002739429473876953
        },
        {
            "start_logit": -6.9296875,
            "end_logit": 4.5625,
            "text": ", irinotecan + oxaliplatin (IROX), raltitrexed",
            "probability": 0.00024580955505371094
        },
        {
            "start_logit": 1.525390625,
            "end_logit": -6.47265625,
            "text": "capecitabine.",
            "probability": 1.8656253814697266e-05
        },
        {
            "start_logit": 1.3681640625,
            "end_logit": -6.453125,
            "text": "ral",
            "probability": 1.621246337890625e-05
        },
        {
            "start_logit": 1.3681640625,
            "end_logit": -6.74609375,
            "text": "raltitrex",
            "probability": 1.2040138244628906e-05
        },
        {
            "start_logit": 1.3681640625,
            "end_logit": -7.1328125,
            "text": "raltit",
            "probability": 8.225440979003906e-06
        },
        {
            "start_logit": -5.84765625,
            "end_logit": 0.016510009765625,
            "text": "ed + oxaliplatin (TOMOX), folinic acid + tegafur-uracil (FTU), raltitrexed, and capecitabine",
            "probability": 7.62939453125e-06
        },
        {
            "start_logit": -6.515625,
            "end_logit": 0.016510009765625,
            "text": "and capecitabine",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": -2.498046875,
            "end_logit": -4.26171875,
            "text": "folinic acid",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": -2.73046875,
            "end_logit": -4.1015625,
            "text": "gemcitabine (FFG), folinic acid + 5-fluorouracil + trimetrexate",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": -2.73046875,
            "end_logit": -4.23828125,
            "text": "gemcitabine",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": -2.73046875,
            "end_logit": -5.23046875,
            "text": "gemcitabine (FFG), folinic acid + 5-fluorouracil + trimetrex",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -2.498046875,
            "end_logit": -5.76171875,
            "text": "folinic acid + 5-fluorouracil",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -5.20703125,
            "end_logit": -4.1015625,
            "text": "trimetrexate",
            "probability": 2.384185791015625e-07
        }
    ],
    "602823e61cb411341a0000f9_8": [
        {
            "start_logit": 8.046875,
            "end_logit": 7.53515625,
            "text": "irinotecan",
            "probability": 1.0
        },
        {
            "start_logit": 8.046875,
            "end_logit": -3.85546875,
            "text": "irinotecan and oxaliplatin",
            "probability": 1.1324882507324219e-05
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.09375,
            "text": "irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer.",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.85546875,
            "end_logit": 7.53515625,
            "text": "Updated efficacy and toxicity analysis of irinotecan",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.37890625,
            "text": "irinotecan and oxaliplatin (IROX)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.39453125,
            "text": "irinotecan and oxaliplatin (",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.4296875,
            "text": "irinotecan and oxaliplatin (IROX) : intergroup trial N9741",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.6328125,
            "text": "irinotecan and oxaliplatin (IROX) :",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.671875,
            "text": "irinotecan and oxaliplatin (IROX) : intergroup trial N",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.6875,
            "text": "irinotecan and oxaliplatin (IROX",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.6953125,
            "text": "irinotecan and oxaliplatin (IROX) : intergroup trial N97",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.6953125,
            "text": "irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.1875,
            "end_logit": 7.53515625,
            "text": "efficacy and toxicity analysis of irinotecan",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.73828125,
            "text": "irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.75,
            "text": "irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.75390625,
            "text": "irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 7.53515625,
            "text": "of irinotecan",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 7.53515625,
            "text": "analysis of irinotecan",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -4.84375,
            "end_logit": -3.85546875,
            "text": "oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -6.85546875,
            "end_logit": -3.85546875,
            "text": "Updated efficacy and toxicity analysis of irinotecan and oxaliplatin",
            "probability": 0.0
        }
    ],
    "602823e61cb411341a0000f9_9": [
        {
            "start_logit": 8.171875,
            "end_logit": 6.953125,
            "text": "irinotecan",
            "probability": 1.0
        },
        {
            "start_logit": 8.171875,
            "end_logit": -3.33984375,
            "text": "irinotecan and oxaliplatin",
            "probability": 3.3736228942871094e-05
        },
        {
            "start_logit": 8.171875,
            "end_logit": -7.234375,
            "text": "irinotecan and oxaliplatin (IROX) as a salvage treatment for patients with gemcitabine- and 5-FU- refractory pancreatic cancer.",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.171875,
            "end_logit": -7.26171875,
            "text": "irinotecan and oxaliplatin (IROX) as a salvage treatment for patients with gemcitabine- and 5-FU- refractory pancreatic",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.171875,
            "end_logit": -7.40234375,
            "text": "irinotecan and oxaliplatin (",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.171875,
            "end_logit": -7.5703125,
            "text": "irinotecan and oxaliplatin (IROX)",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.171875,
            "end_logit": -7.58203125,
            "text": "irinotecan and oxaliplatin (IROX) as a salvage treatment for patients with gemcitabine- and 5-FU",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.171875,
            "end_logit": -7.6171875,
            "text": "irinotecan and oxaliplatin (IROX) as a salvage treatment for patients with gemcitabine- and 5-FU- refractory pancreatic cancer",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.171875,
            "end_logit": -7.6171875,
            "text": "irinotecan and oxaliplatin (IROX) as a salvage treatment",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.171875,
            "end_logit": -7.64453125,
            "text": "irinotecan and oxaliplatin (IROX) as",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.171875,
            "end_logit": -7.6953125,
            "text": "irinotecan and oxaliplatin (IROX",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.171875,
            "end_logit": -7.72265625,
            "text": "irinotecan and oxaliplatin (IROX) as a salvage treatment for patients with gemcitabine- and 5-FU-",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.171875,
            "end_logit": -7.73828125,
            "text": "irinotecan and oxaliplatin (IROX) as a",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.171875,
            "end_logit": -7.73828125,
            "text": "irinotecan and oxaliplatin (IROX) as a salvage treatment for patients with gemcitabine- and 5-FU- refractory",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.86328125,
            "end_logit": 6.953125,
            "text": "combination of irinotecan",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 6.953125,
            "text": "efficacy and safety of a combination of irinotecan",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.296875,
            "end_logit": 6.953125,
            "text": "a combination of irinotecan",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.3203125,
            "end_logit": 6.953125,
            "text": "of irinotecan",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.328125,
            "end_logit": 6.953125,
            "text": "evaluate the efficacy and safety of a combination of irinotecan",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 6.953125,
            "text": "the efficacy and safety of a combination of irinotecan",
            "probability": 1.7881393432617188e-07
        }
    ],
    "602823e61cb411341a0000f9_10": [
        {
            "start_logit": 6.34765625,
            "end_logit": 6.9375,
            "text": "gemcitabine",
            "probability": 1.0
        },
        {
            "start_logit": -5.671875,
            "end_logit": 6.9375,
            "text": "irinotecan/oxaliplatin) and irinotecan/cetuximab regimens. He was started on gemcitabine",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": -5.765625,
            "end_logit": 6.9375,
            "text": "cetuximab regimens. He was started on gemcitabine",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": -6.796875,
            "end_logit": 6.9375,
            "text": ". He was started on gemcitabine",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -6.8046875,
            "end_logit": 6.9375,
            "text": "on gemcitabine",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -6.875,
            "end_logit": 6.9375,
            "text": "(irinotecan/oxaliplatin) and irinotecan/cetuximab regimens. He was started on gemcitabine",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -7.0625,
            "end_logit": 6.9375,
            "text": "oxaliplatin) and irinotecan/cetuximab regimens. He was started on gemcitabine",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -7.28125,
            "end_logit": 6.9375,
            "text": "irinotecan/cetuximab regimens. He was started on gemcitabine",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 6.9375,
            "text": "and irinotecan/cetuximab regimens. He was started on gemcitabine",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 6.34765625,
            "end_logit": -6.78515625,
            "text": "gemcitabine/ca",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -7.4375,
            "end_logit": 6.9375,
            "text": "OX (irinotecan/oxaliplatin) and irinotecan/cetuximab regimens. He was started on gemcitabine",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -7.453125,
            "end_logit": 6.9375,
            "text": "He was started on gemcitabine",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 6.9375,
            "text": "/cetuximab regimens. He was started on gemcitabine",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 6.9375,
            "text": "IROX (irinotecan/oxaliplatin) and irinotecan/cetuximab regimens. He was started on gemcitabine",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 6.34765625,
            "end_logit": -7.296875,
            "text": "gemcitabine/",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -5.671875,
            "end_logit": -4.7421875,
            "text": "irinotecan/oxaliplatin) and irinotecan/cetuximab",
            "probability": 0.0
        },
        {
            "start_logit": -5.765625,
            "end_logit": -4.7421875,
            "text": "cetuximab",
            "probability": 0.0
        },
        {
            "start_logit": -5.671875,
            "end_logit": -5.6796875,
            "text": "irinotecan/oxaliplatin",
            "probability": 0.0
        },
        {
            "start_logit": -6.875,
            "end_logit": -4.7421875,
            "text": "(irinotecan/oxaliplatin) and irinotecan/cetuximab",
            "probability": 0.0
        },
        {
            "start_logit": -7.0625,
            "end_logit": -4.7421875,
            "text": "oxaliplatin) and irinotecan/cetuximab",
            "probability": 0.0
        }
    ],
    "602823e61cb411341a0000f9_11": [
        {
            "start_logit": 7.9609375,
            "end_logit": 7.64453125,
            "text": "fluorouracil",
            "probability": 1.0
        },
        {
            "start_logit": 7.9609375,
            "end_logit": -6.796875,
            "text": "fluorouracil, leucovorin, and oxaliplatin (FOLFOX) of 9.8% was better than with irinotecan",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.94921875,
            "end_logit": 7.64453125,
            "text": "with infusional fluorouracil",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.9609375,
            "end_logit": -7.31640625,
            "text": "fluorouracil, leucovorin, and oxaliplatin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.9609375,
            "end_logit": -7.3203125,
            "text": "fluorouracil, leucovorin, and oxaliplatin (FOLFOX",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.9609375,
            "end_logit": -7.3515625,
            "text": "fluorouracil, leucovorin, and oxaliplatin (FOLFOX) of 9.8% was better than with irinotecan plus bolus fluorouracil and leucovorin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.9609375,
            "end_logit": -7.37109375,
            "text": "fluorouracil, leucovorin, and oxaliplatin (FOLFOX) of 9.8% was better than with irinotecan plus bolus fluorouracil",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.9609375,
            "end_logit": -7.3984375,
            "text": "fluorouracil, leucovorin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.9609375,
            "end_logit": -7.48828125,
            "text": "fluorouracil, leucovorin, and oxaliplatin (FOLFO",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.9609375,
            "end_logit": -7.49609375,
            "text": "fluorouracil, leucovorin, and oxaliplatin (FOLFOX) of 9.8% was better than with irinotecan plus bolus fluorouracil and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.34375,
            "end_logit": 7.64453125,
            "text": "observed 5-year survival with infusional fluorouracil",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.37890625,
            "end_logit": 7.64453125,
            "text": "survival with infusional fluorouracil",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.421875,
            "end_logit": 7.64453125,
            "text": "infusional fluorouracil",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 7.64453125,
            "text": "year survival with infusional fluorouracil",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.7109375,
            "end_logit": -6.984375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.94921875,
            "end_logit": -6.796875,
            "text": "with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) of 9.8% was better than with irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": -7.05078125,
            "end_logit": -6.796875,
            "text": "with irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": -7.25390625,
            "end_logit": -6.796875,
            "text": "than with irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": -7.328125,
            "end_logit": -6.796875,
            "text": "irinotecan",
            "probability": 0.0
        },
        {
            "start_logit": -7.37890625,
            "end_logit": -6.796875,
            "text": "survival with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) of 9.8% was better than with irinotecan",
            "probability": 0.0
        }
    ],
    "602823e61cb411341a0000f9_12": [
        {
            "start_logit": 8.640625,
            "end_logit": 6.5078125,
            "text": "fluorouracil",
            "probability": 1.0
        },
        {
            "start_logit": 8.640625,
            "end_logit": -6.4296875,
            "text": "fluorouracil plus leucovorin (IFL, control combination), oxaliplatin and infused fluorouracil plus leucovorin (FOLFOX",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": 8.640625,
            "end_logit": -6.67578125,
            "text": "fluorouracil plus leucovorin",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 8.640625,
            "end_logit": -7.140625,
            "text": "fluorouracil plus leucovorin (IFL, control combination), oxaliplatin and infused fluorouracil plus leucovorin (FOLFOX), or irinotecan",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 8.640625,
            "end_logit": -7.28125,
            "text": "fluorouracil plus leucovorin (IFL, control combination), oxaliplatin and infused fluorouracil plus leucovorin (FOLFO",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 8.640625,
            "end_logit": -7.41796875,
            "text": "fluorouracil plus leucovorin (IFL, control combination), oxaliplatin and infused fluorouracil",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.640625,
            "end_logit": -7.44140625,
            "text": "fluorouracil plus leucovorin (IFL, control combination), oxaliplatin and infused fluorouracil plus leucovorin",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.640625,
            "end_logit": -7.47265625,
            "text": "fluorouracil plus leucovorin (",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 8.640625,
            "end_logit": -7.48046875,
            "text": "fluorouracil plus leucovorin (IFL, control combination)",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 8.640625,
            "end_logit": -7.49609375,
            "text": "fluorouracil plus leucov",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 8.640625,
            "end_logit": -7.53125,
            "text": "fluorouracil plus leucovorin (IFL, control combination), oxaliplatin and infused fluorouracil plus leucovorin (FOLFOX)",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.640625,
            "end_logit": -7.54296875,
            "text": "fluorouracil plus",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.640625,
            "end_logit": -7.5703125,
            "text": "fluorouracil plus leucovorin (IFL, control",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.640625,
            "end_logit": -7.578125,
            "text": "fluorouracil plus leucovorin (IFL",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.640625,
            "end_logit": -7.6015625,
            "text": "fluorouracil plus leucovorin (IFL, control combination), oxaliplatin and infused fluorouracil plus",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.69921875,
            "end_logit": 6.5078125,
            "text": "bolus fluorouracil",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.98046875,
            "end_logit": 6.5078125,
            "text": "irinotecan and bolus fluorouracil",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.0234375,
            "end_logit": 6.5078125,
            "text": "receive irinotecan and bolus fluorouracil",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.15625,
            "end_logit": 6.5078125,
            "text": ": Patients were concurrently randomly assigned to receive irinotecan and bolus fluorouracil",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1953125,
            "end_logit": 6.5078125,
            "text": "Patients were concurrently randomly assigned to receive irinotecan and bolus fluorouracil",
            "probability": 1.1920928955078125e-07
        }
    ],
    "602823e61cb411341a0000f9_13": [
        {
            "start_logit": 9.2578125,
            "end_logit": 9.5078125,
            "text": "oxalipltin",
            "probability": 1.0
        },
        {
            "start_logit": -0.79052734375,
            "end_logit": 9.5078125,
            "text": "tin",
            "probability": 4.3332576751708984e-05
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -1.2158203125,
            "text": "oxal",
            "probability": 2.193450927734375e-05
        },
        {
            "start_logit": -4.84765625,
            "end_logit": 9.5078125,
            "text": "irinotecan/oxalipltin",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.09765625,
            "end_logit": 9.5078125,
            "text": "ipltin",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -6.98046875,
            "text": "oxalipl",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.265625,
            "end_logit": 9.5078125,
            "text": "of irinotecan/oxalipltin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 9.5078125,
            "text": "/oxalipltin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37890625,
            "end_logit": 9.5078125,
            "text": "Pilot study of irinotecan/oxalipltin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.1484375,
            "text": "oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.19921875,
            "text": "oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.30859375,
            "text": "oxalipltin (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 9.5078125,
            "text": "study of irinotecan/oxalipltin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.3515625,
            "text": "oxalipltin (IROX) combination chemotherapy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.56640625,
            "text": "oxalipltin (IROX",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.59375,
            "text": "oxalipltin (IROX)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.6171875,
            "text": "oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.6171875,
            "text": "oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.6328125,
            "text": "oxalipltin (IR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.6640625,
            "text": "oxalipltin (IROX) combination chemotherapy for",
            "probability": 5.960464477539063e-08
        }
    ],
    "602823e61cb411341a0000f9_14": [
        {
            "start_logit": 2.658203125,
            "end_logit": -2.783203125,
            "text": "irinotecan",
            "probability": 0.54833984375
        },
        {
            "start_logit": 2.658203125,
            "end_logit": -3.375,
            "text": "irinotecan + FU/LV",
            "probability": 0.303466796875
        },
        {
            "start_logit": 2.658203125,
            "end_logit": -6.04296875,
            "text": "irinotecan + FU/LV), FOLFOX4 (oxaliplatin + FU/LV), and IROX (irinotecan + oxaliplatin",
            "probability": 0.02105712890625
        },
        {
            "start_logit": -0.81591796875,
            "end_logit": -2.783203125,
            "text": "IFL (irinotecan",
            "probability": 0.0169830322265625
        },
        {
            "start_logit": -0.81591796875,
            "end_logit": -3.03515625,
            "text": "IFL",
            "probability": 0.01320648193359375
        },
        {
            "start_logit": 2.658203125,
            "end_logit": -6.546875,
            "text": "irinotecan + FU/LV), FOLFOX4 (oxaliplatin + FU/LV), and IROX (irinotecan + oxaliplatin).",
            "probability": 0.01271820068359375
        },
        {
            "start_logit": 2.658203125,
            "end_logit": -6.7421875,
            "text": "irinotecan + FU/LV)",
            "probability": 0.01044464111328125
        },
        {
            "start_logit": -0.81591796875,
            "end_logit": -3.375,
            "text": "IFL (irinotecan + FU/LV",
            "probability": 0.0093994140625
        },
        {
            "start_logit": 2.658203125,
            "end_logit": -6.9765625,
            "text": "irinotecan + FU",
            "probability": 0.00826263427734375
        },
        {
            "start_logit": 2.658203125,
            "end_logit": -7.12109375,
            "text": "irinotecan + FU/LV), FOLFOX4 (oxaliplatin",
            "probability": 0.00717926025390625
        },
        {
            "start_logit": 2.658203125,
            "end_logit": -7.2109375,
            "text": "irinotecan + FU/LV), FOLFOX",
            "probability": 0.006534576416015625
        },
        {
            "start_logit": 2.658203125,
            "end_logit": -7.3515625,
            "text": "irinotecan + FU/LV), FOLFO",
            "probability": 0.005680084228515625
        },
        {
            "start_logit": 2.658203125,
            "end_logit": -7.36328125,
            "text": "irinotecan + FU/LV), FOLFOX4",
            "probability": 0.00563812255859375
        },
        {
            "start_logit": 2.658203125,
            "end_logit": -7.3828125,
            "text": "irinotecan + FU/",
            "probability": 0.00550079345703125
        },
        {
            "start_logit": 2.658203125,
            "end_logit": -7.4296875,
            "text": "irinotecan + FU/LV), FOLFOX4 (oxaliplatin + FU/LV), and IROX",
            "probability": 0.005252838134765625
        },
        {
            "start_logit": 2.658203125,
            "end_logit": -7.46484375,
            "text": "irinotecan + FU/LV), FOL",
            "probability": 0.005092620849609375
        },
        {
            "start_logit": 2.658203125,
            "end_logit": -7.48828125,
            "text": "irinotecan + FU/LV), FOLFOX4 (oxaliplatin + FU",
            "probability": 0.004970550537109375
        },
        {
            "start_logit": 2.658203125,
            "end_logit": -7.5234375,
            "text": "irinotecan + FU/LV), FOLFOX4 (oxaliplatin + FU/LV), and IROX (irinotecan + oxaliplatin)",
            "probability": 0.00478363037109375
        },
        {
            "start_logit": 2.658203125,
            "end_logit": -7.55859375,
            "text": "irinotecan + FU/LV), FOLFOX4 (oxaliplatin +",
            "probability": 0.004634857177734375
        },
        {
            "start_logit": -0.81591796875,
            "end_logit": -6.04296875,
            "text": "IFL (irinotecan + FU/LV), FOLFOX4 (oxaliplatin + FU/LV), and IROX (irinotecan + oxaliplatin",
            "probability": 0.000652313232421875
        }
    ],
    "602823e61cb411341a0000f9_15": [
        {
            "start_logit": -1.9716796875,
            "end_logit": -3.50390625,
            "text": "irinotecan/5-FU/leucovorin (LV) (IFL, n = 264), (F) oxaliplatin",
            "probability": 0.466796875
        },
        {
            "start_logit": -1.9716796875,
            "end_logit": -4.1953125,
            "text": "irinotecan",
            "probability": 0.2337646484375
        },
        {
            "start_logit": -1.9716796875,
            "end_logit": -5.546875,
            "text": "irinotecan/5-FU/leucovorin",
            "probability": 0.060516357421875
        },
        {
            "start_logit": -4.53515625,
            "end_logit": -3.4921875,
            "text": "FOLFOX4",
            "probability": 0.0362548828125
        },
        {
            "start_logit": -4.53515625,
            "end_logit": -3.705078125,
            "text": "FOLFOX",
            "probability": 0.0293731689453125
        },
        {
            "start_logit": -1.9716796875,
            "end_logit": -6.578125,
            "text": "irinotecan/5-FU/leucovorin (LV) (IFL",
            "probability": 0.02166748046875
        },
        {
            "start_logit": -5.140625,
            "end_logit": -3.50390625,
            "text": ") irinotecan/5-FU/leucovorin (LV) (IFL, n = 264), (F) oxaliplatin",
            "probability": 0.0197296142578125
        },
        {
            "start_logit": -1.9716796875,
            "end_logit": -6.70703125,
            "text": "irinotecan/5-FU",
            "probability": 0.0189666748046875
        },
        {
            "start_logit": -5.63671875,
            "end_logit": -3.4921875,
            "text": "oxaliplatin/5-FU/LV (FOLFOX4",
            "probability": 0.01214599609375
        },
        {
            "start_logit": -5.63671875,
            "end_logit": -3.50390625,
            "text": "oxaliplatin",
            "probability": 0.011962890625
        },
        {
            "start_logit": -1.9716796875,
            "end_logit": -7.19140625,
            "text": "irinotecan/5-FU/leucovorin (LV) (IFL, n = 264), (F) oxaliplatin/5-FU",
            "probability": 0.011688232421875
        },
        {
            "start_logit": -4.53515625,
            "end_logit": -4.71875,
            "text": "FOLFOX4, n = 267) and (G) oxaliplatin/irinotecan",
            "probability": 0.0107269287109375
        },
        {
            "start_logit": -5.140625,
            "end_logit": -4.1953125,
            "text": ") irinotecan",
            "probability": 0.0098419189453125
        },
        {
            "start_logit": -5.63671875,
            "end_logit": -3.705078125,
            "text": "oxaliplatin/5-FU/LV (FOLFOX",
            "probability": 0.009765625
        },
        {
            "start_logit": -5.921875,
            "end_logit": -3.4921875,
            "text": ", (F) oxaliplatin/5-FU/LV (FOLFOX4",
            "probability": 0.00910186767578125
        },
        {
            "start_logit": -5.921875,
            "end_logit": -3.50390625,
            "text": ", (F) oxaliplatin",
            "probability": 0.009033203125
        },
        {
            "start_logit": -4.8046875,
            "end_logit": -4.71875,
            "text": "irinotecan",
            "probability": 0.00815582275390625
        },
        {
            "start_logit": -5.921875,
            "end_logit": -3.705078125,
            "text": ", (F) oxaliplatin/5-FU/LV (FOLFOX",
            "probability": 0.0073699951171875
        },
        {
            "start_logit": -4.53515625,
            "end_logit": -5.10546875,
            "text": "FOLFOX4, n = 267) and (G) oxaliplatin/irinotecan (IROX, n = 265) were reviewed.",
            "probability": 0.007251739501953125
        },
        {
            "start_logit": -4.8046875,
            "end_logit": -5.10546875,
            "text": "irinotecan (IROX, n = 265) were reviewed.",
            "probability": 0.00556182861328125
        }
    ],
    "52ecf2dd98d023950500002e_1": [
        {
            "start_logit": 8.9296875,
            "end_logit": 9.25,
            "text": "rs7140952",
            "probability": 1.0
        },
        {
            "start_logit": -1.3759765625,
            "end_logit": 9.25,
            "text": "2",
            "probability": 3.319978713989258e-05
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -1.8876953125,
            "text": "rs",
            "probability": 1.4483928680419922e-05
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -4.6953125,
            "text": "rs7140952 polymorphism is associated with components of metabolic syndrome including blood pressure and central obesity",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -5.28515625,
            "text": "rs7140",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -5.30859375,
            "text": "rs714095",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -5.76171875,
            "end_logit": 9.25,
            "text": "7140952",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.171875,
            "end_logit": 9.25,
            "text": "However, rs7140952",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.66796875,
            "end_logit": 9.25,
            "text": ", rs7140952",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.99609375,
            "end_logit": 9.25,
            "text": "40952",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -6.8203125,
            "text": "rs7140952 polymorphism is associated with components of metabolic syndrome including blood pressure and central obesity.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 9.25,
            "text": "952",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.265625,
            "text": "rs7140952 polymorphism",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.515625,
            "text": "rs7140952 polymorphism is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.5234375,
            "text": "rs7140952 polymorphism is associated with components of metabolic syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.546875,
            "text": "rs7140952 polymorphism is associated with components of metabolic syndrome including",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3759765625,
            "end_logit": -4.6953125,
            "text": "2 polymorphism is associated with components of metabolic syndrome including blood pressure and central obesity",
            "probability": 0.0
        },
        {
            "start_logit": -6.171875,
            "end_logit": -1.8876953125,
            "text": "However, rs",
            "probability": 0.0
        },
        {
            "start_logit": -1.3759765625,
            "end_logit": -6.8203125,
            "text": "2 polymorphism is associated with components of metabolic syndrome including blood pressure and central obesity.",
            "probability": 0.0
        },
        {
            "start_logit": -6.66796875,
            "end_logit": -1.8876953125,
            "text": ", rs",
            "probability": 0.0
        }
    ],
    "52ecf2dd98d023950500002e_2": [
        {
            "start_logit": 8.5625,
            "end_logit": 9.328125,
            "text": "Ala92",
            "probability": 1.0
        },
        {
            "start_logit": -1.15625,
            "end_logit": 9.328125,
            "text": "92",
            "probability": 6.014108657836914e-05
        },
        {
            "start_logit": 8.5625,
            "end_logit": -2.515625,
            "text": "Ala",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": 8.5625,
            "end_logit": -6.17578125,
            "text": "Ala92 type 2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -6.71875,
            "text": "Ala92 type",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -6.81640625,
            "text": "Ala92 type 2 deiodinase",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -6.83984375,
            "text": "Ala92 type 2 deiodinase allele",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.0546875,
            "text": "Ala92 type 2 deiodinase allele increases risk for the development of hypertension.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.23828125,
            "text": "Ala92 type 2 deiod",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.5078125,
            "text": "Ala92 type 2 deiodinase allele increases risk for",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.53125,
            "text": "Ala92 type 2 deiodinase allele increases risk for the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.54296875,
            "text": "Ala92 type 2 deiodinase allele increases",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.56640625,
            "text": "Ala92 type 2 deiodinase allele increases risk",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.57421875,
            "text": "Ala92 type 2 deiodinase allele increases risk for the development of hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.58984375,
            "text": "Ala92 type 2 de",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.59765625,
            "text": "Ala92 type 2 deiodinase allele increases risk for the development of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.15625,
            "end_logit": -6.17578125,
            "text": "92 type 2",
            "probability": 0.0
        },
        {
            "start_logit": -1.15625,
            "end_logit": -6.71875,
            "text": "92 type",
            "probability": 0.0
        },
        {
            "start_logit": -1.15625,
            "end_logit": -6.81640625,
            "text": "92 type 2 deiodinase",
            "probability": 0.0
        },
        {
            "start_logit": -1.15625,
            "end_logit": -6.83984375,
            "text": "92 type 2 deiodinase allele",
            "probability": 0.0
        }
    ],
    "54fe09036ad7dcbc12000009_1": [
        {
            "start_logit": 8.5234375,
            "end_logit": 8.1484375,
            "text": "notothenoids",
            "probability": 1.0
        },
        {
            "start_logit": 8.5234375,
            "end_logit": -2.583984375,
            "text": "not",
            "probability": 2.1755695343017578e-05
        },
        {
            "start_logit": -2.9921875,
            "end_logit": 8.1484375,
            "text": "enoids",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": 8.5234375,
            "end_logit": -6.20703125,
            "text": "notothenoids,",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.5234375,
            "end_logit": -6.5390625,
            "text": "nototh",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.52734375,
            "end_logit": 8.1484375,
            "text": "othenoids",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.65234375,
            "end_logit": 8.1484375,
            "text": "Antarctic and Arctic notothenoids",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.7890625,
            "end_logit": 8.1484375,
            "text": "Arctic notothenoids",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.30859375,
            "end_logit": 8.1484375,
            "text": "glycoprotein of Antarctic and Arctic notothenoids",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 8.1484375,
            "text": "of Antarctic and Arctic notothenoids",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 8.1484375,
            "text": "the anti-freeze glycoprotein of Antarctic and Arctic notothenoids",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 8.1484375,
            "text": "anti-freeze glycoprotein of Antarctic and Arctic notothenoids",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 8.1484375,
            "text": "and Arctic notothenoids",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.7265625,
            "end_logit": 8.1484375,
            "text": "freeze glycoprotein of Antarctic and Arctic notothenoids",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.9921875,
            "end_logit": -6.20703125,
            "text": "enoids,",
            "probability": 0.0
        },
        {
            "start_logit": -6.65234375,
            "end_logit": -2.583984375,
            "text": "Antarctic and Arctic not",
            "probability": 0.0
        },
        {
            "start_logit": -6.7890625,
            "end_logit": -2.583984375,
            "text": "Arctic not",
            "probability": 0.0
        },
        {
            "start_logit": -7.30859375,
            "end_logit": -2.583984375,
            "text": "glycoprotein of Antarctic and Arctic not",
            "probability": 0.0
        },
        {
            "start_logit": -7.4140625,
            "end_logit": -2.583984375,
            "text": "of Antarctic and Arctic not",
            "probability": 0.0
        },
        {
            "start_logit": -7.46484375,
            "end_logit": -2.583984375,
            "text": "the anti-freeze glycoprotein of Antarctic and Arctic not",
            "probability": 0.0
        }
    ],
    "54fe09036ad7dcbc12000009_2": [
        {
            "start_logit": 4.33203125,
            "end_logit": 4.03515625,
            "text": "AFP I",
            "probability": 0.9990234375
        },
        {
            "start_logit": 4.33203125,
            "end_logit": -3.94921875,
            "text": "AFP",
            "probability": 0.00034046173095703125
        },
        {
            "start_logit": 4.33203125,
            "end_logit": -5.43359375,
            "text": "AFP I or AFP",
            "probability": 7.718801498413086e-05
        },
        {
            "start_logit": 4.33203125,
            "end_logit": -5.515625,
            "text": "AFP I or AFP III",
            "probability": 7.134675979614258e-05
        },
        {
            "start_logit": 4.33203125,
            "end_logit": -5.8203125,
            "text": "AFP I or",
            "probability": 5.221366882324219e-05
        },
        {
            "start_logit": -6.328125,
            "end_logit": 4.03515625,
            "text": "I",
            "probability": 2.3543834686279297e-05
        },
        {
            "start_logit": -6.328125,
            "end_logit": -5.43359375,
            "text": "I or AFP",
            "probability": 0.0
        },
        {
            "start_logit": -6.328125,
            "end_logit": -5.515625,
            "text": "I or AFP III",
            "probability": 0.0
        },
        {
            "start_logit": -6.328125,
            "end_logit": -5.8203125,
            "text": "I or",
            "probability": 0.0
        },
        {
            "start_logit": -7.39453125,
            "end_logit": -5.515625,
            "text": "III",
            "probability": 0.0
        },
        {
            "start_logit": -7.51953125,
            "end_logit": -5.43359375,
            "text": "AFP",
            "probability": 0.0
        },
        {
            "start_logit": -7.51953125,
            "end_logit": -5.515625,
            "text": "AFP III",
            "probability": 0.0
        }
    ],
    "54fe09036ad7dcbc12000009_3": [
        {
            "start_logit": 3.013671875,
            "end_logit": 4.5234375,
            "text": "III thermal hysteresis protein",
            "probability": 0.9990234375
        },
        {
            "start_logit": -4.40234375,
            "end_logit": 4.5234375,
            "text": "wild type III thermal hysteresis protein",
            "probability": 0.0005998611450195312
        },
        {
            "start_logit": -5.07421875,
            "end_logit": 4.5234375,
            "text": "thermal hysteresis protein",
            "probability": 0.00030517578125
        },
        {
            "start_logit": -6.08984375,
            "end_logit": 4.5234375,
            "text": "protein",
            "probability": 0.00011050701141357422
        },
        {
            "start_logit": -6.63671875,
            "end_logit": 4.5234375,
            "text": "hysteresis protein",
            "probability": 6.395578384399414e-05
        },
        {
            "start_logit": 3.013671875,
            "end_logit": -5.15625,
            "text": "III thermal hysteresis",
            "probability": 6.246566772460938e-05
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 4.5234375,
            "text": "type III thermal hysteresis protein",
            "probability": 2.5093555450439453e-05
        },
        {
            "start_logit": 3.013671875,
            "end_logit": -6.296875,
            "text": "III",
            "probability": 1.996755599975586e-05
        },
        {
            "start_logit": -4.40234375,
            "end_logit": -5.15625,
            "text": "wild type III thermal hysteresis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.07421875,
            "end_logit": -5.15625,
            "text": "thermal hysteresis",
            "probability": 0.0
        },
        {
            "start_logit": -4.40234375,
            "end_logit": -6.296875,
            "text": "wild type III",
            "probability": 0.0
        },
        {
            "start_logit": -4.40234375,
            "end_logit": -6.640625,
            "text": "wild type",
            "probability": 0.0
        },
        {
            "start_logit": -6.63671875,
            "end_logit": -5.15625,
            "text": "hysteresis",
            "probability": 0.0
        },
        {
            "start_logit": -7.58203125,
            "end_logit": -5.15625,
            "text": "type III thermal hysteresis",
            "probability": 0.0
        },
        {
            "start_logit": -7.58203125,
            "end_logit": -6.296875,
            "text": "type III",
            "probability": 0.0
        },
        {
            "start_logit": -7.58203125,
            "end_logit": -6.640625,
            "text": "type",
            "probability": 0.0
        }
    ],
    "54fe09036ad7dcbc12000009_4": [
        {
            "start_logit": 7.05859375,
            "end_logit": 5.32421875,
            "text": "anti-freeze protein-3",
            "probability": 1.0
        },
        {
            "start_logit": 7.05859375,
            "end_logit": -3.248046875,
            "text": "anti-freeze protein",
            "probability": 0.00018966197967529297
        },
        {
            "start_logit": 7.05859375,
            "end_logit": -4.2109375,
            "text": "anti",
            "probability": 7.253885269165039e-05
        },
        {
            "start_logit": -3.677734375,
            "end_logit": 5.32421875,
            "text": "3",
            "probability": 2.1755695343017578e-05
        },
        {
            "start_logit": -3.830078125,
            "end_logit": 5.32421875,
            "text": "skin-type anti-freeze protein-3",
            "probability": 1.8656253814697266e-05
        },
        {
            "start_logit": 7.05859375,
            "end_logit": -6.62109375,
            "text": "anti-freeze",
            "probability": 6.496906280517578e-06
        },
        {
            "start_logit": -6.09375,
            "end_logit": 5.32421875,
            "text": "-freeze protein-3",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -6.734375,
            "end_logit": 5.32421875,
            "text": "-3",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -6.88671875,
            "end_logit": 5.32421875,
            "text": "protein-3",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -6.9765625,
            "end_logit": 5.32421875,
            "text": "freeze protein-3",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 5.32421875,
            "text": "type anti-freeze protein-3",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.74609375,
            "end_logit": 5.32421875,
            "text": "-type anti-freeze protein-3",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -3.830078125,
            "end_logit": -3.248046875,
            "text": "skin-type anti-freeze protein",
            "probability": 0.0
        },
        {
            "start_logit": -3.830078125,
            "end_logit": -4.2109375,
            "text": "skin-type anti",
            "probability": 0.0
        },
        {
            "start_logit": -6.09375,
            "end_logit": -3.248046875,
            "text": "-freeze protein",
            "probability": 0.0
        },
        {
            "start_logit": -6.88671875,
            "end_logit": -3.248046875,
            "text": "protein",
            "probability": 0.0
        },
        {
            "start_logit": -6.9765625,
            "end_logit": -3.248046875,
            "text": "freeze protein",
            "probability": 0.0
        },
        {
            "start_logit": -3.830078125,
            "end_logit": -6.62109375,
            "text": "skin-type anti-freeze",
            "probability": 0.0
        },
        {
            "start_logit": -3.830078125,
            "end_logit": -6.71875,
            "text": "skin-type",
            "probability": 0.0
        },
        {
            "start_logit": -7.5078125,
            "end_logit": -3.248046875,
            "text": "type anti-freeze protein",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_1": [
        {
            "start_logit": 8.484375,
            "end_logit": 6.9140625,
            "text": "vincristine",
            "probability": 1.0
        },
        {
            "start_logit": 8.484375,
            "end_logit": -5.328125,
            "text": "vincristine, adriamycin and cyclophosphamide) alternating with ICE (ifosphamide, cisplatin",
            "probability": 4.827976226806641e-06
        },
        {
            "start_logit": 8.484375,
            "end_logit": -6.51953125,
            "text": "vincristine, adriamycin and cyclophosphamide) alternating with ICE (ifosphamide",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 8.484375,
            "end_logit": -6.640625,
            "text": "vincristine, adriamycin",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 8.484375,
            "end_logit": -6.703125,
            "text": "vincristine, adriamycin and cyclophosphamide",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 8.484375,
            "end_logit": -7.03125,
            "text": "vincristine, adriamycin and cyclophosphamide) alternating with ICE (ifosphamide, cisplatin and etoposide) for at least six cycles.",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.484375,
            "end_logit": -7.15625,
            "text": "vincristine, adriamycin and cyclophosphamide) alternating with ICE (ifosphamide, cisplatin and etoposide",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.484375,
            "end_logit": -7.26953125,
            "text": "vincristine, adriamycin and cyclophosphamide) alternating with ICE (ifosphamide, cisplatin and etoposide) for at least six cycles",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.484375,
            "end_logit": -7.29296875,
            "text": "vincristine, adriamycin and cyclophosphamide)",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.484375,
            "end_logit": -7.3828125,
            "text": "vincristine, adriamycin and cyclophosphamide) alternating with ICE (ifosphamide, cisplatin and etoposide) for",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.484375,
            "end_logit": -7.3828125,
            "text": "vincristine, adriamycin and cyclophosphamide) alternating with ICE (ifosphamide, cisplatin and etoposide)",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.484375,
            "end_logit": -7.484375,
            "text": "vincristine, adriamycin and cyclophosphamide) alternating with ICE (ifosph",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.484375,
            "end_logit": -7.49609375,
            "text": "vincristine, adriamycin and cyclophosphamide) alternating",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.484375,
            "end_logit": -7.50390625,
            "text": "vincristine, adriamycin and cyclophosphamide) alternating with ICE (ifosphamide, cisplatin and etoposide) for at least six",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.484375,
            "end_logit": -7.5234375,
            "text": "vincristine, adriamycin and cyclophosphamide) alternating with ICE (ifosphamide, cisplatin and",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.484375,
            "end_logit": -7.52734375,
            "text": "vincristine, adriamycin and cyclophosphamide) alternating with ICE",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.484375,
            "end_logit": -7.546875,
            "text": "vincristine, adriamycin and cyclophosphamide) alternating with ICE (ifosphamide, cisplatin and etoposide) for at",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.89453125,
            "end_logit": 6.9140625,
            "text": "VAC (vincristine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 6.9140625,
            "text": "and chemotherapy with VAC (vincristine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.96875,
            "end_logit": 6.9140625,
            "text": "by adjuvant radiotherapy to a dose of 46-50 Gy and chemotherapy with VAC (vincristine",
            "probability": 1.7881393432617188e-07
        }
    ],
    "60274ec61cb411341a0000e5_2": [
        {
            "start_logit": 9.234375,
            "end_logit": 9.40625,
            "text": "dactinomycin",
            "probability": 1.0
        },
        {
            "start_logit": -1.0810546875,
            "end_logit": 9.40625,
            "text": "omycin",
            "probability": 3.319978713989258e-05
        },
        {
            "start_logit": 9.234375,
            "end_logit": -1.2353515625,
            "text": "dac",
            "probability": 2.390146255493164e-05
        },
        {
            "start_logit": -4.94921875,
            "end_logit": 9.40625,
            "text": "vincristine, dactinomycin",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -6.67578125,
            "end_logit": 9.40625,
            "text": "tinomycin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.97265625,
            "end_logit": 9.40625,
            "text": "combination of vincristine, dactinomycin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1640625,
            "end_logit": 9.40625,
            "text": "adding doxorubicin (DOX) to the combination of vincristine, dactinomycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.04296875,
            "text": "dactinomycin, cyclophosphamide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 9.40625,
            "text": "of vincristine, dactinomycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3046875,
            "end_logit": 9.40625,
            "text": ", dactinomycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 9.40625,
            "text": ", adding doxorubicin (DOX) to the combination of vincristine, dactinomycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37890625,
            "end_logit": 9.40625,
            "text": "to the combination of vincristine, dactinomycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4375,
            "end_logit": 9.40625,
            "text": "For patients with localized, gross residual tumor, adding doxorubicin (DOX) to the combination of vincristine, dactinomycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 9.40625,
            "text": "patients with localized, gross residual tumor, adding doxorubicin (DOX) to the combination of vincristine, dactinomycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.37109375,
            "text": "dactin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.45703125,
            "text": "dactinomycin, cyclophosphamide (VAC), and XRT did not significantly improve survival in 39 patients (62% alive",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.515625,
            "text": "dactinomycin, cyclophosphamide (VAC), and XRT did not significantly improve survival in 39 patients (62% alive at",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.94921875,
            "end_logit": -1.2353515625,
            "text": "vincristine, dac",
            "probability": 0.0
        },
        {
            "start_logit": -1.0810546875,
            "end_logit": -7.04296875,
            "text": "omycin, cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -6.97265625,
            "end_logit": -1.2353515625,
            "text": "combination of vincristine, dac",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_3": [
        {
            "start_logit": 6.0703125,
            "end_logit": 6.17578125,
            "text": "cyclophosphamide",
            "probability": 1.0
        },
        {
            "start_logit": -3.41796875,
            "end_logit": 6.17578125,
            "text": "vincristine-dactinomycin (VA) or VA plus cyclophosphamide",
            "probability": 7.545948028564453e-05
        },
        {
            "start_logit": -6.50390625,
            "end_logit": 6.17578125,
            "text": "plus cyclophosphamide",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": 6.0703125,
            "end_logit": -6.640625,
            "text": "cyclophosphamide (VAC) +/- doxorubicin",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": -6.7890625,
            "end_logit": 6.17578125,
            "text": "with radiotherapy (XRT) and vincristine-dactinomycin (VA) or VA plus cyclophosphamide",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": -6.84375,
            "end_logit": 6.17578125,
            "text": "and vincristine-dactinomycin (VA) or VA plus cyclophosphamide",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": -6.89453125,
            "end_logit": 6.17578125,
            "text": "dactinomycin (VA) or VA plus cyclophosphamide",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": 6.0703125,
            "end_logit": -6.9765625,
            "text": "cyclophosphamide (VAC) +/- doxorubicin.",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -7.16796875,
            "end_logit": 6.17578125,
            "text": "-dactinomycin (VA) or VA plus cyclophosphamide",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -7.25390625,
            "end_logit": 6.17578125,
            "text": ", and IV were treated with radiotherapy (XRT) and vincristine-dactinomycin (VA) or VA plus cyclophosphamide",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": -7.28125,
            "end_logit": 6.17578125,
            "text": "were treated with radiotherapy (XRT) and vincristine-dactinomycin (VA) or VA plus cyclophosphamide",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -7.30078125,
            "end_logit": 6.17578125,
            "text": "tinomycin (VA) or VA plus cyclophosphamide",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -7.30859375,
            "end_logit": 6.17578125,
            "text": "clinical groups II, III, and IV were treated with radiotherapy (XRT) and vincristine-dactinomycin (VA) or VA plus cyclophosphamide",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -7.33984375,
            "end_logit": 6.17578125,
            "text": "and IV were treated with radiotherapy (XRT) and vincristine-dactinomycin (VA) or VA plus cyclophosphamide",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 6.0703125,
            "end_logit": -7.2734375,
            "text": "cyclophosphamide (",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 6.0703125,
            "end_logit": -7.29296875,
            "text": "cyclophosphamide (VAC) +/",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 6.0703125,
            "end_logit": -7.41015625,
            "text": "cyclophosphamide (VAC)",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -3.41796875,
            "end_logit": -2.783203125,
            "text": "vincristine-dactinomycin",
            "probability": 0.0
        },
        {
            "start_logit": -6.7890625,
            "end_logit": -2.783203125,
            "text": "with radiotherapy (XRT) and vincristine-dactinomycin",
            "probability": 0.0
        },
        {
            "start_logit": -6.84375,
            "end_logit": -2.783203125,
            "text": "and vincristine-dactinomycin",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_4": [
        {
            "start_logit": 8.75,
            "end_logit": 6.51171875,
            "text": "vincristine",
            "probability": 1.0
        },
        {
            "start_logit": 8.75,
            "end_logit": -5.63671875,
            "text": "vincristine, actinomycin, cyclophosphamide",
            "probability": 5.245208740234375e-06
        },
        {
            "start_logit": 8.75,
            "end_logit": -7.203125,
            "text": "vincristine, actinomycin",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 8.75,
            "end_logit": -7.33203125,
            "text": "vincristine, actinomycin, cyclophosphamide (VAC) regime, described in Kilman, et al. (1973) and Koop, et al",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.75,
            "end_logit": -7.38671875,
            "text": "vincristine, actinomycin, cyclophosphamide (VAC) regime",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.75,
            "end_logit": -7.50390625,
            "text": "vincristine, actinomycin, cyclophosphamide (",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 8.75,
            "end_logit": -7.53125,
            "text": "vincristine, actinomycin, cyclophosphamide (VAC) regime, described in Kilman, et al. (1973) and Koop, et",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.75,
            "end_logit": -7.53515625,
            "text": "vincristine, actinomycin, cyclophosphamide (VAC) regime, described in Kilman, et al",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.75,
            "end_logit": -7.5390625,
            "text": "vincristine, actinomycin, cyclophosphamide (VAC) regime, described in Kilman",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.75,
            "end_logit": -7.56640625,
            "text": "vincristine, actinomycin, cyclophosphamide (VAC) regime, described in Kilman, et al. (1973) and",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.75,
            "end_logit": -7.56640625,
            "text": "vincristine, actinomycin, cyclophosphamide (VAC) regime, described in Kilman, et al. (1973) and Koop, et al. (",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.75,
            "end_logit": -7.640625,
            "text": "vincristine, actinomycin, cyclophosphamide (VAC) regime, described in Kilman, et",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -6.77734375,
            "end_logit": 6.51171875,
            "text": ". This vincristine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 6.51171875,
            "text": "This vincristine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 6.51171875,
            "text": "chemotherapeutic regimen remains unchanged. This vincristine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 6.51171875,
            "text": ", the chemotherapeutic regimen remains unchanged. This vincristine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 6.51171875,
            "text": "Despite numerous molecular and biological studies during the past three decades, the chemotherapeutic regimen remains unchanged. This vincristine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.77734375,
            "end_logit": -5.63671875,
            "text": ". This vincristine, actinomycin, cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -6.92578125,
            "end_logit": -5.63671875,
            "text": "actinomycin, cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -6.9375,
            "end_logit": -5.63671875,
            "text": ", cyclophosphamide",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_5": [
        {
            "start_logit": 9.0390625,
            "end_logit": 9.25,
            "text": "mesna",
            "probability": 1.0
        },
        {
            "start_logit": -1.42578125,
            "end_logit": 9.25,
            "text": "na",
            "probability": 2.8848648071289062e-05
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -1.7294921875,
            "text": "mes",
            "probability": 1.722574234008789e-05
        },
        {
            "start_logit": -6.125,
            "end_logit": 9.25,
            "text": "vincristine, adriablastin, cyclophosphamide (VAC) and etoposide, ifosfamide with mesna",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -6.1875,
            "text": "mesna protection",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.65234375,
            "end_logit": 9.25,
            "text": "ifosfamide with mesna",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.81640625,
            "end_logit": 9.25,
            "text": "induction chemotherapy consisting of alternating vincristine, adriablastin, cyclophosphamide (VAC) and etoposide, ifosfamide with mesna",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.02734375,
            "end_logit": 9.25,
            "text": ", ifosfamide with mesna",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0625,
            "end_logit": 9.25,
            "text": "with mesna",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.23046875,
            "end_logit": 9.25,
            "text": "and etoposide, ifosfamide with mesna",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.265625,
            "end_logit": 9.25,
            "text": "alternating vincristine, adriablastin, cyclophosphamide (VAC) and etoposide, ifosfamide with mesna",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.26953125,
            "end_logit": 9.25,
            "text": "cyclophosphamide (VAC) and etoposide, ifosfamide with mesna",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 9.25,
            "text": "adriablastin, cyclophosphamide (VAC) and etoposide, ifosfamide with mesna",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -7.109375,
            "text": "mesna protection (IE), a local treatment modality was chosen based on tumor and patient characteristics.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -7.48828125,
            "text": "mesna protection (IE), a local treatment modality was chosen",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -7.625,
            "text": "mesna protection (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -7.64453125,
            "text": "mesna protection (IE), a local treatment modality",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -7.671875,
            "text": "mesna protection (IE), a local treatment modality was",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.42578125,
            "end_logit": -6.1875,
            "text": "na protection",
            "probability": 0.0
        },
        {
            "start_logit": -6.125,
            "end_logit": -1.7294921875,
            "text": "vincristine, adriablastin, cyclophosphamide (VAC) and etoposide, ifosfamide with mes",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_6": [
        {
            "start_logit": 8.2890625,
            "end_logit": 6.9140625,
            "text": "vincristine",
            "probability": 1.0
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -1.9658203125,
            "text": "vincristine (V), doxorubicin (A), cyclophosphamide (C) alternated with one cycle of 'VIAc': V, ifosfamide",
            "probability": 0.0001398324966430664
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -6.48046875,
            "text": "vincristine (V)",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -7.0078125,
            "text": "vincristine (V",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -7.0234375,
            "text": "vincristine (V), doxorubicin",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -7.2109375,
            "text": "vincristine (",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -7.21875,
            "text": "vincristine (V), doxorubicin (A), cyclophosphamide",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -7.26171875,
            "text": "vincristine (V), doxorubicin (A), cyclophosphamide (C) alternated with one cycle of 'VIAc': V, ifosfamide (",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -7.3203125,
            "text": "vincristine (V), doxorubicin (A), cyclophosphamide (C) alternate",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -7.40234375,
            "text": "vincristine (V), doxorubicin (A",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -7.421875,
            "text": "vincristine (V), doxorubicin (A), cyclophosphamide (C) alternated with one cycle of 'VIAc",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -7.42578125,
            "text": "vincristine (V), doxorubicin (A), cyclophosphamide (C) alternated",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -7.453125,
            "text": "vincristine (V), doxorubicin (",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.73046875,
            "end_logit": 6.9140625,
            "text": ": vincristine",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.21484375,
            "end_logit": 6.9140625,
            "text": "Induction chemotherapy consisted of two cycles of 'VAC': vincristine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 6.9140625,
            "text": "cycles of 'VAC': vincristine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.32421875,
            "end_logit": 6.9140625,
            "text": "two cycles of 'VAC': vincristine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.43359375,
            "end_logit": 6.9140625,
            "text": "of two cycles of 'VAC': vincristine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 6.9140625,
            "text": "': vincristine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.22265625,
            "end_logit": -1.9658203125,
            "text": "ifosfamide",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_7": [
        {
            "start_logit": 8.21875,
            "end_logit": 8.9453125,
            "text": "vindesine",
            "probability": 1.0
        },
        {
            "start_logit": 8.21875,
            "end_logit": 0.943359375,
            "text": "vindesine and cisplatin have shown the effectiveness of this drug in patients with Ewing's sarcoma (ES) who had relapsed during VAC (vincristine",
            "probability": 0.0003380775451660156
        },
        {
            "start_logit": -2.115234375,
            "end_logit": 8.9453125,
            "text": "ine",
            "probability": 3.272294998168945e-05
        },
        {
            "start_logit": 8.21875,
            "end_logit": -3.03125,
            "text": "vin",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": -5.37109375,
            "end_logit": 8.9453125,
            "text": "ifosfamide both alone and combined with vindesine",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 1.5400390625,
            "end_logit": 0.943359375,
            "text": "vincristine",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.640625,
            "end_logit": 8.9453125,
            "text": "desine",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.125,
            "end_logit": 8.9453125,
            "text": "with vindesine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.34375,
            "end_logit": 8.9453125,
            "text": "using ifosfamide both alone and combined with vindesine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 8.9453125,
            "text": "studies using ifosfamide both alone and combined with vindesine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 8.9453125,
            "text": "Phase II studies using ifosfamide both alone and combined with vindesine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.21875,
            "end_logit": -6.74609375,
            "text": "vindesine and cisplatin",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.21875,
            "end_logit": -7.44140625,
            "text": "vindesine and cisplatin have shown the effectiveness of this drug in patients with Ewing's sarcoma (ES) who had relapsed during VAC (vincristine,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.115234375,
            "end_logit": 0.943359375,
            "text": "ine and cisplatin have shown the effectiveness of this drug in patients with Ewing's sarcoma (ES) who had relapsed during VAC (vincristine",
            "probability": 0.0
        },
        {
            "start_logit": 1.5400390625,
            "end_logit": -5.64453125,
            "text": "vincristine, actinomycin, cyclosphosphamide)/VAd (vincristine, Adriamycin",
            "probability": 0.0
        },
        {
            "start_logit": 1.5400390625,
            "end_logit": -6.921875,
            "text": "vincristine, actinomycin, cyclosphosphamide)/VAd (vincristine, Adriamycin) therapy.",
            "probability": 0.0
        },
        {
            "start_logit": 1.5400390625,
            "end_logit": -7.16796875,
            "text": "vincristine, actinomycin, cyclosphosphamide)",
            "probability": 0.0
        },
        {
            "start_logit": 1.5400390625,
            "end_logit": -7.2109375,
            "text": "vincristine, actinomycin, cyclosphosphamide)/VAd (vincristine",
            "probability": 0.0
        },
        {
            "start_logit": -6.640625,
            "end_logit": 0.943359375,
            "text": "desine and cisplatin have shown the effectiveness of this drug in patients with Ewing's sarcoma (ES) who had relapsed during VAC (vincristine",
            "probability": 0.0
        },
        {
            "start_logit": 1.5400390625,
            "end_logit": -7.26171875,
            "text": "vincristine, actinomycin",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_8": [
        {
            "start_logit": 8.6875,
            "end_logit": 9.09375,
            "text": "vindesine",
            "probability": 1.0
        },
        {
            "start_logit": -1.849609375,
            "end_logit": 9.09375,
            "text": "ine",
            "probability": 2.6464462280273438e-05
        },
        {
            "start_logit": 8.6875,
            "end_logit": -1.4521484375,
            "text": "vindesine and cisplatin have shown the effectiveness of this drug in patients with Ewing's sarcoma (ES) who had relapsed during VAC (vincristine",
            "probability": 2.6285648345947266e-05
        },
        {
            "start_logit": 8.6875,
            "end_logit": -2.314453125,
            "text": "vin",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": -5.72265625,
            "end_logit": 9.09375,
            "text": "ifosfamide both alone and combined with vindesine",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.46875,
            "end_logit": 9.09375,
            "text": "desine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.17578125,
            "end_logit": 9.09375,
            "text": "with vindesine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6875,
            "end_logit": -6.7890625,
            "text": "vindesine and cisplatin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 9.09375,
            "text": "using ifosfamide both alone and combined with vindesine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.421875,
            "end_logit": 9.09375,
            "text": "Phase II studies using ifosfamide both alone and combined with vindesine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4375,
            "end_logit": 9.09375,
            "text": "studies using ifosfamide both alone and combined with vindesine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6875,
            "end_logit": -7.43359375,
            "text": "vindesine and cisplatin have shown the effectiveness of this drug in patients with Ewing's sarcoma (ES) who had relapsed during VAC (vincristine,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3642578125,
            "end_logit": -1.4521484375,
            "text": "vincristine",
            "probability": 0.0
        },
        {
            "start_logit": -1.849609375,
            "end_logit": -1.4521484375,
            "text": "ine and cisplatin have shown the effectiveness of this drug in patients with Ewing's sarcoma (ES) who had relapsed during VAC (vincristine",
            "probability": 0.0
        },
        {
            "start_logit": -1.3642578125,
            "end_logit": -5.5078125,
            "text": "vincristine, actinomycin, cyclosphosphamide)/VAd (vincristine, Adriamycin",
            "probability": 0.0
        },
        {
            "start_logit": -6.46875,
            "end_logit": -1.4521484375,
            "text": "desine and cisplatin have shown the effectiveness of this drug in patients with Ewing's sarcoma (ES) who had relapsed during VAC (vincristine",
            "probability": 0.0
        },
        {
            "start_logit": -5.72265625,
            "end_logit": -2.314453125,
            "text": "ifosfamide both alone and combined with vin",
            "probability": 0.0
        },
        {
            "start_logit": -1.3642578125,
            "end_logit": -7.140625,
            "text": "vincristine, actinomycin, cyclosphosphamide)/VAd (vincristine",
            "probability": 0.0
        },
        {
            "start_logit": -7.17578125,
            "end_logit": -1.4521484375,
            "text": "with vindesine and cisplatin have shown the effectiveness of this drug in patients with Ewing's sarcoma (ES) who had relapsed during VAC (vincristine",
            "probability": 0.0
        },
        {
            "start_logit": -1.849609375,
            "end_logit": -6.7890625,
            "text": "ine and cisplatin",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_9": [
        {
            "start_logit": 8.3203125,
            "end_logit": 8.828125,
            "text": "ifosfamide",
            "probability": 1.0
        },
        {
            "start_logit": -2.1796875,
            "end_logit": 8.828125,
            "text": "osfamide",
            "probability": 2.7298927307128906e-05
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -2.990234375,
            "text": "if",
            "probability": 7.271766662597656e-06
        },
        {
            "start_logit": -6.13671875,
            "end_logit": 8.828125,
            "text": "vincristine, adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, ifosfamide",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.63671875,
            "end_logit": 8.828125,
            "text": ", vincristine, adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, ifosfamide",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.2421875,
            "end_logit": 8.828125,
            "text": ", ifosfamide",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 8.828125,
            "text": ", cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, ifosfamide",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.33984375,
            "end_logit": 8.828125,
            "text": "adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, ifosfamide",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 8.828125,
            "text": "cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, ifosfamide",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 8.828125,
            "text": "trial, vincristine, adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, ifosfamide",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.52734375,
            "end_logit": 8.828125,
            "text": "randomised Euro-EWING99-R1 trial, vincristine, adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, ifosfamide",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -7.46875,
            "text": "ifosfamide (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -7.57421875,
            "text": "ifosfamide (VAI)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -7.63671875,
            "text": "ifosfamide (VAI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.13671875,
            "end_logit": -2.990234375,
            "text": "vincristine, adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, if",
            "probability": 0.0
        },
        {
            "start_logit": -6.63671875,
            "end_logit": -2.990234375,
            "text": ", vincristine, adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, if",
            "probability": 0.0
        },
        {
            "start_logit": -2.1796875,
            "end_logit": -7.46875,
            "text": "osfamide (",
            "probability": 0.0
        },
        {
            "start_logit": -2.1796875,
            "end_logit": -7.57421875,
            "text": "osfamide (VAI)",
            "probability": 0.0
        },
        {
            "start_logit": -2.1796875,
            "end_logit": -7.63671875,
            "text": "osfamide (VAI",
            "probability": 0.0
        },
        {
            "start_logit": -7.2421875,
            "end_logit": -2.990234375,
            "text": ", if",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_10": [
        {
            "start_logit": 8.203125,
            "end_logit": 7.3203125,
            "text": "Vincristine",
            "probability": 1.0
        },
        {
            "start_logit": 8.203125,
            "end_logit": -2.919921875,
            "text": "Vincristine, actinomycin D",
            "probability": 3.5643577575683594e-05
        },
        {
            "start_logit": 8.203125,
            "end_logit": -5.8671875,
            "text": "Vincristine, actinomycin D, and cyclophosphamide",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 8.203125,
            "end_logit": -7.42578125,
            "text": "Vincristine, actinomycin D, and cyclophosphamide (VAC) were",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.203125,
            "end_logit": -7.4765625,
            "text": "Vincristine, actinomycin D, and cyclophosphamide (VAC) were administered to 14",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.203125,
            "end_logit": -7.515625,
            "text": "Vincristine, actinomycin D, and cyclophosphamide (",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.203125,
            "end_logit": -7.55078125,
            "text": "Vincristine, actinomycin D, and cyclophosphamide (VAC)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.203125,
            "end_logit": -7.5703125,
            "text": "Vincristine, actinomycin D, and cyclophosphamide (VAC",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.203125,
            "end_logit": -7.67578125,
            "text": "Vincristine, actinomycin D, and cyclophosphamide (VAC) were administered",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.203125,
            "end_logit": -7.6875,
            "text": "Vincristine, actinomycin D, and cyclophosphamide (VAC) were administered to 14 patients with Ewing's sarcoma. The",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -3.150390625,
            "end_logit": -2.919921875,
            "text": "actinomycin D",
            "probability": 0.0
        },
        {
            "start_logit": -3.150390625,
            "end_logit": -5.8671875,
            "text": "actinomycin D, and cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -7.2421875,
            "end_logit": -2.919921875,
            "text": ", actinomycin D",
            "probability": 0.0
        },
        {
            "start_logit": -3.150390625,
            "end_logit": -7.42578125,
            "text": "actinomycin D, and cyclophosphamide (VAC) were",
            "probability": 0.0
        },
        {
            "start_logit": -3.150390625,
            "end_logit": -7.4765625,
            "text": "actinomycin D, and cyclophosphamide (VAC) were administered to 14",
            "probability": 0.0
        },
        {
            "start_logit": -3.150390625,
            "end_logit": -7.515625,
            "text": "actinomycin D, and cyclophosphamide (",
            "probability": 0.0
        },
        {
            "start_logit": -3.150390625,
            "end_logit": -7.55078125,
            "text": "actinomycin D, and cyclophosphamide (VAC)",
            "probability": 0.0
        },
        {
            "start_logit": -3.150390625,
            "end_logit": -7.5703125,
            "text": "actinomycin D, and cyclophosphamide (VAC",
            "probability": 0.0
        },
        {
            "start_logit": -3.150390625,
            "end_logit": -7.67578125,
            "text": "actinomycin D, and cyclophosphamide (VAC) were administered",
            "probability": 0.0
        },
        {
            "start_logit": -3.150390625,
            "end_logit": -7.6875,
            "text": "actinomycin D, and cyclophosphamide (VAC) were administered to 14 patients with Ewing's sarcoma. The",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_11": [
        {
            "start_logit": -1.59375,
            "end_logit": 0.145751953125,
            "text": "cyclophosphamide",
            "probability": 0.4013671875
        },
        {
            "start_logit": -0.853515625,
            "end_logit": -0.8994140625,
            "text": "vincristine, ifosfamide, doxorubicin, and etoposide (VIDE); vincristine, actinomycin D",
            "probability": 0.2958984375
        },
        {
            "start_logit": -2.462890625,
            "end_logit": 0.145751953125,
            "text": "actinomycin D, and ifosfamide (VAI); or vincristine, actinomycin D, and cyclophosphamide",
            "probability": 0.16845703125
        },
        {
            "start_logit": -2.462890625,
            "end_logit": -0.8994140625,
            "text": "actinomycin D",
            "probability": 0.059112548828125
        },
        {
            "start_logit": -0.853515625,
            "end_logit": -2.740234375,
            "text": "vincristine",
            "probability": 0.0469970703125
        },
        {
            "start_logit": -5.0703125,
            "end_logit": -0.8994140625,
            "text": "ifosfamide, doxorubicin, and etoposide (VIDE); vincristine, actinomycin D",
            "probability": 0.00437164306640625
        },
        {
            "start_logit": -6.40625,
            "end_logit": 0.145751953125,
            "text": "and cyclophosphamide",
            "probability": 0.0032596588134765625
        },
        {
            "start_logit": -0.853515625,
            "end_logit": -5.42578125,
            "text": "vincristine, ifosfamide",
            "probability": 0.0031986236572265625
        },
        {
            "start_logit": -6.42578125,
            "end_logit": 0.145751953125,
            "text": "vincristine, actinomycin D, and ifosfamide (VAI); or vincristine, actinomycin D, and cyclophosphamide",
            "probability": 0.0031986236572265625
        },
        {
            "start_logit": -6.640625,
            "end_logit": 0.145751953125,
            "text": "; vincristine, actinomycin D, and ifosfamide (VAI); or vincristine, actinomycin D, and cyclophosphamide",
            "probability": 0.0025787353515625
        },
        {
            "start_logit": -6.99609375,
            "end_logit": 0.145751953125,
            "text": "vincristine, actinomycin D, and cyclophosphamide",
            "probability": 0.00180816650390625
        },
        {
            "start_logit": -7.19921875,
            "end_logit": 0.145751953125,
            "text": "; or vincristine, actinomycin D, and cyclophosphamide",
            "probability": 0.0014753341674804688
        },
        {
            "start_logit": -7.21875,
            "end_logit": 0.145751953125,
            "text": ", and cyclophosphamide",
            "probability": 0.0014476776123046875
        },
        {
            "start_logit": -7.265625,
            "end_logit": 0.145751953125,
            "text": "or vincristine, actinomycin D, and cyclophosphamide",
            "probability": 0.00138092041015625
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 0.145751953125,
            "text": "VIDE); vincristine, actinomycin D, and ifosfamide (VAI); or vincristine, actinomycin D, and cyclophosphamide",
            "probability": 0.0012874603271484375
        },
        {
            "start_logit": -6.42578125,
            "end_logit": -0.8994140625,
            "text": "vincristine, actinomycin D",
            "probability": 0.0011272430419921875
        },
        {
            "start_logit": -0.853515625,
            "end_logit": -6.53515625,
            "text": "vincristine, ifosfamide, doxorubicin, and etoposide (VIDE); vincristine, actinomycin D, and ifosfamide (VAI); or vincristine",
            "probability": 0.0010547637939453125
        },
        {
            "start_logit": -6.640625,
            "end_logit": -0.8994140625,
            "text": "; vincristine, actinomycin D",
            "probability": 0.0009093284606933594
        },
        {
            "start_logit": -0.853515625,
            "end_logit": -6.73828125,
            "text": "vincristine, ifosfamide, doxorubicin, and etoposide (VIDE); vincristine",
            "probability": 0.0008611679077148438
        },
        {
            "start_logit": -6.78515625,
            "end_logit": -0.8994140625,
            "text": "of vincristine, ifosfamide, doxorubicin, and etoposide (VIDE); vincristine, actinomycin D",
            "probability": 0.0007867813110351562
        }
    ],
    "60274ec61cb411341a0000e5_12": [
        {
            "start_logit": 8.5625,
            "end_logit": 6.8515625,
            "text": "vincristine",
            "probability": 1.0
        },
        {
            "start_logit": 8.5625,
            "end_logit": -4.71484375,
            "text": "vincristine, actinomycin D",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": 8.5625,
            "end_logit": -6.21875,
            "text": "vincristine, actinomycin D, and cyclophosphamide) regimens with anthracyclines",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 8.5625,
            "end_logit": -6.328125,
            "text": "vincristine, actinomycin D, and cyclophosphamide",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 8.5625,
            "end_logit": -6.94140625,
            "text": "vincristine, actinomycin D, and cyclophosphamide) regimens with anthracycline",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.265625,
            "text": "vincristine, actinomycin D, and cyclophosphamide) regimens with anthracyclines resulted in better survival.",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.31640625,
            "text": "vincristine, actinomycin D, and cyclophosphamide) regimens with anthracyclines resulted in better survival. Presence of distant metastases",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.6171875,
            "text": "vincristine, actinomycin D, and cyclophosphamide) regimens with anthracyclines resulted",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.625,
            "text": "vincristine, actinomycin D, and cyclophosphamide) regimens with anthracyclines resulted in better survival. Presence of distant metastases, large primary tumors, and pelvic",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.64453125,
            "text": "vincristine, actinomycin D, and cyclophosphamide) regimens with anthracyclines resulted in better survival. Presence of distant metastases, large primary tumors, and pelvic localization were",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.6796875,
            "text": "vincristine, actinomycin D, and cyclophosphamide) regimens with anthracyclines resulted in better survival. Presence of distant metastases, large primary tumors",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.71484375,
            "text": "vincristine, actinomycin D, and cyclophosphamide) regimens with anthracyclines resulted in better survival. Presence of distant metastases, large primary tumors, and pelvic localization",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.7265625,
            "text": "vincristine, actinomycin D, and cyclophosphamide)",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.7578125,
            "text": "vincristine, actinomycin D, and cyclophosphamide) regimens with anthracyclines resulted in better survival",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.5625,
            "end_logit": -7.78125,
            "text": "vincristine, actinomycin D, and cyclophosphamide) regimens with anthracyclines resulted in better survival. Presence of distant metastases, large primary tumors, and",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.6484375,
            "end_logit": 6.8515625,
            "text": "(vincristine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.2109375,
            "end_logit": 6.8515625,
            "text": "VAC (vincristine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.4609375,
            "end_logit": -4.71484375,
            "text": "actinomycin D",
            "probability": 0.0
        },
        {
            "start_logit": -6.6484375,
            "end_logit": -4.71484375,
            "text": "(vincristine, actinomycin D",
            "probability": 0.0
        },
        {
            "start_logit": -5.4609375,
            "end_logit": -6.21875,
            "text": "actinomycin D, and cyclophosphamide) regimens with anthracyclines",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_13": [
        {
            "start_logit": 8.15625,
            "end_logit": 7.38671875,
            "text": "vincristine",
            "probability": 1.0
        },
        {
            "start_logit": 8.15625,
            "end_logit": -6.66015625,
            "text": "vincristine, actinomycin D, and cyclophosphamide",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.15625,
            "end_logit": -6.83984375,
            "text": "vincristine, actinomycin D",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.15625,
            "end_logit": -7.37109375,
            "text": "vincristine, actinomycin D, and cyclophosphamide (VAC) regiment as an adjuvant chemotherapy",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.15625,
            "end_logit": -7.4296875,
            "text": "vincristine, actinomycin D, and cyclophosphamide (VAC) regiment as an adjuvant chemotherapy.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.15625,
            "end_logit": -7.578125,
            "text": "vincristine, actinomycin D, and cyclophosphamide (VAC) regiment",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.15625,
            "end_logit": -7.62109375,
            "text": "vincristine, actinomycin D, and cyclophosphamide (",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.15625,
            "end_logit": -7.70703125,
            "text": "vincristine, actinomycin D, and cyclophosphamide (VAC) regiment as",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.94921875,
            "end_logit": 7.38671875,
            "text": "cycles of vincristine",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.15625,
            "end_logit": -7.73046875,
            "text": "vincristine, actinomycin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.19921875,
            "end_logit": 7.38671875,
            "text": "of vincristine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 7.38671875,
            "text": "by 6-12 cycles of vincristine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 7.38671875,
            "text": "wide excision with safe margin of 1-2 cm, followed by 6-12 cycles of vincristine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 7.38671875,
            "text": "sarcoma botryoides is wide excision with safe margin of 1-2 cm, followed by 6-12 cycles of vincristine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.40234375,
            "end_logit": 7.38671875,
            "text": "effective treatment for sarcoma botryoides is wide excision with safe margin of 1-2 cm, followed by 6-12 cycles of vincristine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.40625,
            "end_logit": 7.38671875,
            "text": "is wide excision with safe margin of 1-2 cm, followed by 6-12 cycles of vincristine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 7.38671875,
            "text": ", followed by 6-12 cycles of vincristine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.8984375,
            "end_logit": -6.66015625,
            "text": "actinomycin D, and cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -6.94921875,
            "end_logit": -6.66015625,
            "text": "cycles of vincristine, actinomycin D, and cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -6.8984375,
            "end_logit": -6.83984375,
            "text": "actinomycin D",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_14": [
        {
            "start_logit": 8.515625,
            "end_logit": 6.83984375,
            "text": "vincristine",
            "probability": 1.0
        },
        {
            "start_logit": 0.6923828125,
            "end_logit": 6.83984375,
            "text": "Cyclophosphamide dose escalation in combination with vincristine",
            "probability": 0.00039839744567871094
        },
        {
            "start_logit": 8.515625,
            "end_logit": -4.62890625,
            "text": "vincristine and actinomycin-D",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": 8.515625,
            "end_logit": -6.859375,
            "text": "vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response.",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 8.515625,
            "end_logit": -6.87109375,
            "text": "vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.26171875,
            "text": "vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.3984375,
            "text": "vincristine and actinomycin-D (VAC) in gross residual sarcoma",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.3984375,
            "text": "vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.41015625,
            "text": "vincristine and actinomycin-D (VAC) in gross residual sarcoma. A",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.42578125,
            "text": "vincristine and actinomycin-D (",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.54296875,
            "text": "vincristine and actinomycin-D (VAC) in gross residual",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.578125,
            "text": "vincristine and actinomycin-D (VAC)",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.59765625,
            "text": "vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.59765625,
            "text": "vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.6484375,
            "text": "vincristine and actinomycin-",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.65625,
            "text": "vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 0.6923828125,
            "end_logit": -0.29150390625,
            "text": "Cyclophosphamide",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.77734375,
            "end_logit": 6.83984375,
            "text": "with vincristine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.2890625,
            "end_logit": 6.83984375,
            "text": "dose escalation in combination with vincristine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 6.83984375,
            "text": "combination with vincristine",
            "probability": 1.1920928955078125e-07
        }
    ],
    "60274ec61cb411341a0000e5_15": [
        {
            "start_logit": 8.015625,
            "end_logit": 7.4921875,
            "text": "vincristine",
            "probability": 1.0
        },
        {
            "start_logit": 8.015625,
            "end_logit": -5.89453125,
            "text": "vincristine (Vcr)",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 8.015625,
            "end_logit": -6.6328125,
            "text": "vincristine (Vcr) and actinomycin-D",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -6.6875,
            "text": "vincristine (Vc",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -6.75,
            "text": "vincristine (Vcr",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -6.984375,
            "text": "vincristine (Vcr) and actinomycin-D (Amd",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.53515625,
            "end_logit": 7.4921875,
            "text": "with vincristine",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -7.3828125,
            "text": "vincristine (Vcr) and actinomycin-D (Amd), known as VAC, to establish a Cyc dose with myelotoxicity",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -7.3984375,
            "text": "vincristine (Vcr) and actinomycin",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -7.4765625,
            "text": "vincristine (",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.015625,
            "end_logit": -7.4765625,
            "text": "vincristine (Vcr) and actinomycin-D (Amd)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.171875,
            "end_logit": 7.4921875,
            "text": "escalating-dose cyclophosphamide (Cyc) pilot without hematopoietic growth factor (HGF) support in combination with vincristine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.19921875,
            "end_logit": 7.4921875,
            "text": "Intergroup Rhabdomyosarcoma Study (IRS) initiated an escalating-dose cyclophosphamide (Cyc) pilot without hematopoietic growth factor (HGF) support in combination with vincristine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 7.4921875,
            "text": "an escalating-dose cyclophosphamide (Cyc) pilot without hematopoietic growth factor (HGF) support in combination with vincristine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 7.4921875,
            "text": "without hematopoietic growth factor (HGF) support in combination with vincristine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 7.4921875,
            "text": "cyclophosphamide (Cyc) pilot without hematopoietic growth factor (HGF) support in combination with vincristine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.30078125,
            "end_logit": -4.81640625,
            "text": "ifosfamide",
            "probability": 0.0
        },
        {
            "start_logit": -7.234375,
            "end_logit": -4.81640625,
            "text": "myelotoxicity comparable to an ifosfamide",
            "probability": 0.0
        },
        {
            "start_logit": -7.30859375,
            "end_logit": -4.81640625,
            "text": "dose with myelotoxicity comparable to an ifosfamide",
            "probability": 0.0
        },
        {
            "start_logit": -7.34765625,
            "end_logit": -4.81640625,
            "text": "a Cyc dose with myelotoxicity comparable to an ifosfamide",
            "probability": 0.0
        }
    ],
    "60274ec61cb411341a0000e5_16": [
        {
            "start_logit": 9.3671875,
            "end_logit": 9.453125,
            "text": "dactinomycin",
            "probability": 1.0
        },
        {
            "start_logit": -0.939453125,
            "end_logit": 9.453125,
            "text": "omycin",
            "probability": 3.3736228942871094e-05
        },
        {
            "start_logit": 9.3671875,
            "end_logit": -0.86376953125,
            "text": "dac",
            "probability": 3.319978713989258e-05
        },
        {
            "start_logit": -6.01953125,
            "end_logit": 9.453125,
            "text": "vincristine/dactinomycin",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.31640625,
            "end_logit": 9.453125,
            "text": "ifosfamide (VP16/IFOS) cycles, alternating with vincristine/dactinomycin",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.6328125,
            "end_logit": 9.453125,
            "text": "tinomycin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.6484375,
            "end_logit": 9.453125,
            "text": "with vincristine/dactinomycin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3671875,
            "end_logit": -6.890625,
            "text": "dactinomycin/cyclophosphamide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3671875,
            "end_logit": -7.0859375,
            "text": "dactin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3671875,
            "end_logit": -7.15234375,
            "text": "dactinomycin/cyclophosphamide (VAC) cycles.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.23828125,
            "end_logit": 9.453125,
            "text": "etoposide/ifosfamide (VP16/IFOS) cycles, alternating with vincristine/dactinomycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 9.453125,
            "text": "OS) cycles, alternating with vincristine/dactinomycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 9.453125,
            "text": "of etoposide/ifosfamide (VP16/IFOS) cycles, alternating with vincristine/dactinomycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 9.453125,
            "text": "Standard chemotherapy consisted of etoposide/ifosfamide (VP16/IFOS) cycles, alternating with vincristine/dactinomycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.390625,
            "end_logit": 9.453125,
            "text": "/dactinomycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 9.453125,
            "text": "alternating with vincristine/dactinomycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.484375,
            "end_logit": 9.453125,
            "text": "VP16/IFOS) cycles, alternating with vincristine/dactinomycin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3671875,
            "end_logit": -7.55078125,
            "text": "dactinomycin/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3671875,
            "end_logit": -7.6015625,
            "text": "dactinomycin/cyclophosphamide (VAC) cycles",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3671875,
            "end_logit": -7.60546875,
            "text": "dactinomycin/cyclophosphamide (",
            "probability": 5.960464477539063e-08
        }
    ],
    "60274ec61cb411341a0000e5_17": [
        {
            "start_logit": 3.279296875,
            "end_logit": 5.828125,
            "text": "dactinomycin",
            "probability": 0.97607421875
        },
        {
            "start_logit": -0.490478515625,
            "end_logit": 5.828125,
            "text": "adriamycin (ADR) or bilateral pulmonary radiotherapy (RT) to vincristine, dactinomycin",
            "probability": 0.022430419921875
        },
        {
            "start_logit": -4.33984375,
            "end_logit": 5.828125,
            "text": "vincristine, dactinomycin",
            "probability": 0.00047850608825683594
        },
        {
            "start_logit": -5.63671875,
            "end_logit": 5.828125,
            "text": "omycin",
            "probability": 0.00013017654418945312
        },
        {
            "start_logit": -6.58984375,
            "end_logit": 5.828125,
            "text": "if the addition of adriamycin (ADR) or bilateral pulmonary radiotherapy (RT) to vincristine, dactinomycin",
            "probability": 5.0187110900878906e-05
        },
        {
            "start_logit": -6.875,
            "end_logit": 5.828125,
            "text": "of adriamycin (ADR) or bilateral pulmonary radiotherapy (RT) to vincristine, dactinomycin",
            "probability": 3.790855407714844e-05
        },
        {
            "start_logit": -6.98828125,
            "end_logit": 5.828125,
            "text": ", dactinomycin",
            "probability": 3.3974647521972656e-05
        },
        {
            "start_logit": -7.05859375,
            "end_logit": 5.828125,
            "text": "tinomycin",
            "probability": 3.141164779663086e-05
        },
        {
            "start_logit": -7.0859375,
            "end_logit": 5.828125,
            "text": "to vincristine, dactinomycin",
            "probability": 3.069639205932617e-05
        },
        {
            "start_logit": -7.1328125,
            "end_logit": 5.828125,
            "text": "determine if the addition of adriamycin (ADR) or bilateral pulmonary radiotherapy (RT) to vincristine, dactinomycin",
            "probability": 2.9265880584716797e-05
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 5.828125,
            "text": "pulmonary radiotherapy (RT) to vincristine, dactinomycin",
            "probability": 2.777576446533203e-05
        },
        {
            "start_logit": -7.26953125,
            "end_logit": 5.828125,
            "text": "addition of adriamycin (ADR) or bilateral pulmonary radiotherapy (RT) to vincristine, dactinomycin",
            "probability": 2.562999725341797e-05
        },
        {
            "start_logit": -7.30078125,
            "end_logit": 5.828125,
            "text": "the addition of adriamycin (ADR) or bilateral pulmonary radiotherapy (RT) to vincristine, dactinomycin",
            "probability": 2.485513687133789e-05
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 5.828125,
            "text": "to determine if the addition of adriamycin (ADR) or bilateral pulmonary radiotherapy (RT) to vincristine, dactinomycin",
            "probability": 2.4497509002685547e-05
        },
        {
            "start_logit": -0.490478515625,
            "end_logit": -2.251953125,
            "text": "adriamycin",
            "probability": 6.973743438720703e-06
        },
        {
            "start_logit": 3.279296875,
            "end_logit": -6.546875,
            "text": "dactinomycin, and cyclophosphamide",
            "probability": 4.112720489501953e-06
        },
        {
            "start_logit": 3.279296875,
            "end_logit": -6.96875,
            "text": "dactinomycin, and cyclophosphamide (VAC therapy) would improve survival and reduce local recurrences and metastases.",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": 3.279296875,
            "end_logit": -7.13671875,
            "text": "dac",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": 3.279296875,
            "end_logit": -7.36328125,
            "text": "dactinomycin, and cyclophosphamide (VAC therapy) would improve survival and reduce local recurrences and metastases",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 3.279296875,
            "end_logit": -7.515625,
            "text": "dactin",
            "probability": 1.5497207641601562e-06
        }
    ],
    "60274ec61cb411341a0000e5_18": [
        {
            "start_logit": 8.265625,
            "end_logit": 7.25390625,
            "text": "vincristine",
            "probability": 1.0
        },
        {
            "start_logit": 8.265625,
            "end_logit": -6.59765625,
            "text": "vincristine, actinomycin-D, and cyclophosphamide",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.265625,
            "end_logit": -7.39453125,
            "text": "vincristine, actinomycin-D",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.265625,
            "end_logit": -7.53515625,
            "text": "vincristine, actinomycin-D, and cyclophosphamide (VAC) by Dr. Ruth Heyn",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.265625,
            "end_logit": -7.59765625,
            "text": "vincristine, actinomycin-D, and cyclophosphamide (VAC) by Dr. Ruth Heyn, Dr. Harold Ma",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.265625,
            "end_logit": -7.59765625,
            "text": "vincristine, actinomycin-D, and cyclophosphamide (",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.265625,
            "end_logit": -7.640625,
            "text": "vincristine, actinomycin-D, and cyclophosphamide (VAC) by Dr. Ruth He",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.265625,
            "end_logit": -7.66015625,
            "text": "vincristine, actinomycin-D, and cyclophosphamide (VAC) by",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.10546875,
            "end_logit": 7.25390625,
            "text": "Taking the lead from the use of vincristine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.359375,
            "end_logit": 7.25390625,
            "text": "of vincristine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 7.25390625,
            "text": "lead from the use of vincristine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.390625,
            "end_logit": 7.25390625,
            "text": "use of vincristine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.10546875,
            "end_logit": -6.59765625,
            "text": "Taking the lead from the use of vincristine, actinomycin-D, and cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -7.20703125,
            "end_logit": -6.59765625,
            "text": "actinomycin-D, and cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -7.359375,
            "end_logit": -6.59765625,
            "text": "of vincristine, actinomycin-D, and cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -7.37109375,
            "end_logit": -6.59765625,
            "text": "lead from the use of vincristine, actinomycin-D, and cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -6.8203125,
            "end_logit": -7.16015625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.390625,
            "end_logit": -6.59765625,
            "text": "and cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -7.390625,
            "end_logit": -6.59765625,
            "text": "use of vincristine, actinomycin-D, and cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -7.41015625,
            "end_logit": -6.59765625,
            "text": ", and cyclophosphamide",
            "probability": 0.0
        }
    ],
    "5c851c2675a4a5d219000006_1": [
        {
            "start_logit": 9.109375,
            "end_logit": 9.265625,
            "text": "actoxumab",
            "probability": 1.0
        },
        {
            "start_logit": -1.4990234375,
            "end_logit": 9.265625,
            "text": "umab",
            "probability": 2.467632293701172e-05
        },
        {
            "start_logit": 9.109375,
            "end_logit": -1.5810546875,
            "text": "act",
            "probability": 1.9550323486328125e-05
        },
        {
            "start_logit": -4.79296875,
            "end_logit": 9.265625,
            "text": "antibodies actoxumab",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -5.8828125,
            "end_logit": 9.265625,
            "text": "oxumab",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.08203125,
            "text": "actoxumab and bezlotoxumab",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.90625,
            "end_logit": 9.265625,
            "text": ". The antitoxin antibodies actoxumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.90234375,
            "text": "actoxumab and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.9609375,
            "text": "actoxumab and bezlot",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1328125,
            "end_logit": 9.265625,
            "text": "antitoxin antibodies actoxumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.08203125,
            "text": "actoxumab and bezlotox",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.171875,
            "text": "actoxumab and be",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 9.265625,
            "text": "The antitoxin antibodies actoxumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.3203125,
            "text": "actoxumab and bezlotoxumab bind to and neutralize TcdA and TcdB, respectively.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 9.265625,
            "text": "pathology associated with C. difficile infection (CDI). The antitoxin antibodies actoxumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.359375,
            "text": "actoxumab and bezlotoxumab bind",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.40234375,
            "text": "actoxumab and bez",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.55078125,
            "text": "actoxumab and bezlotoxumab bind to and neutral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.58203125,
            "text": "actoxumab and bezlotoxumab bind to and neutralize",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.79296875,
            "end_logit": -1.5810546875,
            "text": "antibodies act",
            "probability": 0.0
        }
    ],
    "5c851c2675a4a5d219000006_2": [
        {
            "start_logit": 9.1953125,
            "end_logit": 9.1953125,
            "text": "Bezlotoxumab",
            "probability": 1.0
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -1.41015625,
            "text": "Be",
            "probability": 2.467632293701172e-05
        },
        {
            "start_logit": -1.697265625,
            "end_logit": 9.1953125,
            "text": "umab",
            "probability": 1.8656253814697266e-05
        },
        {
            "start_logit": -5.625,
            "end_logit": 9.1953125,
            "text": "zlotoxumab",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.48046875,
            "end_logit": 9.1953125,
            "text": "lotoxumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.859375,
            "end_logit": 9.1953125,
            "text": "oxumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -6.94140625,
            "text": "Bezlotox",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.22265625,
            "text": "Bezlotoxumab was recently approved by the FDA for reducing the recurrence of CDI.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.37890625,
            "text": "Bezlotoxumab was",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.421875,
            "text": "Bezlotoxumab was recently approved by the FDA for reducing the recurrence of CDI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.49609375,
            "text": "Bezlotoxumab was recently approved",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.546875,
            "text": "Bezlotoxumab was recently",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.55859375,
            "text": "Bezlot",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.5703125,
            "text": "Bezlotoxumab was recently approved by the FDA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.578125,
            "text": "Bezlotoxumab was recently approved by the FDA for",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.5859375,
            "text": "Bezlotoxumab was recently approved by",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.697265625,
            "end_logit": -7.22265625,
            "text": "umab was recently approved by the FDA for reducing the recurrence of CDI.",
            "probability": 0.0
        },
        {
            "start_logit": -1.697265625,
            "end_logit": -7.37890625,
            "text": "umab was",
            "probability": 0.0
        },
        {
            "start_logit": -1.697265625,
            "end_logit": -7.421875,
            "text": "umab was recently approved by the FDA for reducing the recurrence of CDI",
            "probability": 0.0
        },
        {
            "start_logit": -1.697265625,
            "end_logit": -7.49609375,
            "text": "umab was recently approved",
            "probability": 0.0
        }
    ],
    "5c851c2675a4a5d219000006_3": [
        {
            "start_logit": 9.1171875,
            "end_logit": 9.2265625,
            "text": "actoxumab",
            "probability": 1.0
        },
        {
            "start_logit": -1.623046875,
            "end_logit": 9.2265625,
            "text": "umab",
            "probability": 2.1636486053466797e-05
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -1.59375,
            "text": "act",
            "probability": 1.996755599975586e-05
        },
        {
            "start_logit": -6.09765625,
            "end_logit": 9.2265625,
            "text": "oxumab",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.80859375,
            "text": "actoxumab and bezlotoxumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.07421875,
            "end_logit": 9.2265625,
            "text": "antibodies actoxumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.375,
            "end_logit": 9.2265625,
            "text": "antitoxin antibodies actoxumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.33203125,
            "text": "actoxumab and bezlotox",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.34765625,
            "text": "actoxumab and bezlot",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.38671875,
            "text": "actoxumab and bezlotoxumab bind to and neutralize TcdA and TcdB, respectively.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 9.2265625,
            "text": "The antitoxin antibodies actoxumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.48046875,
            "text": "actoxumab and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.51171875,
            "text": "actoxumab and be",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.58984375,
            "text": "actoxumab and bez",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.59375,
            "text": "actoxumab and bezlotoxumab bind to and neutralize TcdA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.6171875,
            "text": "actoxumab and bezlotoxumab bind to and neutralize TcdA and TcdB",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.62890625,
            "text": "actoxumab and bezlotoxumab bind",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.6484375,
            "text": "actoxumab and bezlotoxumab bind to and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.623046875,
            "end_logit": -6.80859375,
            "text": "umab and bezlotoxumab",
            "probability": 0.0
        },
        {
            "start_logit": -7.07421875,
            "end_logit": -1.59375,
            "text": "antibodies act",
            "probability": 0.0
        }
    ],
    "5c851c2675a4a5d219000006_4": [
        {
            "start_logit": 9.0703125,
            "end_logit": 9.25,
            "text": "actoxumab",
            "probability": 1.0
        },
        {
            "start_logit": -1.560546875,
            "end_logit": 9.25,
            "text": "umab",
            "probability": 2.4318695068359375e-05
        },
        {
            "start_logit": 9.0703125,
            "end_logit": -1.6982421875,
            "text": "act",
            "probability": 1.7762184143066406e-05
        },
        {
            "start_logit": -4.0234375,
            "end_logit": 9.25,
            "text": "monoclonal antitoxin antibodies actoxumab",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 9.0703125,
            "end_logit": -5.89453125,
            "text": "actoxumab and bezlotoxumab",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.33984375,
            "end_logit": 9.25,
            "text": "oxumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.546875,
            "end_logit": 9.25,
            "text": "antibodies actoxumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0703125,
            "end_logit": -7.1015625,
            "text": "actoxumab and bezlotoxumab.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 9.25,
            "text": "by the monoclonal antitoxin antibodies actoxumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0703125,
            "end_logit": -7.203125,
            "text": "actoxumab and bezlotox",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 9.25,
            "text": "antitoxin antibodies actoxumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0703125,
            "end_logit": -7.21875,
            "text": "actoxumab and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 9.25,
            "text": "oxin antibodies actoxumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0703125,
            "end_logit": -7.28515625,
            "text": "actoxumab and bezlot",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 9.25,
            "text": "Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 9.25,
            "text": "Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0703125,
            "end_logit": -7.42578125,
            "text": "actoxumab and bez",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0703125,
            "end_logit": -7.4375,
            "text": "actoxumab and be",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.0234375,
            "end_logit": -1.6982421875,
            "text": "monoclonal antitoxin antibodies act",
            "probability": 0.0
        },
        {
            "start_logit": -1.560546875,
            "end_logit": -5.89453125,
            "text": "umab and bezlotoxumab",
            "probability": 0.0
        }
    ],
    "5c851c2675a4a5d219000006_5": [
        {
            "start_logit": 9.1953125,
            "end_logit": 9.15625,
            "text": "Bezlotoxumab",
            "probability": 1.0
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -1.41015625,
            "text": "Be",
            "probability": 2.586841583251953e-05
        },
        {
            "start_logit": -1.78515625,
            "end_logit": 9.15625,
            "text": "umab",
            "probability": 1.722574234008789e-05
        },
        {
            "start_logit": -5.78125,
            "end_logit": 9.15625,
            "text": "zlotoxumab",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.45703125,
            "end_logit": 9.15625,
            "text": "lotoxumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -6.66015625,
            "text": "Bezlotoxumab: anti-toxin B monoclonal antibody",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.859375,
            "end_logit": 9.15625,
            "text": "oxumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.05859375,
            "text": "Bezlotox",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.0625,
            "text": "Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.3203125,
            "text": "Bezlotoxumab: anti-toxin B",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.36328125,
            "text": "Bezlotoxumab: anti-toxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.40625,
            "text": "Bezlotoxumab: anti-toxin B monoclonal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.53515625,
            "text": "Bezlotoxumab: anti-toxin B monoclonal antibody to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.578125,
            "text": "Bezlot",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.78515625,
            "end_logit": -6.66015625,
            "text": "umab: anti-toxin B monoclonal antibody",
            "probability": 0.0
        },
        {
            "start_logit": -1.78515625,
            "end_logit": -7.0625,
            "text": "umab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection.",
            "probability": 0.0
        },
        {
            "start_logit": -1.78515625,
            "end_logit": -7.3203125,
            "text": "umab: anti-toxin B",
            "probability": 0.0
        },
        {
            "start_logit": -1.78515625,
            "end_logit": -7.36328125,
            "text": "umab: anti-toxin",
            "probability": 0.0
        },
        {
            "start_logit": -1.78515625,
            "end_logit": -7.40625,
            "text": "umab: anti-toxin B monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": -1.78515625,
            "end_logit": -7.53515625,
            "text": "umab: anti-toxin B monoclonal antibody to",
            "probability": 0.0
        }
    ],
    "5c851c2675a4a5d219000006_6": [
        {
            "start_logit": 8.921875,
            "end_logit": 8.828125,
            "text": "Bezlotoxumab",
            "probability": 1.0
        },
        {
            "start_logit": 8.921875,
            "end_logit": -1.947265625,
            "text": "Be",
            "probability": 2.092123031616211e-05
        },
        {
            "start_logit": -2.4296875,
            "end_logit": 8.828125,
            "text": "umab",
            "probability": 1.1742115020751953e-05
        },
        {
            "start_logit": 8.921875,
            "end_logit": -3.724609375,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": -6.2109375,
            "end_logit": 8.828125,
            "text": "zlotoxumab",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -6.609375,
            "text": "Bezlotoxumab (Zinplava\u2122",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -6.81640625,
            "text": "Bezlotoxumab (Zinplava\u2122)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -6.84375,
            "text": "Bezlotoxumab (Zinplava",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.82421875,
            "end_logit": 8.828125,
            "text": "lotoxumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.03515625,
            "text": "Bezlotoxumab (Zinpl",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.12109375,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.15234375,
            "text": "Bezlotox",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.2109375,
            "text": "Bezlotoxumab (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.21484375,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B developed",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 8.828125,
            "text": "oxumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.24609375,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.24609375,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B developed by Merck & Co",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.2578125,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B developed by Merck &",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.29296875,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B developed by Merck",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.34765625,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5c851c2675a4a5d219000006_7": [
        {
            "start_logit": 9.1171875,
            "end_logit": 9.1484375,
            "text": "Bezlotoxumab",
            "probability": 1.0
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -1.55078125,
            "text": "Be",
            "probability": 2.2470951080322266e-05
        },
        {
            "start_logit": -1.7734375,
            "end_logit": 9.1484375,
            "text": "umab",
            "probability": 1.8656253814697266e-05
        },
        {
            "start_logit": -5.93359375,
            "end_logit": 9.1484375,
            "text": "zlotoxumab",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -5.9375,
            "text": "Bezlotoxumab (Zinplava\u2122) is a fully human monoclonal antibody",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.61328125,
            "end_logit": 9.1484375,
            "text": "lotoxumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.875,
            "text": "Bezlotoxumab (Zinplava\u2122",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9296875,
            "end_logit": 9.1484375,
            "text": "oxumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.921875,
            "text": "Bezlotoxumab (Zinplava",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.9375,
            "text": "Bezlotoxumab (Zinplava\u2122)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.07421875,
            "text": "Bezlotox",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.12109375,
            "text": "Bezlotoxumab (Zinpl",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.26171875,
            "text": "Bezlotoxumab (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.3359375,
            "text": "Bezlotoxumab (Zinplava\u2122) is a fully human monoclonal antibody against",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.40234375,
            "text": "Bezlotoxumab (Zinplava\u2122) is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.48046875,
            "text": "Bezlotoxumab (Zinplava\u2122) is a fully human monoclonal antibody against Clostridium difficile toxin B",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.48828125,
            "text": "Bezlotoxumab (Zinplava\u2122) is a fully human monoclonal antibody against Clostridium difficile toxin B indicated",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.5,
            "text": "Bezlotoxumab (Zinplava\u2122) is a fully human",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.7734375,
            "end_logit": -5.9375,
            "text": "umab (Zinplava\u2122) is a fully human monoclonal antibody",
            "probability": 0.0
        },
        {
            "start_logit": -1.7734375,
            "end_logit": -6.875,
            "text": "umab (Zinplava\u2122",
            "probability": 0.0
        }
    ],
    "5c851c2675a4a5d219000006_8": [
        {
            "start_logit": 8.921875,
            "end_logit": 8.84375,
            "text": "Bezlotoxumab",
            "probability": 1.0
        },
        {
            "start_logit": 8.921875,
            "end_logit": -1.9501953125,
            "text": "Be",
            "probability": 2.0444393157958984e-05
        },
        {
            "start_logit": -2.39453125,
            "end_logit": 8.84375,
            "text": "umab",
            "probability": 1.2218952178955078e-05
        },
        {
            "start_logit": 8.921875,
            "end_logit": -3.525390625,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": -6.24609375,
            "end_logit": 8.84375,
            "text": "zlotoxumab",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -6.6015625,
            "text": "Bezlotoxumab (Zinplava\u2122",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -6.8125,
            "text": "Bezlotoxumab (Zinplava\u2122)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -6.84765625,
            "text": "Bezlotoxumab (Zinplava",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.84765625,
            "end_logit": 8.84375,
            "text": "lotoxumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.02734375,
            "text": "Bezlotoxumab (Zinpl",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.09375,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.1328125,
            "text": "Bezlotox",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.19140625,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B developed",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.22265625,
            "text": "Bezlotoxumab (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.23828125,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1640625,
            "end_logit": 8.84375,
            "text": "oxumab",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.3359375,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B developed by Merck &amp; Co",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.33984375,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.35546875,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B developed by Merck",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.36328125,
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B developed by Merck &",
            "probability": 1.1920928955078125e-07
        }
    ],
    "58bc666702b8c60953000004_1": [
        {
            "start_logit": 1.0244140625,
            "end_logit": 1.931640625,
            "text": "amyotrophic lateral sclerosis",
            "probability": 0.96875
        },
        {
            "start_logit": -2.69921875,
            "end_logit": 1.931640625,
            "text": "neurodegenerative disorders caused by protein misfolding and aggregation, including amyotrophic lateral sclerosis",
            "probability": 0.02337646484375
        },
        {
            "start_logit": 1.0244140625,
            "end_logit": -3.92578125,
            "text": "amyotrophic lateral sclerosis (ALS), Parkinson's disease",
            "probability": 0.0027637481689453125
        },
        {
            "start_logit": 1.0244140625,
            "end_logit": -5.12109375,
            "text": "amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and Alzheimer",
            "probability": 0.0008363723754882812
        },
        {
            "start_logit": 1.0244140625,
            "end_logit": -5.3046875,
            "text": "amyotrophic lateral sclerosis (ALS)",
            "probability": 0.0006961822509765625
        },
        {
            "start_logit": 1.0244140625,
            "end_logit": -5.515625,
            "text": "amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and Alzheimer's disease",
            "probability": 0.0005636215209960938
        },
        {
            "start_logit": 1.0244140625,
            "end_logit": -5.63671875,
            "text": "amyotrophic lateral sclerosis (ALS",
            "probability": 0.0004992485046386719
        },
        {
            "start_logit": -6.76953125,
            "end_logit": 1.931640625,
            "text": "including amyotrophic lateral sclerosis",
            "probability": 0.0003998279571533203
        },
        {
            "start_logit": -7.0859375,
            "end_logit": 1.931640625,
            "text": "lateral sclerosis",
            "probability": 0.0002913475036621094
        },
        {
            "start_logit": -7.09375,
            "end_logit": 1.931640625,
            "text": "sclerosis",
            "probability": 0.0002868175506591797
        },
        {
            "start_logit": 1.0244140625,
            "end_logit": -6.33203125,
            "text": "amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and Alzheimer's disease (AD",
            "probability": 0.0002491474151611328
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 1.931640625,
            "text": "cure several common and fatal neurodegenerative disorders caused by protein misfolding and aggregation, including amyotrophic lateral sclerosis",
            "probability": 0.0002416372299194336
        },
        {
            "start_logit": -7.28125,
            "end_logit": 1.931640625,
            "text": "by protein misfolding and aggregation, including amyotrophic lateral sclerosis",
            "probability": 0.0002377033233642578
        },
        {
            "start_logit": 1.0244140625,
            "end_logit": -6.37890625,
            "text": "amyotrophic lateral sclerosis (",
            "probability": 0.0002377033233642578
        },
        {
            "start_logit": -7.359375,
            "end_logit": 1.931640625,
            "text": "disorders caused by protein misfolding and aggregation, including amyotrophic lateral sclerosis",
            "probability": 0.0002199411392211914
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 1.931640625,
            "text": "fatal neurodegenerative disorders caused by protein misfolding and aggregation, including amyotrophic lateral sclerosis",
            "probability": 0.0002199411392211914
        },
        {
            "start_logit": 1.0244140625,
            "end_logit": -6.74609375,
            "text": "amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and Alzheimer's disease (AD).",
            "probability": 0.0001646280288696289
        },
        {
            "start_logit": 1.0244140625,
            "end_logit": -6.8671875,
            "text": "amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD",
            "probability": 0.00014638900756835938
        },
        {
            "start_logit": 1.0244140625,
            "end_logit": -6.93359375,
            "text": "amyotrophic lateral sclerosis (ALS), Parkinson",
            "probability": 0.00013649463653564453
        },
        {
            "start_logit": -2.69921875,
            "end_logit": -3.443359375,
            "text": "neurodegenerative disorders",
            "probability": 0.00010883808135986328
        }
    ],
    "58bc666702b8c60953000004_2": [
        {
            "start_logit": 6.04296875,
            "end_logit": 8.171875,
            "text": "prions",
            "probability": 1.0
        },
        {
            "start_logit": -3.23828125,
            "end_logit": 8.171875,
            "text": "s",
            "probability": 9.316205978393555e-05
        },
        {
            "start_logit": -6.0625,
            "end_logit": 8.171875,
            "text": "Hsp104 dissolves disordered aggregates and prions",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": -6.8125,
            "end_logit": 8.171875,
            "text": "and prions",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": -7.03515625,
            "end_logit": 8.171875,
            "text": "aggregates and prions",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 6.04296875,
            "end_logit": -4.9765625,
            "text": "prion",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -7.1328125,
            "end_logit": 8.171875,
            "text": "disordered aggregates and prions",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -7.203125,
            "end_logit": 8.171875,
            "text": "which Hsp104 dissolves disordered aggregates and prions",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 8.171875,
            "text": "structural basis by which Hsp104 dissolves disordered aggregates and prions",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 8.171875,
            "text": "The structural basis by which Hsp104 dissolves disordered aggregates and prions",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 8.171875,
            "text": "by which Hsp104 dissolves disordered aggregates and prions",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 6.04296875,
            "end_logit": -6.20703125,
            "text": "prions is unknown",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 6.04296875,
            "end_logit": -6.3203125,
            "text": "prions is unknown.",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 6.04296875,
            "end_logit": -7.2578125,
            "text": "prions is",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -3.23828125,
            "end_logit": -6.20703125,
            "text": "s is unknown",
            "probability": 0.0
        },
        {
            "start_logit": -3.23828125,
            "end_logit": -6.3203125,
            "text": "s is unknown.",
            "probability": 0.0
        },
        {
            "start_logit": -3.23828125,
            "end_logit": -7.2578125,
            "text": "s is",
            "probability": 0.0
        },
        {
            "start_logit": -6.0625,
            "end_logit": -4.9765625,
            "text": "Hsp104 dissolves disordered aggregates and prion",
            "probability": 0.0
        },
        {
            "start_logit": -6.8125,
            "end_logit": -4.9765625,
            "text": "and prion",
            "probability": 0.0
        },
        {
            "start_logit": -7.03515625,
            "end_logit": -4.9765625,
            "text": "aggregates and prion",
            "probability": 0.0
        }
    ],
    "52e0141498d023950500000e_1": [
        {
            "start_logit": 7.5859375,
            "end_logit": 8.953125,
            "text": "growth rate deficit",
            "probability": 0.98388671875
        },
        {
            "start_logit": 3.45703125,
            "end_logit": 8.953125,
            "text": "significant growth rate deficit",
            "probability": 0.015899658203125
        },
        {
            "start_logit": -1.904296875,
            "end_logit": 8.953125,
            "text": "deficit",
            "probability": 7.480382919311523e-05
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -3.892578125,
            "text": "growth",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": -5.9921875,
            "end_logit": 8.953125,
            "text": "rate deficit",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -5.44921875,
            "text": "growth rate deficit in both roots",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.9375,
            "end_logit": 8.953125,
            "text": "a significant growth rate deficit",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.01953125,
            "end_logit": 8.953125,
            "text": "to a significant growth rate deficit",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 8.953125,
            "text": "leads to a significant growth rate deficit",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -5.7890625,
            "text": "growth rate deficit in both roots and shoots and lowered activity of specific mitochondrial enzymes associated with respiratory metabolism",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -6.296875,
            "text": "growth rate deficit in both roots and shoots and lowered activity of specific mitochondrial enzymes",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -6.47265625,
            "text": "growth rate deficit in both roots and shoots",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -6.82421875,
            "text": "growth rate deficit in both roots and shoots and lowered activity of specific mitochondrial enzymes associated with respiratory metabolism.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -6.9453125,
            "text": "growth rate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -7.03125,
            "text": "growth rate deficit in both roots and shoots and lowered activity of specific mitochondrial enzymes associated with respiratory",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -7.1015625,
            "text": "growth rate deficit in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -7.171875,
            "text": "growth rate deficit in both roots and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -7.28125,
            "text": "growth rate deficit in both roots and shoots and lowered activity of specific mitochondrial enzymes associated",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -7.3046875,
            "text": "growth rate deficit in both roots and shoots and lowered activity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.5859375,
            "end_logit": -7.41015625,
            "text": "growth rate deficit in both",
            "probability": 5.960464477539063e-08
        }
    ],
    "52e0141498d023950500000e_2": [
        {
            "start_logit": 8.859375,
            "end_logit": 7.8125,
            "text": "growth retardation",
            "probability": 0.998046875
        },
        {
            "start_logit": 8.859375,
            "end_logit": 1.2265625,
            "text": "growth retardation and impaired seedling establishment",
            "probability": 0.001377105712890625
        },
        {
            "start_logit": 8.859375,
            "end_logit": 0.630859375,
            "text": "growth retardation and impaired seedling establishment can be attributed to defects in the oil reserve mobilization",
            "probability": 0.0007605552673339844
        },
        {
            "start_logit": 8.859375,
            "end_logit": -2.029296875,
            "text": "growth",
            "probability": 5.2928924560546875e-05
        },
        {
            "start_logit": 8.859375,
            "end_logit": -3.53515625,
            "text": "growth retardation and impaired seedling establishment can",
            "probability": 1.1861324310302734e-05
        },
        {
            "start_logit": 8.859375,
            "end_logit": -4.18359375,
            "text": "growth retardation and impaired seedling establishment can be attributed to defects in the oil reserve mobilization pathway",
            "probability": 6.139278411865234e-06
        },
        {
            "start_logit": -3.56640625,
            "end_logit": 7.8125,
            "text": "retardation",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": 8.859375,
            "end_logit": -5.328125,
            "text": "growth retardation and",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": 8.859375,
            "end_logit": -5.66015625,
            "text": "growth retardation and impaired seedling establishment can be",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 8.859375,
            "end_logit": -5.6953125,
            "text": "growth retardation and impaired seedling establishment can be attributed to defects in the oil reserve",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 8.859375,
            "end_logit": -6.1953125,
            "text": "growth retardation and impaired seedling",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -6.36328125,
            "text": "growth retardation and impaired seedling establishment can be attributed to defects in the oil reserve mobilization pathway.",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -6.89453125,
            "text": "growth retardation and impaired seedling establishment can be attributed to defects",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -6.9453125,
            "text": "growth retardation and impaired seedling establishment can be attributed",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.14453125,
            "text": "growth retardation and impaired seedling establishment can be attributed to defects in the",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.2890625,
            "text": "growth retardation and impaired seedling establishment can be attributed to defects in the oil",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.34375,
            "end_logit": 7.8125,
            "text": "to growth retardation",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 0.069580078125,
            "end_logit": 1.2265625,
            "text": "impaired seedling establishment",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.04296875,
            "end_logit": 7.8125,
            "text": "selective proteolysis leading to growth retardation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 0.069580078125,
            "end_logit": 0.630859375,
            "text": "impaired seedling establishment can be attributed to defects in the oil reserve mobilization",
            "probability": 1.1920928955078125e-07
        }
    ],
    "52fa73e82059c6d71c000059_1": [
        {
            "start_logit": 8.265625,
            "end_logit": 8.625,
            "text": "Agrobacterium-mediated",
            "probability": 0.9990234375
        },
        {
            "start_logit": 8.265625,
            "end_logit": 1.431640625,
            "text": "Agrobacterium-mediated as",
            "probability": 0.0007491111755371094
        },
        {
            "start_logit": -2.1796875,
            "end_logit": 8.625,
            "text": "mediated",
            "probability": 2.9087066650390625e-05
        },
        {
            "start_logit": 8.265625,
            "end_logit": -2.685546875,
            "text": "Agrobacterium",
            "probability": 1.2218952178955078e-05
        },
        {
            "start_logit": 8.265625,
            "end_logit": -3.953125,
            "text": "Agrobacterium-mediated as well as direct delivery methods",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": -6.5625,
            "end_logit": 8.625,
            "text": ", Agrobacterium-mediated",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.265625,
            "end_logit": -6.4921875,
            "text": "Agrobacterium-",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.265625,
            "end_logit": -6.4921875,
            "text": "Agrobacterium-mediated as well",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.1171875,
            "end_logit": 8.625,
            "text": "-mediated",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.265625,
            "end_logit": -6.9921875,
            "text": "Agrobacterium-mediated as well as direct",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.265625,
            "end_logit": -6.99609375,
            "text": "Agrobacterium-mediated as well as direct delivery methods have",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -2.1796875,
            "end_logit": 1.431640625,
            "text": "mediated as",
            "probability": 0.0
        },
        {
            "start_logit": -5.23828125,
            "end_logit": 1.431640625,
            "text": "as",
            "probability": 0.0
        },
        {
            "start_logit": -6.5625,
            "end_logit": 1.431640625,
            "text": ", Agrobacterium-mediated as",
            "probability": 0.0
        },
        {
            "start_logit": -7.1171875,
            "end_logit": 1.431640625,
            "text": "-mediated as",
            "probability": 0.0
        },
        {
            "start_logit": -2.1796875,
            "end_logit": -3.953125,
            "text": "mediated as well as direct delivery methods",
            "probability": 0.0
        },
        {
            "start_logit": -2.1796875,
            "end_logit": -6.4921875,
            "text": "mediated as well",
            "probability": 0.0
        },
        {
            "start_logit": -2.1796875,
            "end_logit": -6.9921875,
            "text": "mediated as well as direct",
            "probability": 0.0
        },
        {
            "start_logit": -2.1796875,
            "end_logit": -6.99609375,
            "text": "mediated as well as direct delivery methods have",
            "probability": 0.0
        },
        {
            "start_logit": -5.23828125,
            "end_logit": -3.953125,
            "text": "as well as direct delivery methods",
            "probability": 0.0
        }
    ],
    "52fa73e82059c6d71c000059_2": [
        {
            "start_logit": -0.8935546875,
            "end_logit": 1.1728515625,
            "text": "combined use of Red/ET recombination",
            "probability": 0.48291015625
        },
        {
            "start_logit": -0.93896484375,
            "end_logit": 1.1728515625,
            "text": "Red/ET recombination",
            "probability": 0.461669921875
        },
        {
            "start_logit": -3.740234375,
            "end_logit": 1.1728515625,
            "text": "use of Red/ET recombination",
            "probability": 0.0280609130859375
        },
        {
            "start_logit": -5.59765625,
            "end_logit": 1.1728515625,
            "text": "As demonstrated here, the combined use of Red/ET recombination",
            "probability": 0.0043792724609375
        },
        {
            "start_logit": -5.80078125,
            "end_logit": 1.1728515625,
            "text": "of Red/ET recombination",
            "probability": 0.003574371337890625
        },
        {
            "start_logit": -5.80078125,
            "end_logit": 1.1728515625,
            "text": "the combined use of Red/ET recombination",
            "probability": 0.003574371337890625
        },
        {
            "start_logit": -3.2890625,
            "end_logit": -1.693359375,
            "text": "site-directed plasmid mutagenesis",
            "probability": 0.00249481201171875
        },
        {
            "start_logit": -6.21484375,
            "end_logit": 1.1728515625,
            "text": "in vitro DNA synthesis. As demonstrated here, the combined use of Red/ET recombination",
            "probability": 0.002361297607421875
        },
        {
            "start_logit": -6.42578125,
            "end_logit": 1.1728515625,
            "text": ". As demonstrated here, the combined use of Red/ET recombination",
            "probability": 0.0019121170043945312
        },
        {
            "start_logit": -0.8935546875,
            "end_logit": -4.41796875,
            "text": "combined use of Red/ET recombination and unique restriction site elimination",
            "probability": 0.0017976760864257812
        },
        {
            "start_logit": -0.93896484375,
            "end_logit": -4.41796875,
            "text": "Red/ET recombination and unique restriction site elimination",
            "probability": 0.001728057861328125
        },
        {
            "start_logit": -6.58984375,
            "end_logit": 1.1728515625,
            "text": "recombination",
            "probability": 0.0016231536865234375
        },
        {
            "start_logit": -6.84765625,
            "end_logit": 1.1728515625,
            "text": "amplicon size limitations of in vitro DNA synthesis. As demonstrated here, the combined use of Red/ET recombination",
            "probability": 0.001255035400390625
        },
        {
            "start_logit": -0.8935546875,
            "end_logit": -5.66015625,
            "text": "combined use of Red",
            "probability": 0.0005192756652832031
        },
        {
            "start_logit": -0.93896484375,
            "end_logit": -5.66015625,
            "text": "Red",
            "probability": 0.0004987716674804688
        },
        {
            "start_logit": -0.8935546875,
            "end_logit": -6.1640625,
            "text": "combined use of Red/ET",
            "probability": 0.00031495094299316406
        },
        {
            "start_logit": -0.93896484375,
            "end_logit": -6.1640625,
            "text": "Red/ET",
            "probability": 0.00030040740966796875
        },
        {
            "start_logit": -0.8935546875,
            "end_logit": -6.22265625,
            "text": "combined use of Red/ET recombination and unique restriction site elimination enables",
            "probability": 0.0002956390380859375
        },
        {
            "start_logit": -0.8935546875,
            "end_logit": -6.2578125,
            "text": "combined use of Red/ET recombination and unique restriction site elimination enables extensive manipulation regardless of plasmid size",
            "probability": 0.0002865791320800781
        },
        {
            "start_logit": -0.93896484375,
            "end_logit": -6.22265625,
            "text": "Red/ET recombination and unique restriction site elimination enables",
            "probability": 0.00028443336486816406
        }
    ],
    "52fa73e82059c6d71c000059_3": [
        {
            "start_logit": 7.9453125,
            "end_logit": 6.6640625,
            "text": "Bacterial artificial chromosomes (BACs) derived from genomes of large DNA viruses",
            "probability": 0.79443359375
        },
        {
            "start_logit": 7.9453125,
            "end_logit": 5.28125,
            "text": "Bacterial artificial chromosomes",
            "probability": 0.1993408203125
        },
        {
            "start_logit": 7.9453125,
            "end_logit": 1.818359375,
            "text": "Bacterial artificial chromosomes (BACs)",
            "probability": 0.006259918212890625
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -3.28515625,
            "text": "Bacterial",
            "probability": 3.7789344787597656e-05
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -4.109375,
            "text": "Bacterial artificial chromosomes (BACs) derived from genomes of large DNA viruses are",
            "probability": 1.6629695892333984e-05
        },
        {
            "start_logit": -3.1640625,
            "end_logit": 6.6640625,
            "text": "BACs) derived from genomes of large DNA viruses",
            "probability": 1.1861324310302734e-05
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -5.4140625,
            "text": "Bacterial artificial chromosomes (BACs) derived from genomes of large DNA viruses are powerful tools for functional delineation of viral genes",
            "probability": 4.470348358154297e-06
        },
        {
            "start_logit": -4.41015625,
            "end_logit": 6.6640625,
            "text": "viruses",
            "probability": 3.3974647521972656e-06
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -6.12109375,
            "text": "Bacterial artificial chromosomes (BACs) derived from genomes of large DNA viruses are powerful tools for functional delineation of viral",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -6.14453125,
            "text": "Bacterial artificial chromosomes (BAC",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": -4.94140625,
            "end_logit": 6.6640625,
            "text": "derived from genomes of large DNA viruses",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -6.2890625,
            "text": "Bacterial artificial chromosomes (BACs) derived from genomes of large DNA viruses are powerful tools for functional delineation of viral genes.",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -6.2890625,
            "text": "Bacterial artificial chromosomes (BACs",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -6.453125,
            "text": "Bacterial artificial chromosomes (BACs) derived from genomes of large DNA viruses are powerful tools",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -6.58203125,
            "text": "Bacterial artificial chromosomes (BACs) derived",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -5.35546875,
            "end_logit": 6.6640625,
            "text": "chromosomes (BACs) derived from genomes of large DNA viruses",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -5.3828125,
            "end_logit": 6.6640625,
            "text": "genomes of large DNA viruses",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -6.66796875,
            "text": "Bacterial artificial chromosomes (",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -5.40625,
            "end_logit": 6.6640625,
            "text": "from genomes of large DNA viruses",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -7.11328125,
            "text": "Bacterial artificial chromosomes (BACs) derived from genomes of large DNA viruses are powerful tools for functional delineation",
            "probability": 8.344650268554688e-07
        }
    ],
    "52fa73e82059c6d71c000059_4": [
        {
            "start_logit": -2.2109375,
            "end_logit": 2.712890625,
            "text": "large DNA viruses",
            "probability": 0.73876953125
        },
        {
            "start_logit": -4.04296875,
            "end_logit": 2.712890625,
            "text": "DNA viruses",
            "probability": 0.11822509765625
        },
        {
            "start_logit": -4.54296875,
            "end_logit": 2.712890625,
            "text": "genomes of large DNA viruses",
            "probability": 0.07171630859375
        },
        {
            "start_logit": -4.95703125,
            "end_logit": 2.712890625,
            "text": "cloning the genomes of large DNA viruses",
            "probability": 0.047393798828125
        },
        {
            "start_logit": -6.21875,
            "end_logit": 2.712890625,
            "text": "method for cloning the genomes of large DNA viruses",
            "probability": 0.013427734375
        },
        {
            "start_logit": -2.2109375,
            "end_logit": -2.966796875,
            "text": "large DNA viruses as BACs",
            "probability": 0.002521514892578125
        },
        {
            "start_logit": -2.208984375,
            "end_logit": -3.58984375,
            "text": "direct in vitro transposition of viral genomes with a BAC cassette, and subsequent recovery in Escherichia coli",
            "probability": 0.0013608932495117188
        },
        {
            "start_logit": -2.2109375,
            "end_logit": -3.58984375,
            "text": "large DNA viruses as BACs, which entails direct in vitro transposition of viral genomes with a BAC cassette, and subsequent recovery in Escherichia coli",
            "probability": 0.00135040283203125
        },
        {
            "start_logit": -2.208984375,
            "end_logit": -4.08984375,
            "text": "direct in vitro transposition of viral genomes with a BAC cassette",
            "probability": 0.0008258819580078125
        },
        {
            "start_logit": -2.2109375,
            "end_logit": -4.08984375,
            "text": "large DNA viruses as BACs, which entails direct in vitro transposition of viral genomes with a BAC cassette",
            "probability": 0.0008187294006347656
        },
        {
            "start_logit": -2.208984375,
            "end_logit": -4.28515625,
            "text": "direct in vitro transposition",
            "probability": 0.00067901611328125
        },
        {
            "start_logit": -2.2109375,
            "end_logit": -4.28515625,
            "text": "large DNA viruses as BACs, which entails direct in vitro transposition",
            "probability": 0.0006737709045410156
        },
        {
            "start_logit": -3.875,
            "end_logit": -2.966796875,
            "text": "BACs",
            "probability": 0.00047779083251953125
        },
        {
            "start_logit": -4.04296875,
            "end_logit": -2.966796875,
            "text": "DNA viruses as BACs",
            "probability": 0.0004055500030517578
        },
        {
            "start_logit": -4.359375,
            "end_logit": -2.966796875,
            "text": "as BACs",
            "probability": 0.0002944469451904297
        },
        {
            "start_logit": -3.875,
            "end_logit": -3.58984375,
            "text": "BACs, which entails direct in vitro transposition of viral genomes with a BAC cassette, and subsequent recovery in Escherichia coli",
            "probability": 0.00025582313537597656
        },
        {
            "start_logit": -4.54296875,
            "end_logit": -2.966796875,
            "text": "genomes of large DNA viruses as BACs",
            "probability": 0.00024580955505371094
        },
        {
            "start_logit": -2.208984375,
            "end_logit": -5.3671875,
            "text": "direct in vitro transposition of viral",
            "probability": 0.00022912025451660156
        },
        {
            "start_logit": -2.2109375,
            "end_logit": -5.3671875,
            "text": "large DNA viruses as BACs, which entails direct in vitro transposition of viral",
            "probability": 0.00022912025451660156
        },
        {
            "start_logit": -4.04296875,
            "end_logit": -3.58984375,
            "text": "DNA viruses as BACs, which entails direct in vitro transposition of viral genomes with a BAC cassette, and subsequent recovery in Escherichia coli",
            "probability": 0.00021696090698242188
        }
    ],
    "530cefaaad0bf1360c000002_1": [
        {
            "start_logit": 8.984375,
            "end_logit": 9.03125,
            "text": "subgenual cingulate gyrus",
            "probability": 1.0
        },
        {
            "start_logit": -1.3125,
            "end_logit": 9.03125,
            "text": "gyrus",
            "probability": 3.3736228942871094e-05
        },
        {
            "start_logit": 8.984375,
            "end_logit": -1.4033203125,
            "text": "subgen",
            "probability": 2.9325485229492188e-05
        },
        {
            "start_logit": -5.2109375,
            "end_logit": 9.03125,
            "text": "cingulate gyrus",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -5.98046875,
            "text": "subgenual cingulate gyrus (Cg25",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.10546875,
            "text": "subgenual cingulate gyrus (Cg25/24)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.19921875,
            "end_logit": 9.03125,
            "text": ". First clinical studies with small samples have been stimulated at the subgenual cingulate gyrus",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.390625,
            "end_logit": 9.03125,
            "text": "ual cingulate gyrus",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.3671875,
            "text": "subgenual cingulate gyrus (Cg25/24), the anterior limb of the capsula interna (ALIC",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.46875,
            "end_logit": 9.03125,
            "text": "at the subgenual cingulate gyrus",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.53125,
            "text": "subgenual cingulate gyrus (Cg25/24",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.546875,
            "text": "subgenual cingulate gyrus (Cg25/24), the anterior limb of the capsula interna (ALIC)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.67578125,
            "text": "subgenual cingulate gyrus (Cg25/24), the anterior limb of the capsula interna (ALIC), and the nucleus accumbens",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.7109375,
            "text": "subgenual cingulate gyrus (Cg25/24), the anterior limb of the capsula interna (ALI",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.73046875,
            "text": "subgenual cingulate gyrus (Cg",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.7578125,
            "text": "subgenual cingulate gyrus (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.859375,
            "end_logit": 9.03125,
            "text": "the subgenual cingulate gyrus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.85546875,
            "text": "subgenual cingulate gyrus (Cg25/",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.89453125,
            "text": "subgenual cingulate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.15234375,
            "end_logit": 9.03125,
            "text": "been stimulated at the subgenual cingulate gyrus",
            "probability": 1.1920928955078125e-07
        }
    ],
    "530cefaaad0bf1360c000002_2": [
        {
            "start_logit": 8.203125,
            "end_logit": 8.7578125,
            "text": "habenula",
            "probability": 0.370361328125
        },
        {
            "start_logit": 8.078125,
            "end_logit": 8.7578125,
            "text": "medial forebrain bundle, habenula",
            "probability": 0.326904296875
        },
        {
            "start_logit": 8.078125,
            "end_logit": 8.6875,
            "text": "medial forebrain bundle",
            "probability": 0.302490234375
        },
        {
            "start_logit": -2.19140625,
            "end_logit": 8.7578125,
            "text": "bundle, habenula",
            "probability": 1.1205673217773438e-05
        },
        {
            "start_logit": -2.19140625,
            "end_logit": 8.6875,
            "text": "bundle",
            "probability": 1.055002212524414e-05
        },
        {
            "start_logit": -2.3984375,
            "end_logit": 8.7578125,
            "text": "ula",
            "probability": 9.119510650634766e-06
        },
        {
            "start_logit": 8.078125,
            "end_logit": -2.837890625,
            "text": "medial",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": 8.203125,
            "end_logit": -2.966796875,
            "text": "hab",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": 8.078125,
            "end_logit": -2.966796875,
            "text": "medial forebrain bundle, hab",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": -6.16796875,
            "end_logit": 8.7578125,
            "text": "forebrain bundle, habenula",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.16796875,
            "end_logit": 8.6875,
            "text": "forebrain bundle",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.23828125,
            "end_logit": 8.7578125,
            "text": ", medial forebrain bundle, habenula",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.23828125,
            "end_logit": 8.6875,
            "text": ", medial forebrain bundle",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.203125,
            "end_logit": -5.91796875,
            "text": "habenula) are about to be assessed in clinical trials.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -5.91796875,
            "text": "medial forebrain bundle, habenula) are about to be assessed in clinical trials.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.828125,
            "end_logit": 8.7578125,
            "text": ", habenula",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.109375,
            "end_logit": 8.7578125,
            "text": "., medial forebrain bundle, habenula",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.109375,
            "end_logit": 8.6875,
            "text": "., medial forebrain bundle",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1953125,
            "end_logit": 8.7578125,
            "text": "New hypothesis-guided targets (e.g., medial forebrain bundle, habenula",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.203125,
            "end_logit": -6.65625,
            "text": "habenula)",
            "probability": 5.960464477539063e-08
        }
    ],
    "530cefaaad0bf1360c000002_3": [
        {
            "start_logit": 9.109375,
            "end_logit": 9.296875,
            "text": "nucleus accumbens",
            "probability": 1.0
        },
        {
            "start_logit": -1.2158203125,
            "end_logit": 9.296875,
            "text": "accumbens",
            "probability": 3.272294998168945e-05
        },
        {
            "start_logit": 9.109375,
            "end_logit": -1.5673828125,
            "text": "nucleus",
            "probability": 1.9252300262451172e-05
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.421875,
            "text": "nucleus accumbens (NAcc",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.64453125,
            "text": "nucleus accumbens (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.890625,
            "end_logit": 9.296875,
            "text": "to the nucleus accumbens",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.8984375,
            "end_logit": 9.296875,
            "text": "Deep brain stimulation (DBS) to the nucleus accumbens",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.83984375,
            "text": "nucleus accumbens (NAcc-DBS",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.90234375,
            "text": "nucleus accumbens (NAcc-DBS) has antidepressant effects in patients suffering from treatment-resistant depression (TRD).",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.28125,
            "end_logit": 9.296875,
            "text": "the nucleus accumbens",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.09765625,
            "text": "nucleus accumbens (NAc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.1171875,
            "text": "nucleus accumbens (NAcc-DBS)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.2421875,
            "text": "nucleus accumbens (NAcc-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 9.296875,
            "text": "DBS) to the nucleus accumbens",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.5,
            "text": "nucleus accumbens (NAcc-DBS) has",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.55859375,
            "text": "nucleus accumbens (NAcc-DBS) has antidepressant effects in patients suffering from treatment-resistant",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.59375,
            "text": "nucleus accumbens (NAcc-DBS) has antidepressant effects",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.2158203125,
            "end_logit": -6.421875,
            "text": "accumbens (NAcc",
            "probability": 0.0
        },
        {
            "start_logit": -1.2158203125,
            "end_logit": -6.64453125,
            "text": "accumbens (",
            "probability": 0.0
        },
        {
            "start_logit": -1.2158203125,
            "end_logit": -6.83984375,
            "text": "accumbens (NAcc-DBS",
            "probability": 0.0
        }
    ],
    "530cefaaad0bf1360c000002_4": [
        {
            "start_logit": 3.25,
            "end_logit": 5.4140625,
            "text": "ventral striatum",
            "probability": 0.70654296875
        },
        {
            "start_logit": 3.25,
            "end_logit": 4.27734375,
            "text": "ventral striatum, including the head of the caudate nucleus",
            "probability": 0.2266845703125
        },
        {
            "start_logit": 1.728515625,
            "end_logit": 4.27734375,
            "text": "caudate nucleus",
            "probability": 0.049591064453125
        },
        {
            "start_logit": 3.25,
            "end_logit": 1.01171875,
            "text": "ventral striatum, including the head of the caudate nucleus and the nucleus accumbens",
            "probability": 0.0086517333984375
        },
        {
            "start_logit": 2.828125,
            "end_logit": 1.01171875,
            "text": "nucleus accumbens",
            "probability": 0.00567626953125
        },
        {
            "start_logit": 1.728515625,
            "end_logit": 1.01171875,
            "text": "caudate nucleus and the nucleus accumbens",
            "probability": 0.0018939971923828125
        },
        {
            "start_logit": -3.8359375,
            "end_logit": 5.4140625,
            "text": "striatum",
            "probability": 0.000591278076171875
        },
        {
            "start_logit": -3.8359375,
            "end_logit": 4.27734375,
            "text": "striatum, including the head of the caudate nucleus",
            "probability": 0.00019061565399169922
        },
        {
            "start_logit": -5.5078125,
            "end_logit": 4.27734375,
            "text": "head of the caudate nucleus",
            "probability": 3.5822391510009766e-05
        },
        {
            "start_logit": 3.25,
            "end_logit": -4.8828125,
            "text": "ventral striatum, including the head of the caudate nucleus and",
            "probability": 2.384185791015625e-05
        },
        {
            "start_logit": -6.046875,
            "end_logit": 4.27734375,
            "text": "nucleus",
            "probability": 2.0742416381835938e-05
        },
        {
            "start_logit": -7.22265625,
            "end_logit": 5.4140625,
            "text": "The ventral striatum",
            "probability": 2.008676528930664e-05
        },
        {
            "start_logit": 3.25,
            "end_logit": -5.72265625,
            "text": "ventral",
            "probability": 1.0251998901367188e-05
        },
        {
            "start_logit": -6.87890625,
            "end_logit": 4.27734375,
            "text": "the caudate nucleus",
            "probability": 9.059906005859375e-06
        },
        {
            "start_logit": -3.8359375,
            "end_logit": 1.01171875,
            "text": "striatum, including the head of the caudate nucleus and the nucleus accumbens",
            "probability": 7.271766662597656e-06
        },
        {
            "start_logit": -7.22265625,
            "end_logit": 4.27734375,
            "text": "The ventral striatum, including the head of the caudate nucleus",
            "probability": 6.377696990966797e-06
        },
        {
            "start_logit": -7.24609375,
            "end_logit": 4.27734375,
            "text": "of the caudate nucleus",
            "probability": 6.258487701416016e-06
        },
        {
            "start_logit": -7.2890625,
            "end_logit": 4.27734375,
            "text": "including the head of the caudate nucleus",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": -7.40234375,
            "end_logit": 4.27734375,
            "text": "the head of the caudate nucleus",
            "probability": 5.364418029785156e-06
        },
        {
            "start_logit": 1.728515625,
            "end_logit": -4.8828125,
            "text": "caudate nucleus and",
            "probability": 5.185604095458984e-06
        }
    ],
    "530cefaaad0bf1360c000002_5": [
        {
            "start_logit": 8.8984375,
            "end_logit": 9.40625,
            "text": "nucleus accumbens",
            "probability": 1.0
        },
        {
            "start_logit": -0.98583984375,
            "end_logit": 9.40625,
            "text": "accumbens",
            "probability": 5.066394805908203e-05
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -2.025390625,
            "text": "nucleus",
            "probability": 1.0788440704345703e-05
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -3.32421875,
            "text": "nucleus accumbens, the lateral habenula",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": -6.59765625,
            "end_logit": 9.40625,
            "text": ", nucleus accumbens",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.5234375,
            "text": "nucleus accumbens, the lateral habenula or cortical areas.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.14453125,
            "end_logit": 9.40625,
            "text": "., nucleus accumbens",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.8046875,
            "text": "nucleus accumbens, the lateral haben",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3515625,
            "end_logit": 9.40625,
            "text": "when the stimulation focused on different areas, e.g., nucleus accumbens",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37890625,
            "end_logit": 9.40625,
            "text": "stimulation focused on different areas, e.g., nucleus accumbens",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.38671875,
            "end_logit": 9.40625,
            "text": "small samples of patients with treatment-resistant depression when the stimulation focused on different areas, e.g., nucleus accumbens",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.05078125,
            "text": "nucleus accumbens, the lateral habenula or",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.19921875,
            "text": "nucleus accumbens, the lateral habenula or cortical areas",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.34375,
            "text": "nucleus accumbens, the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.484375,
            "text": "nucleus accumbens, the lateral hab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.48828125,
            "text": "nucleus accumbens, the lateral habenula or cortical",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.98583984375,
            "end_logit": -3.32421875,
            "text": "accumbens, the lateral habenula",
            "probability": 0.0
        },
        {
            "start_logit": -0.98583984375,
            "end_logit": -6.5234375,
            "text": "accumbens, the lateral habenula or cortical areas.",
            "probability": 0.0
        },
        {
            "start_logit": -0.98583984375,
            "end_logit": -6.8046875,
            "text": "accumbens, the lateral haben",
            "probability": 0.0
        },
        {
            "start_logit": -4.63671875,
            "end_logit": -3.32421875,
            "text": "lateral habenula",
            "probability": 0.0
        }
    ],
    "530cefaaad0bf1360c000002_6": [
        {
            "start_logit": 8.9765625,
            "end_logit": 9.2734375,
            "text": "nucleus accumbens",
            "probability": 1.0
        },
        {
            "start_logit": -1.35546875,
            "end_logit": 9.2734375,
            "text": "accumbens",
            "probability": 3.272294998168945e-05
        },
        {
            "start_logit": 8.9765625,
            "end_logit": -1.8916015625,
            "text": "nucleus",
            "probability": 1.4185905456542969e-05
        },
        {
            "start_logit": 8.9765625,
            "end_logit": -6.72265625,
            "text": "nucleus accumbens of five patients undergoing deep brain stimulation for treatment of refractory major depression.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 9.2734375,
            "text": "the nucleus accumbens",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9765625,
            "end_logit": -7.14453125,
            "text": "nucleus accumbens of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9765625,
            "end_logit": -7.2421875,
            "text": "nucleus accumbens of five patients undergoing deep brain stimulation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 9.2734375,
            "text": "electrophysiological activity directly from the nucleus accumbens",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 9.2734375,
            "text": "from the nucleus accumbens",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 9.2734375,
            "text": "We recorded electrophysiological activity directly from the nucleus accumbens",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 9.2734375,
            "text": "recorded electrophysiological activity directly from the nucleus accumbens",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9765625,
            "end_logit": -7.45703125,
            "text": "nucleus accumbens of five",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9765625,
            "end_logit": -7.48046875,
            "text": "nucleus accumbens of five patients undergoing deep brain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9765625,
            "end_logit": -7.4921875,
            "text": "nucleus accumbens of five patients undergoing deep brain stimulation for treatment of refractory major depression",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9765625,
            "end_logit": -7.51171875,
            "text": "nucleus accumbens of five patients undergoing deep brain stimulation for",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.35546875,
            "end_logit": -6.72265625,
            "text": "accumbens of five patients undergoing deep brain stimulation for treatment of refractory major depression.",
            "probability": 0.0
        },
        {
            "start_logit": -1.35546875,
            "end_logit": -7.14453125,
            "text": "accumbens of",
            "probability": 0.0
        },
        {
            "start_logit": -1.35546875,
            "end_logit": -7.2421875,
            "text": "accumbens of five patients undergoing deep brain stimulation",
            "probability": 0.0
        },
        {
            "start_logit": -1.35546875,
            "end_logit": -7.45703125,
            "text": "accumbens of five",
            "probability": 0.0
        },
        {
            "start_logit": -1.35546875,
            "end_logit": -7.48046875,
            "text": "accumbens of five patients undergoing deep brain",
            "probability": 0.0
        }
    ],
    "530cefaaad0bf1360c000002_7": [
        {
            "start_logit": 8.3203125,
            "end_logit": 9.2265625,
            "text": "habenula",
            "probability": 1.0
        },
        {
            "start_logit": -0.430419921875,
            "end_logit": 9.2265625,
            "text": "lateral habenula",
            "probability": 0.00015842914581298828
        },
        {
            "start_logit": -1.5556640625,
            "end_logit": 9.2265625,
            "text": "ula",
            "probability": 5.143880844116211e-05
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -2.97265625,
            "text": "hab",
            "probability": 5.0067901611328125e-06
        },
        {
            "start_logit": -5.47265625,
            "end_logit": 9.2265625,
            "text": "enula",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -6.54296875,
            "text": "habenula via",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 9.2265625,
            "text": "Functional inhibition of the lateral habenula",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -6.60546875,
            "text": "habenula via deep brain stimulation (DBS) has antidepressive properties.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 9.2265625,
            "text": "of the lateral habenula",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.69921875,
            "end_logit": 9.2265625,
            "text": "inhibition of the lateral habenula",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -7.03515625,
            "text": "habenula via deep brain stimulation (DBS",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -7.12109375,
            "text": "habenula via deep brain stimulation (DBS) has",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -7.2265625,
            "text": "habenula via deep brain stimulation (DBS)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -7.3671875,
            "text": "habenula via deep brain stimulation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -7.3984375,
            "text": "habenula via deep brain stimulation (DBS) has antidepressive properties",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -7.4140625,
            "text": "habenula via deep brain stimulation (DBS) has antidepressive",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -7.48046875,
            "text": "habenula via deep brain stimulation (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.430419921875,
            "end_logit": -2.97265625,
            "text": "lateral hab",
            "probability": 0.0
        },
        {
            "start_logit": -0.430419921875,
            "end_logit": -6.54296875,
            "text": "lateral habenula via",
            "probability": 0.0
        },
        {
            "start_logit": -0.430419921875,
            "end_logit": -6.60546875,
            "text": "lateral habenula via deep brain stimulation (DBS) has antidepressive properties.",
            "probability": 0.0
        }
    ],
    "530cefaaad0bf1360c000002_8": [
        {
            "start_logit": 8.921875,
            "end_logit": 9.2890625,
            "text": "nucleus accumbens",
            "probability": 1.0
        },
        {
            "start_logit": -1.3369140625,
            "end_logit": 9.2890625,
            "text": "accumbens",
            "probability": 3.4809112548828125e-05
        },
        {
            "start_logit": 8.921875,
            "end_logit": -1.9814453125,
            "text": "nucleus",
            "probability": 1.2636184692382812e-05
        },
        {
            "start_logit": 8.921875,
            "end_logit": -6.01171875,
            "text": "nucleus accumbens might",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.890625,
            "end_logit": 9.2890625,
            "text": "to the nucleus accumbens",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.09375,
            "end_logit": 9.2890625,
            "text": ", DBS to the nucleus accumbens",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -6.890625,
            "text": "nucleus accumbens might offer a new possibility to target depressive symptomatology in otherwise treatment-resistant depression.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 9.2890625,
            "text": "the nucleus accumbens",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 9.2890625,
            "text": "DBS to the nucleus accumbens",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53125,
            "end_logit": 9.2890625,
            "text": "and because there is clear evidence of dysfunctions of the reward system in depression, DBS to the nucleus accumbens",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.41796875,
            "text": "nucleus accumbens might offer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.484375,
            "text": "nucleus accumbens might offer a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.49609375,
            "text": "nucleus accumbens might offer a new",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3369140625,
            "end_logit": -6.01171875,
            "text": "accumbens might",
            "probability": 0.0
        },
        {
            "start_logit": -1.3369140625,
            "end_logit": -6.890625,
            "text": "accumbens might offer a new possibility to target depressive symptomatology in otherwise treatment-resistant depression.",
            "probability": 0.0
        },
        {
            "start_logit": -1.3369140625,
            "end_logit": -7.41796875,
            "text": "accumbens might offer",
            "probability": 0.0
        },
        {
            "start_logit": -1.3369140625,
            "end_logit": -7.484375,
            "text": "accumbens might offer a",
            "probability": 0.0
        },
        {
            "start_logit": -1.3369140625,
            "end_logit": -7.49609375,
            "text": "accumbens might offer a new",
            "probability": 0.0
        },
        {
            "start_logit": -6.890625,
            "end_logit": -1.9814453125,
            "text": "to the nucleus",
            "probability": 0.0
        },
        {
            "start_logit": -7.09375,
            "end_logit": -1.9814453125,
            "text": ", DBS to the nucleus",
            "probability": 0.0
        }
    ],
    "530cefaaad0bf1360c000002_9": [
        {
            "start_logit": 8.953125,
            "end_logit": 9.2578125,
            "text": "nucleus accumbens",
            "probability": 1.0
        },
        {
            "start_logit": -1.392578125,
            "end_logit": 9.2578125,
            "text": "accumbens",
            "probability": 3.1948089599609375e-05
        },
        {
            "start_logit": 8.953125,
            "end_logit": -1.9404296875,
            "text": "nucleus",
            "probability": 1.3649463653564453e-05
        },
        {
            "start_logit": -6.87890625,
            "end_logit": 9.2578125,
            "text": "that DBS to the nucleus accumbens",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.953125,
            "end_logit": -6.83984375,
            "text": "nucleus accumbens might be a hypothesis-guided approach for refractory major depression.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.953125,
            "end_logit": -6.921875,
            "text": "nucleus accumbens might",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.234375,
            "end_logit": 9.2578125,
            "text": "to the nucleus accumbens",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 9.2578125,
            "text": "the nucleus accumbens",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 9.2578125,
            "text": "preliminary findings suggest that DBS to the nucleus accumbens",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 9.2578125,
            "text": "These preliminary findings suggest that DBS to the nucleus accumbens",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5625,
            "end_logit": 9.2578125,
            "text": "DBS to the nucleus accumbens",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.953125,
            "end_logit": -7.390625,
            "text": "nucleus accumbens might be a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.953125,
            "end_logit": -7.45703125,
            "text": "nucleus accumbens might be",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.953125,
            "end_logit": -7.515625,
            "text": "nucleus accumbens might be a hypothesis-guided approach for refractory major depression",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.953125,
            "end_logit": -7.5234375,
            "text": "nucleus accumbens might be a hypothesis-guided",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.953125,
            "end_logit": -7.57421875,
            "text": "nucleus accumbens might be a hypothesis-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.953125,
            "end_logit": -7.5859375,
            "text": "nucleus accumbens might be a hypothesis-guided approach",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.392578125,
            "end_logit": -6.83984375,
            "text": "accumbens might be a hypothesis-guided approach for refractory major depression.",
            "probability": 0.0
        },
        {
            "start_logit": -1.392578125,
            "end_logit": -6.921875,
            "text": "accumbens might",
            "probability": 0.0
        },
        {
            "start_logit": -1.392578125,
            "end_logit": -7.390625,
            "text": "accumbens might be a",
            "probability": 0.0
        }
    ],
    "530cefaaad0bf1360c000002_10": [
        {
            "start_logit": 8.0078125,
            "end_logit": 8.609375,
            "text": "ventral caudate nucleus",
            "probability": 0.9970703125
        },
        {
            "start_logit": 2.140625,
            "end_logit": 8.609375,
            "text": "caudate nucleus",
            "probability": 0.0028018951416015625
        },
        {
            "start_logit": -2.650390625,
            "end_logit": 8.609375,
            "text": "nucleus",
            "probability": 2.3305416107177734e-05
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -2.8359375,
            "text": "ventral",
            "probability": 1.055002212524414e-05
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 8.609375,
            "text": "Deep brain stimulation of the ventral caudate nucleus",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 8.609375,
            "text": "of the ventral caudate nucleus",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 8.609375,
            "text": "the ventral caudate nucleus",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.65625,
            "end_logit": 8.609375,
            "text": "brain stimulation of the ventral caudate nucleus",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.40625,
            "text": "ventral caudate nucleus markedly",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.45703125,
            "text": "ventral caudate nucleus markedly improved symptoms of depression and anxiety until their remission, which was achieved at 6 months after the start of stimulation (HDRS < or",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.4765625,
            "text": "ventral caudate nucleus markedly improved symptoms of depression",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.515625,
            "text": "ventral caudate nucleus markedly improved symptoms of depression and anxiety until their remission, which was achieved at 6 months after the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.5390625,
            "text": "ventral caudate nucleus markedly improved symptoms of depression and anxiety until their remission, which was achieved at 6 months after the start of stimulation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.5546875,
            "text": "ventral caudate nucleus markedly improved symptoms of depression and anxiety",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.5546875,
            "text": "ventral caudate nucleus markedly improved symptoms of depression and anxiety until their remission, which was achieved at 6 months after",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -7.5625,
            "text": "ventral caudate nucleus markedly improved symptoms of depression and anxiety until their remission, which was achieved at 6",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 2.140625,
            "end_logit": -7.40625,
            "text": "caudate nucleus markedly",
            "probability": 0.0
        },
        {
            "start_logit": 2.140625,
            "end_logit": -7.45703125,
            "text": "caudate nucleus markedly improved symptoms of depression and anxiety until their remission, which was achieved at 6 months after the start of stimulation (HDRS < or",
            "probability": 0.0
        },
        {
            "start_logit": 2.140625,
            "end_logit": -7.4765625,
            "text": "caudate nucleus markedly improved symptoms of depression",
            "probability": 0.0
        },
        {
            "start_logit": 2.140625,
            "end_logit": -7.515625,
            "text": "caudate nucleus markedly improved symptoms of depression and anxiety until their remission, which was achieved at 6 months after the",
            "probability": 0.0
        }
    ],
    "530cefaaad0bf1360c000002_11": [
        {
            "start_logit": 6.75390625,
            "end_logit": 8.9921875,
            "text": "caudate nucleus",
            "probability": 0.9951171875
        },
        {
            "start_logit": 1.40625,
            "end_logit": 8.9921875,
            "text": "ventral caudate nucleus",
            "probability": 0.004718780517578125
        },
        {
            "start_logit": -1.935546875,
            "end_logit": 8.9921875,
            "text": "nucleus",
            "probability": 0.0001665353775024414
        },
        {
            "start_logit": 6.75390625,
            "end_logit": -4.73046875,
            "text": "caudate",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -7.1171875,
            "end_logit": 8.9921875,
            "text": "that DBS of the ventral caudate nucleus",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -7.15625,
            "end_logit": 8.9921875,
            "text": "DBS of the ventral caudate nucleus",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -7.359375,
            "end_logit": 8.9921875,
            "text": "of the ventral caudate nucleus",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.578125,
            "end_logit": 8.9921875,
            "text": "the ventral caudate nucleus",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 6.75390625,
            "end_logit": -6.0390625,
            "text": "caudate nucleus could",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 6.75390625,
            "end_logit": -6.875,
            "text": "caudate nucleus could be a promising strategy in the treatment of refractory cases of both OCD and major depression.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.75390625,
            "end_logit": -7.30859375,
            "text": "caudate nucleus could be a promising strategy in the treatment of refractory cases of both OCD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.75390625,
            "end_logit": -7.35546875,
            "text": "caudate nucleus could be a promising strategy in the treatment of refractory cases of both OCD and major depression",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.75390625,
            "end_logit": -7.44140625,
            "text": "caudate nucleus could be a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.75390625,
            "end_logit": -7.45703125,
            "text": "caudate nucleus could be a promising strategy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.75390625,
            "end_logit": -7.4609375,
            "text": "caudate nucleus could be",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.75390625,
            "end_logit": -7.51953125,
            "text": "caudate nucleus could be a promising strategy in the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.40625,
            "end_logit": -4.73046875,
            "text": "ventral caudate",
            "probability": 0.0
        },
        {
            "start_logit": 1.40625,
            "end_logit": -6.0390625,
            "text": "ventral caudate nucleus could",
            "probability": 0.0
        },
        {
            "start_logit": 1.40625,
            "end_logit": -6.51953125,
            "text": "ventral",
            "probability": 0.0
        },
        {
            "start_logit": 1.40625,
            "end_logit": -6.875,
            "text": "ventral caudate nucleus could be a promising strategy in the treatment of refractory cases of both OCD and major depression.",
            "probability": 0.0
        }
    ],
    "530cefaaad0bf1360c000002_12": [
        {
            "start_logit": 9.1171875,
            "end_logit": 8.921875,
            "text": "caudate nucleus",
            "probability": 1.0
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -1.3349609375,
            "text": "caudate",
            "probability": 3.534555435180664e-05
        },
        {
            "start_logit": -1.8662109375,
            "end_logit": 8.921875,
            "text": "nucleus",
            "probability": 1.710653305053711e-05
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -4.08984375,
            "text": "caudate nucleus stimulation preferentially alleviated OCD manifestations, whereas nucleus accumbens",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -5.09765625,
            "text": "caudate nucleus stimulation",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.12890625,
            "text": "caudate nucleus stimulation preferentially alleviated OCD manifestations, whereas nucleus accumbens stimulation improved depressive symptoms.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.828125,
            "text": "caudate nucleus stimulation preferentially alleviated OCD",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.88671875,
            "text": "caudate nucleus stimulation preferentially alleviated OCD manifestations, whereas nucleus accumbens stimulation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.8984375,
            "end_logit": 8.921875,
            "text": "that caudate nucleus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9609375,
            "end_logit": 8.921875,
            "text": "Comparisons of clinical outcomes and anatomical data on electrode positioning showed that caudate nucleus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.36328125,
            "text": "caudate nucleus stimulation preferentially alleviated OCD manifestations, whereas nucleus accumbens stimulation improved depressive symptoms",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.4140625,
            "text": "caudate nucleus stimulation preferentially",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.42578125,
            "text": "caudate nucleus stimulation preferentially alleviated OCD manifestations, whereas nucleus accumbens stimulation improved depressive",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 8.921875,
            "text": "of clinical outcomes and anatomical data on electrode positioning showed that caudate nucleus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 8.921875,
            "text": "clinical outcomes and anatomical data on electrode positioning showed that caudate nucleus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.546875,
            "end_logit": 8.921875,
            "text": "anatomical data on electrode positioning showed that caudate nucleus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.8662109375,
            "end_logit": -4.08984375,
            "text": "nucleus stimulation preferentially alleviated OCD manifestations, whereas nucleus accumbens",
            "probability": 0.0
        },
        {
            "start_logit": -1.8662109375,
            "end_logit": -5.09765625,
            "text": "nucleus stimulation",
            "probability": 0.0
        },
        {
            "start_logit": -1.8662109375,
            "end_logit": -6.12890625,
            "text": "nucleus stimulation preferentially alleviated OCD manifestations, whereas nucleus accumbens stimulation improved depressive symptoms.",
            "probability": 0.0
        },
        {
            "start_logit": -3.9765625,
            "end_logit": -4.08984375,
            "text": "nucleus accumbens",
            "probability": 0.0
        }
    ],
    "58da2a348acda34529000014_1": [
        {
            "start_logit": 7.5,
            "end_logit": 7.99609375,
            "text": "AFP",
            "probability": 1.0
        },
        {
            "start_logit": -6.37109375,
            "end_logit": 7.99609375,
            "text": ", \u03b1-fetoprotein (AFP",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -6.546875,
            "end_logit": 7.99609375,
            "text": "\u03b1-fetoprotein (AFP",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.95703125,
            "end_logit": 7.99609375,
            "text": "Chorionic gonadotropin (CG), \u03b1-fetoprotein (AFP",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.5,
            "end_logit": -6.62109375,
            "text": "AFP)",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 7.99609375,
            "text": "(AFP",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.5,
            "end_logit": -6.66796875,
            "text": "AFP) and",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 7.99609375,
            "text": "-fetoprotein (AFP",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.40234375,
            "end_logit": 7.99609375,
            "text": "gonadotropin (CG), \u03b1-fetoprotein (AFP",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.5,
            "end_logit": -6.92578125,
            "text": "AFP) and unconjugated oestriol",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.5,
            "end_logit": -7.25,
            "text": "AFP) and unconjugated oestriol (uE3) were measured on Siemens Immulite analyzer.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.5,
            "end_logit": -7.41015625,
            "text": "AFP) and unconjugated oestriol (uE3",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.5,
            "end_logit": -7.4765625,
            "text": "AFP) and unconjugated oestr",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.5,
            "end_logit": -7.5234375,
            "text": "AFP) and unconjugated",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.5,
            "end_logit": -7.53125,
            "text": "AFP) and unconjugated oestriol (uE3) were measured on Siemens",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.5,
            "end_logit": -7.53125,
            "text": "AFP) and unconjugated oestriol (uE3)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.5,
            "end_logit": -7.546875,
            "text": "AFP) and unconjugated oestriol (uE3) were measured on Siemens Immulite",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.5,
            "end_logit": -7.546875,
            "text": "AFP) and unconjugated oestriol (uE3) were measured on Siemens Immulite analyzer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.5,
            "end_logit": -7.55859375,
            "text": "AFP) and unconjugated oestriol (u",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.5,
            "end_logit": -7.56640625,
            "text": "AFP) and unconjugated oestriol (uE",
            "probability": 1.7881393432617188e-07
        }
    ],
    "58da2a348acda34529000014_2": [
        {
            "start_logit": 8.421875,
            "end_logit": 7.578125,
            "text": "alpha-fetoprotein",
            "probability": 1.0
        },
        {
            "start_logit": 8.421875,
            "end_logit": -2.115234375,
            "text": "alpha-fetoprotein, human chorionic gonadotropin",
            "probability": 6.157159805297852e-05
        },
        {
            "start_logit": 8.421875,
            "end_logit": -2.548828125,
            "text": "alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol",
            "probability": 4.00543212890625e-05
        },
        {
            "start_logit": 8.421875,
            "end_logit": -2.71875,
            "text": "alpha",
            "probability": 3.3736228942871094e-05
        },
        {
            "start_logit": -3.91796875,
            "end_logit": 7.578125,
            "text": "fetoprotein",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": 8.421875,
            "end_logit": -5.4609375,
            "text": "alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol for the prenatal diagnosis of fetal chromosomal abnormalities",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 8.421875,
            "end_logit": -6.9453125,
            "text": "alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol for the prenatal diagnosis of fetal chromosomal abnormalities in Turkish pregnant women.",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.171875,
            "end_logit": 7.578125,
            "text": "of alpha-fetoprotein",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.421875,
            "end_logit": -7.05078125,
            "text": "alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estr",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.3125,
            "end_logit": 7.578125,
            "text": "-fetoprotein",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.421875,
            "end_logit": -7.31640625,
            "text": "alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol for the prenatal diagnosis of fetal chromosomal abnormalities in Turkish pregnant women",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.421875,
            "end_logit": -7.5546875,
            "text": "alpha-fetoprotein, human chorionic",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.421875,
            "end_logit": -7.61328125,
            "text": "alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol for the prenatal diagnosis of fetal chromosomal abnormalities in Turkish",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.421875,
            "end_logit": -7.62109375,
            "text": "alpha-fetoprotein, human chorionic gonadotropin, and unconjugated",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.828125,
            "end_logit": 7.578125,
            "text": "triple marker screening of alpha-fetoprotein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.87109375,
            "end_logit": 7.578125,
            "text": "to evaluate the reliability of maternal serum triple marker screening of alpha-fetoprotein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.9140625,
            "end_logit": 7.578125,
            "text": "article was to evaluate the reliability of maternal serum triple marker screening of alpha-fetoprotein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.91796875,
            "end_logit": 7.578125,
            "text": "evaluate the reliability of maternal serum triple marker screening of alpha-fetoprotein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -1.482421875,
            "end_logit": -2.115234375,
            "text": "human chorionic gonadotropin",
            "probability": 0.0
        },
        {
            "start_logit": -1.482421875,
            "end_logit": -2.548828125,
            "text": "human chorionic gonadotropin, and unconjugated estriol",
            "probability": 0.0
        }
    ],
    "58da2a348acda34529000014_3": [
        {
            "start_logit": 8.9140625,
            "end_logit": 8.78125,
            "text": "alpha-fetoprotein",
            "probability": 0.9990234375
        },
        {
            "start_logit": 8.9140625,
            "end_logit": 1.6142578125,
            "text": "alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down's syndrome",
            "probability": 0.0007791519165039062
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -1.9990234375,
            "text": "alpha",
            "probability": 2.092123031616211e-05
        },
        {
            "start_logit": -2.361328125,
            "end_logit": 8.78125,
            "text": "fetoprotein",
            "probability": 1.2814998626708984e-05
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -5.58984375,
            "text": "alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.14453125,
            "end_logit": 8.78125,
            "text": "-fetoprotein",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.2421875,
            "end_logit": 8.78125,
            "text": "(alpha-fetoprotein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -6.53515625,
            "text": "alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down'",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -6.6015625,
            "text": "alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down's",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 0.483154296875,
            "end_logit": 1.6142578125,
            "text": "Down's syndrome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -6.96484375,
            "text": "alpha-fetoprotein, beta-chorionic gonadotrophin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -7.1640625,
            "text": "alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.07421875,
            "end_logit": 8.78125,
            "text": "compare triple test screening (alpha-fetoprotein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.14453125,
            "end_logit": 8.78125,
            "text": "triple test screening (alpha-fetoprotein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -7.31640625,
            "text": "alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated oestr",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -7.38671875,
            "text": "alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -7.45703125,
            "text": "alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -7.5390625,
            "text": "alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down's syndrome in women of 35",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -7.54296875,
            "text": "alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.361328125,
            "end_logit": 1.6142578125,
            "text": "fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down's syndrome",
            "probability": 0.0
        }
    ],
    "58da2a348acda34529000014_4": [
        {
            "start_logit": 8.9140625,
            "end_logit": 8.78125,
            "text": "alpha-fetoprotein",
            "probability": 0.9990234375
        },
        {
            "start_logit": 8.9140625,
            "end_logit": 1.6142578125,
            "text": "alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down's syndrome",
            "probability": 0.0007791519165039062
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -1.9990234375,
            "text": "alpha",
            "probability": 2.092123031616211e-05
        },
        {
            "start_logit": -2.361328125,
            "end_logit": 8.78125,
            "text": "fetoprotein",
            "probability": 1.2814998626708984e-05
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -5.58984375,
            "text": "alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.14453125,
            "end_logit": 8.78125,
            "text": "-fetoprotein",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.2421875,
            "end_logit": 8.78125,
            "text": "(alpha-fetoprotein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -6.53515625,
            "text": "alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down'",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -6.6015625,
            "text": "alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down's",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 0.483154296875,
            "end_logit": 1.6142578125,
            "text": "Down's syndrome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -6.96484375,
            "text": "alpha-fetoprotein, beta-chorionic gonadotrophin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -7.1640625,
            "text": "alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.07421875,
            "end_logit": 8.78125,
            "text": "compare triple test screening (alpha-fetoprotein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.14453125,
            "end_logit": 8.78125,
            "text": "triple test screening (alpha-fetoprotein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -7.31640625,
            "text": "alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated oestr",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -7.38671875,
            "text": "alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -7.45703125,
            "text": "alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -7.5390625,
            "text": "alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down's syndrome in women of 35",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -7.54296875,
            "text": "alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.361328125,
            "end_logit": 1.6142578125,
            "text": "fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down's syndrome",
            "probability": 0.0
        }
    ],
    "58da2a348acda34529000014_5": [
        {
            "start_logit": 8.75,
            "end_logit": 7.96875,
            "text": "alpha-fetoprotein",
            "probability": 1.0
        },
        {
            "start_logit": 8.75,
            "end_logit": -2.1171875,
            "text": "alpha",
            "probability": 4.166364669799805e-05
        },
        {
            "start_logit": -3.44140625,
            "end_logit": 7.96875,
            "text": "fetoprotein",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": -4.52734375,
            "end_logit": 7.96875,
            "text": "PAPP-A at 10 weeks of pregnancy was better than the double test (alpha-fetoprotein",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": -5.67578125,
            "end_logit": 7.96875,
            "text": "(alpha-fetoprotein",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.75,
            "end_logit": -6.66796875,
            "text": "alpha-fetoprotein and hCG with maternal age",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.75,
            "end_logit": -6.70703125,
            "text": "alpha-fetoprotein and hCG with maternal age)",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.1640625,
            "end_logit": 7.96875,
            "text": "beta-hCG and PAPP-A at 10 weeks of pregnancy was better than the double test (alpha-fetoprotein",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.75,
            "end_logit": -7.0234375,
            "text": "alpha-fetoprotein and hCG",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.75,
            "end_logit": -7.2109375,
            "text": "alpha-fetoprotein and hCG with maternal age) and similar to the triple test (alpha-fetoprotein, unconjugated oestriol and hCG with maternal age)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.4453125,
            "end_logit": 7.96875,
            "text": "pregnancy was better than the double test (alpha-fetoprotein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.75,
            "end_logit": -7.234375,
            "text": "alpha-fetoprotein and hCG with maternal age) and similar to the triple test (alpha-fetoprotein, unconjugated oestriol and hCG with maternal age",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.453125,
            "end_logit": 7.96875,
            "text": "double test (alpha-fetoprotein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.46875,
            "end_logit": 7.96875,
            "text": "than the double test (alpha-fetoprotein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.484375,
            "end_logit": 7.96875,
            "text": "maternal age and serum-free beta-hCG and PAPP-A at 10 weeks of pregnancy was better than the double test (alpha-fetoprotein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.546875,
            "end_logit": 7.96875,
            "text": "-fetoprotein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.578125,
            "end_logit": 7.96875,
            "text": "using maternal age and serum-free beta-hCG and PAPP-A at 10 weeks of pregnancy was better than the double test (alpha-fetoprotein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.609375,
            "end_logit": 7.96875,
            "text": "better than the double test (alpha-fetoprotein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.7578125,
            "end_logit": 7.96875,
            "text": "serum-free beta-hCG and PAPP-A at 10 weeks of pregnancy was better than the double test (alpha-fetoprotein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.828125,
            "end_logit": 7.96875,
            "text": "of pregnancy was better than the double test (alpha-fetoprotein",
            "probability": 1.7881393432617188e-07
        }
    ],
    "58da2a348acda34529000014_6": [
        {
            "start_logit": 8.2734375,
            "end_logit": 8.0859375,
            "text": "Down syndrome",
            "probability": 0.67919921875
        },
        {
            "start_logit": 7.51171875,
            "end_logit": 8.09375,
            "text": "alpha-fetoprotein",
            "probability": 0.32080078125
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -2.81640625,
            "text": "Down",
            "probability": 1.245737075805664e-05
        },
        {
            "start_logit": -3.205078125,
            "end_logit": 8.09375,
            "text": "fetoprotein",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": -3.255859375,
            "end_logit": 8.0859375,
            "text": "syndrome",
            "probability": 6.67572021484375e-06
        },
        {
            "start_logit": 7.51171875,
            "end_logit": -3.93359375,
            "text": "alpha",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 7.51171875,
            "end_logit": -4.51953125,
            "text": "alpha-fetoprotein, human chorionic gonadotropin and unconjugated estriol",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -6.4375,
            "end_logit": 8.09375,
            "text": "-fetoprotein",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.5078125,
            "end_logit": 8.09375,
            "text": "of alpha-fetoprotein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.59375,
            "end_logit": 8.09375,
            "text": "maternal serum levels of alpha-fetoprotein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.80859375,
            "end_logit": 8.09375,
            "text": ".\"Triple-marker\" screening of maternal serum levels of alpha-fetoprotein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.859375,
            "end_logit": 8.0859375,
            "text": "make recommendations to physicians providing prenatal care on (1) whether prenatal screening for and diagnosis of Down syndrome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.875,
            "end_logit": 8.0859375,
            "text": "whether prenatal screening for and diagnosis of Down syndrome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.88671875,
            "end_logit": 8.09375,
            "text": "Triple-marker\" screening of maternal serum levels of alpha-fetoprotein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -7.1328125,
            "text": "Down syndrome (DS) is advisable and (2) alternative screening and diagnosis manoeuvres.\"Triple-marker\" screening of maternal serum",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -7.265625,
            "text": "Down syndrome (DS)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.51171875,
            "end_logit": -6.73046875,
            "text": "alpha-fetoprotein, human chorionic gonadotropin and unconjugated estr",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.51171875,
            "end_logit": -6.7578125,
            "text": "alpha-fetoprotein, human chorionic gonadotropin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.51171875,
            "end_logit": -7.30078125,
            "text": "alpha-fetoprotein, human chorionic gonadotropin and unconjugated",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.205078125,
            "end_logit": -4.51953125,
            "text": "fetoprotein, human chorionic gonadotropin and unconjugated estriol",
            "probability": 0.0
        }
    ],
    "58da2a348acda34529000014_7": [
        {
            "start_logit": 5.48046875,
            "end_logit": 6.796875,
            "text": "MSAFP",
            "probability": 0.8974609375
        },
        {
            "start_logit": 2.9296875,
            "end_logit": 6.796875,
            "text": "maternal serum alpha fetoprotein (MSAFP",
            "probability": 0.0697021484375
        },
        {
            "start_logit": 2.9296875,
            "end_logit": 6.01171875,
            "text": "maternal serum alpha fetoprotein",
            "probability": 0.03167724609375
        },
        {
            "start_logit": -2.23828125,
            "end_logit": 6.796875,
            "text": "DS fetus due to either advanced maternal age (AMA) or a positive expanded maternal serum alpha fetoprotein (MSAFP",
            "probability": 0.0003974437713623047
        },
        {
            "start_logit": -2.23828125,
            "end_logit": 6.796875,
            "text": "expanded maternal serum alpha fetoprotein (MSAFP",
            "probability": 0.0003974437713623047
        },
        {
            "start_logit": -2.23828125,
            "end_logit": 6.01171875,
            "text": "DS fetus due to either advanced maternal age (AMA) or a positive expanded maternal serum alpha fetoprotein",
            "probability": 0.0001811981201171875
        },
        {
            "start_logit": -2.23828125,
            "end_logit": 6.01171875,
            "text": "expanded maternal serum alpha fetoprotein",
            "probability": 0.0001811981201171875
        },
        {
            "start_logit": -4.296875,
            "end_logit": 6.796875,
            "text": "alpha fetoprotein (MSAFP",
            "probability": 5.072355270385742e-05
        },
        {
            "start_logit": -4.30078125,
            "end_logit": 6.796875,
            "text": "FP",
            "probability": 5.072355270385742e-05
        },
        {
            "start_logit": -4.90625,
            "end_logit": 6.796875,
            "text": "positive expanded maternal serum alpha fetoprotein (MSAFP",
            "probability": 2.753734588623047e-05
        },
        {
            "start_logit": -4.296875,
            "end_logit": 6.01171875,
            "text": "alpha fetoprotein",
            "probability": 2.3186206817626953e-05
        },
        {
            "start_logit": -5.296875,
            "end_logit": 6.796875,
            "text": "fetoprotein (MSAFP",
            "probability": 1.8656253814697266e-05
        },
        {
            "start_logit": -5.5390625,
            "end_logit": 6.796875,
            "text": "advanced maternal age (AMA) or a positive expanded maternal serum alpha fetoprotein (MSAFP",
            "probability": 1.4662742614746094e-05
        },
        {
            "start_logit": -4.90625,
            "end_logit": 6.01171875,
            "text": "positive expanded maternal serum alpha fetoprotein",
            "probability": 1.2636184692382812e-05
        },
        {
            "start_logit": -5.828125,
            "end_logit": 6.796875,
            "text": "serum alpha fetoprotein (MSAFP",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": -5.296875,
            "end_logit": 6.01171875,
            "text": "fetoprotein",
            "probability": 8.58306884765625e-06
        },
        {
            "start_logit": -5.5390625,
            "end_logit": 6.01171875,
            "text": "advanced maternal age (AMA) or a positive expanded maternal serum alpha fetoprotein",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": -6.5234375,
            "end_logit": 6.796875,
            "text": "a DS fetus due to either advanced maternal age (AMA) or a positive expanded maternal serum alpha fetoprotein (MSAFP",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": -5.828125,
            "end_logit": 6.01171875,
            "text": "serum alpha fetoprotein",
            "probability": 5.0067901611328125e-06
        },
        {
            "start_logit": 5.48046875,
            "end_logit": -5.3359375,
            "text": "MSA",
            "probability": 4.827976226806641e-06
        }
    ],
    "58da2a348acda34529000014_8": [
        {
            "start_logit": 9.0234375,
            "end_logit": 8.6171875,
            "text": "Down syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -1.6904296875,
            "text": "Down",
            "probability": 3.319978713989258e-05
        },
        {
            "start_logit": -2.65625,
            "end_logit": 8.6171875,
            "text": "syndrome",
            "probability": 8.463859558105469e-06
        },
        {
            "start_logit": -4.73046875,
            "end_logit": 8.6171875,
            "text": "alpha-fetoprotein in the triple screen test, and with the addition of inhibin-A in the quadruple marker test for detecting Down syndrome",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -4.98828125,
            "end_logit": 8.6171875,
            "text": "estriol and alpha-fetoprotein in the triple screen test, and with the addition of inhibin-A in the quadruple marker test for detecting Down syndrome",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.18359375,
            "text": "Down syndrome in the second trimester of pregnancy.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.99609375,
            "end_logit": 8.6171875,
            "text": "inhibin-A in the quadruple marker test for detecting Down syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.00390625,
            "end_logit": 8.6171875,
            "text": "detecting Down syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.08203125,
            "end_logit": 8.6171875,
            "text": "and alpha-fetoprotein in the triple screen test, and with the addition of inhibin-A in the quadruple marker test for detecting Down syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.49609375,
            "text": "Down syndrome in the second trimester of pregnancy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.25390625,
            "end_logit": 8.6171875,
            "text": "with the addition of inhibin-A in the quadruple marker test for detecting Down syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2578125,
            "end_logit": 8.6171875,
            "text": "quadruple marker test for detecting Down syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3046875,
            "end_logit": 8.6171875,
            "text": "triple screen test, and with the addition of inhibin-A in the quadruple marker test for detecting Down syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.73046875,
            "end_logit": -1.6904296875,
            "text": "alpha-fetoprotein in the triple screen test, and with the addition of inhibin-A in the quadruple marker test for detecting Down",
            "probability": 0.0
        },
        {
            "start_logit": -4.98828125,
            "end_logit": -1.6904296875,
            "text": "estriol and alpha-fetoprotein in the triple screen test, and with the addition of inhibin-A in the quadruple marker test for detecting Down",
            "probability": 0.0
        },
        {
            "start_logit": -6.99609375,
            "end_logit": -1.6904296875,
            "text": "inhibin-A in the quadruple marker test for detecting Down",
            "probability": 0.0
        },
        {
            "start_logit": -7.00390625,
            "end_logit": -1.6904296875,
            "text": "detecting Down",
            "probability": 0.0
        },
        {
            "start_logit": -7.08203125,
            "end_logit": -1.6904296875,
            "text": "and alpha-fetoprotein in the triple screen test, and with the addition of inhibin-A in the quadruple marker test for detecting Down",
            "probability": 0.0
        },
        {
            "start_logit": -7.25390625,
            "end_logit": -1.6904296875,
            "text": "with the addition of inhibin-A in the quadruple marker test for detecting Down",
            "probability": 0.0
        },
        {
            "start_logit": -7.2578125,
            "end_logit": -1.6904296875,
            "text": "quadruple marker test for detecting Down",
            "probability": 0.0
        }
    ],
    "58da2a348acda34529000014_9": [
        {
            "start_logit": 6.16796875,
            "end_logit": 7.046875,
            "text": "alpha-fetoprotein",
            "probability": 1.0
        },
        {
            "start_logit": -2.830078125,
            "end_logit": 7.046875,
            "text": "maternal serum alpha-fetoprotein",
            "probability": 0.0001233816146850586
        },
        {
            "start_logit": -4.5078125,
            "end_logit": 7.046875,
            "text": "fetoprotein",
            "probability": 2.300739288330078e-05
        },
        {
            "start_logit": 6.16796875,
            "end_logit": -3.88671875,
            "text": "alpha-fetoprotein, human chorionic gonadotropin",
            "probability": 1.7762184143066406e-05
        },
        {
            "start_logit": 6.16796875,
            "end_logit": -4.26171875,
            "text": "alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol",
            "probability": 1.2218952178955078e-05
        },
        {
            "start_logit": 6.16796875,
            "end_logit": -5.26953125,
            "text": "alpha",
            "probability": 4.470348358154297e-06
        },
        {
            "start_logit": -6.40625,
            "end_logit": 7.046875,
            "text": "-fetoprotein",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": -6.53125,
            "end_logit": 7.046875,
            "text": "serum alpha-fetoprotein",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": -6.64453125,
            "end_logit": 7.046875,
            "text": "for women undergoing triple-marker testing (maternal serum alpha-fetoprotein",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": -6.9453125,
            "end_logit": 7.046875,
            "text": "(maternal serum alpha-fetoprotein",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": -6.98046875,
            "end_logit": 7.046875,
            "text": "reviewed for women undergoing triple-marker testing (maternal serum alpha-fetoprotein",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -7.07421875,
            "end_logit": 7.046875,
            "text": "triple-marker testing (maternal serum alpha-fetoprotein",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -7.07421875,
            "end_logit": 7.046875,
            "text": "undergoing triple-marker testing (maternal serum alpha-fetoprotein",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 6.16796875,
            "end_logit": -6.921875,
            "text": "alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol).",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 6.16796875,
            "end_logit": -7.0234375,
            "text": "alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estr",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 6.16796875,
            "end_logit": -7.46484375,
            "text": "alpha-fetoprotein, human chorionic",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 6.16796875,
            "end_logit": -7.4921875,
            "text": "alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol)",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 6.16796875,
            "end_logit": -7.6171875,
            "text": "alpha-fetoprotein, human chorionic gonadotropin, and unconjugated",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -2.830078125,
            "end_logit": -3.88671875,
            "text": "maternal serum alpha-fetoprotein, human chorionic gonadotropin",
            "probability": 0.0
        },
        {
            "start_logit": -2.830078125,
            "end_logit": -4.26171875,
            "text": "maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol",
            "probability": 0.0
        }
    ],
    "61f52fca882a024a10000003_1": [
        {
            "start_logit": 9.234375,
            "end_logit": 9.0546875,
            "text": "Joubert syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.234375,
            "end_logit": -1.30859375,
            "text": "Jo",
            "probability": 3.170967102050781e-05
        },
        {
            "start_logit": -1.9853515625,
            "end_logit": 9.0546875,
            "text": "syndrome",
            "probability": 1.3530254364013672e-05
        },
        {
            "start_logit": 9.234375,
            "end_logit": -5.9296875,
            "text": "Joubert",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.76171875,
            "end_logit": 9.0546875,
            "text": "ubert syndrome",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.79296875,
            "end_logit": 9.0546875,
            "text": "odyssey and has prognostic implications for patients with presumed Joubert syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.3125,
            "text": "Joubert syndrome.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 9.0546875,
            "text": "t syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 9.0546875,
            "text": "ends diagnostic odyssey and has prognostic implications for patients with presumed Joubert syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 9.0546875,
            "text": "diagnostic odyssey and has prognostic implications for patients with presumed Joubert syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 9.0546875,
            "text": "presumed Joubert syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.578125,
            "end_logit": 9.0546875,
            "text": "with presumed Joubert syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65625,
            "end_logit": 9.0546875,
            "text": "patients with presumed Joubert syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.66796875,
            "end_logit": 9.0546875,
            "text": "for patients with presumed Joubert syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 9.0546875,
            "text": "Identification of LAMA1 mutations ends diagnostic odyssey and has prognostic implications for patients with presumed Joubert syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.79296875,
            "end_logit": -1.30859375,
            "text": "odyssey and has prognostic implications for patients with presumed Jo",
            "probability": 0.0
        },
        {
            "start_logit": -7.4921875,
            "end_logit": -1.30859375,
            "text": "ends diagnostic odyssey and has prognostic implications for patients with presumed Jo",
            "probability": 0.0
        },
        {
            "start_logit": -7.50390625,
            "end_logit": -1.30859375,
            "text": "diagnostic odyssey and has prognostic implications for patients with presumed Jo",
            "probability": 0.0
        },
        {
            "start_logit": -7.53515625,
            "end_logit": -1.30859375,
            "text": "presumed Jo",
            "probability": 0.0
        },
        {
            "start_logit": -7.578125,
            "end_logit": -1.30859375,
            "text": "with presumed Jo",
            "probability": 0.0
        }
    ],
    "61f52fca882a024a10000003_2": [
        {
            "start_logit": 8.5859375,
            "end_logit": 8.4609375,
            "text": "Joubert syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -2.466796875,
            "text": "Jo",
            "probability": 1.7940998077392578e-05
        },
        {
            "start_logit": -2.8671875,
            "end_logit": 8.4609375,
            "text": "syndrome",
            "probability": 1.0609626770019531e-05
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -4.26953125,
            "text": "Joubert",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": -6.70703125,
            "end_logit": 8.4609375,
            "text": ". Joubert syndrome",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -6.87890625,
            "text": "Jouber",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 8.4609375,
            "text": "ubert syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.28125,
            "end_logit": 8.4609375,
            "text": "Paediatric neurology syndromes are a broad and complex group of conditions with a large spectrum of clinical phenotypes. Joubert syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.70703125,
            "end_logit": -2.466796875,
            "text": ". Jo",
            "probability": 0.0
        },
        {
            "start_logit": -7.28125,
            "end_logit": -2.466796875,
            "text": "Paediatric neurology syndromes are a broad and complex group of conditions with a large spectrum of clinical phenotypes. Jo",
            "probability": 0.0
        },
        {
            "start_logit": -2.8671875,
            "end_logit": -6.9765625,
            "text": "syndrome is a genetically heterogeneous neurological ciliopathy syndrome with molar tooth sign as the neuroimaging hallmark. We reviewed the clinical, radiological and genetic data for several families",
            "probability": 0.0
        },
        {
            "start_logit": -4.62890625,
            "end_logit": -5.48046875,
            "text": "cerebellar dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -6.70703125,
            "end_logit": -4.26953125,
            "text": ". Joubert",
            "probability": 0.0
        },
        {
            "start_logit": -7.1484375,
            "end_logit": -4.26953125,
            "text": "ubert",
            "probability": 0.0
        },
        {
            "start_logit": -7.28125,
            "end_logit": -4.26953125,
            "text": "Paediatric neurology syndromes are a broad and complex group of conditions with a large spectrum of clinical phenotypes. Joubert",
            "probability": 0.0
        },
        {
            "start_logit": -4.62890625,
            "end_logit": -7.015625,
            "text": "cerebellar dysplasia and cerebellar cysts",
            "probability": 0.0
        },
        {
            "start_logit": -6.2265625,
            "end_logit": -5.890625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.23828125,
            "end_logit": -5.89453125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.0703125,
            "end_logit": -5.89453125,
            "text": "families with a clinical diagnosis of Joubert syndrome but negative genetic analysis.",
            "probability": 0.0
        },
        {
            "start_logit": -7.1796875,
            "end_logit": -5.890625,
            "text": "intellectual disability and Joubert syndrome gene panels and promote a wider awareness of the clinical and radiological features of these syndromes.",
            "probability": 0.0
        }
    ],
    "61f52fca882a024a10000003_3": [
        {
            "start_logit": 9.09375,
            "end_logit": 8.78125,
            "text": "Knobloch syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.09375,
            "end_logit": -1.595703125,
            "text": "Kn",
            "probability": 3.11732292175293e-05
        },
        {
            "start_logit": 9.09375,
            "end_logit": -1.8466796875,
            "text": "Knobloch",
            "probability": 2.4318695068359375e-05
        },
        {
            "start_logit": -2.3984375,
            "end_logit": 8.78125,
            "text": "syndrome",
            "probability": 1.0192394256591797e-05
        },
        {
            "start_logit": 9.09375,
            "end_logit": -4.05859375,
            "text": "Knobloch syndrome, and the patients with LAMA1 mutations had Poretti-Boltshauser syndrome",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 9.09375,
            "end_logit": -4.71484375,
            "text": "Knoblo",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -4.7421875,
            "end_logit": 8.78125,
            "text": "had Knobloch syndrome",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.41015625,
            "text": "Knobloch syndrome, and the patients with LAMA1 mutations had Poretti-Boltshauser",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.546875,
            "text": "Knob",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.81640625,
            "text": "Knobloch syndrome, and the patients with LAMA1 mutations had Poretti-Boltsha",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.0234375,
            "text": "Knobloch syndrome, and the patients with LAMA1 mutations had Poretti-Boltshauser syndrome.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.0546875,
            "text": "Knobloch syndrome, and the patients with LAMA1 mutations had Poretti-Boltshause",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.10546875,
            "text": "Knobloch syndrome, and the patients with LAMA1 mutations had Porett",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.1171875,
            "text": "Knobloch syndrome, and the patients with LAMA1 mutations had Poretti",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.21875,
            "text": "Knobloch syndrome, and the patients with LAMA1 mutations had Poretti-Bolts",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.99609375,
            "end_logit": 8.78125,
            "text": ". Further assessments indicated that patients with COL18A1 mutations had Knobloch syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.3203125,
            "text": "Knobloch syndrome, and the patients with LAMA1 mutations had Pore",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.01171875,
            "end_logit": 8.78125,
            "text": "obloch syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.3359375,
            "text": "Knobloch syndrome, and the patients with LAMA1 mutations had Poretti-Bol",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.484375,
            "end_logit": 8.78125,
            "text": "Further assessments indicated that patients with COL18A1 mutations had Knobloch syndrome",
            "probability": 5.960464477539063e-08
        }
    ],
    "6027505c1cb411341a0000e6_1": [
        {
            "start_logit": 9.1875,
            "end_logit": 6.49609375,
            "text": "Thulium laser",
            "probability": 1.0
        },
        {
            "start_logit": 9.1875,
            "end_logit": -1.3291015625,
            "text": "Th",
            "probability": 0.00039839744567871094
        },
        {
            "start_logit": 9.1875,
            "end_logit": -4.78125,
            "text": "Thulium laser transurethral vaporesection of the prostate",
            "probability": 1.2636184692382812e-05
        },
        {
            "start_logit": 9.1875,
            "end_logit": -4.89453125,
            "text": "Thulium",
            "probability": 1.1324882507324219e-05
        },
        {
            "start_logit": 9.1875,
            "end_logit": -5.359375,
            "text": "Thulium laser transurethral vaporesection of the prostate versus transurethral resection of the prostate for men with lower urinary tract symptoms or urinary retention",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": 9.1875,
            "end_logit": -6.12890625,
            "text": "Thulium laser transurethral vaporesection",
            "probability": 3.2782554626464844e-06
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.02734375,
            "text": "Thulium laser transurethral vaporesect",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.10546875,
            "text": "Thulium laser transurethral vaporesection of",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.21484375,
            "text": "Thulium laser transurethral vaporese",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.2578125,
            "text": "Thulium laser transurethral vapor",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.296875,
            "text": "Thulium laser transurethral vaporesection of the prostate versus transurethral resection of the prostate for men with lower urinary tract symptoms",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.3359375,
            "text": "Thulium laser transurethral vaporesection of the prostate versus",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.3671875,
            "text": "Thulium laser transurethral vaporesection of the",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.39453125,
            "text": "Thulium laser transurethral vaporesection of the prostate versus transurethral resection",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.4453125,
            "text": "Thulium laser transurethral vaporesection of the prostate versus transurethral resection of the prostate for men with lower urinary tract symptoms or urinary",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.4921875,
            "text": "Thulium laser transurethral vaporesection of the prostate versus transurethral resection of",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -5.14453125,
            "end_logit": 6.49609375,
            "text": "laser",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.44140625,
            "end_logit": 6.49609375,
            "text": "ulium laser",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.14453125,
            "end_logit": -4.78125,
            "text": "laser transurethral vaporesection of the prostate",
            "probability": 0.0
        },
        {
            "start_logit": -5.14453125,
            "end_logit": -5.359375,
            "text": "laser transurethral vaporesection of the prostate versus transurethral resection of the prostate for men with lower urinary tract symptoms or urinary retention",
            "probability": 0.0
        }
    ],
    "6027505c1cb411341a0000e6_2": [
        {
            "start_logit": 0.43505859375,
            "end_logit": -3.564453125,
            "text": "Transurethral resection of the prostate (TURP)",
            "probability": 0.58203125
        },
        {
            "start_logit": 0.43505859375,
            "end_logit": -5.40625,
            "text": "Transurethral resection of the prostate (TURP",
            "probability": 0.09210205078125
        },
        {
            "start_logit": -1.494140625,
            "end_logit": -3.712890625,
            "text": "TURP versus ThuVARP in men with lower urinary tract symptoms or urinary retention",
            "probability": 0.07281494140625
        },
        {
            "start_logit": 0.43505859375,
            "end_logit": -5.6875,
            "text": "Transurethral resection of the prostate",
            "probability": 0.06951904296875
        },
        {
            "start_logit": 0.43505859375,
            "end_logit": -6.0,
            "text": "Transurethral resection of the prostate (TURP) is the standard operation for benign prostatic obstruction. Thulium laser",
            "probability": 0.050872802734375
        },
        {
            "start_logit": 0.43505859375,
            "end_logit": -6.421875,
            "text": "Transurethral resection of the prostate (TURP) is the standard operation for benign prostatic obstruction. Thulium",
            "probability": 0.033355712890625
        },
        {
            "start_logit": 0.43505859375,
            "end_logit": -6.8359375,
            "text": "Transurethral resection",
            "probability": 0.0220489501953125
        },
        {
            "start_logit": 0.43505859375,
            "end_logit": -6.90234375,
            "text": "Transurethral resection of the prostate (TURP) is the standard operation for benign prostatic obstruction",
            "probability": 0.0206298828125
        },
        {
            "start_logit": -2.2421875,
            "end_logit": -4.8671875,
            "text": "TURP",
            "probability": 0.01087188720703125
        },
        {
            "start_logit": -1.494140625,
            "end_logit": -5.640625,
            "text": "TURP versus ThuVARP",
            "probability": 0.01062774658203125
        },
        {
            "start_logit": -2.2421875,
            "end_logit": -4.92578125,
            "text": "TURP.",
            "probability": 0.01025390625
        },
        {
            "start_logit": -1.494140625,
            "end_logit": -6.09375,
            "text": "TURP",
            "probability": 0.00675201416015625
        },
        {
            "start_logit": -4.484375,
            "end_logit": -3.712890625,
            "text": "urinary retention",
            "probability": 0.0036716461181640625
        },
        {
            "start_logit": -2.306640625,
            "end_logit": -6.0,
            "text": "Thulium laser",
            "probability": 0.0032901763916015625
        },
        {
            "start_logit": -1.494140625,
            "end_logit": -6.953125,
            "text": "TURP versus Th",
            "probability": 0.002857208251953125
        },
        {
            "start_logit": -2.306640625,
            "end_logit": -6.421875,
            "text": "Thulium",
            "probability": 0.0021572113037109375
        },
        {
            "start_logit": -2.306640625,
            "end_logit": -6.59375,
            "text": "Thulium laser transurethral vaporesection of the prostate (ThuVARP) is a technique with suggested advantages over TURP",
            "probability": 0.0018167495727539062
        },
        {
            "start_logit": -5.421875,
            "end_logit": -3.564453125,
            "text": "TURP)",
            "probability": 0.0016679763793945312
        },
        {
            "start_logit": -2.306640625,
            "end_logit": -6.80859375,
            "text": "Thulium laser transurethral vaporesection of the prostate (ThuVARP)",
            "probability": 0.0014600753784179688
        },
        {
            "start_logit": -5.5234375,
            "end_logit": -3.712890625,
            "text": ". We aimed to investigate TURP versus ThuVARP in men with lower urinary tract symptoms or urinary retention",
            "probability": 0.0012979507446289062
        }
    ],
    "6027505c1cb411341a0000e6_3": [
        {
            "start_logit": 9.2578125,
            "end_logit": 9.1796875,
            "text": "thulium laser",
            "probability": 1.0
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -1.1806640625,
            "text": "th",
            "probability": 3.170967102050781e-05
        },
        {
            "start_logit": -1.5625,
            "end_logit": 9.1796875,
            "text": "laser",
            "probability": 1.996755599975586e-05
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -4.47265625,
            "text": "thulium laser transurethral vaporesection of the prostate",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -4.59765625,
            "text": "thulium laser transurethral vaporesection of the prostate in the UNBLOCS randomised controlled trial for benign prostatic obstruction.",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -4.73046875,
            "text": "thulium laser transurethral vaporesection of the prostate in the UNBLOCS randomised controlled trial for benign prostatic obstruction",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -4.8203125,
            "text": "thulium laser transurethral vaporesection",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -5.73046875,
            "end_logit": 9.1796875,
            "text": "ulium laser",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.08984375,
            "end_logit": 9.1796875,
            "text": "The cost-effectiveness of transurethral resection of the prostate vs thulium laser",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.3046875,
            "end_logit": 9.1796875,
            "text": "cost-effectiveness of transurethral resection of the prostate vs thulium laser",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -6.52734375,
            "text": "thulium",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.66796875,
            "end_logit": 9.1796875,
            "text": "transurethral resection of the prostate vs thulium laser",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.75,
            "end_logit": 9.1796875,
            "text": "vs thulium laser",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.78125,
            "end_logit": 9.1796875,
            "text": "um laser",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -6.890625,
            "text": "thulium laser transurethral vaporesect",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.03515625,
            "text": "thulium laser transurethral vaporesection of the prostate in the UNBLOCS randomised controlled trial for benign prostatic",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.09765625,
            "text": "thulium laser transurethral vaporese",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.14453125,
            "text": "thulium laser transurethral vapor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.24609375,
            "text": "thulium laser transurethral vaporesection of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.234375,
            "end_logit": 9.1796875,
            "text": "prostate vs thulium laser",
            "probability": 5.960464477539063e-08
        }
    ],
    "6027505c1cb411341a0000e6_4": [
        {
            "start_logit": 3.279296875,
            "end_logit": 2.19921875,
            "text": "thulium laser",
            "probability": 0.98291015625
        },
        {
            "start_logit": -1.63671875,
            "end_logit": 2.19921875,
            "text": "transurethral resection of the prostate (TURP) compared to the new laser technique of thulium laser",
            "probability": 0.0072174072265625
        },
        {
            "start_logit": -2.33984375,
            "end_logit": 2.19921875,
            "text": "TURP) compared to the new laser technique of thulium laser",
            "probability": 0.0035724639892578125
        },
        {
            "start_logit": 3.279296875,
            "end_logit": -4.26953125,
            "text": "thulium laser transurethral vaporesection of the prostate",
            "probability": 0.0015249252319335938
        },
        {
            "start_logit": 3.279296875,
            "end_logit": -4.734375,
            "text": "thulium",
            "probability": 0.0009617805480957031
        },
        {
            "start_logit": 3.279296875,
            "end_logit": -4.84375,
            "text": "thulium laser transurethral vaporesection",
            "probability": 0.0008616447448730469
        },
        {
            "start_logit": 3.279296875,
            "end_logit": -4.921875,
            "text": "thulium laser transurethral vaporesection of the prostate (ThuVARP) in men with benign prostatic obstruction",
            "probability": 0.000797271728515625
        },
        {
            "start_logit": 3.279296875,
            "end_logit": -5.74609375,
            "text": "thulium laser transurethral vaporesection of the prostate (ThuVARP",
            "probability": 0.00034809112548828125
        },
        {
            "start_logit": -4.8125,
            "end_logit": 2.19921875,
            "text": "laser technique of thulium laser",
            "probability": 0.0003001689910888672
        },
        {
            "start_logit": -5.19921875,
            "end_logit": 2.19921875,
            "text": "to the new laser technique of thulium laser",
            "probability": 0.0002046823501586914
        },
        {
            "start_logit": 3.279296875,
            "end_logit": -6.4375,
            "text": "thulium laser transurethral vaporesection of the prostate (ThuVARP)",
            "probability": 0.00017511844635009766
        },
        {
            "start_logit": 3.279296875,
            "end_logit": -6.6328125,
            "text": "thulium laser transurethral vaporesect",
            "probability": 0.00014400482177734375
        },
        {
            "start_logit": 3.279296875,
            "end_logit": -6.71875,
            "text": "thulium laser transurethral vaporesection of the prostate (ThuV",
            "probability": 0.0001322031021118164
        },
        {
            "start_logit": 3.279296875,
            "end_logit": -6.78125,
            "text": "thulium laser transurethral vaporesection of the prostate (ThuVARP) in men with benign prostatic",
            "probability": 0.00012421607971191406
        },
        {
            "start_logit": 3.279296875,
            "end_logit": -6.78515625,
            "text": "thulium laser transurethral vaporesection of the prostate (",
            "probability": 0.0001232624053955078
        },
        {
            "start_logit": 3.279296875,
            "end_logit": -6.953125,
            "text": "thulium laser transurethral",
            "probability": 0.00010454654693603516
        },
        {
            "start_logit": -6.1328125,
            "end_logit": 2.19921875,
            "text": "of thulium laser",
            "probability": 8.07642936706543e-05
        },
        {
            "start_logit": -6.18359375,
            "end_logit": 2.19921875,
            "text": "of transurethral resection of the prostate (TURP) compared to the new laser technique of thulium laser",
            "probability": 7.647275924682617e-05
        },
        {
            "start_logit": -6.234375,
            "end_logit": 2.19921875,
            "text": "new laser technique of thulium laser",
            "probability": 7.241964340209961e-05
        },
        {
            "start_logit": -6.2421875,
            "end_logit": 2.19921875,
            "text": "compared to the new laser technique of thulium laser",
            "probability": 7.241964340209961e-05
        }
    ],
    "6027505c1cb411341a0000e6_5": [
        {
            "start_logit": 9.1953125,
            "end_logit": 7.01953125,
            "text": "Thulium laser transurethral vaporesection",
            "probability": 0.9921875
        },
        {
            "start_logit": 9.1953125,
            "end_logit": 2.185546875,
            "text": "Thulium laser",
            "probability": 0.00788116455078125
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -1.34375,
            "text": "Th",
            "probability": 0.00023055076599121094
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -3.943359375,
            "text": "Thulium laser transurethral vaporesection versus transurethral resection of the prostate for benign prostatic obstruction",
            "probability": 1.710653305053711e-05
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -4.6484375,
            "text": "Thulium laser transurethral vaporesection versus transurethral resection of the prostate for benign prostatic obstruction: the UNBLOCS RCT.",
            "probability": 8.463859558105469e-06
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -5.234375,
            "text": "Thulium",
            "probability": 4.708766937255859e-06
        },
        {
            "start_logit": -4.3203125,
            "end_logit": 7.01953125,
            "text": "ion",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -6.66796875,
            "text": "Thulium laser transurethral vaporesect",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -6.67578125,
            "text": "Thulium laser transurethral vaporesection versus transurethral resection of the prostate",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -6.94140625,
            "text": "Thulium laser transurethral vaporese",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -6.95703125,
            "text": "Thulium laser transurethral vaporesection versus transurethral resection",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.0859375,
            "text": "Thulium laser transurethral vaporesection versus transurethral resection of the prostate for benign prostatic",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.15234375,
            "text": "Thulium laser transurethral vapor",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.1875,
            "text": "Thulium laser transurethral",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.375,
            "text": "Thulium laser transurethral vaporesection versus transurethral resection of",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.390625,
            "text": "Thulium laser transurethral vaporesection versus transurethral resection of the prostate for benign prostatic obstruction:",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.20703125,
            "end_logit": 7.01953125,
            "text": "ulium laser transurethral vaporesection",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 7.01953125,
            "text": "laser transurethral vaporesection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 7.01953125,
            "text": "transurethral vaporesection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59375,
            "end_logit": 7.01953125,
            "text": "um laser transurethral vaporesection",
            "probability": 5.960464477539063e-08
        }
    ],
    "6027505c1cb411341a0000e6_6": [
        {
            "start_logit": 8.21875,
            "end_logit": 3.583984375,
            "text": "thulium laser",
            "probability": 0.998046875
        },
        {
            "start_logit": 8.21875,
            "end_logit": -3.095703125,
            "text": "th",
            "probability": 0.0012531280517578125
        },
        {
            "start_logit": 8.21875,
            "end_logit": -4.12890625,
            "text": "thulium laser transurethral vaporesection of the prostate",
            "probability": 0.0004451274871826172
        },
        {
            "start_logit": 8.21875,
            "end_logit": -5.3828125,
            "text": "thulium laser transurethral vaporesection of the prostate (ThuVARP) versus transurethral resection of the prostate (TURP",
            "probability": 0.0001270771026611328
        },
        {
            "start_logit": 8.21875,
            "end_logit": -5.51953125,
            "text": "thulium laser transurethral vaporesection of the prostate (ThuVARP",
            "probability": 0.00011038780212402344
        },
        {
            "start_logit": 8.21875,
            "end_logit": -5.625,
            "text": "thulium laser transurethral vaporesection",
            "probability": 9.97781753540039e-05
        },
        {
            "start_logit": 8.21875,
            "end_logit": -5.9453125,
            "text": "thulium laser transurethral vaporesection of the prostate (ThuVARP)",
            "probability": 7.241964340209961e-05
        },
        {
            "start_logit": 8.21875,
            "end_logit": -6.203125,
            "text": "thulium laser transurethral vaporesection of the prostate (",
            "probability": 5.59687614440918e-05
        },
        {
            "start_logit": 8.21875,
            "end_logit": -6.31640625,
            "text": "thulium",
            "probability": 4.976987838745117e-05
        },
        {
            "start_logit": 8.21875,
            "end_logit": -6.60546875,
            "text": "thulium laser transurethral vaporesection of the prostate (ThuV",
            "probability": 3.7550926208496094e-05
        },
        {
            "start_logit": 8.21875,
            "end_logit": -6.90625,
            "text": "thulium laser transurethral vaporesect",
            "probability": 2.771615982055664e-05
        },
        {
            "start_logit": 8.21875,
            "end_logit": -7.0625,
            "text": "thulium laser transurethral vaporese",
            "probability": 2.3663043975830078e-05
        },
        {
            "start_logit": 8.21875,
            "end_logit": -7.08984375,
            "text": "thulium laser transurethral vapor",
            "probability": 2.3126602172851562e-05
        },
        {
            "start_logit": 8.21875,
            "end_logit": -7.09765625,
            "text": "thulium laser transurethral vaporesection of the prostate (ThuVARP) versus transurethral resection",
            "probability": 2.276897430419922e-05
        },
        {
            "start_logit": 8.21875,
            "end_logit": -7.109375,
            "text": "thulium laser transurethral vaporesection of the prostate (ThuVARP) versus transurethral resection of the prostate (TURP)",
            "probability": 2.2590160369873047e-05
        },
        {
            "start_logit": -6.5703125,
            "end_logit": 3.583984375,
            "text": "ulium laser",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.625,
            "end_logit": 3.583984375,
            "text": "of thulium laser",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.66796875,
            "end_logit": 3.583984375,
            "text": "cost effectiveness of thulium laser",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.83203125,
            "end_logit": 3.583984375,
            "text": "laser",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.99609375,
            "end_logit": 3.583984375,
            "text": "clinical and cost effectiveness of thulium laser",
            "probability": 2.384185791015625e-07
        }
    ],
    "6027505c1cb411341a0000e6_7": [
        {
            "start_logit": 9.25,
            "end_logit": 9.1171875,
            "text": "thulium laser",
            "probability": 1.0
        },
        {
            "start_logit": 9.25,
            "end_logit": -1.197265625,
            "text": "th",
            "probability": 3.2961368560791016e-05
        },
        {
            "start_logit": -1.703125,
            "end_logit": 9.1171875,
            "text": "laser",
            "probability": 1.7344951629638672e-05
        },
        {
            "start_logit": 9.25,
            "end_logit": -4.4453125,
            "text": "thulium laser transurethral vaporesection of the prostate",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 9.25,
            "end_logit": -4.92578125,
            "text": "thulium laser transurethral vaporesection of the prostate in the UNBLOCS randomised controlled trial for benign prostatic obstruction",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -5.07421875,
            "text": "thulium laser transurethral vaporesection",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -5.8125,
            "end_logit": 9.1171875,
            "text": "ulium laser",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.99609375,
            "end_logit": 9.1171875,
            "text": "The cost-effectiveness of transurethral resection of the prostate vs thulium laser",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.203125,
            "end_logit": 9.1171875,
            "text": "cost-effectiveness of transurethral resection of the prostate vs thulium laser",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -6.515625,
            "text": "thulium",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -6.8046875,
            "text": "thulium laser transurethral vaporesect",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -6.890625,
            "text": "thulium laser transurethral vaporesection of the prostate in the UNBLOCS randomised controlled trial for benign prostatic",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.7578125,
            "end_logit": 9.1171875,
            "text": "vs thulium laser",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.78125,
            "end_logit": 9.1171875,
            "text": "transurethral resection of the prostate vs thulium laser",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.03515625,
            "text": "thulium laser transurethral vaporese",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.90625,
            "end_logit": 9.1171875,
            "text": "um laser",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.1015625,
            "text": "thulium laser transurethral vapor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.203125,
            "text": "thulium laser transurethral vaporesection of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.32421875,
            "text": "thulium laser transurethral vaporesection of the prostate in the UNBLOCS randomised controlled",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.390625,
            "text": "thulium laser transurethral",
            "probability": 5.960464477539063e-08
        }
    ],
    "55031270e9bde6963400001a_1": [
        {
            "start_logit": 9.09375,
            "end_logit": 8.9453125,
            "text": "Fanconi anemia",
            "probability": 1.0
        },
        {
            "start_logit": 9.09375,
            "end_logit": -1.5634765625,
            "text": "Fa",
            "probability": 2.753734588623047e-05
        },
        {
            "start_logit": -2.083984375,
            "end_logit": 8.9453125,
            "text": "anemia",
            "probability": 1.4066696166992188e-05
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.0,
            "text": "Fanconi anemia and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.41015625,
            "text": "Fanconi anemia and dyskeratosis congenita",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.26953125,
            "end_logit": 8.9453125,
            "text": ": Fanconi anemia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.35546875,
            "end_logit": 8.9453125,
            "text": "nconi anemia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.16015625,
            "text": "Fanconi",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.16015625,
            "text": "Fanconi anemia and dyskeratosis congen",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.01171875,
            "end_logit": 8.9453125,
            "text": "oni anemia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.1640625,
            "text": "Fanconi anemia and dyskerato",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.16796875,
            "text": "Fanconi anemia and dyskeratosis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.3828125,
            "text": "Fanconi anemia and dyskera",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.3984375,
            "text": "Fanconi anemia and dysk",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.5078125,
            "text": "Fanc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 8.9453125,
            "text": "Ocular and orbital manifestations of the inherited bone marrow failure syndromes: Fanconi anemia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 8.9453125,
            "text": "manifestations of the inherited bone marrow failure syndromes: Fanconi anemia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 8.9453125,
            "text": "syndromes: Fanconi anemia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 8.9453125,
            "text": "of the inherited bone marrow failure syndromes: Fanconi anemia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6484375,
            "end_logit": 8.9453125,
            "text": "inherited bone marrow failure syndromes: Fanconi anemia",
            "probability": 5.960464477539063e-08
        }
    ],
    "55031270e9bde6963400001a_2": [
        {
            "start_logit": 9.0703125,
            "end_logit": 8.9296875,
            "text": "Fanconi anemia",
            "probability": 0.9912109375
        },
        {
            "start_logit": 4.35546875,
            "end_logit": 8.9296875,
            "text": "are Fanconi anemia",
            "probability": 0.00885009765625
        },
        {
            "start_logit": 9.0703125,
            "end_logit": -1.572265625,
            "text": "Fa",
            "probability": 2.7298927307128906e-05
        },
        {
            "start_logit": -2.021484375,
            "end_logit": 8.9296875,
            "text": "anemia",
            "probability": 1.5079975128173828e-05
        },
        {
            "start_logit": 4.35546875,
            "end_logit": -1.572265625,
            "text": "are Fa",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.0703125,
            "end_logit": -6.68359375,
            "text": "Fanconi anemia (FA)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0703125,
            "end_logit": -6.83203125,
            "text": "Fanconi",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.7265625,
            "end_logit": 8.9296875,
            "text": "nconi anemia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0703125,
            "end_logit": -7.0390625,
            "text": "Fanconi anemia (FA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.91796875,
            "end_logit": 8.9296875,
            "text": ". The 4 most frequent syndromes are Fanconi anemia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0703125,
            "end_logit": -7.1015625,
            "text": "Fanconi anemia (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.984375,
            "end_logit": 8.9296875,
            "text": "syndromes are Fanconi anemia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0703125,
            "end_logit": -7.203125,
            "text": "Fanconi anemia (FA), dyskeratosis congenita (DC), Diamond-Blackfan anemia (DBA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0703125,
            "end_logit": -7.26171875,
            "text": "Fanc",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.15625,
            "end_logit": 8.9296875,
            "text": "oni anemia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0703125,
            "end_logit": -7.3046875,
            "text": "Fanconi anemia (FA), dyskerato",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0703125,
            "end_logit": -7.328125,
            "text": "Fanconi anemia (FA), dyskeratosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0703125,
            "end_logit": -7.3359375,
            "text": "Fanconi anemia (FA), dyskeratosis congenita (DC), Diamond-Blackfan anemia (DBA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0703125,
            "end_logit": -7.3359375,
            "text": "Fanconi anemia (FA), dyskeratosis congenita (DC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0703125,
            "end_logit": -7.375,
            "text": "Fanconi anemia (FA), dyskeratosis congenita (DC)",
            "probability": 5.960464477539063e-08
        }
    ],
    "55031270e9bde6963400001a_3": [
        {
            "start_logit": 9.1953125,
            "end_logit": 9.234375,
            "text": "Fanconi anemia",
            "probability": 1.0
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -1.361328125,
            "text": "Fa",
            "probability": 2.485513687133789e-05
        },
        {
            "start_logit": -1.4384765625,
            "end_logit": 9.234375,
            "text": "anemia",
            "probability": 2.390146255493164e-05
        },
        {
            "start_logit": -5.171875,
            "end_logit": 9.234375,
            "text": "include Fanconi anemia",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -5.81640625,
            "end_logit": 9.234375,
            "text": "nconi anemia",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -6.22265625,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome, and amegakaryocytic thrombocytopenia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.72265625,
            "end_logit": 9.234375,
            "text": "oni anemia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.30078125,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome, and amegakaryocytic thrombocytopenia.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.37109375,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome, and amegakaryocytic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.39453125,
            "text": "Fanconi",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.4375,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwach",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.45703125,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwachman",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.4921875,
            "text": "Fanconi anemia, dyskerato",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.5,
            "text": "Fanconi anemia, dyskeratosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.5078125,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.5234375,
            "text": "Fanconi anemia, dyskeratosis congen",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.5390625,
            "text": "Fanconi anemia, dyskeratosis congenita",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.5546875,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome, and amegakary",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59375,
            "end_logit": 9.234375,
            "text": "development of pancytopenia include Fanconi anemia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.57421875,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond",
            "probability": 5.960464477539063e-08
        }
    ],
    "55031270e9bde6963400001a_4": [
        {
            "start_logit": 9.1328125,
            "end_logit": 9.1640625,
            "text": "Fanconi anemia",
            "probability": 1.0
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -1.494140625,
            "text": "Fa",
            "probability": 2.3543834686279297e-05
        },
        {
            "start_logit": -1.5615234375,
            "end_logit": 9.1640625,
            "text": "anemia",
            "probability": 2.2649765014648438e-05
        },
        {
            "start_logit": -4.8984375,
            "end_logit": 9.1640625,
            "text": "include Fanconi anemia",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -6.06640625,
            "end_logit": 9.1640625,
            "text": "nconi anemia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -6.20703125,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome, and amegakaryocytic thrombocytopenia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.91796875,
            "end_logit": 9.1640625,
            "text": "oni anemia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.30859375,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome, and amegakaryocytic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.31640625,
            "text": "Fanconi",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.4140625,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwach",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.44140625,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwachman",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.47265625,
            "text": "Fanconi anemia, dyskerato",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.4921875,
            "text": "Fanconi anemia, dyskeratosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.515625,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome, and amegakary",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.5234375,
            "text": "Fanconi anemia, dyskeratosis congen",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.5625,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.58203125,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.58984375,
            "text": "Fanconi anemia, dyskeratosis congenita, Shwa",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.60546875,
            "text": "Fanconi anemia, dyskera",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.8984375,
            "end_logit": -1.494140625,
            "text": "include Fa",
            "probability": 0.0
        }
    ],
    "58839d892305cd7e21000006_1": [
        {
            "start_logit": 8.84375,
            "end_logit": 8.625,
            "text": "growth hormone/insulin-like growth factor genes",
            "probability": 1.0
        },
        {
            "start_logit": 8.84375,
            "end_logit": -2.064453125,
            "text": "growth",
            "probability": 2.282857894897461e-05
        },
        {
            "start_logit": -2.259765625,
            "end_logit": 8.625,
            "text": "genes",
            "probability": 1.5079975128173828e-05
        },
        {
            "start_logit": -2.580078125,
            "end_logit": 8.625,
            "text": "insulin-like growth factor genes",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": 8.84375,
            "end_logit": -4.99609375,
            "text": "growth hormone",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 8.84375,
            "end_logit": -5.29296875,
            "text": "growth hormone/insulin-like growth factor",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.84375,
            "end_logit": -5.6328125,
            "text": "growth hormone/insulin-like growth factor genes (growth pathways), respiratory complex I genes",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -5.6640625,
            "end_logit": 8.625,
            "text": "positive selection in growth hormone/insulin-like growth factor genes",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.84375,
            "end_logit": -6.05859375,
            "text": "growth hormone/insulin-like growth factor genes (growth pathways)",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.84375,
            "end_logit": -6.1171875,
            "text": "growth hormone/insulin-like growth factor genes (growth pathways), respiratory complex I",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.015625,
            "end_logit": 8.625,
            "text": "in growth hormone/insulin-like growth factor genes",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.84375,
            "end_logit": -6.515625,
            "text": "growth hormone/insulin-like growth factor genes (",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.296875,
            "end_logit": 8.625,
            "text": "/insulin-like growth factor genes",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.84375,
            "end_logit": -6.65234375,
            "text": "growth hormone/insulin-like growth factor genes (growth pathways), respiratory complex",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.84375,
            "end_logit": -6.72265625,
            "text": "growth hormone/insulin-like growth factor genes (growth pathways",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.765625,
            "end_logit": 8.625,
            "text": "growth factor genes",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.6640625,
            "end_logit": -2.064453125,
            "text": "positive selection in growth",
            "probability": 0.0
        },
        {
            "start_logit": -2.580078125,
            "end_logit": -5.29296875,
            "text": "insulin-like growth factor",
            "probability": 0.0
        },
        {
            "start_logit": -2.259765625,
            "end_logit": -5.6328125,
            "text": "genes (growth pathways), respiratory complex I genes",
            "probability": 0.0
        },
        {
            "start_logit": -6.015625,
            "end_logit": -2.064453125,
            "text": "in growth",
            "probability": 0.0
        }
    ],
    "58839d892305cd7e21000006_2": [
        {
            "start_logit": 1.28515625,
            "end_logit": 2.208984375,
            "text": "microRNA genes related to reproduction",
            "probability": 0.423095703125
        },
        {
            "start_logit": 1.2373046875,
            "end_logit": 2.208984375,
            "text": "protein-coding and microRNA genes related to reproduction",
            "probability": 0.40283203125
        },
        {
            "start_logit": 1.28515625,
            "end_logit": 0.62646484375,
            "text": "microRNA genes",
            "probability": 0.08697509765625
        },
        {
            "start_logit": 1.2373046875,
            "end_logit": 0.62646484375,
            "text": "protein-coding and microRNA genes",
            "probability": 0.08282470703125
        },
        {
            "start_logit": -4.7578125,
            "end_logit": 2.208984375,
            "text": "both protein-coding and microRNA genes related to reproduction",
            "probability": 0.0010051727294921875
        },
        {
            "start_logit": -5.38671875,
            "end_logit": 2.208984375,
            "text": "related to reproduction",
            "probability": 0.0005359649658203125
        },
        {
            "start_logit": 1.28515625,
            "end_logit": -4.81640625,
            "text": "microRNA genes related to reproduction exhibited evidence of rapid sequence evolution.",
            "probability": 0.0003769397735595703
        },
        {
            "start_logit": 1.2373046875,
            "end_logit": -4.81640625,
            "text": "protein-coding and microRNA genes related to reproduction exhibited evidence of rapid sequence evolution.",
            "probability": 0.0003597736358642578
        },
        {
            "start_logit": -5.87109375,
            "end_logit": 2.208984375,
            "text": "to reproduction",
            "probability": 0.00033020973205566406
        },
        {
            "start_logit": -4.7578125,
            "end_logit": 0.62646484375,
            "text": "both protein-coding and microRNA genes",
            "probability": 0.00020647048950195312
        },
        {
            "start_logit": -6.40234375,
            "end_logit": 2.208984375,
            "text": "and microRNA genes related to reproduction",
            "probability": 0.0001939535140991211
        },
        {
            "start_logit": -6.41796875,
            "end_logit": 2.208984375,
            "text": ", both protein-coding and microRNA genes related to reproduction",
            "probability": 0.00019097328186035156
        },
        {
            "start_logit": 1.28515625,
            "end_logit": -5.73046875,
            "text": "microRNA genes related to reproduction exhibited evidence of rapid sequence evolution",
            "probability": 0.00015115737915039062
        },
        {
            "start_logit": 1.28515625,
            "end_logit": -5.76171875,
            "text": "microRNA genes related to reproduction exhibited",
            "probability": 0.00014650821685791016
        },
        {
            "start_logit": 1.2373046875,
            "end_logit": -5.73046875,
            "text": "protein-coding and microRNA genes related to reproduction exhibited evidence of rapid sequence evolution",
            "probability": 0.00014412403106689453
        },
        {
            "start_logit": -6.71875,
            "end_logit": 2.208984375,
            "text": "addition, both protein-coding and microRNA genes related to reproduction",
            "probability": 0.00014197826385498047
        },
        {
            "start_logit": 1.2373046875,
            "end_logit": -5.76171875,
            "text": "protein-coding and microRNA genes related to reproduction exhibited",
            "probability": 0.00013971328735351562
        },
        {
            "start_logit": -6.8125,
            "end_logit": 2.208984375,
            "text": "reproduction",
            "probability": 0.00012922286987304688
        },
        {
            "start_logit": -6.84765625,
            "end_logit": 2.208984375,
            "text": "In addition, both protein-coding and microRNA genes related to reproduction",
            "probability": 0.00012433528900146484
        },
        {
            "start_logit": 1.2373046875,
            "end_logit": -5.94140625,
            "text": "protein-coding",
            "probability": 0.00011670589447021484
        }
    ],
    "58839d892305cd7e21000006_3": [
        {
            "start_logit": 1.28515625,
            "end_logit": 2.208984375,
            "text": "microRNA genes related to reproduction",
            "probability": 0.423095703125
        },
        {
            "start_logit": 1.2373046875,
            "end_logit": 2.208984375,
            "text": "protein-coding and microRNA genes related to reproduction",
            "probability": 0.40283203125
        },
        {
            "start_logit": 1.28515625,
            "end_logit": 0.62646484375,
            "text": "microRNA genes",
            "probability": 0.08697509765625
        },
        {
            "start_logit": 1.2373046875,
            "end_logit": 0.62646484375,
            "text": "protein-coding and microRNA genes",
            "probability": 0.08282470703125
        },
        {
            "start_logit": -4.7578125,
            "end_logit": 2.208984375,
            "text": "both protein-coding and microRNA genes related to reproduction",
            "probability": 0.0010051727294921875
        },
        {
            "start_logit": -5.38671875,
            "end_logit": 2.208984375,
            "text": "related to reproduction",
            "probability": 0.0005359649658203125
        },
        {
            "start_logit": 1.28515625,
            "end_logit": -4.81640625,
            "text": "microRNA genes related to reproduction exhibited evidence of rapid sequence evolution.",
            "probability": 0.0003769397735595703
        },
        {
            "start_logit": 1.2373046875,
            "end_logit": -4.81640625,
            "text": "protein-coding and microRNA genes related to reproduction exhibited evidence of rapid sequence evolution.",
            "probability": 0.0003597736358642578
        },
        {
            "start_logit": -5.87109375,
            "end_logit": 2.208984375,
            "text": "to reproduction",
            "probability": 0.00033020973205566406
        },
        {
            "start_logit": -4.7578125,
            "end_logit": 0.62646484375,
            "text": "both protein-coding and microRNA genes",
            "probability": 0.00020647048950195312
        },
        {
            "start_logit": -6.40234375,
            "end_logit": 2.208984375,
            "text": "and microRNA genes related to reproduction",
            "probability": 0.0001939535140991211
        },
        {
            "start_logit": -6.41796875,
            "end_logit": 2.208984375,
            "text": ", both protein-coding and microRNA genes related to reproduction",
            "probability": 0.00019097328186035156
        },
        {
            "start_logit": 1.28515625,
            "end_logit": -5.73046875,
            "text": "microRNA genes related to reproduction exhibited evidence of rapid sequence evolution",
            "probability": 0.00015115737915039062
        },
        {
            "start_logit": 1.28515625,
            "end_logit": -5.76171875,
            "text": "microRNA genes related to reproduction exhibited",
            "probability": 0.00014650821685791016
        },
        {
            "start_logit": 1.2373046875,
            "end_logit": -5.73046875,
            "text": "protein-coding and microRNA genes related to reproduction exhibited evidence of rapid sequence evolution",
            "probability": 0.00014412403106689453
        },
        {
            "start_logit": -6.71875,
            "end_logit": 2.208984375,
            "text": "addition, both protein-coding and microRNA genes related to reproduction",
            "probability": 0.00014197826385498047
        },
        {
            "start_logit": 1.2373046875,
            "end_logit": -5.76171875,
            "text": "protein-coding and microRNA genes related to reproduction exhibited",
            "probability": 0.00013971328735351562
        },
        {
            "start_logit": -6.8125,
            "end_logit": 2.208984375,
            "text": "reproduction",
            "probability": 0.00012922286987304688
        },
        {
            "start_logit": -6.84765625,
            "end_logit": 2.208984375,
            "text": "In addition, both protein-coding and microRNA genes related to reproduction",
            "probability": 0.00012433528900146484
        },
        {
            "start_logit": 1.2373046875,
            "end_logit": -5.94140625,
            "text": "protein-coding",
            "probability": 0.00011670589447021484
        }
    ],
    "54cf705ff693c3b16b000014_1": [
        {
            "start_logit": 5.3203125,
            "end_logit": 1.716796875,
            "text": "integrins \u03b1v\u03b23",
            "probability": 0.9921875
        },
        {
            "start_logit": 5.3203125,
            "end_logit": -3.7734375,
            "text": "integrins \u03b1v\u03b23 and \u03b1v\u03b25",
            "probability": 0.00408935546875
        },
        {
            "start_logit": 5.3203125,
            "end_logit": -4.7890625,
            "text": "integrins",
            "probability": 0.0014801025390625
        },
        {
            "start_logit": 5.3203125,
            "end_logit": -6.03515625,
            "text": "integrins \u03b1v\u03b23 and",
            "probability": 0.0004258155822753906
        },
        {
            "start_logit": 5.3203125,
            "end_logit": -6.1328125,
            "text": "integrins \u03b1v\u03b2",
            "probability": 0.0003859996795654297
        },
        {
            "start_logit": 5.3203125,
            "end_logit": -6.1953125,
            "text": "integrins \u03b1v\u03b23 and \u03b1v",
            "probability": 0.00036263465881347656
        },
        {
            "start_logit": 5.3203125,
            "end_logit": -6.4375,
            "text": "integrins \u03b1v",
            "probability": 0.0002846717834472656
        },
        {
            "start_logit": 5.3203125,
            "end_logit": -6.44921875,
            "text": "integrins \u03b1v\u03b23 and \u03b1",
            "probability": 0.0002803802490234375
        },
        {
            "start_logit": 5.3203125,
            "end_logit": -6.66796875,
            "text": "integrins \u03b1v\u03b23 and \u03b1v\u03b2",
            "probability": 0.00022518634796142578
        },
        {
            "start_logit": 5.3203125,
            "end_logit": -7.0546875,
            "text": "integrins \u03b1v\u03b23 and \u03b1v\u03b25.",
            "probability": 0.00015354156494140625
        },
        {
            "start_logit": -4.3046875,
            "end_logit": 1.716796875,
            "text": "\u03b1v\u03b23",
            "probability": 6.55055046081543e-05
        },
        {
            "start_logit": -6.26953125,
            "end_logit": 1.716796875,
            "text": "malignant pleural mesothelioma cells through antagonism of integrins \u03b1v\u03b23",
            "probability": 9.179115295410156e-06
        },
        {
            "start_logit": -6.61328125,
            "end_logit": 1.716796875,
            "text": "3",
            "probability": 6.496906280517578e-06
        },
        {
            "start_logit": -6.875,
            "end_logit": 1.716796875,
            "text": "invasion of malignant pleural mesothelioma cells through antagonism of integrins \u03b1v\u03b23",
            "probability": 5.0067901611328125e-06
        },
        {
            "start_logit": -7.16796875,
            "end_logit": 1.716796875,
            "text": "pleural mesothelioma cells through antagonism of integrins \u03b1v\u03b23",
            "probability": 3.7550926208496094e-06
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 1.716796875,
            "text": "v\u03b23",
            "probability": 3.0994415283203125e-06
        },
        {
            "start_logit": -7.40234375,
            "end_logit": 1.716796875,
            "text": "of malignant pleural mesothelioma cells through antagonism of integrins \u03b1v\u03b23",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": -7.52734375,
            "end_logit": 1.716796875,
            "text": "inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins \u03b1v\u03b23",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": -7.53125,
            "end_logit": 1.716796875,
            "text": "attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins \u03b1v\u03b23",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": -7.546875,
            "end_logit": 1.716796875,
            "text": "of integrins \u03b1v\u03b23",
            "probability": 2.562999725341797e-06
        }
    ],
    "54cf705ff693c3b16b000014_2": [
        {
            "start_logit": 9.2109375,
            "end_logit": 9.390625,
            "text": "integrins \u03b1v\u03b23",
            "probability": 0.97802734375
        },
        {
            "start_logit": 5.38671875,
            "end_logit": 9.390625,
            "text": "\u03b1v\u03b23",
            "probability": 0.0216064453125
        },
        {
            "start_logit": -0.54736328125,
            "end_logit": 9.390625,
            "text": "3",
            "probability": 5.704164505004883e-05
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -0.86572265625,
            "text": "integrins",
            "probability": 3.457069396972656e-05
        },
        {
            "start_logit": -5.51953125,
            "end_logit": 9.390625,
            "text": "As there is evidence for expression of the integrins \u03b1v\u03b23",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -5.703125,
            "text": "integrins \u03b1",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -6.21875,
            "text": "integrins \u03b1v\u03b2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -6.30078125,
            "text": "integrins \u03b1v\u03b23 and \u03b1v\u03b25",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.6953125,
            "end_logit": 9.390625,
            "text": "\u03b23",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.7578125,
            "end_logit": 9.390625,
            "text": "v\u03b23",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -6.58203125,
            "text": "integrins \u03b1v\u03b23 and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -6.84375,
            "text": "integrins \u03b1v",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.23046875,
            "end_logit": 9.390625,
            "text": "the integrins \u03b1v\u03b23",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.40234375,
            "end_logit": 9.390625,
            "text": "expression of the integrins \u03b1v\u03b23",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4375,
            "end_logit": 9.390625,
            "text": "of the integrins \u03b1v\u03b23",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.38671875,
            "end_logit": -5.703125,
            "text": "\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": 5.38671875,
            "end_logit": -6.21875,
            "text": "\u03b1v\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 5.38671875,
            "end_logit": -6.30078125,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25",
            "probability": 0.0
        },
        {
            "start_logit": 5.38671875,
            "end_logit": -6.58203125,
            "text": "\u03b1v\u03b23 and",
            "probability": 0.0
        },
        {
            "start_logit": 5.38671875,
            "end_logit": -6.84375,
            "text": "\u03b1v",
            "probability": 0.0
        }
    ],
    "54cf705ff693c3b16b000014_3": [
        {
            "start_logit": 9.1484375,
            "end_logit": 9.1171875,
            "text": "\u03b1v\u03b23",
            "probability": 1.0
        },
        {
            "start_logit": -1.17578125,
            "end_logit": 9.1171875,
            "text": "3",
            "probability": 3.272294998168945e-05
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -1.4052734375,
            "text": "\u03b1",
            "probability": 2.6881694793701172e-05
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -3.884765625,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -5.9375,
            "text": "\u03b1v\u03b2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -6.34765625,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.33984375,
            "end_logit": 9.1171875,
            "text": "v\u03b23",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -6.68359375,
            "text": "\u03b1v\u03b23 and \u03b1v",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.828125,
            "end_logit": 9.1171875,
            "text": "\u03b23",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -6.94921875,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -7.23046875,
            "text": "\u03b1v\u03b23 and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.23046875,
            "end_logit": 9.1171875,
            "text": "of \u03b1v\u03b23",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 9.1171875,
            "text": "that these effects of cilengitide were, at least partly, due to antagonism of \u03b1v\u03b23",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 9.1171875,
            "text": "antagonism of \u03b1v\u03b23",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 9.1171875,
            "text": "effects of cilengitide were, at least partly, due to antagonism of \u03b1v\u03b23",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7578125,
            "end_logit": 9.1171875,
            "text": "to antagonism of \u03b1v\u03b23",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 9.1171875,
            "text": ", at least partly, due to antagonism of \u03b1v\u03b23",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 9.1171875,
            "text": ", due to antagonism of \u03b1v\u03b23",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 9.1171875,
            "text": "due to antagonism of \u03b1v\u03b23",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.17578125,
            "end_logit": -3.884765625,
            "text": "3 and \u03b1v\u03b25",
            "probability": 0.0
        }
    ],
    "54cf705ff693c3b16b000014_4": [
        {
            "start_logit": 3.640625,
            "end_logit": 4.8828125,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins",
            "probability": 0.5283203125
        },
        {
            "start_logit": 3.640625,
            "end_logit": 4.765625,
            "text": "\u03b1v\u03b23",
            "probability": 0.4697265625
        },
        {
            "start_logit": -2.048828125,
            "end_logit": 4.8828125,
            "text": "integrins",
            "probability": 0.001789093017578125
        },
        {
            "start_logit": -5.33203125,
            "end_logit": 4.8828125,
            "text": "3 and \u03b1v\u03b25 integrins",
            "probability": 6.723403930664062e-05
        },
        {
            "start_logit": -5.33203125,
            "end_logit": 4.765625,
            "text": "3",
            "probability": 5.930662155151367e-05
        },
        {
            "start_logit": 3.640625,
            "end_logit": -4.69921875,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25",
            "probability": 3.653764724731445e-05
        },
        {
            "start_logit": -6.1875,
            "end_logit": 4.8828125,
            "text": "\u03b1v\u03b25 integrins",
            "probability": 2.849102020263672e-05
        },
        {
            "start_logit": -6.890625,
            "end_logit": 4.8828125,
            "text": "v\u03b23 and \u03b1v\u03b25 integrins",
            "probability": 1.4126300811767578e-05
        },
        {
            "start_logit": -6.890625,
            "end_logit": 4.765625,
            "text": "v\u03b23",
            "probability": 1.2516975402832031e-05
        },
        {
            "start_logit": -7.33984375,
            "end_logit": 4.8828125,
            "text": "\u03b23 and \u03b1v\u03b25 integrins",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": -7.33984375,
            "end_logit": 4.765625,
            "text": "\u03b23",
            "probability": 8.046627044677734e-06
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 4.8828125,
            "text": "of \u03b1v\u03b23 and \u03b1v\u03b25 integrins",
            "probability": 7.987022399902344e-06
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 4.8828125,
            "text": "selective inhibitor of \u03b1v\u03b23 and \u03b1v\u03b25 integrins",
            "probability": 7.808208465576172e-06
        },
        {
            "start_logit": 3.640625,
            "end_logit": -6.265625,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins and was developed for antiangiogenic",
            "probability": 7.62939453125e-06
        },
        {
            "start_logit": -7.515625,
            "end_logit": 4.8828125,
            "text": "and \u03b1v\u03b25 integrins",
            "probability": 7.569789886474609e-06
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 4.8828125,
            "text": "RGD cyclic pentapetide, cilengitide, is a selective inhibitor of \u03b1v\u03b23 and \u03b1v\u03b25 integrins",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 4.765625,
            "text": "of \u03b1v\u03b23",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 4.765625,
            "text": "selective inhibitor of \u03b1v\u03b23",
            "probability": 6.973743438720703e-06
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 4.8828125,
            "text": "inhibitor of \u03b1v\u03b23 and \u03b1v\u03b25 integrins",
            "probability": 6.67572021484375e-06
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 4.765625,
            "text": "RGD cyclic pentapetide, cilengitide, is a selective inhibitor of \u03b1v\u03b23",
            "probability": 6.4373016357421875e-06
        }
    ],
    "54cf705ff693c3b16b000014_5": [
        {
            "start_logit": 8.875,
            "end_logit": 8.890625,
            "text": "\u03b1v\u03b23",
            "probability": 1.0
        },
        {
            "start_logit": -1.423828125,
            "end_logit": 8.890625,
            "text": "3",
            "probability": 3.3736228942871094e-05
        },
        {
            "start_logit": 8.875,
            "end_logit": -1.8818359375,
            "text": "\u03b1",
            "probability": 2.092123031616211e-05
        },
        {
            "start_logit": 8.875,
            "end_logit": -3.2109375,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25",
            "probability": 5.543231964111328e-06
        },
        {
            "start_logit": 8.875,
            "end_logit": -3.630859375,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrin",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": 8.875,
            "end_logit": -4.6171875,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrin receptors",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 8.875,
            "end_logit": -6.078125,
            "text": "\u03b1v\u03b23 and \u03b1v",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.875,
            "end_logit": -6.17578125,
            "text": "\u03b1v\u03b2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.875,
            "end_logit": -6.23828125,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.49609375,
            "end_logit": 8.890625,
            "text": "RGD-peptide of sequence cyclo[RGDfNMeV] that was was developed as a highly active and selective ligand for the \u03b1v\u03b23",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.875,
            "end_logit": -6.65625,
            "text": "\u03b1v",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.875,
            "end_logit": -6.6875,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrin receptors.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.875,
            "end_logit": -6.7578125,
            "text": "\u03b1v\u03b23 and \u03b1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.85546875,
            "end_logit": 8.890625,
            "text": "v\u03b23",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 8.890625,
            "text": "\u03b23",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.43359375,
            "end_logit": 8.890625,
            "text": "cyclo[RGDfNMeV] that was was developed as a highly active and selective ligand for the \u03b1v\u03b23",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 8.890625,
            "text": "an RGD-peptide of sequence cyclo[RGDfNMeV] that was was developed as a highly active and selective ligand for the \u03b1v\u03b23",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 8.890625,
            "text": "RGDfNMeV] that was was developed as a highly active and selective ligand for the \u03b1v\u03b23",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 8.890625,
            "text": "sequence cyclo[RGDfNMeV] that was was developed as a highly active and selective ligand for the \u03b1v\u03b23",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 8.890625,
            "text": "[RGDfNMeV] that was was developed as a highly active and selective ligand for the \u03b1v\u03b23",
            "probability": 5.960464477539063e-08
        }
    ],
    "54cf705ff693c3b16b000014_6": [
        {
            "start_logit": 8.921875,
            "end_logit": 9.4453125,
            "text": "\u03b1v\u03b25",
            "probability": 1.0
        },
        {
            "start_logit": -0.77099609375,
            "end_logit": 9.4453125,
            "text": "5",
            "probability": 6.109476089477539e-05
        },
        {
            "start_logit": 8.921875,
            "end_logit": -1.900390625,
            "text": "\u03b1",
            "probability": 1.1742115020751953e-05
        },
        {
            "start_logit": 8.921875,
            "end_logit": -4.0390625,
            "text": "\u03b1v\u03b25 was the predominantly expressed integrin",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 8.921875,
            "end_logit": -5.1328125,
            "text": "\u03b1v\u03b2",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.80859375,
            "end_logit": 9.4453125,
            "text": "v\u03b25",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -6.4296875,
            "text": "\u03b1v",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.22265625,
            "end_logit": 9.4453125,
            "text": "\u03b25",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -6.86328125,
            "text": "\u03b1v\u03b25 was the predominantly expressed integrin heterodimer in meningiomas, whereas \u03b1v\u03b23 was mainly detected in tumor blood vessels.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.921875,
            "end_logit": -6.9453125,
            "text": "\u03b1v\u03b25 was the predominantly expressed integrin heterodimer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.046875,
            "text": "\u03b1v\u03b25 was the predominantly expressed integrin heterodimer in meningiomas, whereas \u03b1v\u03b23 was mainly detected in tumor blood vessels",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.12109375,
            "text": "\u03b1v\u03b25 was the predominantly expressed integrin heterodimer in meningiomas",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.14453125,
            "text": "\u03b1v\u03b25 was",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.33984375,
            "text": "\u03b1v\u03b25 was the predominantly expressed integrin heterodimer in meningiomas, whereas \u03b1v\u03b23",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.77099609375,
            "end_logit": -4.0390625,
            "text": "5 was the predominantly expressed integrin",
            "probability": 0.0
        },
        {
            "start_logit": -0.77099609375,
            "end_logit": -6.86328125,
            "text": "5 was the predominantly expressed integrin heterodimer in meningiomas, whereas \u03b1v\u03b23 was mainly detected in tumor blood vessels.",
            "probability": 0.0
        },
        {
            "start_logit": -0.77099609375,
            "end_logit": -6.9453125,
            "text": "5 was the predominantly expressed integrin heterodimer",
            "probability": 0.0
        },
        {
            "start_logit": -0.77099609375,
            "end_logit": -7.046875,
            "text": "5 was the predominantly expressed integrin heterodimer in meningiomas, whereas \u03b1v\u03b23 was mainly detected in tumor blood vessels",
            "probability": 0.0
        },
        {
            "start_logit": -0.77099609375,
            "end_logit": -7.12109375,
            "text": "5 was the predominantly expressed integrin heterodimer in meningiomas",
            "probability": 0.0
        },
        {
            "start_logit": -0.77099609375,
            "end_logit": -7.14453125,
            "text": "5 was",
            "probability": 0.0
        }
    ],
    "54cf705ff693c3b16b000014_7": [
        {
            "start_logit": 9.171875,
            "end_logit": 9.2109375,
            "text": "\u03b1v\u03b25",
            "probability": 1.0
        },
        {
            "start_logit": 9.171875,
            "end_logit": -1.3759765625,
            "text": "\u03b1",
            "probability": 2.5451183319091797e-05
        },
        {
            "start_logit": -1.455078125,
            "end_logit": 9.2109375,
            "text": "5",
            "probability": 2.4497509002685547e-05
        },
        {
            "start_logit": 9.171875,
            "end_logit": -4.3203125,
            "text": "\u03b1v\u03b25 integrin",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 9.171875,
            "end_logit": -5.77734375,
            "text": "\u03b1v\u03b2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.27734375,
            "end_logit": 9.2109375,
            "text": "v\u03b25",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -6.5078125,
            "text": "\u03b1v\u03b25 integrin and were not sensitive to cilengitide, suggesting that cilengitide's action largely depends on \u03b1v\u03b2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -6.98046875,
            "text": "\u03b1v\u03b25 integrin and were not sensitive to cilengitide, suggesting that cilengitide's action largely depends on \u03b1v",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.01953125,
            "text": "\u03b1v",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.17578125,
            "end_logit": 9.2109375,
            "text": "\u03b25",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.28515625,
            "text": "\u03b1v\u03b25 integrin and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.31640625,
            "text": "\u03b1v\u03b25 integrin and were not sensitive to cilengitide, suggesting that cilengitide's action largely depends on \u03b1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 9.2109375,
            "text": "UW479 cells expressed only \u03b1v\u03b25",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.4140625,
            "text": "\u03b1v\u03b25 integrin and were",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.4375,
            "text": "\u03b1v\u03b25 integrin and were not sensitive",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.453125,
            "text": "\u03b1v\u03b25 integrin and were not",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 9.2109375,
            "text": "only \u03b1v\u03b25",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 9.2109375,
            "text": "expressed only \u03b1v\u03b25",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 9.2109375,
            "text": "cells expressed only \u03b1v\u03b25",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.455078125,
            "end_logit": -4.3203125,
            "text": "5 integrin",
            "probability": 0.0
        }
    ],
    "54cf705ff693c3b16b000014_8": [
        {
            "start_logit": 9.28125,
            "end_logit": 9.265625,
            "text": "\u03b1v\u03b23",
            "probability": 1.0
        },
        {
            "start_logit": 9.28125,
            "end_logit": -1.119140625,
            "text": "\u03b1",
            "probability": 3.0934810638427734e-05
        },
        {
            "start_logit": -1.185546875,
            "end_logit": 9.265625,
            "text": "3",
            "probability": 2.8431415557861328e-05
        },
        {
            "start_logit": 9.28125,
            "end_logit": -5.49609375,
            "text": "\u03b1v\u03b23 expression",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -5.984375,
            "text": "\u03b1v\u03b2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.11328125,
            "end_logit": 9.265625,
            "text": "v\u03b23",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.55078125,
            "end_logit": 9.265625,
            "text": "\u03b23",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.65234375,
            "text": "\u03b1v\u03b23 expression and sensitivity to anoikis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.79296875,
            "end_logit": 9.265625,
            "text": "glioma and neuroblastoma cells appears to be dependent on \u03b1v\u03b23",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.91015625,
            "text": "\u03b1v\u03b23 expression and sensitivity to anoiki",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.13671875,
            "text": "\u03b1v\u03b23 expression and sensitivity to anoikis.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.24609375,
            "text": "\u03b1v",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.3125,
            "text": "\u03b1v\u03b23 expression and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.296875,
            "end_logit": 9.265625,
            "text": "neuroblastoma cells appears to be dependent on \u03b1v\u03b23",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.41015625,
            "text": "\u03b1v\u03b23 expression and sensitivity to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.4375,
            "text": "\u03b1v\u03b23 expression and sensitivity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59375,
            "end_logit": 9.265625,
            "text": "action on glioma and neuroblastoma cells appears to be dependent on \u03b1v\u03b23",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.703125,
            "end_logit": 9.265625,
            "text": "on \u03b1v\u03b23",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7421875,
            "end_logit": 9.265625,
            "text": "on glioma and neuroblastoma cells appears to be dependent on \u03b1v\u03b23",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 9.265625,
            "text": "Cilengitide's action on glioma and neuroblastoma cells appears to be dependent on \u03b1v\u03b23",
            "probability": 5.960464477539063e-08
        }
    ],
    "54cf705ff693c3b16b000014_9": [
        {
            "start_logit": 5.51171875,
            "end_logit": 6.8828125,
            "text": "\u03b1v\u03b23",
            "probability": 0.9951171875
        },
        {
            "start_logit": 5.51171875,
            "end_logit": 1.130859375,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins",
            "probability": 0.0031681060791015625
        },
        {
            "start_logit": 5.51171875,
            "end_logit": 0.10821533203125,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25",
            "probability": 0.0011425018310546875
        },
        {
            "start_logit": -4.0,
            "end_logit": 6.8828125,
            "text": "3",
            "probability": 7.390975952148438e-05
        },
        {
            "start_logit": 5.51171875,
            "end_logit": -5.46875,
            "text": "\u03b1",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": -7.0234375,
            "end_logit": 6.8828125,
            "text": "v\u03b23",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": -7.13671875,
            "end_logit": 6.8828125,
            "text": "small molecule inhibitor of \u03b1v\u03b23",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": 5.51171875,
            "end_logit": -5.7734375,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins, from day 30 to 55 after tumor cell inoculation of MDA-MB-231 breast cancer",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 6.8828125,
            "text": "with cilengitide, a small molecule inhibitor of \u03b1v\u03b23",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 6.8828125,
            "text": "of \u03b1v\u03b23",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": -7.40234375,
            "end_logit": 6.8828125,
            "text": "\u03b23",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 6.8828125,
            "text": "bone metastases were treated with cilengitide, a small molecule inhibitor of \u03b1v\u03b23",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 6.8828125,
            "text": ", a small molecule inhibitor of \u03b1v\u03b23",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": 5.51171875,
            "end_logit": -6.15234375,
            "text": "\u03b1v\u03b2",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": -7.53125,
            "end_logit": 6.8828125,
            "text": ", nude rats bearing bone metastases were treated with cilengitide, a small molecule inhibitor of \u03b1v\u03b23",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 5.51171875,
            "end_logit": -6.5546875,
            "text": "\u03b1v\u03b23 and \u03b1v",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 5.51171875,
            "end_logit": -6.66796875,
            "text": "\u03b1v",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 5.51171875,
            "end_logit": -6.796875,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b2",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -2.630859375,
            "end_logit": 1.130859375,
            "text": "\u03b1v\u03b25 integrins",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 5.51171875,
            "end_logit": -7.1796875,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins, from",
            "probability": 7.748603820800781e-07
        }
    ],
    "54cf705ff693c3b16b000014_10": [
        {
            "start_logit": 5.68359375,
            "end_logit": 6.8671875,
            "text": "\u03b1V\u03b25",
            "probability": 0.91259765625
        },
        {
            "start_logit": 3.296875,
            "end_logit": 6.8671875,
            "text": "\u03b1V\u03b23/\u03b1V\u03b25",
            "probability": 0.084228515625
        },
        {
            "start_logit": 3.296875,
            "end_logit": 3.3984375,
            "text": "\u03b1V\u03b23",
            "probability": 0.00262451171875
        },
        {
            "start_logit": 5.68359375,
            "end_logit": -2.306640625,
            "text": "\u03b1V\u03b25 integrin",
            "probability": 9.489059448242188e-05
        },
        {
            "start_logit": -4.5703125,
            "end_logit": 6.8671875,
            "text": "5",
            "probability": 3.224611282348633e-05
        },
        {
            "start_logit": 3.296875,
            "end_logit": -2.306640625,
            "text": "\u03b1V\u03b23/\u03b1V\u03b25 integrin",
            "probability": 8.761882781982422e-06
        },
        {
            "start_logit": -6.47265625,
            "end_logit": 6.8671875,
            "text": "3/\u03b1V\u03b25",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": 5.68359375,
            "end_logit": -5.484375,
            "text": "\u03b1",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": -7.0546875,
            "end_logit": 6.8671875,
            "text": "V\u03b25",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": -7.2578125,
            "end_logit": 6.8671875,
            "text": "V\u03b23/\u03b1V\u03b25",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 6.8671875,
            "text": "/\u03b1V\u03b25",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 6.8671875,
            "text": "The \u03b1V\u03b23/\u03b1V\u03b25",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": -7.546875,
            "end_logit": 6.8671875,
            "text": "\u03b25",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 5.68359375,
            "end_logit": -6.39453125,
            "text": "\u03b1V\u03b2",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -7.6484375,
            "end_logit": 6.8671875,
            "text": "\u03b23/\u03b1V\u03b25",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 5.68359375,
            "end_logit": -6.875,
            "text": "\u03b1V\u03b25 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 5.68359375,
            "end_logit": -6.90625,
            "text": "\u03b1V\u03b25 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model.",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 5.68359375,
            "end_logit": -6.91015625,
            "text": "\u03b1V\u03b25 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 5.68359375,
            "end_logit": -7.09765625,
            "text": "\u03b1V\u03b25 integrin inhibitor cilengitide augments tumor",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 5.68359375,
            "end_logit": -7.10546875,
            "text": "\u03b1V\u03b25 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model",
            "probability": 7.748603820800781e-07
        }
    ],
    "54cf705ff693c3b16b000014_11": [
        {
            "start_logit": 8.5,
            "end_logit": 8.734375,
            "text": "\u03b1v\u03b23",
            "probability": 1.0
        },
        {
            "start_logit": 8.5,
            "end_logit": 0.2037353515625,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins",
            "probability": 0.0001971721649169922
        },
        {
            "start_logit": -1.658203125,
            "end_logit": 8.734375,
            "text": "3",
            "probability": 3.886222839355469e-05
        },
        {
            "start_logit": 8.5,
            "end_logit": -2.458984375,
            "text": "\u03b1",
            "probability": 1.3709068298339844e-05
        },
        {
            "start_logit": 8.5,
            "end_logit": -2.8203125,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25",
            "probability": 9.59634780883789e-06
        },
        {
            "start_logit": 8.5,
            "end_logit": -6.26171875,
            "text": "\u03b1v\u03b2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.5,
            "end_logit": -6.359375,
            "text": "\u03b1v\u03b23 and \u03b1v",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.5,
            "end_logit": -6.39453125,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.75,
            "end_logit": 8.734375,
            "text": "v\u03b23",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.5,
            "end_logit": -6.703125,
            "text": "\u03b1v",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.08984375,
            "end_logit": 8.734375,
            "text": "\u03b23",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.5,
            "end_logit": -6.93359375,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins has shown encouraging activity in patients with glioblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 8.734375,
            "text": "the \u03b1v\u03b23",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5,
            "end_logit": -7.15625,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins has",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 8.734375,
            "text": "Arg-Gly-Glu(RGD)-containing pentapeptide that selectively blocks activation of the \u03b1v\u03b23",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.53125,
            "end_logit": 8.734375,
            "text": "of the \u03b1v\u03b23",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.625,
            "end_logit": 8.734375,
            "text": "activation of the \u03b1v\u03b23",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 8.734375,
            "text": ", a cyclized Arg-Gly-Glu(RGD)-containing pentapeptide that selectively blocks activation of the \u03b1v\u03b23",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.5,
            "end_logit": -7.4140625,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins has shown encouraging activity in patients with glioblastoma as",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.67578125,
            "end_logit": 8.734375,
            "text": "that selectively blocks activation of the \u03b1v\u03b23",
            "probability": 1.1920928955078125e-07
        }
    ],
    "54cf705ff693c3b16b000014_12": [
        {
            "start_logit": 8.90625,
            "end_logit": 9.15625,
            "text": "\u03b1v\u03b23",
            "probability": 1.0
        },
        {
            "start_logit": -0.6513671875,
            "end_logit": 9.15625,
            "text": "3",
            "probability": 7.086992263793945e-05
        },
        {
            "start_logit": 8.90625,
            "end_logit": -1.525390625,
            "text": "\u03b1",
            "probability": 2.300739288330078e-05
        },
        {
            "start_logit": 8.90625,
            "end_logit": -2.599609375,
            "text": "\u03b1v\u03b23, \u03b1v\u03b25, and \u03b15\u03b21 integrin",
            "probability": 7.808208465576172e-06
        },
        {
            "start_logit": 8.90625,
            "end_logit": -4.67578125,
            "text": "\u03b1v\u03b23, \u03b1v\u03b25, and \u03b15\u03b21 integrin receptors",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 8.90625,
            "end_logit": -5.13671875,
            "text": "\u03b1v\u03b2",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -5.359375,
            "text": "\u03b1v",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -5.55078125,
            "text": "\u03b1v\u03b23, \u03b1v\u03b25, and \u03b15\u03b21",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -5.9921875,
            "text": "\u03b1v\u03b23, \u03b1v\u03b25, and \u03b15\u03b21 integrin receptors, which play important roles in human tumor metastasis",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -6.1796875,
            "text": "\u03b1v\u03b23, \u03b1v\u03b25, and \u03b1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.80859375,
            "end_logit": 9.15625,
            "text": "v\u03b23",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -6.62890625,
            "text": "\u03b1v\u03b23, \u03b1v\u03b25, and \u03b15",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.03515625,
            "end_logit": 9.15625,
            "text": "\u03b23",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -6.8125,
            "text": "\u03b1v\u03b23, \u03b1v\u03b25, and \u03b15\u03b2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -6.9375,
            "text": "\u03b1v\u03b23, \u03b1v\u03b25",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.2734375,
            "end_logit": 9.15625,
            "text": ", potent antagonists of the \u03b1v\u03b23",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.359375,
            "end_logit": 9.15625,
            "text": "1, and its parent peptide cyclo(R-G-D-f-V) 2, potent antagonists of the \u03b1v\u03b23",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.6513671875,
            "end_logit": -2.599609375,
            "text": "3, \u03b1v\u03b25, and \u03b15\u03b21 integrin",
            "probability": 0.0
        },
        {
            "start_logit": -0.6513671875,
            "end_logit": -4.67578125,
            "text": "3, \u03b1v\u03b25, and \u03b15\u03b21 integrin receptors",
            "probability": 0.0
        },
        {
            "start_logit": -0.6513671875,
            "end_logit": -5.55078125,
            "text": "3, \u03b1v\u03b25, and \u03b15\u03b21",
            "probability": 0.0
        }
    ],
    "54cf705ff693c3b16b000014_13": [
        {
            "start_logit": 1.783203125,
            "end_logit": 3.630859375,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins",
            "probability": 0.59521484375
        },
        {
            "start_logit": 1.783203125,
            "end_logit": 3.2421875,
            "text": "\u03b1v\u03b23",
            "probability": 0.402587890625
        },
        {
            "start_logit": -4.48828125,
            "end_logit": 3.630859375,
            "text": "integrins",
            "probability": 0.00112152099609375
        },
        {
            "start_logit": -6.1875,
            "end_logit": 3.630859375,
            "text": "3 and \u03b1v\u03b25 integrins",
            "probability": 0.00020599365234375
        },
        {
            "start_logit": -6.42578125,
            "end_logit": 3.630859375,
            "text": "\u03b1v\u03b25 integrins",
            "probability": 0.0001615285873413086
        },
        {
            "start_logit": -6.1875,
            "end_logit": 3.2421875,
            "text": "3",
            "probability": 0.00013935565948486328
        },
        {
            "start_logit": 1.783203125,
            "end_logit": -5.09765625,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25",
            "probability": 9.655952453613281e-05
        },
        {
            "start_logit": -7.46875,
            "end_logit": 3.630859375,
            "text": "5 integrins",
            "probability": 5.716085433959961e-05
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 3.630859375,
            "text": "new drug targeting \u03b1v\u03b23 and \u03b1v\u03b25 integrins",
            "probability": 5.418062210083008e-05
        },
        {
            "start_logit": -7.546875,
            "end_logit": 3.630859375,
            "text": "targeting \u03b1v\u03b23 and \u03b1v\u03b25 integrins",
            "probability": 5.2869319915771484e-05
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 3.630859375,
            "text": "drug targeting \u03b1v\u03b23 and \u03b1v\u03b25 integrins",
            "probability": 5.251169204711914e-05
        },
        {
            "start_logit": 1.783203125,
            "end_logit": -5.83984375,
            "text": "\u03b1v",
            "probability": 4.595518112182617e-05
        },
        {
            "start_logit": -7.6875,
            "end_logit": 3.630859375,
            "text": "and \u03b1v\u03b25 integrins",
            "probability": 4.595518112182617e-05
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 3.630859375,
            "text": ", Darmstadt, Germany) is a new drug targeting \u03b1v\u03b23 and \u03b1v\u03b25 integrins",
            "probability": 4.380941390991211e-05
        },
        {
            "start_logit": -7.734375,
            "end_logit": 3.630859375,
            "text": ", Germany) is a new drug targeting \u03b1v\u03b23 and \u03b1v\u03b25 integrins",
            "probability": 4.380941390991211e-05
        },
        {
            "start_logit": -7.7421875,
            "end_logit": 3.630859375,
            "text": "; Merck KGaA, Darmstadt, Germany) is a new drug targeting \u03b1v\u03b23 and \u03b1v\u03b25 integrins",
            "probability": 4.3511390686035156e-05
        },
        {
            "start_logit": -7.76171875,
            "end_logit": 3.630859375,
            "text": "Merck KGaA, Darmstadt, Germany) is a new drug targeting \u03b1v\u03b23 and \u03b1v\u03b25 integrins",
            "probability": 4.2498111724853516e-05
        },
        {
            "start_logit": -7.7734375,
            "end_logit": 3.630859375,
            "text": "\u03b23 and \u03b1v\u03b25 integrins",
            "probability": 4.214048385620117e-05
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 3.2421875,
            "text": "new drug targeting \u03b1v\u03b23",
            "probability": 3.6656856536865234e-05
        },
        {
            "start_logit": -7.546875,
            "end_logit": 3.2421875,
            "text": "targeting \u03b1v\u03b23",
            "probability": 3.5762786865234375e-05
        }
    ],
    "54cf705ff693c3b16b000014_14": [
        {
            "start_logit": 8.9296875,
            "end_logit": 9.171875,
            "text": "\u03b1v\u03b23",
            "probability": 1.0
        },
        {
            "start_logit": 8.9296875,
            "end_logit": 0.288818359375,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins",
            "probability": 0.0001398324966430664
        },
        {
            "start_logit": -0.951171875,
            "end_logit": 9.171875,
            "text": "3",
            "probability": 5.143880844116211e-05
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -1.7900390625,
            "text": "\u03b1",
            "probability": 1.7523765563964844e-05
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -5.921875,
            "text": "\u03b1v\u03b2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -6.05859375,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins is in advanced clinical development in glioblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -6.203125,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.453125,
            "end_logit": 9.171875,
            "text": "v\u03b23",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -6.51171875,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins is",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.8046875,
            "end_logit": 9.171875,
            "text": ", a cyclic RGD-mimetic peptide of \u03b1v\u03b23",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.8359375,
            "end_logit": 9.171875,
            "text": "cyclic RGD-mimetic peptide of \u03b1v\u03b23",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.859375,
            "end_logit": 9.171875,
            "text": "\u03b23",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -6.62890625,
            "text": "\u03b1v",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9765625,
            "end_logit": 9.171875,
            "text": "of \u03b1v\u03b23",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -6.78515625,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b25 integrins is in advanced clinical development in glioblastoma.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -6.83203125,
            "text": "\u03b1v\u03b23 and \u03b1v",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -6.984375,
            "text": "\u03b1v\u03b23 and \u03b1v\u03b2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.09375,
            "text": "\u03b1v\u03b23 and \u03b1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.38671875,
            "end_logit": 9.171875,
            "text": "RGD-mimetic peptide of \u03b1v\u03b23",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.25,
            "text": "\u03b1v\u03b23 and",
            "probability": 5.960464477539063e-08
        }
    ],
    "5324cca79b2d7acc7e00001d_1": [
        {
            "start_logit": 8.7421875,
            "end_logit": 3.23046875,
            "text": "obesity",
            "probability": 0.986328125
        },
        {
            "start_logit": 8.7421875,
            "end_logit": -1.0947265625,
            "text": "obesity prevention",
            "probability": 0.01311492919921875
        },
        {
            "start_logit": 8.7421875,
            "end_logit": -4.58984375,
            "text": "obesity prevention and treatment, healthy eating, and physical activity",
            "probability": 0.00039768218994140625
        },
        {
            "start_logit": 8.7421875,
            "end_logit": -6.24609375,
            "text": "obesity prevention and treatment, healthy eating, and physical activity promotion",
            "probability": 7.623434066772461e-05
        },
        {
            "start_logit": 8.7421875,
            "end_logit": -6.83984375,
            "text": "obesity prevention and treatment",
            "probability": 4.208087921142578e-05
        },
        {
            "start_logit": 8.7421875,
            "end_logit": -6.96875,
            "text": "obesity prevention and",
            "probability": 3.68952751159668e-05
        },
        {
            "start_logit": 8.7421875,
            "end_logit": -7.2578125,
            "text": "obesity prevention and treatment, healthy eating, and physical",
            "probability": 2.759695053100586e-05
        },
        {
            "start_logit": 8.7421875,
            "end_logit": -7.39453125,
            "text": "obesity prevention and treatment, healthy",
            "probability": 2.396106719970703e-05
        },
        {
            "start_logit": 8.7421875,
            "end_logit": -7.453125,
            "text": "obesity prevention and treatment, healthy eating, and",
            "probability": 2.2709369659423828e-05
        },
        {
            "start_logit": 8.7421875,
            "end_logit": -7.45703125,
            "text": "obesity prevention and treatment, healthy eating,",
            "probability": 2.2530555725097656e-05
        },
        {
            "start_logit": 8.7421875,
            "end_logit": -7.45703125,
            "text": "obesity prevention and treatment, healthy eating",
            "probability": 2.2530555725097656e-05
        },
        {
            "start_logit": -5.2109375,
            "end_logit": 3.23046875,
            "text": "Mobile apps for pediatric obesity",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -5.53515625,
            "end_logit": 3.23046875,
            "text": "pediatric obesity",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 3.23046875,
            "text": "apps for pediatric obesity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 3.23046875,
            "text": "for pediatric obesity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.2109375,
            "end_logit": -1.0947265625,
            "text": "Mobile apps for pediatric obesity prevention",
            "probability": 0.0
        },
        {
            "start_logit": -5.53515625,
            "end_logit": -1.0947265625,
            "text": "pediatric obesity prevention",
            "probability": 0.0
        },
        {
            "start_logit": -7.5234375,
            "end_logit": -1.0947265625,
            "text": "apps for pediatric obesity prevention",
            "probability": 0.0
        },
        {
            "start_logit": -7.5703125,
            "end_logit": -1.0947265625,
            "text": "for pediatric obesity prevention",
            "probability": 0.0
        },
        {
            "start_logit": -5.2109375,
            "end_logit": -4.58984375,
            "text": "Mobile apps for pediatric obesity prevention and treatment, healthy eating, and physical activity",
            "probability": 0.0
        }
    ],
    "5324cca79b2d7acc7e00001d_2": [
        {
            "start_logit": 0.4521484375,
            "end_logit": 7.5078125,
            "text": "dermatology",
            "probability": 0.998046875
        },
        {
            "start_logit": -6.97265625,
            "end_logit": 7.5078125,
            "text": "Mobile applications in dermatology",
            "probability": 0.0005946159362792969
        },
        {
            "start_logit": -7.0703125,
            "end_logit": 7.5078125,
            "text": "in dermatology",
            "probability": 0.0005393028259277344
        },
        {
            "start_logit": -7.3046875,
            "end_logit": 7.5078125,
            "text": "applications in dermatology",
            "probability": 0.0004267692565917969
        },
        {
            "start_logit": -6.97265625,
            "end_logit": -7.22265625,
            "text": "Mobile applications",
            "probability": 0.0
        },
        {
            "start_logit": -7.3046875,
            "end_logit": -7.22265625,
            "text": "applications",
            "probability": 0.0
        }
    ],
    "5324cca79b2d7acc7e00001d_3": [
        {
            "start_logit": -1.6435546875,
            "end_logit": 3.505859375,
            "text": "VisualDx",
            "probability": 0.6474609375
        },
        {
            "start_logit": -0.603515625,
            "end_logit": 1.1240234375,
            "text": "dermoscopy",
            "probability": 0.1693115234375
        },
        {
            "start_logit": -3.935546875,
            "end_logit": 3.505859375,
            "text": ", VisualDx",
            "probability": 0.06536865234375
        },
        {
            "start_logit": 1.3173828125,
            "end_logit": -2.109375,
            "text": "dermatology",
            "probability": 0.04559326171875
        },
        {
            "start_logit": -4.64453125,
            "end_logit": 3.505859375,
            "text": "included Ultraviolet ~ UV Index (355 reviews), VisualDx",
            "probability": 0.0322265625
        },
        {
            "start_logit": -5.77734375,
            "end_logit": 3.505859375,
            "text": "x",
            "probability": 0.01038360595703125
        },
        {
            "start_logit": -5.80859375,
            "end_logit": 3.505859375,
            "text": "Index (355 reviews), VisualDx",
            "probability": 0.01006317138671875
        },
        {
            "start_logit": -6.25,
            "end_logit": 3.505859375,
            "text": ". The most reviewed apps included Ultraviolet ~ UV Index (355 reviews), VisualDx",
            "probability": 0.006473541259765625
        },
        {
            "start_logit": -6.609375,
            "end_logit": 3.505859375,
            "text": "apps included Ultraviolet ~ UV Index (355 reviews), VisualDx",
            "probability": 0.004520416259765625
        },
        {
            "start_logit": -6.67578125,
            "end_logit": 3.505859375,
            "text": "reviews), VisualDx",
            "probability": 0.004230499267578125
        },
        {
            "start_logit": 1.3173828125,
            "end_logit": -4.71484375,
            "text": "dermatology-related apps were identified in the following categories: general dermatology reference",
            "probability": 0.003360748291015625
        },
        {
            "start_logit": 1.3173828125,
            "end_logit": -6.4375,
            "text": "dermatology-related apps were identified in the following categories: general dermatology reference (61 [26.6%]), self-surveillance",
            "probability": 0.0005998611450195312
        },
        {
            "start_logit": -1.6435546875,
            "end_logit": -5.453125,
            "text": "VisualDx (306), SPF (128), iSore (61), and SpotMole (50).",
            "probability": 8.308887481689453e-05
        },
        {
            "start_logit": -1.6435546875,
            "end_logit": -6.3125,
            "text": "VisualDx (306), SPF (128), iSore (61), and SpotMole",
            "probability": 3.522634506225586e-05
        },
        {
            "start_logit": -1.6435546875,
            "end_logit": -6.3203125,
            "text": "VisualDx (306",
            "probability": 3.4928321838378906e-05
        },
        {
            "start_logit": -6.5078125,
            "end_logit": -2.109375,
            "text": "229 dermatology",
            "probability": 1.823902130126953e-05
        },
        {
            "start_logit": -4.046875,
            "end_logit": -4.71484375,
            "text": "general dermatology reference",
            "probability": 1.5735626220703125e-05
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -2.109375,
            "text": "total of 229 dermatology",
            "probability": 1.4781951904296875e-05
        },
        {
            "start_logit": -4.59375,
            "end_logit": -4.71484375,
            "text": "dermatology reference",
            "probability": 9.119510650634766e-06
        },
        {
            "start_logit": -3.935546875,
            "end_logit": -5.453125,
            "text": ", VisualDx (306), SPF (128), iSore (61), and SpotMole (50).",
            "probability": 8.404254913330078e-06
        }
    ],
    "5324cca79b2d7acc7e00001d_4": [
        {
            "start_logit": 6.54296875,
            "end_logit": 5.734375,
            "text": "myFitnessCompanion\u00ae",
            "probability": 0.98095703125
        },
        {
            "start_logit": 2.59765625,
            "end_logit": 5.734375,
            "text": "health and fitness app called myFitnessCompanion\u00ae",
            "probability": 0.018829345703125
        },
        {
            "start_logit": 6.54296875,
            "end_logit": -4.55859375,
            "text": "myFitnessCompanion",
            "probability": 3.30805778503418e-05
        },
        {
            "start_logit": 6.54296875,
            "end_logit": -5.1171875,
            "text": "my",
            "probability": 1.8894672393798828e-05
        },
        {
            "start_logit": 6.54296875,
            "end_logit": -6.23046875,
            "text": "myFitness",
            "probability": 6.198883056640625e-06
        },
        {
            "start_logit": 2.59765625,
            "end_logit": -2.30859375,
            "text": "health and fitness app",
            "probability": 6.079673767089844e-06
        },
        {
            "start_logit": 6.54296875,
            "end_logit": -6.328125,
            "text": "myFit",
            "probability": 5.662441253662109e-06
        },
        {
            "start_logit": -5.703125,
            "end_logit": 5.734375,
            "text": "\u00ae",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": 6.54296875,
            "end_logit": -6.5234375,
            "text": "myFitnessCom",
            "probability": 4.589557647705078e-06
        },
        {
            "start_logit": 6.54296875,
            "end_logit": -6.55859375,
            "text": "myFitnessCompan",
            "probability": 4.5299530029296875e-06
        },
        {
            "start_logit": -6.34375,
            "end_logit": 5.734375,
            "text": "fitness app called myFitnessCompanion\u00ae",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": 6.54296875,
            "end_logit": -7.3046875,
            "text": "myFi",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -7.08984375,
            "end_logit": 5.734375,
            "text": "FitnessCompanion\u00ae",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -7.09375,
            "end_logit": 5.734375,
            "text": "and fitness app called myFitnessCompanion\u00ae",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 5.734375,
            "text": "mobile health and fitness app called myFitnessCompanion\u00ae",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 5.734375,
            "text": "called myFitnessCompanion\u00ae",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -7.6484375,
            "end_logit": 5.734375,
            "text": "developed a mobile health and fitness app called myFitnessCompanion\u00ae",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 2.59765625,
            "end_logit": -4.55859375,
            "text": "health and fitness app called myFitnessCompanion",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.6953125,
            "end_logit": 5.734375,
            "text": "team has developed a mobile health and fitness app called myFitnessCompanion\u00ae",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 2.59765625,
            "end_logit": -5.1171875,
            "text": "health and fitness app called my",
            "probability": 3.5762786865234375e-07
        }
    ],
    "5324cca79b2d7acc7e00001d_5": [
        {
            "start_logit": 2.26171875,
            "end_logit": 2.3046875,
            "text": "tracking drinking consumption",
            "probability": 0.6669921875
        },
        {
            "start_logit": 1.3740234375,
            "end_logit": 2.3046875,
            "text": "alcohol-use behavior change or recovery. Aside from tracking drinking consumption",
            "probability": 0.27490234375
        },
        {
            "start_logit": 1.3740234375,
            "end_logit": 0.65478515625,
            "text": "alcohol-use behavior change",
            "probability": 0.052764892578125
        },
        {
            "start_logit": -3.599609375,
            "end_logit": 2.3046875,
            "text": "drinking consumption",
            "probability": 0.001903533935546875
        },
        {
            "start_logit": 2.26171875,
            "end_logit": -3.9140625,
            "text": "tracking drinking consumption, a minority utilized empirically based components of alcohol treatment",
            "probability": 0.0013284683227539062
        },
        {
            "start_logit": 1.3740234375,
            "end_logit": -3.9140625,
            "text": "alcohol-use behavior change or recovery. Aside from tracking drinking consumption, a minority utilized empirically based components of alcohol treatment",
            "probability": 0.0005474090576171875
        },
        {
            "start_logit": -5.15234375,
            "end_logit": 2.3046875,
            "text": "few apps addressed alcohol-use behavior change or recovery. Aside from tracking drinking consumption",
            "probability": 0.0004019737243652344
        },
        {
            "start_logit": -5.828125,
            "end_logit": 2.3046875,
            "text": "apps addressed alcohol-use behavior change or recovery. Aside from tracking drinking consumption",
            "probability": 0.00020372867584228516
        },
        {
            "start_logit": 2.26171875,
            "end_logit": -6.38671875,
            "text": "tracking drinking consumption, a minority utilized empirically based components of alcohol treatment.",
            "probability": 0.0001125335693359375
        },
        {
            "start_logit": -6.56640625,
            "end_logit": 2.3046875,
            "text": ". Aside from tracking drinking consumption",
            "probability": 9.775161743164062e-05
        },
        {
            "start_logit": 1.3740234375,
            "end_logit": -5.7109375,
            "text": "alcohol-use",
            "probability": 9.042024612426758e-05
        },
        {
            "start_logit": -5.15234375,
            "end_logit": 0.65478515625,
            "text": "few apps addressed alcohol-use behavior change",
            "probability": 7.736682891845703e-05
        },
        {
            "start_logit": -6.859375,
            "end_logit": 2.3046875,
            "text": "recovery. Aside from tracking drinking consumption",
            "probability": 7.265806198120117e-05
        },
        {
            "start_logit": -6.9140625,
            "end_logit": 2.3046875,
            "text": "addressed alcohol-use behavior change or recovery. Aside from tracking drinking consumption",
            "probability": 6.93202018737793e-05
        },
        {
            "start_logit": 2.26171875,
            "end_logit": -6.90234375,
            "text": "tracking drinking consumption, a minority utilized empirically based components of alcohol",
            "probability": 6.717443466186523e-05
        },
        {
            "start_logit": -7.10546875,
            "end_logit": 2.3046875,
            "text": "Aside from tracking drinking consumption",
            "probability": 5.704164505004883e-05
        },
        {
            "start_logit": -7.10546875,
            "end_logit": 2.3046875,
            "text": "behavior change or recovery. Aside from tracking drinking consumption",
            "probability": 5.704164505004883e-05
        },
        {
            "start_logit": 2.26171875,
            "end_logit": -7.0859375,
            "text": "tracking drinking consumption, a",
            "probability": 5.5730342864990234e-05
        },
        {
            "start_logit": 1.3740234375,
            "end_logit": -6.21484375,
            "text": "alcohol-use behavior change or recovery",
            "probability": 5.4836273193359375e-05
        },
        {
            "start_logit": 2.26171875,
            "end_logit": -7.171875,
            "text": "tracking drinking consumption,",
            "probability": 5.1140785217285156e-05
        }
    ],
    "5324cca79b2d7acc7e00001d_6": [
        {
            "start_logit": 7.6640625,
            "end_logit": -3.681640625,
            "text": "monitoring",
            "probability": 0.5693359375
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -5.3203125,
            "text": "monitoring urine flow for patients with enlarged prostates",
            "probability": 0.11053466796875
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -5.6015625,
            "text": "monitoring urine flow",
            "probability": 0.08343505859375
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -5.67578125,
            "text": "monitoring urine flow for",
            "probability": 0.07745361328125
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -6.2734375,
            "text": "monitoring urine flow for patients with enlarged prostate",
            "probability": 0.042633056640625
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -6.6015625,
            "text": "monitoring urine flow for patients with enlarged prostates to reminding people prone to kidney stones to drink more water",
            "probability": 0.03070068359375
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -6.7890625,
            "text": "monitoring urine flow for patients with enlarged prostates to reminding people prone to kidney stones to drink more water.",
            "probability": 0.02545166015625
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -6.89453125,
            "text": "monitoring urine flow for patients with enlarged prostates to reminding people prone to kidney stones",
            "probability": 0.022918701171875
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -6.90234375,
            "text": "monitoring urine flow for patients with enlarged prostates to",
            "probability": 0.0227203369140625
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -7.328125,
            "text": "monitoring urine flow for patients",
            "probability": 0.0148468017578125
        },
        {
            "start_logit": 0.253662109375,
            "end_logit": -5.3203125,
            "text": "urine flow for patients with enlarged prostates",
            "probability": 6.705522537231445e-05
        },
        {
            "start_logit": 0.253662109375,
            "end_logit": -5.6015625,
            "text": "urine flow",
            "probability": 5.060434341430664e-05
        },
        {
            "start_logit": 0.253662109375,
            "end_logit": -5.67578125,
            "text": "urine flow for",
            "probability": 4.678964614868164e-05
        },
        {
            "start_logit": 0.253662109375,
            "end_logit": -6.2734375,
            "text": "urine flow for patients with enlarged prostate",
            "probability": 2.586841583251953e-05
        },
        {
            "start_logit": 0.253662109375,
            "end_logit": -6.6015625,
            "text": "urine flow for patients with enlarged prostates to reminding people prone to kidney stones to drink more water",
            "probability": 1.8596649169921875e-05
        },
        {
            "start_logit": 0.253662109375,
            "end_logit": -6.7890625,
            "text": "urine flow for patients with enlarged prostates to reminding people prone to kidney stones to drink more water.",
            "probability": 1.5437602996826172e-05
        },
        {
            "start_logit": 0.253662109375,
            "end_logit": -6.89453125,
            "text": "urine flow for patients with enlarged prostates to reminding people prone to kidney stones",
            "probability": 1.3828277587890625e-05
        },
        {
            "start_logit": 0.253662109375,
            "end_logit": -6.90234375,
            "text": "urine flow for patients with enlarged prostates to",
            "probability": 1.3768672943115234e-05
        },
        {
            "start_logit": 0.253662109375,
            "end_logit": -7.328125,
            "text": "urine flow for patients",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": -5.90234375,
            "end_logit": -3.681640625,
            "text": "from monitoring",
            "probability": 7.152557373046875e-07
        }
    ],
    "587d2700fe8a08052f000001_1": [
        {
            "start_logit": 9.25,
            "end_logit": 9.3203125,
            "text": "dbSUPER",
            "probability": 1.0
        },
        {
            "start_logit": 9.25,
            "end_logit": -1.25,
            "text": "dbS",
            "probability": 2.586841583251953e-05
        },
        {
            "start_logit": -1.3564453125,
            "end_logit": 9.3203125,
            "text": "ER",
            "probability": 2.5093555450439453e-05
        },
        {
            "start_logit": -5.6953125,
            "end_logit": 9.3203125,
            "text": "UPER",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.28515625,
            "text": "dbSUPER: a database of super-enhancers",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.328125,
            "text": "dbSUPER: a database of super-enhancers in mouse and human genome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.4609375,
            "text": "dbSUPER:",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.52734375,
            "text": "dbSUPER: a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.53515625,
            "text": "dbSUPER: a database of super-enhancers in mouse and human",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.53515625,
            "text": "dbSUPER: a database of super-enhancers in mouse",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3564453125,
            "end_logit": -7.28515625,
            "text": "ER: a database of super-enhancers",
            "probability": 0.0
        },
        {
            "start_logit": -1.3564453125,
            "end_logit": -7.328125,
            "text": "ER: a database of super-enhancers in mouse and human genome",
            "probability": 0.0
        },
        {
            "start_logit": -1.3564453125,
            "end_logit": -7.4609375,
            "text": "ER:",
            "probability": 0.0
        },
        {
            "start_logit": -1.3564453125,
            "end_logit": -7.52734375,
            "text": "ER: a",
            "probability": 0.0
        },
        {
            "start_logit": -1.3564453125,
            "end_logit": -7.53515625,
            "text": "ER: a database of super-enhancers in mouse and human",
            "probability": 0.0
        },
        {
            "start_logit": -1.3564453125,
            "end_logit": -7.53515625,
            "text": "ER: a database of super-enhancers in mouse",
            "probability": 0.0
        },
        {
            "start_logit": -5.6953125,
            "end_logit": -7.28515625,
            "text": "UPER: a database of super-enhancers",
            "probability": 0.0
        },
        {
            "start_logit": -5.6953125,
            "end_logit": -7.328125,
            "text": "UPER: a database of super-enhancers in mouse and human genome",
            "probability": 0.0
        },
        {
            "start_logit": -5.6953125,
            "end_logit": -7.4609375,
            "text": "UPER:",
            "probability": 0.0
        },
        {
            "start_logit": -5.6953125,
            "end_logit": -7.52734375,
            "text": "UPER: a",
            "probability": 0.0
        }
    ],
    "587d2700fe8a08052f000001_2": [
        {
            "start_logit": 9.265625,
            "end_logit": 9.3359375,
            "text": "dbSUPER",
            "probability": 1.0
        },
        {
            "start_logit": -1.2431640625,
            "end_logit": 9.3359375,
            "text": "ER",
            "probability": 2.753734588623047e-05
        },
        {
            "start_logit": 9.265625,
            "end_logit": -1.224609375,
            "text": "dbS",
            "probability": 2.6047229766845703e-05
        },
        {
            "start_logit": -6.4921875,
            "end_logit": 9.3359375,
            "text": "UPER",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.82421875,
            "end_logit": 9.3359375,
            "text": "developed dbSUPER",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.1953125,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.328125,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.3359375,
            "text": "dbSUPER (http://bioinfo.au.tsinghua",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.40234375,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.43359375,
            "text": "dbSUPER (http:/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.82421875,
            "end_logit": -1.224609375,
            "text": "developed dbS",
            "probability": 0.0
        },
        {
            "start_logit": -1.2431640625,
            "end_logit": -7.1953125,
            "text": "ER (http://bioinfo.au.tsinghua.edu.cn/dbsuper",
            "probability": 0.0
        },
        {
            "start_logit": -1.2431640625,
            "end_logit": -7.328125,
            "text": "ER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/)",
            "probability": 0.0
        },
        {
            "start_logit": -1.2431640625,
            "end_logit": -7.3359375,
            "text": "ER (http://bioinfo.au.tsinghua",
            "probability": 0.0
        },
        {
            "start_logit": -1.2431640625,
            "end_logit": -7.40234375,
            "text": "ER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/",
            "probability": 0.0
        },
        {
            "start_logit": -1.2431640625,
            "end_logit": -7.43359375,
            "text": "ER (http:/",
            "probability": 0.0
        },
        {
            "start_logit": -6.609375,
            "end_logit": -6.8984375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.4921875,
            "end_logit": -7.1953125,
            "text": "UPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper",
            "probability": 0.0
        },
        {
            "start_logit": -6.4921875,
            "end_logit": -7.328125,
            "text": "UPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/)",
            "probability": 0.0
        },
        {
            "start_logit": -6.4921875,
            "end_logit": -7.3359375,
            "text": "UPER (http://bioinfo.au.tsinghua",
            "probability": 0.0
        }
    ],
    "587d2700fe8a08052f000001_3": [
        {
            "start_logit": 7.51953125,
            "end_logit": 8.1171875,
            "text": "SEA",
            "probability": 1.0
        },
        {
            "start_logit": 7.51953125,
            "end_logit": -6.62890625,
            "text": "SEA: a super-enhancer archive",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.51953125,
            "end_logit": -7.42578125,
            "text": "SEA: a super-enhancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.51953125,
            "end_logit": -7.484375,
            "text": "SEA: a super-enhancer arch",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.4375,
            "end_logit": -6.62890625,
            "text": "super-enhancer archive",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -7.42578125,
            "text": "super-enhancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -7.484375,
            "text": "super-enhancer arch",
            "probability": 0.0
        }
    ],
    "587d2700fe8a08052f000001_4": [
        {
            "start_logit": 6.91015625,
            "end_logit": 6.59375,
            "text": "SEA",
            "probability": 0.5126953125
        },
        {
            "start_logit": 6.48046875,
            "end_logit": 6.59375,
            "text": "Super-Enhancer Archive (SEA",
            "probability": 0.336181640625
        },
        {
            "start_logit": 6.48046875,
            "end_logit": 5.8046875,
            "text": "Super-Enhancer Archive",
            "probability": 0.1514892578125
        },
        {
            "start_logit": 6.48046875,
            "end_logit": -5.01171875,
            "text": "Super",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": -5.32421875,
            "end_logit": 6.59375,
            "text": "ive (SEA",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": -5.32421875,
            "end_logit": 5.8046875,
            "text": "ive",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -6.28125,
            "end_logit": 6.59375,
            "text": ", Super-Enhancer Archive (SEA",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -6.83203125,
            "end_logit": 6.59375,
            "text": "(SEA",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.9765625,
            "end_logit": 6.59375,
            "text": "-Enhancer Archive (SEA",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.05859375,
            "end_logit": 6.59375,
            "text": "Archive (SEA",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.28125,
            "end_logit": 5.8046875,
            "text": ", Super-Enhancer Archive",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.12109375,
            "end_logit": 6.59375,
            "text": "present a specifically designed web-accessible database, Super-Enhancer Archive (SEA",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.9765625,
            "end_logit": 5.8046875,
            "text": "-Enhancer Archive",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.05859375,
            "end_logit": 5.8046875,
            "text": "Archive",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.12109375,
            "end_logit": 5.8046875,
            "text": "present a specifically designed web-accessible database, Super-Enhancer Archive",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -4.99609375,
            "end_logit": -5.734375,
            "text": "SEA incorporates 83 99",
            "probability": 0.0
        },
        {
            "start_logit": -4.99609375,
            "end_logit": -5.95703125,
            "text": "SEA",
            "probability": 0.0
        },
        {
            "start_logit": -4.99609375,
            "end_logit": -6.08203125,
            "text": "SEA incorporates 83 996",
            "probability": 0.0
        },
        {
            "start_logit": -6.28125,
            "end_logit": -5.01171875,
            "text": ", Super",
            "probability": 0.0
        },
        {
            "start_logit": -4.99609375,
            "end_logit": -6.8671875,
            "text": "SEA incorporates 83 996 super-enhancers computationally or experimentally identified in 134 cell types",
            "probability": 0.0
        }
    ],
    "587d2700fe8a08052f000001_5": [
        {
            "start_logit": 7.7109375,
            "end_logit": 7.91015625,
            "text": "SEA",
            "probability": 1.0
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -5.375,
            "text": "SEA focuses on integrating super-enhancers in multiple species",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -6.7109375,
            "text": "SEA focuses on integrating super-enhancers in multiple species and annotating their potential roles in the regulation of cell identity gene expression",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -6.8125,
            "text": "SEA focuses",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -7.2109375,
            "text": "SEA focuses on integrating super-enhancers in multiple species and annotating their potential roles in the regulation of cell identity gene expression.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -7.28125,
            "text": "SEA focuses on integrating super-enhancers in multiple species and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -7.30859375,
            "text": "SEA focuses on",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -7.30859375,
            "text": "SEA focuses on integrating super-enhancers in multiple species and annotating their potential roles in the regulation of cell identity gene",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -7.3828125,
            "text": "SEA focuses on integrating super-enhancers in multiple species and annotating their potential roles in the",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.3203125,
            "end_logit": -5.375,
            "text": "species",
            "probability": 0.0
        },
        {
            "start_logit": -7.34765625,
            "end_logit": -5.375,
            "text": "multiple species",
            "probability": 0.0
        },
        {
            "start_logit": -7.5390625,
            "end_logit": -5.375,
            "text": "in multiple species",
            "probability": 0.0
        },
        {
            "start_logit": -7.3203125,
            "end_logit": -6.7109375,
            "text": "species and annotating their potential roles in the regulation of cell identity gene expression",
            "probability": 0.0
        },
        {
            "start_logit": -7.34765625,
            "end_logit": -6.7109375,
            "text": "multiple species and annotating their potential roles in the regulation of cell identity gene expression",
            "probability": 0.0
        },
        {
            "start_logit": -7.453125,
            "end_logit": -6.7109375,
            "text": "cell identity gene expression",
            "probability": 0.0
        },
        {
            "start_logit": -7.4765625,
            "end_logit": -6.7109375,
            "text": "regulation of cell identity gene expression",
            "probability": 0.0
        },
        {
            "start_logit": -7.01953125,
            "end_logit": -7.2109375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.5390625,
            "end_logit": -6.7109375,
            "text": "in multiple species and annotating their potential roles in the regulation of cell identity gene expression",
            "probability": 0.0
        },
        {
            "start_logit": -7.3203125,
            "end_logit": -7.2109375,
            "text": "species and annotating their potential roles in the regulation of cell identity gene expression.",
            "probability": 0.0
        },
        {
            "start_logit": -7.34765625,
            "end_logit": -7.2109375,
            "text": "multiple species and annotating their potential roles in the regulation of cell identity gene expression.",
            "probability": 0.0
        }
    ],
    "587d2700fe8a08052f000001_6": [
        {
            "start_logit": 7.70703125,
            "end_logit": 7.890625,
            "text": "SEA",
            "probability": 1.0
        },
        {
            "start_logit": 7.70703125,
            "end_logit": -5.99609375,
            "text": "SEA incorporates 83 99",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 7.70703125,
            "end_logit": -6.8046875,
            "text": "SEA incorporates 83 996",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.70703125,
            "end_logit": -7.1953125,
            "text": "SEA incorporates 83",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.70703125,
            "end_logit": -7.23046875,
            "text": "SEA incorporates 83 996 super-enhancers computationally or experimentally identified in 134 cell types",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.3984375,
            "end_logit": -6.0546875,
            "text": ", mouse (5879, five of which were experimentally identified), Drosophila melanogaster (1774) and Caenorhabditis elegans",
            "probability": 0.0
        },
        {
            "start_logit": -7.50390625,
            "end_logit": -6.0546875,
            "text": ", Drosophila melanogaster (1774) and Caenorhabditis elegans",
            "probability": 0.0
        },
        {
            "start_logit": -7.54296875,
            "end_logit": -6.0546875,
            "text": "Drosophila melanogaster (1774) and Caenorhabditis elegans",
            "probability": 0.0
        },
        {
            "start_logit": -7.078125,
            "end_logit": -7.1640625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.3984375,
            "end_logit": -6.9609375,
            "text": ", mouse (5879, five of which were experimentally identified), Drosophila melanogaster",
            "probability": 0.0
        },
        {
            "start_logit": -7.45703125,
            "end_logit": -6.9609375,
            "text": "human (75 439, three of which were experimentally identified), mouse (5879, five of which were experimentally identified), Drosophila melanogaster",
            "probability": 0.0
        },
        {
            "start_logit": -7.3984375,
            "end_logit": -7.03515625,
            "text": ", mouse (5879, five of which were experimentally identified), Drosophila melanogaster (1774) and Caenorhabditis elegans (904",
            "probability": 0.0
        },
        {
            "start_logit": -7.3984375,
            "end_logit": -7.04296875,
            "text": ", mouse (5879, five of which were experimentally identified), Drosophila melanogaster (1774) and Caenorhabditis elegans (90",
            "probability": 0.0
        },
        {
            "start_logit": -7.50390625,
            "end_logit": -6.9609375,
            "text": ", Drosophila melanogaster",
            "probability": 0.0
        },
        {
            "start_logit": -7.3984375,
            "end_logit": -7.09375,
            "text": ", mouse (5879, five of which were experimentally identified), Drosophila melanogaster (1774",
            "probability": 0.0
        },
        {
            "start_logit": -7.54296875,
            "end_logit": -6.9609375,
            "text": "Drosophila melanogaster",
            "probability": 0.0
        },
        {
            "start_logit": -7.3984375,
            "end_logit": -7.1328125,
            "text": ", mouse (5879, five of which were experimentally identified), Drosophila melanogaster (1774) and Caenorhabditis elegans (",
            "probability": 0.0
        },
        {
            "start_logit": -7.50390625,
            "end_logit": -7.03515625,
            "text": ", Drosophila melanogaster (1774) and Caenorhabditis elegans (904",
            "probability": 0.0
        },
        {
            "start_logit": -7.3984375,
            "end_logit": -7.15234375,
            "text": ", mouse (5879, five of which were experimentally identified), Drosophila melanogaster (1774) and Caenorhabditis elegans (904)",
            "probability": 0.0
        },
        {
            "start_logit": -7.50390625,
            "end_logit": -7.04296875,
            "text": ", Drosophila melanogaster (1774) and Caenorhabditis elegans (90",
            "probability": 0.0
        }
    ],
    "587d2700fe8a08052f000001_7": [
        {
            "start_logit": 9.140625,
            "end_logit": 9.25,
            "text": "dbSUPER",
            "probability": 1.0
        },
        {
            "start_logit": -1.515625,
            "end_logit": 9.25,
            "text": "ER",
            "probability": 2.3543834686279297e-05
        },
        {
            "start_logit": 9.140625,
            "end_logit": -1.5546875,
            "text": "dbS",
            "probability": 2.0325183868408203e-05
        },
        {
            "start_logit": -6.07421875,
            "end_logit": 9.25,
            "text": "UPER",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.3359375,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.33984375,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.41796875,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.4765625,
            "text": "dbSUPER (http://bioinfo.au.tsinghua",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 9.25,
            "text": "developed dbSUPER",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.53125,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/), the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.5390625,
            "text": "dbSUPER (http:/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.578125,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsup",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.515625,
            "end_logit": -7.3359375,
            "text": "ER (http://bioinfo.au.tsinghua.edu.cn/dbsuper",
            "probability": 0.0
        },
        {
            "start_logit": -1.515625,
            "end_logit": -7.33984375,
            "text": "ER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/)",
            "probability": 0.0
        },
        {
            "start_logit": -1.515625,
            "end_logit": -7.41796875,
            "text": "ER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/",
            "probability": 0.0
        },
        {
            "start_logit": -1.515625,
            "end_logit": -7.4765625,
            "text": "ER (http://bioinfo.au.tsinghua",
            "probability": 0.0
        },
        {
            "start_logit": -1.515625,
            "end_logit": -7.53125,
            "text": "ER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/), the",
            "probability": 0.0
        },
        {
            "start_logit": -1.515625,
            "end_logit": -7.5390625,
            "text": "ER (http:/",
            "probability": 0.0
        },
        {
            "start_logit": -1.515625,
            "end_logit": -7.578125,
            "text": "ER (http://bioinfo.au.tsinghua.edu.cn/dbsup",
            "probability": 0.0
        },
        {
            "start_logit": -7.62890625,
            "end_logit": -1.5546875,
            "text": "developed dbS",
            "probability": 0.0
        }
    ],
    "587d2700fe8a08052f000001_8": [
        {
            "start_logit": 9.15625,
            "end_logit": 9.4140625,
            "text": "dbSUPER",
            "probability": 1.0
        },
        {
            "start_logit": -1.1064453125,
            "end_logit": 9.4140625,
            "text": "ER",
            "probability": 3.510713577270508e-05
        },
        {
            "start_logit": 9.15625,
            "end_logit": -1.5078125,
            "text": "dbS",
            "probability": 1.817941665649414e-05
        },
        {
            "start_logit": 9.15625,
            "end_logit": -1.9560546875,
            "text": "dbSUPER lists genes associated with super-enhancers and also links to external databases such as GeneCards",
            "probability": 1.1682510375976562e-05
        },
        {
            "start_logit": 9.15625,
            "end_logit": -5.09765625,
            "text": "dbSUPER lists genes associated with super-enhancers and also links to external databases such as GeneCards, UniProt",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.03515625,
            "end_logit": 9.4140625,
            "text": "UPER",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.15625,
            "end_logit": -6.7578125,
            "text": "dbSUPER lists genes associated with super-enhancers and also links to external databases such as GeneCards, UniProt and Entrez",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.15625,
            "end_logit": -7.19921875,
            "text": "dbSUPER lists genes associated with super-enhancers and also links to external databases such as GeneCards, UniProt and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 9.4140625,
            "text": ", dbSUPER",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.15625,
            "end_logit": -7.28125,
            "text": "dbSUPER lists genes associated with super-enhancers and also links to external databases such as GeneCards, UniProt and Entrez.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 9.4140625,
            "text": "Furthermore, dbSUPER",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.15625,
            "end_logit": -7.328125,
            "text": "dbSUPER lists genes associated with super-enhancers and also links to external databases such",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.15625,
            "end_logit": -7.359375,
            "text": "dbSUPER lists genes associated with super-enhancers and also links to external databases such as GeneCards, UniProt and Entr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.15625,
            "end_logit": -7.48828125,
            "text": "dbSUPER lists genes associated with super-enhancers and also links",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.15625,
            "end_logit": -7.4921875,
            "text": "dbSUPER lists genes associated with super-enhancers and also links to external databases",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.15625,
            "end_logit": -7.49609375,
            "text": "dbSUPER lists genes associated with super-enhancers and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.1064453125,
            "end_logit": -1.9560546875,
            "text": "ER lists genes associated with super-enhancers and also links to external databases such as GeneCards",
            "probability": 0.0
        },
        {
            "start_logit": -2.57421875,
            "end_logit": -1.9560546875,
            "text": "GeneCards",
            "probability": 0.0
        },
        {
            "start_logit": -1.1064453125,
            "end_logit": -5.09765625,
            "text": "ER lists genes associated with super-enhancers and also links to external databases such as GeneCards, UniProt",
            "probability": 0.0
        },
        {
            "start_logit": -2.57421875,
            "end_logit": -5.09765625,
            "text": "GeneCards, UniProt",
            "probability": 0.0
        }
    ],
    "587d2700fe8a08052f000001_9": [
        {
            "start_logit": 9.1875,
            "end_logit": 9.28125,
            "text": "dbSUPER",
            "probability": 1.0
        },
        {
            "start_logit": -1.43359375,
            "end_logit": 9.28125,
            "text": "ER",
            "probability": 2.4318695068359375e-05
        },
        {
            "start_logit": 9.1875,
            "end_logit": -1.439453125,
            "text": "dbS",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": -6.19921875,
            "end_logit": 9.28125,
            "text": "UPER",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.05859375,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 9.28125,
            "text": "developed dbSUPER",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.32421875,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.3515625,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.421875,
            "text": "dbSUPER (http://bioinfo.au.tsinghua",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.4609375,
            "text": "dbSUPER (http:/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.52734375,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsup",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.53515625,
            "text": "dbSUPER (http://bioinfo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.54296875,
            "text": "dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/), the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.43359375,
            "end_logit": -7.05859375,
            "text": "ER (http://bioinfo.au.tsinghua.edu.cn/dbsuper",
            "probability": 0.0
        },
        {
            "start_logit": -1.43359375,
            "end_logit": -7.32421875,
            "text": "ER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/)",
            "probability": 0.0
        },
        {
            "start_logit": -1.43359375,
            "end_logit": -7.3515625,
            "text": "ER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/",
            "probability": 0.0
        },
        {
            "start_logit": -7.4140625,
            "end_logit": -1.439453125,
            "text": "developed dbS",
            "probability": 0.0
        },
        {
            "start_logit": -1.43359375,
            "end_logit": -7.421875,
            "text": "ER (http://bioinfo.au.tsinghua",
            "probability": 0.0
        },
        {
            "start_logit": -1.43359375,
            "end_logit": -7.4609375,
            "text": "ER (http:/",
            "probability": 0.0
        },
        {
            "start_logit": -1.43359375,
            "end_logit": -7.52734375,
            "text": "ER (http://bioinfo.au.tsinghua.edu.cn/dbsup",
            "probability": 0.0
        }
    ],
    "587d2700fe8a08052f000001_10": [
        {
            "start_logit": 9.234375,
            "end_logit": 9.3984375,
            "text": "dbSUPER",
            "probability": 1.0
        },
        {
            "start_logit": -1.1494140625,
            "end_logit": 9.3984375,
            "text": "ER",
            "probability": 3.11732292175293e-05
        },
        {
            "start_logit": 9.234375,
            "end_logit": -1.2939453125,
            "text": "dbS",
            "probability": 2.282857894897461e-05
        },
        {
            "start_logit": -5.55078125,
            "end_logit": 9.3984375,
            "text": "UPER",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.15234375,
            "text": "dbSUPER: a database of super-enhancers",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.33203125,
            "text": "dbSUPER: a database of super-enhancers in mouse and human genome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.37890625,
            "text": "dbSUPER: a database of super-enhancers in mouse and human genome.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.45703125,
            "text": "dbSUPER:",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.1494140625,
            "end_logit": -7.15234375,
            "text": "ER: a database of super-enhancers",
            "probability": 0.0
        },
        {
            "start_logit": -1.1494140625,
            "end_logit": -7.33203125,
            "text": "ER: a database of super-enhancers in mouse and human genome",
            "probability": 0.0
        },
        {
            "start_logit": -1.1494140625,
            "end_logit": -7.37890625,
            "text": "ER: a database of super-enhancers in mouse and human genome.",
            "probability": 0.0
        },
        {
            "start_logit": -1.1494140625,
            "end_logit": -7.45703125,
            "text": "ER:",
            "probability": 0.0
        },
        {
            "start_logit": -5.55078125,
            "end_logit": -7.15234375,
            "text": "UPER: a database of super-enhancers",
            "probability": 0.0
        },
        {
            "start_logit": -5.55078125,
            "end_logit": -7.33203125,
            "text": "UPER: a database of super-enhancers in mouse and human genome",
            "probability": 0.0
        },
        {
            "start_logit": -5.55078125,
            "end_logit": -7.37890625,
            "text": "UPER: a database of super-enhancers in mouse and human genome.",
            "probability": 0.0
        },
        {
            "start_logit": -5.55078125,
            "end_logit": -7.45703125,
            "text": "UPER:",
            "probability": 0.0
        },
        {
            "start_logit": -6.97265625,
            "end_logit": -7.37890625,
            "text": ".",
            "probability": 0.0
        }
    ],
    "571f2b5bbb137a4b0c000010_1": [
        {
            "start_logit": 9.1484375,
            "end_logit": 8.828125,
            "text": "CCM3",
            "probability": 1.0
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -1.294921875,
            "text": "CC",
            "probability": 4.035234451293945e-05
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -1.9580078125,
            "text": "CCM3/PDCD10",
            "probability": 2.0802021026611328e-05
        },
        {
            "start_logit": -2.119140625,
            "end_logit": 8.828125,
            "text": "3",
            "probability": 1.2934207916259766e-05
        },
        {
            "start_logit": -6.2265625,
            "end_logit": 8.828125,
            "text": "M3",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -6.77734375,
            "text": "CCM3/PDCD1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.671875,
            "end_logit": 8.828125,
            "text": ", CCM3",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.85546875,
            "end_logit": 8.828125,
            "text": "genetic variants and molecular phylogeny of cerebral cavernous malformation gene, CCM3",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -7.28125,
            "text": "CCM",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.16796875,
            "end_logit": 8.828125,
            "text": "Surveying genetic variants and molecular phylogeny of cerebral cavernous malformation gene, CCM3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -7.5078125,
            "text": "CCM3/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -7.52734375,
            "text": "CCM3/PDC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 8.828125,
            "text": "ing genetic variants and molecular phylogeny of cerebral cavernous malformation gene, CCM3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 8.828125,
            "text": "malformation gene, CCM3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.43359375,
            "end_logit": 8.828125,
            "text": "cavernous malformation gene, CCM3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4375,
            "end_logit": 8.828125,
            "text": "molecular phylogeny of cerebral cavernous malformation gene, CCM3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 8.828125,
            "text": "variants and molecular phylogeny of cerebral cavernous malformation gene, CCM3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.119140625,
            "end_logit": -1.9580078125,
            "text": "3/PDCD10",
            "probability": 0.0
        },
        {
            "start_logit": -5.83203125,
            "end_logit": -1.9580078125,
            "text": "PDCD10",
            "probability": 0.0
        },
        {
            "start_logit": -6.671875,
            "end_logit": -1.294921875,
            "text": ", CC",
            "probability": 0.0
        }
    ],
    "571f2b5bbb137a4b0c000010_2": [
        {
            "start_logit": 9.21875,
            "end_logit": 9.21875,
            "text": "CCM1",
            "probability": 1.0
        },
        {
            "start_logit": 9.21875,
            "end_logit": -1.353515625,
            "text": "CC",
            "probability": 2.568960189819336e-05
        },
        {
            "start_logit": -1.5,
            "end_logit": 9.21875,
            "text": "M1",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": 9.21875,
            "end_logit": -6.90234375,
            "text": "CCM1/KRIT1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.109375,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CCM3/PDCD10",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.14453125,
            "end_logit": 9.21875,
            "text": "namely CCM1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.40234375,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CCM3/PDCD1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.484375,
            "text": "CCM1/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.51953125,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CCM3/PDC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.52734375,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.5546875,
            "text": "CCM1/KRIT1, CCM2/MGC460",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.55859375,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CCM3/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.55859375,
            "text": "CCM1/KRIT1, CCM2/MGC46",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5625,
            "end_logit": 9.21875,
            "text": "three cerebral cavernous malformations (CCMs) genes namely CCM1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 9.21875,
            "text": "The three cerebral cavernous malformations (CCMs) genes namely CCM1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.58203125,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CCM3/PDCD10 have",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.58203125,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CCM3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.59765625,
            "text": "CCM1/KRIT",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.609375,
            "text": "CCM1/KRIT1, CCM2/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.609375,
            "end_logit": 9.21875,
            "text": "cerebral cavernous malformations (CCMs) genes namely CCM1",
            "probability": 5.960464477539063e-08
        }
    ],
    "571f2b5bbb137a4b0c000010_3": [
        {
            "start_logit": 9.015625,
            "end_logit": 9.2265625,
            "text": "CCM1",
            "probability": 1.0
        },
        {
            "start_logit": -1.4775390625,
            "end_logit": 9.2265625,
            "text": "M1",
            "probability": 2.753734588623047e-05
        },
        {
            "start_logit": 9.015625,
            "end_logit": -1.8359375,
            "text": "CC",
            "probability": 1.5556812286376953e-05
        },
        {
            "start_logit": 9.015625,
            "end_logit": -6.546875,
            "text": "CCM1/KRIT1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.2578125,
            "end_logit": 9.2265625,
            "text": "in CCM1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2734375,
            "end_logit": 9.2265625,
            "text": "Loss-of-function mutations in CCM1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 9.2265625,
            "text": "mutations in CCM1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.2734375,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CCM3/PDCD10",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 9.2265625,
            "text": "function mutations in CCM1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.43359375,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CCM3/PDCD1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.44140625,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CCM3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.46484375,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CCM3/PDCD10 genes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.48046875,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.52734375,
            "text": "CCM1/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.55078125,
            "text": "CCM1/KRIT",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.5703125,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CCM3/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.58203125,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CCM",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.5859375,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.58984375,
            "text": "CCM1/KRIT1, CCM2/MGC4607 and CCM3/PDC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.58984375,
            "text": "CCM1/KRIT1, CC",
            "probability": 5.960464477539063e-08
        }
    ],
    "571f2b5bbb137a4b0c000010_4": [
        {
            "start_logit": 5.890625,
            "end_logit": 5.984375,
            "text": "CCM1",
            "probability": 0.9990234375
        },
        {
            "start_logit": -1.5009765625,
            "end_logit": 5.984375,
            "text": "KRIT1/CCM1",
            "probability": 0.0006165504455566406
        },
        {
            "start_logit": -5.18359375,
            "end_logit": 5.984375,
            "text": "M1",
            "probability": 1.5437602996826172e-05
        },
        {
            "start_logit": 5.890625,
            "end_logit": -5.12890625,
            "text": "CC",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": -6.265625,
            "end_logit": 5.984375,
            "text": "proteins KRIT1/CCM1",
            "probability": 5.245208740234375e-06
        },
        {
            "start_logit": 5.890625,
            "end_logit": -6.38671875,
            "text": "CCM1 (krev interaction trapped 1/cerebral cavernous malformations 1), cerebral cavernous malformations 2, osmosensing scaffold for MEKK3",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": -6.61328125,
            "end_logit": 5.984375,
            "text": "/CCM1",
            "probability": 3.7550926208496094e-06
        },
        {
            "start_logit": 5.890625,
            "end_logit": -6.59765625,
            "text": "CCM1 (krev interaction trapped 1/cerebral cavernous malformations 1), cerebral cavernous malformations 2, osmosensing scaffold for MEKK3 (CC",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": -6.6953125,
            "end_logit": 5.984375,
            "text": ". These genes encode for the proteins KRIT1/CCM1",
            "probability": 3.3974647521972656e-06
        },
        {
            "start_logit": 5.890625,
            "end_logit": -6.62890625,
            "text": "CCM1 (krev interaction",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": 5.890625,
            "end_logit": -6.66796875,
            "text": "CCM1 (",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": -6.76953125,
            "end_logit": 5.984375,
            "text": "Mutations in three genes are associated with CCM. These genes encode for the proteins KRIT1/CCM1",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": -6.7734375,
            "end_logit": 5.984375,
            "text": "genes encode for the proteins KRIT1/CCM1",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": 5.890625,
            "end_logit": -6.71875,
            "text": "CCM1 (krev interaction trapped 1/cerebral cavernous malformations 1), cerebral cavernous malformations 2, osmosensing scaffold for MEKK3 (CCM2",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": -6.8125,
            "end_logit": 5.984375,
            "text": "IT1/CCM1",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": 5.890625,
            "end_logit": -6.875,
            "text": "CCM1 (krev",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 5.890625,
            "end_logit": -6.88671875,
            "text": "CCM1 (krev interaction trapped 1",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": -7.109375,
            "end_logit": 5.984375,
            "text": "three genes are associated with CCM. These genes encode for the proteins KRIT1/CCM1",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": 5.890625,
            "end_logit": -7.01953125,
            "text": "CCM1 (krev interaction trapped 1/cerebral cavernous malformations 1), cerebral cavernous malformations 2, osmosensing scaffold for MEK",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": -7.12109375,
            "end_logit": 5.984375,
            "text": "These genes encode for the proteins KRIT1/CCM1",
            "probability": 2.205371856689453e-06
        }
    ],
    "571f2b5bbb137a4b0c000010_5": [
        {
            "start_logit": 4.73828125,
            "end_logit": 4.515625,
            "text": "CCM1",
            "probability": 0.994140625
        },
        {
            "start_logit": -0.48046875,
            "end_logit": 4.515625,
            "text": "KRIT1/CCM1",
            "probability": 0.005405426025390625
        },
        {
            "start_logit": 4.73828125,
            "end_logit": -5.546875,
            "text": "CCM1 (krev interaction trapped 1/cerebral cavernous malformations 1), cerebral cavernous malformations 2, osmosensing scaffold for MEKK3 (CCM2",
            "probability": 4.2438507080078125e-05
        },
        {
            "start_logit": -5.32421875,
            "end_logit": 4.515625,
            "text": "proteins KRIT1/CCM1",
            "probability": 4.2438507080078125e-05
        },
        {
            "start_logit": 4.73828125,
            "end_logit": -5.78125,
            "text": "CCM1 (krev interaction trapped 1",
            "probability": 3.355741500854492e-05
        },
        {
            "start_logit": 4.73828125,
            "end_logit": -5.82421875,
            "text": "CC",
            "probability": 3.224611282348633e-05
        },
        {
            "start_logit": 4.73828125,
            "end_logit": -5.83984375,
            "text": "CCM1 (",
            "probability": 3.17692756652832e-05
        },
        {
            "start_logit": 4.73828125,
            "end_logit": -6.234375,
            "text": "CCM1 (krev interaction",
            "probability": 2.1338462829589844e-05
        },
        {
            "start_logit": 4.73828125,
            "end_logit": -6.2421875,
            "text": "CCM1 (krev interaction trapped",
            "probability": 2.1338462829589844e-05
        },
        {
            "start_logit": -6.1640625,
            "end_logit": 4.515625,
            "text": "M1",
            "probability": 1.8358230590820312e-05
        },
        {
            "start_logit": 4.73828125,
            "end_logit": -6.40625,
            "text": "CCM1 (krev interaction trapped 1/cerebral cavernous malformations 1), cerebral cavernous malformations 2, osmosensing scaffold for MEKK3",
            "probability": 1.7940998077392578e-05
        },
        {
            "start_logit": 4.73828125,
            "end_logit": -6.44140625,
            "text": "CCM1 (krev",
            "probability": 1.7404556274414062e-05
        },
        {
            "start_logit": 4.73828125,
            "end_logit": -6.5078125,
            "text": "CCM1 (krev interaction trapped 1/cerebral cavernous malformations 1), cerebral cavernous malformations 2, osmosensing scaffold for MEKK3 (CC",
            "probability": 1.633167266845703e-05
        },
        {
            "start_logit": -6.6875,
            "end_logit": 4.515625,
            "text": "/CCM1",
            "probability": 1.0907649993896484e-05
        },
        {
            "start_logit": -6.9296875,
            "end_logit": 4.515625,
            "text": "IT1/CCM1",
            "probability": 8.52346420288086e-06
        },
        {
            "start_logit": -7.0859375,
            "end_logit": 4.515625,
            "text": "genes encode for the proteins KRIT1/CCM1",
            "probability": 7.271766662597656e-06
        },
        {
            "start_logit": -0.48046875,
            "end_logit": -4.0859375,
            "text": "KRIT1",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -0.48046875,
            "end_logit": -5.78125,
            "text": "KRIT1/CCM1 (krev interaction trapped 1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -0.48046875,
            "end_logit": -5.82421875,
            "text": "KRIT1/CC",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -0.48046875,
            "end_logit": -5.83984375,
            "text": "KRIT1/CCM1 (",
            "probability": 1.7881393432617188e-07
        }
    ],
    "5547d700f35db75526000007_1": [
        {
            "start_logit": -2.15625,
            "end_logit": -2.708984375,
            "text": "flaccid",
            "probability": 0.72119140625
        },
        {
            "start_logit": -2.15625,
            "end_logit": -4.6875,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic",
            "probability": 0.09991455078125
        },
        {
            "start_logit": -5.57421875,
            "end_logit": -2.708984375,
            "text": ": flaccid",
            "probability": 0.0237274169921875
        },
        {
            "start_logit": -5.91015625,
            "end_logit": -2.708984375,
            "text": "types of dysarthria: flaccid",
            "probability": 0.0169525146484375
        },
        {
            "start_logit": -2.15625,
            "end_logit": -6.67578125,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic dysarthria",
            "probability": 0.01373291015625
        },
        {
            "start_logit": -2.15625,
            "end_logit": -6.73046875,
            "text": "flaccid dys",
            "probability": 0.012908935546875
        },
        {
            "start_logit": -2.15625,
            "end_logit": -6.89453125,
            "text": "flaccid dysarthria associated with lower motor neuron impairment",
            "probability": 0.01103973388671875
        },
        {
            "start_logit": -2.15625,
            "end_logit": -6.921875,
            "text": "flaccid dysarthria",
            "probability": 0.0106964111328125
        },
        {
            "start_logit": -6.38671875,
            "end_logit": -2.708984375,
            "text": ". There are six major types of dysarthria: flaccid",
            "probability": 0.010528564453125
        },
        {
            "start_logit": -2.15625,
            "end_logit": -6.98828125,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic dys",
            "probability": 0.01004791259765625
        },
        {
            "start_logit": -2.15625,
            "end_logit": -7.08203125,
            "text": "flaccid dysarthri",
            "probability": 0.00914764404296875
        },
        {
            "start_logit": -2.15625,
            "end_logit": -7.12890625,
            "text": "flaccid dysarth",
            "probability": 0.00872802734375
        },
        {
            "start_logit": -2.15625,
            "end_logit": -7.15234375,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic dysarth",
            "probability": 0.00846099853515625
        },
        {
            "start_logit": -2.15625,
            "end_logit": -7.171875,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic dysarthria associated with damaged upper motor neurons",
            "probability": 0.008331298828125
        },
        {
            "start_logit": -2.15625,
            "end_logit": -7.1953125,
            "text": "flaccid dysarthria associated with lower motor neuron",
            "probability": 0.00814056396484375
        },
        {
            "start_logit": -2.15625,
            "end_logit": -7.1953125,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic dysarthri",
            "probability": 0.00814056396484375
        },
        {
            "start_logit": -7.015625,
            "end_logit": -2.708984375,
            "text": "a: flaccid",
            "probability": 0.00559234619140625
        },
        {
            "start_logit": -7.078125,
            "end_logit": -2.708984375,
            "text": "accid",
            "probability": 0.005252838134765625
        },
        {
            "start_logit": -5.3203125,
            "end_logit": -4.6875,
            "text": ", spastic",
            "probability": 0.004222869873046875
        },
        {
            "start_logit": -5.57421875,
            "end_logit": -4.6875,
            "text": ": flaccid dysarthria associated with lower motor neuron impairment, spastic",
            "probability": 0.0032634735107421875
        }
    ],
    "5547d700f35db75526000007_2": [
        {
            "start_logit": 8.4609375,
            "end_logit": 5.6640625,
            "text": "mixed",
            "probability": 1.0
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -3.8515625,
            "text": "mixed dysarthria",
            "probability": 7.367134094238281e-05
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -6.1953125,
            "text": "mixed dys",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -6.7890625,
            "text": "mixed dysarth",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -6.81640625,
            "text": "mixed dysarthri",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": -6.94921875,
            "end_logit": 5.6640625,
            "text": "stroke patients with mixed",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 5.6640625,
            "text": "with mixed",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.97265625,
            "end_logit": 5.6640625,
            "text": "voice problems of stroke patients with mixed",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.99609375,
            "end_logit": 5.6640625,
            "text": "address voice problems of stroke patients with mixed",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.23046875,
            "end_logit": 5.6640625,
            "text": "of stroke patients with mixed",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.94921875,
            "end_logit": -3.8515625,
            "text": "stroke patients with mixed dysarthria",
            "probability": 0.0
        },
        {
            "start_logit": -6.96484375,
            "end_logit": -3.8515625,
            "text": "with mixed dysarthria",
            "probability": 0.0
        },
        {
            "start_logit": -6.97265625,
            "end_logit": -3.8515625,
            "text": "voice problems of stroke patients with mixed dysarthria",
            "probability": 0.0
        },
        {
            "start_logit": -6.99609375,
            "end_logit": -3.8515625,
            "text": "address voice problems of stroke patients with mixed dysarthria",
            "probability": 0.0
        },
        {
            "start_logit": -7.23046875,
            "end_logit": -3.8515625,
            "text": "of stroke patients with mixed dysarthria",
            "probability": 0.0
        },
        {
            "start_logit": -7.45703125,
            "end_logit": -3.8515625,
            "text": "dysarthria",
            "probability": 0.0
        },
        {
            "start_logit": -6.94921875,
            "end_logit": -6.1953125,
            "text": "stroke patients with mixed dys",
            "probability": 0.0
        },
        {
            "start_logit": -6.96484375,
            "end_logit": -6.1953125,
            "text": "with mixed dys",
            "probability": 0.0
        },
        {
            "start_logit": -6.97265625,
            "end_logit": -6.1953125,
            "text": "voice problems of stroke patients with mixed dys",
            "probability": 0.0
        },
        {
            "start_logit": -6.99609375,
            "end_logit": -6.1953125,
            "text": "address voice problems of stroke patients with mixed dys",
            "probability": 0.0
        }
    ],
    "5547d700f35db75526000007_3": [
        {
            "start_logit": 0.80419921875,
            "end_logit": 1.1845703125,
            "text": "ataxic",
            "probability": 0.9853515625
        },
        {
            "start_logit": -4.5546875,
            "end_logit": 1.1845703125,
            "text": ", ataxic",
            "probability": 0.004634857177734375
        },
        {
            "start_logit": -4.64453125,
            "end_logit": 1.1845703125,
            "text": "hypokinetic dysarthria, ataxic",
            "probability": 0.004238128662109375
        },
        {
            "start_logit": 0.80419921875,
            "end_logit": -4.94140625,
            "text": "ataxic dysarthria",
            "probability": 0.002155303955078125
        },
        {
            "start_logit": 0.80419921875,
            "end_logit": -6.296875,
            "text": "ataxic dys",
            "probability": 0.0005559921264648438
        },
        {
            "start_logit": -7.11328125,
            "end_logit": 1.1845703125,
            "text": "autosegmental-metrical analysis of spontaneous speech in hypokinetic dysarthria, ataxic",
            "probability": 0.00035881996154785156
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 1.1845703125,
            "text": "in hypokinetic dysarthria, ataxic",
            "probability": 0.00033211708068847656
        },
        {
            "start_logit": -7.2109375,
            "end_logit": 1.1845703125,
            "text": "an autosegmental-metrical analysis of spontaneous speech in hypokinetic dysarthria, ataxic",
            "probability": 0.0003254413604736328
        },
        {
            "start_logit": -7.2265625,
            "end_logit": 1.1845703125,
            "text": "a, ataxic",
            "probability": 0.0003204345703125
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 1.1845703125,
            "text": "spontaneous speech in hypokinetic dysarthria, ataxic",
            "probability": 0.00031065940856933594
        },
        {
            "start_logit": 0.80419921875,
            "end_logit": -6.89453125,
            "text": "atax",
            "probability": 0.0003056526184082031
        },
        {
            "start_logit": 0.80419921875,
            "end_logit": -7.06640625,
            "text": "ataxic dysarthri",
            "probability": 0.0002574920654296875
        },
        {
            "start_logit": 0.80419921875,
            "end_logit": -7.078125,
            "text": "ataxic dysarth",
            "probability": 0.00025343894958496094
        },
        {
            "start_logit": -7.46875,
            "end_logit": 1.1845703125,
            "text": "motor speech disorders: an autosegmental-metrical analysis of spontaneous speech in hypokinetic dysarthria, ataxic",
            "probability": 0.00025153160095214844
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 1.1845703125,
            "text": "disorders: an autosegmental-metrical analysis of spontaneous speech in hypokinetic dysarthria, ataxic",
            "probability": 0.00024175643920898438
        },
        {
            "start_logit": -7.515625,
            "end_logit": 1.1845703125,
            "text": ": an autosegmental-metrical analysis of spontaneous speech in hypokinetic dysarthria, ataxic",
            "probability": 0.00024008750915527344
        },
        {
            "start_logit": -4.81640625,
            "end_logit": -4.22265625,
            "text": "Characterizing intonation deficit in motor speech disorders: an autosegmental-metrical analysis of spontaneous speech",
            "probability": 1.5974044799804688e-05
        },
        {
            "start_logit": -4.5546875,
            "end_logit": -4.94140625,
            "text": ", ataxic dysarthria",
            "probability": 1.0192394256591797e-05
        },
        {
            "start_logit": -5.34375,
            "end_logit": -4.22265625,
            "text": "intonation deficit in motor speech disorders: an autosegmental-metrical analysis of spontaneous speech",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": -4.64453125,
            "end_logit": -4.94140625,
            "text": "hypokinetic dysarthria, ataxic dysarthria",
            "probability": 9.238719940185547e-06
        }
    ],
    "5547d700f35db75526000007_4": [
        {
            "start_logit": 7.99609375,
            "end_logit": 6.453125,
            "text": "ataxic",
            "probability": 1.0
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -3.099609375,
            "text": "atax",
            "probability": 7.086992263793945e-05
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -5.31640625,
            "text": "ataxic dysarthria (AT)",
            "probability": 7.68899917602539e-06
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -5.8515625,
            "text": "ataxic dysarthria",
            "probability": 4.470348358154297e-06
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -6.3125,
            "text": "ataxic dysarthria (AT",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": -5.28515625,
            "end_logit": 6.453125,
            "text": "ic",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -7.140625,
            "text": "ataxic dysarthri",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -7.15625,
            "text": "ataxic dysarthria (",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -7.5234375,
            "text": "ataxic dysarth",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 7.99609375,
            "end_logit": -7.66796875,
            "text": "ataxic dys",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -5.28515625,
            "end_logit": -5.31640625,
            "text": "ic dysarthria (AT)",
            "probability": 0.0
        },
        {
            "start_logit": -5.28515625,
            "end_logit": -5.8515625,
            "text": "ic dysarthria",
            "probability": 0.0
        },
        {
            "start_logit": -5.28515625,
            "end_logit": -6.3125,
            "text": "ic dysarthria (AT",
            "probability": 0.0
        },
        {
            "start_logit": -6.9609375,
            "end_logit": -5.31640625,
            "text": "dysarthria (AT)",
            "probability": 0.0
        },
        {
            "start_logit": -5.28515625,
            "end_logit": -7.140625,
            "text": "ic dysarthri",
            "probability": 0.0
        },
        {
            "start_logit": -5.28515625,
            "end_logit": -7.15625,
            "text": "ic dysarthria (",
            "probability": 0.0
        },
        {
            "start_logit": -7.48828125,
            "end_logit": -5.31640625,
            "text": "AT)",
            "probability": 0.0
        },
        {
            "start_logit": -5.28515625,
            "end_logit": -7.5234375,
            "text": "ic dysarth",
            "probability": 0.0
        },
        {
            "start_logit": -6.9609375,
            "end_logit": -5.8515625,
            "text": "dysarthria",
            "probability": 0.0
        },
        {
            "start_logit": -7.60546875,
            "end_logit": -5.31640625,
            "text": "arthria (AT)",
            "probability": 0.0
        }
    ],
    "5547d700f35db75526000007_5": [
        {
            "start_logit": -0.1396484375,
            "end_logit": 1.03125,
            "text": "spastic dysarthria",
            "probability": 0.93359375
        },
        {
            "start_logit": -0.1396484375,
            "end_logit": -1.904296875,
            "text": "spastic",
            "probability": 0.049652099609375
        },
        {
            "start_logit": -5.55859375,
            "end_logit": 1.03125,
            "text": "apraxia of speech and spastic dysarthria",
            "probability": 0.00414276123046875
        },
        {
            "start_logit": -6.203125,
            "end_logit": 1.03125,
            "text": "and spastic dysarthria",
            "probability": 0.00217437744140625
        },
        {
            "start_logit": -6.6484375,
            "end_logit": 1.03125,
            "text": "between apraxia of speech and spastic dysarthria",
            "probability": 0.001392364501953125
        },
        {
            "start_logit": -6.66015625,
            "end_logit": 1.03125,
            "text": "dysarthria",
            "probability": 0.0013761520385742188
        },
        {
            "start_logit": -6.70703125,
            "end_logit": 1.03125,
            "text": ". This paper aims to distinguish between normal and pathological speech, more specifically between apraxia of speech and spastic dysarthria",
            "probability": 0.0013132095336914062
        },
        {
            "start_logit": -7.07421875,
            "end_logit": 1.03125,
            "text": "pathological speech, more specifically between apraxia of speech and spastic dysarthria",
            "probability": 0.0009098052978515625
        },
        {
            "start_logit": -7.08984375,
            "end_logit": 1.03125,
            "text": "This paper aims to distinguish between normal and pathological speech, more specifically between apraxia of speech and spastic dysarthria",
            "probability": 0.0008955001831054688
        },
        {
            "start_logit": -7.09375,
            "end_logit": 1.03125,
            "text": "specifically between apraxia of speech and spastic dysarthria",
            "probability": 0.0008921623229980469
        },
        {
            "start_logit": -7.21484375,
            "end_logit": 1.03125,
            "text": "paper aims to distinguish between normal and pathological speech, more specifically between apraxia of speech and spastic dysarthria",
            "probability": 0.0007905960083007812
        },
        {
            "start_logit": -7.23828125,
            "end_logit": 1.03125,
            "text": "more specifically between apraxia of speech and spastic dysarthria",
            "probability": 0.0007719993591308594
        },
        {
            "start_logit": -7.25390625,
            "end_logit": 1.03125,
            "text": "a",
            "probability": 0.0007600784301757812
        },
        {
            "start_logit": -0.1396484375,
            "end_logit": -6.703125,
            "text": "spastic dys",
            "probability": 0.00040841102600097656
        },
        {
            "start_logit": -0.1396484375,
            "end_logit": -6.78125,
            "text": "spastic dysarth",
            "probability": 0.000377655029296875
        },
        {
            "start_logit": -0.1396484375,
            "end_logit": -7.296875,
            "text": "spastic dysarthri",
            "probability": 0.00022554397583007812
        },
        {
            "start_logit": -5.55859375,
            "end_logit": -1.904296875,
            "text": "apraxia of speech and spastic",
            "probability": 0.00022029876708984375
        },
        {
            "start_logit": -6.203125,
            "end_logit": -1.904296875,
            "text": "and spastic",
            "probability": 0.00011515617370605469
        },
        {
            "start_logit": -6.6484375,
            "end_logit": -1.904296875,
            "text": "between apraxia of speech and spastic",
            "probability": 7.37905502319336e-05
        },
        {
            "start_logit": -6.70703125,
            "end_logit": -1.904296875,
            "text": ". This paper aims to distinguish between normal and pathological speech, more specifically between apraxia of speech and spastic",
            "probability": 6.985664367675781e-05
        }
    ],
    "5547d700f35db75526000007_6": [
        {
            "start_logit": 0.006206512451171875,
            "end_logit": -0.190185546875,
            "text": "phonatory instability",
            "probability": 0.7529296875
        },
        {
            "start_logit": -1.3232421875,
            "end_logit": -0.190185546875,
            "text": "Long-term phonatory instability",
            "probability": 0.1990966796875
        },
        {
            "start_logit": 0.006206512451171875,
            "end_logit": -4.3515625,
            "text": "phonatory instability in ataxic dysarthria.",
            "probability": 0.011749267578125
        },
        {
            "start_logit": 0.006206512451171875,
            "end_logit": -4.35546875,
            "text": "phonatory instability in ataxic",
            "probability": 0.0117034912109375
        },
        {
            "start_logit": 0.006206512451171875,
            "end_logit": -5.11328125,
            "text": "phonatory instability in atax",
            "probability": 0.00548553466796875
        },
        {
            "start_logit": 0.006206512451171875,
            "end_logit": -5.54296875,
            "text": "phonatory instability in ataxic dysarthria",
            "probability": 0.003570556640625
        },
        {
            "start_logit": -1.3232421875,
            "end_logit": -4.3515625,
            "text": "Long-term phonatory instability in ataxic dysarthria.",
            "probability": 0.003101348876953125
        },
        {
            "start_logit": -1.3232421875,
            "end_logit": -4.35546875,
            "text": "Long-term phonatory instability in ataxic",
            "probability": 0.00308990478515625
        },
        {
            "start_logit": 0.006206512451171875,
            "end_logit": -6.0234375,
            "text": "phonatory",
            "probability": 0.0022068023681640625
        },
        {
            "start_logit": -1.3232421875,
            "end_logit": -5.11328125,
            "text": "Long-term phonatory instability in atax",
            "probability": 0.0014476776123046875
        },
        {
            "start_logit": -1.3232421875,
            "end_logit": -5.54296875,
            "text": "Long-term phonatory instability in ataxic dysarthria",
            "probability": 0.000942230224609375
        },
        {
            "start_logit": 0.006206512451171875,
            "end_logit": -6.95703125,
            "text": "phonatory instability in ataxic dys",
            "probability": 0.0008683204650878906
        },
        {
            "start_logit": 0.006206512451171875,
            "end_logit": -7.19921875,
            "text": "phonatory instability in ataxic dysarth",
            "probability": 0.0006809234619140625
        },
        {
            "start_logit": 0.006206512451171875,
            "end_logit": -7.2265625,
            "text": "phonatory instability in ataxic dysarthri",
            "probability": 0.0006628036499023438
        },
        {
            "start_logit": 0.006206512451171875,
            "end_logit": -7.31640625,
            "text": "phonatory instability in",
            "probability": 0.0006060600280761719
        },
        {
            "start_logit": -1.3232421875,
            "end_logit": -6.0234375,
            "text": "Long-term phonatory",
            "probability": 0.0005826950073242188
        },
        {
            "start_logit": -7.24609375,
            "end_logit": -0.190185546875,
            "text": "term phonatory instability",
            "probability": 0.0005326271057128906
        },
        {
            "start_logit": -7.39453125,
            "end_logit": -0.190185546875,
            "text": "-term phonatory instability",
            "probability": 0.0004591941833496094
        },
        {
            "start_logit": -7.62109375,
            "end_logit": -0.190185546875,
            "text": "instability",
            "probability": 0.00036597251892089844
        },
        {
            "start_logit": -1.3232421875,
            "end_logit": -6.95703125,
            "text": "Long-term phonatory instability in ataxic dys",
            "probability": 0.00022995471954345703
        }
    ],
    "5547d700f35db75526000007_7": [
        {
            "start_logit": 3.7109375,
            "end_logit": 4.48046875,
            "text": "ataxic",
            "probability": 1.0
        },
        {
            "start_logit": -5.91015625,
            "end_logit": 4.48046875,
            "text": "phonation in ataxic",
            "probability": 6.657838821411133e-05
        },
        {
            "start_logit": 3.7109375,
            "end_logit": -5.2578125,
            "text": "atax",
            "probability": 5.918741226196289e-05
        },
        {
            "start_logit": -6.3359375,
            "end_logit": 4.48046875,
            "text": "ic",
            "probability": 4.3332576751708984e-05
        },
        {
            "start_logit": 3.7109375,
            "end_logit": -5.87890625,
            "text": "ataxic dysarthria and a",
            "probability": 3.170967102050781e-05
        },
        {
            "start_logit": -6.80859375,
            "end_logit": 4.48046875,
            "text": "in ataxic",
            "probability": 2.7120113372802734e-05
        },
        {
            "start_logit": -6.8203125,
            "end_logit": 4.48046875,
            "text": "evaluate phonation in ataxic",
            "probability": 2.6702880859375e-05
        },
        {
            "start_logit": -6.8671875,
            "end_logit": 4.48046875,
            "text": "to evaluate phonation in ataxic",
            "probability": 2.5451183319091797e-05
        },
        {
            "start_logit": -7.0078125,
            "end_logit": 4.48046875,
            "text": "is to evaluate phonation in ataxic",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": -7.01171875,
            "end_logit": 4.48046875,
            "text": "objective of this study is to evaluate phonation in ataxic",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": -7.0625,
            "end_logit": 4.48046875,
            "text": "this study is to evaluate phonation in ataxic",
            "probability": 2.110004425048828e-05
        },
        {
            "start_logit": 3.7109375,
            "end_logit": -6.30859375,
            "text": "ataxic dysarthria",
            "probability": 2.0802021026611328e-05
        },
        {
            "start_logit": -7.0859375,
            "end_logit": 4.48046875,
            "text": "study is to evaluate phonation in ataxic",
            "probability": 2.0444393157958984e-05
        },
        {
            "start_logit": 3.7109375,
            "end_logit": -6.4375,
            "text": "ataxic dysarthria and",
            "probability": 1.817941665649414e-05
        },
        {
            "start_logit": -7.328125,
            "end_logit": 4.48046875,
            "text": "The objective of this study is to evaluate phonation in ataxic",
            "probability": 1.621246337890625e-05
        },
        {
            "start_logit": 3.7109375,
            "end_logit": -7.10546875,
            "text": "ataxic dysarthria and a control group of normal speakers",
            "probability": 9.357929229736328e-06
        },
        {
            "start_logit": 3.7109375,
            "end_logit": -7.2421875,
            "text": "ataxic dysarth",
            "probability": 8.165836334228516e-06
        },
        {
            "start_logit": 3.7109375,
            "end_logit": -7.29296875,
            "text": "ataxic dysarthri",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": 3.7109375,
            "end_logit": -7.4296875,
            "text": "ataxic dys",
            "probability": 6.735324859619141e-06
        },
        {
            "start_logit": -5.91015625,
            "end_logit": -5.2578125,
            "text": "phonation in atax",
            "probability": 0.0
        }
    ],
    "5547d700f35db75526000007_8": [
        {
            "start_logit": 8.7109375,
            "end_logit": 9.0546875,
            "text": "Dysprosody",
            "probability": 0.9970703125
        },
        {
            "start_logit": 8.7109375,
            "end_logit": 2.79296875,
            "text": "Dysprosody is a common feature in speakers with hypokinetic",
            "probability": 0.0018949508666992188
        },
        {
            "start_logit": 7.52734375,
            "end_logit": 2.79296875,
            "text": "hypokinetic",
            "probability": 0.0005822181701660156
        },
        {
            "start_logit": -1.6103515625,
            "end_logit": 9.0546875,
            "text": "ody",
            "probability": 3.2842159271240234e-05
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -2.119140625,
            "text": "Dysp",
            "probability": 1.4007091522216797e-05
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -3.35546875,
            "text": "Dysprosody is a common feature in speakers with hypok",
            "probability": 4.112720489501953e-06
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -3.35546875,
            "text": "hypok",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -5.8046875,
            "text": "Dysprosody is a common feature in speakers with hypokinetic dysarthria",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.78515625,
            "end_logit": 9.0546875,
            "text": "rosody",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -6.6953125,
            "text": "Dyspros",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -6.96875,
            "text": "Dysprosody is a common feature in speakers with hypokinetic dysarthria.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -5.8046875,
            "text": "hypokinetic dysarthria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -7.1484375,
            "text": "Dysprosody is a common feature in speakers with hypokinetic dysarthri",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -7.265625,
            "text": "Dysprosody is a common feature in speakers with hypokinetic dysarth",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -7.35546875,
            "text": "Dysprosody is a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -7.375,
            "text": "Dysprosody is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -7.3984375,
            "text": "Dysprosody is a common feature in speakers with hypokinetic dys",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.6103515625,
            "end_logit": 2.79296875,
            "text": "ody is a common feature in speakers with hypokinetic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -6.96875,
            "text": "hypokinetic dysarthria.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -7.1484375,
            "text": "hypokinetic dysarthri",
            "probability": 0.0
        }
    ],
    "5547d700f35db75526000007_9": [
        {
            "start_logit": 9.453125,
            "end_logit": 8.046875,
            "text": "hypokinetic",
            "probability": 1.0
        },
        {
            "start_logit": 9.453125,
            "end_logit": -0.47412109375,
            "text": "hypok",
            "probability": 0.00019872188568115234
        },
        {
            "start_logit": 9.453125,
            "end_logit": -4.6796875,
            "text": "hypokinetic dysarthria",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": -3.32421875,
            "end_logit": 8.046875,
            "text": "inetic",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": 9.453125,
            "end_logit": -6.25,
            "text": "hypokinetic dysarthria is similar to those of other languages (for example, English",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 9.453125,
            "end_logit": -6.7890625,
            "text": "hypokinetic dysarthria is similar to those of other languages (for example, English).",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.453125,
            "end_logit": -7.00390625,
            "text": "hypokinetic dysarthria is similar to those of other languages (for example, English)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.453125,
            "end_logit": -7.109375,
            "text": "hypokinetic dysarthria is",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.453125,
            "end_logit": -7.16796875,
            "text": "hypokinetic dysarthria is similar to those of other languages",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.453125,
            "end_logit": -7.17578125,
            "text": "hypokinetic dysarthri",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.453125,
            "end_logit": -7.37890625,
            "text": "hypokinetic dysarth",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.453125,
            "end_logit": -7.41015625,
            "text": "hypokinetic dysarthria is similar",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.453125,
            "end_logit": -7.41796875,
            "text": "hypokinetic dysarthria is similar to those",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.453125,
            "end_logit": -7.4453125,
            "text": "hypokinetic dys",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.78515625,
            "end_logit": 8.046875,
            "text": "prosodic profile of Cantonese speakers with hypokinetic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8515625,
            "end_logit": 8.046875,
            "text": "Cantonese speakers with hypokinetic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1328125,
            "end_logit": 8.046875,
            "text": "with hypokinetic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 8.046875,
            "text": "The prosodic profile of Cantonese speakers with hypokinetic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5,
            "end_logit": 8.046875,
            "text": "of Cantonese speakers with hypokinetic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.78515625,
            "end_logit": -0.47412109375,
            "text": "prosodic profile of Cantonese speakers with hypok",
            "probability": 0.0
        }
    ],
    "5547d700f35db75526000007_10": [
        {
            "start_logit": 6.5625,
            "end_logit": 4.46875,
            "text": "spastic",
            "probability": 0.9990234375
        },
        {
            "start_logit": -0.9892578125,
            "end_logit": 4.46875,
            "text": "flaccid, spastic",
            "probability": 0.0005249977111816406
        },
        {
            "start_logit": 6.5625,
            "end_logit": -5.88671875,
            "text": "spastic, ataxic",
            "probability": 3.165006637573242e-05
        },
        {
            "start_logit": 6.5625,
            "end_logit": -5.9609375,
            "text": "spastic, ataxic, hypo- and hyperkinetic and mixed dysarthria",
            "probability": 2.956390380859375e-05
        },
        {
            "start_logit": 6.5625,
            "end_logit": -6.80078125,
            "text": "spastic, ataxic, hypo- and hyperkinetic and mixed dysarthria.",
            "probability": 1.2814998626708984e-05
        },
        {
            "start_logit": 6.5625,
            "end_logit": -7.0546875,
            "text": "spastic, ataxic, hypo- and hyperkinetic and mixed",
            "probability": 9.894371032714844e-06
        },
        {
            "start_logit": 6.5625,
            "end_logit": -7.1640625,
            "text": "spastic, ataxic, hypo- and hyperkinetic and mixed dysarthri",
            "probability": 8.881092071533203e-06
        },
        {
            "start_logit": 6.5625,
            "end_logit": -7.2734375,
            "text": "spastic, ataxic, hypo- and hyperkinetic and mixed dys",
            "probability": 7.927417755126953e-06
        },
        {
            "start_logit": 6.5625,
            "end_logit": -7.328125,
            "text": "spastic, ataxic, hypo- and hyperkinetic and mixed dysarth",
            "probability": 7.510185241699219e-06
        },
        {
            "start_logit": 6.5625,
            "end_logit": -7.4765625,
            "text": "spastic, ataxic, hypo- and hyperkinetic",
            "probability": 6.496906280517578e-06
        },
        {
            "start_logit": 6.5625,
            "end_logit": -7.53515625,
            "text": "spastic, ataxic, hypo-",
            "probability": 6.139278411865234e-06
        },
        {
            "start_logit": 6.5625,
            "end_logit": -7.59375,
            "text": "spastic, ataxic, hypo- and hyperkinetic and",
            "probability": 5.781650543212891e-06
        },
        {
            "start_logit": 6.5625,
            "end_logit": -7.59765625,
            "text": "spastic, ataxic, hypo- and",
            "probability": 5.781650543212891e-06
        },
        {
            "start_logit": -5.62890625,
            "end_logit": 4.46875,
            "text": ", spastic",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": -6.66015625,
            "end_logit": 4.46875,
            "text": "comprises flaccid, spastic",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -0.9892578125,
            "end_logit": -1.560546875,
            "text": "flaccid",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -7.16015625,
            "end_logit": 4.46875,
            "text": "accid, spastic",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -7.19921875,
            "end_logit": 4.46875,
            "text": "Classification of dysarthria types comprises flaccid, spastic",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -0.9892578125,
            "end_logit": -5.88671875,
            "text": "flaccid, spastic, ataxic",
            "probability": 0.0
        },
        {
            "start_logit": -0.9892578125,
            "end_logit": -5.9609375,
            "text": "flaccid, spastic, ataxic, hypo- and hyperkinetic and mixed dysarthria",
            "probability": 0.0
        }
    ],
    "5547d700f35db75526000007_11": [
        {
            "start_logit": -1.7197265625,
            "end_logit": -5.48046875,
            "text": "flaccid",
            "probability": 0.275390625
        },
        {
            "start_logit": -1.7197265625,
            "end_logit": -5.6796875,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic",
            "probability": 0.2257080078125
        },
        {
            "start_logit": -1.7197265625,
            "end_logit": -5.94921875,
            "text": "flaccid dysarthria",
            "probability": 0.17236328125
        },
        {
            "start_logit": -1.7197265625,
            "end_logit": -6.8515625,
            "text": "flaccid dysarthri",
            "probability": 0.0699462890625
        },
        {
            "start_logit": -1.7197265625,
            "end_logit": -6.89453125,
            "text": "flaccid dysarthria associated with lower motor neuron impairment",
            "probability": 0.06671142578125
        },
        {
            "start_logit": -1.7197265625,
            "end_logit": -7.05859375,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic dys",
            "probability": 0.056610107421875
        },
        {
            "start_logit": -1.7197265625,
            "end_logit": -7.13671875,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic dysarthria",
            "probability": 0.052337646484375
        },
        {
            "start_logit": -1.7197265625,
            "end_logit": -7.20703125,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic dysarthri",
            "probability": 0.048828125
        },
        {
            "start_logit": -5.29296875,
            "end_logit": -5.8359375,
            "text": "hyperkinetic",
            "probability": 0.00543212890625
        },
        {
            "start_logit": -5.5078125,
            "end_logit": -5.6796875,
            "text": ", spastic",
            "probability": 0.005100250244140625
        },
        {
            "start_logit": -5.734375,
            "end_logit": -5.6796875,
            "text": "spastic",
            "probability": 0.004070281982421875
        },
        {
            "start_logit": -6.19921875,
            "end_logit": -5.48046875,
            "text": ": flaccid",
            "probability": 0.00312042236328125
        },
        {
            "start_logit": -6.19921875,
            "end_logit": -5.6796875,
            "text": ": flaccid dysarthria associated with lower motor neuron impairment, spastic",
            "probability": 0.0025653839111328125
        },
        {
            "start_logit": -5.29296875,
            "end_logit": -6.8125,
            "text": "hyperkinetic dysarthria and hypokinetic dysarthria, which are related to a disorder of the extrapyramidal system.",
            "probability": 0.0020294189453125
        },
        {
            "start_logit": -6.19921875,
            "end_logit": -5.94921875,
            "text": ": flaccid dysarthria",
            "probability": 0.0019521713256835938
        },
        {
            "start_logit": -6.4140625,
            "end_logit": -5.8359375,
            "text": "ataxic dysarthria primarily caused by cerebellar dysfunction, and hyperkinetic",
            "probability": 0.0017642974853515625
        },
        {
            "start_logit": -5.29296875,
            "end_logit": -6.9765625,
            "text": "hyperkinetic dysarthria and",
            "probability": 0.0017366409301757812
        },
        {
            "start_logit": -5.29296875,
            "end_logit": -7.08984375,
            "text": "hyperkinetic dys",
            "probability": 0.0015439987182617188
        },
        {
            "start_logit": -5.29296875,
            "end_logit": -7.140625,
            "text": "hyperkinetic dysarthria and hypokinetic",
            "probability": 0.0014629364013671875
        },
        {
            "start_logit": -6.96484375,
            "end_logit": -5.48046875,
            "text": "accid",
            "probability": 0.0014505386352539062
        }
    ],
    "5547d700f35db75526000007_12": [
        {
            "start_logit": -1.7197265625,
            "end_logit": -5.48046875,
            "text": "flaccid",
            "probability": 0.275390625
        },
        {
            "start_logit": -1.7197265625,
            "end_logit": -5.6796875,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic",
            "probability": 0.2257080078125
        },
        {
            "start_logit": -1.7197265625,
            "end_logit": -5.94921875,
            "text": "flaccid dysarthria",
            "probability": 0.17236328125
        },
        {
            "start_logit": -1.7197265625,
            "end_logit": -6.8515625,
            "text": "flaccid dysarthri",
            "probability": 0.0699462890625
        },
        {
            "start_logit": -1.7197265625,
            "end_logit": -6.89453125,
            "text": "flaccid dysarthria associated with lower motor neuron impairment",
            "probability": 0.06671142578125
        },
        {
            "start_logit": -1.7197265625,
            "end_logit": -7.05859375,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic dys",
            "probability": 0.056610107421875
        },
        {
            "start_logit": -1.7197265625,
            "end_logit": -7.13671875,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic dysarthria",
            "probability": 0.052337646484375
        },
        {
            "start_logit": -1.7197265625,
            "end_logit": -7.20703125,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic dysarthri",
            "probability": 0.048828125
        },
        {
            "start_logit": -5.29296875,
            "end_logit": -5.8359375,
            "text": "hyperkinetic",
            "probability": 0.00543212890625
        },
        {
            "start_logit": -5.5078125,
            "end_logit": -5.6796875,
            "text": ", spastic",
            "probability": 0.005100250244140625
        },
        {
            "start_logit": -5.734375,
            "end_logit": -5.6796875,
            "text": "spastic",
            "probability": 0.004070281982421875
        },
        {
            "start_logit": -6.19921875,
            "end_logit": -5.48046875,
            "text": ": flaccid",
            "probability": 0.00312042236328125
        },
        {
            "start_logit": -6.19921875,
            "end_logit": -5.6796875,
            "text": ": flaccid dysarthria associated with lower motor neuron impairment, spastic",
            "probability": 0.0025653839111328125
        },
        {
            "start_logit": -5.29296875,
            "end_logit": -6.8125,
            "text": "hyperkinetic dysarthria and hypokinetic dysarthria, which are related to a disorder of the extrapyramidal system.",
            "probability": 0.0020294189453125
        },
        {
            "start_logit": -6.19921875,
            "end_logit": -5.94921875,
            "text": ": flaccid dysarthria",
            "probability": 0.0019521713256835938
        },
        {
            "start_logit": -6.4140625,
            "end_logit": -5.8359375,
            "text": "ataxic dysarthria primarily caused by cerebellar dysfunction, and hyperkinetic",
            "probability": 0.0017642974853515625
        },
        {
            "start_logit": -5.29296875,
            "end_logit": -6.9765625,
            "text": "hyperkinetic dysarthria and",
            "probability": 0.0017366409301757812
        },
        {
            "start_logit": -5.29296875,
            "end_logit": -7.08984375,
            "text": "hyperkinetic dys",
            "probability": 0.0015439987182617188
        },
        {
            "start_logit": -5.29296875,
            "end_logit": -7.140625,
            "text": "hyperkinetic dysarthria and hypokinetic",
            "probability": 0.0014629364013671875
        },
        {
            "start_logit": -6.96484375,
            "end_logit": -5.48046875,
            "text": "accid",
            "probability": 0.0014505386352539062
        }
    ],
    "5547d700f35db75526000007_13": [
        {
            "start_logit": -1.650390625,
            "end_logit": -5.30078125,
            "text": "flaccid",
            "probability": 0.326416015625
        },
        {
            "start_logit": -1.650390625,
            "end_logit": -5.7265625,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic",
            "probability": 0.214111328125
        },
        {
            "start_logit": -1.650390625,
            "end_logit": -6.26953125,
            "text": "flaccid dysarthria",
            "probability": 0.12396240234375
        },
        {
            "start_logit": -1.650390625,
            "end_logit": -6.90625,
            "text": "flaccid dysarthri",
            "probability": 0.0657958984375
        },
        {
            "start_logit": -1.650390625,
            "end_logit": -7.11328125,
            "text": "flaccid dysarthria associated with lower motor neuron impairment",
            "probability": 0.05328369140625
        },
        {
            "start_logit": -1.650390625,
            "end_logit": -7.171875,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic dys",
            "probability": 0.05047607421875
        },
        {
            "start_logit": -1.650390625,
            "end_logit": -7.265625,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic dysarthri",
            "probability": 0.04595947265625
        },
        {
            "start_logit": -1.650390625,
            "end_logit": -7.28125,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic dysarth",
            "probability": 0.04522705078125
        },
        {
            "start_logit": -1.650390625,
            "end_logit": -7.28125,
            "text": "flaccid dysarthria associated with lower motor neuron impairment, spastic dysarthria",
            "probability": 0.04522705078125
        },
        {
            "start_logit": -5.1015625,
            "end_logit": -5.64453125,
            "text": "hyperkinetic",
            "probability": 0.007328033447265625
        },
        {
            "start_logit": -5.7890625,
            "end_logit": -5.7265625,
            "text": ", spastic",
            "probability": 0.0034084320068359375
        },
        {
            "start_logit": -6.22265625,
            "end_logit": -5.30078125,
            "text": ": flaccid",
            "probability": 0.00337982177734375
        },
        {
            "start_logit": -6.14453125,
            "end_logit": -5.7265625,
            "text": "spastic",
            "probability": 0.0023784637451171875
        },
        {
            "start_logit": -6.29296875,
            "end_logit": -5.64453125,
            "text": "ataxic dysarthria primarily caused by cerebellar dysfunction, and hyperkinetic",
            "probability": 0.00223541259765625
        },
        {
            "start_logit": -6.22265625,
            "end_logit": -5.7265625,
            "text": ": flaccid dysarthria associated with lower motor neuron impairment, spastic",
            "probability": 0.0021991729736328125
        },
        {
            "start_logit": -5.1015625,
            "end_logit": -6.98046875,
            "text": "hyperkinetic dysarthria and",
            "probability": 0.001941680908203125
        },
        {
            "start_logit": -5.1015625,
            "end_logit": -7.01171875,
            "text": "hyperkinetic dys",
            "probability": 0.0018825531005859375
        },
        {
            "start_logit": -5.1015625,
            "end_logit": -7.0703125,
            "text": "hyperkinetic dysarthria and hypokinetic",
            "probability": 0.0017671585083007812
        },
        {
            "start_logit": -6.671875,
            "end_logit": -5.64453125,
            "text": "and hyperkinetic",
            "probability": 0.0015354156494140625
        },
        {
            "start_logit": -7.01171875,
            "end_logit": -5.30078125,
            "text": "accid",
            "probability": 0.0015354156494140625
        }
    ],
    "5c61cdd7e842deac67000004_1": [
        {
            "start_logit": 9.3203125,
            "end_logit": 9.2890625,
            "text": "Dolutegravir",
            "probability": 1.0
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -1.08203125,
            "text": "Dol",
            "probability": 3.11732292175293e-05
        },
        {
            "start_logit": -1.4677734375,
            "end_logit": 9.2890625,
            "text": "ir",
            "probability": 2.0623207092285156e-05
        },
        {
            "start_logit": -5.4609375,
            "end_logit": 9.2890625,
            "text": "utegravir",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.5546875,
            "end_logit": 9.2890625,
            "text": "gravir",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -6.89453125,
            "text": "Dolutegravir/rilpivir",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -6.9375,
            "text": "Dolutegravir/rilpivirine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.3203125,
            "text": "Dolutegrav",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.44140625,
            "text": "Dolutegravir/rilpivirine (Juluca\u00ae)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.48828125,
            "text": "Dolutegravir/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.52734375,
            "text": "Dolutegravir/rilpi",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.56640625,
            "text": "Dolutegravir/rilpivirine (Juluca\u00ae) is the first two-drug single-tablet regimen (STR) to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.58984375,
            "text": "Dolutegravir/rilpivirine (Juluca\u00ae",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.62109375,
            "text": "Dolutegravir/rilpivirine (Juluca\u00ae) is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.625,
            "text": "Dolutegravir/rilpivirine (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.4677734375,
            "end_logit": -6.89453125,
            "text": "ir/rilpivir",
            "probability": 0.0
        },
        {
            "start_logit": -1.4677734375,
            "end_logit": -6.9375,
            "text": "ir/rilpivirine",
            "probability": 0.0
        },
        {
            "start_logit": -1.4677734375,
            "end_logit": -7.44140625,
            "text": "ir/rilpivirine (Juluca\u00ae)",
            "probability": 0.0
        },
        {
            "start_logit": -1.4677734375,
            "end_logit": -7.48828125,
            "text": "ir/",
            "probability": 0.0
        },
        {
            "start_logit": -1.4677734375,
            "end_logit": -7.52734375,
            "text": "ir/rilpi",
            "probability": 0.0
        }
    ],
    "61f7d017882a024a1000002f_1": [
        {
            "start_logit": 8.125,
            "end_logit": 7.37890625,
            "text": "atenolol",
            "probability": 1.0
        },
        {
            "start_logit": -4.6015625,
            "end_logit": 7.37890625,
            "text": "Polycap (comprised of atenolol",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": 8.125,
            "end_logit": -6.6328125,
            "text": "atenolol, ramipril, hydrochlorothiazide, and a statin",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 8.125,
            "end_logit": -6.71484375,
            "text": "atenolol, ramipril",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.1796875,
            "end_logit": 7.37890625,
            "text": "whether the Polycap (comprised of atenolol",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.4453125,
            "end_logit": 7.37890625,
            "text": "FDC polypill on major CV outcomes in a primary prevention population. This study aims to determine whether the Polycap (comprised of atenolol",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.46875,
            "end_logit": 7.37890625,
            "text": ". This study aims to determine whether the Polycap (comprised of atenolol",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.125,
            "end_logit": -7.43359375,
            "text": "atenolol, ramipril, hydrochlorothiazide, and a statin)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.6953125,
            "end_logit": 7.37890625,
            "text": "effect of a FDC polypill on major CV outcomes in a primary prevention population. This study aims to determine whether the Polycap (comprised of atenolol",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.7109375,
            "end_logit": 7.37890625,
            "text": "of atenolol",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.125,
            "end_logit": -7.515625,
            "text": "atenolol, ramipr",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 7.37890625,
            "text": "comprised of atenolol",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.25,
            "end_logit": 7.37890625,
            "text": "the Polycap (comprised of atenolol",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -4.6015625,
            "end_logit": -5.9375,
            "text": "Polycap",
            "probability": 0.0
        },
        {
            "start_logit": -4.6015625,
            "end_logit": -6.6328125,
            "text": "Polycap (comprised of atenolol, ramipril, hydrochlorothiazide, and a statin",
            "probability": 0.0
        },
        {
            "start_logit": -4.6015625,
            "end_logit": -6.71484375,
            "text": "Polycap (comprised of atenolol, ramipril",
            "probability": 0.0
        },
        {
            "start_logit": -4.6015625,
            "end_logit": -7.43359375,
            "text": "Polycap (comprised of atenolol, ramipril, hydrochlorothiazide, and a statin)",
            "probability": 0.0
        },
        {
            "start_logit": -4.6015625,
            "end_logit": -7.48046875,
            "text": "Polycap (",
            "probability": 0.0
        },
        {
            "start_logit": -4.6015625,
            "end_logit": -7.515625,
            "text": "Polycap (comprised of atenolol, ramipr",
            "probability": 0.0
        },
        {
            "start_logit": -6.1796875,
            "end_logit": -5.9375,
            "text": "whether the Polycap",
            "probability": 0.0
        }
    ],
    "621215ec3a8413c653000012_1": [
        {
            "start_logit": 8.734375,
            "end_logit": 8.90625,
            "text": "single-targeted antibodies",
            "probability": 1.0
        },
        {
            "start_logit": -1.810546875,
            "end_logit": 8.90625,
            "text": "antibodies",
            "probability": 2.6285648345947266e-05
        },
        {
            "start_logit": 8.734375,
            "end_logit": -2.05078125,
            "text": "single",
            "probability": 1.7523765563964844e-05
        },
        {
            "start_logit": 8.734375,
            "end_logit": -5.8203125,
            "text": "single-targeted antibodies, bi-specific antibodies",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.734375,
            "end_logit": -5.88671875,
            "text": "single-targeted antibodies, bi-specific antibodies (BsAbs), and antibody-drug conjugates (ADC",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.36328125,
            "end_logit": 8.90625,
            "text": "Therefore, when developing anti-tumor therapeutic antibodies, including single-targeted antibodies",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.40234375,
            "end_logit": 8.90625,
            "text": "targeted antibodies",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.45703125,
            "end_logit": 8.90625,
            "text": "-targeted antibodies",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.734375,
            "end_logit": -6.29296875,
            "text": "single-targeted antibodies, bi-specific antibodies (BsAbs)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.56640625,
            "end_logit": 8.90625,
            "text": "including single-targeted antibodies",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.734375,
            "end_logit": -6.546875,
            "text": "single-targeted",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.734375,
            "end_logit": -6.61328125,
            "text": "single-targeted antibodies, bi-specific antibodies (BsA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.734375,
            "end_logit": -6.74609375,
            "text": "single-targeted antibodies, bi-specific antibodies (BsAbs",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.734375,
            "end_logit": -6.79296875,
            "text": "single-targeted antibodies, bi-specific antibodies (BsAbs), and antibody-drug conjugates",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -1.810546875,
            "end_logit": -5.8203125,
            "text": "antibodies, bi-specific antibodies",
            "probability": 0.0
        },
        {
            "start_logit": -1.810546875,
            "end_logit": -5.88671875,
            "text": "antibodies, bi-specific antibodies (BsAbs), and antibody-drug conjugates (ADC",
            "probability": 0.0
        },
        {
            "start_logit": -1.810546875,
            "end_logit": -6.203125,
            "text": "antibodies, bi-specific antibodies (BsAbs), and antibody-drug conjugates (ADCs), many factors, such as target biology",
            "probability": 0.0
        },
        {
            "start_logit": -1.810546875,
            "end_logit": -6.29296875,
            "text": "antibodies, bi-specific antibodies (BsAbs)",
            "probability": 0.0
        },
        {
            "start_logit": -6.36328125,
            "end_logit": -2.05078125,
            "text": "Therefore, when developing anti-tumor therapeutic antibodies, including single",
            "probability": 0.0
        },
        {
            "start_logit": -1.810546875,
            "end_logit": -6.61328125,
            "text": "antibodies, bi-specific antibodies (BsA",
            "probability": 0.0
        }
    ],
    "621eb93b3a8413c65300005b_1": [
        {
            "start_logit": 9.140625,
            "end_logit": 9.484375,
            "text": "VEGF-A",
            "probability": 1.0
        },
        {
            "start_logit": -0.59716796875,
            "end_logit": 9.484375,
            "text": "A",
            "probability": 5.918741226196289e-05
        },
        {
            "start_logit": 9.140625,
            "end_logit": -1.373046875,
            "text": "VEGF",
            "probability": 1.9252300262451172e-05
        },
        {
            "start_logit": -5.80859375,
            "end_logit": 9.484375,
            "text": "-A",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.140625,
            "end_logit": -6.41015625,
            "text": "VEGF-A and Ang-2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.09375,
            "end_logit": 9.484375,
            "text": "bispecific antibody that inhibits VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.140625,
            "end_logit": 9.484375,
            "text": "inhibits VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -6.80078125,
            "text": "VEGF-A and Ang",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2890625,
            "end_logit": 9.484375,
            "text": "pecific antibody that inhibits VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.328125,
            "end_logit": 9.484375,
            "text": ", a bispecific antibody that inhibits VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.125,
            "text": "VEGF-A and Ang-2, is in phase 3 trials for nAMD and DME.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 9.484375,
            "text": "antibody that inhibits VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.2265625,
            "text": "VEGF-A and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 9.484375,
            "text": "a bispecific antibody that inhibits VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.29296875,
            "text": "VEGF-A and Ang-2, is in phase 3 trials for nAMD and DME",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.484375,
            "text": "that inhibits VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.33984375,
            "text": "VEGF-A and Ang-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6953125,
            "end_logit": 9.484375,
            "text": "b, a bispecific antibody that inhibits VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.36328125,
            "text": "VEGF-A and Ang-2,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.5078125,
            "text": "VEGF-A and Ang-2, is in phase 3 trials for nAMD and",
            "probability": 5.960464477539063e-08
        }
    ],
    "621eb93b3a8413c65300005b_2": [
        {
            "start_logit": 9.2265625,
            "end_logit": 9.34375,
            "text": "VEGF-A",
            "probability": 1.0
        },
        {
            "start_logit": -1.080078125,
            "end_logit": 9.34375,
            "text": "A",
            "probability": 3.3736228942871094e-05
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -1.203125,
            "text": "VEGF",
            "probability": 2.6464462280273438e-05
        },
        {
            "start_logit": -5.65234375,
            "end_logit": 9.34375,
            "text": "-A",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.5703125,
            "text": "VEGF-A and the Ang-Tie/pathway",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.58203125,
            "text": "VEGF-A and the Ang-Tie",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.28125,
            "end_logit": 9.34375,
            "text": "targeting VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.19140625,
            "text": "VEGF-A and the Ang-Tie/pathway.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.2265625,
            "text": "VEGF-A and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.30859375,
            "text": "VEGF-A and the Ang-Tie/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.4453125,
            "text": "VEGF-A and the Ang",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 9.34375,
            "text": "promising bispecific drug targeting VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.484375,
            "text": "VEGF-A and the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.625,
            "end_logit": 9.34375,
            "text": "bispecific drug targeting VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 9.34375,
            "text": "drug targeting VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.080078125,
            "end_logit": -6.5703125,
            "text": "A and the Ang-Tie/pathway",
            "probability": 0.0
        },
        {
            "start_logit": -1.080078125,
            "end_logit": -6.58203125,
            "text": "A and the Ang-Tie",
            "probability": 0.0
        },
        {
            "start_logit": -1.080078125,
            "end_logit": -7.19140625,
            "text": "A and the Ang-Tie/pathway.",
            "probability": 0.0
        },
        {
            "start_logit": -1.080078125,
            "end_logit": -7.2265625,
            "text": "A and",
            "probability": 0.0
        },
        {
            "start_logit": -1.080078125,
            "end_logit": -7.30859375,
            "text": "A and the Ang-Tie/",
            "probability": 0.0
        }
    ],
    "621eb93b3a8413c65300005b_3": [
        {
            "start_logit": 9.28125,
            "end_logit": 9.40625,
            "text": "Tie-2",
            "probability": 1.0
        },
        {
            "start_logit": -1.080078125,
            "end_logit": 9.40625,
            "text": "2",
            "probability": 3.170967102050781e-05
        },
        {
            "start_logit": 9.28125,
            "end_logit": -1.1376953125,
            "text": "Tie",
            "probability": 2.6285648345947266e-05
        },
        {
            "start_logit": 9.28125,
            "end_logit": -4.61328125,
            "text": "Tie-2/angiopoietin pathway",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -5.6484375,
            "end_logit": 9.40625,
            "text": "-2",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.23828125,
            "text": "Tie-2/angiopoietin",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.96875,
            "text": "Tie-2/angiopoietin pathway and VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.1171875,
            "text": "Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 9.40625,
            "text": "targeting the Tie-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.38671875,
            "text": "Tie-2/angiopoietin pathway and VEGF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.40625,
            "text": "Tie-2/angiopoietin pathway and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.40625,
            "text": "Tie-2/angiopo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 9.40625,
            "text": "investigational agent targeting the Tie-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 9.40625,
            "text": "the Tie-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.4765625,
            "text": "Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 9.40625,
            "text": ": an investigational agent targeting the Tie-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.515625,
            "text": "Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.56640625,
            "text": "Tie-2/angiopoietin pathway and VEGF-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.080078125,
            "end_logit": -4.61328125,
            "text": "2/angiopoietin pathway",
            "probability": 0.0
        },
        {
            "start_logit": -1.080078125,
            "end_logit": -6.23828125,
            "text": "2/angiopoietin",
            "probability": 0.0
        }
    ],
    "621eb93b3a8413c65300005b_4": [
        {
            "start_logit": 9.375,
            "end_logit": 9.125,
            "text": "Ang-2",
            "probability": 1.0
        },
        {
            "start_logit": 9.375,
            "end_logit": -0.8291015625,
            "text": "Ang",
            "probability": 4.756450653076172e-05
        },
        {
            "start_logit": -1.703125,
            "end_logit": 9.125,
            "text": "2",
            "probability": 1.5437602996826172e-05
        },
        {
            "start_logit": -5.3671875,
            "end_logit": 9.125,
            "text": "-2",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.375,
            "end_logit": -6.71484375,
            "text": "Ang-2 and VEGF-A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.375,
            "end_logit": -7.11328125,
            "text": "Ang-2 and VEGF-A for treatment of diabetic eye disease.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.375,
            "end_logit": -7.15234375,
            "text": "Ang-2 and VEGF-A for treatment of diabetic eye disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.375,
            "end_logit": -7.34375,
            "text": "Ang-2 and VEGF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.375,
            "end_logit": -7.3515625,
            "text": "Ang-2 and VEGF-A for treatment of diabetic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.375,
            "end_logit": -7.41796875,
            "text": "Ang-2 and VEGF-A for treatment of diabetic eye",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1796875,
            "end_logit": 9.125,
            "text": "bispecific antibody designed for intravitreal use, to simultaneously bind and neutralize Ang-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.375,
            "end_logit": -7.5078125,
            "text": "Ang-2 and VEGF-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 9.125,
            "text": "novel bispecific antibody designed for intravitreal use, to simultaneously bind and neutralize Ang-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 9.125,
            "text": "ize Ang-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.609375,
            "end_logit": 9.125,
            "text": "pecific antibody designed for intravitreal use, to simultaneously bind and neutralize Ang-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 9.125,
            "text": "simultaneously bind and neutralize Ang-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 9.125,
            "text": ", a novel bispecific antibody designed for intravitreal use, to simultaneously bind and neutralize Ang-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1796875,
            "end_logit": -0.8291015625,
            "text": "bispecific antibody designed for intravitreal use, to simultaneously bind and neutralize Ang",
            "probability": 0.0
        },
        {
            "start_logit": -7.56640625,
            "end_logit": -0.8291015625,
            "text": "novel bispecific antibody designed for intravitreal use, to simultaneously bind and neutralize Ang",
            "probability": 0.0
        },
        {
            "start_logit": -1.703125,
            "end_logit": -6.71484375,
            "text": "2 and VEGF-A",
            "probability": 0.0
        }
    ],
    "621eb93b3a8413c65300005b_5": [
        {
            "start_logit": 7.90625,
            "end_logit": 7.01171875,
            "text": "Ang-2",
            "probability": 1.0
        },
        {
            "start_logit": 7.90625,
            "end_logit": -1.9736328125,
            "text": "Ang-2 antibody that upregulates the Tie-2",
            "probability": 0.00012540817260742188
        },
        {
            "start_logit": 7.90625,
            "end_logit": -3.16015625,
            "text": "Ang",
            "probability": 3.820657730102539e-05
        },
        {
            "start_logit": -4.3828125,
            "end_logit": 7.01171875,
            "text": "2",
            "probability": 4.589557647705078e-06
        },
        {
            "start_logit": -4.7734375,
            "end_logit": 7.01171875,
            "text": "VEGF/Ang-2",
            "probability": 3.0994415283203125e-06
        },
        {
            "start_logit": 7.90625,
            "end_logit": -5.828125,
            "text": "Ang-2 antibody that upregulates the Tie-2 signaling",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 7.90625,
            "end_logit": -5.93359375,
            "text": "Ang-2 antibody that upregulates the Tie-2 signaling pathway",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": 7.90625,
            "end_logit": -6.31640625,
            "text": "Ang-2 antibody",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": -5.44140625,
            "end_logit": 7.01171875,
            "text": "anti-VEGF/Ang-2",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 7.90625,
            "end_logit": -7.1640625,
            "text": "Ang-2 antibody that upregulates the Tie-2 signaling pathway and promotes vascular",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 7.90625,
            "end_logit": -7.18359375,
            "text": "Ang-2 antibody that upregulates the Tie",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.90625,
            "end_logit": -7.29296875,
            "text": "Ang-2 antibody that upregulates the Tie-2 signaling pathway and promotes vascular stability",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.4140625,
            "end_logit": 7.01171875,
            "text": "-2",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.90625,
            "end_logit": -7.3515625,
            "text": "Ang-2 antibody that upreg",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.90625,
            "end_logit": -7.40234375,
            "text": "Ang-2 antibody that upregulates the Tie-2 signaling pathway and",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.90625,
            "end_logit": -7.44140625,
            "text": "Ang-2 antibody that upregulates the Tie-2 signaling pathway and promotes vascular stability; it is undergoing phase 3 trials with potential for 12- or",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.90625,
            "end_logit": -7.4921875,
            "text": "Ang-2 antibody that upregulates the Tie-2 signaling pathway and promotes vascular stability; it is undergoing phase 3",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.90625,
            "end_logit": -7.51171875,
            "text": "Ang-2 antibody that upregulates the Tie-2 signaling pathway and promotes vascular stability; it is undergoing phase 3 trials with potential for 12",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 7.01171875,
            "text": "bispecific anti-VEGF/Ang-2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 7.01171875,
            "text": "pecific anti-VEGF/Ang-2",
            "probability": 1.7881393432617188e-07
        }
    ],
    "621eb93b3a8413c65300005b_6": [
        {
            "start_logit": 6.23828125,
            "end_logit": 6.2578125,
            "text": "angiopoietin 2",
            "probability": 1.0
        },
        {
            "start_logit": 6.23828125,
            "end_logit": -2.791015625,
            "text": "angiopoietin 2 (Ang-2) and vascular endothelial growth factor A",
            "probability": 0.00011682510375976562
        },
        {
            "start_logit": 6.23828125,
            "end_logit": -4.65625,
            "text": "angio",
            "probability": 1.806020736694336e-05
        },
        {
            "start_logit": -4.90625,
            "end_logit": 6.2578125,
            "text": "2",
            "probability": 1.4424324035644531e-05
        },
        {
            "start_logit": 6.23828125,
            "end_logit": -4.95703125,
            "text": "angiopoietin 2 (Ang-2) and vascular endothelial growth factor",
            "probability": 1.341104507446289e-05
        },
        {
            "start_logit": 6.23828125,
            "end_logit": -5.4453125,
            "text": "angiopoietin",
            "probability": 8.285045623779297e-06
        },
        {
            "start_logit": 6.23828125,
            "end_logit": -6.55078125,
            "text": "angiopoietin 2 (Ang-2",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": 6.23828125,
            "end_logit": -6.75,
            "text": "angiopoietin 2 (Ang-2)",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 6.23828125,
            "end_logit": -6.8203125,
            "text": "angiopoietin 2 (Ang-2) and vascular endothelial growth",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 6.23828125,
            "end_logit": -6.8828125,
            "text": "angiopoietin 2 (Ang-2) and vascular endothelial",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": 6.23828125,
            "end_logit": -6.96484375,
            "text": "angiopo",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 6.23828125,
            "end_logit": -7.25390625,
            "text": "angiopoietin 2 (Ang",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -7.34375,
            "end_logit": 6.2578125,
            "text": "poietin 2",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 6.2578125,
            "text": "izes angiopoietin 2",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 6.2578125,
            "text": "bispecific antibody designed for intraocular use, simultaneously and independently binds and neutralizes angiopoietin 2",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 6.23828125,
            "end_logit": -7.42578125,
            "text": "angiopoietin 2 (Ang-",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 6.23828125,
            "end_logit": -7.52734375,
            "text": "angiopoietin 2 (",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 6.2578125,
            "text": "pecific antibody designed for intraocular use, simultaneously and independently binds and neutralizes angiopoietin 2",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 6.2578125,
            "text": "first bispecific antibody designed for intraocular use, simultaneously and independently binds and neutralizes angiopoietin 2",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 6.2578125,
            "text": "binds and neutralizes angiopoietin 2",
            "probability": 1.0132789611816406e-06
        }
    ],
    "621eb93b3a8413c65300005b_7": [
        {
            "start_logit": 9.140625,
            "end_logit": 9.3046875,
            "text": "VEGF-A",
            "probability": 1.0
        },
        {
            "start_logit": -1.2021484375,
            "end_logit": 9.3046875,
            "text": "A",
            "probability": 3.24249267578125e-05
        },
        {
            "start_logit": 9.140625,
            "end_logit": -1.400390625,
            "text": "VEGF",
            "probability": 2.2649765014648438e-05
        },
        {
            "start_logit": -5.65234375,
            "end_logit": 9.3046875,
            "text": "-A",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.140625,
            "end_logit": -6.51953125,
            "text": "VEGF-A and the Ang-Tie",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.03515625,
            "text": "VEGF-A and the Ang-Tie/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.20703125,
            "text": "VEGF-A and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 9.3046875,
            "text": "targeting VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 9.3046875,
            "text": "promising bispecific drug targeting VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.45703125,
            "text": "VEGF-A and the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.484375,
            "text": "VEGF-A and the Ang",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.671875,
            "end_logit": 9.3046875,
            "text": "gimen. Faricimab is a promising bispecific drug targeting VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 9.3046875,
            "text": "bispecific drug targeting VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.2021484375,
            "end_logit": -6.51953125,
            "text": "A and the Ang-Tie",
            "probability": 0.0
        },
        {
            "start_logit": -1.2021484375,
            "end_logit": -7.03515625,
            "text": "A and the Ang-Tie/",
            "probability": 0.0
        },
        {
            "start_logit": -1.2021484375,
            "end_logit": -7.20703125,
            "text": "A and",
            "probability": 0.0
        },
        {
            "start_logit": -1.2021484375,
            "end_logit": -7.45703125,
            "text": "A and the",
            "probability": 0.0
        },
        {
            "start_logit": -1.2021484375,
            "end_logit": -7.484375,
            "text": "A and the Ang",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": -1.400390625,
            "text": "targeting VEGF",
            "probability": 0.0
        },
        {
            "start_logit": -7.61328125,
            "end_logit": -1.400390625,
            "text": "promising bispecific drug targeting VEGF",
            "probability": 0.0
        }
    ],
    "621eb93b3a8413c65300005b_8": [
        {
            "start_logit": 9.3125,
            "end_logit": 9.203125,
            "text": "Ang-2",
            "probability": 1.0
        },
        {
            "start_logit": 9.3125,
            "end_logit": -1.029296875,
            "text": "Ang",
            "probability": 3.594160079956055e-05
        },
        {
            "start_logit": -1.57421875,
            "end_logit": 9.203125,
            "text": "2",
            "probability": 1.8656253814697266e-05
        },
        {
            "start_logit": -5.5078125,
            "end_logit": 9.203125,
            "text": "-2",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.12890625,
            "text": "Ang-2 and VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.2578125,
            "text": "Ang-2 and VEGF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.21875,
            "end_logit": 9.203125,
            "text": "bispecific antibody designed for intravitreal use, to simultaneously bind and neutralize Ang-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.45703125,
            "text": "Ang-2 and VEGF-A for treatment of diabetic eye disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.49609375,
            "text": "Ang-2 and VEGF-A for treatment of diabetic eye disease. By targeting both Ang",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.5390625,
            "text": "Ang-2 and VEGF-A for treatment of diabetic eye",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.54296875,
            "text": "Ang-2 and VEGF-A for treatment of diabetic eye disease. By targeting both",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.59375,
            "text": "Ang-2 and VEGF-A for treatment of diabetic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.59375,
            "text": "Ang-2 and VEGF-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.59765625,
            "text": "Ang-2 and VEGF-A for treatment of diabetic eye disease. By targeting both Ang-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 9.203125,
            "text": ", a novel bispecific antibody designed for intravitreal use, to simultaneously bind and neutralize Ang-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 9.203125,
            "text": "novel bispecific antibody designed for intravitreal use, to simultaneously bind and neutralize Ang-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 9.203125,
            "text": "simultaneously bind and neutralize Ang-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 9.203125,
            "text": "ize Ang-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 9.203125,
            "text": "pecific antibody designed for intravitreal use, to simultaneously bind and neutralize Ang-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.21875,
            "end_logit": -1.029296875,
            "text": "bispecific antibody designed for intravitreal use, to simultaneously bind and neutralize Ang",
            "probability": 0.0
        }
    ],
    "621eb93b3a8413c65300005b_9": [
        {
            "start_logit": 6.65234375,
            "end_logit": 7.37109375,
            "text": "angiopoietin-2",
            "probability": 1.0
        },
        {
            "start_logit": -4.2109375,
            "end_logit": 7.37109375,
            "text": "2",
            "probability": 1.9252300262451172e-05
        },
        {
            "start_logit": 6.65234375,
            "end_logit": -4.62109375,
            "text": "angio",
            "probability": 6.198883056640625e-06
        },
        {
            "start_logit": -5.85546875,
            "end_logit": 7.37109375,
            "text": "ietin-2",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": -5.9140625,
            "end_logit": 7.37109375,
            "text": "poietin-2",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": -6.40625,
            "end_logit": 7.37109375,
            "text": "-2",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 6.65234375,
            "end_logit": -6.49609375,
            "text": "angiopoietin-2 and vascular endothelial",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -7.32421875,
            "end_logit": 7.37109375,
            "text": "bispecific antibody targeting angiopoietin-2",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 7.37109375,
            "text": "BOULEVARD trial compared safety and efficacy of faricimab, a novel bispecific antibody targeting angiopoietin-2",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 6.65234375,
            "end_logit": -6.703125,
            "text": "angiopoietin-2 and vascular endothelial growth factor",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 7.37109375,
            "text": "targeting angiopoietin-2",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -7.453125,
            "end_logit": 7.37109375,
            "text": "novel bispecific antibody targeting angiopoietin-2",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 6.65234375,
            "end_logit": -6.73828125,
            "text": "angiopoietin-2 and vascular",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 7.37109375,
            "text": ", a novel bispecific antibody targeting angiopoietin-2",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.484375,
            "end_logit": 7.37109375,
            "text": "compared safety and efficacy of faricimab, a novel bispecific antibody targeting angiopoietin-2",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 6.65234375,
            "end_logit": -6.78125,
            "text": "angiopoietin-2 and vascular endothelial growth",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 7.37109375,
            "text": "phase 2 BOULEVARD trial compared safety and efficacy of faricimab, a novel bispecific antibody targeting angiopoietin-2",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 6.65234375,
            "end_logit": -7.13671875,
            "text": "angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 6.65234375,
            "end_logit": -7.18359375,
            "text": "angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A), with ranibizumab in patients with diabetic macular edema",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 6.65234375,
            "end_logit": -7.32421875,
            "text": "angiopoietin-2 and vascular endothelial growth factor-A",
            "probability": 4.172325134277344e-07
        }
    ],
    "621eb93b3a8413c65300005b_10": [
        {
            "start_logit": 9.0,
            "end_logit": 9.3125,
            "text": "VEGF-A",
            "probability": 1.0
        },
        {
            "start_logit": -1.04296875,
            "end_logit": 9.3125,
            "text": "A",
            "probability": 4.3332576751708984e-05
        },
        {
            "start_logit": 9.0,
            "end_logit": -1.64453125,
            "text": "VEGF",
            "probability": 1.7523765563964844e-05
        },
        {
            "start_logit": -5.98046875,
            "end_logit": 9.3125,
            "text": "-A",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -5.76953125,
            "text": "VEGF-A and Ang-2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.03515625,
            "text": "VEGF-A and Ang",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37890625,
            "end_logit": 9.3125,
            "text": "bispecific antibody that inhibits VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 9.3125,
            "text": "inhibits VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 9.3125,
            "text": "pecific antibody that inhibits VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 9.3125,
            "text": ", a bispecific antibody that inhibits VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 9.3125,
            "text": "Areas covered: Faricimab, a bispecific antibody that inhibits VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 9.3125,
            "text": "a bispecific antibody that inhibits VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.3125,
            "text": "VEGF-A and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.33203125,
            "text": "VEGF-A and Ang-2,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 9.3125,
            "text": "b, a bispecific antibody that inhibits VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.375,
            "text": "VEGF-A and Ang-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7421875,
            "end_logit": 9.3125,
            "text": "Faricimab, a bispecific antibody that inhibits VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.46875,
            "text": "VEGF-A and Ang-2, is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.5078125,
            "text": "VEGF-A and Ang-2, is in phase 3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.5234375,
            "text": "VEGF-A and Ang-2, is in phase 3 trials",
            "probability": 5.960464477539063e-08
        }
    ],
    "621eb93b3a8413c65300005b_11": [
        {
            "start_logit": 9.328125,
            "end_logit": 8.8984375,
            "text": "Tie-2",
            "probability": 1.0
        },
        {
            "start_logit": 9.328125,
            "end_logit": -0.845703125,
            "text": "Tie",
            "probability": 5.918741226196289e-05
        },
        {
            "start_logit": -2.0078125,
            "end_logit": 8.8984375,
            "text": "2",
            "probability": 1.2040138244628906e-05
        },
        {
            "start_logit": -2.8046875,
            "end_logit": 8.8984375,
            "text": "Ang-2 antibody that upregulates the Tie-2",
            "probability": 5.424022674560547e-06
        },
        {
            "start_logit": 9.328125,
            "end_logit": -3.759765625,
            "text": "Tie-2 signaling pathway",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": 9.328125,
            "end_logit": -5.421875,
            "text": "Tie-2 signaling",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.3046875,
            "text": "Tie-2 signaling pathway and promotes vascular stability; it is undergoing phase 3 trials with potential for 12- or 16-week dosing. PAN-90",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.03125,
            "end_logit": 8.8984375,
            "text": "VEGF/Ang-2 antibody that upregulates the Tie-2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.53125,
            "text": "Tie-2 signaling pathway and promotes vascular stability; it is undergoing phase 3 trials with potential for 12- or 16-week dosing.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.125,
            "end_logit": 8.8984375,
            "text": "-2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.15625,
            "end_logit": 8.8984375,
            "text": "anti-VEGF/Ang-2 antibody that upregulates the Tie-2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.921875,
            "text": "Tie-2 signaling pathway and promotes vascular stability; it is undergoing phase 3 trials with potential for 12- or 16-week dosing. PAN",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.0234375,
            "text": "Tie-2 signaling pathway and promotes vascular",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.0390625,
            "text": "Tie-2 signaling pathway and promotes vascular stability",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.2890625,
            "text": "Tie-2 signaling pathway and promotes vascular stability; it is undergoing phase 3 trials with potential for 12- or 16-week dosing. PAN-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.35546875,
            "text": "Tie-2 signaling pathway and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.9375,
            "end_logit": 8.8984375,
            "text": "-2 antibody that upregulates the Tie-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.23828125,
            "end_logit": 8.8984375,
            "text": "ulates the Tie-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3515625,
            "end_logit": 8.8984375,
            "text": "the Tie-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 8.8984375,
            "text": "c anti-VEGF/Ang-2 antibody that upregulates the Tie-2",
            "probability": 5.960464477539063e-08
        }
    ],
    "621eb93b3a8413c65300005b_12": [
        {
            "start_logit": 9.0859375,
            "end_logit": 9.4140625,
            "text": "VEGF-A",
            "probability": 1.0
        },
        {
            "start_logit": -0.77978515625,
            "end_logit": 9.4140625,
            "text": "A",
            "probability": 5.1856040954589844e-05
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -1.4736328125,
            "text": "VEGF",
            "probability": 1.8656253814697266e-05
        },
        {
            "start_logit": -5.8125,
            "end_logit": 9.4140625,
            "text": "-A",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -6.22265625,
            "text": "VEGF-A and Ang-2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 9.4140625,
            "text": "bispecific antibody that inhibits VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.328125,
            "end_logit": 9.4140625,
            "text": "inhibits VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.03515625,
            "text": "VEGF-A and Ang",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 9.4140625,
            "text": "pecific antibody that inhibits VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.08984375,
            "text": "VEGF-A and Ang-2, is in phase 3 trials for nAMD and DME.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 9.4140625,
            "text": ", a bispecific antibody that inhibits VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.1953125,
            "text": "VEGF-A and Ang-2, is in phase 3 trials for nAMD and DME",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 9.4140625,
            "text": "Areas covered: Faricimab, a bispecific antibody that inhibits VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.29296875,
            "text": "VEGF-A and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 9.4140625,
            "text": "a bispecific antibody that inhibits VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.34765625,
            "text": "VEGF-A and Ang-2,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 9.4140625,
            "text": "b, a bispecific antibody that inhibits VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.359375,
            "text": "VEGF-A and Ang-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.50390625,
            "text": "VEGF-A and Ang-2, is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.51953125,
            "text": "VEGF-A and Ang-2, is in phase 3 trials for nAMD and",
            "probability": 5.960464477539063e-08
        }
    ],
    "621eb93b3a8413c65300005b_13": [
        {
            "start_logit": 1.0146484375,
            "end_logit": 0.0894775390625,
            "text": "Ang-2",
            "probability": 0.79638671875
        },
        {
            "start_logit": 3.515625,
            "end_logit": -4.83203125,
            "text": "vascular endothelial growth factor-A",
            "probability": 0.0706787109375
        },
        {
            "start_logit": 3.515625,
            "end_logit": -5.625,
            "text": "vascular endothelial growth factor",
            "probability": 0.031982421875
        },
        {
            "start_logit": 3.515625,
            "end_logit": -6.1875,
            "text": "vascular endothelial growth factor-A (VEGF-A)",
            "probability": 0.018218994140625
        },
        {
            "start_logit": 3.515625,
            "end_logit": -6.44921875,
            "text": "vascular endothelial growth factor-A (VEGF-A",
            "probability": 0.0140228271484375
        },
        {
            "start_logit": 3.515625,
            "end_logit": -6.82421875,
            "text": "vascular",
            "probability": 0.0096435546875
        },
        {
            "start_logit": 3.515625,
            "end_logit": -6.83203125,
            "text": "vascular endothelial growth",
            "probability": 0.00955963134765625
        },
        {
            "start_logit": 3.515625,
            "end_logit": -6.8359375,
            "text": "vascular endothelial growth factor-A (VEGF",
            "probability": 0.00952911376953125
        },
        {
            "start_logit": 3.515625,
            "end_logit": -6.95703125,
            "text": "vascular endothelial",
            "probability": 0.0084381103515625
        },
        {
            "start_logit": 3.515625,
            "end_logit": -7.265625,
            "text": "vascular endothelial growth factor-A (",
            "probability": 0.006198883056640625
        },
        {
            "start_logit": 3.515625,
            "end_logit": -7.30859375,
            "text": "vascular endothelial growth factor-",
            "probability": 0.005939483642578125
        },
        {
            "start_logit": 1.0146484375,
            "end_logit": -4.83203125,
            "text": "Ang-2 and vascular endothelial growth factor-A",
            "probability": 0.005802154541015625
        },
        {
            "start_logit": 3.515625,
            "end_logit": -7.37109375,
            "text": "vascular endothelial growth factor-A (VEGF-",
            "probability": 0.005580902099609375
        },
        {
            "start_logit": 1.0146484375,
            "end_logit": -5.625,
            "text": "Ang-2 and vascular endothelial growth factor",
            "probability": 0.00262451171875
        },
        {
            "start_logit": 1.0146484375,
            "end_logit": -6.1875,
            "text": "Ang-2 and vascular endothelial growth factor-A (VEGF-A)",
            "probability": 0.0014963150024414062
        },
        {
            "start_logit": 1.0146484375,
            "end_logit": -6.44921875,
            "text": "Ang-2 and vascular endothelial growth factor-A (VEGF-A",
            "probability": 0.0011510848999023438
        },
        {
            "start_logit": 1.0146484375,
            "end_logit": -6.82421875,
            "text": "Ang-2 and vascular",
            "probability": 0.0007910728454589844
        },
        {
            "start_logit": 1.0146484375,
            "end_logit": -6.83203125,
            "text": "Ang-2 and vascular endothelial growth",
            "probability": 0.0007853507995605469
        },
        {
            "start_logit": 1.0146484375,
            "end_logit": -6.8359375,
            "text": "Ang-2 and vascular endothelial growth factor-A (VEGF",
            "probability": 0.000782012939453125
        },
        {
            "start_logit": 1.0146484375,
            "end_logit": -6.95703125,
            "text": "Ang-2 and vascular endothelial",
            "probability": 0.0006928443908691406
        }
    ],
    "621eb93b3a8413c65300005b_14": [
        {
            "start_logit": 9.28125,
            "end_logit": 9.21875,
            "text": "angiopoietin-2",
            "probability": 1.0
        },
        {
            "start_logit": 9.28125,
            "end_logit": -1.1513671875,
            "text": "angio",
            "probability": 3.147125244140625e-05
        },
        {
            "start_logit": -1.50390625,
            "end_logit": 9.21875,
            "text": "2",
            "probability": 2.0802021026611328e-05
        },
        {
            "start_logit": -5.96484375,
            "end_logit": 9.21875,
            "text": "ietin-2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.00390625,
            "end_logit": 9.21875,
            "text": "poietin-2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.16015625,
            "end_logit": 9.21875,
            "text": "-2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.1796875,
            "text": "angiopoietin-2 and vascular endothelial",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.1875,
            "text": "angiopoietin-2 and vascular endothelial growth factor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.21484375,
            "text": "angiopoietin-2 and vascular endothelial growth",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.21484375,
            "text": "angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.17578125,
            "end_logit": 9.21875,
            "text": "bispecific antibody targeting angiopoietin-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.3671875,
            "text": "angiopoietin-2 and vascular endothelial growth factor-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 9.21875,
            "text": ", a novel bispecific antibody targeting angiopoietin-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 9.21875,
            "text": "targeting angiopoietin-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.390625,
            "end_logit": 9.21875,
            "text": "safety and efficacy of faricimab, a novel bispecific antibody targeting angiopoietin-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.390625,
            "end_logit": 9.21875,
            "text": "compared safety and efficacy of faricimab, a novel bispecific antibody targeting angiopoietin-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 9.21875,
            "text": "novel bispecific antibody targeting angiopoietin-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.17578125,
            "end_logit": -1.1513671875,
            "text": "bispecific antibody targeting angio",
            "probability": 0.0
        },
        {
            "start_logit": -7.3671875,
            "end_logit": -1.1513671875,
            "text": ", a novel bispecific antibody targeting angio",
            "probability": 0.0
        },
        {
            "start_logit": -7.3828125,
            "end_logit": -1.1513671875,
            "text": "targeting angio",
            "probability": 0.0
        }
    ],
    "621eb93b3a8413c65300005b_15": [
        {
            "start_logit": 9.0546875,
            "end_logit": 8.84375,
            "text": "angiopoietin 2",
            "probability": 1.0
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -1.5986328125,
            "text": "angio",
            "probability": 2.8848648071289062e-05
        },
        {
            "start_logit": -2.091796875,
            "end_logit": 8.84375,
            "text": "2",
            "probability": 1.430511474609375e-05
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -5.7265625,
            "text": "angiopoietin 2 (Ang-2)",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -5.8359375,
            "text": "angiopoietin",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -5.9453125,
            "text": "angiopoietin 2 (Ang-2",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -6.1484375,
            "text": "angiopoietin 2 (Ang-2) and vascular endothelial growth factor A (VEGF-A).",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -6.8203125,
            "text": "angiopoietin 2 (Ang-2) and vascular endothelial growth factor A (VEGF-A",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.05078125,
            "text": "angiopoietin 2 (Ang-2) and vascular endothelial",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.09375,
            "text": "angiopo",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.1328125,
            "text": "angiopoietin 2 (Ang-2) and vascular endothelial growth factor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0546875,
            "end_logit": 8.84375,
            "text": "ietin 2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1875,
            "end_logit": 8.84375,
            "text": "bispecific antibody designed for intraocular use, simultaneously and independently binds and neutralizes angiopoietin 2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 8.84375,
            "text": "izes angiopoietin 2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2890625,
            "end_logit": 8.84375,
            "text": "poietin 2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.091796875,
            "end_logit": -5.7265625,
            "text": "2 (Ang-2)",
            "probability": 0.0
        },
        {
            "start_logit": -2.091796875,
            "end_logit": -5.9453125,
            "text": "2 (Ang-2",
            "probability": 0.0
        },
        {
            "start_logit": -2.091796875,
            "end_logit": -6.1484375,
            "text": "2 (Ang-2) and vascular endothelial growth factor A (VEGF-A).",
            "probability": 0.0
        },
        {
            "start_logit": -7.1875,
            "end_logit": -1.5986328125,
            "text": "bispecific antibody designed for intraocular use, simultaneously and independently binds and neutralizes angio",
            "probability": 0.0
        },
        {
            "start_logit": -7.26171875,
            "end_logit": -1.5986328125,
            "text": "izes angio",
            "probability": 0.0
        }
    ],
    "5e4f0a4f6d0a277941000031_1": [
        {
            "start_logit": 7.97265625,
            "end_logit": 7.40234375,
            "text": "gamma",
            "probability": 1.0
        },
        {
            "start_logit": -4.4140625,
            "end_logit": 7.40234375,
            "text": "monoclonal immunoglobulins consisting of only one type of heavy either the gamma",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": -4.8984375,
            "end_logit": 7.40234375,
            "text": "plasma cells causes synthesis of very large amount of monoclonal immunoglobulins consisting of only one type of heavy either the gamma",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": -5.421875,
            "end_logit": 7.40234375,
            "text": "the gamma",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 7.97265625,
            "end_logit": -6.0,
            "text": "gamma, alpha, mu, delta or epsilon chain",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 7.97265625,
            "end_logit": -6.84765625,
            "text": "gamma, alpha, mu, delta or",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.296875,
            "end_logit": 7.40234375,
            "text": "proliferation of single clones of plasma cells causes synthesis of very large amount of monoclonal immunoglobulins consisting of only one type of heavy either the gamma",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.30078125,
            "end_logit": 7.40234375,
            "text": "neoplastic proliferation of single clones of plasma cells causes synthesis of very large amount of monoclonal immunoglobulins consisting of only one type of heavy either the gamma",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.97265625,
            "end_logit": -6.87890625,
            "text": "gamma, alpha, mu, delta or epsilon",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.97265625,
            "end_logit": -7.19921875,
            "text": "gamma, alpha, mu",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.62890625,
            "end_logit": 7.40234375,
            "text": "either the gamma",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.97265625,
            "end_logit": -7.3046875,
            "text": "gamma, alpha, mu, delta",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.796875,
            "end_logit": 7.40234375,
            "text": "he neoplastic proliferation of single clones of plasma cells causes synthesis of very large amount of monoclonal immunoglobulins consisting of only one type of heavy either the gamma",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.80078125,
            "end_logit": 7.40234375,
            "text": "single clones of plasma cells causes synthesis of very large amount of monoclonal immunoglobulins consisting of only one type of heavy either the gamma",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.8984375,
            "end_logit": 7.40234375,
            "text": "very large amount of monoclonal immunoglobulins consisting of only one type of heavy either the gamma",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.8984375,
            "end_logit": 7.40234375,
            "text": "synthesis of very large amount of monoclonal immunoglobulins consisting of only one type of heavy either the gamma",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.06640625,
            "end_logit": 7.40234375,
            "text": "clones of plasma cells causes synthesis of very large amount of monoclonal immunoglobulins consisting of only one type of heavy either the gamma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.10546875,
            "end_logit": 7.40234375,
            "text": "of plasma cells causes synthesis of very large amount of monoclonal immunoglobulins consisting of only one type of heavy either the gamma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.109375,
            "end_logit": 7.40234375,
            "text": "of monoclonal immunoglobulins consisting of only one type of heavy either the gamma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.16796875,
            "end_logit": 7.40234375,
            "text": "heavy either the gamma",
            "probability": 2.384185791015625e-07
        }
    ],
    "5e4f0a4f6d0a277941000031_2": [
        {
            "start_logit": 8.6328125,
            "end_logit": 6.67578125,
            "text": "gamma",
            "probability": 1.0
        },
        {
            "start_logit": 8.6328125,
            "end_logit": -5.73046875,
            "text": "gamma, alpha",
            "probability": 4.112720489501953e-06
        },
        {
            "start_logit": 8.6328125,
            "end_logit": -6.04296875,
            "text": "gamma, alpha, mu, delta and epsilon",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": 8.6328125,
            "end_logit": -6.9375,
            "text": "gamma, alpha, mu",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 8.6328125,
            "end_logit": -6.94140625,
            "text": "gamma, alpha, mu, delta and",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 8.6328125,
            "end_logit": -7.20703125,
            "text": "gamma, alpha, mu, delta",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.6328125,
            "end_logit": -7.3984375,
            "text": "gamma,",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -7.0078125,
            "end_logit": 6.67578125,
            "text": "using heavy chain specific gamma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.02734375,
            "end_logit": 6.67578125,
            "text": "heavy chain specific gamma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.1953125,
            "end_logit": 6.67578125,
            "text": "specific gamma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0078125,
            "end_logit": -5.73046875,
            "text": "using heavy chain specific gamma, alpha",
            "probability": 0.0
        },
        {
            "start_logit": -7.02734375,
            "end_logit": -5.73046875,
            "text": "heavy chain specific gamma, alpha",
            "probability": 0.0
        },
        {
            "start_logit": -7.1953125,
            "end_logit": -5.73046875,
            "text": "specific gamma, alpha",
            "probability": 0.0
        },
        {
            "start_logit": -7.2421875,
            "end_logit": -5.73046875,
            "text": ", alpha",
            "probability": 0.0
        },
        {
            "start_logit": -7.2890625,
            "end_logit": -5.73046875,
            "text": "alpha",
            "probability": 0.0
        },
        {
            "start_logit": -7.0078125,
            "end_logit": -6.04296875,
            "text": "using heavy chain specific gamma, alpha, mu, delta and epsilon",
            "probability": 0.0
        },
        {
            "start_logit": -7.02734375,
            "end_logit": -6.04296875,
            "text": "heavy chain specific gamma, alpha, mu, delta and epsilon",
            "probability": 0.0
        },
        {
            "start_logit": -7.1953125,
            "end_logit": -6.04296875,
            "text": "specific gamma, alpha, mu, delta and epsilon",
            "probability": 0.0
        },
        {
            "start_logit": -7.2421875,
            "end_logit": -6.04296875,
            "text": ", alpha, mu, delta and epsilon",
            "probability": 0.0
        },
        {
            "start_logit": -7.2890625,
            "end_logit": -6.04296875,
            "text": "alpha, mu, delta and epsilon",
            "probability": 0.0
        }
    ],
    "52f88d292059c6d71c000036_1": [
        {
            "start_logit": 8.9375,
            "end_logit": 8.140625,
            "text": "growth hormone",
            "probability": 0.7119140625
        },
        {
            "start_logit": 8.9375,
            "end_logit": 7.23828125,
            "text": "growth hormone deficiency",
            "probability": 0.287841796875
        },
        {
            "start_logit": 8.9375,
            "end_logit": -1.8798828125,
            "text": "growth",
            "probability": 3.1828880310058594e-05
        },
        {
            "start_logit": -3.115234375,
            "end_logit": 8.140625,
            "text": "hormone",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": -3.115234375,
            "end_logit": 7.23828125,
            "text": "hormone deficiency",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": -4.0078125,
            "end_logit": 7.23828125,
            "text": "deficiency",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.9375,
            "end_logit": -7.17578125,
            "text": "growth hormone deficiency and responded well to growth hormone therapy.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9375,
            "end_logit": -7.203125,
            "text": "growth hormone deficiency and responded well to growth hormone",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9375,
            "end_logit": -7.33203125,
            "text": "growth hormone deficiency and responded well to growth hormone therapy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9375,
            "end_logit": -7.37890625,
            "text": "growth hormone deficiency and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9375,
            "end_logit": -7.47265625,
            "text": "growth hormone deficiency and responded well",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9375,
            "end_logit": -7.53515625,
            "text": "growth hormone deficiency and responded",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9375,
            "end_logit": -7.58984375,
            "text": "growth hormone deficiency and responded well to growth",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9375,
            "end_logit": -7.59375,
            "text": "growth hormone deficiency and responded well to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 8.140625,
            "text": "report a boy with confirmed Williams-Beuren syndrome, who was found to have classical growth hormone",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 8.140625,
            "text": "classical growth hormone",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46875,
            "end_logit": 8.140625,
            "text": "We report a boy with confirmed Williams-Beuren syndrome, who was found to have classical growth hormone",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 8.140625,
            "text": ", who was found to have classical growth hormone",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 8.140625,
            "text": "who was found to have classical growth hormone",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 8.140625,
            "text": "uren syndrome, who was found to have classical growth hormone",
            "probability": 5.960464477539063e-08
        }
    ],
    "52f88d292059c6d71c000036_2": [
        {
            "start_logit": 4.21875,
            "end_logit": 7.3984375,
            "text": "TSH",
            "probability": 0.9248046875
        },
        {
            "start_logit": 1.69921875,
            "end_logit": 7.3984375,
            "text": "elevated TSH",
            "probability": 0.07415771484375
        },
        {
            "start_logit": -3.6953125,
            "end_logit": 7.3984375,
            "text": "a population of 95 WS patients, half of them followed for more than 5 years. Our study confirms the increased incidence of both elevated TSH",
            "probability": 0.0003380775451660156
        },
        {
            "start_logit": -5.609375,
            "end_logit": 7.3984375,
            "text": "study confirms the increased incidence of both elevated TSH",
            "probability": 4.988908767700195e-05
        },
        {
            "start_logit": -6.05078125,
            "end_logit": 7.3984375,
            "text": ". Our study confirms the increased incidence of both elevated TSH",
            "probability": 3.218650817871094e-05
        },
        {
            "start_logit": -6.40625,
            "end_logit": 7.3984375,
            "text": "Our study confirms the increased incidence of both elevated TSH",
            "probability": 2.2470951080322266e-05
        },
        {
            "start_logit": -6.43359375,
            "end_logit": 7.3984375,
            "text": "in a population of 95 WS patients, half of them followed for more than 5 years. Our study confirms the increased incidence of both elevated TSH",
            "probability": 2.1755695343017578e-05
        },
        {
            "start_logit": -6.51171875,
            "end_logit": 7.3984375,
            "text": "population of 95 WS patients, half of them followed for more than 5 years. Our study confirms the increased incidence of both elevated TSH",
            "probability": 2.014636993408203e-05
        },
        {
            "start_logit": -6.61328125,
            "end_logit": 7.3984375,
            "text": "patients, half of them followed for more than 5 years. Our study confirms the increased incidence of both elevated TSH",
            "probability": 1.8358230590820312e-05
        },
        {
            "start_logit": -7.1015625,
            "end_logit": 7.3984375,
            "text": "increased incidence of both elevated TSH",
            "probability": 1.1205673217773438e-05
        },
        {
            "start_logit": -7.1171875,
            "end_logit": 7.3984375,
            "text": "the increased incidence of both elevated TSH",
            "probability": 1.1026859283447266e-05
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 7.3984375,
            "text": "half of them followed for more than 5 years. Our study confirms the increased incidence of both elevated TSH",
            "probability": 1.0669231414794922e-05
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 7.3984375,
            "text": ", half of them followed for more than 5 years. Our study confirms the increased incidence of both elevated TSH",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -7.203125,
            "end_logit": 7.3984375,
            "text": "95 WS patients, half of them followed for more than 5 years. Our study confirms the increased incidence of both elevated TSH",
            "probability": 1.0132789611816406e-05
        },
        {
            "start_logit": -7.24609375,
            "end_logit": 7.3984375,
            "text": "followed for more than 5 years. Our study confirms the increased incidence of both elevated TSH",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": -7.2734375,
            "end_logit": 7.3984375,
            "text": "both elevated TSH",
            "probability": 9.417533874511719e-06
        },
        {
            "start_logit": -7.28125,
            "end_logit": 7.3984375,
            "text": "confirms the increased incidence of both elevated TSH",
            "probability": 9.357929229736328e-06
        },
        {
            "start_logit": 4.21875,
            "end_logit": -5.19140625,
            "text": "TSH serum values",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": 4.21875,
            "end_logit": -6.3515625,
            "text": "TSH serum",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 4.21875,
            "end_logit": -6.41796875,
            "text": "TSH serum values (37.9",
            "probability": 9.5367431640625e-07
        }
    ],
    "52f88d292059c6d71c000036_3": [
        {
            "start_logit": 8.703125,
            "end_logit": 8.8203125,
            "text": "GHD",
            "probability": 1.0
        },
        {
            "start_logit": -2.234375,
            "end_logit": 8.8203125,
            "text": "D",
            "probability": 1.7642974853515625e-05
        },
        {
            "start_logit": 8.703125,
            "end_logit": -2.228515625,
            "text": "GH",
            "probability": 1.5795230865478516e-05
        },
        {
            "start_logit": -6.89453125,
            "end_logit": 8.8203125,
            "text": "have GHD",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 8.8203125,
            "text": "female infant with confirmed WBS who, through provocative testing, was found to have GHD",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.33203125,
            "end_logit": 8.8203125,
            "text": "report a female infant with confirmed WBS who, through provocative testing, was found to have GHD",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 8.8203125,
            "text": "We report a female infant with confirmed WBS who, through provocative testing, was found to have GHD",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 8.8203125,
            "text": "through provocative testing, was found to have GHD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 8.8203125,
            "text": "a female infant with confirmed WBS who, through provocative testing, was found to have GHD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.578125,
            "end_logit": 8.8203125,
            "text": ", through provocative testing, was found to have GHD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.89453125,
            "end_logit": -2.228515625,
            "text": "have GH",
            "probability": 0.0
        },
        {
            "start_logit": -7.18359375,
            "end_logit": -2.228515625,
            "text": "female infant with confirmed WBS who, through provocative testing, was found to have GH",
            "probability": 0.0
        },
        {
            "start_logit": -7.33203125,
            "end_logit": -2.228515625,
            "text": "report a female infant with confirmed WBS who, through provocative testing, was found to have GH",
            "probability": 0.0
        },
        {
            "start_logit": -7.34765625,
            "end_logit": -2.228515625,
            "text": "We report a female infant with confirmed WBS who, through provocative testing, was found to have GH",
            "probability": 0.0
        },
        {
            "start_logit": -7.51953125,
            "end_logit": -2.228515625,
            "text": "through provocative testing, was found to have GH",
            "probability": 0.0
        },
        {
            "start_logit": -7.5703125,
            "end_logit": -2.228515625,
            "text": "a female infant with confirmed WBS who, through provocative testing, was found to have GH",
            "probability": 0.0
        },
        {
            "start_logit": -7.578125,
            "end_logit": -2.228515625,
            "text": ", through provocative testing, was found to have GH",
            "probability": 0.0
        },
        {
            "start_logit": -7.18359375,
            "end_logit": -6.94140625,
            "text": "female infant",
            "probability": 0.0
        },
        {
            "start_logit": -7.18359375,
            "end_logit": -7.0,
            "text": "female infant with confirmed WBS who, through provocative testing",
            "probability": 0.0
        },
        {
            "start_logit": -7.18359375,
            "end_logit": -7.04296875,
            "text": "female infant with confirmed WBS who, through provocative testing,",
            "probability": 0.0
        }
    ],
    "52f88d292059c6d71c000036_4": [
        {
            "start_logit": 5.77734375,
            "end_logit": 7.74609375,
            "text": "cortisol",
            "probability": 1.0
        },
        {
            "start_logit": -4.625,
            "end_logit": 7.74609375,
            "text": "elevated cortisol",
            "probability": 3.0219554901123047e-05
        },
        {
            "start_logit": -6.55859375,
            "end_logit": 7.74609375,
            "text": "while participants with WS had elevated cortisol",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": -6.7890625,
            "end_logit": 7.74609375,
            "text": "had elevated cortisol",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": -7.1875,
            "end_logit": 7.74609375,
            "text": "familiar setting, while participants with WS had elevated cortisol",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": -7.2109375,
            "end_logit": 7.74609375,
            "text": "and TD participants had similar profiles in a familiar setting, while participants with WS had elevated cortisol",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": -7.40234375,
            "end_logit": 7.74609375,
            "text": "WS and TD participants had similar profiles in a familiar setting, while participants with WS had elevated cortisol",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 7.74609375,
            "text": "setting, while participants with WS had elevated cortisol",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 7.74609375,
            "text": "participants had similar profiles in a familiar setting, while participants with WS had elevated cortisol",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -7.46875,
            "end_logit": 7.74609375,
            "text": "profiles in a familiar setting, while participants with WS had elevated cortisol",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 7.74609375,
            "text": "with WS had elevated cortisol",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 7.74609375,
            "text": "TD participants had similar profiles in a familiar setting, while participants with WS had elevated cortisol",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 5.77734375,
            "end_logit": -5.83984375,
            "text": "cortisol late in the day in the novel setting when social demands",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 5.77734375,
            "end_logit": -6.31640625,
            "text": "cortisol late",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 5.77734375,
            "end_logit": -6.6640625,
            "text": "cortisol late in the day in the novel setting when social demands were higher.",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 5.77734375,
            "end_logit": -7.09375,
            "text": "cortisol late in the day in the novel setting when social demands were",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 5.77734375,
            "end_logit": -7.15625,
            "text": "cortisol late in the day in the novel setting when social demands were higher",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 5.77734375,
            "end_logit": -7.3125,
            "text": "cortisol late in the day in the novel setting",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 5.77734375,
            "end_logit": -7.33203125,
            "text": "cortisol late in the day in the",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 5.77734375,
            "end_logit": -7.3515625,
            "text": "cortisol late in the day in",
            "probability": 2.980232238769531e-07
        }
    ],
    "531b1e3cb166e2b80600003b_1": [
        {
            "start_logit": 9.40625,
            "end_logit": 9.46875,
            "text": "H3K27me3",
            "probability": 1.0
        },
        {
            "start_logit": 9.40625,
            "end_logit": -0.75048828125,
            "text": "H3K",
            "probability": 3.647804260253906e-05
        },
        {
            "start_logit": -0.8564453125,
            "end_logit": 9.46875,
            "text": "me3",
            "probability": 3.4809112548828125e-05
        },
        {
            "start_logit": -5.81640625,
            "end_logit": 9.46875,
            "text": "27me3",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.40625,
            "end_logit": -6.7890625,
            "text": "H3K27me3, was not enriched at promoters found previously to be enriched for H3K27me3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.09375,
            "end_logit": 9.46875,
            "text": "to H3K27me3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.109375,
            "text": "H3K27me3,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.328125,
            "end_logit": 9.46875,
            "text": "Bmi1), which binds to H3K27me3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.34375,
            "text": "H3K27me3, was not enriched at promoters found",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.34765625,
            "text": "H3K27me3, was not enriched at promoters found previously to be enriched",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.34765625,
            "text": "H3K27me3, was not enriched at promoters found previously to be",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.36328125,
            "text": "H3K27me3, was not enriched at promoters found previously to be enriched for H3K",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.36328125,
            "text": "H3K27me3, was",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.3671875,
            "text": "H3K27me3, was not enriched at promoters found previously to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.43359375,
            "end_logit": 9.46875,
            "text": "that a component of the PRC1 complex (Bmi1), which binds to H3K27me3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.3828125,
            "text": "H3K27me3, was not enriched at promoters found previously",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.40625,
            "end_logit": -7.390625,
            "text": "H3K27",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5625,
            "end_logit": 9.46875,
            "text": "found that a component of the PRC1 complex (Bmi1), which binds to H3K27me3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 9.46875,
            "text": "PRC1 complex (Bmi1), which binds to H3K27me3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.8564453125,
            "end_logit": -6.7890625,
            "text": "me3, was not enriched at promoters found previously to be enriched for H3K27me3",
            "probability": 0.0
        }
    ],
    "531b1e3cb166e2b80600003b_2": [
        {
            "start_logit": 9.1328125,
            "end_logit": 8.8515625,
            "text": "H3K27me3",
            "probability": 1.0
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -1.3046875,
            "text": "H3K",
            "probability": 3.886222839355469e-05
        },
        {
            "start_logit": -2.171875,
            "end_logit": 8.8515625,
            "text": "trimethylation of the lysine 27 residue of histone H3 (H3K27me3",
            "probability": 1.233816146850586e-05
        },
        {
            "start_logit": -2.205078125,
            "end_logit": 8.8515625,
            "text": "me3",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": -3.337890625,
            "end_logit": 8.8515625,
            "text": "H3, with later recruitment of Polycomb repressor complex 2 (PRC2) and trimethylation of the lysine 27 residue of histone H3 (H3K27me3",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -6.2890625,
            "text": "H3K27",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -6.421875,
            "text": "H3K27me3), a modification associated with heterochromatin",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -6.984375,
            "text": "H3K27me3)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.99609375,
            "end_logit": 8.8515625,
            "text": "27me3",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.125,
            "end_logit": 8.8515625,
            "text": "(H3K27me3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.41015625,
            "text": "H3K27me3), a modification",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1328125,
            "end_logit": 8.8515625,
            "text": "later recruitment of Polycomb repressor complex 2 (PRC2) and trimethylation of the lysine 27 residue of histone H3 (H3K27me3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 8.8515625,
            "text": "lysine 27 residue of histone H3 (H3K27me3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3203125,
            "end_logit": 8.8515625,
            "text": "Polycomb repressor complex 2 (PRC2) and trimethylation of the lysine 27 residue of histone H3 (H3K27me3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3203125,
            "end_logit": 8.8515625,
            "text": "and trimethylation of the lysine 27 residue of histone H3 (H3K27me3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.171875,
            "end_logit": -1.3046875,
            "text": "trimethylation of the lysine 27 residue of histone H3 (H3K",
            "probability": 0.0
        },
        {
            "start_logit": -3.337890625,
            "end_logit": -1.3046875,
            "text": "H3, with later recruitment of Polycomb repressor complex 2 (PRC2) and trimethylation of the lysine 27 residue of histone H3 (H3K",
            "probability": 0.0
        },
        {
            "start_logit": -3.337890625,
            "end_logit": -2.310546875,
            "text": "H3",
            "probability": 0.0
        },
        {
            "start_logit": -2.171875,
            "end_logit": -4.86328125,
            "text": "trimethylation",
            "probability": 0.0
        },
        {
            "start_logit": -3.337890625,
            "end_logit": -4.86328125,
            "text": "H3, with later recruitment of Polycomb repressor complex 2 (PRC2) and trimethylation",
            "probability": 0.0
        }
    ],
    "531b1e3cb166e2b80600003b_3": [
        {
            "start_logit": 9.0546875,
            "end_logit": 9.3203125,
            "text": "H3K36me",
            "probability": 1.0
        },
        {
            "start_logit": -1.2333984375,
            "end_logit": 9.3203125,
            "text": "me",
            "probability": 3.3974647521972656e-05
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -1.6494140625,
            "text": "H3K",
            "probability": 1.722574234008789e-05
        },
        {
            "start_logit": -5.22265625,
            "end_logit": 9.3203125,
            "text": "methylated histone H3 Lys36 (H3K36me",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -5.6484375,
            "text": "H3K36me)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.18359375,
            "end_logit": 9.3203125,
            "text": "H3 Lys36 (H3K36me",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -6.359375,
            "text": "H3K36me), a mark associated with activation, by the PRC2 subunit Phf19",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.8046875,
            "end_logit": 9.3203125,
            "text": "36me",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.87890625,
            "end_logit": 9.3203125,
            "text": "histone H3 Lys36 (H3K36me",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -6.78515625,
            "text": "H3K36",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.16796875,
            "end_logit": 9.3203125,
            "text": "Lys36 (H3K36me",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.28125,
            "end_logit": 9.3203125,
            "text": "that direct recognition of methylated histone H3 Lys36 (H3K36me",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.08984375,
            "text": "H3K36me), a mark associated with activation, by the PRC2 subunit Phf1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 9.3203125,
            "text": "recognition of methylated histone H3 Lys36 (H3K36me",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 9.3203125,
            "text": "(H3K36me",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 9.3203125,
            "text": "36 (H3K36me",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.22265625,
            "text": "H3K36me), a mark associated with activation, by the PRC2 subunit Phf19 is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 9.3203125,
            "text": "direct recognition of methylated histone H3 Lys36 (H3K36me",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.31640625,
            "text": "H3K36me), a mark associated with activation, by the PRC2 subunit Phf19 is required",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.375,
            "text": "H3K36me), a mark associated with activation",
            "probability": 5.960464477539063e-08
        }
    ],
    "531b1e3cb166e2b80600003b_4": [
        {
            "start_logit": 9.3828125,
            "end_logit": 9.34375,
            "text": "H3K27me3",
            "probability": 1.0
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -0.82666015625,
            "text": "H3K",
            "probability": 3.8504600524902344e-05
        },
        {
            "start_logit": -1.2548828125,
            "end_logit": 9.34375,
            "text": "me3",
            "probability": 2.4139881134033203e-05
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -5.05859375,
            "text": "H3K27me3 deposition",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.21484375,
            "end_logit": 9.34375,
            "text": "27me3",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -7.0234375,
            "text": "H3K27",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3203125,
            "end_logit": 9.34375,
            "text": "Phf19 binds to a subset of PRC2 targets in mouse embryonic stem cells and that this is required for their repression and for H3K27me3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5,
            "end_logit": 9.34375,
            "text": "subset of PRC2 targets in mouse embryonic stem cells and that this is required for their repression and for H3K27me3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5,
            "end_logit": 9.34375,
            "text": "that Phf19 binds to a subset of PRC2 targets in mouse embryonic stem cells and that this is required for their repression and for H3K27me3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 9.34375,
            "text": "PRC2 targets in mouse embryonic stem cells and that this is required for their repression and for H3K27me3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 9.34375,
            "text": "that this is required for their repression and for H3K27me3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 9.34375,
            "text": "for H3K27me3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 9.34375,
            "text": "and that this is required for their repression and for H3K27me3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 9.34375,
            "text": "of PRC2 targets in mouse embryonic stem cells and that this is required for their repression and for H3K27me3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.2548828125,
            "end_logit": -5.05859375,
            "text": "me3 deposition",
            "probability": 0.0
        },
        {
            "start_logit": -7.3203125,
            "end_logit": -0.82666015625,
            "text": "Phf19 binds to a subset of PRC2 targets in mouse embryonic stem cells and that this is required for their repression and for H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.5,
            "end_logit": -0.82666015625,
            "text": "subset of PRC2 targets in mouse embryonic stem cells and that this is required for their repression and for H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.5,
            "end_logit": -0.82666015625,
            "text": "that Phf19 binds to a subset of PRC2 targets in mouse embryonic stem cells and that this is required for their repression and for H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.5,
            "end_logit": -0.82666015625,
            "text": "show that Phf19 binds to a subset of PRC2 targets in mouse embryonic stem cells and that this is required for their repression and for H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.56640625,
            "end_logit": -0.82666015625,
            "text": "PRC2 targets in mouse embryonic stem cells and that this is required for their repression and for H3K",
            "probability": 0.0
        }
    ],
    "531b1e3cb166e2b80600003b_5": [
        {
            "start_logit": 7.8359375,
            "end_logit": 8.6171875,
            "text": "H3K27me3",
            "probability": 0.9990234375
        },
        {
            "start_logit": 0.86376953125,
            "end_logit": 8.6171875,
            "text": "K27me3; rather, some display affinity towards both histone H3 trimethylated at K9 and H3K27me3",
            "probability": 0.0009398460388183594
        },
        {
            "start_logit": -2.505859375,
            "end_logit": 8.6171875,
            "text": "me3",
            "probability": 3.212690353393555e-05
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -3.396484375,
            "text": "H3K",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": 0.86376953125,
            "end_logit": 2.041015625,
            "text": "K27me3",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -5.93359375,
            "end_logit": 8.6171875,
            "text": "7me3; rather, some display affinity towards both histone H3 trimethylated at K9 and H3K27me3",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -6.05859375,
            "end_logit": 8.6171875,
            "text": "H3 trimethylated at K9 and H3K27me3",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -6.25390625,
            "end_logit": 8.6171875,
            "text": "K9 and H3K27me3",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.6015625,
            "end_logit": 8.6171875,
            "text": "to K27me3; rather, some display affinity towards both histone H3 trimethylated at K9 and H3K27me3",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.62109375,
            "end_logit": 8.6171875,
            "text": "and H3K27me3",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.671875,
            "end_logit": 8.6171875,
            "text": "histone H3 trimethylated at K9 and H3K27me3",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.8984375,
            "end_logit": 8.6171875,
            "text": "27me3",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.00390625,
            "end_logit": 8.6171875,
            "text": "trimethylated at K9 and H3K27me3",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -6.23046875,
            "text": "H3K27me3, and one CD prefers K9me3",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.03515625,
            "end_logit": 8.6171875,
            "text": "me3; rather, some display affinity towards both histone H3 trimethylated at K9 and H3K27me3",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.08984375,
            "end_logit": 8.6171875,
            "text": "Not all CDs bind preferentially to K27me3; rather, some display affinity towards both histone H3 trimethylated at K9 and H3K27me3",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.125,
            "end_logit": 8.6171875,
            "text": "all CDs bind preferentially to K27me3; rather, some display affinity towards both histone H3 trimethylated at K9 and H3K27me3",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.171875,
            "end_logit": 8.6171875,
            "text": "CDs bind preferentially to K27me3; rather, some display affinity towards both histone H3 trimethylated at K9 and H3K27me3",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -6.52734375,
            "text": "H3K27",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -7.1796875,
            "text": "H3K27me3, and one CD prefers K9",
            "probability": 1.1920928955078125e-07
        }
    ],
    "61f7d535882a024a10000034_1": [
        {
            "start_logit": 8.4765625,
            "end_logit": 7.015625,
            "text": "KIT",
            "probability": 0.94921875
        },
        {
            "start_logit": 8.4765625,
            "end_logit": 4.09375,
            "text": "KIT/PDGFRA",
            "probability": 0.05108642578125
        },
        {
            "start_logit": 0.60400390625,
            "end_logit": 4.09375,
            "text": "PDGFRA",
            "probability": 1.9431114196777344e-05
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.3984375,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842V genotype.",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.41015625,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842V genotype. To date, only a minority of PDGFRA",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.45703125,
            "text": "KIT/PDGFRA inhibitor",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.49609375,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842V genotype. To date, only a minority of PDGFRA-mutant",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.5625,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842V",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.56640625,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.65625,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842V genotype. To date, only a minority of PDGFRA-",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.66015625,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842V genotype. To",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.4765625,
            "end_logit": -7.66796875,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 7.015625,
            "text": "potent KIT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 7.015625,
            "text": ", potent KIT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.609375,
            "end_logit": 7.015625,
            "text": "apritinib is a novel, potent KIT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.11328125,
            "end_logit": 4.09375,
            "text": "/PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -6.84375,
            "end_logit": 4.09375,
            "text": "RA",
            "probability": 0.0
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 4.09375,
            "text": "potent KIT/PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 4.09375,
            "text": ", potent KIT/PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -7.609375,
            "end_logit": 4.09375,
            "text": "apritinib is a novel, potent KIT/PDGFRA",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_2": [
        {
            "start_logit": 7.8515625,
            "end_logit": 7.8046875,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": 7.8515625,
            "end_logit": -6.35546875,
            "text": "KIT and PDGFRA",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 7.8515625,
            "end_logit": -7.15234375,
            "text": "KIT and PDGFRA, in patients with unresectable or metastatic GIST",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.8515625,
            "end_logit": -7.2421875,
            "text": "KIT and PDGF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.8515625,
            "end_logit": -7.29296875,
            "text": "KIT and PDGFRA, in patients with unresectable or metastatic GIST.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 7.8046875,
            "text": "safety and antineoplastic activity of avapritinib, a selective, potent inhibitor of KIT",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 7.8046875,
            "text": "selective, potent inhibitor of KIT",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.5,
            "end_logit": 7.8046875,
            "text": "of KIT",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.5,
            "end_logit": 7.8046875,
            "text": ", dose escalation and expansion study designed to evaluate safety and antineoplastic activity of avapritinib, a selective, potent inhibitor of KIT",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.515625,
            "end_logit": 7.8046875,
            "text": "evaluate safety and antineoplastic activity of avapritinib, a selective, potent inhibitor of KIT",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 7.8046875,
            "text": "dose escalation and expansion study designed to evaluate safety and antineoplastic activity of avapritinib, a selective, potent inhibitor of KIT",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.53125,
            "end_logit": 7.8046875,
            "text": "single-arm, dose escalation and expansion study designed to evaluate safety and antineoplastic activity of avapritinib, a selective, potent inhibitor of KIT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 7.8046875,
            "text": "antineoplastic activity of avapritinib, a selective, potent inhibitor of KIT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 7.8046875,
            "text": ", single-arm, dose escalation and expansion study designed to evaluate safety and antineoplastic activity of avapritinib, a selective, potent inhibitor of KIT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 7.8046875,
            "text": ", a selective, potent inhibitor of KIT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 7.8046875,
            "text": ", potent inhibitor of KIT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.8515625,
            "end_logit": -7.609375,
            "text": "KIT and PDGFRA, in patients with unresectable or metastatic",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.8515625,
            "end_logit": -7.625,
            "text": "KIT and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.8515625,
            "end_logit": -7.65625,
            "text": "KIT and PDGFRA,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.8515625,
            "end_logit": -7.65625,
            "text": "KIT and PDGFRA, in patients with unresectable or",
            "probability": 1.7881393432617188e-07
        }
    ],
    "61f7d535882a024a10000034_3": [
        {
            "start_logit": 9.140625,
            "end_logit": 9.296875,
            "text": "PDGFRA",
            "probability": 1.0
        },
        {
            "start_logit": -1.3564453125,
            "end_logit": 9.296875,
            "text": "RA",
            "probability": 2.753734588623047e-05
        },
        {
            "start_logit": 9.140625,
            "end_logit": -1.53515625,
            "text": "PDGF",
            "probability": 1.9848346710205078e-05
        },
        {
            "start_logit": 9.140625,
            "end_logit": -5.21875,
            "text": "PDGFRA D842V-mutant GIST",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.140625,
            "end_logit": -6.4375,
            "text": "PDGFRA D",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.140625,
            "end_logit": -6.9453125,
            "text": "PDGFRA D842V",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.16015625,
            "end_logit": 9.296875,
            "text": "Targeting PDGFRA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.171875,
            "text": "PDGFRA D842V-mutant GIST with avapritinib resulted in an unprecedented, durable clinical benefit, with a manageable safety profile.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.18359375,
            "text": "PDGFRA D842",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.3671875,
            "text": "PDGFRA D842V-mutant",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 9.296875,
            "text": ": Targeting PDGFRA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.48828125,
            "text": "PDGFRA D842V-mutant GIST with avapritinib resulted",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 9.296875,
            "text": "CONCLUSION: Targeting PDGFRA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.5078125,
            "text": "PDGFRA D842V-mutant GIST with avapritinib resulted in an unprecedented, durable clinical benefit",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.578125,
            "text": "PDGFRA D842V-mutant GIST with avapritinib resulted in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.59375,
            "text": "PDGFRA D842V-mutant GIST with avapritinib",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.6015625,
            "text": "PDGFRA D842V-mutant GIST with avapritinib resulted in an unprecedented, durable clinical benefit, with a manageable safety profile",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.6171875,
            "text": "PDGFRA D84",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.62109375,
            "text": "PDGFRA D842V-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3564453125,
            "end_logit": -5.21875,
            "text": "RA D842V-mutant GIST",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_4": [
        {
            "start_logit": 8.1796875,
            "end_logit": 7.41796875,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": 8.1796875,
            "end_logit": -4.14453125,
            "text": "KIT/PDGFRA",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": 8.1796875,
            "end_logit": -6.62890625,
            "text": "KIT/PDGF",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.1796875,
            "end_logit": -7.42578125,
            "text": "KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon 18",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.1796875,
            "end_logit": -7.51953125,
            "text": "KIT/PDGFRA,",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.1796875,
            "end_logit": -7.53515625,
            "text": "KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon 18-mutant unresectable or metastatic gastrointestinal stromal",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.1796875,
            "end_logit": -7.5625,
            "text": "KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon 18-mutant",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.1796875,
            "end_logit": -7.5703125,
            "text": "KIT/PDGFRA, is approved in the U.S",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.1796875,
            "end_logit": -7.5859375,
            "text": "KIT/PDGFRA, is",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.1796875,
            "end_logit": -7.6015625,
            "text": "KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.1796875,
            "end_logit": -7.609375,
            "text": "KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 7.41796875,
            "text": "of KIT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 7.41796875,
            "text": "inhibitor of KIT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 7.41796875,
            "text": "novel inhibitor of KIT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 7.41796875,
            "text": ": Avapritinib, a novel inhibitor of KIT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.625,
            "end_logit": 7.41796875,
            "text": ", a novel inhibitor of KIT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.015625,
            "end_logit": -4.14453125,
            "text": "PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -7.35546875,
            "end_logit": -4.14453125,
            "text": "/PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -7.36328125,
            "end_logit": -4.14453125,
            "text": "of KIT/PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -7.56640625,
            "end_logit": -4.14453125,
            "text": "inhibitor of KIT/PDGFRA",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_5": [
        {
            "start_logit": 8.796875,
            "end_logit": 8.1328125,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA)",
            "probability": 1.0
        },
        {
            "start_logit": 8.796875,
            "end_logit": 0.30078125,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA",
            "probability": 0.0003921985626220703
        },
        {
            "start_logit": 8.796875,
            "end_logit": -2.091796875,
            "text": "platelet",
            "probability": 3.594160079956055e-05
        },
        {
            "start_logit": -2.65234375,
            "end_logit": 8.1328125,
            "text": "PDGFRA)",
            "probability": 1.0609626770019531e-05
        },
        {
            "start_logit": -2.91015625,
            "end_logit": 8.1328125,
            "text": ")",
            "probability": 8.165836334228516e-06
        },
        {
            "start_logit": 8.796875,
            "end_logit": -4.40625,
            "text": "platelet-derived growth factor receptor alpha",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": 8.796875,
            "end_logit": -5.09765625,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA) and KIT",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -4.63671875,
            "end_logit": 8.1328125,
            "text": "(PDGFRA)",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 8.796875,
            "end_logit": -5.73828125,
            "text": "platelet-derived growth factor receptor alpha (",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.796875,
            "end_logit": -5.93359375,
            "text": "platelet-derived growth factor receptor alpha (PDGF",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.796875,
            "end_logit": -6.28125,
            "text": "platelet-derived growth factor receptor",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.796875,
            "end_logit": -6.3046875,
            "text": "platelet-derived growth factor",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.796875,
            "end_logit": -6.59765625,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA) and KIT activation loop mutants",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.12109375,
            "end_logit": 8.1328125,
            "text": "-derived growth factor receptor alpha (PDGFRA)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.796875,
            "end_logit": -6.9296875,
            "text": "platelet-derived",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.796875,
            "end_logit": -6.99609375,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA) and KIT activation loop",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.796875,
            "end_logit": -7.046875,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA) and KIT activation loop mutants.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.796875,
            "end_logit": -7.35546875,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA) and KIT activation",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.9609375,
            "end_logit": 8.1328125,
            "text": "growth factor receptor alpha (PDGFRA)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.04296875,
            "end_logit": 8.1328125,
            "text": "of platelet-derived growth factor receptor alpha (PDGFRA)",
            "probability": 1.1920928955078125e-07
        }
    ],
    "61f7d535882a024a10000034_6": [
        {
            "start_logit": 7.921875,
            "end_logit": 7.71875,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": 7.921875,
            "end_logit": -6.55078125,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.921875,
            "end_logit": -6.75,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA)",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.921875,
            "end_logit": -7.1953125,
            "text": "KIT and platelet-derived growth factor receptor",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.921875,
            "end_logit": -7.19921875,
            "text": "KIT and platelet-derived growth factor receptor alpha",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.921875,
            "end_logit": -7.2109375,
            "text": "KIT and platelet-derived",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.921875,
            "end_logit": -7.265625,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.921875,
            "end_logit": -7.3046875,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA) mutants by targeting the active conformation of the kinase.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.921875,
            "end_logit": -7.3125,
            "text": "KIT and platelet-derived growth factor",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.921875,
            "end_logit": -7.4296875,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA) mutants",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.921875,
            "end_logit": -7.44140625,
            "text": "KIT and platelet-derived growth factor receptor alpha (",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.921875,
            "end_logit": -7.4921875,
            "text": "KIT and platelet-derived growth",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.921875,
            "end_logit": -7.52734375,
            "text": "KIT and platelet-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.375,
            "end_logit": 7.71875,
            "text": "oncogenic KIT",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.921875,
            "end_logit": -7.58984375,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA) mutants by",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.921875,
            "end_logit": -7.58984375,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA) mutants by targeting the active conformation of the kinase",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.921875,
            "end_logit": -7.59375,
            "text": "KIT and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.453125,
            "end_logit": 7.71875,
            "text": "inhibit oncogenic KIT",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 7.71875,
            "text": "protein kinase inhibitor designed to selectively inhibit oncogenic KIT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 7.71875,
            "text": "selectively inhibit oncogenic KIT",
            "probability": 1.7881393432617188e-07
        }
    ],
    "61f7d535882a024a10000034_7": [
        {
            "start_logit": 7.80859375,
            "end_logit": 7.83984375,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": 7.80859375,
            "end_logit": -6.88671875,
            "text": "KIT, for the treatment of advanced systemic mastocytosis",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.80859375,
            "end_logit": -7.0078125,
            "text": "KIT, for the treatment of advanced systemic mast",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.14453125,
            "end_logit": 7.83984375,
            "text": "mutant KIT",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.15234375,
            "end_logit": 7.83984375,
            "text": "D816V mutant KIT",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.80859375,
            "end_logit": -7.2890625,
            "text": "KIT, for the treatment of advanced systemic mastocytosis, patients experienced rapid and durable disease control.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 7.83984375,
            "text": "targets D816V mutant KIT",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.46875,
            "end_logit": 7.83984375,
            "text": "phase I trial of avapritinib (formerly BLU-285), which targets D816V mutant KIT",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.80859375,
            "end_logit": -7.44140625,
            "text": "KIT,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 7.83984375,
            "text": "816V mutant KIT",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.80859375,
            "end_logit": -7.5,
            "text": "KIT, for the treatment of advanced systemic mastocytosis, patients experienced rapid and durable disease control",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 7.83984375,
            "text": "a phase I trial of avapritinib (formerly BLU-285), which targets D816V mutant KIT",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 7.83984375,
            "text": "trial of avapritinib (formerly BLU-285), which targets D816V mutant KIT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 7.83984375,
            "text": "In a phase I trial of avapritinib (formerly BLU-285), which targets D816V mutant KIT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.80859375,
            "end_logit": -7.609375,
            "text": "KIT, for the treatment of advanced systemic mastocytosis, patients experienced rapid and durable disease",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.80859375,
            "end_logit": -7.6484375,
            "text": "KIT, for the",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.80859375,
            "end_logit": -7.65234375,
            "text": "KIT, for the treatment of advanced systemic mastocytosis, patients experienced rapid",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.80859375,
            "end_logit": -7.65234375,
            "text": "KIT, for the treatment of advanced systemic mastocytosis, patients experienced",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.14453125,
            "end_logit": -6.88671875,
            "text": "mutant KIT, for the treatment of advanced systemic mastocytosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.15234375,
            "end_logit": -6.88671875,
            "text": "D816V mutant KIT, for the treatment of advanced systemic mastocytosis",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_8": [
        {
            "start_logit": 7.47265625,
            "end_logit": 6.21875,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": 7.47265625,
            "end_logit": -1.814453125,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA), attenuates the transport function of both ABCB1",
            "probability": 0.00032520294189453125
        },
        {
            "start_logit": 7.47265625,
            "end_logit": -3.216796875,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA)",
            "probability": 8.028745651245117e-05
        },
        {
            "start_logit": 7.47265625,
            "end_logit": -4.78125,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA",
            "probability": 1.6689300537109375e-05
        },
        {
            "start_logit": 7.47265625,
            "end_logit": -5.1015625,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA), attenuates the transport function of both ABCB1 and ABCG2",
            "probability": 1.2218952178955078e-05
        },
        {
            "start_logit": 7.47265625,
            "end_logit": -5.7890625,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGF",
            "probability": 6.139278411865234e-06
        },
        {
            "start_logit": 7.47265625,
            "end_logit": -5.98046875,
            "text": "KIT and platelet-derived growth factor receptor alpha",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": 7.47265625,
            "end_logit": -6.4140625,
            "text": "KIT and platelet-derived growth factor",
            "probability": 3.2782554626464844e-06
        },
        {
            "start_logit": 7.47265625,
            "end_logit": -6.5,
            "text": "KIT and platelet-derived",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": 7.47265625,
            "end_logit": -6.62109375,
            "text": "KIT and platelet-derived growth factor receptor",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": 7.47265625,
            "end_logit": -6.796875,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA), attenuates the transport function of both ABCB1 and ABC",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 7.47265625,
            "end_logit": -6.9140625,
            "text": "KIT and platelet-derived growth",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": 7.47265625,
            "end_logit": -7.15234375,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA), attenuates the transport function of both ABCB1 and ABCG2.",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 7.47265625,
            "end_logit": -7.21875,
            "text": "KIT and platelet-derived growth factor receptor alpha (",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 7.47265625,
            "end_logit": -7.24609375,
            "text": "KIT and platelet-",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 7.47265625,
            "end_logit": -7.4140625,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA),",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 7.47265625,
            "end_logit": -7.421875,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA), attenuates the transport function of both ABCB1 and",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -6.640625,
            "end_logit": 6.21875,
            "text": "of KIT",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 6.21875,
            "text": "study, we discovered that avapritinib (BLU-285), a potent, selective, and orally bioavailable tyrosine kinase inhibitor against mutant forms of KIT",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 6.21875,
            "text": "mutant forms of KIT",
            "probability": 3.5762786865234375e-07
        }
    ],
    "61f7d535882a024a10000034_9": [
        {
            "start_logit": 5.95703125,
            "end_logit": 2.408203125,
            "text": "PDGFRA exon 18",
            "probability": 0.6923828125
        },
        {
            "start_logit": 5.95703125,
            "end_logit": 1.591796875,
            "text": "PDGFRA",
            "probability": 0.3046875
        },
        {
            "start_logit": 5.95703125,
            "end_logit": -3.970703125,
            "text": "PDGFRA exon",
            "probability": 0.0011701583862304688
        },
        {
            "start_logit": 5.95703125,
            "end_logit": -4.32421875,
            "text": "PDGFRA exon 18 (including D842V) mutant GIST",
            "probability": 0.0008234977722167969
        },
        {
            "start_logit": 5.95703125,
            "end_logit": -5.6171875,
            "text": "PDGF",
            "probability": 0.00022518634796142578
        },
        {
            "start_logit": 5.95703125,
            "end_logit": -6.7421875,
            "text": "PDGFRA exon 18 (including D842V)",
            "probability": 7.30752944946289e-05
        },
        {
            "start_logit": 5.95703125,
            "end_logit": -6.78515625,
            "text": "PDGFRA exon 18 (including D842V",
            "probability": 7.027387619018555e-05
        },
        {
            "start_logit": 5.95703125,
            "end_logit": -7.0390625,
            "text": "PDGFRA exon 18 (including D842V) mutant GIST and is undergoing regulatory assessment in the USA as a 4th-line treatment for GIST.",
            "probability": 5.429983139038086e-05
        },
        {
            "start_logit": 5.95703125,
            "end_logit": -7.13671875,
            "text": "PDGFRA exon 18 (including D842",
            "probability": 4.941225051879883e-05
        },
        {
            "start_logit": 5.95703125,
            "end_logit": -7.14453125,
            "text": "PDGFRA exon 18 (",
            "probability": 4.9054622650146484e-05
        },
        {
            "start_logit": 5.95703125,
            "end_logit": -7.390625,
            "text": "PDGFRA exon 18 (including",
            "probability": 3.8504600524902344e-05
        },
        {
            "start_logit": 5.95703125,
            "end_logit": -7.47265625,
            "text": "PDGFRA exon 18 (including D842V) mutant GIST and is undergoing regulatory assessment in the USA as a 4th-line treatment for GIST",
            "probability": 3.534555435180664e-05
        },
        {
            "start_logit": 5.95703125,
            "end_logit": -7.51171875,
            "text": "PDGFRA exon 18 (including D842V) mutant GIST and is",
            "probability": 3.403425216674805e-05
        },
        {
            "start_logit": 5.95703125,
            "end_logit": -7.5234375,
            "text": "PDGFRA exon 18 (including D842V) mutant GIST and",
            "probability": 3.349781036376953e-05
        },
        {
            "start_logit": 5.95703125,
            "end_logit": -7.55078125,
            "text": "PDGFRA exon 18 (including D842V) mutant GIST and is undergoing regulatory assessment",
            "probability": 3.266334533691406e-05
        },
        {
            "start_logit": 5.95703125,
            "end_logit": -7.5546875,
            "text": "PDGFRA exon 18 (including D842V) mutant GIST and is undergoing regulatory",
            "probability": 3.24249267578125e-05
        },
        {
            "start_logit": 5.95703125,
            "end_logit": -7.55859375,
            "text": "PDGFRA exon 18 (including D842V) mutant GIST and is undergoing regulatory assessment in the USA",
            "probability": 3.24249267578125e-05
        },
        {
            "start_logit": -6.71484375,
            "end_logit": 2.408203125,
            "text": "for PDGFRA exon 18",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": -6.99609375,
            "end_logit": 2.408203125,
            "text": "18",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": -6.71484375,
            "end_logit": 1.591796875,
            "text": "for PDGFRA",
            "probability": 9.5367431640625e-07
        }
    ],
    "61f7d535882a024a10000034_10": [
        {
            "start_logit": 7.90234375,
            "end_logit": 5.65625,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA",
            "probability": 0.97265625
        },
        {
            "start_logit": 4.31640625,
            "end_logit": 5.65625,
            "text": "PDGFRA",
            "probability": 0.0267333984375
        },
        {
            "start_logit": 7.90234375,
            "end_logit": -2.923828125,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA)",
            "probability": 0.00018155574798583984
        },
        {
            "start_logit": 7.90234375,
            "end_logit": -3.189453125,
            "text": "platelet",
            "probability": 0.0001392364501953125
        },
        {
            "start_logit": 7.90234375,
            "end_logit": -5.18359375,
            "text": "platelet-derived growth factor receptor alpha",
            "probability": 1.901388168334961e-05
        },
        {
            "start_logit": 7.90234375,
            "end_logit": -5.25390625,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation",
            "probability": 1.7702579498291016e-05
        },
        {
            "start_logit": 7.90234375,
            "end_logit": -5.38671875,
            "text": "platelet-derived growth factor receptor alpha (PDGF",
            "probability": 1.5497207641601562e-05
        },
        {
            "start_logit": 7.90234375,
            "end_logit": -6.4921875,
            "text": "platelet-derived growth factor receptor alpha (",
            "probability": 5.125999450683594e-06
        },
        {
            "start_logit": 4.31640625,
            "end_logit": -2.923828125,
            "text": "PDGFRA)",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": 7.90234375,
            "end_logit": -6.5859375,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA) exon 18",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": 7.90234375,
            "end_logit": -7.1953125,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation.",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": 7.90234375,
            "end_logit": -7.2109375,
            "text": "platelet-derived growth factor receptor",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": 7.90234375,
            "end_logit": -7.296875,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA) exon",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": 7.90234375,
            "end_logit": -7.32421875,
            "text": "platelet-derived",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": 7.90234375,
            "end_logit": -7.41015625,
            "text": "platelet-derived growth factor",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": -5.55078125,
            "end_logit": 5.65625,
            "text": "RA",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -5.671875,
            "end_logit": 5.65625,
            "text": "gastrointestinal stromal tumors harboring a platelet-derived growth factor receptor alpha (PDGFRA",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 4.31640625,
            "end_logit": -5.25390625,
            "text": "PDGFRA) exon 18 mutation",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.72265625,
            "end_logit": 5.65625,
            "text": "(PDGFRA",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 4.31640625,
            "end_logit": -5.38671875,
            "text": "PDGF",
            "probability": 4.172325134277344e-07
        }
    ],
    "61f7d535882a024a10000034_11": [
        {
            "start_logit": 7.96875,
            "end_logit": 7.6796875,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": 7.96875,
            "end_logit": -5.24609375,
            "text": "KIT and PDGFR\u03b1",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": 7.96875,
            "end_logit": -7.17578125,
            "text": "KIT and PDGFR",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.96875,
            "end_logit": -7.203125,
            "text": "KIT and PDGFR\u03b1 that Reverses ABCB1 and ABCG2",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.96875,
            "end_logit": -7.25,
            "text": "KIT and PDGFR\u03b1 that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.96875,
            "end_logit": -7.26171875,
            "text": "KIT and PDGF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.96875,
            "end_logit": -7.31640625,
            "text": "KIT and PDGFR\u03b1 that Reverses ABCB1",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.96875,
            "end_logit": -7.38671875,
            "text": "KIT and PDGFR\u03b1 that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.96875,
            "end_logit": -7.55078125,
            "text": "KIT and PDGFR\u03b1 that Reverses ABCB1 and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.96875,
            "end_logit": -7.5625,
            "text": "KIT and PDGFR\u03b1 that Reverses ABCB1 and ABCG2-Mediated",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.96875,
            "end_logit": -7.5703125,
            "text": "KIT and PDGFR\u03b1 that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.96875,
            "end_logit": -7.60546875,
            "text": "KIT and PDGFR\u03b1 that Reverses ABCB1 and ABCG2-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.96875,
            "end_logit": -7.62890625,
            "text": "KIT and PDGFR\u03b1 that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.96875,
            "end_logit": -7.6484375,
            "text": "KIT and PDGFR\u03b1 that Reverses ABCB1 and ABC",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.96875,
            "end_logit": -7.66796875,
            "text": "KIT and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 7.6796875,
            "text": "Selective Inhibitor of KIT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.421875,
            "end_logit": 7.6796875,
            "text": "of KIT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 7.6796875,
            "text": ": A Selective Inhibitor of KIT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 7.6796875,
            "text": "Inhibitor of KIT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 7.6796875,
            "text": "apritinib: A Selective Inhibitor of KIT",
            "probability": 1.7881393432617188e-07
        }
    ],
    "61f7d535882a024a10000034_12": [
        {
            "start_logit": 9.34375,
            "end_logit": 9.2421875,
            "text": "PDGFRA",
            "probability": 1.0
        },
        {
            "start_logit": 9.34375,
            "end_logit": -0.99609375,
            "text": "PDGF",
            "probability": 3.534555435180664e-05
        },
        {
            "start_logit": -1.431640625,
            "end_logit": 9.2421875,
            "text": "RA",
            "probability": 2.0802021026611328e-05
        },
        {
            "start_logit": 9.34375,
            "end_logit": -6.87890625,
            "text": "PDGFRA exon 18 mutation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.34375,
            "end_logit": -7.1953125,
            "text": "PDGFRA exon 18",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.34375,
            "end_logit": -7.2421875,
            "text": "PDGFRA exon 18 mutation including D842V mutations) and ripretinib (a broad-spectrum kinase inhibitor of c-Kit and PDGFRA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.34375,
            "end_logit": -7.24609375,
            "text": "PDGFRA exon 18 mutation including D842V mutations) and ripretinib (a broad-spectrum kinase inhibitor of c-Kit",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.17578125,
            "end_logit": 9.2421875,
            "text": "selective inhibitor for PDGFRA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.34375,
            "end_logit": -7.359375,
            "text": "PDGFRA exon",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.34375,
            "end_logit": -7.4375,
            "text": "PDGFRA exon 18 mutation including D842V",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3515625,
            "end_logit": 9.2421875,
            "text": "GIST including avapritinib (a selective inhibitor for PDGFRA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.34375,
            "end_logit": -7.48828125,
            "text": "PDGFRA exon 18 mutation including D842V mutations)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.34375,
            "end_logit": -7.5078125,
            "text": "PDGFRA exon 18 mutation including",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.34375,
            "end_logit": -7.5234375,
            "text": "PDGFRA exon 18 mutation including D842",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.34375,
            "end_logit": -7.52734375,
            "text": "PDGFRA exon 18 mutation including D842V mutations",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.34375,
            "end_logit": -7.55078125,
            "text": "PDGFRA exon 18 mutation including D842V mutations) and ripretinib (a broad-spectrum kinase inhibitor of c-Kit and PDGF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.34375,
            "end_logit": -7.5703125,
            "text": "PDGFRA exon 18 mutation including D842V mutations) and ripretinib (a broad-spectrum kinase inhibitor of c-Kit and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 9.2421875,
            "text": "for PDGFRA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 9.2421875,
            "text": "treatment of heavily pretreated advanced/unresectable GIST including avapritinib (a selective inhibitor for PDGFRA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 9.2421875,
            "text": "new tyrosine kinase inhibitors for the treatment of heavily pretreated advanced/unresectable GIST including avapritinib (a selective inhibitor for PDGFRA",
            "probability": 5.960464477539063e-08
        }
    ],
    "61f7d535882a024a10000034_13": [
        {
            "start_logit": 7.8046875,
            "end_logit": 7.8515625,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": 7.8046875,
            "end_logit": -6.9140625,
            "text": "KIT, for the treatment of advanced systemic mastocytosis",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.8046875,
            "end_logit": -7.109375,
            "text": "KIT, for the treatment of advanced systemic mast",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 7.8515625,
            "text": "mutant KIT",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 7.8515625,
            "text": "D816V mutant KIT",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 7.8515625,
            "text": "phase I trial of avapritinib (formerly BLU-285), which targets D816V mutant KIT",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.515625,
            "end_logit": 7.8515625,
            "text": "targets D816V mutant KIT",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.8046875,
            "end_logit": -7.484375,
            "text": "KIT,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.8046875,
            "end_logit": -7.4921875,
            "text": "KIT, for the treatment of advanced systemic mastocytosis, patients experienced rapid and durable disease control",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.546875,
            "end_logit": 7.8515625,
            "text": "816V mutant KIT",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 7.8515625,
            "text": "a phase I trial of avapritinib (formerly BLU-285), which targets D816V mutant KIT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.609375,
            "end_logit": 7.8515625,
            "text": "In a phase I trial of avapritinib (formerly BLU-285), which targets D816V mutant KIT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.8046875,
            "end_logit": -7.62109375,
            "text": "KIT, for the treatment of advanced systemic mastocytosis, patients experienced rapid and durable disease",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.8046875,
            "end_logit": -7.63671875,
            "text": "KIT, for the treatment of advanced systemic mastocytosis, patients experienced",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.8046875,
            "end_logit": -7.640625,
            "text": "KIT, for the treatment of advanced systemic mastocytosis, patients experienced rapid",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.8046875,
            "end_logit": -7.65234375,
            "text": "KIT, for the",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.8046875,
            "end_logit": -7.67578125,
            "text": "KIT, for the treatment of advanced systemic mastocytosis, patients experienced rapid and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -6.9140625,
            "text": "mutant KIT, for the treatment of advanced systemic mastocytosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.28515625,
            "end_logit": -6.9140625,
            "text": "D816V mutant KIT, for the treatment of advanced systemic mastocytosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -7.109375,
            "text": "mutant KIT, for the treatment of advanced systemic mast",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_14": [
        {
            "start_logit": 7.9765625,
            "end_logit": 7.6796875,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": 7.9765625,
            "end_logit": -5.7265625,
            "text": "KIT and PDGFRA",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 7.9765625,
            "end_logit": -6.98828125,
            "text": "KIT and PDGFRA inhibitor that potently inhibits PDGFRA D842V, in patients with advanced gastrointestinal stromal tumours",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.9765625,
            "end_logit": -7.0,
            "text": "KIT and PDGF",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.9765625,
            "end_logit": -7.5,
            "text": "KIT and PDGFRA inhibitor that potently inhibits PDGFRA D",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.9765625,
            "end_logit": -7.5078125,
            "text": "KIT and PDGFRA inhibitor that potently inhibits PDGFRA D842V, in patients with advanced gastrointestinal stromal tumours, including patients with KIT and PDGFRA",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.9765625,
            "end_logit": -7.53515625,
            "text": "KIT and PDGFRA inhibitor that potently inhibits PDGFRA",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.9765625,
            "end_logit": -7.5390625,
            "text": "KIT and PDGFRA inhibitor that potently inhibits PDGFRA D842V",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.9765625,
            "end_logit": -7.56640625,
            "text": "KIT and PDGFRA inhibitor",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.9765625,
            "end_logit": -7.5859375,
            "text": "KIT and PDGFRA inhibitor that potently inhibits PDGFRA D842V, in patients with advanced gastrointestinal stromal",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.9765625,
            "end_logit": -7.5859375,
            "text": "KIT and PDGFRA inhibitor that potently inhibits PDGFRA D842",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.9765625,
            "end_logit": -7.6171875,
            "text": "KIT and PDGFRA inhibitor that potently inhibits PDGFRA D84",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.9765625,
            "end_logit": -7.64453125,
            "text": "KIT and PDGFRA inhibitor that potently inhibits PDGFRA D842V,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.9765625,
            "end_logit": -7.66015625,
            "text": "KIT and PDGFRA inhibitor that potently inhibits PDGFRA D842V, in patients with advanced gastrointestinal stromal tumours, including patients with KIT",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 7.6796875,
            "text": "novel KIT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 7.6796875,
            "text": "safety, tolerability, and antitumour activity of avapritinib, a novel KIT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 7.6796875,
            "text": ", a novel KIT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 7.6796875,
            "text": "antitumour activity of avapritinib, a novel KIT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.7109375,
            "end_logit": -5.7265625,
            "text": "PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -7.42578125,
            "end_logit": -5.7265625,
            "text": "novel KIT and PDGFRA",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_15": [
        {
            "start_logit": 7.42578125,
            "end_logit": 5.35546875,
            "text": "KIT",
            "probability": 0.9990234375
        },
        {
            "start_logit": 7.42578125,
            "end_logit": -2.9453125,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA)",
            "probability": 0.0002491474151611328
        },
        {
            "start_logit": 7.42578125,
            "end_logit": -3.478515625,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA), attenuates the transport function of both ABCB1",
            "probability": 0.00014531612396240234
        },
        {
            "start_logit": 7.42578125,
            "end_logit": -5.47265625,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA), attenuates the transport function of both ABCB1 and ABCG2",
            "probability": 1.9848346710205078e-05
        },
        {
            "start_logit": 7.42578125,
            "end_logit": -5.5,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA",
            "probability": 1.9252300262451172e-05
        },
        {
            "start_logit": 7.42578125,
            "end_logit": -5.83203125,
            "text": "KIT and platelet-derived growth factor",
            "probability": 1.3828277587890625e-05
        },
        {
            "start_logit": 7.42578125,
            "end_logit": -6.05078125,
            "text": "KIT and platelet-derived growth factor receptor alpha",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": 7.42578125,
            "end_logit": -6.0703125,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGF",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": 7.42578125,
            "end_logit": -6.515625,
            "text": "KIT and platelet-derived growth factor receptor",
            "probability": 6.973743438720703e-06
        },
        {
            "start_logit": 7.42578125,
            "end_logit": -6.71875,
            "text": "KIT and platelet-derived",
            "probability": 5.662441253662109e-06
        },
        {
            "start_logit": 7.42578125,
            "end_logit": -6.90625,
            "text": "KIT and platelet-derived growth",
            "probability": 4.708766937255859e-06
        },
        {
            "start_logit": 7.42578125,
            "end_logit": -7.1015625,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA), attenuates the transport function of both ABCB1 and ABC",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": 7.42578125,
            "end_logit": -7.14453125,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA), attenuates the transport function of both ABCB1 and ABCG2.",
            "probability": 3.7550926208496094e-06
        },
        {
            "start_logit": 7.42578125,
            "end_logit": -7.203125,
            "text": "KIT and platelet-derived growth factor receptor alpha (",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": 7.42578125,
            "end_logit": -7.21484375,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA), attenuates the transport function of both ABC",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": 7.42578125,
            "end_logit": -7.3671875,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA),",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": 7.42578125,
            "end_logit": -7.42578125,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA), attenuates the transport function",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": 7.42578125,
            "end_logit": -7.45703125,
            "text": "KIT and platelet-derived growth factor receptor alpha (PDGFRA), attenuates the transport function of both ABCB1 and",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": -6.87109375,
            "end_logit": 5.35546875,
            "text": "of KIT",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.38671875,
            "end_logit": 5.35546875,
            "text": "tyrosine kinase inhibitor against mutant forms of KIT",
            "probability": 3.5762786865234375e-07
        }
    ],
    "61f7d535882a024a10000034_16": [
        {
            "start_logit": 8.40625,
            "end_logit": 7.14453125,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": 8.40625,
            "end_logit": -4.05078125,
            "text": "KIT/PDGFRA",
            "probability": 1.3828277587890625e-05
        },
        {
            "start_logit": 8.40625,
            "end_logit": -7.16015625,
            "text": "KIT/PDGF",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.40625,
            "end_logit": -7.26171875,
            "text": "KIT/PDGFRA inhibitor",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.40625,
            "end_logit": -7.4453125,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.40625,
            "end_logit": -7.484375,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842V",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.40625,
            "end_logit": -7.5390625,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842V genoty",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.40625,
            "end_logit": -7.5703125,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.40625,
            "end_logit": -7.6015625,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.40625,
            "end_logit": -7.60546875,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842V gen",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.40625,
            "end_logit": -7.61328125,
            "text": "KIT/PDGFRA inhibitor with",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.40625,
            "end_logit": -7.625,
            "text": "KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D84",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 7.14453125,
            "text": ". Avapritinib is a novel, potent KIT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.6484375,
            "end_logit": 7.14453125,
            "text": "potent KIT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.671875,
            "end_logit": 7.14453125,
            "text": "apritinib is a novel, potent KIT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.671875,
            "end_logit": 7.14453125,
            "text": ", potent KIT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.73828125,
            "end_logit": -4.05078125,
            "text": "PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -6.765625,
            "end_logit": -4.05078125,
            "text": "/PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -7.58984375,
            "end_logit": -4.05078125,
            "text": ". Avapritinib is a novel, potent KIT/PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -7.6484375,
            "end_logit": -4.05078125,
            "text": "potent KIT/PDGFRA",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_17": [
        {
            "start_logit": 7.76171875,
            "end_logit": 5.75,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA",
            "probability": 0.96142578125
        },
        {
            "start_logit": 4.52734375,
            "end_logit": 5.75,
            "text": "PDGFRA",
            "probability": 0.037872314453125
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -2.37109375,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA)",
            "probability": 0.0002846717834472656
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -3.33203125,
            "text": "platelet",
            "probability": 0.00010889768600463867
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -5.46484375,
            "text": "platelet-derived growth factor receptor alpha (PDGF",
            "probability": 1.2874603271484375e-05
        },
        {
            "start_logit": 4.52734375,
            "end_logit": -2.37109375,
            "text": "PDGFRA)",
            "probability": 1.1205673217773438e-05
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -5.66796875,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation",
            "probability": 1.055002212524414e-05
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -6.31640625,
            "text": "platelet-derived growth factor receptor alpha",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -6.69140625,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA) exon 18",
            "probability": 3.7550926208496094e-06
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -6.8984375,
            "text": "platelet-derived growth factor receptor alpha (",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -7.2421875,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation. Muta",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -7.375,
            "text": "platelet-derived growth factor receptor",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -7.3828125,
            "text": "platelet-derived growth factor receptor alpha (PDGFRA) exon",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -7.421875,
            "text": "platelet-derived",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": -5.50390625,
            "end_logit": 5.75,
            "text": "RA",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 7.76171875,
            "end_logit": -7.56640625,
            "text": "platelet-derived growth factor",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": -6.5078125,
            "end_logit": 5.75,
            "text": "gastrointestinal stromal tumors harboring a platelet-derived growth factor receptor alpha (PDGFRA",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.67578125,
            "end_logit": 5.75,
            "text": "(PDGFRA",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 4.52734375,
            "end_logit": -5.46484375,
            "text": "PDGF",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 4.52734375,
            "end_logit": -5.66796875,
            "text": "PDGFRA) exon 18 mutation",
            "probability": 4.172325134277344e-07
        }
    ],
    "61f7d535882a024a10000034_18": [
        {
            "start_logit": 8.2109375,
            "end_logit": 7.32421875,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -3.154296875,
            "text": "KIT/PDGFRA",
            "probability": 2.8192996978759766e-05
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -6.984375,
            "text": "KIT/PDGF",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.4140625,
            "text": "KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon 18",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.5078125,
            "text": "KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon 18-mutant unresectable or metastatic gastrointestinal stromal",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.55078125,
            "text": "KIT/PDGFRA,",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.58203125,
            "text": "KIT/PDGFRA, is",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.5859375,
            "text": "KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.58984375,
            "text": "KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon 18-mutant",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.58984375,
            "text": "KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.60546875,
            "text": "KIT/PDGFRA, is approved in the U.S",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.64453125,
            "text": "KIT/PDGFRA, is approved",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.66015625,
            "text": "KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon 18-",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.671875,
            "text": "KIT/PDGFRA, is approved in the",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.2109375,
            "end_logit": -7.68359375,
            "text": "KIT/PDGFRA, is approved in the U.S. for the",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 7.32421875,
            "text": "of KIT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 7.32421875,
            "text": "inhibitor of KIT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.31640625,
            "end_logit": -3.154296875,
            "text": "PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -7.08203125,
            "end_logit": -3.154296875,
            "text": "/PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -7.36328125,
            "end_logit": -3.154296875,
            "text": "of KIT/PDGFRA",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_19": [
        {
            "start_logit": 8.328125,
            "end_logit": 7.08203125,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": 8.328125,
            "end_logit": -4.2890625,
            "text": "KIT/PDGFR\u03b1",
            "probability": 1.1563301086425781e-05
        },
        {
            "start_logit": 8.328125,
            "end_logit": -7.0625,
            "text": "KIT/PDGFR\u03b1 activation loop",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.328125,
            "end_logit": -7.09765625,
            "text": "KIT/PDGFR\u03b1 activation loop mutants (exons 17/18).",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.328125,
            "end_logit": -7.2109375,
            "text": "KIT/PDGFR\u03b1 activation loop mutants",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.328125,
            "end_logit": -7.26171875,
            "text": "KIT/PDGFR",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.328125,
            "end_logit": -7.35546875,
            "text": "KIT/PDGFR\u03b1 activation",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.328125,
            "end_logit": -7.4140625,
            "text": "KIT/PDGFR\u03b1 activation loop mutants (exons 17/18",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.328125,
            "end_logit": -7.453125,
            "text": "KIT/PDGF",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.328125,
            "end_logit": -7.45703125,
            "text": "KIT/PDGFR\u03b1 activation loop mutants (exons 17",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.328125,
            "end_logit": -7.50390625,
            "text": "KIT/PDGFR\u03b1 activation loop mutants (exons 17/",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.328125,
            "end_logit": -7.53515625,
            "text": "KIT/PDGFR\u03b1 activation loop mutants (",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.01171875,
            "end_logit": 7.08203125,
            "text": "targeting KIT",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.26953125,
            "end_logit": 7.08203125,
            "text": "imatinib-resistant gastro-intestinal stromal tumors (GIST) by targeting KIT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -3.306640625,
            "end_logit": -1.603515625,
            "text": "c-KIT",
            "probability": 0.0
        },
        {
            "start_logit": -4.984375,
            "end_logit": -1.603515625,
            "text": "vulvar melanoma, harboring an exon 17 c-KIT",
            "probability": 0.0
        },
        {
            "start_logit": -6.71875,
            "end_logit": -1.603515625,
            "text": "metastatic vulvar melanoma, harboring an exon 17 c-KIT",
            "probability": 0.0
        },
        {
            "start_logit": -6.79296875,
            "end_logit": -1.603515625,
            "text": "-KIT",
            "probability": 0.0
        },
        {
            "start_logit": -7.01953125,
            "end_logit": -1.603515625,
            "text": "clinical case of a patient with metastatic vulvar melanoma, harboring an exon 17 c-KIT",
            "probability": 0.0
        },
        {
            "start_logit": -7.08984375,
            "end_logit": -1.603515625,
            "text": "KIT",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_20": [
        {
            "start_logit": 7.97265625,
            "end_logit": 7.68359375,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": 7.97265625,
            "end_logit": -6.9765625,
            "text": "KIT and PDGFRA",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.97265625,
            "end_logit": -7.20703125,
            "text": "KIT and PDGFRA, in three patient-derived xenograft (PDX) GIST",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.97265625,
            "end_logit": -7.4375,
            "text": "KIT and PDGFRA, in three patient-derived xenograft (PDX) GIST models",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.97265625,
            "end_logit": -7.51953125,
            "text": "KIT and PDGF",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.26953125,
            "end_logit": 7.68359375,
            "text": "mutated KIT",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.5,
            "end_logit": 7.68359375,
            "text": "activity of avapritinib, a potent and highly selective inhibitor of mutated KIT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.26953125,
            "end_logit": -6.9765625,
            "text": "mutated KIT and PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -7.26953125,
            "end_logit": -7.20703125,
            "text": "mutated KIT and PDGFRA, in three patient-derived xenograft (PDX) GIST",
            "probability": 0.0
        },
        {
            "start_logit": -7.5,
            "end_logit": -6.9765625,
            "text": "activity of avapritinib, a potent and highly selective inhibitor of mutated KIT and PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -7.34375,
            "end_logit": -7.20703125,
            "text": "patient-derived xenograft (PDX) GIST",
            "probability": 0.0
        },
        {
            "start_logit": -7.26953125,
            "end_logit": -7.4375,
            "text": "mutated KIT and PDGFRA, in three patient-derived xenograft (PDX) GIST models",
            "probability": 0.0
        },
        {
            "start_logit": -7.5,
            "end_logit": -7.20703125,
            "text": "activity of avapritinib, a potent and highly selective inhibitor of mutated KIT and PDGFRA, in three patient-derived xenograft (PDX) GIST",
            "probability": 0.0
        },
        {
            "start_logit": -7.5078125,
            "end_logit": -7.20703125,
            "text": "PDX) GIST",
            "probability": 0.0
        },
        {
            "start_logit": -7.53515625,
            "end_logit": -7.20703125,
            "text": "three patient-derived xenograft (PDX) GIST",
            "probability": 0.0
        },
        {
            "start_logit": -7.55859375,
            "end_logit": -7.20703125,
            "text": "in three patient-derived xenograft (PDX) GIST",
            "probability": 0.0
        },
        {
            "start_logit": -7.5625,
            "end_logit": -7.20703125,
            "text": "(PDX) GIST",
            "probability": 0.0
        },
        {
            "start_logit": -7.27734375,
            "end_logit": -7.5,
            "text": "with human GIST xenografts with KIT exon 11+17 (UZLX-GIST9 KIT 11+17 )",
            "probability": 0.0
        },
        {
            "start_logit": -7.27734375,
            "end_logit": -7.5078125,
            "text": "with human GIST xenografts with KIT exon 11+17 (UZLX-GIST9",
            "probability": 0.0
        },
        {
            "start_logit": -7.34375,
            "end_logit": -7.4375,
            "text": "patient-derived xenograft (PDX) GIST models",
            "probability": 0.0
        }
    ],
    "61f7d535882a024a10000034_21": [
        {
            "start_logit": 8.046875,
            "end_logit": 7.60546875,
            "text": "KIT",
            "probability": 1.0
        },
        {
            "start_logit": 8.046875,
            "end_logit": -6.234375,
            "text": "KIT and PDGFRA",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.2421875,
            "text": "KIT and PDGF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.4140625,
            "text": "KIT and PDGFRA inhibitor that potently inhibits PDGFRA D842V, in patients with advanced gastrointestinal stromal tumours",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.578125,
            "text": "KIT and PDGFRA inhibitor that potently inhibits PDGFRA D842V, in patients with advanced gastrointestinal stromal tumours, including patients with KIT and PDGFRA",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.609375,
            "text": "KIT and PDGFRA inhibitor that potently inhibits PDGFRA D",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.609375,
            "text": "KIT and PDGFRA inhibitor that potently inhibits PDGFRA",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 7.60546875,
            "text": "novel KIT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 7.60546875,
            "text": "safety, tolerability, and antitumour activity of avapritinib, a novel KIT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 7.60546875,
            "text": ", a novel KIT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 7.60546875,
            "text": "antitumour activity of avapritinib, a novel KIT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 7.60546875,
            "text": "assess the safety, tolerability, and antitumour activity of avapritinib, a novel KIT",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.36328125,
            "end_logit": -6.234375,
            "text": "PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -7.48828125,
            "end_logit": -6.234375,
            "text": "novel KIT and PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -7.56640625,
            "end_logit": -6.234375,
            "text": "safety, tolerability, and antitumour activity of avapritinib, a novel KIT and PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -7.5703125,
            "end_logit": -6.234375,
            "text": ", a novel KIT and PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -7.6015625,
            "end_logit": -6.234375,
            "text": "antitumour activity of avapritinib, a novel KIT and PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -7.60546875,
            "end_logit": -6.234375,
            "text": "assess the safety, tolerability, and antitumour activity of avapritinib, a novel KIT and PDGFRA",
            "probability": 0.0
        },
        {
            "start_logit": -7.36328125,
            "end_logit": -7.2421875,
            "text": "PDGF",
            "probability": 0.0
        },
        {
            "start_logit": -7.48828125,
            "end_logit": -7.2421875,
            "text": "novel KIT and PDGF",
            "probability": 0.0
        }
    ]
}
